From a778eb9bcf7e63515b4ca35941d16c6f960872ec Mon Sep 17 00:00:00 2001 From: Matthijs Berends Date: Sun, 4 May 2025 16:38:09 +0200 Subject: [PATCH] (v2.1.1.9272) (v2.1.1.9271) add sensititre AB and animal codes --- .github/ISSUE_TEMPLATE/1-bug-report.yml | 28 +- .github/ISSUE_TEMPLATE/2-feature-request.yml | 15 +- DESCRIPTION | 2 +- NEWS.md | 2 +- R/ab.R | 18 +- R/sir.R | 68 ++- R/sysdata.rda | Bin 117128 -> 115852 bytes data-raw/ab.md5 | 2 +- data-raw/datasets/antimicrobials.dta | Bin 10334 -> 10373 bytes data-raw/datasets/antimicrobials.feather | Bin 138962 -> 141418 bytes data-raw/datasets/antimicrobials.parquet | Bin 109944 -> 112077 bytes data-raw/datasets/antimicrobials.rds | Bin 45484 -> 46544 bytes data-raw/datasets/antimicrobials.sav | Bin 368632 -> 371568 bytes data-raw/datasets/antimicrobials.txt | 472 +++++++++--------- data-raw/datasets/antimicrobials.xlsx | Bin 78716 -> 79564 bytes data-raw/sensititre_ab.R | 498 +++++++++++++++++++ data/antimicrobials.rda | Bin 45412 -> 46464 bytes index.Rmd | 30 +- man/as.sir.Rd | 13 +- vignettes/welcome_to_AMR.Rmd | 2 +- 20 files changed, 841 insertions(+), 309 deletions(-) create mode 100644 data-raw/sensititre_ab.R diff --git a/.github/ISSUE_TEMPLATE/1-bug-report.yml b/.github/ISSUE_TEMPLATE/1-bug-report.yml index d82bf5440..737a087c5 100644 --- a/.github/ISSUE_TEMPLATE/1-bug-report.yml +++ b/.github/ISSUE_TEMPLATE/1-bug-report.yml @@ -16,6 +16,24 @@ body: placeholder: Description validations: required: true + - type: textarea + id: reprex + attributes: + label: Minimal Reproducible Example (optional) + description: Please include a short R code snippet that reproduces the problem, if possible. + placeholder: + e.g. + ```r + ab_name("amoxicillin/clavulanic acid", language = "es") + ``` + validations: + required: false + - type: markdown + attributes: + value: | + > 💡 If you're not sure what's causing it, you can copy-paste your R session info using `sessionInfo()` or `devtools::session_info()` for us to help faster. + + Otherwise, please fill in the below AMR package version. - type: dropdown id: version attributes: @@ -28,13 +46,3 @@ body: - One of the latest GitHub versions (2.1.1.9xxx) validations: required: true - - type: checkboxes - id: field-impact - attributes: - label: Impacted Field - description: Which field is probably impacted by this? You may select more than one, or choose none at all. - options: - - label: Medical (human) microbiology - - label: Veterinary microbiology - - label: Environmental microbiology - diff --git a/.github/ISSUE_TEMPLATE/2-feature-request.yml b/.github/ISSUE_TEMPLATE/2-feature-request.yml index 6e0791fb4..c1dc6ba56 100644 --- a/.github/ISSUE_TEMPLATE/2-feature-request.yml +++ b/.github/ISSUE_TEMPLATE/2-feature-request.yml @@ -16,12 +16,11 @@ body: placeholder: Description validations: required: true - - type: checkboxes - id: field-impact + - type: textarea + id: use-case attributes: - label: Impacted Field - description: Which field is probably impacted by this? You may select more than one, or choose none at all. - options: - - label: Medical (human) microbiology - - label: Veterinary microbiology - - label: Environmental microbiology + label: Use Case (optional) + description: When or why would this be useful? + placeholder: Describe a situation where this would help you or others. + validations: + required: false diff --git a/DESCRIPTION b/DESCRIPTION index 8fd6d26db..1f9186c53 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,5 +1,5 @@ Package: AMR -Version: 2.1.1.9270 +Version: 2.1.1.9272 Date: 2025-05-04 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) diff --git a/NEWS.md b/NEWS.md index d9cf835fe..a7f38344d 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,4 +1,4 @@ -# AMR 2.1.1.9270 +# AMR 2.1.1.9272 *(this beta version will eventually become v3.0. We're happy to reach a new major milestone soon, which will be all about the new One Health support! Install this beta using [the instructions here](https://amr-for-r.org/#get-this-package).)* diff --git a/R/ab.R b/R/ab.R index 65501e65d..0031f7c24 100755 --- a/R/ab.R +++ b/R/ab.R @@ -279,7 +279,12 @@ as.ab <- function(x, flag_multiple_results = TRUE, language = get_AMR_locale(), # length of input is quite long, and Levenshtein distance is only max 2 if (nchar(x[i]) >= 10) { - levenshtein <- as.double(utils::adist(x[i], AMR_env$AB_lookup$generalised_name)) + levenshtein <- as.double(utils::adist(x[i], AMR_env$AB_lookup$generalised_name, + ignore.case = FALSE, + fixed = TRUE, + costs = c(insertions = 1, deletions = 1, substitutions = 3), + counts = FALSE + )) if (any(levenshtein <= 2)) { found <- AMR_env$AB_lookup$ab[which(levenshtein <= 2)] x_new[i] <- note_if_more_than_one_found(found, i, from_text) @@ -350,7 +355,7 @@ as.ab <- function(x, flag_multiple_results = TRUE, language = get_AMR_locale(), ab_df$lev_name <- as.double(utils::adist(x[i], ab_df$generalised_name, ignore.case = FALSE, fixed = TRUE, - costs = c(insertions = 1, deletions = 1, substitutions = 2), + costs = c(insertions = 1, deletions = 1, substitutions = 3), counts = FALSE )) ab_df$lev_syn <- vapply( @@ -362,7 +367,7 @@ as.ab <- function(x, flag_multiple_results = TRUE, language = get_AMR_locale(), min(as.double(utils::adist(x[i], y[nchar(y) >= 5], ignore.case = FALSE, fixed = TRUE, - costs = c(insertions = 1, deletions = 1, substitutions = 2), + costs = c(insertions = 1, deletions = 1, substitutions = 3), counts = FALSE )), na.rm = TRUE) ) @@ -374,7 +379,7 @@ as.ab <- function(x, flag_multiple_results = TRUE, language = get_AMR_locale(), ab_df$lev_trans <- as.double(utils::adist(x[i], ab_df$trans, ignore.case = FALSE, fixed = TRUE, - costs = c(insertions = 1, deletions = 1, substitutions = 2), + costs = c(insertions = 1, deletions = 1, substitutions = 3), counts = FALSE )) } else { @@ -637,12 +642,17 @@ generalise_antibiotic_name <- function(x) { # spaces around non-characters must be removed: amox + clav -> amox clav x <- gsub("(.*[A-Z0-9]) ([^A-Z0-9].*)", "\\1\\2", x, perl = TRUE) x <- gsub("(.*[^A-Z0-9]) ([A-Z0-9].*)", "\\1\\2", x, perl = TRUE) + # rewrite ph to f, and th to t + x <- gsub("PH", "F", x, perl = TRUE) + x <- gsub("TH", "T", x, perl = TRUE) # remove hyphen after a starting "co" x <- gsub("^CO-", "CO", x, perl = TRUE) # replace operators with a space x <- gsub("(/| AND | WITH | W/|[+]|[-])+", " ", x, perl = TRUE) # replace more than 1 space x <- trimws(gsub(" +", " ", x, perl = TRUE)) + # remove last couple of words if they are 1-3 characters + x <- gsub("( .{1,3})+$", "", x) # move HIGH to end x <- trimws(gsub("(.*) HIGH(.*)", "\\1\\2 HIGH", x, perl = TRUE)) x diff --git a/R/sir.R b/R/sir.R index 3bcfecf70..365bc3dfa 100755 --- a/R/sir.R +++ b/R/sir.R @@ -64,6 +64,7 @@ #' @param include_PKPD A [logical] to indicate that PK/PD clinical breakpoints must be applied as a last resort - the default is `TRUE`. Can also be set with the package option [`AMR_include_PKPD`][AMR-options]. #' @param breakpoint_type The type of breakpoints to use, either `r vector_or(clinical_breakpoints$type)`. ECOFF stands for Epidemiological Cut-Off values. The default is `"human"`, which can also be set with the package option [`AMR_breakpoint_type`][AMR-options]. If `host` is set to values of veterinary species, this will automatically be set to `"animal"`. #' @param host A vector (or column name) with [character]s to indicate the host. Only useful for veterinary breakpoints, as it requires `breakpoint_type = "animal"`. The values can be any text resembling the animal species, even in any of the `r length(LANGUAGES_SUPPORTED)` supported languages of this package. For foreign languages, be sure to set the language with [set_AMR_locale()] (though it will be automatically guessed based on the system language). +#' @param language Language to convert values set in `host` when using animal breakpoints. Use one of these supported language names or [ISO 639-1 codes](https://en.wikipedia.org/wiki/ISO_639-1): `r vector_or(paste0(sapply(LANGUAGES_SUPPORTED_NAMES, function(x) x[[1]]), " (" , LANGUAGES_SUPPORTED, ")"), quotes = FALSE, sort = FALSE)`. #' @param verbose A [logical] to indicate that all notes should be printed during interpretation of MIC values or disk diffusion values. #' @param reference_data A [data.frame] to be used for interpretation, which defaults to the [clinical_breakpoints] data set. Changing this argument allows for using own interpretation guidelines. This argument must contain a data set that is equal in structure to the [clinical_breakpoints] data set (same column names and column types). Please note that the `guideline` argument will be ignored when `reference_data` is manually set. #' @param threshold Maximum fraction of invalid antimicrobial interpretations of `x`, see *Examples*. @@ -611,6 +612,7 @@ as.sir.mic <- function(x, include_PKPD = getOption("AMR_include_PKPD", TRUE), breakpoint_type = getOption("AMR_breakpoint_type", "human"), host = NULL, + language = get_AMR_locale(), verbose = FALSE, info = interactive(), conserve_capped_values = NULL, @@ -631,6 +633,7 @@ as.sir.mic <- function(x, include_PKPD = include_PKPD, breakpoint_type = breakpoint_type, host = host, + language = language, verbose = verbose, info = info, conserve_capped_values = conserve_capped_values, @@ -652,6 +655,7 @@ as.sir.disk <- function(x, include_PKPD = getOption("AMR_include_PKPD", TRUE), breakpoint_type = getOption("AMR_breakpoint_type", "human"), host = NULL, + language = get_AMR_locale(), verbose = FALSE, info = interactive(), ...) { @@ -671,6 +675,7 @@ as.sir.disk <- function(x, include_PKPD = include_PKPD, breakpoint_type = breakpoint_type, host = host, + language = language, verbose = verbose, info = info, ... @@ -694,6 +699,7 @@ as.sir.data.frame <- function(x, include_PKPD = getOption("AMR_include_PKPD", TRUE), breakpoint_type = getOption("AMR_breakpoint_type", "human"), host = NULL, + language = get_AMR_locale(), verbose = FALSE, info = interactive(), parallel = FALSE, @@ -711,6 +717,7 @@ as.sir.data.frame <- function(x, meet_criteria(include_PKPD, allow_class = "logical", has_length = 1) meet_criteria(breakpoint_type, allow_class = "character", is_in = reference_data$type, has_length = 1) meet_criteria(host, allow_class = c("character", "factor"), allow_NULL = TRUE, allow_NA = TRUE) + language <- validate_language(language) meet_criteria(verbose, allow_class = "logical", has_length = 1) meet_criteria(info, allow_class = "logical", has_length = 1) meet_criteria(parallel, allow_class = "logical", has_length = 1) @@ -734,7 +741,7 @@ as.sir.data.frame <- function(x, if (missing(breakpoint_type) && any(host %in% clinical_breakpoints$host[!clinical_breakpoints$host %in% c("human", "ECOFF")], na.rm = TRUE)) { if (isTRUE(info)) message_("Assuming `breakpoint_type = \"animal\"` since `host` contains animal species.") breakpoint_type <- "animal" - } else if (any(!suppressMessages(convert_host(host)) %in% c("human", "ECOFF"), na.rm = TRUE)) { + } else if (any(!suppressMessages(convert_host(host, lang = language)) %in% c("human", "ECOFF"), na.rm = TRUE)) { if (isTRUE(info)) message_("Assuming `breakpoint_type = \"animal\"`.") breakpoint_type <- "animal" } @@ -1035,38 +1042,43 @@ get_guideline <- function(guideline, reference_data) { guideline_param } -convert_host <- function(x, lang = get_AMR_locale()) { +convert_host <- function(x, lang = NULL) { x <- gsub("[^a-zA-Z ]", "", trimws2(tolower(as.character(x))), perl = TRUE) x_out <- rep(NA_character_, length(x)) x_out[trimws2(tolower(x)) == "human"] <- "human" x_out[trimws2(tolower(x)) == "ecoff"] <- "ecoff" - # this order is based on: clinical_breakpoints |> filter(type == "animal") |> count(host, sort = TRUE) - x_out[is.na(x_out) & (x %like% "dog|canine|Canis lupus" | x %like% translate_AMR("dog|dogs|canine", lang))] <- "dogs" - x_out[is.na(x_out) & (x %like% "cattle|bovine|Bos taurus" | x %like% translate_AMR("cattle|bovine", lang))] <- "cattle" - x_out[is.na(x_out) & (x %like% "swine|suida(e)?|Sus scrofa" | x %like% translate_AMR("swine|swines", lang))] <- "swine" - x_out[is.na(x_out) & (x %like% "cat|feline|Felis catus" | x %like% translate_AMR("cat|cats|feline", lang))] <- "cats" - x_out[is.na(x_out) & (x %like% "horse|equine|Equus ferus" | x %like% translate_AMR("horse|horses|equine", lang))] <- "horse" - x_out[is.na(x_out) & (x %like% "aqua|fish|Pisces" | x %like% translate_AMR("aquatic|fish", lang))] <- "aquatic" - x_out[is.na(x_out) & (x %like% "bird|chicken|poultry|avia|Gallus gallus" | x %like% translate_AMR("bird|birds|poultry", lang))] <- "poultry" - # additional animals, not necessarily currently in breakpoint guidelines: - x_out[is.na(x_out) & (x %like% "camel|camelid|Camelus dromedarius" | x %like% translate_AMR("camel|camels|camelid", lang))] <- "camels" - x_out[is.na(x_out) & (x %like% "deer|cervine|Cervidae" | x %like% translate_AMR("deer|deers|cervine", lang))] <- "deer" - x_out[is.na(x_out) & (x %like% "donkey|asinine|Equus africanus" | x %like% translate_AMR("donkey|donkeys|asinine", lang))] <- "donkeys" - x_out[is.na(x_out) & (x %like% "ferret|musteline|Mustela putorius" | x %like% translate_AMR("ferret|ferrets|musteline", lang))] <- "ferrets" - x_out[is.na(x_out) & (x %like% "goat|caprine|Capra aegagrus" | x %like% translate_AMR("goat|goats|caprine", lang))] <- "goats" - x_out[is.na(x_out) & (x %like% "guinea pig|caviine|Cavia porcellus" | x %like% translate_AMR("guinea pig|guinea pigs|caviine", lang))] <- "guinea pigs" - x_out[is.na(x_out) & (x %like% "hamster|cricetine|Cricetinae" | x %like% translate_AMR("hamster|hamsters|cricetine", lang))] <- "hamsters" - x_out[is.na(x_out) & (x %like% "monkey|simian|Simia" | x %like% translate_AMR("monkey|monkeys|simian", lang))] <- "monkeys" - x_out[is.na(x_out) & (x %like% "mouse|murine|Mus musculus" | x %like% translate_AMR("mouse|mice|murine", lang))] <- "mice" - x_out[is.na(x_out) & (x %like% "pig|porcine|Sus scrofa" | x %like% translate_AMR("pig|pigs|porcine", lang))] <- "pigs" - x_out[is.na(x_out) & (x %like% "rabbit|leporine|Oryctolagus cuniculus" | x %like% translate_AMR("rabbit|rabbits|leporine", lang))] <- "rabbits" - x_out[is.na(x_out) & (x %like% "rat|ratine|Rattus" | x %like% translate_AMR("rat|rats|ratine", lang))] <- "rats" - x_out[is.na(x_out) & (x %like% "sheep|ovine|Ovis aries" | x %like% translate_AMR("sheep|sheeps|ovine", lang))] <- "sheep" - x_out[is.na(x_out) & (x %like% "snake|serpentine|Serpentes" | x %like% translate_AMR("snake|snakes|serpentine", lang))] <- "snakes" - x_out[is.na(x_out) & (x %like% "turkey|meleagrine|Meleagris gallopavo" | x %like% translate_AMR("turkey|turkeys|meleagrine", lang))] <- "turkey" + # Veterinary breakpoints - matching clinical_breakpoints$host (type == "animal") + x_out[is.na(x_out) & (x == "CAN" | x %like% "dog|canine|Canis lupus" | x %like% translate_AMR("dog|dogs|canine", lang))] <- "dogs" + x_out[is.na(x_out) & (x == "BOV" | x %like% "cattle|bovine|Bos taurus" | x %like% translate_AMR("cattle|bovine", lang))] <- "cattle" + x_out[is.na(x_out) & (x == "POR" | x %like% "swine|suida(e)?|Sus scrofa" | x %like% translate_AMR("swine|swines|porcine", lang))] <- "swine" + x_out[is.na(x_out) & (x == "FEL" | x %like% "cat|feline|Felis catus" | x %like% translate_AMR("cat|cats|feline", lang))] <- "cats" + x_out[is.na(x_out) & (x == "EQU" | x %like% "horse|equine|Equus ferus" | x %like% translate_AMR("horse|horses|equine", lang))] <- "horse" + x_out[is.na(x_out) & (x == "POUL" | x == "AVI" | x %like% "bird|chicken|poultry|avia|Gallus gallus" | x %like% translate_AMR("bird|birds|poultry", lang))] <- "poultry" + x_out[is.na(x_out) & (x == "AMP" | x %like% "amphibian|frog|toad" | x %like% translate_AMR("amphibian|frog|toad", lang))] <- "amphibian" + # Additional animals (not necessarily present in guidelines) + x_out[is.na(x_out) & (x == "CAM" | x %like% "camel|camelid|Camelus dromedarius" | x %like% translate_AMR("camel|camels|camelid", lang))] <- "camels" + x_out[is.na(x_out) & (x == "CER" | x %like% "deer|cervine|Cervidae" | x %like% translate_AMR("deer|deers|cervine", lang))] <- "deer" + x_out[is.na(x_out) & (x == "EQU" | x %like% "donkey|asinine|Equus africanus" | x %like% translate_AMR("donkey|donkeys|asinine", lang))] <- "donkeys" + x_out[is.na(x_out) & (x == "ROD" | x %like% "ferret|musteline|Mustela putorius" | x %like% translate_AMR("ferret|ferrets|musteline", lang))] <- "ferrets" + x_out[is.na(x_out) & (x == "CAP" | x %like% "goat|caprine|Capra aegagrus" | x %like% translate_AMR("goat|goats|caprine", lang))] <- "goats" + x_out[is.na(x_out) & (x == "LAG" | x %like% "rabbit|leporine|Oryctolagus cuniculus" | x %like% translate_AMR("rabbit|rabbits|leporine", lang))] <- "rabbits" + x_out[is.na(x_out) & (x == "ROD" | x %like% "guinea pig|caviine|Cavia porcellus" | x %like% translate_AMR("guinea pig|guinea pigs|caviine", lang))] <- "guinea pigs" + x_out[is.na(x_out) & (x == "ROD" | x %like% "hamster|cricetine|Cricetinae" | x %like% translate_AMR("hamster|hamsters|cricetine", lang))] <- "hamsters" + x_out[is.na(x_out) & (x == "PRI" | x %like% "monkey|simian|Simia" | x %like% translate_AMR("monkey|monkeys|simian", lang))] <- "monkeys" + x_out[is.na(x_out) & (x == "ROD" | x %like% "mouse|murine|Mus musculus" | x %like% translate_AMR("mouse|mice|murine", lang))] <- "mice" + x_out[is.na(x_out) & (x == "POR" | x %like% "pig|porcine|Sus scrofa" | x %like% translate_AMR("pig|pigs|porcine", lang))] <- "pigs" + x_out[is.na(x_out) & (x == "ROD" | x %like% "rat|ratine|Rattus" | x %like% translate_AMR("rat|rats|ratine", lang))] <- "rats" + x_out[is.na(x_out) & (x == "OVI" | x %like% "sheep|ovine|Ovis aries" | x %like% translate_AMR("sheep|sheeps|ovine", lang))] <- "sheep" + x_out[is.na(x_out) & (x == "REP" | x %like% "snake|serpentine|Serpentes" | x %like% translate_AMR("snake|snakes|serpentine", lang))] <- "snakes" + x_out[is.na(x_out) & (x == "AVI" | x %like% "turkey|meleagrine|Meleagris gallopavo" | x %like% translate_AMR("turkey|turkeys|meleagrine", lang))] <- "turkey" + x_out[is.na(x_out) & (x == "CET" | x %like% "cetacean|whale|dolphin|porpoise" | x %like% translate_AMR("cetacean|whale|dolphin|porpoise", lang))] <- "cetacean" + x_out[is.na(x_out) & (x == "PIN" | x %like% "pinniped|seal|sea lion|walrus" | x %like% translate_AMR("pinniped|seal|sea lion|walrus", lang))] <- "pinniped" + x_out[is.na(x_out) & (x == "PAC" | x %like% "pachyderm|elephant|hippopotamus|rhino" | x %like% translate_AMR("pachyderm|elephant|hippopotamus|rhino", lang))] <- "pachyderm" + x_out[is.na(x_out) & (x == "MAR" | x %like% "marsupial|kangaroo|koala" | x %like% translate_AMR("marsupial|kangaroo|koala", lang))] <- "marsupial" + # Standardise label for ECOFFs x_out[x_out == "ecoff"] <- "ECOFF" x_out } @@ -1086,6 +1098,7 @@ as_sir_method <- function(method_short, include_PKPD, breakpoint_type, host, + language, verbose, info, conserve_capped_values = NULL, @@ -1108,6 +1121,7 @@ as_sir_method <- function(method_short, check_reference_data(reference_data, .call_depth = -2) meet_criteria(breakpoint_type, allow_class = "character", is_in = reference_data$type, has_length = 1, .call_depth = -2) meet_criteria(host, allow_class = c("character", "factor"), allow_NULL = TRUE, allow_NA = TRUE, .call_depth = -2) + language <- validate_language(language) meet_criteria(verbose, allow_class = "logical", has_length = 1, .call_depth = -2) meet_criteria(info, allow_class = "logical", has_length = 1, .call_depth = -2) @@ -1167,7 +1181,7 @@ as_sir_method <- function(method_short, } } host.bak <- host - host <- convert_host(host) + host <- convert_host(host, lang = language) if (any(is.na(host) & !is.na(host.bak)) && isTRUE(info) && message_not_thrown_before("as.sir", "missing_hosts")) { warning_("The following animal host(s) could not be coerced: ", vector_and(host.bak[is.na(host) & !is.na(host.bak)]), immediate = TRUE) message() # new line diff --git a/R/sysdata.rda b/R/sysdata.rda index 42685b83c67610f6aad551ed9553ce78558c6516..d2e47a1aeda7dc13106c790b9a58ca4f5b59dd13 100755 GIT binary patch delta 53589 zcmV(rK<>YYlLw562e2LR1%>ks)Jd}<@XQ2%!&%(YB~B`eV932DA2NVG2Kp!5xF@Gj z4hZD;H+S>)nXx%#*~!L-yp}sR_&yejORE4xKlgkHC4F98@5;b*hCyWzp!H0QY^QtAoM~Lw%lGFk(+{nQnby1gv+jbll31hCv|;Hc|mCU$O{)ngP7X zT362>of~IJxx*iQq8WEmr=bj;+AMgw(j#i}Iv;Bazq(<{UvXZ2xs9MEeM*-2?+>u-Zu&EwHi8gU`pXZwo!>`XCx45o_3HOG$v>Kezpcty zYukzoehtfxxC3=0#Yj5wrsB(gjwEV)LAEzondBYuDPwi-9%zrX$x3?$rO#-MVj46T z(9+`eEWSb#WKL+*UL-9*qso)l0fpA=ixn;3~t>Dy>&G0+!0w-evV(91vEGvETgoouIWBJfq}VlhYQC2MUv>Li=7 z_=Rivmn$lw=JDcm&=HJNA4L6F5~9LXa!I7>J;4s>#d^3obSxuqso{8wuEfRydPxn7 zc)?7U%Bf#D9~%htbN(BDpUPa*4#Sm8dX=66mT`s?8#Hat0?Rhe4oOZahwnjvvuhV+% z&CX|g<^Mv%(PAo}G&Dn_8oce^;U&zONYJ3Kll~Z!bK`VRR=t#e)!NkWOLB>mLF#!I z4mFylKzmEIo=^>oBQgzAco&HtCfQZFLDguxaL;k}sk?@vD(;0y@d?6ckjBLK&lXzm|w6h^tGETjyb+0%fDk zO6iPAqFlmLuxSzh8-YetzXVRZJt$~`E^d@IKk1~Q<)6cUef&*3wi~WihrAIZCKAN( z^t-`ffgK|LP(<7E1o|huzTnc+Di}LOcnN6qmUyIi!6;gOS$H01IP9p*>N*qL4LFUP3FI=+rYRGfOz`i(|N) z>K@lV*3)Ck(hkldGzvWzy~SirHF9WFihr^!W{-0ECnCi=i1AAqVGRa9PoHLfBB0!{bZTV}_Or)Mjn`1LZ| zYm&GWy0hUj;B~WZ@}>P+tlYPWJ$=ib%2Um1=s=TxhvdDYTlE>x3;JgRoOWtDjS}R} z5;5Aob>$4&s{g;lh?dXKJL%n>0g%-D>RYDO)k7@JlTpRWz?FuS=g(07x3tTJ_i3ox+tJ$J(+`{6amB$r5`}?M}@(Y`udQ`YK{M zm=33fh5mv(HFGPEB}d~Lnq`~@UB{n81dMj zjOW=}4S^)XfZpTUZw6bt+Df=AmM~E$QNL`8c!#%|vztX=S#2@V^@B*8imXttUxI}< z4_G#Rm%_D|9zdB^*ez?7Q6`kHww8yLzHG-wH(}mIhdOGjQvkODh*@;j{=9+liG}-r zIZp4g)uyY?E<~|6lZUh_$6=F3%m!8jwc62U?rHZ*4j(KB;-vI}!=s)8fn!@>WIPG< z^I%S$FlRXzG@I%!%{Lp+j8m0!X#*IEmT1i;5R~C63iRRoNeHh{AQ9LWLj4x0Yp{UI zev>@65}n)mRGUHYc`{yk&Kcj76ULr@FE@ZLH$w?UJLmAq;F5+`7{f4$Vb@s2kv}F< z&@W3K>>fvKo9$0Y)Vh0gnB{1T+9%2er1|P9fyXXO3R$W|+~2z$EAiE51BP{tk-PR| z7kPw*GlYmlRN}#4hjb@lED-K=JaUdA70}gPo4NxokFMcbRNWpooKi_E|{n zd@!b*ZY1`y@I;(U9QhsHT)dbfaX*K7DvMxS zD`SZ4T?HIzD*#rL`BL{dZ55=4}aLNV5$y>JK32qP3j z35Fy521gGB3+*17#HtnDZLd*(@#S16I)d)mYX3|XTaS#}&Md^r13{5$P2GJOf*`B7 zH!}lZCe5?=l=t#W+)n{nWUGGSy~UG+?*Uc1Dkn*esS87DuRVIyd$(h{V(>#`jA@2P zuz@+@I)%+zs7m`tJD0knF0n)(GUuvA_e$_n+1Ef?L{U{a!L~-)5hSO7EG3jN+~Z_* zCb5tf6m{sikWicfWx;|W<}vwUXt)u|ZIP1Mym)w2hCnpvoRNF#KpqQip&>rQ?{xUg ze5jQQTYRS5E~_!#GKM@N0`c(0aFkO_fP{i%MM)$JhgD&c0EJhRh!HpvZc$gASOv<2 zK1V-d0)7m`hm&LH7L7-L!L%^83jY0wXI3Ch`h@_yDszIPA!Xb`QPN5mA&Y83e5nm3 zu#eeV;~o}1d#ZMJ@Vhbzh0;=d4sInZikiHo5(3SeMH*MF=PSA`2AF5U_XUVUb_}Z) zUBs*%PI9HdyksmDR#zs4#g7GoE1Ri*#1L2s`kk+CeBem_rLTm4BACZEr%e|78gM)M z8~3&(1oiwc4-m6fGxjVdcLSxTcp^2%MW9~QH4+n0GW3prk2ZF~f0n-qJLy*La@6lF z=UPv>PY2#fw-Y2aTJO1*Ds7_}bh^+#Dk70V;TTXejSj87(tDBLaewV-{+~ZFyQ5f^ z5X}K@z}3&_mvcma1WjO^P$6p{_mDi86pK!#rCl6XWHDAMb4V?J! zGT>>G<`Lz}p&aN4*$Eku#LfN~+3Cjh6k0hC>fnQmnmJALh}<$|ntB;NzEU4HfS#LT z%uTB|Tp4yn3imQ$)!dKsLHGoG8(iq@)STqZQPZ0tszH*a zrE*rGsJ)=U&kc<}jJ>RXX6Kkd-r%A5JUvE>bcK>{lLuYm!7tc#Nt6&}t25QUUj`e9 zpC(1d9>QkFB#ckBiwUw^+l%#+1P%biwRc!! z#4E{vI~vk-wYn>lkcwrSjDD@6-$e%ITJt6B-@XfN*99&t#z2$0Q%Zk=`84cS@CJP(ir*X)4D#qJqx45fBG5+;9 ztDwZlW<I*LxRWjNo0gyiCtCG>Q@o6$i>6(&2h&V)UbB8LQQ0V z=s@>C(i+PBN=`<;ZD@tlFWcuY5-vA?zv}_nRo)9Ml_ygCsF#+YBuuw=a0$MfhOK!2 zqyy(>5COs)fXp|4HhSLjnEoB<(0a(*Fsdveob{u#O9@Z7-zaZH4dL5r0gns0Hy5wLuHBk}wF~}LkwS>*Wfgs%6(}Rr8)46Cp`iNmR^ckx z9BFK!tElezJbpP9XJ|;wheD9RuL;Aaesaw?bO@Lb`gvoatNn`0ErF9Hjy9{9v%s|; ztcKu$x5k=3PLTo#+19at=PV1wYX7;o$mqX_APhlL94r>1W8>Iot>?lVlbGY` zfYmKL_G6^$N5C>EfQBFln2LJ$LfscAX~a7JJGL_Lrpj#9d#915k-Yjx=?3BNlG2U7 zvKx&SgbeQKuHGUSdLB+O{>*c7Yw+CUttKTiUCX zxE$3$ErEZM>bT~fV=JqL?|!Gk%;qmK98QQ4@?#OhOM<{N-_24Lct;pQQ^?9oZWNFyG39TmCQzr@uD)MMiZZ zLXo-H6nqp`Kg7l97huTa;T^v!kF4oZ@$oLs1N8jFa0@xG*2h$T`=|Uh3|uYeE6aMC zTy7F)1F&j~sUHT0m%LLoBlOKFADtA`4=18wmaV3Pms?u0iX8SC27s4N?`;^B4OkMo z)EAt2u2F?Vbpd}7gc8c)&B_!VnJv7C9caWii0zYXolZFK_=?K?iO;q(lcZdBtrX_? zRjdWIFLup#=2s?v^P_`>3m}6$awKggdqm*)1iiLXj5D1VG=)_;9{(rAPY1W#_Rw8` zMeQ`LjI;S%I06n+;Op*Mz*KI)ZfrWsbB4$t!4a z0Bami>1dV+V#5%Dki%~8-WmWSpHuQhrenKEcLmfjc??H?2MiX&u~G;WrbsVn-@r7= zsEoa-?Gyk(eGxSnTBWOdGIfn8nV3E+L2`c|NXl&0JJL|uHu?%uJ;9d|^M35N1cPEj z1e=G8MmxWS?x8Sb$Wv^CsW-O_8kO^h7pvhYMe8X>Ys}Tkw6wA#uW>pl-SyHvs}0f| zIlov6bM^9nXG}J6?Ee!lD89C9B|#>H@opUZ(l_i4eA^S=PJTQ$>?78d)OJxTm&Vr$ z%z+zwwIR&f;^xHNR>e6c92geCWbR@|$H96uuaJhoQlQJC)M_d@8ipfhcuj1V9}pNw z$NqjCUkIwu{$qKssXx_6lIrXe#kxQCp8T)%e7LB8y5@A@-0(P)K{30;H`qOV^E9X}-4AWk50~u8<5rWQ)AcgGV#PmKb6LDU9V1f|7lQ-$43k z@Y!FI@8qCWc)?qUL!~4?bAfiHw=&T`NjZ#~iQqH9!wWi?mVwNDHfvouTS+UJ&v*|% z$`g`*W$zG zV)L18tJhXK2_)i6q)b{Z==znog{dQTm=bRO#YE!2nVdCo@PtY1Cx6{qPy!ZV?IFlb z&Wd2KE7#}8Anc20tT$%Q-zNAgmg>}>SUbUg)Pm|jU|k{ahG5N>Wnq2z)V_ZlD4)nb zGO)!PE34oKqdZUVaY?QKh$M1jowebB7JIV_12)s$15ow*7ARf@8sN=6L>JvhJ!gOn zzW3g)82V{kfJIR`1PO$W&h2G{@WrS(Q^@unAR28V<|_$m)x?yiARwh8b@=2so*`s^ zGK64!lTVZUNpE8|_6-dF-LCb%bmZCXM7|qi(aT*@fhjfvHQ}D>!}Lrx{1cO`9LifK ztWGATyg}1ihzraTXEK4AbiE3|P3vSPTOqBV0;@!Z?Gb--`i<`2RN{=5WQWI7yG|0n z(qQmJ1K>;7rqkZK!~wB>l=3ER^!YM>6qNc>f*^B4)fe@khRIT@6^st4$fEx|y8*o( zxqaflAX=-8^Y&yU)cy>#$KaijN}hZhdQeh%_ID7U9+YQ}c*n{XMPD8B05alE-*g6r z3=#A?t>Ygj`bJO_OZ6*lYakbpQ%;hKbM#3hR-Tb#H@yKG<&@6WvzgF~c#x-mAG|B8 zc8|PRHyxt5cdYOig_5ejqi~UOwyn(BGdrwlYQUniUcIiIh3zPf%>}NCf*Mc_lkVTK#X#cVL>n&mX)q{jS63Klm zJ1;9%i#Dg}gwqo%kJ3y}hR#-hV4bC&5p=cv%Yqs z*)xj}%CxXfnT&zsv60QP`0y^P+=hnBewp=0xR3@jpx5@W)_>BHaDB`>K_fYoS`8p; zH3{JGSmdSPe@zDcxD{A~$ew*aykNP6oo=I#RurB7IP&=Wz=8xT@+8=Q^eS#t8kl8R zMEze4kw-3y$oMRNStdW<0ufgfuJ}+|G98_PN+udxcX|J@Y7)(Y-jR~ zdZ5}*M^0A*{g{hNCjA9~=RaCrQ1k{Fl@CPo&bW({`!zcMMB`z9miAyFDDz&xFs-TI z=q9840qc3a5vlc00fSfF8~-`m8W!ZW@nSbM+5DIU4FGwy!z;p1?#HS%mH>WRXQRyK;nBOzG0nHmC zLh54%4?#y^wN~$cGcH`T>xG3uBTbyH0gy(Ih_kt$+|4rOi;w&MnX5=Cs@tl>j*H}- z>msBusfQugedX{{@uO1I0H?vKGBSg^toaG6lNNQ^fq03loMFgD9G7m^rp?gI@ z=~6$W3pBaMG%MHrDWqz!EJo{B&0T$fbr#2PKNUwae4jUMvXSJ1mnJ2wJY0gd#4KnpTe( zfCEda?MgsMZ9&IE8ohF!LC~y5g<_(n949*FuAJt747kzmk(mXKG$itMI}2+F*U=R! zM|jUHAn{h=xV2ryc@rJRRs1I?8CB%GDL}>rd)Ir<$^lF|ENzvz%am#Gh3J(Fz7Rcr zDtjP&N8aw=S1Z{|jK>g5QZHn8Sup$xKudA&9)a^QMTUMWl*}Kh^q|6IERnRR>k}U< zkFfK9CyR|laH#HOm<)%>GP7WQS~1i55)hA2bnQ22JBMa>Bb5B)h|1wxgJ=s|giI-XrhxbTme=Ty3h_Srbl`jQqmnrTlf?83ZrKz5OJ?Fl)V95+~&>r@2 zH&fha&d)e9wCt$I$G-hq(}~HLvmL@|XDN$+?N3>b0R*U7U|A4F#VAt$0DYn!)vMFk zIHWwy7W?<`b}Du~wX_3WU18E|cQy@t!XGYifvK4Cin%-_Lenr(*(J@eX#~edeTg-X zZ~jFt#BF)C30`Y=x0)sV3E}ny#j%!BLh;D<{lHCu9bd70gD-Ol@01*!d6LA9@QKua zqnm#`4mVBzr~mn?;>BsN>XYSk?+;iVvNr0OUd54KbES*f;0Ave?gd=}cIQxz)kn9| zcXYt#4e2w%BuHU$hhlNTyQ=(!WvwSx(?V}%A8klU3RDreo&K?O$=8I<{J~}9J=Fw? zs-32jge-4WSv|vM4{MVc?pzM=Qw*_xfj>7LzSLY20mgTnyfg5k05A4ST4+4+4AQ(N z(>_2yP`PAx><(^H>x8AyhoL);Oh7MJM1!z1i;9jeUt}k7QN;_h zEMitQJH|%)Ley6eM7|H=1`J%cjUDlJJS3GHv-QWz@6tKg%3K6ZmwS&v7Fp_l<7Pb< zgv2M6)*TP17raWC&H9w5QMxPBNwH?0d^Q7>1FFvPjXt~BU?t}7({$PgeKbt{x)g0F zOd|2^-hQktq2bUm(PE!nTMbb)lDQp)-e&G5k|_ON4~Y2LXzTCsyV zJ}@S}8poFYRA*jr8aL$yo{h9?-lG4btqf)ygkMvA^Rau&A2rl9D<#u^V8VI$3q*Z|P$W|4417|@7N|@Aj>Yl?;{rU*pQB_KiNTRxa*v=oE4Cq6= zC=^`k@^EO3cz9p7T1SA~EGpl&!@hc_CuX($@?Qv9z=-|lqRAwA zRpbzxzQ|rEY7^%6rfJ6VvjQ%%XbHYuy}tR2PT%~sWla18p{(}3L3gTeA|Hsw@Sn}w zr_OxuI7kAwablJ@@2Ow~IHnMGyu||I8NA(t>wKq}c@Rj7<0Da*i*P7t$c4?e{RPU; zI7vhCAD}DgZiYaAD#MW#JRu=)bCPrb&`aRG0f}>W!j~9hhg&b4&Gdr&BQB}D z3Q$rh$Td%+E+$M3*f6B5k7ONZy>U`djTK+~C`oU|0|kA5x|GT;nPJeJ%J6Rac?r!+ zQh{A5ILB?uKuJT_O^-@!k}|qL9Byig2D4`nSqVW-pHKmr&dv1tMlv%p!_7M8KNfd6 z$ShIsc67kp$uH3feO?y%E~F1i0*r!uW#$kOPD3}T-$=BlL!j#pMo5pYrF!o)oa=W+dBfP zJ#o{6ee+B`e#Iv;+w>TE`VthrRNDe>Ont)J=A6W9sCA0J1>W5%hcWXg(NC0yDg*|v zt=$<>&yG#Ga0%Xx>It9Ar^-XX3tG$BN}6K^v?LVrGomHObY$miitGuB|s`zvsNOCF+Su zD4Cak4~)Q5(+{afCbTc|@aI_fii-SflYRgWeZZ_t6uNN^e;X9O090gsB1acSPlYki zZiYyx%-zHP|4HBz$Wq-MoNVk;(QEuguzsD_^>TDbKo9kSn^O&(+u6vRnyR!x5NXwO zV{skuC&uapF_I8M@7v7BJt@W+0W|Iq~oZS-b!4#>1~yggBfSo>EP zNK8)nDs7uWAYh$oY2ej_g84Fdm{JQeP;x~}@ z02gn>O0~vG7R71D(X28Dz=kD4D!Xw`NvBz5-SV+8yxIe>+eqCU3U=e9bjv4!oBTU} zSVIjovc%%b5f9VGY@^+=Np9T0M=EHHVvCrN)h-*G#yq(rM5r5ZP&oMnJUfi=C-#UU z*KHsx!--eA+wh;OSPayb%Js*{(vX3&X(!WDk!_**qk>N(T1W&6X`;BqMgj~}ZhM;% zGi_)hg8>}2l6*waKkI~6GUR)v>L=-cH@>w@Mz-(|9v;8*ZPkv5g6u*Kzc3*?Vw#WZ z=FW{Q_{#*cmF(F#sMC{G;-=QSpz8gXDK3Jj@Ma0mEcPs!4& z)*8JBBo*BO2y6Q&4t*ci6^E%RRMWC{vj(!{N)k=@NlQln>+elNrM`WoXj}m4ey_q1 zx30rh8g*w>i&na}H9WCbMoj2`g95pn=tTliycbfWi*f)U>8YKtX$$Z;q)lsK;gWy0 zI?=Tcn6`na1wzdJ{*QO8lF5LS*7$h&Lzi0RD?u8`{u5P=j&kpqZ1tYV2x3%MN^+B&)O(aZo}P~872VW6p|gns?VKJ2U?BP2cil8sM)^%>g-X#l^> z3@cAP+5gOcfjGgwXu7}2L_Qf6-N_Whbnx07%tOnstU9P3Q zoPPL!ty3IllU<%+2JhwNNt)V^$iHk>4JNOyk$fWOlfQ3>U;|zTkUTy!VDrL9mY5hc z7Bh~_k!dYy_@+)*{51Zm$iMv@O5VVOaI@Ju*9=xub@I-AZZGVA+Hp1>4< zg1S2*2O!E=pU8;K?Ysdt7y$F{PLH3 z%DTN`C&=F(K7vdUKST5~>dk$w#C_H_MZFi!B(Z|oFo;A42G~3*5B@|<85y}0ZI+r) z6?lxXoc(bF_>U8RBol)S*xm@9m1sQ-M^igM=qpw&KxjY*gkR5#2$+KtldY!){DNNB z>;VBe@bo*yZ!49hYVr%aiS%i|w^C_T%^2Pm1dL-r@W)X_aM^)R%)2uUzaS? zh${vIt!8lD)HTu;h$huC@O+bkj`ZiFA7{d={`}KtqYR{Ue`I?Xc8X7<{lfF-X6kQO zhW%>|9nfcg+@2Qk($DxV(X9@#hPtqgj;tq2v~VS_3eFF~R>tVMi`fDl70NyIN#ZJD zbnoxLc>a1k3Z#PxyXg06v$uTsjHUL=G3xyPlAtz!uqYqhzB^Q-D4wWkPcYuUf>fsl zl)e``qJ0y8+984#V#8xg>p4#$)wd7$%@q%=l@^k6a{$3@t?;v*36mX9J$`}t}inF{$kD2J>ypR?CiR zA*h?bUdG~b&X6pZe2y3}Uc#Aj;P(4~-jJ2k-LK`i6>Aj&Pk@LGgaja)RT-1^C z{69(Dg`U17m4j1@D`m?b7TFB_>e1Na?8?HFa;+5fzB${KGWAiU4Gi;$7P7Cx?-9R$ zA zX7TP=Ho8ZeFeCbN*2{ug?9XwjLzH9aGx1I0o&?Mc)DL2M5QfdZrRp>>L%-J2l+2dE zIKGbRYE?z5;7J}}6BpV`-g)_R+5wr5P1hg^&?!3r#IyTniPPr}=9yFA9?@QZNlcU( zEt^jslcXfE+#5)+!(RyOdZgUWcW^n&}v6fyu?uP-f>_1n@!U z=(o|*!$XHUmu-uwZ-saO(f+fPZd*>f4! zY6;d`8#*6hX&`h-TF5~Bspd^WqxGK#)R9X+ZP)v}3}VEr$#ww1`PrbiASyEful+HT z#f>EEzP+Pk(kj*PYJFhLhrOF1%g%Qad27rNcH|d&so;>!gIe&RVp2SRA_Q!kKW^Z* z+&sAcjGgWjT~{MvIEpZzf5@><4jsdL2(f`7RX2tW?343R$j;N^>8ztTPXK&(21?t3 zf-EXGW(aav{3D#a4V>Rt=His|!zlXd+wH`5YCf30c+lzo-|kZar}$Suw!68BX27({ zMw=wuhmbM3S}&CL1h^P~`J!LL?R`gHTnI7Run$q)fTg9D7U$UZuuy6IUb!!2pAVAB zk29K$8nl0t3A&&ye-%o9C$1U+vUx8Wx?ISogf4dtL?lmfut)oEoJ{@A2w>wC&S$H& z!S%wpB(!RsLqWx}3w~}{+jTmX3chQPr-MWBU%+srGrF19{sIzzd`lr>vQT%&XJm()R*|r5P4rwDXj7S?c5bL+ zo(vq0U)HnZ67&y$H-aRxa2H-EK-2A=Qp@9x=AS{)7q}^>=&+~F`Hel=_B{ldH~Jk| zL#QVBlC*1Qe3d^We6*VI{-C$owEB0QS$;HROk?fj)PvaNQ4o>~Ol7&3dlPcUo3wr0&z$^P16rI41#U8=?^ob5kzj^+v4v z`JjKU{}2}0i>h7@@*KSR*zjgggGW=VPc39;i+J4Ip(k(DZNn~RKNpo+`KMmGg_$_? zQKaw&ycm9^ab#TQ1!;~KM>Al7pOTXT%D&wn*R=Le4c(DFrtJ=<++VBIC;N|VAa`py zt`!Q)pxrNj0=ltUjl>Y=V&B`L2+69Y=xYwb-+83S(=a}Yo4HjXfAq%JltsQVgmIPu z9D5FHgB-YkRt8qvq`g#UL#tYmLGw)l05T7AeN*G_N`H{+ys`A9Gj}P0IJjpUc~4kx zt%$rnr{+6xkm2C)+t~Xd1c6fNqFZz9kBCxA%@Cn~YHd&ws~vJ;%D1u`bCj{x{j zsNegI&=22Wo5K~bh9!Sg1m=AjDX_P47sgFF5ko)HsM;DtV`%czCR`yK3-3;tsx}&Z zm7jrsUfO8qDY7W=AOcd1HZ!h;ylyVJncvXKbWo%*t8tIuJ;M8&T%YQt4m?}DYvcp>qqdW5 zK}-zB5 z8##+Ft3a^|zjyz~h`06A4|4A~2QYyVcjZ4pu_Jk%(RJt|Tv(t7*Q23pq5|yzpSAv= zt7IH*K?~ClHB3U%1RnoJ=!vvTOQ8nUjS>v}g(@z+%2V9S6s4MG)j2VGlUmi!n@S>o zszBw{c0KCVeS*Rr{ZUQ}We3=aXGITjX;D*CE}o$Ikn9hsZn(|IFI4%3AHSRQ33fAH zpAdRu^r5;6P$QSgwOC(b?soXCL`BYu`dgokzcX8Q?@K(f)q`*=uN@5&Y26(jryo&V z=!dgzbbJ$ATSq5T8JmDc;nC=pnZkd6VBdSbF)CL@`*}f;gY8AG1aBf8gB+x1t?bPC z$Ed`yI)aCU@kXu&x0xNO=y`S=O(t)n3*!B-0C#pEZA@Vi2|U-R!4(KL-MJ{lC#Lop z2<*zNF*iro9GlaVhtQ_*I*oa_|1yKSoPujV-}xdsBL7tl4ExHDRIBas9ncnkE`1Er zO+Gw+^+>;8RhVHXcM(R0(I`rISDDVtVT+JpJ=)i~xT>z{AxD6W>=aH|ZHGcr)xYsY zT8!Is>B-#;i_8mzof=9w#%|<7TrAAASy7m?;_i7Q>*swmINps+w&`S$$=NuUbp zW6VHr)y&9=1tNg>D*z;Vj>m@M@pA5v>*mR?zS-8ghW2by^{e26x3%}72d^O^Z75sm zjMasKaECwGZS`DtL(+YJ)b@>lI!@;Cg;I!8WeP}y@k+~*wia3@sF{Bkf=BA)_ynqA z4t0oiY{rnC8zA<`oC^G^t=|nydI1+6@uO)$UoA~0yJLcKYGdm-au5MhjRRxf0#E<+ zPcj6OWolT0<4GzpuSxwzGs#Fn2rIH1xjr{;9D}%-zc1*2lk?k^!S9hN{HMno z7cvW1v8C(v!q^~c_*e;zLUL_KL0i^98C%=B~oD#D{SB=di;t|!?)Psqi zme0({0|&#W=QGZKWH-fKWX}fhA4AOFV8U<;L3+vDig)W|9%7pl8{KiJbgOiR_>KxU zY^f<0HKJZKMZ7R>tOf8Za_t=?BLiqq0#p{L>!7>W!B^-z27CkN6oMwFGX4r{j7e_+ ze$23ESdte1zVN|CC)*&UF4-KL?0KyOTCYfD0aH&MV-%Nvt<@_l1ufM=gH3(B+%ebN zcu@xV$E{6}MDzemZh0fvOCPJUR6mRa z%rfkNtsI0i=40&OjvU=nU=no<-@`s)W-R2yZM$8uf~VBLNgHo*L~k$n=$Y4~EC_%5 zj0nXYkr8lzlsRS1_2k;;-z{4FlltJnh$SM-gBG&Ty+L1bw&qX_TT3Hqf7SB?Lfcj% zc*_+v@p#KxG!LPIBa!^Kup=#u@cPfgye6_^89BEUAV~_oUEmm|pt6$eOE+zH{jNu{ zFRRAvVrmvFH4W7=u=;LyMFLq>bR@zyVQTK~7>Njf?b_4)+|a)uFG_#$6{ct4a`K7eb2pK1KRCstYmOO~I4bH7C-b}@E9Xm(~3 z#mv`#<8okGg@_M|Ko?%9bd}9{d5l+oyGn2M2V}<p z-;MLIebQj0iP< z!z;HCOdq^9cZUd`&BDk9qe@_!Y?1fqMu=kln3gs3nN4Nqj+okzNMq~Q$%a1oIzS8&JMp%?9HsNVGNC@hSWYsn z?hwh_L|?kvs(onF!~%A1nPE4^!TXed!2};sp@4Bc(mw$i+qz8SbCgz6C7!AAb$1ZqQ`xtB^@w_Ol`8WQOEsGER7+WenCL6jp*5xyRZMX5isiZFud)+9W(;KZ* zCyK&+L>Kv>G{G&E9)$Zl%I+9a`nzL45sWU0WrxjY&!e@PkCzJMz z*>T&Q2Gyy6>~ARx-zT@u+hOD=%2Pd%9QvC96=tKVnpmZG5*vRT^blTuX|+dfdku$F z27^ezTMiPrUlS`;G<&-caar3g-~TIq#aU2P>)wvsx+(AldxTQK`}e_0X-eb(YK$02 z*6JAZf&+;m*o;2N9A$Ju>v*QdbJ2b?5o{foj?~Mj^-kpI^q}NmvEYCh8YS#Vz1sJo z5o|V=M{ujs+(Ph2EI)~Vbq}|4{b`q$+GOx!%>y5VRM_N-(Az_2c9KALEbCOv29?UP z9Q7TO+B#PT7t8$&WoMIDBPh=Vsg6P{fRLyZ<8o+B{l2dXAcr~Y9Ze_37E%Q#l^p;=zo#?+#w?wPSk|79%5eq4IU!mw08`1s^|m8)J|FNW2au~T`( z`C7pYMTG?<;XR{*-Ddy8X+Dw#($!EdF*mUEkqurp`EZESO4JHGg0P0m*;$TK$^;~u^>LTU0buI&VD;TI?f`v4q;uN=; zUGVs0nvOQWAVcpSg>OW>`q4+?WF0Vfr5lWbY=qB#^=OQB3^t<-`x1alRsLQs>45jRxr~Zn$8i+l>v>|OI3lC zm7GK3q{`nlwsG{smfoW@I`T62pWw-V)7*fAuY7T@nr!peG3=5NMg4%JA5LY7W!?Y$GHZ zf+Tj+DM)>0_TID?J2in!kO2+)n>=l`fvlMTx*! z8PMuR){}vbCH===-GQ1TZu2Zqpyn?{xiMd5XKaY1WYf`ZNOndeSnBrtG9Gn9Df;Pj zT+9p9=F4uHc5s_W+yC3sN>cNb%#jW{L0x3Bx}0c8$uRa(!+vL+{D%)w)Ao*1pfoRk z-NcVG)3h;{+KKXJtEl9h-i2Oce@k>7#^?Cp>F8I7M6ON8QDu(4Tc*`{5+DNQBA*Aj zusK(&fC<0@Ly-LZE7!!N6zyx2DB<0QwdBh@-Dl7HHM?F6f=EwtimwkJ9ck1Y0zR~R-nWDG0XHp zr(J&L&9>iU?XuIiy7CTRaHf%zoyO~y_P5r6vYl#Ei1FCE$BV*TK|bZsOT`?2Dwbe; zoO9J=ZWW|oVpi(wNImi0utY6tbJ_OxT52i+Di*Xh*u2|l zZ;^%H#!qP36X=2_tb#590U}R-T7!;h0zE52wwcE6Tj$%?hcg1{NT~W&Ys|E8{L{-f z!8#dqgsGH}*GC_QlUb8rt5$tnTBk8Q!-z+~$5uod6?@oYK)6zD5vCO|!5P9o=uodb<-gF;# zR!+8I^e6Rp%r_~EEqM?CD_M1d!DIYa;~*}L1&6kaHarUYS*k}`BT^db*|ZM8kO^m%7X(z>NZ0^jT69D;W@Q$gqOErBTwmE0?0EE%~b6UnuCaL zaNhEZ^KaRPDmiY;En^TkxSGPUQ33=}U3BymIR=(OvRp=Z`ddxos(Fy7AMwTrA z{}j8n@vP#S{@P)GdyazUq>Qbd`tXpjUTfHMcfKTyYIjTd(#$B+ML(Aqj4IqL47hCOHRkfg7D1f>9KVB4Ra5BE)>G|&jD+(IEP5!K{++K)CXKc@ z)IR^;>=dA;Uu}z1(~0hxeJ<1B$v9*7_WWofKqPk0vx-NY;C#s}R-TyIFPYBaDMsO| zLlripr@0r!36j7Z*)biM9MjRwvPEB%Q@(jI38}Oh-#t-b{}YeYuzS z+%gC>fE5&f&d0sL5Izg`HYB8Bt`t8}t(Ll#U1+;+a*}VNr$h%2Y^lAV3+rvWSPA#= zdh$)#eu`n;3tnCl>)qr8{zes}@A;A&=_l*Td3xeX(xesq9Qq`=BF@L#^qx>1*OQ!G zLJ7Ri9%zW1Jhq7a9SmiEa_A4y%Gi{H)20{@2 zKke#wx}iwhVt}Sql3cb&du;5Q{0Kcxyw_d-l*`J7C6;iLw)2ivPh3IHk^<8M6m1W} zAABZgxp>_ue|ZdGl2mecJH0lkyWzk)qog&+bdXt3h?<*ELZL$R+$?QCgB@<72y+wh ziBrU90}ECdR=w_OIqiM(BAtx-JJA)*^e+fgE-OxP+~U$zq{6CHVNixV*M;VxJskf_ zODE56I5oynA^-O#GT!Tr8}^wT-AIzW{e(@%p02p>f9+Uhr;JY-GQ9yo#dxv=QOAjQ z1)S;wHX{<+)Pd9k#1q94>o;>utvxoq2w*~QzO$QzYxop7cYee|m5}S6H=uhib8unU zqwTadqf>B|mGDa9J-19_72Z2#Y@#r4Z*GaW5?CelA}6Fhw49DdvL5WO^h^fGs!rYP5S$7yH$ zmA675+HP?xk~)MYzsXfHat=Wlq#^Cf0_3IF5q$>_k{g$fyq8r8>a_N5c^7NZGWSy2 zdJfmRgp9<6Un|xSQF&URg@zXR-(k-ik}^P3e~8`Crg^SIsg|4R9SMNe+eEWysnHQH z4a87|@|$lvXRYs9e|2_r7RxYsG-&a~Y#BG*l&R$64k_nre6o_!u3){}BRrfd)QAVr zHko~@>g%mn&l+d%6v{@&hW~^HhVOJQYB^<*j2Rxd-G$CVb2*O8c6j4cO9V|X$BEO( ze_bZ`4Y~-^wf;-Cw1s)MuxqLJf`?%E;Y+}43A{;+C@pH1n45)2`@uGe()n^_C+CAQ za*=L`1BI-Eu8KZ^45#s{_J}Q}SC&@~q;1MZ=NS{O%@qrYShgq^2By~7g)qgu&xN3* zf(5b_wuZnNU+){98iJGRj!>d07i9?he`H_l3uN=#`SPz~1kC$y0nA`9;xtAKFaD5j zN-UmfUd8&#MH0KQOc1m^4!f#NnG!ST)$^1om-Q?4-kBLnzVLW<{LFG1n`+A8d6CFq z(PiRbNUk3URN(1d84!gr@xc53!q-Qla1kMq@ew~VZ`!i$77`!!3QYt?qR9)afALi~ zx$k|buB^?8IvcY^&u#aNPf0*F*Vv*6o)apyf6Z>mb4qVU%sPv@oTgJs>mea z6BuEt&J@HW1T#hLl=aK?pg=K1)p@mHBd{KM(RH5DEZK?#b^pI+SA}b*-%^b0@N0xQ z;**95*BGi$42aO{3)u6o>0kCsf9g?=UXw{IjU`IvfoSnj+YopQG%CZ+JOzJiqo$o2Bl#{eD63K3?-w6vQK!Si-uHhQ`bjWi zl2ut0MhTR?R>rYNNCLy@kK0A~r&e@V+fbwtSHq7}x2_+p zS|)FR)q>sK642IMM{cgGEYu!W*0a4i?62jaf2Z1T0GWASj{NAnYFJd-nQ^z@Xs?GU zRgH!UTMLOD;d|WYr)BS1RhvQ~YwrhW`sE2T0xD^B!E9P=6x5pwJP^@?Q#Kln4jE6! zzZE5)k{FhZGnjYBe>ynoLzWE{545vje0wFXtTeRfmumBy$HR6fcER2lt zTxFY%gY@Z-iP^hd!FK>6_+Fg~0ke#Mfp?hs73`>bC_b(uf2h+Gt*Na%CP0cRqQ!HY zDOv8U`v`S+Xm%ZwjB}7+EkUeflwub~H03z0Rur6qVzM)?EQnJh%?K%=W`sx})O23p zd)=@1dxW#Y!qlE={jTnX!n%mwPV6ibeJy<)BbbWp1#QtK^ny)%@er0TBq(_|#@JO| zupI~%oTwf=e>K|;E1MBLMUuR_8loVuDr7TnfLWUVd@R%6KOxOc&j9PU)G0#W153y$ zU(E2XYQ_Qw;9@ZbY&{;iNEDCit$I36e}n)9{AxE4*ziOasN_e;z_}P!Q9ot?PQ6%sJ}Vm%PaC zk?L~qA{LnuzVu6_l5qE&(;KvFDp%9pMe1L+z^VMec?6r^e{Qb*ys8zruN7Ko)Jb3h%UmIg$8j!YQ*k>40*>X9fbpKY7z8eMtMciiN-!xK*{jf=Inyi zoq)A=Y_9;^9zCx}4WVTS);j-=L&{F~jAoNz0KAuiC2#`uh{=H6Pp8sF6O{s}XKv+- zf5dXfgZa%KVxTnn@bq82`Xg<|Y+&V;gV+b(wsBV~*HLNIT9JUU-#pMHkkrbND9drmpb!vczbR5P;_z^R2df}L`@B`;AEvn9B`EnfBy8_?EDH%7VMo6?H12be((s1jp%6Cr2NicWiXc8EwoY(bHx|!5uJ!Pk7j1oAHE@_EwQ>dOd>BgZ3(-RS0mhcpArY3;ZtJU`Qt8U0pEyyPY4on(L$}{=D(kZ$k~)5BE!AA&tgb`S6;K0E9&XB_WLBjkZ;@WH0?R|$}baa`#s&^ zI!z!H!!HSIbXPZ7<`oRGRTcwSMunOB@tPx?{?Lx#7#k#)*%?Uv@0N2R%gQ`jOX%+9%qHvnD1~3n~8d2VgO?z2BUNLimA*Pg?Ye zsG%dWn*-G88p_c;j;2V7e>$uZIoZqv$pY1oR8yZQ>#_$=zT2Q;#dCZfMK3j)5`o2CeHVGQpWJ8fHLVN@b{I9=qN( zp-#>Gr@Ej+hZyman3C{|(s8w#_R%TWpum_jOq#$Sf~PeG$LoO`e-J(`c)j+0yt^=>6np?Yb)Bqe6xTB*bqBo_7h+r~1;efv zsZ!ilxSppze@WuP&MPe+lzqOe>JPKRyT#BrR-@(Pk>5S6fY5H30YQ0&qb8OzJM2^4 zqB45UMW1W}CQY2oe+FKY<>#}i3Ht0yBh$lXojOUwQ}2!`NB|JNnOxqRaX`7vMhwe$ z*~zp7@z7Qh2olH%&aQIqWrACajl<5iP34Gn(bLJx_H zxE8X-y~P+abjRMb2RX`T--5uP?1fMJhipY##&EDCP+O`hMR@B3flPqI zpYS!aj!gu7Br|aG-wI2Yd9(Pth5C>}JpXP3_@jzTeZ!BofTGP`ajf9cJ%$Rq6L08vbR8<-q`dNq`aLNZ(di$OGJDdBD?Z3{4Z}xi# zNFevq#7}I@lEw8Z#=%FdEKn)k2|E0-swf8lLI+ z3)1jg)bm=E8=Gn~N zf{4=-^`h*!O?$kb`~$C|Ai;xITuYaAy}abq=N-k-p{vO=DqkW1ho=qrO`*EgeDN8I zt=cs3(pCH;3Jp@OiPBJRzU;9<+S0+Px`B=1=`SH*@R}5+9WDO&SbrSidK zy&W9B2z^6mkcuk4P-L_GWL4}9go#$PJ-2W~eG`!9DOh3;xr#rJ38IdE)BTqM8wtkLSl~OGU|N}-k}zM2X!b#te?2%~ zO!}r-;A_Nd6k>{bsydqdi9yk_^UT2kOKb>cSI@F{0yZjt>d{3+j|xmVg|S0LQc@Pb zh#x+2nMU-N!}<cPX`*BTfq6>4@!M6ekE!dqAre1m z-YbjrDl{BQT+a#0Lk4`qD7vp^S2nkn590krF}&-a1gKN^;TlOeuAETBM`U5!h{ zelYBGg|xf91xZ1N%`akO=)^TH;o%YK$eVp^vEXHXQYPF8Htxu`--q~`EIf9o5(EuU z@bcwq^dsNo?)#JGvb3&Ne>t&UR*DOQ=|+kayiRLrjSq2+LEUIkA z&A^e51k7Wrg?8qfTPk^jEmRiS@N74*FSu*~FJQ)FXH_GPWNFS=*U~8i2itr52aoROW#o49 z$K*_|=j!bxiPMEDe}P!X&06t_sUMZ}S)BDEyYZUKth&CJfO5u!Sx2ia0__MKn>>BT3>%2j%*)BYS z#LZA~0%Y-lxnt6K6CdyDnFVjj`^4hSkwe@TOyel4NSth;A2Cbky{6vX4Wi!y|>7y^l+4fla|hADbsW|Q8mU#-7e%Dwl&e4;g9ZjqB?+3?W8 zw6qjlLVRe4`rfZK40@Btb-r$YuUqYG1c&1d#7y%8#Ad->aGaKMeU5 zRn{zNY}o?h5rkMK;_Q?B0k(IYjXf-18OgZq$icV+tH}wR5UE;&Aig zRTl9ys1hb$T0Ivm5(9WuL3Fn<%`zUES6k1-krjcewljdN`I1ogYIBYU*zV}xlwcDD zC0%|W0^;-~d&hr=n%}tGGzt5MTt6mR_&W?cc zi`z$CCtNms!VXTr9fB><(V#69&=~(NHntT^MRCfh6j=qF6?|v(P+K83NfJcrunzvV z6#yv5U=d*o`{{ks7DH*rJdM|{tXrNL;;O*IDAqsQ$HFpOU}v!kZxr|enE`laZFX*? ze~XG-02uk*WuI<*YYRv~U`(PnMwj-SCFGGDej!js=oU@sDB7H$vrvnTAeFI_Q)cjs zcy=}}?`#E7E*~**K^%r$o|Zp7yFHPZ4wLzk%wBJl~V{*;#f=gMn}(7B?K? zN@*iCv2P6G*Ypw7DL#SxW7r*SJ57_+fAmV>{8jk)JF2KbGM>*b1bK4wAnxB7>r_%V z?lb`J@mB5ZOiOzB_7Z*;&lJ_zqJq0fMt;jQxAqci1 zYOrr~Nh04HSDX_*Uw z-V{|d?^qiVfCzrwi}${TI3lEpf20#Fg;&rX{mX*mB0KVR7xsLM11~~~&PU#Vx7oFx z*+=zsoxq=rlVYsN z!u}*N)U6$BJA374LB_*lW*I0hG1@h&Goq5wqOAQP#iQy^^a?krhs%fsV2>T+^ zJrLnyR714$%wj<~d1FyxjpPKRTMS#j0G8jkh70v9^~>8!uZT`Ce`eUoOwXc+*k9d! zDG5b&Oc*4fMM0~?Jma}ZIiV@l^m`MVC^PyeqXyBc#*mZW`czOgp4!XU6I-?t$-N-3 z7hNlCywx|Vz}biMTaGyELt>pKz-Rq0#EQ;5PlAl4EU9wV{a4o|m8hO1D=ni@e9*(C z8$wt5mwD|Dq&)G6e=YtYtXZqYOmaus*D&}nsvVqtf-OL)=O#e6=$KX7E~>$+Ao~)0 zVipNY-TlWN)#UwBd+c!yeR0US>FKjTEudkiOGRr{r#l(NCf6WRsuu2OS=3IqU3n^rbs=%?jZngA# zY?fH3ja6X@qxBzveXWXG*2B%Hg7xrs&Jl`6FDJ5=dU8A3cFMv>zArc;he%^eo0yG@ z=r?Ks!DpAnfAo(#lIFU}X%^6PIok@kjZ3++FaX;&Y~QJW*fSzQuNr0?9am`sC0&7Z z8-1XgqKqPDg0T zSHe-3YQb~lFYkWK3IOUiLv3t#qcNigY8)Zm^M{JsFqB{bs{`6M=1R3K=AMrB341jv z9eST{BddF-HpE9^=?TETp0&+RTO4<0gk!UZCkinsQVE_!+F%g3rJz=n%?ra*Fa+9M zTiF^qe>JP`xqCd~0hmW!qRI<{ezzCPmM>r3L ze-bH9*a69XHa$QR8M#_C>$#`F8(Oc-xW=e%ymL!dO-D)_aFT|+xe6sB(Pbmk1yHKw zP%B~V6Exa-%X|ZMCs+|+)WepQe?BRGT)WEqt=g$#x%52E<9=Fhrxe#gsQ&7c zr_@kGtw~1ibYM{Ei3X2s)+=OZ7caR`e?nZ-;&P+zv-omyzC&0UEnh(Xa0Fl7W6@2eAfVl6); zZw;QSQF#s*@z4djtlE(63Q49ixrU7;Nn6RqOX4JMmPp|HKeT{blq`h1tNHMuqlc8 zQ=n<;1>~8O-hk>fLVW1z1Y3?Pe^dO&nEv8hE0cz5NEEH`kH*`<@SY#DD5B$24dH6C6AVNhrOB=J#smcTYi|-5 z-k<20sy=cFg!_q?;H$-?4wL^H+-pHh{~zhsQesX$h*ln@&(xZ0QHUhte;WT$f6gBn zRT0xra^O1c1=-NgPZ>R8$aj1NMR|FnImO!4feIDk%PZ=@S=M@=~UfHj)&BG-z?j$Dh2w2SzRxMj@~h z6MW_Y>UEt}Gk?KY2N3>lH=doDUp1vrkxq!-xNL=UmPD%V_L?;87`l8Oj_d{=w)av~ zG^Au^Q#5PxkqKJ^?t5-goNJU0gMz7xA&43reg zr@{KOs*O;+f0L1nN`HMMFO#Hw`>B<^>vu5wm4()w;Bbq!N+W3?{oYCP( zgIrN4#(w$d{b$G@wQZO47_Nd8(H%j|Wizyl3m zJkMAxe_Rd*U*k9GRvcYz^aqqc!iTm+^z;mcpc%A48sCu&9YjZWq3;?)XP^~2zz^4A z4#zO8|A3hY=TPR+80h$IWVF7A?4B2{O%R^dQAK;*=c<}gDBRbWh&$jrv$$Gu{`Az0 zJ0cAmWpm}n61>3H+ZZ}bf*|9eGnp35(gl#;e-UVTvT_t}a*t)OnRlw6Axhsi3Th(u zTA5<{KMVNnUcaLwq>E1_DWP2*Rn|VlK}q%>WLeW49!t)pG6qJ=fe3sjMlD7EC$ZJL zN@ZoCCeofzD4sxo7!^939wcuTtCHc}@{J<7Oa=CJgr2n6lALrAL{MJmZDBIayG+wN zfAAd%z@MwW8PfEc$cZA|$BcA`H%@k~R;>_)g@!n0%u$S&r5{EKQ2yrl# z$i}_Tg~Y}Ix%-`0bGd6TU#FA@H%E@F-QE>^X!sNQ!%|GpI0;t~R#QJ)JJ3+^POYIm zHNcHQ6~WMc#{rtl8g(mDh2wRi!V(Uze<&yJ?fYhIwul2cHL2#>(p~q=BX!0^{;_fj zVa(hfMC{G-sB5l2G3-0~0-FDAXg7GfbtkUo{KN07Oi--J!n@tx2I2;kT*L{XT@;Lzj--+o!-{6m5m<_PQH8nNBVe-(tF zSk#O+4vJO&e$SO*D=*6AvrlQHIuyPjTOLI+N0ztMPudw7p0=$A8UQTK(s4W+akGd^ zAe+K_x!0G1VaIYl6?d5AgtB2IhccH$@gg5a(2qE_*a|DUw!fQ7pu7oH+^1b$(XKLR z!S!V9HBNv#@I!lX*(+}X1)f9se~|V9o& zkQ=(j^^R`!psW%4QYlD{9=cl=U18z&mPy`p!KLF;Qj;Ml_TJu4dsX2#f6jG?D79p4 z%Rfb*F^*UEtZRW68k}R?qVt3m4E4DtelJ#0@)pGkc==`mA}I@)f51{C^o>zuL@XNp z>TMSk7inNY?=8u9(bwWAZ2D!YbnG~}gq^(c8RTo@ zQ+r09{58MP{6wnG?wtgL3{{o&E>1^q8VDgsPmwiRHmKzHPd2TaIAqt6Jx^vu?_+;ShEm9nJoUpz%Gou2Q zk(S8liG@OTW3Ll8TW@o8Ahe0G^wdZm(X%Mf{URscVc+Av{Dq9%9)JT9@ z$jp&a3{NJlYlN%b4ex&;iX^K9h)0lYoCNC9sG^k67zZ=Nflp1ZgK znZDv`ST(^WX-suY;_BN`kqZ-@BaLB*E_W&-7nf5|eZ1{8d~qGrf|m*Wr%p^cNp^v7 zJ5J_WiG?C8gTF3DIg+C222(vQbg6h0ky=mGDvBGoQKLzXO_!)uMW;`U8|AUQ>v|8> z1U9(!9i$X?V{Z9+c9zLo%8UZf`Imrb@I6CN~rlX=9evZr*B&iCYuGR-lo z_pNTGCMT7`?>N2=)E>&ZA-I`9zs2O)t-;WDix!F&k)d$*sKlnjU?Uj;`QoXni{^y+wY-sIYQWxn2GF55@E!* ztFOQ|MB}wL=I9yf)L2J&pboThM?FBvdN-{Qbxu4!_$V4jk>~C_9P8?tl^Pa(NO>=h zOEExFq417tMU41El<%c13(x_OaNVH^e_oMN4V+B5M9Hbz@qeQ;r4J$WF8}F1XsYZp zwVE`3_qxqkpE3TDXVFf_fIh2L1G5Ll-^z{sJQ9gC@3o9Vjlsx#S^iRgZFxL{<+sL*K;6qq+reIea4QWG=wm>j140v09hE20;e|KDK z@s0uq#q!lBKG&mC$m;n!YK^E0DBrV`?6Zp3O==c^Lnhl0&YFy+m%cnw`(B@e^@~sH&8?OC3oT{HcDIE_Xc9=-{l{=KyVYbSbw2F z(5KmFj;S4`JF}Ed0iP?()(3adoaqbk=B9;3z6O{gItCjj9VSK~+n+YsYZJZID5EFW zcb6o;e6x<~qdP{7iv?m$-^4~C&xAZ$Vgsp&^$4D2;VitV$6M69^&0))f5JQ!+9ExmpAN+m=iGB!V^ z8LVPgIRSB~_u2^@iy6qxbsjkNk*0(lTU4w%rqq17pJ*aTbdC(0Y`K1?C@Jv1b4YD{H`O5ScMF-1Qe=!9{`IcPrDe^|( z@aH<{Ez@DLmN$M&eZy1^)dJaxr?fxf+=jlSr=h~6FUmymqe`#Ev>!a5eE@Ma&e0j)J z>04EVHy+ah)7!ST%H~3j_J+a0>Jp|9ne8J+7cd&Kn_Oil!Z(Zya@}X`#h<1R27K!B z^#Nla<)J>4)w5JVQX(%XT3T?tEC)UQ6&sx+o)Pm4EYz{v-ji*Fc9?C*W54)=jraP} zBsB2>FkG$Ae}s9qZy#sqY~a&7h&&s#kxpn=usr+2XhCQ(tp8TR&DKbOPmUW;!$U_j8cwdm zD+oXp8j4QKu@3bYaPIa+^wpmVGBQd>r!f4ma5KIze;(UeBc;c=95De>SNeGNCRS#9 z&pPA8XK07Ivg==sM!tr7L6!_a5MA1@FbS2Wkf&2{rsIBaD|v6_*M7ALrvwBI5~nRV z%3hNv-ZCyobRFF)IPy~qzhCxAt^klk?%OPbwo&BwOcj@4~(Sx3zd_ zul;@%fBQ3salufU65n|Uo`8Us)HIP9qrqISq|B`jKqPlQPZ!(V(GoAVhW(Lu@?Y4Y z#+wuNzJW_~GE~XrH>LFLfWe5y3XsPVDdz^V5xj`Ss-mn%k$N&W@1ZFxPkw7SV)S9| z{;ICs4)|(rC9%H#omgz#74Y#$Rrw_h5dKxye{bsMK!g$@M+|PBp$BLAyfUx{C7PgD zVRa0uM|)CLx~j!-k(Tx&DR8_lJ6Xbmb9G=cw163UD|}8Kna^^5n%*`yB4f)F%a8b5NQV&^PcMCV+DVPV#M(dem%6u zb%CVy9}gt2-ESZADwBs*#t1C0DM%^|e@$he2fx)Xc7T52m}|@p>6qg1_!1xEGv4!X zEBK?|$Zdio6}mI^k|7=WaC%TBP9f-IOC!mj7yXr8P7Jt6?|3hQ3sOQx<~{y>bf%K} z1H%HchBw@*<^N0 zjz<@Rp%JK;f@sp&21OZkhQN_DqY$@g3e&2Iq%}vdyalH{z;Y8v|4+eqe;`TBgM*M* zM1TfT{o@+Yr8}&Qm{3h`raN=b zI(EN*jN2E8II&3 zIqtR(wN-z^GGbNE&+n^w_mVfNYYBzXs%jD8A(c1EI4w$Ysy!=rR}M)d4Z`%{`u?m3 zi`oUV30oXIuH?=`l<4f1`Z_6giLPydi+M zvflW1|Dy||mgzeq0_qAFsOn>zkKq;^_^^l@#GxD*4DMv z;eJh=C3AcaVvSZ128y`3Y*DR>ErWirKBIx=l>#%iLvm2dw+`v%-uL6kGcN{#m%4jx zakh84rhPK`meanae~OgtdabF(>av#IH7qXNU9V9we^z>ccI6`nn8^^n=}$ndv63V` zv(J;s4j%BpLbxU*6CqC40f@d1wqwGxDKHw`j?gMny>1O!$eIh>W^}&E=CSc z%#F0#z$3UMfAF%T_n=$9_MWXNIU@VlbEl7%(8Q%i7pt_2^c%)g8bi-#03~E|tS#~- z({2weIB~ZQawH{l0Nv4B>7xe&X+?t7XlHA43DR13pX-DZ*ntx1-CrmNqCz5c@`VVP zgHUV7r;5cB{w?rxr~ey<7%H?E6#x|Y{$HBBi^u8Kf5FsWD?WRl(ox9f`+jslYZo4q z+i3olO4YXWA4f%DK*``ahvx{o0e~LjL512c#N;_rl`s*D(E`2WE$pst!C zSy7xze{-Dwy~YBTa0(_`!beSi^;I@7x_R}~h;Y68*^mxqTwH-Id9)hu8wqAITLg*$ z)+2@ycsxidNVM+0g56ZE0H`n>G4lzJ@hwTbignB`m(a5&&)uC@#eS)sPuf}!eiVm5 z)08~GxQd6n?U4AG31u4}YD;h-Y>Q*j!J*f7e}6NKn%W1C!Y59=pTOIgLQ?ZZ3^xUK zVNVxJrRJ;c^e#|NKEIxA=@@KlaqdaJ&W1#E!>6TW6D;~Te6d1=d>=2*uzFi(Bc<>p zA(_r%57&m9jNqE$j0N^Z|KvYSYl_`lA1#fu860VBDph%mp2PKsXzOLX1dR=e>PQ>0 ze~)H&z=+&OA=dxMQk;>Z?S<|<3j_vmkqA%pKkQU zg(<7Z_a494UptX(`!!&e1uWkrT}D)re=}^wn#eEvoOo&1UTd|f*)YrV&-Kc~7W+QU zlE^gXydBR`rTgzej^~>2?|s^2uAd6Np`fE11|q7rH@T`au~sVO8aROVx9)cTh;@EF zT2R2Y-McF^_-mej;13{1PkF`;E0o_W;NAif;u&*;vptsd(_L7!4W~+gpguxTe{!(k z9L+((7lUQ3ezaWlhmRspjAE=@LFy^a!_GX(?ddtERp=^to1X{gHS~5*>7Q1hz-jeR zyRtA(T7}_=Sj|P=uF;wD1{fIaw~)iESzXe74OFZ=$!T&EUvnVXzG!DA`(*bn72%$Z z#k6C5>+8_a&uxlVbrEef=J-V)e+su|C=SPVrPW+H~K(OU1?HMY~ zZ$+|?Wc0ezs>kN)VlHMK@G`VIkSA{q~=baocFrfJViq!6~*vck(Mq7H79^GXInvE5U|fIvKy zz8cy!gksZPhPg+IyC3!qZkG2iAlDN2W0kR#WPUwjUw#!Va9rX#I!-nzTNA!FHzW%L z;I+x_2lCAzV(!j9e_o5VdO>a#=?(F*pPUwSIK@0|a8hn}SogMS!aX^@H({493B65L z=|m(X%UATOWOg@!>#9+tk{1&D@-eKIU$cF^@EAESTy}EQdhjG+^IF@Y1P&A+Y4ax5 zhlR?(ESH;tjZ$Dym@LS!sQQhzUWEvr4D^EpY-Vo!4dEdGfk-AkHK96@Q5s zG9JE1U9%CXFD&BKT%NXEbacNouWiK(c~1$$*YPmO&Ix`ol(`L`-PYe7^bi4`g%T3S zQe2o2g7ObDf8g%=269<&r3$!Q%iHUZJ5f)y*u8!(hQAvY%}cTsabxe!&E2057cym} z9}Mj5clQPLkB;VC#kCLl_MDabWiwM8Di(!A6Q)0!J)33e5RSsdbud=Y<06lE6=>df zw-le**~p06vE-kIb_T!ZCVV-={eesj@jESEZI-_(f6lyp(D;l#6bHnVkA&qLOQZ3r9?|#vApL5PJi*5NlA76-e-mWwx@Ho@@n?W ze6|pKf7|PxVkv+@Zzl%Vm|n_?*K0~!ACTk$e6r?2%CnB|oDfzO-X%-OS1*WbF-HB~ zG78sJ((3qF@`itpoKClQHG4CNC}_HH;Qb0{vf0VKjGJqD&ub~&)lpdcfvvH)B}8i1 z)bh(u*yVqf!1kn>mwMnkfjvro(T9n-KT(5QfBW2CT!gHf_=Tf~7FceQXO2?LfG=SF zgCg+f*S>!>-+eP#IPp!Wz@vKR`Venir6m{j-f$PFopLoCUDOUfp!k-Hi2dQ^Mujq; z8{aUA))t0c5n^}9Y5K~;X1)?pf0ea^SVP2zl8Ns$^N^)GUBGt<&EUGyG03p7~JSJH?sJJ3y0xfr)r~G zlFbmGLbAC-4QtKtfT2(&SXLP|!A*uae~t-^FfD_aT*0_L0g3KRl2O_qJ?1S1zG}rH z(w2WRH^gHQ1e{CzS}pMHda7F>iKRQ-vt;3(ecd&^(zsg(-TWq=nR5JCzts-ZRrQ6w zHD-qfyL_Mxt785FZ->+&TTp-qaW44VR4=8d-f?3LEt%(Ye+FB1 zUO2*Voeiusntao@&!fad9_w9*<`GuX%ERT?=!bf8N(r}Ae|C-Pr(J&hX><(_nPnTX7$WPj^VTV*t47tHz#C_X zvP5`6VEova?o|ndkiS#@3S@wEn(`$7{QqWX(nOn&ZT*{lmkwc{1xQSe&*?6Z0bx&*#!D?XzE(aA+5xWg zHlzS#M%M%1p0S(lFpPD|f9hWTy!$9wGt*HSZB!boEAltc)fml%j<`P*49aJ1+XZDA zEkYMUVPY)d_*ORpBHOyS8U?1DQW=XU*NAp=iXDZifseq?O3H@b$CEBsMX@is>vFz? zR(CmCe*#BUSPSRm+F)i0K$s@H%2ODt{vd2lcFz;F6O~CNDMj-Ne|LeAR!K>k)?wf%AuH5sygR zM!x>iy>}boc~f?mxKI$X|7Co0G-} zf0RiBDU&GkLQ4Da-kZ`q+Sa6}D? zgl;ZK=R4>g8u>#6k56Pf_hxO$8iNN@@(n-zWc^e4YM*@5cP+xLyRHP@YyzkL%9s$P z{hYGJvz&>lmAuazpU8jawI2gnFFPJf;uCWA%b*9dLH5cOhJPYx_FGr=_;5xwo=%%c z$Y&&ywMs?i7RjL*ElmqoyTexX^1_pr;T@LMjnoXwQl4xib$$77d!K8uUpqYyfM9`M6whj&( znd--p>lGc#MJ536uV`nh*h_OpggR># zgB^20Wq*i+hA=;D_2?`Jd{MqeCu6bDdrA6BiZemaDD_`=6de!)bn#cF6+M(v=Q-xG zgqgV_;XT=0jeHB95s4`Pn>G3DAkhH(h9zH=v~0U!8j)5jq-n@#5W#yYkl2ZZerVVy zKpbzwiQUAUbp^RJ(Uur4A2hCq9v;K{No`_B_{Tdlj1O-#GF$gHGbEZ3Pi*YU!j(X(Dq z*?;_~F-nL(20I#hkR)@o@wk24Vs)0EsQJn+FDGYo0*}C^CVtK%U85e~KD=kh7ey3D z1?a#OT!#p5dQ)N`AZEC};_-^POF2>8<$v%~Vea4a9j)9{e*^g(g2H|~8nJszXL9&S zt^fFuKh|*+8pD!yveGLVc?wK7S_ZW+IZu$L{2p`Z(x9^`ya{wkI<@n)h+WN|i&JWB za*?%jMD0zlmQ>i_e#alkh;$f)nI4`PK_G6VFz?(ZL4Fl>zPW$^En$i1garYiLS7k}h(VKq*GJAWkz82@W^ZKge+vON}5aASF3(M#hZM9h_H?OCqnfk!`H zMGlgT6y*J7^Nym~Xjubznb!|r_AMcK;0M;f-3mh=7ILTGi8`a}_zsb7qXULI=dlzc zlA9RD26A_Q)eHRD@_gjx9X>$RJPLSw`(A7gvXX)NPr%PcPyNLoYkzJEhN5~`TYEHW zeZ8!SfD7$fPw-F2U=@mq@qY3G>l&I*BOs`=!noCI!vb#OtB!JxeAN*~)6BY8(K5|{ zpy%J$w5eV@qB5Q<(0`Ol{{uAio~pAdL>8FBGQ;6PVO!M8V9CF2G3R%$H zSk|ENkF4?9fPzx|^qce|^LaJAacn?X1mhlpf^fMN10L#ZE#|HU?#-li#lhj>RB{-m zp58HK*HO-eC4cVsT~`Pcg~{>^B#~W+0L6WXoQLYNYb5*_6tWU5j8ssSP$UFC6DuwH zw>xhzqUy1JCuD9(wV3cZvgg2&-p-Sz9FSc97dhvN8?;N~;-7p+fEZ++epbKH&ug~i zW2b3d=Bu-2u@h7PeXfphQRZ#>(H{)?fpgDjGE)WmVt4xe%Zj03*WYiU@gt-`e_W^*R>pC1~=zm)2Wq<^_Q&8%nubeY|bHQsnAG2!% zKCIX5AM!M9#VVa>-zy4@TQ2td^jzj#hWMGey3(8f=S-`4&W2ys|Dlo$tu;~6czyjl zlNmAhjeo@uW6wrXNwD4CmzAGdaatdzLW$CuovuGfm2S%ASb#sop@}e2i)v$2GkyYy zkbewZUp-wsK%d?{q?F1@Y!Xbj}{uD2*hf;7cN48Ta$kx-DuMG(_+Vm5%VA>bC+_55IpTa zYCV@D`G3MYw>?0&?@4s^@l2~-W|mr%{D1o|EBHg)2_0K_U=_r`?cui#dDSMq)7cId zl85sY#qd^v1^^Ue)DDm96Uy_(J6IoIy#{=7SoQuzRknkV?Lte;^v?YY@xRqW;i*f= z_`tH!sqQJD4?p1>L<-DbQkFY%zOTrSpzOwl4U`mV^{&P8UZDD~K}OrHa6W4lb$@6r zXw%~nQn^26e42KpJQzAmM?S zYH(cg7EpM;ceaCAnQCJvp3UQ^I)Cs(&c5mlJftLuxuS+DUzTk4Z*Z{7c{lMkf8rQBi?C@=nDH(W^JT4C;xnYQ5WMD53*}P9iO1A)PEi5=jI?W)CGsx1qmN|ar zzz&zXsODWHdqjF)K-MpqDSxJVm6NbNt-sVxcKK#}YopmcI77w6CVg&LXWF(dVnyl1 z-Fc|P%b{oicFgk!G@U@%P1oO*{zKSSgz&Qrw1Z7UnEAlzLhnj4`hJCl&!si1=y-yoNJ{mhL ze!-%x6LHL?(DBnuH15K0Bmwko2{ z>bWR=Tw7yzj!bryA`xzX)^#ssqzJX)&?%JT zH(q~2)OWyLG|JS&uP;A$x5#d^@&2vuVCWqE=rS#O>~OCW4}Yza%88fZ)?{GX8=PDd zPUZ?>abTycM}JXLJ%^>HD0e)wOd9hXV*gaJr^53Cyc0wtb?2P~#4-GPwA_g!RHdCB zYo2H3yVXBa2sUv;n|QoM0Y#WmfpqjPo2P;*8}1_Nh8?QEr=HWXrnzg|#l-&vfLYne zl5wvD>*PQ3B!3GIYgq1j6rI55iz$IxPyW5F;ahfb6xVP+Gji;JUq8yZ^l>NwPu``> zz!6@o)pV3Y58@bQ$$_XYnl&(jgkc6=Gw5w+OKEeCErhE}SwjfK1YaQu>D}x|RGS$o zL<&8zGLGkvaiBT0fQpPNJURN!2!Hu0Uu+ib&~p)VaygXY36 zxPv}`JBvc#$}}p?cy!2Jbzh-UtDd|&-tojCZ^nbf)R|4&>P@KmYv)$jB6<3&pAD2W z7n5A@ndzwlOxl+U`8udrMJ}U%rNtl%fu#{p96sRsOQF81;>?oq&Jp3LgQ_e zE1sc?sL28}dt9{#P^Br~fWxKy{&tXR2M#5BK%!*l%1r&!`L0GU7Lu&kVaCE+z%)&w zo(GJx&U3(DNViniZdPR~L3kjs|JYDIt~F@yQ-7?V3j*;(yK!r|haJJ%kF|D=GQt&6 z>`+$~m`6M1Dv0z3`=ZjKmg478VZPE2ph?6?I@i&&tTQmT)pn;!J8~gaLQwOx{(E}|$VtsQCaDQ(Q73lhN5&3Tf4pt zL=B*gnz;l0t5g z)&a!n^D%NIN{w;N}{0JAze0Raebiz%jk*(Tx(B5#0CSy#)%(d1QDfOn0jkvHVKqnzAgK& z9%R$V7QQ9UsfJ(4Qh6-7LS9hWQl%xyQQb9M*NM$^SKRSp`0KWiv_wF)`hT;yg5?#= zs{XMQReb6mcuWK0Z=l~t>w9bc^Mq!m6Fu?P&WS&5j?AO~_zW%U1j+nQ_Pyb#Y9Q3% zN(#o1KcR~6b~0gpV4l9!d;?;wclPV5ScBn}XW!WB?=2F&Xm$%MW3Rh8h*Nc;{ z^j6b&0a`%epe7DS9+A-~L-sr8C(AtCX_ujf`~bogZ6`DN!!J1&N@!Q+Xx-D%#15FX zmr%9Xo4s1v?H7y{tv9B?b*58-hnOYPd5e$j2DbGIWT191{~bWmt$!@mWhQI-bE2%Y z&g3L@@kiL)z$(@Q^f>e2_Hxu)vPezl53D1nx%8OovLpSl`Y#{Zh@yFfH#0XhfWs>2 zRc&&|iNag1Wr{^luf%G!Uh@e+!%}l#0HYt}*5!V(SVAS2r)zgJn1sKkUYX0UcI1d0 z#3Lm$$!kO>TbPsFMt}cSlaA!@GuIwlzZvTz4r#C`a>yn@mXq5a5}{E<_bU8a(4|Jb z7}-(-3$PB%USlPP)<+a_b>}FzxI*7qv^^4VB-?vPO>3DA7GD#)?$T;ZW5Ubzv=7x6 zby!@l>ztSY73hJtlBkN69y?AfddJ zQgc3qvr+6p3K6_^q!}OP19($`p227`L=th=?rGHiRg&1Sms88Qke?s$pz-lft^*V6 z==40<9$wYXLVqBx2&wV=j7|m;^u)fhVVYw(kC2S!;?TpO+^7H^u|#8~z6F8@68IjE@C)EgE`3gPG$z976=p{JAyVgXP5 ziEVoTx4!2-MF|nP8pI-p5MEZg zxy!Wi4hv26Yzl%)enQWvCO-^8rlIBxG2QRO!$3!=uF)-AMFt)?(mC{RXTTG`TGd;d|2Oy|%yZJTjtgit9C z0ZTx+L4O>}e3bxG|NO&myB*`(Ok70>6674_8{FqysrhC5#cdj(FM9L_cfs>gBUyNb zBtCENEf{&?+-i8cLnmOPbS0`sRQFia9weeQvEwT!%l`Ucgfzx zRbLoy86-Dm?*R^v9zyL_rOIDYx4&a62~XDA6ha2@?uva_T*JdQb9U-yfGd(0WESuL zwfS`&n-SyxBqaY)c)%C~M$3Q~!`D&IF7S_n8VB*g^T+RR`E2`$FIxToCTIyC>IbMb z0DtzIu?L$=ncAaMv!+a{F@{*2$tyn<`lyZbUEdD{dAqVbFB`NX!ZUdfMhlVj8?SOw z<>vlieOZUQBaWMq8AJ-WyooSnnfa6yzZWAjc-%p5X$G_4H1+qXBogh`hW07 z3|2Pu7}@cM6pa-=UtX?cQdteX7{|w?Mer#sPHU-}`B(dB8uo&}@zV zxIeu$(Ho`QCa~yY^=%46pe$mh9^2{S_RL;{QMsh4s$`zojWCZCCJjkbRU;DndsFL| zA%JJ93H{#IAC7i5HFoPn0mz5z=YOZa{p7d2O|4$_HfmmAY$w#2bblGOB%K5jpBHck zuvNYHTwPev;G2R*J!G1{&|={@D$&<1fN0}_bXLJC(OQ5#fNOsvJ-vIeB+Y=wj9s+Y z>hD`uB%-`QD8}Yh1DXW_+;`Og%$VmdXIOZrpTM`@e;ez@AJPh}n|Fxa$3=UuKA# zJqi6*Q&5$!@v4Ka4}n{a7niD;NTj(YRF^K-nwf+)UJ#@zNZII=47)Lyhs|Kl+%-?i!)vvBsXzh#^8ko#xWDq|;(rgvo5e5zfq!$) zGN2YoeR#JK<}KEE{?d6LA0cb>f9MnLnpHYm1x=P1!>0%u8A4=va~_0CQWct6kTy91 z1QPaB7Pmh%zmpQ8WRRI&BFc}v>J7Us4R=w)9tT#ss`;S$@HQD)wn?Dt7Hcr_I_5QSYuD$6|!eI5fx8FR)V()S{YzqIn$RZx?+U zx|x#2%%Ig~Jg)S;^pBge{*ikSHI|jO!M&cBvFhKU!=TZPuz&7|Ms6&W_Zj$q>_pkN zmu*yOR9bTtVOSfn2apCY40DKTNe|RsxC4au4EW9K3!5wdpiTs!PO=u2s(2TN;eHYr z>~r=Z$uLW~uRw&y#HI&_B?V5=X`k?L+}?;Cz)v#IQ5-=?FGO>+GplD-S&p_#PLbu4 zFa7YvboZ?1VSiIa{KY?BNg}Mud-9spfXa2a+*6{fsLbadF9C(Osmv1HJXl{MKcFe= zyTYGcwi1JV&}$oL8r7qcfQbWxEc+*`;s9R8Kop7`6F1U9oTkiOr2-~`X=^FY|&~NC{W)t zx`j4xAk`2(YX;iEGm7$Q&Qh6YaE`X2tEabn)wY^b7Hc0s4{7aZkE3#Qs!Hu#%)3ee1QPZKWjR!&*t9VF^ z>SHR&o&jfISI?qkd(=9T(v-;Wn>T%2#f`JI-jsx-N5>=c(wG&X`>%kqFrAS@>L(;! zAnY>5lM4rNcHIN4wjUOMLg$?{?ft|HHh&rsjP5ce&mYUltAmvRo;(1dM>lUm<>K4D zIWaccovhyQ$&A!A^aoaA>9eMbofn_^-Gwec3CqUFq|LvmVP<3FvUr?66{st-|J5@z6P~UC_pKX{kqhWp7{rDX zY(i+fdMb+f21PuRJ|bq@mB)*!w0};am3H-e458HVavQ6e9ese%d=6jV;Lo?Da{>;G z+h4kB-ictpcaKkJ6J=WXW#2(qlEL(IVd%bS| zUkyjJ3if;_2UheDUi_w&V7lQK$-1i zD=pWiAYgR38XO_8fSO0dV ztUe{&6);e`MX=;M?tBA`=t9PNuNOo*n!5 zsZCS9(wsClIwZ8GRDTwC;56h`UC?8~r;54eo6(G|^59>7gHG^Ln4yh`QVMwW<1}R0 zgI5t{N6m1!xs+ed;z=qHUwp zhl021Xsy`iqQ$(mLOy@mW1l*hMF>#3RDT|rXosN1%30^Dm4DTNh^cxtEPWi1v5ld% z;Mj+hB&TTiVdbTX(F2_P6Tm!Bf8MHN`7s*`Av2{LGmsy4SwT1^`YnD$AN-2}a)l3Y z8nMDPA=BpRJ&(;nY2)O)r>n4C7VlHOX1*)AMO+5dgv@jH;Cdo#T)tMuo)X4CkC6e5 zI|dxtk@>bkaeqlsgr|kMu3D5oDRurOZU}7zy=%aeB~as*9T0-0!qEaSRcdHb)I1$H znDtW)V@7;_3mxs3AUs$sDx)rBYrQs1;zu5wwkCi?Xm(Y1a>Q=Z}Gq zCc+IEvW6bLZKJPI5%0|^N^9qFmRh@G#kPMJh00H2Ab)DuKVa?|{3ig2Ep{Q)lC>Vfp^RGC$$?3~z?b;KSQ)uu>5E=PmW8r^rB#eWCCk{V{9-2}CA^WU6Pg(c`|q2BvDNtzNT zK-p0{>?r_eIw8v{;5}JBx>5P^7q+`V4B)dq;oK{fo_T6 zRnwCO_pB00b4?gPCF&VL2;-nU4=zcxKKiVnI^fY95wbYMyfi@AFpn`n@{X(bZYlTP zBY$c7hF@7p&+>G8k|4@uja)ys?ersL7boMT8AC42c$Y^5@56&XIx>)S{#lWOe2K67 z8iT@pN(B{?e6Ery)peBlTV4(fX5&NmD+H;aft4+XMJ_X3_Dm6OkyOf*zQylYfWy6q zl%N>(t)gD;{+{{Fx=n|ljGm#dN-@fpQGXeJAj&n9ZrngPx)+}OLS^6M3DtPvF6hV@M7>Ijbrgj)z}Kvp>q_=5 zY9eWk;oqdf@mFcED{Wt010Nmw4&|__xiy?v%WQ-6yl$ENPb=uL)w{jfXaZ6k;(zY6 zwe?(5UF7xp|3Sgx<-g zZ9W(X`RzM?2pprOQ-zK_Gciona3d`jtnjJK9Ic8oaAO-Q7W+lY+z8j6&^-oh*{OZY z3w(pilBzp@lMF@SZr<-Tl|&y;Uw2p~3!C%^eST(3r?lliI_ohVYR!EI337fX}#U-Dk+>LV0$HQ#X68Tg@3rH$^;^M z{giV|$foFYA4g#5Te7G!m#nQTJiI^)=2ZgYK!|kv3_DWR|g}}aj(6&uA`s*3W zsjRRVpfWSCtsN6RfO5^qNN$|Xp8DLEC$XU_b*NMP?&=-%dA3&uK$%r`ZiSO8Yjx2Q z)75;UWG|X9?*IfUmVa7R9wW|S2*MU!7B!-;85hdQ{_)i6!o!5>7Xvl$ul&3xed(aJ zNx_>s$Dt!A&@0D{JQO11xom~J7Ac~#|J%as8{7rb2#W8;KwZa2HHqkt zZW^9)W*^uv;XRc=P|$>(rkY$${J-V`m`9(dt#28x5TA*FLw^>ja3uuC?LcId$SWvv zbtgEgs;7yx6#Sy(LP$>(y=VZX667&6B1wE>uRe2C+Tb~@!*u+&o@-jf=Qz>!T%w5Z z;|XT5V4fdK?%$6)od0JR@u{kTiainw1IY0q_6=-Qnn&jsukzSc+3RxuGXUBYANip3 zthyT%?pnpl@_(Ra#fjnv6&5p`ba*r!+Ro+n`Qz&jc8ZVU&db^5$0`({y=Kl8l57$< z`=tZ^s^8964$O*VOM}D`jRS=el&24Jydc<$8e*Ad-sg$69+xBtq8OKGp~zbSv2E=$ zCp4wKHHrKmaySo#sX4T*hQHPsph7WCjFj-j5h0ixO@EhDo$d|YMGwly7V|jGBpg;7 z3HS0A_SV=ZGEhY4)qj|EVLFSaI|rUV5CHzrZSXFmlF8Nn%ArK(p+C~a8yi#1y>|>? zsX^i6{L3VAGmvc4BW!y5rV{i>;s+fmduv&NEfC31|Y$`?ffD3(B$ zOSUN7O)?{yg=%uF`-P6O4)rE(lXqi5>5r}R^^6`^4H^Cr55p%*Wza^hkpL-b2EHOJ zgnyMkNzXS9vDN?PPq?(stH61+M?;#Nw_XTHsp}j8m#Oq!_I{|K&OrEAZDE0Ccbn6`oGo9DFE5+E5K&wjUEGMye3X?U;GloTSEa^`eP#d73DF zoxk+bj3yb9ksls@pZi|i|Es7O~ z!i3-=DF*92~PF@GRd z-Q1#KegLtI9%4mT7V>`}Qcc!NleAEeqR9lXCXD+*7(^DkK#kzvQ4f#4o0t9g7d)kh zL*hu1+<60#G-NwcK1`xskj;9g{0!#;#o>)bWR?GPcpJX_;AQda7Nw@~=tEss)BJfZy^ycj?b`%_Jw!GHGqz3C%1Y8;^k9i+8UQOem7^VmHY>O4y3AdVe2nIK~eP zh4>W_lq^uPLjqOMXR6@`;!a7X%bS@xk|`o30`jBv=(1iw@fEAmT;UrDwFuIN+O&W$ zcv_X;Pe+)-z0Vrb@5~Wi_LPEx1+>zmsrCUeqw$es`no2$ACmMnRY_VB(0@T`3D8W> zm%Qu^5DjcJr#qnsYxvb43xBT*Z|G*^%tbudKOotZvaEhg55nEB;BeA*v~$oAmJHZr z^8j+cWi#U0r)ar5Y6jo4)(j7$76l()Y1mLL$%Tsny#SAt{+_FJ6B6 zs*?+zIrP_Qvb#Nf1Sh3@1vQiae?zw~$oo|6UeMX?>_%&#UvtL;BZw@7 zX*R-4!%^~aE-;eNN_5}$dMv;{tLc&S5o&hl;useVKo|`_7=Ocy_N_aoWW=PmX_oii ztMw+1G4+jl(7%b~|6oFGh654oFitF4D_~(@QOb1)$@Y@)dO_e$tshUa%QZp9c7$8< zVw^WbIypongBc1!N$S$w<(JGk+#P^3rBnfP!`GCV)+)mZVeK$W{ulZdghe)fdx^8MCDgq;-dRFASXL0eUiWnB&4zg zuFM%JR9W39%=KKk91&yC|1<|y_k5UbgNAssW;AAkAhu14bY9*3WIU~3M)a_DX*g=K zgjnIJcdl7UmSVPw9&K+W@nz{#)>93}sOd8zDd~Fk3x90S^p7J)cuDfO^MuWP!N~B0 ztV;dWkq-xk3VP+KK{et?;c>dz_gGQ56^KE%^td^N^=+{c*w3;`MOsguhkFg8|B$!} zaY3z;!=IFs!U+CG>nyC@Ly3%7A*$2EK+*yLmnLNbIUb|8pwgbv?}mBg8L}BXT{kf?&+y<&#QvnRc{19isxBgc=9I&%UGRC)l^BgIZz;bi zFuFQyJ(^dSrE@ygTSZ+y3p-~UMtm;29YuV|l)>ubrZbira)<@`97Mv;P(H87A=5+Y z9Dm5;46zsM$DFL38yY6Fd%d8*_9R`L?+L0w=zk3N64uEXSnaRgUhq!c2w!tCyCyY(B1J~RPl4byzLb~L00yT)qC#G~1Bj=%2_>R{#kPaPU>mO;>)Zv--ISRzz3WLvHcy zNFVyWA3JW?Z}(F*B8X4U*% zh==qGwo>;+hNMN`WfrrT{0IYR&TE3US4jLnSy}*ia{O%`EW+aQAylbCQ4f$9?V#>& zM_J6H;Vi<|D*ka#Fd>G>dx8$7Yw(^@ ze7Aga%w@zq6dbY=oev@%mNxjUB@LM_i#EKga5E$ro9fx&!!?iPl|#EjH=iZ6&J7O; zC1EvUq&F;ciUMYgf3JJ;KEP*NdPV*}`ppfteoD)@wo6UAP-jE5zklGwG%*17 zIeydjCU8REApgfmVc72cf40g&`_$b`lsYTlPQaUfKml{_s=5jNaW}xkMy^@PJP)VTO|AIJ!rRqMu z26bnKw2ii4W}9z>WPfBTu}CpNhJA`Fp)j#cd{U;?D;D0~$*?`MI^ZGYCfkii#@)Ym_L}c*R!oU-VP+PC1fx zq0Kpbi_*9!N+(R`yNvUCS%JPe9PWleHok;8>2z+Y}}DscK0ja-=0<_an@o@5mvK#3eflKJ{O>wJ=M+}u#Ah_A=^`Bpsmv_IA@tf*+q@leiMvL- zeVwwRhlVnYWPdto^#aoM19I%U`;ijzeaYwCex)mD!KvCiwCLaYU|fBO+z$)^a&`GI zD5EH>YCVy{%?Mu(JY8v|*BsRe9rWh;`yM$VEfyS_q&r_-V4p%XF+vZ3F# znI=KIgsWJ|8Xf0&Y_QzRWwjbLu_{~!m-lNyloRLcJ%5>&UJb~cytGs25*e7+bw2Xe zcgDTuR$d!X2xvT{NV?!RembF8_HU5TRdj5&EgyxlmywN1s)K)e)Ty(d*_KQk2cR*lJd_=|XI>XNpYXH#2`!APnhi zIhhuYpVtp+nK7h&=_3)UhdLFS?`$|>Z!kjspMQKe5LF#CMw4Wqwl$iPNhN{v#t(v%>{wz`G7j(m7Z((tZ{x54tRUuHSTV$*Ej*X3vZ0U^Jco zrywyYX|jYHz`r#iPg5X65ww7l+|{oq<*Uw&22DI9r8FJuDX!=Rpg_KyK^~uuzInBR zFn`m82~9@onf*`$3Ysm~^ttZlsyy&VQlmR0h24Q<$zL9}aNgsw6bLQwk4JQkz9lfi zbLdN3rFFhApJCt!I_vW;9rM;lrGLC>^^W&ju;LjJol0bx!~y^fB=CAPcq%TdEAn+! zbu>k<)uq`;L3^p<&FW^!syqX8CS0sFwSPg*$a4mr!->ER`1b7fD;#?k7Vp7h_$~e& z<&lZiM$ne#>do!Gf0i6+Biuv*rr>7cJqk(I?$p0fWYc1)wJ3{7Zq0OM7Y-!e{dSyRf)*aW~A0OTk}h$UWLtJYj5Nf$O5&wO370W77x)RN;?{3V(ev zC|zh1i1~T(z%QV&2y_>$H?1coYZg1nRVTY3&14UkjyD~!P7;2-l0x)(vx1cLDSpy# z$EoLtiI5|&s%>o>dp8xqdcNBtP$6qRxW&7uFXN9Dn`3XHkrr zxynVr0mU7_t04{llwiAmLlWi%2Y+C>&(vF!)r?Ke3sd4|$IJqwNMV-ftpc7DJHrD- z{5{zoKH$53CTU$>lwTk_ikZm)4g3a6PF7>$qH^II3s|2&uxb`G$VCt(Ide&^{d3r$ zxbR$xKax|BfsYRDFIv@f|d;1 zA@N$zJgrf}GtUK9zVFGBnL_$iw)TPyS+dSE)M~0(K#?Q+Qm@Vfy4_)se45(1r*XhE zOmmMd;~ocr4kQc!P*p}(Y(7^z9A*cNlHULxmw1_SyV`eUq@U!Ij@ACKQBl3!x*i@B=wY+9_>Wgrj#Jgx*2*$@fhre)%scmMVy zN0^3IU6awt{>)bp$A3*_b0x1{=Z?Rz6~E%v*B&vj*US|iANO{sm9LajQ4JR`S4(yv z-?|)D4w@sjfAvLcDS%2o06Y~CHEdYn9J_333dr%a2{SB^AV7*Gk@2!!g^Rqsnq3MaB3Y> z4I)uoZaq?%;i+0e@`6sso2Rd&vjpo3WDDR42mdp84jgycyTxqBsU9yP)=&a^Rqk+A>|9 zb%H-X?gWrH@mxy49fif&O9D{pn}c# z>Y5}7ynW#U1;9OjnR2?bIjx35L30%~u@oqfAdBwymtVz16>;yTG==1+B!5gOAZzhd@u{eVY(AEOjkDp)MH`Uv7#fCqn53p994)fw^C?f`)MTH0NAInF z;a&m^!{#b50>Jg*_ZI5OS1w$QDs$Od<}|@GuChu>$}OxJ$5Uv@l$l^By4jh5xp{8T&sV3l=+@_}{F|du6UcrZ-rC!To@@E`gR^jr_BNC~AO*0vJRwAs`_!)T z>%X#l`QM|yn@A&vg(a-~cn`sP^xa&4p@3B&$c*iXJPDzy;_Y|7FJS4P+lIn!zULs8)sXuU>&co-E}_a`T*+K^1`bNsI$JX@n9IiE`gAI>ER6D;LSH~lqbaE2 zonTrdXI&r9i%?4Ns;ZcKhhCs0iZ|RG!{wUHA=Ntpj#L_Gfoc=!Z8kQYPPp>RDe?BD zMcDW%dVR&`Z4ua*c$?$1zJ-I|_w!wt3p*tt5$T@bvngY7eMYE^>#gQlAX?lM^IJ=oUIIC}^S+D_0;in!r#D8>p z>sC5MCtRLG3fj+Xk+5bN(?r`L$5k=_kDLPli0Ev`iHGY~KyaKw$l6#1T5keW3Odac zC{>L>WG&aRx{!56oXRyEf@&g2#(9GLRD2M`Qz5f#TVQSffm}@NOi?ZM0p1WH?{5^o zdQ6Xhd=UkwXh@fKIU@F>$mN7)Fts!#b&!AMn{1DxkgI{#md5=uD`Nk~!QiWAIsTw; zr`1w5(W>0CTB)7?lhwU$@pxen3YZ@T_XA7;>XAu}A=Okr z#;VRXA!W@r(T!yyd>~?SbYJg*F^& z#9q!aQ|b-(p^ZC5!a3{t*7=0<(9q+P=5(M7A3n{E4n~<%9=Fo*i4yLgeQopWZGEbx znyQl%_g1idr58a|1sjuRpMQ56)sBBe(z%1nwR{PHDfvm_u@N*&)MLh%xRZP)!K1a_>*k*1^2A2M_{fR5!I5em2CwNZQ&MJK4t7VkmH>*y7h&xw z0Z;p9g7fvCX4_HhqV(vCRn!dT&QUFF0-Yr+Td$=D#W%HI-|y!Ta{Ac9DWrcYIPxW? zwuVzw4jA~dKik_<=5LKTSH$h*+gyR8t#N8^gwqckSJYMvj)vq@`AM7&laSK1c0T%# zV?Un1s$OLxZ_8P}zx|}#dkY31Z)x9l-B|4|MXDg)`<;-cX0|q1H+TnqZatRdB*I?F z>=poC{KWf4d6yYi-sj+QLneO*x^M=H8%p9J$>Pz>z^U+QTa@FY(f!{P3yqq|hVa-@ID;BvS&O0(%U_>C@l_IOYK|Gkg3-opTxqL9R)}GY zjMCAUv&UN&f>-WG)csx5f!B!1IluO@!Mf3l=9Qs&UzsUfWIcZ@)shW!Z0F#b2eg$) z3*ERQPfvHa5NQr(gyVs$8v-%B!4bF}`tRmgpXkl2PK3F)Wxw}YJ0{2v`)0lYs7!Ic zd*50qA=cJnveKK!LSIv0OOFPQpTG{Wa=k;%)f?+!w`C|di(S2r;gH{1}dWXOMO`~K$Xu<{HQDhd+z(MV71?t_wy7 z zMbCe~?|K5^f!Gc1)qEI!2+L++-UXtz?_hrUR9FHpx*ez z0V$G1RkCXvK(4=G66eR=GjR$`3^`Ide83PomI{w9SEE8~Jw3i2ttc00S|SCRmY1J4 ze6;P!Ga=eq(9d@sH=~*k9~A6)?^=J(EhK$GOsRrY$NHA`=x9LU3Td$WO1N*{OybGK z(*OD=o`OgXgVK<6C%uh|6hB`yr%;TrUZbGVpzV9g5Re>qOW-*$vSz1haowu1!jaIe zhOVycaKkbQ#661k-9>zXKqW66S+jRfrKQF23hZ`_@P2DA{aWMQ;4if22g`r`FG5&0 zAcKrgCUgLARYALjVXe3s8&y9K;OH>|!0yRK*K_EckJG!Gmrw%$Pr9*YLrAQ#EE~p( zTb1_ffa;e;$pwcxJX(prN(4_W<3n8Ov`aZ-+vAQNpR(+_Ky~sq+d_xs%RUol8Cbh+ zuJq`Nh4G<3=f=RXGjWw=t8#x=F8vX%YV3%FZ8*539kriVYBF3fz*R;jI3h55yw4>U z?wh_;oO3)+thj4UKIX=H%U9NQI`PELLswjYUybm3aVjE;)H`x}<407k6mZ9?zXsH! z?=)l@ZZ@+2t#!C=#EE*lr7QrY)|98rmB#9CF&kp$?kj#qeo15tUH5;qT3EmMZP`%maF5H+0_xQa>zXx=#8F3gBl6i-}~|(Fbyc@w7TfOD;K6mSRJ@`kjl&ua@(*jU*>D z>*5x2-X_g%h=bPUcuIf4j5%FP>Ihn!nl_WtpD3?L-g#+u0U#F&1QB}RmTyjxcPRYB zo@Ne=t1}t>kcVnTA@hu+{qdqwboHWw6eWjey;lep_Xk%G6@MI$Bm*ZB$l>du{X4UD zu{Q;UK5`KmmX%~g-nM)OG4j*C6=>#k9+kta{ge4Hv@G)0LAifV28^lxkRJ`9s4a^U86>;N0t!?0 z#uu7w33GLqyrMij-vg|P(G6^H1!FzUex}Zj<#9|J)7pKey1H-|{@L81o^13&P2b#J zesV8%?LabS8a2z;8WSfVDVj|wRI7i6W8a+Do$_2=5ORNf-{F3>(u6iXaOl$+_(`-S z%pltLxZy?Hg1k=oojpQ1gv+pj`E#p*oK5Mq!mRJ<9^iKoJ-txRMiURa0pyubgp&6G z-vVvk{|AkhQ>UU>aLRmFTg0a+I2`MW_F4@#=K@v1GPY5Er{PG$@{+|baupML)~^>c zE{a#9a2bEmdujJ?nAPsVyqN6(1oKMc<~vHOdnaV*?-wG`_H;-EAKQxbTB0t@^fbhm ztr5Bo!Ac;gKQ)EEnEziQ8+IrYk!Wau?w>R^mV7~89ace9Lva~X@RZFSCk_ni^R30R(v_Pta{2rCoZh_@an{%eu8_(DOfbCngOsVradK zKnQ<=Jbxfo@aE|g6}L7%DHx(h`Qo$(M>je8+VA`}h@NX*rCER&*tZ1FSC>PA{3Kc{ z(+3-q#{0Y&w}z|mru0)qtDkuxRYR1U`1*yt550&abh!)uC2wE6zy@dt%;axdCT_?uG1>MiiKm5S(P{SvNxP-JJH9VWpBEo)(c2G5yNOYdqJ*typRtA$2OWY7mNaO$jMIZFeXNMTNHzN)?k!79ti6J~!u zp}rfx-s1qR=83P8-!34HmmV8BkbthZn$*_J;tGV-Z;ded!IdhSsyBW~#f@)8+7SMS zs7#$gnt9%N{Ne2 zH4|ms&RcfqXyN-a7C#~rw}DtT!tQ@8xmSM!ky|PK)Z5+hGF|f`@5Cicw%8O?uWIc)iXz_`qdgf{cIemb&OYi$r8HN>0 zE)P~<{*FRKVNL@fKB8KqJKh3Q9CK9+Q(h4JXwgU zc4DA%&8_{eDKpKBe`rpEUTuG(l<)?$$c-mLoPq@Z=|uFYr!k8|z5|B>2y&YooM+Ns zLD0s#r`HCt@vuZvE#e&BsX)ESx`R_vRwr4xLhtpP|IhJ8*D_H84c`(%b=HaWMx*lIx~^0j z7&-jZ*=%q(&RSQfZPgQ)2P)5<=;05hXANC5N}GJEXkv!Xvt=FAgv^azG2c@K()#)3 zT)%?C&EsjqLWVC?{x*MvT4gRa5A?YtpK#y6?|>+&Peyf7O=o_Yg`d6jRACTl0v_!B z;JL}Tn<>PRwbhKBpt;QdcpN3*uUBo+eR<#^LBg2F45uq2GBu>Jsq7ycqi1<+ccb~o z$+OdAf**V+oYB2NLK$JNp+DEIFbP~NyowPQ*s`)EABFbJSYklSbL^D)G9L*^ONCt2 zLOvOqAa1$Yy{AT0p*AXqtH79Qjl^!Fb#_W000000a;p@ C%vy2) delta 54875 zcmV(uK@XQ2%!c_&!C>I5oY_h_E0%2h!Vu0a@OIf`X zm}ea}euud>8=F5t%0aNlu2&9T0N@Npc4Y=Y81%}}_nb<+RmB$7Q6o;)1#i*mCO?7z z>XEANi^zMtm30~| z30J#3o80w#i!@%UoIpq|aje*^DwAZts88Z=qb0@~FKkc^78Jm*a1{tJ@!x-5M8Eb* z;rJ>wd5{?^erWciK48$Wg@QI`6LZ0T@PNC3zY@O=&6`*wfRfl9fSH{XOhC&w+rsUC zgV#P}4IFDyQo=|uBR#ol+VMC=e^C)7q$s{GfyJTBa}lv=d$5$!f^)}6i%Swpc7KtPn>QxSK$uIW`k^_YQOkbqm_TumsG325DwNI0>dq-QXb_lle>tngz%X$mx39$Dt1oqjKgd9mcxRmkZ#I9aQd`aYNy00_~h>p)vP*uY4*3>Yb$Z+vcwy(=|Tze7m8CusXbJk5R@D zW7VPH!2y$hzjmutWc5l4&#XS@WgPkYVvPtC#(UYg3=7I6~X<^j&6Y3{*f0lrz^UVlf zQ1jwuk2OCB+V6x!<+oB>t@ULP_3dVHKZs*%#_%D3OB`8}*JxXLO~7%r-GGrw87Xt*0hwvz9hH=qY|JpOjiT4 z-7q27wQg$Fcbt~}%kq8j{y12(sqStf3C#<4*liMC@Xey+8yJ&eeupk#=kEU5_H+Dh zT^g-_aBBWiq)ehr>I%dYV*imvL!3V%#U2V9O~F0nn&R7n2WY{C zmUJ5VEA|KiT-v8(ff@9wJK9|$MFKOtUqD*`a*DCL_xhDO>!m=v82AMrR0tG* zcJnx&xBbO0Boui}`;vKaF)ASgeiSIl43|1D-o;ei^vs*@WBT@(<>I?LT#AX=edW7UTPdf*UtdF6Bd@~q-{V=zJ=wcQ>U2a^n zm{v#HUpn(lf_JND_|4cQ-Qu*Z0d<8WD)k9r1kXNqZtA)^KeF`fcLfx;>tGH=M+HPj zDFHi9^t<8ZqZuhEm?uaeFDnmkjTJ(RdKu6kjpL@1TJ4JYKN=#$aX{XNwNMa9Bvd_9 zL$+w+mwX)==FJCxTH8fT@$Q=?a$*b?xR^bPWu;O}pci>Tll7>30DAE5G;qF-tsCdq zpAXzcItC|ZytF4FFY(hZXs`={Mg40R^U>{@SRT#?Gl(8(#6$`YYdXAsn(ge!Pv(Xb zr{ld8_z%{dZJMS5dPVmx%yl!bhP06UY)$?^V>076kjI{X18Z2CO4FhXK`x@^v1q+C8YP=H8UJR-FmlBpBeQNnjBz+mqYC1&s+fD@H{Ked<`y>25n# z($CZs-k89mH2QMa7d$x+)C_FATIN~iAz#i5<=n*09Um9pn_VU@BpFrDC8VP%&x$GaXGsC zq?rcOt9{i(`+bF+097j*vTZy*SU24*Mk{5zbPIoN4n1ZoGE7jMIKZOI!M(v^Q*Wpx za96}2z)Q0ifnGvmYp9fw_NWI8pZdk2uV0H!@f0C{2A-OXYXUog(UV`ZRac~Q4c|MM zx{`5-e%r-YC6ZB5d-C_&u4~V=n~n7Smw?Nfdf?Yb9Rs()S+JeYx&)B(F9dL7regSd zF=`&!pa+1d3x&o4ciku=rNN~YG8@(bvKPsi{1W-cW zc$Oo7y$CUWpQal(4@_CZk=&&N4bahm{cu=XF^B?o5$fL@F0<9Q2ZcKmP%$>fd3TWp zaI^2_lP`%lNEP_+@j}sA>W?FUY2kinE2ccqB*dHAvsLmH#yR9=qv8s;mD9F-`ebdg zPU-b@qtiWWYnxSKrYV~SF*ZZif(_bhGHhUf^bQvtaO2@{sJY}- zlzK*Bo=`0ivbhLD-(8`fala|K=FUk3kT1gxVo}Aw8XMNUTfUnaNt06a0Heh}>#Wzi z5o@(Pox6tbV%NpXpzsL~cki9>abo~~RyJagphBKIla33*Uy+i%!sRBLE@aG$zN1S> zy}W5VTkN#_seB@R*Jia;HSXFFy6Ni2LQrsUCN_hV`%&DbcB#s{3RMeUywY?4K-mauO}j z2UO5;p6OF-t#pZFOMAj9cRHh`F+*cOe{^!5y8uMPbtnahT&9cPM5|VRdX-0iQM3lQbPMoB5x= zYf3r0j0cnk5baYUnzoXLTwftJ{QpO7xr0F%C=WrNb8bICwT-&U=ekFkcTIEk!I1GtmGpRj{9p$-00!|932O(g%v6i|}#wZgwx$YzFr@RswNKIrFH`qdbi zU@JN^Qo~rjy6il-g5H~AP^rWcm7pqw!`6DXvutlEy-#l}(ws{l&(p=8D%-{^o`as* zQIf0-TM)kfxtCEVwnt#sg`f2|dqw{b0Rk|z_bFNtj7YZ)@mh`P(8`urxcrp>NIPPM zJt}pnB)#AUk}XhwhX4;i>k46fy{esU6ah7hm_I5Lg@qDQOu^zYcBHKqm?p<0tMbUG zoy|>RYh)8eK<_=$!vY>IJ*Ki!AW{G>9sJDcW^48`3I?jj~m=75r)9w$rWEP))0SXFj@9L5?JxV9 z9q=fq#_gtm(3vM}tU9!$EoNuc%OFx^_1A&oMkAYm0k!^(#7oF~>upvRNueS^oz#$X z9R30DZE5$D;%(B(@2^$_48zxSg)&tv;G(ywKL`?-tOhk8X^kN88E~)LL>-|$3*eBv z#Ux<*1UyHl6GPHEvmeQmZ3DLLOw93n)#UL?Up{4j0=wASMa;dMLf}{usC&E%blD9{ zV$%$14@a~I1`A9dstt~g!ER~_gLkk#xZ(#==cnDd*h89xj_E#X;I&9NwT%6dtVj5D zOJ3HD@yf3I6$Z;RTnuu0w6bY<*CJdX4noAeU?_l4hwOb#2Wjr82HX=#!6T#E+V$*+ z817Yn59kjtURa?2jz&2K4AQhZ_c8A zfzwz6&KS~#-bBb!H5%;NRF?_XQ$V~n5rlGoh$_AYkwaCXqwr=x6ql8 z7$lVvC+eP-D7mPvANC5B@QNe>PcKTN{-^4mtStxwB~8G3jhdQ7jti$FWaRir(lEz= zY3YEasZKI>Vd>GmCQA$CA=l%q9V3U7>qtO`yr^_nKAm;nHA~dM)A`b+P;N;qnC0KPC2*KqUjSr=2go%U@w?A-ulTxM6 zwtUazp2misXN81e7(C#JW+dwa?hBq#Pv)E?!D(JZTmAnBkcW;=CJR^P=j%LwE&x=) z8U#K4oL_K~b(;U1d-aEQPp$NK$n0pK0EmPUQGB?pK#nnhs_KU4SfUy`r{aaB8?GVP zz1a&!OZi*`LGPBFQ3=;4&j~W-L|`Clvzs~W?G#qKs4l`gEboC5f2$4P=WJc!4C~Rt zxhG+OAD>jgFf&vCIsT)7q+DA&!NhNF>)x*kpyKberRWS3m3vhbX&qc7`5fqM&I*$g9Ga6oZGh|NODE@hRJps7g8>lo4AI4?EtR!`<YXLSPzw0;nurI0;y7Xq2vUeN8+9Z4XjOSpxzjs(H}3^* zk^b=s*HFphlynFA&|}S?QVvWj4hx{HQF4=1EMX&mloFa$A=Ge! z$Y4&ns(XOOhB%?}WFserlXTw9a=%O!LuMxHsG{|;IFuNQBO zSwTwNOKCsxsNEIVxUz}1C{N(t9?+nwj&_)w1GkS3vye~Q)MF$+@q|PK=qZk%8lN}C z$3Fto1U<>~+5JTpFN+hl8DX~xA1S=fD{n4GnZ)UT3}-g#;~ z+BO$|XDX(A91!HZF2wEpJl|H^@FQ|~tOn!@qEadIram5{7 zzs*y#hP?Pvj%+7ZfX(9}o9ziEf#g0OcBRjMiQwqgM)A)p&`f4`E}m`8SWeZ{M5uT3 z#V(cO58=iNACpFt_oIe5ii-&t-K>x+TJwsr!rPZ8rEC$yB8V+)Q(DVK#A~s)od^nj zbzhNSs#KW41nVd|i)d|NbSd6iY&X>eZutKZXbUMlR@{vGZ*ajav*SzNJ%Is# zn497D)vYdD2!Bw{N>kjR#VFg;QbiQ?Nu-(roDt<(byKat{3>mo4L%+ImP2qq&5KQR zEJPiEeE1gqWx! zPZ**yRTdx3^AOu14i{?cuq%j)JHL`;vU-(AX72;D7kYAV!ph+hgNklyE28Sh+%RWb z9|sHr_H{iG;x0{E$#%c@rKwV10IS~%F61~k?06`$XLPcpnMq{nG8%lxcS`?%F565w z2cc1K@G1wWW4udebvOi`xEX8>?7R}0+k)BRK2m8TOb7#Bm1(Q@IFb-m1TWuE$)N>p zTS^casU&igU}u-!G7TrTM#fxtwnGjWdS%D~@S<(ZS#4^8AbzI|1Hw4f%C)7zY$aJRB9kM^U_?u}y01inn>!c$O9ek=xm?n^~0%@!0u z?(jnluVxO$-=HmnTs1D9t|?47y$<^#r#!H}<@uI_I&5RT;6}mt;cRlPe)YR!Jw6{W zYVPr1*@ux7bQNt9j86EhfN|aEGj#o&K7`h9^pLxKDOk++wgV7q5*x2>GuH!^SnjHw z_(nc*eKWlDSOdd+WBN0HZROp?c98$=wk|&$v63>eO|`so8Gb07PzHFoFyx2?TimSH z49T9mr)Bs^MZ)!sk}B)zvx`*F;FpFOCXp8$y5{Gd#+mgoxV_HU7g<0 zVuHHCY#zuu$Y*853n=(!@E)+aga7e~?|altQHpagXV|o)o!J}zvjnxAtBwbZu}!g? zZTkTGVw8<(-5?nn5;G~|qqE!C-blRP7`P=^&KQK-vc0^FylC6HnjBO?hS2Awn-!oR-&|4Js`ujuR$i)Y)BU+g#S4sk}Y#RjM z41qTVH{pvglVIXhY>x+SbvTP-mxSmMg_!ZAwCo#zW%=7|%pdjq_UCDcHrQZ({njM) z=}!h{o&&c5*s$@}y|nI6HUbaQf9eoqZXmG2;x-&i8s^l%I8lNRb*??@t@&N?XUeOtL{oM^6$-*W99s=cB0Gy{baB{R)*^2VpYhO zN?mX~80hf5z%($|FyfXU5yWXl^Neg}`!bB);HtD`?WRK$mSsZVvQB9Bd~MoWx@N#l zr>)%t)PmSS0Y+&K!~OD4$WkIh8$QP>h9jz20WV&8G(IUlu4Z$| z<_GeT71)rv4QXyO+!1JrQd};Z0gfyHZ}ZXn2O@547?YT<=cVE_9KL}?|0tw0c=CA2 z54k>nT%j5^L$)f<63l+X*>ajPJ{)KHctNO2rcK?E6p``$ZKR1Rg}&^ZpT%TOCsq=Zt-PWE_* zZ^dY1awT#^|zCiw_`h8G5hvd;P7}}!@1;t zgB|CXtA)z8+~D>v5L7NFLD=I-6&2@Xg<>*7KKs~Ou2&Ob!0VQ4C{4oMT$ z-){TktsM#}BQzoxm)>-Zb(Y{$>w)~BLeYzaQjQ7R#~Hl80+=e7iZO7{Hw0WIc=%B| ztHEa1s^&5BQ+G&*{kE{*WdXGUqajk8y>Nkc(Ik0G5R8%9FNJYPCYnL@@E>@8>{=q0 zf^))G0Z>=h*OQx>Atu%0qc5A3G{5V@PArQ6)Eo>)Alk-9gswdV%7{$z@BH%?olNI> zT?D3583uq#KBmOp_=GJJW+0AYPBTiD?41%fQN!Rt%RlNa=CDc_e2tvDfL8x@ z|Nkdbm*!3n+*e%dXHijd4I(=d=#CGW_*E9PM4igK9agGWwC#=-Q>Jsri~e=B4YJU| zbSCXT!k>=S5j%!srP~aD=c;mz@1h?@-+<}{#|QAwBX$S2-ytEh&NV#TzAMKc`R}#eJc#r<|uO6;-#DGKeoq%No#DIS7+e9wco&|4V6qqRD zdprFiU`VrqC9Lj$SLHF_Qr5emUNvG~0h{2_euleVtRthrwvE~y;Bn`Q+m-z%WQ^Lt z`LT}+!&Yx$0q(jX_g}KCJNt8lavM{%q6}txtSNKpOAXpX# zCA-l+l_`9FKc0l&R;K?gXMuq_Mw&!`EaW?3er z0(vj!X%8EVuspOfe23_$enn(oE>>Q*4RC;1OkTmn39nPZr}=d3cw(j&&i z0XIUln9RuUiU3_gUo4!CAuuxM2{VFsVt}w)W!=kvEvrn2@I}x6a4KqvypXKf!0I6i zZHTDB5WGQ)4efZ8_;wh{G!U7mo` zdL?!xj%v-g-E1s(?Fup0fLhZhfCM!EM5ox`{>NVcw19`N)AVe++hAE_@+> zn*y>Rm=sV0FSTirGR3L#@M=*$ce`e z(w($#Vf0qF#T%%*OS6dDcfJ;HZ~Jp`bF=QzUiURc?3vV19awXeM~zS5HAlQ-tW}@D zO$mbM9=2Znd#n$^XBYDL@~2y04tA%-Mv+OYb zJ%}Z9OMooAw}56}5m82C;V0x?)NtgO>!m2+B1l4olqiO-)@gaxPNy}Tsbsq%9$DK4 zCXxk(x(CQ325RRSsyG^JcN$A;!j!4u)N;jwu6&W7Z{-yCbfo|P`Z;^_4vB75z=GscFaH6I?6-|61Zd~Kr|#7mQz8(1 zK%(!Qrv`;o)s?%vi$gM3HEk7tZ_jqq3i(W;#vt7=)h5pVI!kj+CR7Ho@Eh*zp+ZqR zSV9!E3Qr#ekB*Y#3jkoNeoU=KB91WtA|Mh2XD_5XR&tnVSnHhFSTKO=b|BTbsLC!B z|$J+gCw zYJ|3ZsSQbSoPdP49*W^Ej??%$tB0^y?O>@bR~66@I;hVsW9 zi#5VjA>cft$x%JuZK^pKM(kGNdvYEvbaFc&P6GosjTa}!6yNsu*Tnd=lioRHZ>OBe zoCENBpAo1fKdCo=npnagxY&lan0LZf(B|Ul5={vPxVe~w&zsBad)`nXS^xpWT&fHH z_Nmm}I}xgf%LiFL7*ZA)u~`BdtH>&dGu2)$a^=L6d<9v$C!seiA$n=(H@+Z)iK|du zi)0DcnE49EKkc;(d-M;N&^8l+Sf;s;^{PBHP$ZZwhAP;9Qz^t)fBNurCiJnY&T}Z~ zaKsv;xxU}>2O7G{Z}{oJfjI=~@|{44UzaGAG111V!g*A#Kj+LU11Sjpo07Wi zY=x94hi0bKAwru5GOFQWU_x0O1@+TEAGxq;%x{~l@@y;|)A10d62byMOWk)z+YU1CdW} z+)^!5-*)n%x0C`yH_O&noWXc*ZG?VmSLS~Y2~p&DC^QSt(EH(DiK#xr!-@!d%=EfC5FSZOKnCi`aX z-1!!Nx<=_FJw7}o_FEd8=xf^+6CPp^zTFZJ>3|rC3kMC=s=7qII@V>SnWHqdNz#DN zG&~AtQ9k^}wTS7TilYErp{5N_Ry+XkACw7HIm+=X<_@I9S3wa_1~R{9>rTouoAiTp zm7q5#;5TtXi9hTeBY7MLx%AAZFKC+rP_Nk-J=zzv8fd1^Gj*&?rAvUJtXc35vPGHj!#ngiOv{VrOb^*VYt z&#Ew%8gGWM!9pkCvO7by#c9i@B}v33G!?cx20N?*|Cr|(K0h{kFB#W_FB*z}?7?0N zT*JAY91Ru6&*VSQSHdCKuZcshsS~NMx(g&YV$4;7pvEWt?8;w96-@zT*YW4BQodA~ zc2|oBL38j`O8q+>J*OoWhizH6fGj5mwg);0U9xh}&o3v41l~<}dhW^DL!iuupgqn5 z!P5eRIKU1W*H9M(7fK~&9co;E%@@9cAAmG|gM%1be~9S4xdY7=_b7&s&-oQmRNo8E z+$4=5E<FgFY!(m?nZDSZ&et(K1bzjd?>tYxx~08cJjljyGi zKz);GcS_ipz*;p3SLY$jwO#%df7oFK7si(urd0=sbc6$7^~v@NRRp`=$O$%hJ#qP1NrI$SONgB z(LLSKkKUgBWt)0QfA6f|NB(2&M6}WaMr#Jn)a}M;u<_@`b3Edtr*XuJ*YDp4n!Qy#{-9;hsXw z&IM5>pF8Lkh#(-URLV$`UJcJ)J8q_5P8D8bEtRN(J@h+&h9q91kA;nymi^<_;PD7Q z*Qnn;hgh?mgdBj?e%J_h4N3Ru6>Q1w*>QY=<=H@8m1GxO{mp~&C`_RlGG@*Q*Uu5i zhc_J?1mp(b+N+mL-ZMgXxG3sQPCCj8VU{pQS^i=U5fx$o%y3%pHHQ#orVe(=;s4)p zbVoT}F0CxhxV`Z92*(lJ4F1h9UEqTC;ZmX^dmV|l_p=D=qT&W*hp5>d>e{T!kO({l=EemcN%69jc}-cK5BXLsZ7B(617>@DWJd83z6Ew z!-x=U(!u26!C_0{cNSq7XJoF+-cx4ZUV9KKNCQlDayWvASD#3x=RQAV#h?duMcV1F zjw(#{(7FvJh?6Ap%kRXGE|zfA+tXOHpi$Grb84#OW&;662EmUP zMG^p&srwy}(BX>_J$~9YH1$O6-Sw-l4lSL3H+y|;#uJ86RSL*qTqEefHoBy!U=aSH zsnz9fjGpr}Xzs0#${y570#qxcJ8nl~^(3do zstk#BsRwPIWb!&Vp;t??k97kjmmXRxpD&Qc1WG2Vt(w#Ykr}YmlON$vEkg_s*((Hp zRCiyQ?p!pJlT6F7q%D9al_2?Jry%;-p*WCZd@FZ4X_}&iiCv_YAJi{CrvM10QlVRS zM&E807yk=v!Y@sQ+(JZ~%APsbzsKvG1}F|C;~s^wsyDVm%%I4gL=~tO_2|q69#^)_ zp@cF^d*e(u#qCJg-KLVQ-bE?i$?Z>n+=e=oOY{T1r26-CYPM!h+u*5r=96o{>ROfN z15)JP!LZ_eX#n{hR0H5w?nUXKA+eXo7{4EF(>GGMPPZ7?)pW?(yIXm4`>@KHyd!3RIq)uh zC&wo`BiUS-u!Vq1Huk%>+{>G;3_1Ndq5+QGjEfE>jJCbv?T}Ctofhq-Y?4|doW(MR zcz?uv;e^z}z#4*bq|r+bS7NC`2>P#{PcCAopRitIzwJ}%4LdwA^E=gRGC@HKIWSSb zOf>{*FWE)ef+6M999*1{DKJ!jS-DQ*7uX?;l97=fCWQ!ED*hfLDCo)>TUu9v4fVf6 z$JKkd6*0(d-yA;S&G(~_5rbq?-(aNQ4L=iI+^X)~me!Y|I8ttl(Ay{2ap|VeOR1aX zOg8tC>#)$qyAD+^9GP-siQ}jO*omNJ8k?dL0d#f@3>va=Pp57W3LUV24gNrQY?lgY zN%7`%!e$G^Ze1)P7CFRO7}uznB)Pa0d;TIeCVFMfa*(l6eqSK957uZNDB1mYnV7`} zdb@TuX(BNW?=tr2={6qU#y^qp`95ONrFaKny<+t(vNGFiZ*!=lG9GawT8HHhR}BET~~X#cuK}oi9Of^f_oBg=+!(Aq~|5h zs{A7#-NZB)tO|}^qBd4J)IYIi)-Zow)?c)A&&4Z>N#HH8^4xzff(zNwR(MnRt=VBNRvb z<^Riw5_bfK;Fwf3v7HERh4p=k{;rC3KQ^u6odnaw(7l^~@wL-0#hK3qiPF8Ll{F5N zt?BZzqbO+knowlZgvWUvmN5{ib?yK?!>jzX@?@^f2z0IYh$^Re({otRex^dlmXoy- z!R3WVJQ zh-VxYj+Z4hYl2zrJFs+lIxOom`vYQYc+r0raL?^$%r!bG}Nupk8 zW|a&S!|6KGK)=Qx3U&+kL9szmcV8%P5OmwAO*9FAu@k=RCWA=8oGF9xx-FQVxtCxz zNRG9$i`Zmx3zYAKu=h5K4AS}mjpv9yJQE`u&hqzTYLu13y|oU6E$V%MP;k4k?htn$ zXVTN}D*&h4VI43+u^NUfxIX`dHUga>3^2QpTNi#mvWD{65L#G!F>RdY*b3QY)oh!f zg9M*{$FjTRorXU0!*(~!2F-|IjM%|CQ6>eeDhhezzd|fg3)@Rl2h!EOm7KyKl#9 zz$lQ9feJ%zkA<=O5P^m{0)ZrYy6#1%OTBLZ7d;e+MVHtV!w7zKOR0*nwtgJ>Mqa-w zUJ@}#EES3I$RL&+qG$m_qX4gxIwO!ku36I&s?k~Zmf&$DT;T2is7|S{0HHu&u$j7l zC2q&h>7=3zdqlhuN3jq)L=;1xxko0!CNen~I}ePH1ms*t{I0H_qQg)^O;uu$XVt94 zPPWkd4mX`ZC${@_`l*~z#x6xpNJ1$jKqoUgi`r`TxZ=|c*97Dn^douKx%N??HiOMGhhq5jxjcl zR-0zM2sBzuuAwOJpgRp~L-4zXZB76GCq+I@Slli%rzxsi{u<3Qc8K)$r<8q`<1MOU z{k!U^-e+vTjci(!ekO;eLR%FK!Z%%xXflkXj4J_lj49z@}CV&zMY^BVuPu{*y%URh?_(uOdG*#rJJbNgXx-8&Y&xre{U)4@ZC%0g}hjFpJadfh-ve}}J>$EDyiWj{{ zvA~1;Rp4tlscI$Us(Iz9Ll$9w9t|TfFgjfA;QdhX42KM8p`Ct`)kF`>fbX_@gjBHX zO@YoN5p<&$D0hbwe&T_#BEu6noXKs&`I}l-B*NZMGqS!WYNLJA@bHp&4iRV*tPeo- zW*4kq_&Ge-RohlE6Sr{xAZQ5Ux&k0Hc;CO&h-&RVU5JNfA~PmCOtqnZ+Qh732j);c z6$&K;I`qiF%DB&XuLXix;k z%~9Mfb$SQXM0*S(2tx2DrSHoHv<8tyO+3|;`J5#VM*kco>G<8*u?|IfmAj5DQ)0=d z45rPc!tS3Kq6y@FhP*hh^GA_7;$Rp_mX4i_T~@SxLpQT<0_g{TOn3-URVR+WDE$~j zVi$gfonU>*%-y2w4TaVo$QYxr1BWMrBT< z%zA=h9I7qW4GBUN>w))dI-b&UT$JVxt(b1|H-gGRRdp;gF8_HfT4CD%cv6y9RPm8w z$b4zW0(v|CwmOf0b-gDN1<5h3NK_XYuEXDwh97^@sWD91Y%I9~#NSrTCvH^KSN|w1 z+U6%TU8UZO9VoS)=m*o)NlhuvtV!Km)L-c=k6<(Cy7OX_ZQPSA?Ej&#X+wiI8GMF> zLY*RKCNJi_QDu6k=&$eY+l-iqIcP0P4~Kj{N(j~^UuxQaZinStSJhS`a4fueEVQlBU?dC z&Z(Tp$`izK_D8+06pPj1j-B-P7*)y+vEv_$QO;IQ?E1T~=^p@PBCT^yl7ne5pjlPB zh#HW=HJ56Cf7Hrc;&PPCg-pGl;ypkl}4y*^Z22RbQEd}kD{38#M5gjsO)UwPA$P#9f~ zX6=|DKxhAwf=QLoHv#M>IAkmDu4^_{UCNwni)0 zK*R7ZZ|YrWe<3_7Szz!rpjRZrN8hQ&ZlVH$!~eSLw$)(E!K-v6J;(JCJlU#0;MWqX z9p5-6p@*)}pSDeZ?nLQV=a@&qU92r-i8;|*TUHI$?AlI&SPi6~ z42O?Cf2XTul5_9}Dk~a%k*G!U=;|8F-vbD@0@+9Nas*@GpElv}2wQ%K)fgh?JUadt z9Q)E^@HLgLgsqCkKpWHF^ji3};j5jC3rcErMYhLZaJZag#^Ug*(gcf5KLa_=55+HD zhL_h`{~B2(cv(7BQ~0oLNK0-YDnCvKpy$wle`=SQ2$4So;lEpYlEMFqf%Wr))KPiR zcDxsRa4^p98mx^JJ*Y+a`CQ-gY^L7UGaFP#hxF z$P%aQjk?7O#nXmyOTbn?zt%tW!W?E}e<1#mw4iXhg|l5UINcL#9&F92qV2}@RURSC zzDD1r)7R!a{YYA_z|m6bFw9_OnqnBH6F1ZR$T$dE#S3ejlRH44Ar?RmntUn-u3x?% zO!rx22C*Zvw>fD+8-l7pe?J=eWg7)y1(71aeS2qNeD})Nuw2?|lPjsmgJK8Ge~pm~ zL6wkYjWpA|PcJQWE2=TU3OFKqcN8+>2?)dH%3@d$P#Z)Ao%y_^Dr18YZUJMC#ACGp~HJ$@Lp z8#RB$wc+B`OmPJJ5#grnNe8CJF}af?57$}g(xoi->;{ve=S2HA6WElyf1kV0aJO-P zm9JQ>oH|8zcw#w0j4xvkK0Juy#(Z|W$bS6`0DI2AaKE*!;=*7ySu&QFXysfcko4`W_TPu2LG-85TN#7LZiNa+36bXjxS zyn_V8M+W7qHoB}StS$8SN^upW`GWUvlCuuAOf{6=zs~{~vaDDsO9;vl>u<%s;EJ?iPE zl==Q+dhywH5*#5H^zL&vh+`rykJF^F5ExkzP`*^zhs22?uFM1hB9l|3yCn-&+o*~} z{ane|JPC!+bvET2@Fz1RwN6TJlf<(K2~%ys+qNu46!5UG>?_MAjxs4PouISvgq&IM zwz~#Eu3cI6BurN{e|=fc=n@d#hl)Es0Ev?+@duxIngy4`QR_Cy{9T*+1ULxgD-#81 zGmK#1@x~Z0WlLA0_p8?y4`<&XJfaBkOT+-?^i0=LzrsM3?t1BSU@Os_8SA<(rrJ9=Dr zdygeV3`C!`Yd1NTdoSKY;)nk>(bmC%_PF&R@sfN>TP51gb#A1GHKgL^?H(n^p{5WF zU5n` zO-Wj*p9 zm)FM-Sp-D&$obcMVwUmYfjC);inX_kYg?n^N}q<~V>WUGu=BUvw_m)`I>%=8ORih( zlmF-Hhb-7+Jn&*%oa${2Ddi7CxC*VurAHH8dpnu45e=i#W z9yYMs3^bdhdAJS?7R%9RBUmh2%~r@pM-cpg76r^*NPgQyAbexM17`NH%iw@!&V9{* z-Q*@Xp@qJho4Q8duSXPg?{Zb$3m`<*zzdw~h7L7wrxZ#Z+%Re+^i@kAL%4%29m=EU zIJ7CZV_Nl*fddAu8H(UE7|LGce;ab*C(*Spx9DzRrwg4p+UWc*NgVz;@U?c3JZi4FLx-p1(*Q;5#)ZDY%S14 zVYz=cSlPVvK`qCbe&*Gm@P{v{0kl3HXK2Y%>`%0G@;3HVS-8#EnN;Hyf0EB@j8#co zLkkR1FP>K367ZK1+0U^m==_E$=}Tvs&c?_a2P07howa{Y^F{z&y$S#3hGsW9H?PL~ z(v|FhoE4-wX4KV~T?o3J-0zcJsLn+z=ARvjPQWXB=`F=4W)K~aLV0{8PnPqlL7&SnUXgGJNn+l!4!2$pm!3D0)Ee?UkPY!yafg$!7=bB^XvJ`lHlKSwf8SmDd>{Pr)XWrVly%}wvne+KV!FtV0#^k9$< z=cUezbbU>??J&+r)l5hY0_s&Z4IK|*;z0VIlK#@;K6qmkSFw3L$_uOJw3VYsk?7k$zk{<_J@gzKW* z<5$`uCw5RBf9r2wY4`=gSW2y%1$pJQic!MUEs6xX7#9bIa4wfBJFAL1TJ%v&yqaU@ zFubg?f?Cq;b4R{;&MQ`RShMO?z?DKygonpkduG5LMcW}}K8%-hit~;KM@iQgHM-QC zQu;l;v%+*O?rwBgLBs$j19a~$m3~qjUgG;<_@JnVfA*L-636<;gAio!eZtAhXBmNh zxgf;!AlzEgRlYt*(_H{quCEOlc+gg~h9ZX?n&U4eIkuIAiNYfT<#ITpFr>S$YC^E( z!jC97>X;o=F|baizWnv_zERAOWH=b3k5i;s*f5F{vPfY2lrg#fIL3H^DRIs*zkDz_ zh?ijLe+~6%9M2}s*D14N+k8xOU9A^Fg?Q;7%poy}>|KsANbUKO@`p_+xE~lemB$3e z57~Y<9vxDoQ}`}qAhw;J@B*3VX0}pZdp6`2&er*|rcqx`?Ax&=j1(sDOSo9V4XsnP zuIb#j`DY7Pw7IRrJFH+Rkdd|P*o@*{_uv-me~?`8XQ5i;cp~8%HjaD^UVAel`ARuK z#fJmYXuL}%xR%2M)NfYb(?kU!5;5tEpHIxOGOEN-`?Z>ky%vN2jcd6fi&hqG-z9W1 z0*OiKhKafMIs5Sf>{#NTx>-Hi<%iRym} zexdhgMw;KWfM7j_zpI%)LhhDWlb%U0Qk4eY5DnZN#^u% zQzW#>Le_V;EXA~et%qA9NbdMz7)?>mm_B524tk!sd@)PpD1U{z=S@&lY*uEq6zRd2 zCv^t0eJ!5QJP7rAFpFtA3Fs=C8Bb3ae>#1gp?xV5`VnHXQkQ6YNj(!Z37yhs-4b`? z(GBn+B3}mEc)gH{TNr(7oe?DUg0dpX3py_N0vG0`Qb1g|Q#XzVx$+o4USOiDtYk)i z0sHh+%47qlL_$@1&_}J2t`1pv6d)#DC2L z6f?6swgV?);{*o4Ks0u0qw@NM#!>WNU~8`#*f~Vqz>82(Rn>m`Y%T}*e-l2Ti;F=p zx(0BV%tV7yE%5ZP`$F7i%(k`S@()5)u^VMwbQh+k|{F}grU6gdFVkfW>b0i zsEbg{C0RL`LQ~gmia+?;x<%C#Q0tu>bD4}0Vu`0O#k_k}+d6@c-R1M*H|iE6&w|N` zC4uw`C+LGQ8xUEHfK~f8AiJIVR)cE7I_%x;zll!1mLK%Re^|NK z0SS_p6_90amJxr{UP5^u^Pc3p{)B1IW^Jie&txSmI3Z!bpq+BO&kdyAZ7_Baa}B7x z(NUA}6<7>0e^*MeDauqwCFO*pmWdVKD(b*wj}A0%jXIm5_D3RZ{uNy>HY;UD(%t1^ z%y4r~*;=KF!+PhPf=W@L4Uq=$Ss@I6chOrCsb|UK;x~VOxbK|)N*iwOv-2cgq8TSAGdRWwzo#ls#soB zSq!6~e|%V%+^uW>`TT;oH4$^|hu1PbDQisn6rf+@9Ha|MU4)9D^b@tSMRzH1Pag@Pz>t+W|Yw1$Ix@b`rE} zjo}yh_w&Mh6`ge+^ESC?0*nWWuH~=FtWW+2e>4g0t=V|R4Km^(-mdh(m^U(D)?|$4 zC$`z=#tx)9$FHq6zz&jBjW6}s6T50?=NPj@TB3l#u|!F5FnEvXz_s6+*iemopIw)W z-*D6enSd-(O2N3rc_AWQ9mEiR5%>-`>MLV1uBDBFi2ydyczkCOsduqH1Gu4cX>C6i ze?Qx8L9{rHF~?jUoTYJTYg_4W_#hXq3Hw9zUo;;{&dA02nme3UxNm5IL-uIGQ+r$(x^F!rGX>wr}uuYk8F~fqCRGrmyp2 zZII=}DOnQzJLeSUpQYQYJS6p30JjN3e~_q~K|4@0wLbIOncWVjZ08%zEpUEWN^0z1 zYzF?WP9e8Z$zM(r^7hCFGBt`^-Kx5S%A;OLlM*pmg@4-KlBbWEq;JmJ%DUUUvVN+q z>nfYccMNJuGua*zi0`3CFUMg}-@cM}&Fimqh2*2Z8{WScSKraeLz ztM)Tv5kLFwGzXwljS}p(@)aj`e4jw9#n1}<-1hE)sXMGJ0ZTla`_ zb{ewSvWDy!CXL)%rl|i;7%MR1?S-k`8xh+yXKf>qqvo8RiUBC>wxtcOIu}_4Mv-fz zBVzm7=^T*0POU-`%u)HadE@Fy(())St-?iEmasYdCJsuTAcfowT4}Rks zBB=NJ!;1luDLx)?db$F#>90x1(cvS;-L<$5)7tp`HlN%DtOTZ7e;FO{&^jYH@Gpzl zK1QGp;PV?K#enbrbxx@xR)2sqIL{(WSTbwD6KPS<3SuWVT?=Gwm-dq|sh|plqPgT% z(WC!Cc%tgnjQm$mtJ&s;^~+MJ09HrYy3wToulvS0D#~PyWJFHGto*$_8$kCY`I{C1 znd5xhl8HS|xY@#ce+6QDnwx^DAKiH>(+SSspcrTjaeg}O$weqvW(=t%9p!{{9$CM4 zr+*b|k^vp~6j-`ZXP?L;RA+{k-UAEAxF@~FLe1@Jctr9i&JBITc5rs4<>&O$3X)Q&yR4@b>!V9(j99I!aeN7dzg1^)6I3I6^lD!PABF)Z z4_#XQ1v%Z~QxU8n=eJ5U-7ne?m_0wFEN(cTjFA9uqp^(5Ma3 z3oeguo={1bEWIwsrSmn*#;P8m_=DrN+~10H$u%w=ShQLsi)#KSX7m$o+%JKoYQ>#K z){#!ZP8kFokb|k4%Lp1Y=MnFHY(nPkZ$NDlY(@)@%SgM(yeFm9erU51X-8^Z(CHy(?Umf&|EEKTIO?e}P5$+FJ@yYs0ZDg8V9_*0I|7RGw~{Q5DWjKdZ?G~z(rr~P zPvX-Yn>yN2@KuawyBxayoK+9x(qnD>e+qakf5EFdiDc*vFDL0hV$mGJbW?s8R#&d1 z3wlket>lwyxe)~FZRGnxPn5DU#>cc)vubd zxd8_@5pI0*5+Z4BovFCMny*FtIhJbPOc}D(Lp^lYp>%O3;$`r~oTL3+=HZ|qAB^I2 z4w77j;1Jnt<}b3j3Nr0EsZ+tflL=ypMT^~XB=N~=&w}XQl&#c!e%@}M3 zmc}18#9EnVxV+fkh=p*?-|knoyZgj1>BBkf-tQeO$;rBM^~~rQctXUF+}~)VN?nL?Wwlt3>YM_UdkA+`yl@~%s*tMykGg3+ zIP;l{9Hd!j4MK;8B)^x-egXLolh76bW;Q%X-jqv31$oGZ&^nnN44#-Ue|q-eMyPtM zsBUgg*MCE!i=Ckcr+KMSbICN^r(jZ;qeJZ{vwkLAvc1w-;qjt5Q#w(Mlc`^_YJWPN zsZF$EMK|gxtxsK05Zy&9P#-(Bv60LQmGGU!qQ63xj_{M9XsG{ax!6jK(@B(syH8{g z(>}kVPJ08(rDsC@mg^^Ff2*l3WM6&dECGxO2@$&B4aGnnfgUgBtl}5Zybb5|Vj-yO z_GJwJ<@Yi}&}FUVF59rOlouf9!ezPEF@dF zQ-ikG5&nYq8<4mJbFjvcW}M`>SFBzb|6L+^%XJneSXeOeJSE3&ihPk4Ug+FOq^Jiw zw9xfW!mncwZ!WmEfKQ(S1?w$d8Yt`#Ah^FpHeQ9XXSB@?0jA?+NOw7jf z_Oraso)>~qf0Kl;m%-G~v06AKdu8r_t-IFbJmipgU8G>ssLNCnBVx(j%{cO0fe%H! zqas%gccXJ?w%b?99oi)Nq<1catX*AZhT|VxI)!nXPc%&CiEB4?t~p)a=F3?V*8LId zP{Aizdd1tz012B2ny*c~5vWR`N!g%4BGJ++jKe54}{Q-yTG9Un1a_!-yxn>SHdch%t~8v zMOXA$CoLn;kGA-J=@6klepG%1+;1vD@H<{p4UtlylObu!m7*(hI~7!Lkt@F!=o_%0 zSgejCe-<8sj>WxCe1rl~rNrL=?`tYk@M7ymSFFoVK}ASZYZ=m3KCZsU6x`u2`i@*U5gSoKgprx7lBh@u? zx`{48j*Xi46uk;x2~}N>Ak~4vG{<@23iCa$6s0cR)iWUXGN8KA|Ab0fwZN$EsDA~j zJS&=7jQ-3DSVJJA%{sJ0zv8M zWTVX1+tH*Mk4$|Z(G;h%oAEyi5xCx8E(8T6*?UD?Iv!~kh7+^zR_>tdcWec-VX$V* zex*_2(@=msbg=9o#3e`R0#g3z8X-O2e@PTs?P1yAmIC2`hOGl#S_9+?07Mrxm03#x zpoEc;LM1xGWYh^07yVM?nW5<5&krre=v0Hd(aD}ThV26eMAdN^w;$Zx)vFTy3Z!Od zYWO-x?A8bc`gHiowG?mOGEZ=_wPeqPB-(CK$uI<728!tz9lB!J2LWbb2&^)qeZaz{dw%Z)e#daauJO?j)ivg_%1ZPN zEjS$zYaO`fwF%`?75`@?V)FAce`M+!%)-?S44%AOVm37oiFVON{vHYZsza1j`MOHb zHu~e%O=6aEBMfnoF6r~;l)n;|0@)6Wh`O?dC$ThE3PpuN-R=4FA9Vo(TidG2ZYHN| z(=8kZ?c?XAx@ei_0`}A+1@B# z1q>w{`QN!@z}19N)cNBeKfsQ zV()uBTB+Gnlul)9l@FZce@oQs-1yC-UYT+skAFpRrfe-;ucS16X(1+tB6x>j|GKu4 zkL#F74N3HYj!+OprI!TlW!$y-ZW%iH?bU0`$^;}&7w_FU?9m4DcrWb zM=ReMP;EKiup;{5K(i3#CX4lrnm;Ie?bV_B`%87MDir-r3Mv&8e^kul;%#O4UgLXm3t9iLpC6O9(qKBlVd0jeABIaKDN`W{G-afl z*dj#p`9Sk6NnDS7!b7yduWXgu_AU`VqaJEowM8#emAAGGIWGfTPrYA3O;j5O8@vPq zo8B%cFA<l%4X4L zDCE9&xEp>5`%JIVYu9hAahwBL(^CQCa@OIQY9z*YNJtDOdy1r;`5+HY!1`GjA1ftXk#~znh8EIe}4jvD>k-$tognG{ol`EXw9AB z*p8_#A9U~PtYKHWKJSypVn}2Ffkw=RV?9?nOBow*GT;Sd4e5dJ>Sa5_34ifusBy}v zvsjChar@h2~%gmk%bCA;=URYjC252oLDoH?{LH9PcIyS);qT|6dXC7RbH(~I2s$0Ae%D^J6Oz&0}NW^kkVH9@S=|6Y>iG4BDlpP3+;pW#21ir!Nu*IFd ze~^RQ{hgd~7M~j%l8h)Zj*b#=^jo!R zYO3}H-zI&h=58l*Q=S)G=GlAM{i;x^e_eo?5W)#`42uY&RH%mMAn68DZOG}qKCv6< zD1;WL@u3n6nkkR1ntYm#1Uet6`NxZ~gqw`CO1q4r(G0W)PBmq9xFJDx_KSn$HEab1 z;0W`i;Vlp)dGyJoNI*LNM)aiXO5cm?9Q7tIg7{vH(d0XO!jI#o`Be=A{|eHDd^d}R`F(2Q=W!T4&{^ZDI`X}FDz!}g)= zkvC`Y<%qBJs2o)gEJ$j<(8jlr7%Ch`mg@PSn(nSXsv$Js8|dJsZmH1T>*PuZ!osfc z6%bAZNVYhD19hsi_E(6d5!DZ@BXI*KuMQ&T>rzEFb1$g)M$edMc&T(ke|VLYL!p$L z^Sky&A@8LBhe%5=SIRCY&WVjR)p)1ag(I~_gKrba4ykJHGG4$71a0$>UxAba%1-_m zC3a8rZ#}1-mo8lLD=)(IMDGhDBv0hG8UP|V{gwdY+HYd;u|Jp&U zqd%Ufs8BR(akZ@y8nl=XMB)ns2>i;tMA+epChqhf$~l{!JI(a@3^~V zel{YAxcJ*m(JhNIU~DUMquOpF`&uR{yfWt6+K`2e4{({_Lk<@-2Y}6d(V2X+A=|>i zh-kBcJPICGL{Hr8RcC&or@-}z>0pLVJ)Zoz8lbyJ{aAl6hH;x9xS4O(^~jAR?nmep z$i98J5V35*4vQM$f8o!Q`>R;=WzY}DX_$PK_Z;(dT-xYxEB~Ts_j^MwVXuIw4`#pv zawR-PyMjle`eq$3yLAZ9{H6RqeRAw z9arGYVqcFKpL)JAhlZm|DtBUqkw>k7W}S5t1=<}D8r`6=bL>v13-!++)sYfKpyv45BoC~Ae(?qY#n)7OPnF)gmIr1uBNA{V!B0H9?H1E=xk^36RC0 zMs&si=#$z#f7&3)68)K}M{=QyQ*stLHiyo8x>L%_p?Zc!kZ#V(dK@qX=`&DrJ!$JKHcdI~+=i=>a_DV*%p+4wObflf9WvIp z!L^CgfR|7bS&V=foJgpH*!H?t2PW~XGcB9y8{=6&e?pOR* zTgquIv*g#4#;`F0s?O+-gj>sI_{0fkW-kYQFy(34i}_hLRuTYa-y?`3WVb;`76}M} z=_s39h9f^`quW|2fKAN+7ssJCtZ-J^4{yk%KxFFs*I*%F3A3e1{?5UgU^K4 zxE`jpf6H(4DqabA>}{CxT594OxXK1gk3r5vhakVseVcmdOOR+aeTG96aRSyKY(qen zAxB|+>R{6=@dS---8Yvf8?JMisNnOX?J)rVz*?nh?L#wGycxT zIV|8y$QP6QMx3`=kBr@grszK0%UOOx*AM2;Vt2nsLJZsBLd)z$u1O{DdY>s>=;47! zIOh-QMNzS>t@%-4S0gNI#qQiCFYj$MFMusOtooBQUdsll`pilda|HCqFEpIxmt5FO ze@9!aSt;ugcQnn(is^*CCMp!A@F5TWFBPIT#5BZ@LQTjC`1TGCeQbXP>UF6OWN?rW zZ6*QwmeE^R(1fRnPET-ld8U{!{uJXT>_Z^z`qg2JBLrZqti4AqT0W!Jh*aP;Oq2Z~ zf#&OTHSD*y-%ZaEy;<3}j3&7@2+fS}e}(3v=>8CL*@^(OJ5(l2qU|$pS}lx|PnJt= z)%jU*;5mTMwKP!;cm_0?1-#feMdTIk#hGojKX_O3ghkq@zAzeeXufJV- z-v^}s$(-0@cVgTi_Ti|>%ilde{Wc8e3+94hM*n6I%j#)3Thq%E)U>;fbgVq4e=LOt z0n=DvTD^!FGOf+17I6~5zWX?@bcDTN1%EM42T+>H)G}yBVS(lceR2fmf;n%_-`8a^MKulYKDERRz^bh@2`-@4QZS}E8*3YR%W`EXq2alNg?&o zF-b9Q@U{1T%FRXU$y~RnoLPT{e?pR@v|jdQ^3(gwz<|z0>IX`RTl- zusDDeITX~`IC&AUb{`%a->X&`2-&}4AlW-rMw66hlIrUMd) zebO4+fpwl{XX{BfU6wb#nGO>a07B1*W%9Ppk`xR*32s={GD>EMw!V}La+50m4hD-} z7WRXROUPCck0yI|LjNpuE*Lb9@xwFe>aJJ+6^5^4{=^+r3_za2TH;U|cT72jh9D zjX(vLys)%fY%M3`cbKa_m*W>6xw9&hvRN@LM616AwrC>hz(mV!fmC9>50lF3WN9wp zYX0@N=c}6xs5LS($44W>SvuRF?9Z8>(?S&X1th7m8WMY`7mGgHe^X2&eTVZgfze=k zQuqG<->p5P?SKt~+MdBa-?wjOYEE;jV^xx47S!C&?ud@oIx68%ww%R&rZ&mwdGbgum^JoIQ5I=_7;t%c}(J zY@!$u68V!(!5_|jf13T7%9od%FpVk35brd8jug{*@0!n%bsxD@+1~nrI&nHae1hZZ2Vo|MD!efX0cPPj+q04S$X?AJglwby~_!Ck6 zI2PE(J*dUJ($BMzOd-(9Kjl7HxP^!6+q`5khU-r4Jp!Luf206$S^*hod;**!^r$6E zjO1f}T+9N4fYLg2Yv6KYoef!tvE8E%7%_nbkm42J(V&ssRykUNqIAid8$N!46@raz zq*@)RFYyhgFW9!y_p zQC+XpAmAp7ZFGFZfNH8iztx-yevBfSN-W_NiP-890_g*BMx;#wj`VI(%~b8*49~EG zd-huY4_2w)B#oSfhEE2LZ8c*CMFGjFipZ2su+Fvsll| z+(a0u&LG}w1g>$z;><%%*-p&O6366nT=cvd67obMzUvIpPOjP}aopY`eKWxO;F+D% zo*JGFe=&UJ2hd93-3Vu_eymh<4UlA!;+T13+0G_~ns@s!;hg?W-7o~yt1NS$Qs_0P z`3?D~PhlWy^AtG6WM&JGgsC@)SdUf?D-k>Z4Tov!Tx=>$BmNo&UGNOSynZ=AGR*3d zPv@$x7!uF-7Zpo_f||6bf7i+2{4#|R$H{ta%d+4Hp`v)lLW(R5 zZI^0$av-9!srLl0*Zdq7)qH6_@sLc6*zW;Plo*T85g&zqKjP2OSANP+xHH+ADd)g3a7V)chY8s<;_q zf8GG^gJS*2pdP;c1AB6XfGUG^WE?mgnmm{N)V7kEm1&VmRAXm)3A(k17F+7}_I~IN zN%iE`pF2%e%Hx(vxFbr@#V%F<0-ADy=EkAk)W0ScRIE~w>Nl(ygb6q7qt@r9RbVAcR;v5c(5- z-y=|oC+7J`5(?etc7Rin{H;fFPla?q+(=RoA}3Kf3&Ff zpg!TT*e;s@45WlMoy#vdc!tL%_@@7CUqhrJ@))R%wyl*{Z?Z3Peh=J!=Uq?JlhOv% zUfX;vop=s6NNH>=!@q^4FY>$-)`Com87b9)g?=76VtlSD%1(;YdtT75vYkLV<04u( zX4j&WC6z7H(#?lO);j9ba9Yg7||@eIYA>>zfBQf6hB68?csyVsyWy=LlecxC$2L8uKx!2CJ$&LRO#Yk^A_GEjUF^ zU1Dbt8R=HV@=G7KPq%t-QWT+B3aA?)wW0AzBIJ~qjBAZT@?zjKe>B|hAiCa2@ZJH7 z9xh&mwuv=bwgPo?&vYax__@=1oTochqZrnC-iIYn8p+!HI2}q;+L`@!X%*n0*g;>w zDHx5QMTUQNjcjXbMG9+zNl-M6V{X*H2+9);Z(r9_ziA_=vp54#_Yb5K+%6T;Gu;Wg zYAbJV89e1J?d8vwe@(V*9=N@xp9U=dYXZiOoJUx(eFM#Itsi9D3|ge@p-#s?vE?BX z0kKs9u;`4cMx&2422{S)L1OK8#=Nh#J9tmI+o( z2iV~7aK@Ju`bP(*b>$DuhYIx9_}~pF)Uu@gkD&6z;SyT)?6(~jd#DDl>aY$9ZEqOf z9-JltIAewve>n^L>?F?Pv+qc(2m>OY9B;h5lP3l#7&CRHL6qAdy)6Hfe16bwy#q^i zQ^CR*k8s(mha*N;7s>BTBC^j}BP^~Ugj8;cjHj>+V}d#ppXP{$uOXR3p^EJsTSZ7w zS?&84a``U(T)tr5UpOnyII;NutB``w*hoJs9SVmbca-_!!sAqZ?~;`XI`+hNXYX#HLljb!PA4@*3!XdB4U~e93ccG9 zhz-rBhN@%}a4eC$!5z^|L$S=@knnAA*RWC!f9B*=*vJ2M&nuwe?)_jSgr|6?viP&O zD!XmQf5Cumjvje+!|#BAT-(36b-$z&2jqzalq^p3O#jQf$vUHN_H_?i0dE}WcM`BHJ5vwEri=x ze}1*2QlRho?MI|`;d)b6ef01t<9em)^#Ee-uW+?g~63la^LOERI4|Ja6L_UDV%|O9gV& zD|T?7zZLIw2z$!!pymO5%%D=(t~4jf<{{p1_-?lOJ+X;!Y0_mnq2s7p!zId2O41`;9V}ZE#DX%j+LJNi}5~qO$mH>e-2j; zR6@}B;S#`9wtz*V%=KzPo7v#G1dkGIA6m(DX(AlKuZ=*-{3q?GZ)U9iHV4i#AzBGBn{F_w9Al_oe zXleiEvI)3lIMzoRWhS@onO%Z%f2GqgpDREf*Nf+HFdiA9f%$YMW}?}p!Z}inSS<$I zSI+mSP7)Ao+Ui`$3s8Lb?Q?-(OgGkmXsUb0xfU-tPQe_#3R!h>5Y z#%c4xG|IMc;?PND4Pgn}$ttD+x%S;X5GJ1iRKU7xePh!0*TN;e_7AOjlImnDJ%!ZDsmO>*l3=VtNETc9^-SQP1pLUd4FjUXSQ@>HI7te@VVs&d!!)*7*0e zACiT^bTB13(mP|r_O>?t_ts-kM>HX2P5mA!tN<@S(7z_`NTh2GRW4h5O^OO;Lt&(L zWv!mepyD%V5b&J>K~sm(JW^eFU41jNgX)a!HKm7L4_UWT^A}>WV>u{Q4qkvFIbbhC4 zZf`ng9B7XQe=GrlF)RQ9PMT+UmWh=~J09Toxh=pG-kZ&{(3;aiYNwSpdLPNIc6 z+RCbPz?>xPc4P*Y=_`bvXjN}lM0oOdZmz6x3n;JLQ`DvJV-v`5d z&-T~)b4mG!Mk|&k?0<7?wQw*3Xo_er`YhLRO!!J>JH+sB;^Tg3n4-~OoI{U*PZBGN zu5t8DuhaXY__)(VL1xncr)dG4? z)!k$`-Gj@Aj7p+y2PX^r)6vi%T&un4x7%Sz#%Q986{pd| zhUgA`KqhKeC?2m$u#mJCIGTjM>0tQn|W-Lv95`x-p8 zqz_WH1XMb{Hn`5RAhaIW%r*W*oFaFX`3B$Kh50EWMh<}h^gC~(_~LXnNumg&=$@{; zq!+fwMgnPNK~cx0oT}llZ?id>Mj;8R-N6SR@@@yPbV4@=30g#ai;X=}Sr3ht+1$d! z4S)JZ%}mxVkl)ZeX;RIB>ujja=n-+2{lkyXc~%?C=hFr#W_z$^Q!)q;;t8Xlv($ad zJPw$;)}kcrT=y}9xL5w^=au^G>?a&+(qRgXZ!l4zDc47Xy#OQ7z9LF6ZqzMyhC3bg zGdFg7G=ZtTo~&FUFcIYRkUwztJ8&O25r3Ss7pV8^*un;pmJoJ?-%&JjE$lBOZ*mh` z7i?Q`REZ_B5TaUM{1`+V)ZJz)H^MLR7nKIKOSHnnj^W?|oZX01W;DH@<{Jx<9ElojGPm{KZIIj~ zy?_&3uCHZLy&KDIemjax_8wTeOD;i;zj*|9x$I?P%9In*OM()OB6*X7fC<7V-zoJD z4||xr@^qUCn$yu3ibajA5dgcO{eST?SgC@7{<{>;3SE4JEtVa38BaC;jcFb|Ys%Li zp8N0DU;e3=1E~1&4b24EgxEG}`=!DP&)@uQh~?>lFs{K`IF4#6rCbYHiMJMlyTidx zNeGf;exo1!J=#&A;;b4yMu!PQn?$zqyq+~*BS$)908g;bEzu+{B)nF80Dr`*gM^od zZA0L`_!E5J{o9a)#((cjwO?%-Yz4NsGU&g%an!~Y^CN@z;*ilUN&m(eoX9|T3y7Cn zldhLO4v5N#n?CfPYZ3ZHrr9jP=!R#=0g416xOh^E2Di-JMP89Kj`=NDO%XfIBirOz z>u+`Ai0g!<123YCpQ*d-?SHaN3*ioGKrsS8!C}d*GuQxN_dxBHjT)IMV~LAfSF?%n18=10lff`CilDaO2V&5n#F==&kq*I7R^jek-}=KI955nSDR z4T4cOSR+GJ4F15rHKXS3I#DJcjSXGS;l~Z(MWlIwo-C; z19Ob$QV#vdPgX$KO5;GE0v8X`u9l973JKIg|yvPQJo(SO9FKS6E?3<`RG+vJ^}9-XfYl;^uAR*P+EL&AnY&nARr>p|0A zKOA92GBa3HLXQ_{T)|*T_4C8rip4w^1bJO*!#iPM4R%gubGzzriFaSDROFF7L0Py` zQ5oi&REh#*W7AH!NK2S9sv%xtYEY1-IfPdrbbGzA=0+@zYJaCu=GzmDsm(`b zBuCVO_J~Sd`znH0h;Z5wV#(K1O%0WKmO+dj1h*j6G7}>gDz@2L4m@u75RH>_Gy`|u z3|=Ht5>~^1Bc;RztD!38QgOjR8xlkjYv^fYsl%;}#1y5eWI+dy+UC zX4pesP`mI%RvZErZo4N1H{=?iDyMW4b|rR@^n&Nb1NBaXAIJq+J9m4=Z|t1ursX8q z#0kLV2`|f?O@0{tQrJ)NC6-|QnaC4mjlONT_5BtR*_>;tQnTaUfa@- zoL4J5TU+CjCBL(53t(RvjtPPJGk!V~2=>!&J?|_3N){LvYMSK-=Z?SP{J98GYUZyM za6vnn>C={=S{Y{wu3d9bj)frDM{_xsFP_%Q7q+%2dHt@c6!WOt)*&dexi9a<{j3}$ zGJk_NhJUFFY0{S6-?B)#ZwuWZ#;o<7HrtZ;ISq5%eJ8qE1iOH8)fsA-n!MJom6iPq zK1|es%$+)^wyO6u3SOAeiu!-`A&|p$_{G~k%5s&kVRlCqR*X9~`egMHHrc`)U~PcH zgSmR7b49@thO`2Q*Q2$N9gkEiH%K^&m)y7CAQ8;&vAsI!*V^zUn z0O*Jiw@|*7aq?PQ3=IdL>YGLOZ7Pnmw%k* zZolD-w^n%S8dMgg8;XQj(u7X3Sj%-X7bL~B5$ryYBOwj!X=SMaV(`f&&`H-0&dSPl zYuOTHs(nRv$0oObr~fEnP+y%d<(qj933A7JpPR#$8Bb`J@34oEg(Xou;q2|Vt(E*);$ORXF_&y z8)hT)Sif6oQ10cm&$k)f8)Ff_?4z^^ck)=FMIFr_q_%Kt_Y-=U!5NP6=dyb+3LkBnZ8KEVIjGlm0#bPzbJkuSgBy zNFCLVvL5No)iu9BfPa=|LD05o+kowowJOZ=5i2%j*Y6Ig5`S$XtREXA5^P3wf7)^z zLNsMu3M)_p0zHY@QAJ*}44@;5nqp8PV`l{nmI1b;V=MCJOtypY+xtQWiF zbas#EF$gTc%PDc?TrcnRN37e^UL_9`p^B~U&B+#kLPn(9flE9}6Z=dyC$*6)JKCNx zuyNk)x+&K&DelYJSICz=`_XqZ0rq>#@_;eg;p=eL2!GQbl5D(3sO0O9KVBF5*}wpq zVz>y%?unFc@qZ+ZCGrfAAEB&sYwtC$Cu5^3OlRc1!rG)tpER<- zMRfe!k}%@ZngmJ?XeeBXRBNn(`*D9(NtIl3C zJ$#Oztdq4FhA}_-)(iC;=qZdpjMWyp*OWGOc) zL(GSI+go7swVC{itBS#Qaro60(aGO2+OATfd-8Gu0z_|g)1S6`WkbsA26-CNwUect z-G9i%W+CRZDcKac?4!`INMwMqUk3uV1mh(}C4CKuNJ5kZyB?+f%WL@$$I)DA4W^&t z+bdE6yemXrd;yj!Oj%IkVzpWb%#d{UoQS9P!T+p9qxo5KHgh5X&1?s)gurrQF-F_i z3@Z9!1T$qB%kuOSDOo@|=#@3Ev3F)N=zr-Me9E3GARDUPc-Pyx8=9e6fS##Mkyg|O zz5igXaeE0+Xs&+Ek-*Rm@Hj744MGYVSDYERc%*cWr2M&9piq9>Z|sZ$y36UwwhMI9 z?1Q<0J1@OUs`7SB(fZpp99|AEYEiJyQRmht~IG|hDV`oS=p=qvPWQh_CE z-ZX`q?dQE+nFqXi$om4|<;Jzy*g3Tu+1h_*J8RDhL>)Z|!%kp!O9*vq3%Ge9QBq03 zIQQIG$btcuu-i}Z8rr_)CZYMZcAQW-frzM@;y%2qC8-E*c5;2?B7ZY$eZ30pG0`~O zMYIWWKgywL`3_dRhLvclUp|>coVB&EKFqzL&Cvv5vGEhuNd5YAbWUlzqaET+7o>{F>lZ08#f~m2T3PfWnK2 z7t|n_Qqa)7p?ot~+B7xF9v;4E5`dKt{Q(b#^`9v+G1W9fnT@B(==jWVd7R(38`Zee z}Crb=+ zj&(f@s^S43+oqGxx`vlLto8zTp|eWj_V7nJAblpwtbg4BHWi4(D+ZeH?(tYXlDcYY;D4@AL^>>oX4&oxvrkGMv>(p#rOZ?@kWL!NRDkul{G zLy+EL=YJvc_3HVpoEd@e6mp1YXeALzbLk6b@XMZL4`)g16Wm#sVk?!4nkcUl4oU$& z>HA;e2cPRW#WLZtqs)bCyQ@#%Vb1;k2%6;RbZ54@{sN&SIDFt|w$|TcrS*`Njo&-v zJI&zb+5TSPQgoI*vTdZC%=NN7$Ydl_rVE5FR6C!90<>m>?Tv9h#&B5MC|plNAB5Ra{+j)V zDLky)%Ms=T3#iu%dc&J@;LH|QEWY0NK1C$!9E&&Y*Jb|~Cuzm;u54!mfO^O9DYk79 zynnbEp((6>6FFjhfM8jUb@SDS=rF;$Shw!iS0}E>ZJAt!O_KdO5+5XjZZLHP7W>7s z^ZyWRB9)C~9b(Gn&`j0IkYVOHdw*t-z38ntn0~w%$I*)eTog!h0Gd6LI@(oY1UII& z$DjQ$%Sa(lJEqY0z<>0f!5Nn!Wbod^3xBF%BjwB@z@z6&*W*MZCr;=Ywz}=wxTZrf zR<9E=9e}VVY3CEorIv_3j+OVvDA-jb;-_0?th#SR)k>hkpS$otaciuK%8IM(WemSj z1H1|+w{F?-z(tMw5(V1*b3q8`EaO~2_Myb@0ompR3c$m{P)hb88er_ydNS8HAAg18 zpF@3WGYDn27475RKClB1`2caLKyoYtD=V)mNM#-AoA}NyjZV_4gd(+vC*?d=zXemD z^JYv1}Co5J5UU}xan%6Rn+abC+BGoYd*EpI3{U49Q zn+vYz&nzO2#Q8Z$oQ2Z^Of~NPnAJsA-R(`P8dmX0MBeIz#l3WrlHjLq+sDBaXzmdF zy077d>e0nV8E?ICvH^_S?Aoz{LkpF}^Pz6RknlUV8H z`j?%tJEqCzhU76l^+A9qY zwryr}m|eX=WikWutIrg62!Hz#yc>w}(9PlT!a1WO3y zTiY~#7QHnD3lhFk!Xu@1utxjB`~CCt#{F>Ql;=7xB0UOHekCV;%}Je-uxYfu;iisB zY?m*ywXDt~^t zQ=~cxjNBZ?qJ*IL5Dz=BtP2N)`aYNK%lAU}D>%B}H2$BVTyz8JfhkA$A9FoXJD9=z zit0x|&QB9K@awZAP=C~Nfmulg)%`RBYXT%pX~hpNFi$egQpg`y(CMHU6)l+GGFFSxpJKy`G0a zJdVx`NfI*mrWVCx%;C04; zv!P@eOwdD3biU2i&JQ}64}g1JFtNzj(16{ou{OzY>%40AEzxTHA7Vx^kk$8m5T)ee z+La5J3$mZZ5Pv_$Pk!=N%w<*ggq) zVI{}^a@pCu23_4jZvy`+o7Yr{(lX)v_?O#yw4o2z&*(yWi!Xd6ES0t5MCYqmT^80y zahH;zt_q_P3oVV%*m{$u;EQIVLCC(?fJi~UMszZ zud4C7kXY;p0J7jw=%00bo9X~MFgZ7Kwe7wsPOpR?$9O0$E# zSUTZafq!I&V{0IFst&!04mjgsQnc5ns%VgZv8&;G_=0DD2G4WSb|cAsf_e z)mHds+T8vkp2(o3?LsG&Kok2IspdT6n@g+hynij5UUXDHlMDuK)8+S@jWn7}k>9lk zC95!&hC?gjw0uK)849S0bFw$S^U_}gOGP3)^Ay{D95iM~AXKo|KY%157$H+1hjT#_ z;0v)Oy$0CTALiCq?tnKIIB_HswD0z^amdvcr@$E=apG8`z%FJ6>ClW5t^&GHXYd^M zbAR#ownP_0AfB2JoFsaZ@gagk#4W~m47{eyFT_W;#*-XR(XoZ;eVC-D5MJu%@aMl5 zXRppUw+eL@$4_ zK3zUqo~NC-NySGy+iTDPQitXu&pg;4(SMfk_uq?ILtb((wwJk`si3J3x_NO_Q}G}> z0^LanIR~^62>Uqgzi8ARBT}%%v27(jhLqp@`PWq*7~&@~bZ_v;hJi*SPA~EEno@ue z_BEg|*p%nYIa@YWi}y_ z^tMHu^e9}U03>oI%oZs-oFc=iB==s7QOPo}a`}!uRlYKfD934f&ey-ZUNgTN= z@HZZE#G$a&zKA+U^wC_u7>VyqS25>mBo>c{SOT8$>}SldR2TXfkMQH(h<_eiF|(uO z<5kgGh#`|2p5O8;q$~vX<&L}6;@}Pp&O5wJ4<8%vQh|q$7P2a`7dya<9;n>{`tM^j z)#B-3$67**Tlt0i-NXY-N>Fm)k8vJ3>{g9V+}!S1`OKWZ`K2b-En~*xY&3tA(4Qsh zTG)lY^tvYQOnDwV_5O61zVS2BPdg!*G!}_a z6ekQ464I?#k7&_JIRm?dY5Eo?8}iSj z80nrT%m2_%>B|FY50lRI}}t)S=@Gg>ujm|)S0mK#!E9r7DugMU;&#-%c(AREyd zqwTOb8Fa@eJoGWJs_h*-buBxw~dGvC!tyC7DZa=IS@1AwvgNe0)KM#mxvZ z(W!^n~$=vWanYIK6)#aGbA zln)-Ro!+FoJC3YUBv9(d1$S6L8s|WOt@-#!vM!mo(!u%vV1L2IEUiDZH4R4R>q*SuUuq&&_zR~)*%x}_3h9!_cn3mH=ZQi~Se=sD8~2|eVzJ?{u=rn_jm zXN5!*T%ldgd!?pNoNHsP8}+^8&TfnXols?ajc)~h{eLnzxYk{Z7ysf;eHCp8TMM4} z5-()tuaz8I_cxP3L)wUhGs8bq19kyGX@LB%j`pm|CzN{0Ldt$BTdGsF@|5m zQF1^lcAsw9wfHI}I+6V3r0kGWl z4=>LjAu_w+QN@k<4{tPhaTIxO6LX?=Q+bh%LJ}46?Y4?1^4g=2}cRx_Iv)^@7i2AgJ!1JSh* zHHJ0!HuemeS}=-B%+V5gdw4PuEU;JG6Mu%>heXT7W;bcQrUnv}XT!^`rk9g@f(l^N z$>>2@fY(4I%-2dqP#6+nCc73azlabtMsbKUb1CS3fb)MkOK{|J0Jw$O`2)9(2g+kd zYI<{elaa8epU8&;2bg*KJBtrp$u5dt&QY&UU3X|IR;x0vDO2s9!wY$?9yXdv;eXwA z&Wi`fIs>}B$>@8RB&-xNl{s@VLOPhmh1PxtY}v_YnUC?4;3Bo9bKx;nwM@rZ^h34FhC0|+p zSVo{dS~-R2G5Tyt2Tgs^{A_9J|HCxemplA_s?h;TS}p$@-bi`r-WRt}b$?j( zOnGX(s~z@>%P?pTe%2DEABdIyt-er5%f9T=45PVQb5cF(uU zcFcnqpt6k8sKO<09jQiZbbkzhi=(>fWmdRgI5I`mqY~9y8X9jT$44_JbYu|JsV{h= z?wtpiBthVES+GK-Nrg=^(~iHtLv~=!=2sbPc1WzB|M>+dl(wkh?K8<48| z^BiYQHopDdD}LyR6Wn#R7=FJ2pPF#~Q#_a=7-&4gzaqwYlRKX4#(xg;#;3=OddbCmEWPOV<0(9 zZT+g9LIxX|_4Eiqun^pLtp#$!3rNONlYHgL!?-#{7lzmbibiGf3jB&nmX}sh3IX%c zU%24W&ax{wtCGY#XMYJewNW$Wpq0gFh>d8TVMvE07|L(gYb#!H2`1&G8p}R+*;Vua zMg(1&?NzLXfsL*??hWgm*pVhD#v-hOa0$kH1diB-lw!jenJfuz@v39g0Qhu{pkE z+2CaYHF=o9FjsxZBBDH255c11alq7LGF&~=)pDBMr3y6KS$X;ZbK*3|9E~9(;tb%B zyL1X`O7?_$iwzrye>}+#xa$NE2+@gkI{ZSB1ys@)h8u%j|7C9q?vnlYD^|VMCWHiEapVPwT+2jc+09a7`n)N({n0%Cm}+H0s_FqZd|N%S~gy-bYXqr`Ro zaXp$4g=-rgHm5DM*t9KJq6gu&lWcQ{ZJGb;S!EA*hz5xn%MaxFxSg%Zb+0uhPT`5M z+p8cOCl1oy4zd8cve;n(*$}}q6=sk|dS-A~aes{*7E$|mt4!!LG=IDPAIu0E&l80v zYLJRVqHMOtb8EW+&G(3I56&`p@4y4OVon_jK+&ST2Jw!UU7*+{??cx>ID;4`w-i^@ ze098SEeN&^#{hv)-}*|cC20Wz3FRw=a$b1NiSgxG92j>x7ap8$S-!bV?GIN4QHJ|- zvVWen&mu~+*@Fi3jI9-Sq0h7-Qjq2NL-@`uYmFv4@Iv1PJgo*RzqnwH3(_zFbP(Q5 z0R+sW!{<6eX^xU=ZM@@kGeOkn?>$cq+o_Bn@}(o`zw;G$>!95?y1tazHyoY1N0s}C z@Y3^3eZ-s)8*Zb};4;BqQev+G#johgn16hQ zOH%XOjqgkZ*?7CK)L5IQF|ey2L)^OE**Y|6ofM9mla5(QvFv+bJG1t#|gWcKQeW&pN?8BAZufTKD)xWmb!l)MN9vHU+)M$0*RR ztSS~UT%xHt&jvPejg67%H1C2&gnxRen`^*FoV1>ClwoLaXh~P18I+)I@PP%SALG;k zg&OxB1syJ@jYay*-4WQB(-E*iH3Yo)TA1CB2e~Q<=l6}+Pxb?UkU{&0+&gcEHFc|) z*BtpnBnM7G2qt{mK6fmf$Uub1R-Ah+EPo=3CWK~6D=mYtH>CF z33hoj!KF(>>$iSQp*hDQ2pnm;WYKW^%10nr_oh=X2&!iGzC!%w(9ec%XjKLpH>JRq zp1n3Os9M@FvgLWOK+!S=qkkdbL?e=)2Hw;aQB;)JPPP zTByJQec&MZ1!vSdfZVSF&4B%+ZlQje{@4OPJO%S^*1xu-Bq|Jxf`21GV7DFDkXv`w zqxpmOaQ@E-8?A;%18?nv0dU(rMi(nGF=+@`u>kA`#)E*oWx{4NlRAZ$N=j0(YIRhv z=h(*EFm2{&ENZ7l3y>90s0cb4(Db1b*A$0fd%G8SgP}R5cD$&aT!9v1PceGH&#b_v zWJuQy{a5-fEfDWqDSyE+e+y4#8zXHK6>YuVKA=ug`NVoo+csW)j>91{0bfASPe+ZB zYA`P}o2|*&=|QS#pr(=^Y~14k=sWU0ME8X4Jxopj+I}xp?w~z!7slz#rK586Od73O z>$lBEFh5!P`JApl(<~e0B&t;MmhE!kk>#VF)AGI0m(af_6@SS+7CyeP3d=roVX0ZM z)NZAaq3Q_&X(75_E2mxaH>)8_z(%sNBvd^&3EwVxKrVweyPjVNXtF~aM3+3KBPh7X z4cqDQ=}A*E=(;}hGU&A8!Sg6GTz7`#9Kc)9P-Flv&Jo#HK}t7iYz4Jt1#${8Vq4q8gmg3nd~`M+SG?nG8aJWx|OBQ)wK z+;dF(7Ze2Uuk{xUEgt%z;&|s-cpI;yS5Sv%=RP31WPf*Wj}O#kQk&nkARvhiv5OOn zi_=Qnz#S?63`pzgL~JNNYGgfkh+1JuS8HN<@<0aU7KzDi*AX&zjV*(3Y_Pp*H{u1k z%Wny;G>~x=@Bbk0J>L)kR_Xe(8XEmU{!v;7x8tcU@42b=#6GE+tb&CPj5NLf7wPv$ zC0|g+k$(p!Yj71DJWk6-#ZMOYFsT{p8Q*_;Z%*k1rtTt4ZeSJWauYG~(`#WL^*`Am zcZO4_#uHx|7QfX!yrUml7j2K^^gyrw%lvu`2x&+W-IGEg$snx+AiCQIfBCY$OVn-z zNfe2c@119lTyf?M#Hh*Fu>njL;6lw~h^h`pnSUV2<-l|OZ+2kV$+cMykW_ky=%DKl&Fzp9P$urZmTf#bb%RW9ltWrFTS> zn_P2ts=xvHloT4npBGq>B|e4P?%2Y!cIz5`qCS$~l; z<&olll%Do~GX!+Ygf6N+$T>in7)>Y&4Pt&E8OrcvS;O^ZoM`IUh)fkwNpQk;MLOBq zaM$uZAg~gR#u)Q)JlyCXj!phIxQBiS9ehWJ5;+cZq~mRF=#PiO+6IM{=6U(<$~1%- z=K_xZqvNt-epT@nHIo^3$UvQ85Pwby*p0;j%}NXmu3T}W{UCS$u&(0dleOWOd9VBs zgi&e3#Oa3amso2PMDfTIwZZZ|W=1!SvTxQpX+|~@_-xrdy%hCHtRdQs_ZRhFD~NPe z&LO2&TuY0rz8w4(xcwcaJstn-P*?Heh7kLZ({RE z$)vBy;8%twIB6TEu0dGf4}Ta^L8bCn<`~V~8ntRi<=ISwa`sGv-REH`d)S$4$}{R! z!f0F|(M80Mghy-PaP(Bpz)4c?_}Br`&1Q{Z$B~eiM>^P4-=p&G z`lIVx#XyhuA|!J1*C&WYvb+9Ft=~bZwmF8Nai~YS`DFYDJI%z<~U-1UwqzAPM%VocgW#W#6LYOApO82BB zK3;h)QNgwC)gMyx&BsN?Ej^QR!0fAXmK08jU?f3du%BE0;+OKjIAxF32o= z35WT7+xb&y?T~O@Wyi%%p~qw zX=#WD3~aP`{XnIQ4|umfR=K^db+&sKY$}}lf z+@~7KYPLXBmMxg${b6%EpLelvl1BlU=>@pp0G-#naW!XmiBMP=z?OlU#j2@ZnH3ln zzT0{(xq{ycH?tIWjjdI99~a>aenB>Wu%YUzLA>J5_%lD4KSG4cH$mQ^(_%E4wG(B> zDI6p2UVjltXOV1wdfsBj#aQ+Pk7sl6hQjrs8;V4f}*D~H3h=Ne4*s!6Sw`Ev{RGRH_xW~6g zBa0NjVf&+Eas}9o{o{>Y$?r5~&)yyk(RYfHw|_@WRv`>_wY)4)gq)pawnfGYzC1P) z!>94kGEEuGlQwnn?&cZWdK>*2ig_CdZx5D(`ol zA{yBXf?`VKnnNDFIN@y(+bKtY9=EH}n8=9$J&aEfG` zD&>l7@Q#q=Iiy*=`cp<4;-A2q-Z*j{*=CZF(0DqnspPbMhXT82T2veKd1&?RoEaJb z5djHYh|4$wBU_QU43Mme?GSUb$YKM?by8#sdhm>S`uE5Z<#w_SM95mx3d))==zsa# zcdZ{OY3+`2?HYQs!i)stUjv9l(k4InipH>>mp%GV2tZ5W>&2-H4m=t$d+zlO5Ynt* zP-@s$KcwSKr;kZyce`v@-wCSUCvLPNQ$CPyioDmB*tqvpF;L$M@zsb=763Q&<6e39~IZhziH_)$ge%isW`vUV~|L!|6@*1Nz&c7+&b2|t9`f)?X1 zg*TxHdS@?3{rEvcdJQ;kW_ZD=8%t@Es~RGr3+>SLp)U{UVqguB4G+rY)=U;#Pa|0v zm_HoXhV{oDZ%(`S?&OjIM-;-XEnj$fv zO&7>2Ly}gAp|#R@b)Vm{f5o8LO4I2m-TwOd@(;fLlI}!XzV3b|!87#a66utk9-2hS-G3+4k#K9-x&Xw0HCMu;gAI}07f(s_<0YhBqnIa4sAODe6%Ldnqzoq2b-A& zkx_gLRqJ~zczyVFW<`d2f{VHC2)4#HUL3K{$u#rHI=++M9$cS^WSVr#v`J1I+ zy-}iFRU**n0!neA$Ha$&VKpJJ>-}M~F@I9c>k>CkO#6G6g&#t^(P$ry89b)(32Y-C z&=W`ij*%BPn=I*TT_@)oxJhZz(Y7Wkj<2&Z+?q#5K7VKqgB~CIA_(xhvXEALenUe2p?XGh_9V101fA&-(Ev+eWqKKbf_s>Q*2O8*E=2yZgfH$LE^ET z{$^CR*9Q>wA{RHx_ml#RV-Ht}#m}E}CZZ~;e_g>H)$CA2%S#+iKG)9$a5oJbp^C54 zlmEq@!+&P4ob|E-op4AR1v}Nrscw!~n2XCIn<^WZn2^9q><~?B^*7;~BNnTut+taL z6r-|9SH6}Xs#RT2tJub(1~Q#vN7?OO&%$W=B^#qB1wkF1M?2%Mad;t0;Be}(LC%w~ z(j@XsEpL561nUrjyhzJF#fAqgx7RyRF(eAW zKr3b+;EDvL-upn(+xNf9H$1_YT4h)&fR*t#B$^Cw?+S}Hwbf~R%TSWKJt=J6iuC-W znSYJR(#9sIUH40%mc>BRTO*tF*L(gj;b33Io^$TS;*JI)&9cif1UA}4Pz zXnKa>Mqoi?W0s$B3=!esxERXn6$$x%8T4@9_7L4({qmpv@MJ1+i=Vn13i*^b#z_vBZu<}NS zW9{aCgyQaPnhCa=LQ#IG3Mht{=0Kr{JQQ66cl9GBf$jOku~b;7?zh?ja65Uy@y(eLGxYK0k!vI0?#TF>hDjE6>%z6%-x2KZ%NX4&veEy z9KD%SMnud`$!u-N`dP`toSd>kngRrhN29taR@H@_a-5b8w8qQy(+_d$?^UJ_h- znHjpv5iL=l<0P&UmCoq)PcgtZeYkXofJcAd)X3iN@CSbJ(R+D(PaD&RnYO|2MJ~DerTKlSkYARs0f~jX7 zq+w7aiHvCDtDmi}DZ!d7kn!SQ+v`^xVk05G|3$)#1do3_*Y~F?w%JfVI&0RH-dKMD zmtrv+afLkn*(!b&VhKci?k+?3>)}~*cLCL+Zh5t{`Ae*5bH4Ie9js$lbvk!U6ylWz zwHB5&ERSxbBAVGrLJe%-MD;(a`**hJ?ieV1LxQz`dBSFH!L>^su2rD~<$61+VuV$i zbDT52LOxK1r1T=|EgG7~Otq=X zst)geohC~Rp;i65c}`8o5n;Jd-8u3BGc&D*10@eD8(Y5JmjoqMDZqcW96Piz zJkEhfX2bA1AG47Pn5tB*1j_!du+)|VJaF{zv)GKkQr$a^_)s`t;!IpjbMCVVmlJa? z_bNml*D6R_p?NEk`9FdMekmD^t@Qk_A6#mLe+%7NR$cGcUL1Hrj6Zz)t5EfoWr*AI zQlwEg+WDER+6ZxsnOqlbCm0L zf1wIurEv(HSt@mxb7bkQHIa$wPwxaG$se@I&wR>ZgYE{f>D*vD zVQ&55qCd|jD_H%6Tf>X>+pf}ds(xG~Em9oGuZs6UD*o)Yuho>qUMPhNdR2UPMT%?b zNfdACQ-=DjrQieSl*xbM2>;H1eBL|v{;|B{ViC;9Ao$TQyVU!KYJ&ZvTokJbQc)^jsz+3T)Y%_?O}_5^&$7_RM8WJU1Yp8Y8%Rd?&+f1x788dq%Cv6-N-7ek+gFb` z9>%A!7xU#m(IwkrTmnS^|JU?N9xe24>P%cjS(gzhShYi8Qs*gAg=)XyPX|C5@macS~3XrNf9Rgv9o2hl`<=O zrcL=PIBMtPcA=5%cfKnv76$|0quj`#kQPhSBN2jJQWAf5EbYahqke03{8)z-r?C!3 z@ve}0Ts!hy8C`BQF~kr3-wHM8s^^7s0)E48ffOGfzZXg$$gUYzJLzP(O+%`##iUrz z2h@cwyA$~rALdI30p^fAG$85J!IuZlWz{W8r;X-Io2yX z&()wOrrCcaNCN~RMqSb!h$QfvzWHia=$fVa{7miKrMKIi3DvPN*@;8q3z%i`eVS<` zCFT+KGGiA9u+id%SGnn1#A8JM1bT;?2mdc+Dx z?=x#^eg3`4%@F&+uO^{9fs+?zXGnuj4KHws$pn8msZVlIKXlFFUs|WeYKD{O`pWoE zqPz}h0q*6nE$d-;X5i-ijf4>!3|yp%j2rlDQlQkf`-~N)oo}c)WH$?W#7>`US4Gd& z(@PY7=@Ab~`uH*5p}Bw9buS7=K)c<1f-hmO3#cbog!`K_y$t} zCvJalby;>7cQM&_yQ7}-%kg^@h9M{Wf3u3t5x8BTa~0Y%HwFp=K?mHiK|k_}Csh@H6(r_5Pvow-2pQ~Em%Q1)j~rKU%I4|=DnuKA;2O|Hj!GG*v? z`+BCE`&y}S3=aJ2*AS#>QX6<+zcPP~Z2Zs6*c^$DAw+_}0n2w0W*H`)^4E+@@-(Pya-mivm71+AtIvYu zG=4rLf^_ylwT{tjYL)X=g>ZjJjnkCZ;~@gS?+h9q2f3&ccEWd!27*K(xoJAZ$4HWp z+ehX-Z^;lZfIc0H9`#*N8=tpK&#tFCGw)Fw1*PidfM#-gdr8Zeoy9m{x7#3+2h>@Z z&29Im@z^m#Y&d^QLpK5ZLGdBUI_}%PH0Kf4v@=&Kp$V^BHh$W|{?~uMCesm!r!mf7 zYI*UpJgj#^$5j)Q^g>iLPX@a(lMajF5x^jzM;to6lFtOok0{%C*~eT`VPypR@|x!W zz?5htf8D%nHPgCd_O`{slz-`8aC(i36x}+7BQYd8Z(X^!`?|Dcz)tax(l0~HwNwYWOWJSECSO-R`WMs97oT!0jHX0Gs3*vt^_(sx`Urh^Am$usb zK!)z;zlVfX+YF_Ygv+29ODe9bQj5)_XrGahB_JC%x4{MiMF_ zvtB=C|3OWnxoCy=8rcjX*khdU`V?Ot@EDjyu0-2)>ZQg;SBET`*3=Rm79Yh%9;W3#fte!fN^ zxAY?%_4gXPGfanWJVUtj)sfblf&wQctMGgyDhA`-$w=2QTOJlzeK2j>-UnAx7#33X z)UrE+a|ftR>Gi>{-kM}*a>I?aSY(_)Xc%dOyK`1HF~NU1a$Mco$P4-etagVsz1IzJ zf}QjrSgY2Ju{o?t5UQC@A=P(n`?1>K{%}e$D+gicr)2tAbN1N!`z!LHVR2%A`+Vkj51Rrg#tRqfZT(8z`a7H}=Z0<{{K_%|R7CA7H zx-*a4u+p7;>C&!9@wBH<+9aU&n!swUB=Ohc&h%lDyjOY*zU=A*EojH-^ zg5WjTr+H4>ntbDM&Ww4C6^3F-K_w1)U!FAWvXXyBMwgvUY?bc&`>}&8Tpj5vsfycw8Ob*sbgg1c?xL|Tgf#bd7eKcldL8QJtKUscq&s_5I~DL{ z(6yx>LKV5-Ke>J+EKt#p;!Tk=6MX%zHHw4%pKnO2U9XRbJ2 zRcC*IlF(G*-J>glL+QC$oNg~Lfsf?*qIwIvKEGop_$kNux|FGq0_5X!TLjC z6xj(usj5H%FH5_b=gkLFT*HleB(SRo_MIV0x zp8U4?{<~z^L1CJ=!p1lCn$zM9jl8#G@5iKW@lYgt_h-1t!tr=pSopcHNuCih1LNKz z7;^i76UE?24{JOS>^+QNb<7Ztl6Cegmi8e*DAz7&7aTV#x8@QB-9eV}E>8e0Y80*;h{9@B0m%zHO1 zd$c$5w&9T<`gK}x0O^*tYWD=zd{G${TcSh2dt_LsV3=b{@ed?jnk3-v$nKU*AFOh) zO-ZshSAnMC{{J5nO)mg}ez)GYA!<0wnqOTBo5!XV;0YwczD$Y2LNK~OX)AxOFGR-! zd%UkE!hp<*%x82#RXL2A^$GTq3b_bybo_hOyGoVq4|)&P^zFl3>k&eU9`*XK78Ntd zJ*~ML`jX>0z(39L@n0##iFZ2qwBMU|$2g&X(#zd$nZAHrXJu3RAvXmKY zNK3W+MUs%YKWqR@C)*ZJfB*hOIM#Ek`nEN`CR>4Guo99`;u6fs^naJH=$hwy%FzUF z(J4}Jj>rK_h81Mb@EVmlon4;$*zYLSn9>4g5t1Xk;qrE;uXbN&|b7F0c(WEz`1{cl}P%)ps0I?wYnEI zm)#qzah?YP(WE~m6`?9o4H-rKFC2x1zfuVaptkWHO+G-@&#Z3v>*V8m_?N}{QF1R# zm8`7mM24tsGbNLKr_WSMOyyh#eDHmdHK}a1ehRO~O|TrIO53Cuc`r5QolGT{?hl0Q7zpez(8P{NWbHoE2hGbS zbzX$A$kNcmt|rKlKT`i};IPR;0;x5(S;_Wbpj7<6$|7cI0in;3nSMqDTQ%jtj3-2V za=M2)Rv&*X_Utf(j7@|8sSPS}da$#DMJ#kPZ4TrkwdIr^Q5Wxx8)$N;uv4$z7F_z< zKyYUDUcXNoLAhDHz8eg?#tqW)KteS87<(w`KYrSED&&MNMSL%c;q}kW;6Fc9HyXfU z+L}r8JNf2kq3*z2roQu`*!4t+V{gVE>eI69hVp+eO=x;P2%{O0qA(Xt+fA(Z^ycpu z6|B_mi0!11q9NgS{c}~sU>`_&Thu&Z89E+hY|d|h4T!3%XbQX=&1wA2qwFk_-4`OU zLBobr0l!{xEB9^1hbB@UkMai1qQ44yF3uxL7S1ipkI2Xl^Xu39v#RaTGv&5 zCaLuu=L*|^>T#b5q{6eyp1+Bu@Z(Y3_7Y~BkhaL&>fg#{>%&d-NyFnG*cESbMRfqU z842qf%h~Pg|9E`>&M;jFE?jNwJKBiid-#8XGCxBcwu)%wU?k=&-y{cOkBalQxj?gV zm&T4|ToA;ZXj!-L=0*s3;9Fi-egY(CBd+DN;&9K0KbU$|Ku)0~;F8$u;AGCpZ6t9* zp}VmS${&=ckO_L$LFb5zCHJa;<`uvS7txoN_s`1K?YL$2?AWSzb>PvQf0F)A|C% zi7ievB`vPSm>#+b9j&b5Gx`w)&v=>o^T!V85y0*mBDU;5-4-BJW`_M+ySp>-!-(s5 z-jK1*@HD+Lji+5{&chCRNfO7jA#;COF3j&+&b-hW`dtw@{pLPpFyl9ARyI%AR|89P zdaePL$Gl9L+9_3K5o#b4qpIdGsZuNFa#ok&QseVXv6UD%h7_J@QJujG%t4+$16V#g z6w@0?;o?zaw!Ft$uDA%g?}J`Qy+FKRfh?F&Kfwd)5;>ByvV4?e9Weud8xB5kT9A8wq)ND}d5oS@1!(J*H*3gvIf@ obKKf3VgLXD0C+qJxc~v;k_VOTI|Dq+4?Zvrivj=u00045S}R3;=>Px# diff --git a/data-raw/ab.md5 b/data-raw/ab.md5 index 4b47e6f36..e38d1aada 100644 --- a/data-raw/ab.md5 +++ b/data-raw/ab.md5 @@ -1 +1 @@ -5091adc0d127495bad3ddaa7f3501661 +959459b92fe6ff57c02bab08381a73a8 diff --git a/data-raw/datasets/antimicrobials.dta b/data-raw/datasets/antimicrobials.dta index 40f3a7a2b3b43f7903d79b283ec5ff1ea27a269b..18229fcc2b1bde92f78c600728f1a2c951340782 100644 GIT binary patch delta 61 zcmcZ?&>A?QmBq};*kWR5med~wb_Nhw62}3i4?^j)ag%u&wHWg@TQE*no!r2vzWKab GKO+DJnGkCL delta 57 zcmZn-ycaN`mBqx$$Yf$?mXzyNHUt_T2 Dm~agr diff --git a/data-raw/datasets/antimicrobials.feather b/data-raw/datasets/antimicrobials.feather index 65ec74e2017ad21296d909cb165c15ca3a90d3ff..9e8ba94e40698f321cb0f28af574588e50d7debe 100644 GIT binary patch delta 8715 zcmY+~d3+S*{lM{Ovr7`f;f5<16gFHc2qZxeMJ1wgh+q&ADlKGob|yPyE@o%r?pj$C z6}6(lw4$OCK(V6IAPUy1fCngQL9F~lMZ8*+q6UJ1a-^S!z#l&{?|HtnJLfac^L=LL z#g5nW_ifK_{IqvY)t75O>%BRUeMq$aYr3notZLs{R-XQ1+Ue!LK6!e@)5V$PJ$bDk z+_SQ^yd=@|)@9Mq`hi#yYW<+%-qt;x`Tmj9 z%k6@#-~aXg*6*)9z5UVC%V*ZFT-f@3r_=k3FZ%!c+jwgE_d=}7Y2AbS=hhW2IlaTi z)61t9#hK+ZS6uga>-ssZg?QwN)?nhfty_HmYW;8hRu=3yeZC)ywX6E~n_J&Y%g@R> z4Wk>1&;z~D4;Nw(hM*K>D91$@hT*svBOp)p3XH;4kaaNu*I^>AM(665j={=(17JwA-8^>-~}{d z4PL}ryo7aFk5}+_yoybD6K~;dyo1fyf`4Kgw&Npwi9PrR-(nyBi~aZ!hveBG#t|IF zuQ&#ICxd8%wkSY5bi`RGL?;xZ2YR9xA}B$BoQJ^}f>M;B9GBs8jKku^YXjlz^+Y#f zDsI9w+>BYMf`TaGFfbb)lDGvaq>;g`xDE3m`_bLF2eQxHhX+vy+2$WYeSn+r7lMbe z7>`1>XW53IL<5##Iac5)JdKrj7JtJUyoi_ZGS*=|Ucuk-Dqh3ucmtd84z}X`05{H4}=MQ!gPx)=A=f3d2^1&fIu z#}jxGOVNO3Sb?YTG*;H1|J-?P*AcD9EA`W#>y>?nXfxi!Hf+Z(e1^~Q1$N_0?7?1q zkA3(r_TxwVgeDxoK{VqKe!*d!z)7?~1i7Qg3DS0h1R=CR9@?S+a&%~q4(Nz53egFj z(FI-64c&1ziqQk-;9T@XFO;A+`k*h)!-W_UBsG>2lwkxe!{xXFqfmh>F&bClYFvXc z7>jWjk83dj*I^lp80p(S*=m1^~A=vmxDN|r#V-));4Ghxl$)|35n+7?gYi?iM}`w127n6 zkOTXrxQvxYk0Q7VV=+;Vxzh=FU^z8PrzvIC%*CCMBd{EO{|q_u%29VImP0<8t-=fJ zwWAzu<>>l4-oks3qvt31JS2*~W~H2OS@;j+(Ak9MkT{Yp{)I@6m&YN;$`JA($H@*T zL|60(iKQi!{V*^@@4ZxxhH?}f4mlEzh8zheVLD=v z5jv8)fk=)d??MhDJMgcNXeyE;h#WP(!(Qxz95D_;juLWoI1%_!G*gXoRA`G12ty76 zGV#l#Ujmur2cZlyxo2fI9|f7o$3rITshEM8kjYsl<~V8~lX3!SS?#wH%*E|kfcvlz zb$FN+I>}VL94jFoNnb!C*5YNnlBHJPAb1m-snsbT5bWTNeZl4h->~p+{D2=JGpfv_ zheM+NIAsofDxVc+%B(1}U=d{2I~Ni3L4U{$R}PujWJ0?dGGR@~GLzY9GGu0&h8dWN z7-agfAXAP^H@D+1dFe8rJP4Uj{tTH@9)nCJPld$6u`+KoLgtM1_y=U}*a(?3He+j$ z2L_oOcH#?sga2SZns5k5@EcA-ggACFGf{vrI-?u9qbK@e00yHxB&Lj@lpU}4D1xhT zEhgaxObv1TX#_W8CZdSLgvVC>Qv?~z!<|@w`%nk&uy_nlU@4a4Y5X-LIx!cOM>sP4?p1`e!)>3!$|~4Ktbe%#K#>dJEI76&SQhm zA?SrZxBvrDhKn&0qi_wzV*(~2djqrSpazUG=Nu$DisQ)1ZEe#z?Fi07SM)#$Co;Sr z!9bK@7)IhsjKu^@#*LVcnTW!Mhg)zP7RuUQMDUkf>VFBrlURyncnZ(r1-yuLcr7HR zZKR}!7JWe09KM5vo%jOZ;Ct-HK^(?!5P39LO+afb zqBR~V*vZ0Y*p08T7eAtjQ#nNWTS!DtPzGh%DbC9$)1ouFp$Nt3iN5HM3os}o{;!Pk zVq6OP;o`BB6Y}YQQ#o$VG?s40OvF&l%^r{?n2&q05cPN%k6;Ow;VC?W=dcDZgYl$( z6Xl2am>uQrB-n-B_!j@h_gwN%T>rE~EYQb}jX6$`!|2`y`Dl+qbjH~@7kzLZ24N^J z!AM+=Q5cOexDJyrSyt+e1k*7S3Sx-ErvG>LsmR<~meQDuJ8(Z93W+@rQ$CIctfc=p zcYB6t6`sdxG-54Y!E4wA^2@Q@tpxwXzpxX#@GZk>?p}f)aR5iM%znl3@dfh>gvdo( zD(0+^SkjgFZ1my;JCzXh#rYVFaty;LT!RTA(SvKPpGrIfT1fP&VOVc2cUVdwjl1wC zJb*epTEP8ZO0WXY;8{G6M!bYqLFa4kw1MCqe1L8E7@y!%d=8Rl5y`VN$+NlRem?ja z%{YP+$Z1C}1Y^aNV#){`^r!x33}B&@EiaN=j$mOVuE1!F!8lBSyu4|Ye?S#m$GAVU ziEVh0L&cK01b2Wjvgl77>Otbagv5*`l*{M^Pg6dNzu{%tMz;7BqSx>y-o_TZkL~yv zyRaMFyXNBW2=<`~%{YwTAb3m-As=1Pk3$cnEF*DUOnEuWS5c1VHcjNzri8@j@+II5 z`POO{cCdYRxK*noHN z9=73Q?80siQLu;L>-OZ|?+EtcCp6bPRX&90(Nm?2eURn0S0!!8jYu`W|tX({vaT+zsZUA|I=B$S&-8;K-4O)w=DH<2Vz zY=bUvAdk;o#bia-Q>?V&MYS45ai0_6L>`+d3Ey)prPg3;C8J~vCQ{y&aZkx~;`&V` zW76j4u)VMNR*|Ulm5g5op1(>pCmIS=x=}@?ac=k7x67Z+#BwB3ohwSz5xJsJ$rXX_ zVzO$OrqN&I6o|n2qQdbMw^TH>k0ex2)9k30FmyAj`N|+uQK=9mp>@oP+zz6PIY9I^ z{Q?m-G=3RH4b{nTDO8KfMbUy*iAqo9%0i+-v(;#BKv4S~99`AixT316scNdK=?a0a zQmA@RR1kX|#3DY9d8!^ug~gf}8z`ox>Sk)Fn5?;`V|(L89cxm7y6JZp%PfTjOVus= z91(WAh=}iTkr^#lG_`e9J;P+G88zdWx{|5MaMWmWfN0=E)tDNy)mXWxigDt4jLl*; zKU5V_rnwifJ@z`7nZ6UDOFEd zG0uk2*d-#CW}cZD?M0(w8*J*hT+tj}`D9dAbu%oxn#Vkmtd#F!Dp(`&ttfSdmY0fo zzA{SH9beYa!44_aSN#-=Ol7{3VzM-wxov6Zh~S5TkJOZEvdjsy?(f8bTwkj%S>HKZ zB?1qN!dhNo|5JpW_eC8i>Z|N3)sBYORfNkf6mG`h>|7%hC~;{Zl@8VFYJn=(;fmal zsB%;{<~l*)UgV~@gJusAHa`_ruE!T1?~e!mD>t-?)ag!FAMV`@t zprY9xNAr_Wjq3BMoPUXVgteOID{R`v)ifWL=B1g2mNVm|D&v|T=ld!vnkC|ZO+m-j z6^~A$n@X)?>83`tDo#o_9V=Iqdb+kolydy@10`mXCzX)wS1f0AGc!ytZWB&+5tV75 zPx|v1o~E?4Ih-*Goj>{(zl*tX?Ab|J=>a*VmhL^+rl~_#Pm*IDUD3(bs=?f-Ry?k+ zTJbrr10mh4)+|z@YFBHd{nBbprhOLdvhoqkhjFWHuBk-f*VY=V+N#zVKD4+Q7L!j6 zBn6_YH8!uJ+SBMwO>GpNi|0txJ!#X(T7iWP?%Sm0B zAKa8%XKJQa%ft%vbN?DtMm8^d_r!dB=)MOs%FJClRn#E0L;y~M7&2lZzr5DE4bgpPHR6+wD zKP_Cxw(N|>D_z&LG{!lrov2_OwT|XD1sS{bq(zg5$BIU5c0TXE8p%>t+@i{Cix)%l zx%C!%@p3A-P;T2s-Lz7=m2{a{jCjuR;5@^$c``8V3j+~b35PnHU2_}ktl}vNF4nQQ zlC)}bUR-xu)6(@JmLAi6+prC0e%Wwl)PEg!!l%*Lq{Kr)w;hjau~YmJP7~XmTE|Az zu+s^eg*X^2rH7nqeP5*%M^8DXrr30|=+59*+<%`A=hNg7D#MP{y78`J zk!#nwwKhXm`%sf`4VPUp&$vb==@y82Zq{HlGFPfr8&PR72HIUjfS*fei%5cAzEO2tPqP%A z=FZ^IG|VSwI=-9slsQAPu{kkij)7!M@!Uk(X41&vJf^uOT{ForNkcKBj$+GJ?-_a& zGP@L5>`~_tgt_avJVMoQw%(~0Q0m7MMLA7^p5iIGnJ}!{1igsdW2F;@--Q88Nw|tf z{&V?SrTI@i)tdc;>nDt&b`=S(mDPEcxs#-z!!7)>~;*#-Fxag#7+D2dp(V4%IY(n{!wi-TWjenPi0S!OA|mqU+Yv2Pw7 z%^II=s$b0t)l4!csA*np4ksPaZEWB29Y$y-4p5?y#{;7S zfdY{`IZ*05@q-L4$tWl0TiiQtF_U$R%6P}G;TsYu-yiaPK=cjNQ7cKL{9Wx`?i2U9 zR`yXv_j#)J<9^z7{93zKsa2TSD&Gmms-<5^sxyDYYtM{$El|OK{8)eK@xUX!{|BV| BviSf2 delta 6235 zcmY+}33wFc{lM{eH$xIa2q6T5MoFMtDiTg9Pm#-_1wlDPYAMI;>`XFduFOv2W;r$- zQV$d)T2!clRS~cjuR^tzSU|0{1%Vp06;$d4RTm=nvHiYoc>d3y%xB);JG=AF%scP< zdlNmfCwK3kbGIDm5q@X?%OCZ4E0mlsGXDw8xh3(#7n9=lOkL#8%bdAJ$sBktnW9n%taNdVZnxr8u*AIKmzkH9}BP;OCVqS{a6k;v{qmx9>OX# z;$g^P^=o;5s|kJsIgXyhI;_W2_$@YK6E@>{ynQ~(2r&TUXvjl51S4=gMq(63V=QjKPcaTR;wJnoloVn- z!30diB;0~qF&R@Z71MAVreg+X;+L3(*_ea5P!WNKD0CR8gb52CYTzR#Cv`pK?3WXM zJ{CY8Z@?lfhMc@|!pb?g91q|@tiVb<1Udg2A?MwrcnptY4c6i}cmhvi9o8fHEW78h z5u5Qmeuo$EB3{DF*otlVBVNPn*p4Rbz)tMKTX-Aq;IDWWyRirFV=wk$KmIA-{|5xk zIDn7vF%IGoKEbE>42N+9NAX{LgA|UV1>fTYPT~yC;vCN70xlvA5oTZ_jJ9Fke;z?Q zbU-0Gq6nQ(jLx_Wm!lL{;7W8u8OqTeJQ9BgBx)ZCSwYwVj6D4bli?vn2kA@3l$M)h(d>fN>sr_@=kUhYTzS=0JW&Y zU5KL|3CzQMEWkp@2Uvu~Sc0Xv8_V!3+=F{@AMVF;Jb(wWA}kvHjhzQRM*KL|U@g|+ zX*`2xu>sFvBQ{}k>=GJuj z*x^&dR+gPUmK=5Q*t`$Y@lh8qRPHW&GJR~=%?poJtW2NQ&z7W~zW9&&g&h`@A3A+_ z$Kdm4PLDa?5K5-Er<>;7bFuG|MNOw$Iy5wOY*@E_ch31yOOxqQUw6%1mba3hiCS-< zlwXd@1e2;I%)^N`kjuIJQh_2`ii!w|AbPvo`X3 zP)ot@sBJ+~E|;%iC-y+Di~m-{WVz0r8WFmIhs@)w&Wcc)FQak=%F#m+oqBVAP%`mEQDMb zmhwTK{IyN42y!J@g-5U&k1Jx1%=S+yBDdsuMWnNTPwi4Fm+AWrH1X-V>>cv@GHc6> z{T^h--b?G3%k2CiWLB0LS!UwT@fBnyK7lj1Aa6dzAjm>C+9Dr?@?FR@T7pu@)LD)m z=nXjrvir+4A`{|ukhyOJMk=CtEaf=-3=Sg-7H%@F+J@AXCs2SPz+gWZKz`7qCSUr;1)7*oN2f z24v2Wxkly~nP2|SO}e&$UHF!H{oVE4sIowhUvHiGcg-;6)_`9S;dW2Q@V;MVMLYOCHs9I z2Nq&+lHD?_!mkxk`mF4XO;ldMi+BmIU@Kn7b|%9PIkev9E{p!gk=@vbW_*N$_!OVx zYk9Gw1mEC09LEWq;Z7JkMlww$OX1Dt$Sb#Ha^{24Bjg_}U2r*iVlY=8rilFJpHN|p zh_M()JL5TfA|}&9-ZT#0h8dWNS)eOKR1vG`3Q>((;yC4eh2KLM7|r)kxgRUAO5XA& zf*0@-Ud2|triep-rex}fop=YG_A|l4%|svJAU?ri**{;>PWULbZ*dGKa7qy~&rzo3 zs0fialUeNAAQ$;4Ku6hVF+o?9q8ms!qPZtQA6$c>O!VQD*UNVEMiPy|4H$=;Fafu4 zrSKGj>6n3EfX+x~R}olAb`EM#3%W%qrC-w73#l!_-MAOa!3fEp^EkoN1TDRvBYGY$ z;SIcr9e59Wupb}bLwt-+LEof{z99H7TG}xGP7<8Od884}{$UE_w&djy<)HvY=!)*> z$4D5!QGdHy3@JNzxR<2Z@4xX3lbg8!xvMjNz6Cwe{Itus*xE=M#+l#O85QZSP0XpF@;jK{Pbt{)*VxQE`A1b4!Mix>jjg#~E95-h`gcn~Y; z+=uDp)rwg281=PSr-<91rrf|XDmD=O-@i+>*54z(lFy$Ss#dGE$wpDFI;!pZs>VL9 z+HtjlNV8PiQfn*Ylm=TwwY@4zw>(l_WmXbaS)D|7q4=#=0AqUO?yt{G-r zGvYR_+l1};J6fc&5}K!Z3B&a~okmW2H8sJ_a;u66y%kCoC*lE*s@CzS7NJGA8If8ohy*54f;&m{3Z**412d6uY1LHY zw88TQzUI40E$|IL9@wE&TaMLo8*$CIwYW{}yYV=^*-xa38F+>t)wC*$&E?Ka?$C5x z&7n<(m8Y4%m(O0skYw{Ui^1t@8oh4O#k^TNs^*Gy<)#y@W$aiCf__o8aEu7`4d-?i z$Hu$7S~}IDJ&V_1YB4QF-)i-m6;-WBRQ1?`sBWoI8jQNW8Fk}qjb+5Y=ItBaiGdHEZvVY-5Gd>MVDH&3ByVZHRxfjmYR!t!{F7s z{1|R5OOzY_`&ms!ZOp7x15;m6$vqYoe#QAYt-_2@p+&b5(j|B@u zg%%eLxkjA#7r1d!8Jm_H(%g8AXprFX3=0Kfs-Zi&kyfrV%j-@nPnFksPMufhsKHj{ zct_9l5}ujhuK4kij6X`<^Sp|HfE<-AQu(fDQVSS1UZ8nFB1m{%#B(jS9HG`z)R*Up z$+j6coemwesnK93I1Fzm!Ybv5OQMHDwSW_ESeJ@t;`1GF{;Q@>YR3ts$ z3z#it%(UxbX3ULwq%PHG2zxpkMG*5$KNbt@Sm3kiF-9UR8GC`dB%GBmLL-&i;Yv2%CNI$m?7$7&2%E2naD^Pz*_%Wv zH*l*O-CbRJO^d~YpyCYky_UO+2RwsY7t}d*YMsi?(dy`&C3|*l*t07%n*Wiob#I&S Hqdooye(6zD diff --git a/data-raw/datasets/antimicrobials.parquet b/data-raw/datasets/antimicrobials.parquet index 6d9c023bc17082aa4377ebe054a4c900b749f1f0..af37651742848c195f1e02d5a38713ec11ed3284 100644 GIT binary patch delta 5565 zcmZ8Ed3+RA(yz(uo}M@v z#39J68w8aztSbvBQGu1in`4RS=C{BnE6A~as4M7#KxDHXpM;>9uV%mhzCXJ9y*l2j zs#jI7Uf0F+QyuC18>Yp(70(aVQ#}93^dL7vzgFh;LI_FqX;eBfG|Xh+`gD$9NoM+@ zdb${em_lsYbQY4iEEHwRh#A$mG8CnUqoJG^%Q~Hn4V@cAWL=_jaHN)+grZylQkkh( z4KM^-b<7ansxzHTdW}~#8E?Q_r`6Umz71bZ%a6-gGH44M7B`zzl$UcZQdwTkOv9GO zxrrugbQvBRrmIkZ>x07)?llx<%3(kgVud5r5E2IQY!cFfbU6z!!u*T1Bwc16<1Je< z8tDSw4k+~!?LwAs7{D-<$+%d@HVxXvH)wGkW4cn;V5+0D?y>@D~KO3ZT z2-5xcQukm(qDLaN=3OGIhL}$eXFescT}>ZwOH5(DAgUA-`v5VQU4X zUWz-CY$_*HoLZErLu%P_q?InmYE=1^1Z9cvdxPKA>F{E0N*3giP&$ z6w2h=Al@kGvyacn^}M@$>Tz%cpeUat%nDs8Kf^`)yg4S7P9)4ITOp5LR$%-O`MvyG)5f`gQAN8AUsx32VWsP6jf z6ghFL^eI-Z)19@Yq*2y|AcJLX>P)PKYTjYBkQrqHP{`K^?-IZ_k44(lcX`dSA@A?N zDs*h^uUMB7)f7RE+Am0_zk<5XeJf!EWqHE_?t*}zYe-c zm$y?wi5GAYSqtb2Pu-$R`sN~!C-=%zefx?lk$!V3*3C0Jklwrz)-BshbTe9(hfQ4@ z$pQ$&mSOrj3MVG{s!=+nvtWYhKFE-ur2Dr*eUcieetb|0nQHrC*ijryf^o@eeGN#J zBbb52az?l-T~uy!UmR4lGkj1n6xscE1`0sd-x=yd_?Mof2=gWhYO2S@+ECx=;?%Wv zgd)4{;GpSWMuOm_nY(og`A|o}S&%ha&S3clX$u_N2O6gKV>1eF#%{3G$?GJO)@VKxYSGjT$k#%Jq z^*z-@KuLEWCM8RMlA0t&fk8}TIs|E;8o#@sZ~_zGn zC!b?^4H^;4-QvQU(HsFlFC?0w(IY6*Tu8Z)a^(WjYW5Q?EGZ7Fg%wNK$U&mGzvXx> zY=$&t4Avas1c6oM#CN$%OlUD0eKe`l>#JXN@6JN?!n0W7RV(#xV zd7!B}{VvuG|2Cv^S@8Im0^Ro0!K%?BZDW%p8!`YkpT zilu5n#UEiP{+$?#O@9t%SP3^W+zl>l*y2~L0a4ogJr#E$O<{q@@uva1Fp>pMvvd{; zffo!#c?B3_dXt|bN-0QBCcqlYzXATzxOZ7imQ;5D8b_@roi#MsZk`LxXRu&=wp7VH zgk;~#AagStzzBj2;XH?on-wXK`n|~DwkXeJ#oyvZHr0!k{uLWhF@TLoI}1R_;~`H3 zJ|wBK=I&x~Nb-#VK!1ut)uqyXBqZtXjx4|wJe@@?20mK~ivw{;NhMfwO=^${$Eq9E zm+6&Q9qMm@4uZOf)b=mHwu?BVwKnr1E$&o|q-~-(wr?&)#Dma$I;!wzf}sk0NY zCFoI(Ls9w&in_hfqnh^MW0^p&xd@g7n743aI3cB~TZnpomx#<72O2Tqcq;IsBHaC| zTVr@rSEP{t7;D;rRNHL}r@53!L!6#MKb!wIa``h~IS6R}Pr(@yB%B!yOB+&S?oZ4h zY)Zl_Jj@#NM=-o4g>5PE8|XvT*7>=XVnZ>Z#-*nH$MMiXhD_yeL{&oWWdypR6MM5> zu|*jt`W!0VeJ0ZA?pRbyoe(o5h-Z!@fI)@#BDj@V{2Q3&VhwC{qajlOmk8-@U_ zIY+{p;hzLBOfQEeZuE|`Va<`6AHiXZ{u+P~gQ$ffJ_&`zw_)yIajeo8gUCD!FQ)Z4 ztYwYOr9L5HOLM=H;*=6)kThYZU>G4`r!s#S80B1n_mOa@Hz4fxRI#_jdjKm4DVi|Z z!{j5=oky}JdpJJs9_OMx)nBmTh#nBOxha>hiSRIy>%f!m6QoQ_%fSCWTWuHUCZ~Jfp(y_1Odv`3qfCkuWt2ht=!9 zQsy^s)1b|Hl64ea6Y^na#Sk$?Y6hf6%qmtfOqmN|JJ19xDC>k?Ictvrvm>9#hdp*( zg!=1VM~EXgZvB9F>fiw;Zsr|LG9v!z(4}9z-h!N)(_kZ;`3?J(~X=ZDCAxupip}ub`1LS#BS`Ei9y6M z1OE5pu(sr0*qe6w=Vc{abk?Kwv;{R}Zmwg7BdUHmPw5R(rCZ&9%+7c5SvRvOA9~{0 z1uUDbqX19>m4m}kW;7b=z6+ExluB^FmhYsVt-{BB{&N-;U_9qVrm+d8X6qf$jmu;m zIE}J+2Wk|yFxY9JZ=;69dE6lR?k`^DZU-Nag}hXL3(R$KbTSH!^KCo61?9`ULv2VlaYES%wG=8G@7|xxu_!ylR+RQH_p~vTKX=xYYQN{<1xPdaoHA~a;wbu`%-(|f2 zeR{u|rN=8W`bR!nno-br?LbE1@~-bQyiKI?c;Twtz;WO2ie5fGV9oHaj}Lrd;(!xH z8|MU0h+Bd$pD2FG`TE45?W+cyEZMm+aI*CEoiA@V@<2)avH$FI_jP{IJ6rhS;|bHp{`|$$ z)5k@xy_G%w*RCJ4@28mId^O$I;U8d1-{vQ9o^MW1;Qd8sCg#o!p7G}?JI_q&7y0Lz z2fc}+Pai7U6kK02XvfC&ljCcPaVOtr&OMrID6{IFIUZ;R(10)y&oKV`={PB z_G0nejENrQ+{}l>)^oF_jJR@c_6)yxe$Je^%K5qTl-BbPFNj<@|H$Hmcwt^}lXBtF zy4KbU^YwSGTzJg7ncK1;d}eOT<4;`P)Ut5d_vc#{#VKLS;-_;S-XcBY+q@<4Yz2K` zi+p6vhA$`R@vB>(Ss0seo1NBI(-`BC3*`!0Fk_e}p-m+yDJ)uRS9i!Vk8tS;UC z{(xu84s{J!Q*mOq2a7gLt-4*b zapvUF;-1$hK z-KDSZSY0)ESL=(h!Mk_uJ~VjG8;81u!GAh%vg+QNEv8D@?$vJL>x^O|oNms1@7!W)=al~igSjbQ delta 3526 zcmW+&3w#vS)xS4;Z}v{u-8{@L5JQrM%qA<302VCxpaHfJ%R>}CO6B3~?967GnVn%~ zvfXTJH$Xzk&mdC#2*uzB*3gnbf?A70e+D14z$XtYR9;eOp+ZoCC{#n6?b+_{H~&4a zd*dRL*l0lGo+Z3jSx64i{_NN za|%U8Rh1aNfy+1#D&wn=kzXDuvqV#pVw)a+q9ipQhgn#)-5!6WJgkU%QqUSig>H0- zf??wABrMQ3k&D6fseb zgzjUq5b=A#MomCek}Ob0WPx7*T9tp4q(nK`3R*43Ek#MLBD32D&O?%VXeKO$WI#c( zi5Q{dQG|O4MQ9VegnCiLeVxcs=zid8?uT%;5Ygb@VX|c4xlo#f5h`G!BGQ*#2}4u; zvx`MZ76n@nxfHxw;@XkIeN5z3f=*%)QRWs9C4mL`=!~XSk_U%e-ep{{6_}@3~|>F@e?-*>HbAjEFlA>HKD7@au@7 zOV2KM;OgBUI?$IGX5fjwu_98R5q-JI&cgsL`inW*Z)a;B>amWXK4Un7ef zff~50EF!3U>UZFfo&egQr6eM8M^QxUVG%g}ccI~)az*q+1GZd}sK<7MD13dy0L zGg+7EG@@Iy5`dq_WK-bEX%my{Ex@Q?^LZ$GWHpOQG3g@`)$qe4Dsj7juWi19OOS9i zwUFf^1hYZA6QvW7xoZ|tw3?+z@dX%DG^P1Z!1Ie-iY3JH4x+^9B$r~F0?uW%YMuXk z1y3+k=X;#F>V%kpFQPhrKB-$l$CEmt<|?a`Y}(K2Y;n~UmnzkZ!EJah(t?*(3`KR%a#dM|H2F5h#rQJ@5^g$*b-a#LzMH7Y z<|9Pa_-CQc{B)-3TIge!s+&UfGlhZ{fpT2`05>76CI}D5G|4P@m?4cH$28Nx8VGDY z)k!p|Wg5|9R0lzlD>*WVG-z~1xxOX;{Sg-i^x^HO;U0M zKL@p3j$$-QVv6Jg;Ld>SLuD+co1u?jyB3Kh3OZPZ|MVbWobF|@28+(G=_k+uTbT}x zasuf`e!+B8fex4tQSqe!zEzAtstd+u{w#bf!;FxbA<3aT861)F!N`p9ALYT|l(LI< zaHK5mKmWisE_9I@u{gd>jJU_*SWK{6`ur8lPz=7?WhlvdI*QLl#;$c4Q7DqZ=Eq@T zx|mUA(^#Qm*h12Y6EuhRAtN{&3~Xr(G73D57uqx^Fn0#HV$EyZE_Ql-EtdbzGW^v zY?xu|nJG-?M zmLmKBu_d}Q1DAnUq~F7hGe~SB^hyS%BKz2JP+or)lp6OWku>*{z8yp0`(S!=2eN}v zmo3?5^;Kqz4RcRa|8&>CVYG)VW-Fp}h1gXb%-2-Dk6VKjegd+OtS5GqD{!4 ze)JRnWg_aCt4_y0oKLI-Hw9JkpCj9M!3~DKsW~hKTlcNzLhre3Q;*{Zi5;hJqB!p$ zae+5jT!`_cG7eqsfPoMWN_l=A{T`&pW?f z?`QyG$feh!`*QQp@M!L(KVjG4_b0;FFRx~-P7MY2HfZSZ)REVK)SoO3-ip*W<5$n*?i)F8`|KTI`kZgv@`LOAV)pu?$+1g^cZkjnC6E0aaU&xv z-ydo%uKwlBBL#uE?T@S~2puhaVA1Y5Z?EQ`+dOvZ{=~Ogfz~Y(B1gAOSrb^lb&`7S ztp-QM^X*gYzB6yHso3!Hqdyz?=37VQ3)`!ka)wWBs@(WWsI_R<%GB5F$?}>_m5W}t zxu*hiU$Tw9E7$LuC|^P zN+Z2*a_bK#1poNF{|7tO;cv*tU%tB9H@B!=In}x3z}m4d{a(AUzu{i?xc0YJUOD=! zhkr5d(+BHsoO#pwr)T*i4PRY5{l-sHxho!f_TKGVH$LkxJ=mD#EErRJtL(j|oS_rd zYq$I#tShK^a(C^QBmdZ1^pN@awJ%2xe=b!$|vd@?NPC4Bzo&U=hPrtSD>hX@JKe@T=4-I#2UOoRw|B8dFXl`KXnOnjK zE#4~m!kI6{!yEbeJC~llEq(Z_N%}u7oc$_#az|)GVA;8^l~cPG^~j%|yHj`OHR;68 zW#{jHadwkDdYltO3&U^C^2omB5ggAdJn8ba{=nBgIk59`R^T6RXJrmv+cg=_bFS@o z241|C)%Iu<*JS^zl?!~>($*TqV)o6ATwwRcwmVTg&3Sw?7ifHuYx9i5W83yeaY@_S yTI|hke2ELZv$btUEuNdb?#-M))3&y+YjM!E_gud3Z_WVo?Yx$=FR0*G=lloS7QN2^ diff --git a/data-raw/datasets/antimicrobials.rds b/data-raw/datasets/antimicrobials.rds index 1652b77a9afc02ac944d24e1fa6bce9844d9c19a..e0b8c4702a2b5b438a4dae2e353da3fbd7ce4719 100644 GIT binary patch delta 36244 zcmV(hK={9`;{wp@0+1O5&V{v+u^mh)f2}^uwIcl?q0E)(K;Fh#(7V$>F?z??+$tSF zJw-nk^#3^A#Q?f!hI}nS|`}>L+NOjh3Fj1 zUS3RJSMf=oZIVp}9`|NoT3Ogt?Jgq`PpKX}$qmBu>czqCQ!0)t=%}eMri@*oe~6e2 zSrJb3_*pyLCC334n}wNKDi5Q1bt6diEn+e+rBE5f2GpIhseWfq+57=q+mVC~=xn`< z#Qy~&*a|RA+}Md=waGTj6+E=sgq0Z{TyU7r<-#8QDi{4Jq?Tay$)2%EAOKN>Mha(_ zGacx2l1IkVXLnCms9KQXb?nmLe=;CWLw2VKqK=oIK{Gj7-d@$5gaLkCuMg?{{4>WM zzB?TJ)R*PnZH7iq`dk0~uTEW2rU|Q0XQ~AskqFWpj)V>Xvj3Qy&e=vlTJPfds z6yYn$4-n-8N{e{w&GEpz{$mgM>&6oE>&ylR9v(lV|TgeNCXYLVG%m?RIg8t7XU+i?-0*9g&Xfi}>e?usZj> zu|1n%v^0Q&2Mt>~9|1=8iBiAiHrGQ0#f4*|8&Bo}fHvS=J zGq_Z0{#2=Y!s+NHKR8XaOVV(A-YC-oEi2=cUJzA>GdA0;!P(bq8!gKF5+o<}+dWa6 z;^n6sF;4}oHC>Zw0(H?5gab2z@Z|wvqXOvF&qNObA-TG4PP3y@PgDN&WrFteS&Lpt z5R@DsA{*FwIWl8Le+UCyjKL9yO0TZ0Bay@VVYPmqQ(~HsRD5)7X!Cv+V;AQgQ~hXX z@`07uMG3Q354mvNwm4#SPjelrY~vLVN{5`H<>(C+?H02T{O^|!g89*BfBqo-OFiv~{JHT7uy{y% z=JCSb4|I;o#7Y@V>GQ=aE46yP1~&=HQ&3d;`ZjMf8wAL9a)XD$!+wp!nW<;dA^|0$ zvlU6*#IVQoV9Z}cmGI(XM-M>enX}16$I$5nOEYP!SOS3c!x<)aA1!OTHcnKpnEWRu>sYt(Jo zi;FmQ@Z04Y4XktZ_e;#h0rn|*e$Q$o5fvnT)Pm7j_=KwV1%NkxJnv||%c<==6)ZHA`uF`)ltKJ<9zni+D)9yiu zg7CmghkEm7piQdiVfM7vanOWsnH^$)61+*3_1AM*N7|yRFp&J(1_lvQ1W<^WpPxig zobdOXBe(i6$0=d!hk5WRkFN9Q3ROJs&2uyVe<~{Ug2V7#bOx5UUCF&y>#oa!j@s%Z zTn+u(hi(^cYSQI71RWnMkbD2g#fnI89^mljbx}~>Z=ydG!Jm$(IcY*F?ODDr1wQLJwKBwYiPuhouR3_bKf;M*io*AiXmtU6f4+ zKY;-f9h6z>vvmI*o#NRt)kFKH|3V#de+5filwoOEjiArYntA?wsOh|+vYPd;bzc>P zdcDv+S_x{tm1iqAm+}0MLSQX0=B=iSCAMdzysZ#Z)_NEKl)Hi zafc6y$JYyXJl+kSTOQt|yu|P1tqr)*O&&gGmpZYpj#WrmQ(86E$WH}v{$cxre|fX% za(Pd#1V_W$f3HSYez=FeA}u3U!+Cw6kv&-@9UWZa9a9-|u^QD%;>-LGT19T>@uR(v zh1+ccU1P9g_qYN;7j{+K-#d5*wxb}F7LIGl0h6KyIJHdqm80eUm%fE?l7%kz*t}LHke_@_WDBh$T+)!413+c{^F3@RT_RPAcs?w*hnKYHa zF&@DYJW4c$1%Z`xWBd8?-2$^LM_T)Tb*?*@d&g+hlop-Kqwh_9Ih0()1!FPa|zv;V``e~B*ZX@;6q z*%j)oza@PypY>|Z6*DjFa^_;6R!N~p;bf=%%EF)M;_N?8Pgtkvq!|(Kf>6GO-?Yu zM}^B{g3u7QQ9@8F>w_bRrzt|D<)0t{R3Z%eoy#=U`JaxHTRrO=h`jl`yjD^yuEVR^ zGBmr3?tVkPEjSQ>iD9Sf9bm83O}q-K%E&b)I2Ee{dw+?cXJ^VxJ|z8uJSIi1uMR;V&d{S z*H$m=4*_*RM}#PGOd3+0kS1v-6sr*v+6=imi>2&tpZKEjF_r#;_N69>fymD z5KF@M9FVEzlw|*B0G-+2C@Tde7pOD8%!N;l$V9`&*CP;Af6w&K;?V&&3$ig=X@(KQ zgbaW|tWi+L8gkMVt9JS;fe|mhdS^y9PM3m2mU6HipOqmJs9?_)4fJ9z1{Oo^C`Ubu z1E9D7;I>_nk)7Ta(7Uw8f}i67FLpU*WrqxyXY-;U|G+?^U1_lO)*rNNgg?2XTzimJ zd8(TDnL5Tae}s|vOOXf(3d4{+<4PJ7yOz%(=la}`@m4;Vu^?Yq3{dvUVwn~zu2Qx! z;zdWLB{&xFwGeUQoRIn(4G(4T65pfXpNcF7JMjU+0pf7}IFfsL4~*8d-cI~9ZZb1;!G z`V#@u?6u=vWjr^E&Afxn|I9BbF+nE<1H5)MrbqHOOBNxrX6S;lR|*+5wG%8I{Q;g6 zcTeE*QI(oYYONaTEK+|_6vOvF18&Wn`PQzUUuNhr;fuTZP#cbc$6(SX8Wa3WIaZ39 z!Qx#Qe?gyJW^S;U|NgP3X7DbuxEP51{+jJxHc_P+^G@!)|o#bSLv?<#6i~ zF(@!xC9^J)zu~+tuj)>;MRJkpr)LUINFR_S|JWe&$Kg0Y#1jZ@u*I{>QUZwtUzzpS zf5@X5&Q{A|6vQ`b-~iJ|LAMC{X6DZOR^1ZQVi`X7b3|l0Haj~K4M52RkCf<1~oY4lbt(#Fdo1$2L3b>?l zltC>dt0qOL2ktOiUorJ&Q+`!>?O`Q$e~n|TNct#|X|yW;nsT5NJH>b=7C+QJGqsbF zS|pVJi{V@$CcH3ACS>c>Jlo5?vzGcy{M!Qku9g#5x5NOD3Vc$AUAkjC(yRmF)MuK) z5m|zeXR4sj#9$>&k#)d<^ja7CJubG(Z!UQP2Rxg4zvzp0yI&HCZ7ffY2?rRef6)JH zSy{aH*=l4B^}Y|RQ+M?_S>*CZ@?I|rzcrvnN?a@xvOP;2P1wv*7l>3(Dfw`v0HrhNXVaTr zSz6|J{J35SQmx3pJprFkyTFQ2fAUBD9ce?{qvI0SnRAMZHm$*RCew$TRMc?Up*SqzuGw4MP^Hzq*{D489gTpOh8 zm0ksQlFDa6m5(Eqw6{}q*OgMM01x2DsxLco^O%T=Dwf(LTeU7O%d?nDm^$5lL zg{9c8Sba{A#EQc8RTA1l$|;a|z~{Hoc~0;qM6V=Fu^`LyY4__P&K4pFH0u9XkW4WP z--3UuFir?BClk%4oyV`>f8*bn2Y{6?sJwK}X?Ah^gMIit2=^Kih4`>mnNYffKn~G> z499x1(n>%}pwfi#Vr*JMiDLpp@Kd@=v?qk!6U*bLC5Qdo%XiTMa}}AUEfzBV@ka>v zjtHw?8DN+LA3ao^f8=0Zw6nW4Gg@u;5O`zhu$XOJA?zaN3rprKf1X=OI(rl>z+u;F z->!|o4NZpZu=tbarG9*FlM3*oHH+vwU5!$L;7ez>iZRg~`GJ~r48!Bd{Cc=ZL^E-+ zwffp^OOdN0?i>{N#-gj^MMimxnCK+PT-E_$w+j{Bn{DVO@-q&lTKw8w+Y2Svm zNt$UZVDvYQ zkKd-;hfu2_!s53yWM!67ixaQ?XT2B?2fDzwHM6c^Yw(EP@mV~D2i21q_7nYbz<2@O zwOS90&9Z>9=#UX1KM8`c!BL&`xC+NbSsIMifzKIy8Y=;qe+pi`R6$}s1i=*^VCX>> z((7j{V1H-MfgsMi*aNF(BZU{@lX&KbS>?V~jkzv0Rxe~7!-;t+s3#-{So_!QIi)7L z^A1$ArT3&FB@pUc@>)82mjDFYb)37K#HN;aLPIvKw3zSaavlb(y*>jPCKz*<9d6rg zxZzNO@(`9Wf7sG{&#jlS%&$YVfdLYP1 zs0Z9-`s`VEk?IP!6Rx$3*MHb$HL-Inwn(6-`q4yy>&86n>L4=24t1~;spy{HYTn(e zXg9wDaptnh3|bkdyZ~d}5>521@^!mL)j19)8fsj{fWt^;Da`*e+G>?ZsVNMMzuE?A zF!fOYf8*kQqDDzDA#I2G#6uqlCVsh{sHym9E|B7J5VH#?N&UGMu2IxIpF6&r!t-SM zTTN?5O8}fQaqwc3;~>b`eq(?QJ=Au6`M3me4}q<-2gzXc|N6!xhP%xkN8=O5qb3ex z5VKVm?*$u~a*n&VDR-iTF>6Q*-bZCdaEHc8f7Z^nU8x{d8c&VZ+-wA-fwCdK`z$Al zTio1qQC{K7$_S5Qbn~D|{Ejr~16BZBrojsi4PD7k>+X+x+V&SKb6-v2)F(InznrM-GA~DvZl(f! zf76o)=!jjp^nl*O9Q92GNU9{+KDwWqZT6GwAdiMi?89{1rM0MVz(eZj6q`98#__granGIlF6@e`Dpq2Sod| zTt<-WwwG@S2g5nHcsHiOW9-wm_PT?R2#P2+(G*`O4Hg$lSpn~M1poQTVR{ioJ2@RM zE0$Z3*|a-9nst|;#B84kd?`aFgz3%+Pj5@VgjnakM|^1!-n^DW*0T4|W-MBET$kE! zv2{1qxqDawwS|WOc{MX^e>-#l;bCY4%7loQ*|pb=fJCCpL{+F#!f_8xqhml#>GlnY z?NNK;(wiEtiJ5lW*qO}?E~hBG4pUI@kP7VNc%Cb; zf?4Se?*Wh}_hAkBGP>Dkj+JMYf`cdHd;bTiE)UKDu7O@2py&FGf080=#(Y*(VwcPX zRbd(4k5k8&+(k>O0Xp|F7maSXom$sf#lo@gMdxmNrnvu-<1LHTw|z*3%QhGwc7w!D z36y0ju%Soe$9)c;-*4dpFnqv+`^%-2$y;Y=m+K}5?+3#N(0IS<2^lXp+|X?L5$Th) zL6C)UIwnn`74P60e?{VBR6kDWURsQo%R=VtL@2(}u(z|vnjv6od_b>B3#ZGeYIZ;; ztSUev)+ejZd__b@5_`zWJBQhXoaPc= zMqjvqZ5?z51z>q_$q_oOLD@aM&c zx_A00`?kasfAZEVyXxp0{f!7a_eq`F_8@s&Xfo-yFt!WT3K1f=&qaY9Ez(5`tyPaNvUq_;y??_k8p}Av*;j-EGI$~XZPo7pt>|Kw?LtnD#DZyy1s;p}8D_8RhsGfurW8O=+Wo7S+sd^lx4nEOf)M;cAtZE}y zn0&OY`yf!uWNRNa@P}mQbaLQ0B8IB)*CNTJl2b3SHzQ{9@ot@pMCKU4;3>^rtB>iU5NGLIE}S&%J&CH_-}`I}5`zNUscLfA@=bDc0hhxs3@?%g&=;Lt$ahMy1_` za+!AkIWIf}J@0j;bF356FsCN675G~jTxSW%bxh(0Ij;bENFtXPj=&T^_d~iO>DSJD zd8AIx7Kk39hN>gW)qgmd!U%uA)KT(C2;9*JMp|f;KhSxpbUI2HmU%c8jIew8$;kMa ze^_p0wd+u&s0u3Ds&f*pJQEMdZc+hA$T^o_=xDxEbEU}^-pMj2_F=x5uCQgysD^?q zv|W<2qlKQ;F@OqVXOAQT@N~N*9MKBXWCjFqw197W{m0p(KoqNK@kyDxW)!LXk6Q_N zA^b(jg4G8_kXXYs2V+<@`z7WRDNBNAf5CI%o>U1X*>r5IY)7pK2!8&-fah}j(9*<7 zj+UH@K?G8OVr1r#?1>`;yk@f(Z{*Jc^(i`zq+w3&B(^0j?TPs8Rk=A857Dys|5S&*=`6-EkEoA7@KHqz)p}T4~5Mls$@h8F$Hte*;8_ zcV0wF=RRr8QjW}27yVq)&yN4j5+G6n5eksK^h(M>eNx$-!fx}M4F4SOp>_tX4hQQQ zJRax@{@uQ*wXN*%v~YTna+hll!tff7PWyW&_Knaf)>M}yUOJ}INS#1DragL<4LTNs z4dUzt%!?}`%d!hIHPS@W*-dI$e>>9Kofh>tGL~Tvas}0fwk>Sw|12t3X!azBl_+zm z1I@+tGnl6ciJZV~ooKD_DU>DXZo<}t5JU@3$hGww_&E)Zh@B29RLVP$6`4zc*;2LG zzobWv^=Kg<_{F`@F0G=9{MkT+Q9Kvin_y7qd1y&nUc(=Bz`mntHXAV?f2n-piuu&e z3@>l>_w*mXM#3n-8Au2{hBH9(hVsnk_q>^*ThYDLW2_Aj=Z*PV^sdImn@D zjL!5XHc%Ed7*e0GRRMirGg08kf5P%a(5gh2nKsy^&5-g;qM_qN~s_Z z48qO)b648qu|^Gcplrs&e_eow^3-&RD3u3tD??1={pCgX0_e0qXO|9_8kPn5GI zUuBU$MIwdIOtqc7m;E;XZHA;26176gw>5r>lwhl1=hmNryvI`9!B3*5XUK~shg}=* z*3)Zjnw^z3lSQY*j)4Ci_-b!c63E9O-vy*^9><#9UX309TBOhue-EQ_^`8|#L|J(L zb^U1d;)24iWN$l|_rM%(lsnZ|B&Ac1--s+bJ3IG{QTj^DTq3ePc|j+&x52KYKD5uP z*34o(Fv|n(7eH~igHAeRv+wVXvH?B*$(i#`pYjETP@=T_TaKP?IP?kB`~PqGb6d)_ zcPq?Sw0tg}T81kDe?w4C0J2t9Ht%VNw~vWNMY8|B$m0*dFm5V%40MskE07} zytYY?6nwtcWw**0IPA^_ZZWjyKNq=BynA7)ng7{MG;R7^9ynT?EFidTcYa&#ie0EKA3H8P4}G2i1Qu; zEL;XCql#RiU0j6PoC9$c(jL)8e6OAIL&(l&mhAoJd(9f<3j$hqD=aY(EVL2r1$Az( zlbF~>3np3gf0Wm{p{6i7o2EU65u%_?HaOX^)&LK`sS~c@)sA-%6%y%>gzmzybdwM` z%(|{6JU=gog)RV~468#ymp2y)Y+m(yO14OBFY8@N*4H}dp@b3=kGZUHlW^1V$r>rq zZ7MsNtUHOxCN-s-x#hLBhBfHUhw-x64eNG@_yVj9e>TiWwooeuMY(B);qt|vG6SW3 z6R49of;HxtlKt5{XUtt*D2_-KpkXyrrTQjUP27p~jihZ~xo43G2@DnKrJUtSK*{ki z7I0qd?EiIXPgAQ(`l;X{od+mPm@qf1_yS=5H0H+S?lSrFNaw(5)Ey9w1W#3T+}9&e z;*}&AfA079Nxs*RBl-<2L{Y|JuWc_cT>(A|FYq0kE3CO<|ETi(Lu8P&ijyjHkA3(_ zX)_6sGAHk!=gYGu5?;6z#6JOcx%u|deJq1*m3tiy+uNepkiqzTmb6U?z%z#_^4R%S zz9rdNq^2N2FMuIwkPDb#xxIiT$GO_ZTW%c1e{p5c>%VY`C!kjt8a`wfyPq?wm`+-f z9Yl!F^Yf%^bC!Xz(&k$foO<1VN@WP!&T+m{-&FnB!A+r8xA5_jNU0paEH$Kfp!~eC zuJu|AVGP0=@3g7vONMM$!{CorYe#!H>MS52g>oR;WW887x+pWW9u(`De*KE|saAre zfBlcKi0ZC`%Rc-<#DHWqa?=E|(pbbM)&Wk#V!uhTcIr@PD;gRj?2y#Cp`5UD5;*_n z{f>YdP_}g{F!K7w-M94!t+(*|a=W}dEGgUu5C>~ms0Im2?)pX43kyoA!3 zj}eDP2~Q&%U;ud5WfHuJ$)w`{s)#aG#WL96B}q(zx+Br;v0m}!KNVQ)cjbdq-Gz0b zF_i8o#tp`G%W6UPnvyjAORji{zo0!lXo*{b&rj_bu=!fqK3u^_b`?Jx#n=KB%h5?wlFSuOj+Hsd$awcTKU zq`n+5cv~RYAblGqTVcnGbTOd=N8Y*@2VIb$*0(k+(hgL%O3jWun#pTF41Uu(g40{t zv^5Wdmp2{2$GX(C5qfyWnm?<&;Cmf@=}bkq&o!qc2`;KNW!&1mNh0Zd>Rx(>Sl~U*?aY?AwKrndQFXSbi7?2xc|?CfawJKeLSM^YPvVa z2};4Sre=&avW%08cz_c3e{2Gu{vnJM`G8~j;Au>XK1&ui4~J)@mK0Rzhp9{21{^jt z8R^7$Fu!5dEz?a13Y;-6$i)$~>b_&B15I?=UkYbDx6F=fP2g3myKDFZ%!=h7^&45< zXmxk?6{yZX_9j^N)eXoJ0bHxu5&$7N%Tby7JDT@LMsiLt>d{~Bf4+*7(4-5POoj#? zYt4G4aK2Xt%}_lJ?=EuMx3#eUF9xYvc{N#~M)6QE3l*-O5z z7$O1zv9*=TA&VIfkNqhGTAdnO$9+(ZeH@^P^H&aj=+|7Nsq5woF7;2q1k3HD<8K3J zS?A2%mMZm5f4^|-(ZM_Pf)^35XM6@um>RRqSvr@kRp%I8jy{)2xi3}!qU^{Df^`@Z zYK=;eA`*bfUa>D>5T{JT&Jd_7}6t+FP=GE#fRyFQ1$i1!h5)1c1%&fuoog8*sq zlVvx3nn)8wRQ%e-U7fxxaht0F3F?C4(TpYB*`i$ZJbBo7V01Gh$!0>$>^|}zajQww zJ!3#5f9CrzY$Ac>k%920t>!NJq509VHb1L1Ycer-PGFFe1GA$~w2-^@T4{EHRtUtE zzkP+ST_t~QI@577|M>$elteanfbw~^Z7P-5Q3S5d3+VA+-S^G9k%@I2&iHBj4ye^f z(s`7!3%82Cb&F&*I;7~;g5_Ww)CWqm4&q1Rf185mkr(gE%T0zex3~+}1CKi?{Pm{^3cAezexbOnjA!d;=c$8 zf9ExX=!F5F$yxGmw+lxi?!UjGEA5er)>|V`%Pe@zJeEl}U6b);xe;@+&#Wn#w?Ten z`V!C(wKWIvT1goZO^wdM&0>(AwW?jI;#>s1IR^2%2yv_ydJqRXeWkaXzwjsX6kd{< z6vTxJJAolwuhT9167kdFH7Da{jTiV|fA3v~4ww6y{ixx{sTcsPVn3H`G4YShjuX`c z*EKgPP~*XkO+K}-$H}u%d9auP{;t62#jWUiHoN{%)1`f~oW0eb^(5rCvYj@ZyAchi z?jw8NzaXEALc8P7Ssn(Y;5Bk-53q>oxjVrILShPqHCMzSthRc%MwF=pBzq!%e+N;K z;B6l*^G`0^V&QOhyD}K3Q3`XJ7UlMwUv7sm-~7^kc|SGJO@BbzFLFx=5gyd9=>Q zElTtnKBFQlufdrCcch*ozNJ*F08+ zLT9sKDV^N7*G&=^3N6YezTmS})l4t6WxtPWjBQ)QtL*LqvsMc|l&v)DDpkjJE~&6D zS+OK5M=2rZg#P<0HnV!N!zO_UIq3c+^MpEi815{m8f$n+0B}}Fu@&sLe~7G3B)-*Z zNSqb5Lc{DLF0!00PZ-iPKFNhrsV1v+LNToxlVF6FUvmutITt=}9S_mIA<#LjkV%8+ zlO6y69pq5=fXGJ=j=aigTtpln1#}dsS=k}g8GB&U?WtGJ%TABM?#=%=J z;?mK7C?64d@S(m0C>J#Me=f|KpN59^1lNdTaj&^Rhva-QT`njb%T1?VlUQAFMcJ>K zEt@;sk=y>BJ7U_3|4|t7xjSTindZ2cf02Q&@r!IfZZe$d z2e9uh%&A1~*;nhMoc+`A{+95v)`4js2&?x*K8=0R%NtbYXmh14MPu~YkDqCkHWVnX zqg|5bcT=Q2rigtL(j%K4smek_kcUr6r>R@BLOC?Ivqj25cvMAdPAZm)t_bTxTQ_hf zJOnp>F!d!KG>?U8f8F5`j9hV(QTH9LEohx;V_H{~oikbWNy5HlgN{t~)C-2L=m0z4 zUx+piYx^-g>GU@tSMAvB*H>-h*mtCGb5#_M#;t~H$qarYBHW)N@z-xOuDZgp0>%a! znqKA(F{U>-olR+L-<)yb6b--n_5(BEZU_f}XZooaKiy5$e;hA8ORuScBmXL67%NXo zzxR8ReybTY1Ap~p)im5-HZ>riG_}b7dl+N}^(0{E-Moupn)IN@gpD*B)Bc@*>Mts+ z7962TZx}jcytzSz1R<7d#tQd&Pk?YLM@P+{cTnmTZx>g)*IyE+`^X&)y&D$t3D3wK z5ux6s=O{_Oe<(vwsonL?q7tC@*Bj01V8;V2<;xXQ*4BKfeB<~?S8id5) zGj|ydm^01(8HxDdIjF7)c)?8!HzGaY6Ya(2t*gl9WvJ-oM544G^G+(tE%NZbais?! z{NC|4m>lXV*XPy{WOLwG$Lts z^w-;Bm|nfHFBB~>-@W3bgGUHyE50?Kk(u`eJ1#i0^BcnurgO|QZ*--~jLge>LlD@T z3F|DlrzDmMoD~uffl9ocBazT2-4#dY${byL2LaC!UBYt}^rU{W;6!n$?y4b0JDm8E zn7yo4e~N%$Jpz~GunM_2s}eNlY4-3WNL>|ov@Y!K^9VIWiL+!vJy}^Ca_(ge(Vs8< zrczDIJaBOnpZK&+|1>W8b?=5{`7uuv<$`-UF%X*>Q0{j_ozvb*n<)Hle+f4t;+<#tQ4h$D&1G`8$wf!gbd!XEGFgJeZ&_?!;d6>Ts9l9lK3jFdB*>=8 ze??xko>_uB&xsTxc5y5FuPY?&CV)yKz^~t1RRgl^M;Ay;w&DQNdEi9LH-&ee~NvcSRNX2(>MJMc?7e(FXq5H#R!rPcb-}L ztE#uaDJq9fyH8=!a=`M&nTzJM(;r1QSbz`s-6P6a(9pm9Bd+uJV5xK+^Q@>WqLTSD5u0LOECtX*Xe_#;q&mEIqDd)qC!~tOGXS+Sn+#TLYyz zPCET%MxL(otP~?|TNn$Qs8g2ujZ&cCL<<4n6xSk5^zxd!*wy0lG@WTUpP}T+xJ}Rj z{Q(FH&E@e=z#_rSXb5WrHofe;e=&Jstn*Q~&B6^0@lFRi1SQhrG8bk23-!M^mkENY z^1Q2E__LJjSC@Q+pxd@ma-#kqOYrpUWgQEnYF+&JXwFp9x~M=^ckAQ{u8M@K@w7U_ zXckA;L`9&qNuzkFmZUr&oVKBh4^3=Frbq>8K4KZ;@0C=l(+FRYH={ece{+8ONfK4g z)0qT*0O)cknN;+*-0&`po9--qKrO^6+M~*uIjIl_UQAPzcV6dFX^3~BO&2^`b>+l& z;KZlaM2UEqi`cYzm=S@#y20rAsu7R?HZR8FTmA>8#eMK&ztV?V)1YfS));C*Hof;2 zqGSaxdjAMjOb0bZbh(ZJe;~BrR@+AM?9kzfPAx!KSp-vQ(Q~fMEAc4c9IAcXPZl8% zzsad)M6144@Aerk0}*+);)k|w8zq7N&*tym-04wEOEtaJ3Zy*F~wjWpfDo! zz3wVCL;+%GwI)-iz>$VR1E(R_mRYR@(r^hX(J=u}wMr80T|?i{e^(VAFFnKv_2&^$ zrw|?#XWo)w&nafe8V_fQ({!!Lpfw_j8MI;7OAC_3r2zz(TJNy^@+7FdqTUq>7$u>b zaTM}KE};#~)zB`qnP58Ru@5trK$zH1h3j?(5c)&@Sq-nW3im_OWVm{i`#$q2p!#o( z6_b;w>UuXHcl^zUf4hYiJ~!IpussMj9~9xMq3LvrhO;m0PK?4}V_MoPBlolB1Sot7 zo!?+8>!f1<2NE-wvzjMjRF+NRwdRGI-)&M+z2llt@mtzoN~YVi<|n@Hc3Fbavk_^& zBrPOA)(GiTf7D0K!p0lxV7j1x>E)3k?(dXL#7f8A zRhx13gZes~{rnNs4-GwfI;AaIyHmKe-fbC%8eY zxwHL44P-bz;SC_#g@)pqRlTV@f|c*|`YGqLp6Snj>7COyM}(?3 zn=TzC-9@@G4(a%Z2B3IAoA}yxDQW* zz8Snre~{CYML>@c$IE-dFX6T~E{Wl!FnL}WP|n0fs{})AKF?;3`;AX|Vol>iyt=nV z{bcO2dZ(N)&d&OFFlo7uU>D<&f$WVF*8w?ZK$#+FdP5L$6lED-EZ6ksvDCQTrFg#< zNRX}l@+e|6u7FWefkPJa?n>(jTV5{^<|I#Tf26L_<%&UIWS~>qhdg)t?df@GM%mnP zC<7Wz44aLRzXBvK=ybv?U?VUnN+J=-jWKa`i6&FGTi?mEoIdF(rFRQK|KZ~WRpKc1 zKKtyMJ(gFt+lX4i8h46pTuVL{MRFLVJu}$8WW%61@$<$3g20QZAvT~*K4hD5)lyaA ze_AOkbL$4;033RfSUMxv0`A1r?Hgg!#(|!LGRYOSxd^>t`)!(TPCdjEtEWDn(G0!d zzm+53>HT97=(@ki#wlSa{61jQPn}0D)dWY@TKw}|7_n52-Sfnt_(OCS33A7c03I5G z564k_@BXRsjIpzf*V_C=eR4m6gm&7pf0)n7Te|_xFHolo{46ut5LwC-uKtxeuGK}7 zB(`JXgXIQM6J2S4RW$qoSRvAjmr44Z22%~2Vau3y+4dNQb+~4ZqpyOcTYNY{`R9ic36@O zNW}E8*CY;G)Bf)Cq?3E3n-}LLf5_xHZ@-F0G`wLwZRDiq|8!~wZ4m~t?RH7RtSY#WXh z_IA~4g%?Y#?1)|>Kp8}mfLfT>+p``%)oo=G)0OYL7@pf0=UQ524yK?Sf4`=PM}(`k z=gdYxHw5dX;b(nBY*6hM6TA?K`jjCiDVy1O$n*101wVKAiSd?%U*yKEIrUxfso-ff zo#;EA)awszZrwbY?g;IjbMlT}poh&s8Z=mIvdScmxm8r4BZ_Z=Ls)&Q6#9ABPi6!1 z4f>qetBGK=u>%GMbAiD@f9%}}IS85eZ(+as=gj2Y!#>TbfI5Ot}S=CF&+t2gXfw5*~{|9;1bL0|sN~Gh6_2117DL)!H&Je;Yeq1q1OW6WWgf z^f>BnSHbuvgLk)Legeq|vC$B_8;WrSmWo&cvE;yK_wHF+6j1N zagKFEaCG_%$tI{W^4_%keJ?=FKyzS#Rq_uxS;C?^$5>dwhXp+9~(s8jJEe>c67N*R`#eH_(r z_o~x>5i0aFM%uw*$(7d|HK5v2Y#CQmm3^hXs7uk7O+6kvp=%#RooF$Nd}PRT{lhVstfCBIs4KfDZ7L z1=rc5GNZO6e`RWq3TJn-q}GnhDl@ZoAUTO}00DLTD51c1cvL$1%pOe$0I1$Kdvsrm zzBYb4W=pxvG9a< zr&93@f0-ZjeZ&IynbRFvXc4$>X;da^4gBI{-ZoBsDw3uGP+zQ9pIlkiAz>VDxMjWd z3TUdgq(EU3O?{#93j1-qT})xmF&5@u{;kws5${9*<;#_K3jRNo>)yqtb{!m`X362c z!OJ;m8d@@}{o;DG)-b2UIk->tgC4Y4`Sn)Bf937D?!Q*#{1Vz2+ODpGFLX*59i=bL z%ZvAxCcUSqfFIxB?x|a|pM4N26wFO{2#Nh%*c?B%am8)E-pE;tb|IhHGwQU_!tI9< zN+ExG1Ckya%t*+{&ElQN$ ze>p-5BwTD?YB}6C2~j$8lV%w z`EFI(S5kZDV78dLmiUyYja$u@fzNNnncT=I8NC(mW%XPp4_U;Dw+0? zj{T@bBSrPu-NfQmu6N1^g~;77f05dRIDRLt-$ZsOmDWUhe}HVe0kcMH%KRc1`^Htp z4hM#xG0;Pbwe;A!K>8jzX}+f2@32s5%GT5`ZN1zSJzE>?y+`Hxw3dN$bw#eC6&jXk zIR$+1UfHavAjQ5*0dq8T_ox0uay{o1 z2h$y-XhAxLN&FF(lyOxTT-AMBr@7wLHA}hriUKlO{^?kIUR7-0Ll5BTjH^9v3`^uf zDZmo0O1<)UKDElIsO<$ze;dKJ1L^`&l_jLY7bZ1u`eZW_2*^BN64ogjzjO<*Zp81B zNlRyfiJQ~JabqX9S$mm#xwO%LbE`BHNl1t_Vbdnbl*?b929&`>F^bl$!s@H1Cb@tU zmFDnJk?H13xys6)2jEYD2hS{OP;L)mC!I`v3S;oo^BJVXrauw+Hdn!T=|D}EuQEm57bcj zKqpl_yYfYYm#!k%y<%tR21RK}^)3B8mW>U=9L*EuU#Z4uf89k**CDACG$}J!1%4tp za<7tGgi&8_wV$WcLRUJCgD`z?t#o1~N&QIWZEjzHM17-YeN&dVdQ2m;JMCr^U?|`u z5$Aiods#i?RK`@o)?t+_KRg7^2dbV~)p;kk>BBDItVE!phQC*m0=lGWI9I+om?uaN z%jl9Kk3kpgd?S>xnu)p`XU(@p7u<2CL?7 zMAsY}_Bkx{v9~lp*{13vc%^ytK6MBfWnal=a|U7ve?$cT$dFj>$P+aC=qsq#>Flji zA?4Fz^ne^MX15F{aG)yC06Lm}jd^S%-ve{1oX|}6GYrTlEz@YNfo{{W0n9F8XQ;M0 zp;E?2cFZ%+PK=P7{4UNFY0HC%VI|J+6d?1SGio6qYZ#5(UQcIYrHHs4-n*!cJp!b; z+%tmke+G?-IqGAm2JM(lo7yCs;aT)9h=8@n2RQ~nw3(06u6P-_hx#4up*faMUnWxC zNwZ#-tRdg@Eh=k2Z)FmkUen!A_tC{Xs{K&2?KC6k7ubcjsFB3btuR%$Hr#R99d6#S zTnSO&95<{hu4Co_|2q%-T&n;rK+?aUo65WVOzRhhSA#qTCzoIYPpd^+%P0uevk4w2x zh5ULq=O3$~KURKt%$A}}E`JZu*c$7;m(Z_CsJN*rgbdtKpZi;Zkns(kc2falouQX; zX~Nu(ap1cRQ&_Oi!j$2qc8T)uqS~(p6@Ri9vVLONnFPF!fBfBkUP{KFyu-P`QluCq z3WOtVSZxTHAIeyIIolA(rsJm0aA((sVY=$Nu6H=L;y~gl2W2&(dvf~0EH-$-_=eeFu-AECeBtYwMp@4Hg zY%gX)M-h7ivV@;e?o4dkRvwLpjyWI{{$Ne=0>jytmy$JRKgyIfElqF)AbMc zU(;(s{Vb7n;cjOpD_Zg;^>fuvah*LhIQ99HkCPi!BSaaJ|IYhWBT% zUI-&|S)ZDKq!5gS+K7BCnR}~|hxem)30N&miQ6!9N1)fFc`Q56H6ioa>VNaAXL|JW zR3eX#h6-`f7zKy|uPLtOYz;SjK-1YeyEj%K`O*GLeOh;2J%d!#hT~Wow6CR{K)G(rc!Wmx32Bip|YAtLIP-b zi|UymzAByI1f2mMf&rSne1A`^@-JmPUnAR{$;3F}-Fl|R&z`&%2FyDep}ee7URN*? z4kDhHfmHBe$ffcO+upTlNZfH3Y0&%sB7KbyC?_E~Nj>|_U(UDodwz+Y_5H4c|6C8- zF$x#{VBTN}`QkAU2OU?||4z)Q)<^lpp)Ja1)JwxzQZ&UUCgk>iz0d}4SG^BrjZzvN^U?+544smZ+BFDt;C5N3cFqSmAw!!iDZ_rx zFfF8-$3a77M}=yisnP%?4DxIL+mw0?4-q68_~8-UoYzlyAB!^li}-Jb8F203)p>^! zLM_e}qY~!R1WZu&!hc*&SpT&`l_2h#4g-E$v}plK-(nLo=4Y_4AQ!i1ob8+cVlaQC=_lKS<5$E$ihm95R*a^ zqhsCf_=Tb~!tIU9t16+bUIrsxE$}w8CUQlD0(X-@j|>yzbAM+xotgt-)x(Tjk0<^X zxsprFi+O;NM^D(}npv^gDPq=)TzJ8XU3wQmKz`o=gXkGG`}yqB=e~L4WaH&J>l5!d$Ljuf5seE8cN1vfV3@m z5Vp(00#uITGk*cxM)zk`o`l#P+7S`v>r)4xeJ>oBaJ)!MrF=A`e$4oAk24(WBW@~0 zs#mPIzrXokG4lu784Sc2D_rc=vn78h;l=kn*>@xd zvBoWb_#+r^0W|@&NR%3{AZZVloI(aHq{uAWb+a`WUlN>xOykRI-djX5-EI13Yr$46 zN0;;%^?wg=0dVG-4dePpGmaeNkBzF0kTPEsJQ`XOARqW%tC%H-e^yl8Avw@9ds>{N zV!K9W`g0&@8mXg$nSu$aqD8)g-lAY;&nA8q53DzWXG`k8rc9Y|V0^AF0m=Wc(jk&+ z_>2flrjNI%Y4IBJnMl!aE<=@71=nBuRGTW$;D5RZV(^M>s2di)yoT{_^%w@ehbeT|U}4s37Xk3oxMPC!yP? zl^r7@Vea$Vqusw*U=z5UecAn4_@|{I40bBK#%2dVk#qjIW);TFrEnBmAU5%1X`(XN z+wJy9iUWpVSQ;==Ky!^nmm5ntvhR+PfnP5z$b(E*CIUa$ogbvcsR3DU z`id~A?LcJfcjCN!-GV@mqvt`X4p8uXBh_>bkhqmge1tAh;99$$5NT}oValED!4#z7 z^D?j$CK%Ch!+J290wUY+zQ8a^yR}ifIe%%&6YOA0ITzsga|>?@*~3VlzWO+Ih@=EP zU2OwwE=lq+nwL@%Gy;`@ikx#E+=JacS5;{jt#J;nYMgnDt;>_ud9ir{&D5ik0&=#1 z%rZ(%=eKW?APP!GsnpaxXUzE!IX+EU-3uMDzY~)YY5o0?^jfoJi1dH_~{zqP#T;a^l8&{2-cx0#l zp0Mv~h?Vz4j`G#(A+YpxK&$4^rJhX& zg=G64cy*%JNjgr-2Y7$5Rz7=h@?~kV; zL)ua77TJayLM|Uex^FzJagn$0Zm>UJi?BoE@{=PQimM^6LtvQqkJt3hjFzb>ixzvG zl{1OsViP{mWEgREMTk@xTb)}^S=|GxZA*43u1(66``bI?S_q}u6phz)mw#t4X9+Cx zOtDi(kdjZ?m_g+_fr#GWVP0HtXG5;%gZHS#bK+3knYZHiir?eJylB6Q&dt~@citIe zMaa7hqQjG8Qn!`bAADfV!mxxS>LA9H-H)WwJ%T$^?A4l{GW#R+W0h07fBAlY)K%DD z%LWVfd6L_p-pvN;TFi_cQGZ2M`h`KQs3RijbZu~JA+G&H3-`q{1`Ul*>X{PERpKCK z{G&+*RHCRCw&CC3i>74XAT_pIj`GaG{_2g7Uk(@^9^C|gZwb(V&xOk?3=^X2+W9?7 zqhFz0`1rv`MER1SBSzlYRBkpHAF%ukQZs&)xifiTze4#|=n8-oZ-4O{VrPndME1eA zyGy1)ggR_t{it=32)4l&>4>viqSlNfn4R?c=t>w!*=n1(aCfZx1m;e@@zRHFTs{UN zkQ|R+d7CM^zES;`qrG|IwnnDxStZ40vSgM&vVO*X1ym?x#d9~Q23PAnKSlBNZ({4A z`3e|0**F=*wd*8SAb;*Ut__#+p-PsmrXo=0WLPoN`9ZE|(l!4uWRDn1xM*))MY@_&t~kq;#X1vBJVzM<+csa3oiZvFXG z#64uly7s3`^fcruS0&d$EXc0hw4sFXo%S{JB^>`9KcvrR>e$6wgwd4jn!ofHrGk4P z&7pw{8sp~aX(2+yv2@OfG*dkLMmQbr5 zfxL5~>m&47j(T|&AE6@0Uustk9sgrXu{pl3xnp*2;d@5X-3H0S(Q;;w=vI1Szyo)z zb5AQ*kALe(R%|SL;40Q@q)DB4J0z3bCncP0tjAnA`8*{caxR1(4@|q zKcVc_cP?%)zB=ZsroW-=Sq5?g0gd{`IOV;6r=}E7>&49WWm9PA+>LcEV(M50~*UeIhHRAP9lUC!`xlF=ABE%#3v{LcG5-TYop( z;KhPap*ZU#p8O40-<5Z*rDPmuzv>SH3p4#_~XYyPSEnojN7Z)wTW+mQJ0-M$dDA1 zVQlE8s?Snveem=s+ZMOW^|3ww!LbbVkS*agJB>y}Rai)=3wE|7d#kBMcB+J~qiCI0 zyG+s^%whL-AY@dLmz2q;5O(>eLSOltN*Z%K+v)$aSRls=!i!Fo_~f0h)qlPhdWOgr zy0cZo0>EU16IirhImbqd2UulEcyUBH2%b8jk`g!?=I_iZz{?N3EtBS)SzdR1UVEEC zWedZyxZ8^=e-?B*%|d_Gzt`noH0}Qi^ma6%$7pPseLwG2)Lgq1;;6QW;tRZ_^&$CL zdu;m%atkwy1<}*5V2D0MFGx+oukW<#Yd|wh-EK|2Mb5TuIy&t>TI}01HYFnr@z6wB)9^o zNNRwawo$v$+BQSGLFatVSx$MhCrj{eRWTF&)GSqggPXT&~6fhozu;^D6Uxo@b4sU#S9&vS#MM!h{G^ zU&yvNWCv1Gdmx%a-U2uDN#3j~c9g#wD)DKa?n_HNh(7IbVhCbWTE_j|v_#E)E?o|7 z{l5c!u;>%=i#-z{Wi{Wk3@)a^_;oo3HI^spfrP?Kz%{R&o`2gzoR%C72PLv_)E!h) z?5Q;`#46qs=kcUnCGT6!oJ!s-Gi#8rMBs?Ay0#5xz{6}c!<^ue=$5#t1)_+0j>c{h z@DoMq(ne5Y7;Fmqe-IEuKZT7Rkx_H7c{sxr9onB zhC!95%^XP5cQR@>Mzk3-AA6*{Ne9A}eBz6=aDMgr7>}2%MT+h>^XiZtE%cN08Plwy zz*^`l`~78j(9X`N&5MG(>4xCw5LG$I>N%m#(t|O*x__o>XiX*zo)__d33_}c(BQP(vG?ur`eg)>1bM;_dD2YgXBnJNa> z&F=j)!u7K4dl7|_X7bB^YAzMVwKGkoB3b}0N*8~2jMWPpV zyBH6%s(-os7%QFIt1?2FdktSlMzDl{&I$x_?0x(N5YI#f5eLMSqKh%eC+?AIaBDszKPUL)78hEX5QYmZtjwD(QrEj8xEG{S?3S1zL6Z3padlW zbrd>s53DA>vRyQnWipVN8sh^^JP7q1l7CT=@+v!zif%5ddZkIOtLd5?O2WxOic;&p zd3JzipojcW^nwz2WGr6tYhzRTwjIA?lg}CM(pBWN@x5S1>nnNnj1!6r^HGdNiS|6j9z<6d@zs~3>lXn(CPcYw+c>Vep4(98> zN8v-~ukR|MI9@E;R2h9QX(-lBMb-dGfQ;@vGulYw=Ou3k(iiWq{dFl=oOcj1g23`%4yd z#t5hH=Q5{1{U~k&Q-6|?kXCz=Y=f>+yJwp&th<}jv+i9!9mFIWKX$O)SJBok(6QU6MN?5w(^u+`Py|Cz183!{ z+)xjPkNL$+JAa}-bd(e1ml+S;T|v&AM{}(4?#Y=A#6iBy0ubLzx`Lnl-<#mSIN z8PG>zIJbl#!|~qql65%Q=cb9$>agizD#BU4n10dp3K~NO7P0nzkR3vw?n|+1HF{@O zW1W&&D2-baF&n*zLI6kE^+U)c02Oq7kxlRo)s}Ehet&PA+?(i2B0+2kvBjbs1(3@m z9phi#HN&12;7dM4VRMWPyfLI)tTc`R^gG zm@5DE_&k`>UF$T+@Z0NpQmT2y<}y9KF)+cG^ncG2TCs3;A4M+U?nxU;wiKDX$Aa`z zwgHNvIL}pxJ@OapJ&1lfwKpfZL3%duVPRM|?5@nl(bi?c0~QxtBL8A5+q0dlZTY+k zRsC(~^oTO%0u5^j-pobV_l~8;O5sZLc?DeAT0WxOJ&^imEF|45Kg4Gx8#xY7Jm>H z=k@wyxTjpJp`to&GLp0<85!B{7%S9-@ZL8NH%%IiIstJbqM|$S%Z%$&^G;^hNbO+? zR88@sz;p}7>95!`HMzE$a6NG4_67c_;`M>hL>0I6z?BLT9D}L;g}OJw(SS@*5JbKM zz=xI0ZtW%8S%r;2Zi;%{o5ST*bAJX$UZi!1evvNEci@`v_zrM9&GDOa@lGFbx(I|) z&4R(zfM54ejYx@KPmx0HJPl=jM>&}Vc^jiZKkRpa#n(}e{VAdm=rVdJdc|+aUoQQu zHM#O)XreOltvmFD!!a#zb;x=YLVmi!56g z&~~3WKy#0}$qz50(a+x6Ix5glM%YLaA;T(3g`)79FlOAP%^}XqbAc+jeYUy|;3yWC z-gS@*${dZ3f&Hw}8YcJAWR!vEN0w9anR`tE<=6l)v&F7qNt=m?S@n%$9p{gY1rq ziL)goz-El>p9lC53DEgN8RmrwUxeInV1@r@iwXP#Y<9cwkUjxETAt z{f~R7e%DJy!@qo6VKKhbhlfM*)9JB#h#y&e{(tR??O{@h=r)<)OP?fV` zQ4o5;gDRkfWausDe(Djdm_(;YsOVv30mc%?CTcreOHn%iekz+X0^mKqHv7ebm#>3% z44JqFi#jQ*7?ULPEq}saLf>8vT>d?DD> z%N)Xeu?&qZ?*M!5gOU6FmNaE2lllGN3e}uSXDageTHHXZt%vm1#d}incpVm+%m>q4 z3&nMh)^x}uLS^*CDK*Q(E{vGKV2X|L>1waI&PD1$RZ-I`&wuET3HsW-JMlYmXcqG} zqKlvExZHgD>^A~cmGy+rqFlmk7VobD+G08-@30$`32R|=NVXUd&}sv?a{Hih4f^f^ zyf0SBc#0zjj~XfAvGohFH#f5^6L7E5qvN9OaKv&1C;*5@twT9BgEF}U?3hf7(~OoC zKQvqQ&{=*~GJnhvd7;Ahhh(!U|FZ9Ns)M>NA+>9k907fxHOi)@h&Tob?|eHh!VTC5s||<) z+Jo06O07?!g|n<~b{iC=Gs@BnCmctNmw;JR8Nx0+qkqS!udtaDPYY?=MieW)OfI0` za@8c$H=`kZGmO?TUSe7zl#dVk$zowM7d}jP5RoWfQP3wvK$9hzCt-X9k*0(fu#luC zU-JckP2|+}=mw{$e`Siyq+0ncqian_d_l-s#kD@HJrR~UEuKDRDvDC_?5sZM%?)cY z(%r#!Uw;zwz~F^goYVvOvq=D*%D*0V`0qU9`v?xn@^hC!8H24lSUp&-IUR7=C8o)0 zGo*FjQt823C3^?hVP?T_Z%4T~6d^T`xL8Z;53IYiB)J@MUdS(U&7Em45|Eg|yzn(JJ%9Bm%0Wv>O_-~FDA$XMvI^j*b~Xav zFuWHzDm7M(*OF&Wq_YORae@Khc8x%MJqH2;^CmJzu_;K+|2l&)mc&1I@MT^9RPfab zntgL%nMG4gs&Ov3S|z;KW&i^zikMNtCkRZq0Edrg2OJA+6{g0I&o@Q%ZTA+w(}gk8 z$bY*e*iYk(HItJe1UrOTH!ic&_aug1kx&pVT}(XK7043<5!(hZm+Qbxj`r1&np8>u zaI_SIG{~ZIHmj+Wz>`$<=a;&P05x-)0Fl0#h9xD9&_C;B8Y>BFEQ*Aw?GvQ#pS4s! zDdwdZhfhGXElpNAB0l@3tCnPI)BaOaD1ZF75wFzba1X1RI=;)wpcGZLziL?kUF6lwfMO(y6ZU zSd4YVOJxn3%f2>{CYtF>f@unu-ggBb!Ter)sMu>^c(0R(A%1 z`oP|Hk)02g$!l|?dILA}7+hgl(SJss6&_6+(EdGrxT78KYjDF~HvFE*4K(<*dN<)T-`3&yp>HJ>j)?vFLI=;NFY=M38Y<&9{t+U z5uJyd>&G$RJe8ep)SpC_ZK3vQL$yaAH~F&q0=t|S(mZA-$<_cn@pw9yVUa+U_p!0c#Pz)mb6+lX$v5y8z3o z$rON#AvvqCbq*F#l=&-*w_H;?`EN>0E*+V?BW4~Dz9>qur(PXhPJc8Bp+S2WRxLQo zxOP|)?@D=T*@frFI@0JSG;cOoU`3jMbS@(zFZ!B<8DK4zZ3zH+{J#Z}G{S?k#8)bJ zXkxlEMx7mFP&%?MPOujVNxe^0@wNTY(KYHb{Eu%Z^ zhXmOjM#7MNgH1$CTYsGpDK8Bs6eh9UnZ!@$g4?XjF=JFq&r_#Boz|yROn@|3-j)e6 z5`2NmAxtufF5ITa{Q@`6SNad#r-0it3dKk;$_@CP<}rE^sz75&2Uz{%C4nL8BU`GD zKxNRh2kxLraVsG5kCe!>s?JESy+Zs==LH4|4~w@BB?`MjfqytF*UauD(*x34Kf!=b zOc(s2(;feg)uPQ|fV;EIPp!;-cG?DYw_EBQS?~nUF#fHRkmriLdD&9?)|%9TjU_%A zD`e%@fWH|W!3N~6Bamj7We2OGC6R-rZXj?G&|LGed!F8rVsr6E$JjME_GBj>_<){G zdt~nXX?D!vYkv%#leIkIGbdbet_B4_%c4Jwv{Qe74YOJN`bTd6^7kSNi)Ry}Zskg^SDs{FeC63EjpN9XVia)jaNOl<2OSbK@JTijQgk3@Zxp2I^F>9^L` zDp2x(k{!TGL$!CgO#Gmbbo&fOK94FqcB-!QE}MWrjz~cBV`%eoW{D>y=`kl)63%)% z!2#Ncm4Etly7N0Y|6kAMI@sTjkd-#96$k*!>&KDeiM%gNB3}8JC+RKZU`}X-lV1!c zI-5`pJE;Ihl&tqD>p^Ke;Y}^wX0xN0+5kSoqiDjjLgcqes z!|Z3@D!dM?1OK8hw-xqO^3QADTI2Ae!kGp&&wqIc-UaRHH;#r{*`ZgU=SUz)O-*Ay zAv?F3cg4@}4uEFU2DSH;3LPnL4Fk@#M< z2Cz)?y|+)){^h)pHf!a40*F<0yNz0dHpy56&<&Ds`-~6BN|85vV-`gt*cqroU;I3zb*Vz`(u-rE!LuZ`M6wLKE|I(blT?~;c1-N|=gsjHH z>VrICj4-^LBK3{nl;h+B$ITX4TX|l24dcWj)WY~zHc~#S3LYPluPxGm-mO;}1+t>r zDDw(GtDY@&$-%|xQN83cd&=q_>A8&qc6*R7p;IS0_Z;1G%jv8qTI!S%xqnDGwdM|U z#%aMgZKTndOOsQsZ5v&WKbmBVYH)8l2<&b0Vv*V)$j766A)B(20+i-km%dd3{TFno z70{%Z_XJOHk-73f$%KCjo>s?z7iG!|FPoETrD((QxOHqfD&gP9&Dv=Iw})aBUN5|v zgotxYT=cv!18Bu08xj)6%zp(oi-`q*rz^ENzb!G_bUH{@rIF?`yf570==Jb;E0Y(Q zhZ#k1J??(de<;rKnB3?DFkjIh7qfF-3|Sy3c=DkjqoA;yN=OO36c21P4JL1s$VC&h znBLBq>=W14JV^|2Bzdti8?$Y!Dtw={Wv3^x;LWS@ONx{^T`f4zV}AwK%TL*j;wiPB zBrN$Sgn!{+2o;2j*a937bqOdrqPAE4CP$}aOWR&-2ieJd53T`0Vzpi#vLH{A`!S|j zzPZKhmCK1=#*4*{P0MXC?V_kOIN{b>G!`X`pj`6`aBv_ch>UsYv%H7apb;M!Px{Z+lWzqKhpz8ydsfCu`hw4 zXnA9vBVZqdI9A-VSQCjM8%+=Pn5+%PN}soZzGq{z~AoYsTj{z<+LC($&7T21$rpfOnoP z{!6fa_jZpPReP3~QMaT9vlex8WwdN}ez%i3m4~X6a?_scPh*sDhVcS7EJD-LZ{wFU zMInlyK2VZZ0?rQw*wYhrnC^U0wDCpe4Oj19n_wIRCp)aeGD zVb6pT?Pa&=wSS{!eQRZF0#=s2-ZAfgn?8a4TY#Ig6Qs+LzySo5i%R4I%+;b_i7*{k z`%}fbz*0JOD7z;UE}tuD4mD~Mmd%3O5;|5zmI7qv$nN^1rJEH?!H7O@|}12J{Bw>JeBjFYrU>Y8wS=(gntLu_dmBltsyOOrRtTk(IwKj zMr{R@3a)Rq)cQnHx7x{g`1?QLdOtG@qxZ4mLlFfD?+E_|i8{vi)<=U;EX)5gDoy;O zwow{Li_cs1AMW)+E2=_AH4wD-E0GD4$>1BL9V9G>Q__SuG3GqLP1Ku#Q(i4BfMv@} zVKI7Q^ncHp%uG8D@sN7P%Glvc5snEuOv-dyHj}2_%RgBH?r2QF)oN0Dzd)k*fCV#+ zw@C;1MmSszVID5&Nlg}Og{w|vBwlKYY-YM^r9^M)vwQdB!H^t;28zm|o;#bN#$w6P z#V7T3Pm5v99cK)z_p0h9+MbYdU)<0)c{1gyO+ z36HzhvokjqupE>g74yM=jxh=VTn@_j#!Vgbj)J&w3A0h!u*cBH<~JwX2B<&=y+Nab zWOd27xq_AZi^ud+@!1S^9&LmuF#16Xk-9XhP8wrEIRQdH8Z#`K7kLV4jQVQ3Q} z)_;kAL3BiDTbKrtxUG)DmhLc)ILtEZs-+tsP!2{@w0Ij9QUcLM>3E#&8=`vcm2c4* z>7O{deYHT2ULlYyXD)%~5=bkpnG(Mt7WV%dHDp^d^bj4d0R zUW5k-J;*+GjQ*|R{?u52?3U>8HJMWc6Mv&81=Jy$Xp0IS2*6R`vl^z7l9?1t zL_aiS?xoi=e3$MR9_CUgGL-4KEV<>}i8{jxVv=NVU*(Dn!;H$>CfB1CJ%GOtMd7u& zGq|3PjV|z$m7<*+%YLD@{;biJH)4_uSr^8rDM`j-9?dS*uz3cMcA@iaHY5+soPWpE z1K_eTFnh;aGP#8LZvu0cH?u>O$``%D@zqQBU05ha;56E&+6D7h&R*fPf$$->_G)cH z4?^XUW=y^G+TUqH6}TVk_PLBYW%m`~M{Qn_>1KL3!}^XO*xs7mBZ5jw9}nFzP37|H zJSswtSltXj$q|&26?5;=^D3QG2!Cf!u6f;l+i{OCGEeP3&*ZqdEe8UYO)r9UG}c4+ zkz)7Gv4_mc{!vAQxNTxa;p*0XlUWGVnEzKX(`FL3u<>b8YZECXrK-y$j`ZooPts9# zb2lE+qrcv5znY^K;esjhM6>srUMq|xFy*ojU0h3U-OxQlPLpRaUd}PZj(=-4AJuWh%+E3mqZqJ~);|i9!rnlGdgXRW;S&>bgAAheryo zfCTwZE9J()P(_~{`7(*^fAc4p77u+dTq-tP6owWyVR z=RU^)ds4m+R%D6ga0C_)8-E_$Cmys~0r3<80rsY%J{BOtr6lsFL8KcEeQ^`>^ec?9 zlmgHrE@;N@ts-f2dqOH-@n@+PE5$(K*=yR(n>@`rEb|-_AF>-8MBkU}=XEGrJcVM! z8MIDw7;jw8d!=J>0BS2CTpu4J<4#xs#XYA|0^KaUm%!1H2{W~+;g zxYm2SLJWj?O>tgqUybgbeI_ZGQ%i&{fPYu#ZXexD;)U>4d?4vrK70^Zwt7sEt}B!jGW$@E@Jd zFKF+D;)UEE*~m4W;CMJ=VRx1+GD6Eg?a;#pYBVm;l_C{cP-u?YhZ?T#=z>9Pe(2Zs zV*F+~NUm-_-S>K1PHW{Z?^J=s;SYdWg8&uH?gp^`+TJ3UgMW2!$tet^D0JKkqVaqP zRF^%ZbOcsK7lweGt8ACV^EmHQCPUyZJcg&JV)jh|5t0R4b5?uZ5@MIdNd4uu>O4OR zDpjfc2CKsfZO|6S)OSGdy0?dwuNd7dPD-iJ1GbPBD|oT0mqZ%n;xU!$2!h-(3C*ri z(6pkd_X_T)Gk*cP*!LH>){I{&!>A}Mo-JIplSv|$^oPQkjc>zp7%jXjmC45+ zU6~Xlvg2B}n^qh-*s;PZTvgQE&-k5DM;Q|;Ht*YLN`HQB=pbmu{LegyJZ9tnMWrByurr{J5DaL;W5y zHKK9JTz}A>n`*FJ*7AQ)@Rlo+e?k6%Yn(42>l<$@Yvn#}F`aSve3z=<*!e-$Lf ze}KHPI&JjMh=UEAnQT21k!l8wLF>LA4MwuF>rN~S50}BwG)uI&(Hl@Qf|n3CdJf2N z5^PZXNcuc(G^DNpNRIR&B-gzl{zivL)pBbyhJVv=pyn(^*HuFfdM1P!Re8papy<+cxeUB68ONXc^5;?9owQg@VgS;7<3v1BbQ+Sx}*7U zcX<=wx~&8=NDkB4JSTaz?olsTE?8OLfPZBe_uvR}j`(v;BsoT}v686vZOr%n-7e%e z6A;bzi0b@Sa2vUrnN7}l=2TQ$?}#~Uu+wJGYX@gx7>HXlnwZYCa&9(Q z-wFM?-PY^wHXdtr>GueD4ZR(bXA^G+JJ?s1AD}9yNfhA5OxDvAq(uG|W;p`>Fn?+E zIQdo;;4BW$RN)$GfLVRUF=ZQj@qpUP^`BP&AUDm5>lzHSYiT6ty2#lVrZy$u=)3K% zXC429W|I&y_fCr(H0$2UkD**DZ{c1v82k2H_ii<=S!D3RCrxY_seu`Pve(XE9}E-h zYFoxWoKPXZwgPH{=!j!#BCBSeF@F=e*XJ0#JnmKSjnhKS7v3$4xmWiZA^mg!k|!)S zFdu!)Dfi&6t<29AlVl?>JCD(emBXh3zeT1H_WPJT;_s{8=ac9o;qKiI)SYUsfBZ%X%pqC(_4-z2fv!3SJB#pXgl zQ%*>L>iX-+0=V%1iO5vuq-DLBrQ%G&V7lY%{Ps?WJ)|kxbKU}%^v1F0c3`IfkL^_a z{Ylj-ejGu5CFK2`OeK0?;(sH~wM*piH>HIUwjPDD{2=}^+lcMPr&cH!Wa7T%?dpG> zK9O<$exKph9||-?HXHH~3s~v;P}?Ry!X5;5nq_~pwDLcj0tWp!G54vso}3>qrkn?gWrKDfE#tf;=mrrfKx>b30tHFrk>l4|$H$aDM@XE3C!VpK`?u zew<76>UIU^Xh~c%G)aivE6rV3zbeo1?Xer?){PcV1~p_4CwBrNa?8QMg{jn3Wb>Jt zkaM5Y6g+91-)0UKo3+8HMgN`M*Gb? zu^>}UP0>R-PiX%w*;gEX-}`W;3q6tTST^E5DNJc2!sQ8_%e zUTSS45;35ypNJ3|Cmu|yKm((+4VTwfR`X~E5f-5xvfmNy4uAH8WRnd4;+Y9b$>WvB z+;PY8V^aL)fH90R;C{lceO;MxPNpwX}L3R)F@YI_>z)^qyu{I!CTJlEy zL#|nmqfvK|7nm@U6IGpzI3Is>S#(3HmU;$RXDn9lc77p*Q!D=Q{(LJEoT*3&sCtyi z-=2Am0n<~*Os$?_D74oQa~yae8nDz{^;Q^~#j~&{%6~sbx-rv=3FGB$EP`5WPM84u zg2vp`nyAPQd3H2=A7w!orn#s$u(Fs7+~SS}^ThC6Mgzrr()bT~?u+}=^f_ZC4J zLox}-EqJ3)8j(P=d<|gnejX^M%4yk^>qfU9Xt5FakLf#hF?q7J$#L{}tE3j?&!_kU zNbRDsYJXHS&=SFVtGvSxP@jJ$ zu`DwSF#jWjPU^z7V3OZ(P`iYqzdMU|-A}$K8I43t3w6kvlA{Oo8(!HQDXScI;DJy6 zpzEw_>e>KuEL41mZ_yY@^EAsI^zektZedm zS31cUQQ2bTL$k2`hbXJ^May)U?^#o)!uAD|OkTgR46$5$@H)H^-ZbsxZa_LMgiJpp zFwOJ({@82QW{gZZ{!a$fcVc%~Sh@C@s|sl>ZFaHSW5FZ3A>dW%NBrI_P)7 zv!+)ED8%}=D*6M}l>mjf_IuRBWS-XzaXFkv#p$|=Elq<0o~La3lpPdmJw3_w@NpF1>9Q``cv4GqIhKu=Z z$($V@_3OHu$&PVmT9+Z1qJ2mSeyIWX>?OiQX@Bq*Qg6(zK+#FTTMw6}fh&fxF)$~l zUy;R+ewJ53YFJGTB7%y_#Gj|A_J5ztdV0>lk@NBzBTuzON$9H?)5#b|0o{GZBJ#A5*0Bckd5TC6MwLCGYx^~ zDJ0}(le?JM_-K*ssj;CHu7I0@5PWudM{VudE`vAXY~&MwW#`5YqaC*_wNHn(QqO1l zZv+p_+2hgllkG!In)2tTiE^NjtYH2rbGpk}Wi(k~&T+F;I~t1db)^VI5_yi9M|yE7 z)s0+`@Oue@v?6wTod`vHmw&;aGoBU&119!Fm&g&Z_CBU~9r)GhKune2E>68Bhc+*# zZO=B6H_zth*pP7(%+BLuXcv()%V`9o!I65uQf>-$wb3@`l0Pf_s!h8ng1cnsJ+O)P z`CqiX$djn^`H<)yyl?{@|C*xbAYGpYVVD&I&+xIJ*H(uqi>;7l{(pM-LBZWbCcL8A z>s4Kw10A$ZcH!Xs@?2#}!EKNmIJNDJ($e#Jd(DwO55q52crxSoe@~)ldN0XHIJm02 z@a5Asjm6JAXbs#c7H_L=9<038$l~4=Da#y zeiSHRWW(+T-h8(f#g+ifm`5hjH{DD_yEIxwFJ~&Ml>05VTh$u;+dth z=$#2Sl7*FRvoNMP;?#exN4ogpBP0_h?~Ho;ZN`C2Y+*H9f{O%Mp=9e5ttXwAy<5Pn z)L!~0GgbY|Y7)TZY9T}N*>R_&D3w}-b2Hj3Q6#kIF(Jrjz?G;Ja%!Z4fYAC6nK7l* zX!T~GL^ep-dPa&7xMq29h_0^I_EAMO?LI1{{)QvLs8XEm1#5ptCGW0!9ff`nzruj7 zWF#K8F)}^f9ZW>~4e`AW`~*br$$S1Fs`1g&<2Z-sNpq9m4F% z8(1{R*hsaOR&+h>KxCN-lX%Zy)ROEGboFpD?x-vUy##+-bEWLEb%>$CnFjk+1=^w2 zsCUQm!a0P@^>Q^$mQFK7kT8Q@Ia+xBR9WS{hrLn>JXKE0*CrD6^|-(fM712Pcdf%} zJ?Vl|51jj3vLk;d7HwbsL?d#>2BClF`yrx14gs4S+N(V-QuMb9h!=|W{-+QBpK+4- zvA#bzff9e6Na@5;Q5=H{ZsfqYhK?6tZaf7(D_1z9?8DYIDbymvE?t%%?B-bh9kRQE z8R5d*I9zPe_u?uUN^N^|lJTrN<1`H)#X03P12X?{9s(P;Lt}HcePk+fB^VMQ4y}rF z3sje%iAo5e_$Y~OLbUlr>0-+`Tc!Sxqp`QzAd`P*@>@?Hmr(_yyG}{I)!1V;a{(8| zNOZxtCUEz|2tE&8^87@xM}(Rn9}|-jg*d=*MAGtfEDx^H?_^woj8}JO#os8N9sH=X zk*Vl|t7_G_tAtt1Z%l6)NrCIp1+>DPkt0|h4lrCWa}L6a`y!w+H6uH%3beiOKBc@W zKOTPo+&%*N`DgZni=$w3l1VijfIH%!JGq6rx5)=}KY6YQJjG!UJko(^du`@O_a)Co zR2Jy6Xz$`S?5X2{9U5_(=n#gPY=Ov-5r_UU%YzRxxlpY$b`?rFLu-imK1kY9&op(# zx*wFYa#ug;AUHZrDfO*@Lec6)%^Xq8F5iFcl}Qoml6$><-U2>SgI5LGad<2EN5QCF zYKRt5Hg0E^P}$lM7HJKdqI?5?qCnt|KI4B9 z%JTflDZ}126w*u~WdNH`oSX|H8gprw>qAlgIVRw!2`W@$p8+bpeDe3A*$n+CX|od) zm!NWt>LV~{6J2w{Z`Oqo9$KlTf@QpN9~Dy%?fn=-5-cuYslR{F-8U=vq}u&ahdb){ zJ=XlRzyXN6D+kM80T~69I2qEjF;{iI)sQriZJvPzmI$B%1-?3fhUB0y%x z`)$lQzs*G{(Xw`EhmIDUg1`@Jlc-8$q}kxl1nZzn?zVV~(0m4J9+E``VmsrRF-`z&C0~siSvTy|Cf!_mfH;*kZlAo3w*GxBZ8{ie+ zDs4lZ&R@zIoj*KN7L@>34G4dxR@%?Nvg{yo;8^KL=m5l2{ra^79-oeIWvDEyP01Qw zc8D8_k;r_6sdknaBF+Bfx_Bk=QqB9sq-A{XXfR=uD!hqiE}Bm9piv>{6d9ppaKNaIj(FI~1RK z#*|U#hhNeq2GYIirwV@>Hm=yQ!=1- zM){7AFh1;PISGyho|vY4H`^@kf$+RKFqavIwafjS8JzizCwG6q5FCOdz0(?kDu2}< zONaP;SHno|7>EqTI>6>qZ*9eg99%%A{89VdFOX=Zy07=`qE*kbdMa>~P-HJ6N|5Z0 zt>?ZYJ0n_;qfC&>%jZbv=VFU zcIZ5+jRrr%+Q5IsPP*V$A-(M9A6VkG_|;GqhG*Nm}py ziwc#Xia(+rSJ20PB~?)oG?pI>nceEuoP27S6Y^r3`C5a7Z)-*Hi|^r{gx5xIHmsu+ zC~|6tuVR1r4~EaT9Dj#|jOc*pEz7H<_!Tzmt{vi83Cl|$ht&X`mJLa6hXOiQyVZk^ zFJw!KUD-J;9I_8;CrL%9*Sp8ek&=3|G-s#(?|xqp(> zUT#QZR>GX0H*NeJfdk=8uGvJN8y6fMYO39#AK!m_%#ADffZ)rHHRS?iru=42(w>h! zIq@U(TdH6q#%8KD3w}(p)43O|&{dw#v|}5QF`R}~A7|_)CWC-7{Ja2`X%s=ymF+PO zoC2GUj+>x!iG=a?J1&AHX;d`q`(=bS?@b~UG@EH$D70=xXJSIpi;^%MTIq7PbydVC zGuwau{?GaK-+!9kha9v}$r8?7VVLyp2?hO%$Zr4E)97Fd^DIDdW;{i->6bouCV=k> znPz$n$aiGSDmXFmS%6#;{}3!vGC_2f8}hpYV1gH#A^jo1kkdA98o9vED>X9a%j;K3 zyQ7UiaFwERW>SQOCxd-3?Lk;&i$b?UMG=3#Bzu1!1rCbWcZ-oXhf)7%b3LY|J{dB$JWZM_ufQ+S5So0>;WRF6ja5#HOa_{cYw5jx^Z zz3_4hu2}vBnq4#4xx{ z{G=X+3;-LJlXC@_CZgc>r(Z{CN%`<=y=%GG`JNSR_dEi{I z(1Ni`l=8Z(zW85W1LF~87^$Aw#4UjCNzA0%nG@b%^rZO_TKGfoCjI47qp7C-sW?d z3cY7b*QY!PA3=z1ePCL>?yl+qcDuwB zeEKOshOJ$47Dw~z-#{RA9IiOQz=S!C!o^#YWVwr!lkZ3%GJvlzm2!XQ#SfJI;GK4% z8Mi3gp%-O!PBvPVWsE5~a0|f|!9RqFeNXw_?~LW;bAIdb#gb^O%lXjlEfk-%L?Y`` z?}^Q-cGzb-B60l{rLE3m{#X?P*0u_(`g%`_=q!c>u{l$q00000dot*V00F7%0*0Lr UN+hGXJ}?c70ssI2009D7S_JuNSO5S3 delta 35175 zcmV(tKjJFf0+1O5!t=3iu^mh)f2>sove%q$Q!5ML)n$MgxHhs1cnj*f#FhuA z#0n5y5I#Q`27JFX$S)6ICB+mR-DRFm&_#vc)Z3j~A7bSF{VJ&=mEZeM#ACVI81ZAJ zs4yH#2xcp%(jlNKsA4STdAdFWy~9nS8?dM~1%beHY(jz-smgbw``na*vr8>CV!!^l ze^R*`9GW~>!7E9o*SLq2+*%gPCP5eA71Rg)l;e zi}SvY_5w!)x-OUUl{{;;dq!BBrMkFX7OggfC{P;-ddw{S2H;Z{I%Vmdut^LbI7UXBTzUL&i=$v0 zn2$jB)W~A=nO_5VP!EYEn3^v{lBwOs6Q!LtZuVAP`Z7tW&>n4DWoXKKuVwsF?X@v+ z-6tmAX9x}(UMH_RzNH-Uf3IF<@D1|7RR3$78Y*0LK42cf;b_+ZuIzw_yY_H^?mV>E zvIVj~?r?Vli-Dh1>j{+;;%0+-WCwkCM>du8WPZ7#OYoA;e-ry>v3wA?5u~0?CHbyY z`Sy}oN2l|tjOnm*&vVZC8F`>YxZ!X#J&Q<6Bj$9Et1%=pzjJ6(e-9sSUdHkvMYUHF7ilm5fCg16!!K7fSwBl&mSPRv=LLR{7bi36Dt)q^FOsN`EiyhRN~% zEUKx(WU>!C{w@1vpy^b7OqSnG#xT`C)O-l`Bzks*Db<@Z#`5b{FYPYH z;{nOeHh#z#wo&sze1t6G$d$pHT{NODD3}cili@Rbf9SH%&OLky;%C+7jJs_VO?Lng zO-sZ0`4oIPKC;qp_3b9-t&M(CKZxjwZoAWvi^QYtQJ-A(d;g{MRA5bfXDITC5~5gE zRuK*FURK`F%X(xwoew7h9z}}Wo%t-nTH*rB;_p$JgWvV%rpK*BLj2tT@&?5;F`=zA z`fO)>f6?mw;^8~fV6}uza^Iw;EeYPId>&>~aUOLD_-*d^yp-+C z*%ufg#RXa~hibd?pnRS6uvIZ##HOFoaQ z+MI<_%|8;Jge17;j^j(wYSzSEyVjsKfBs|2dhb)L{;Ss{a+y{=--VlzFYx75&eUW5 z#a{noE~g99OzXvsl-1wuYe$ZmKywJ5u40Zplp#6DSTr$z;E=U2gHW0x?9=foKFN7- z8vlT6llL8{6TM^q!{$o1Cbznkan116KJ0i&vnCpU-yCE>oR(bGj^(k3`^JhJe*=ae znfhW^D7MU8HCW()ShO_oMK~_IWdaMBAsN<&fsWDrCEC6si&(jlsVGJJ7Z`$fZuS*aR1lQO^e~b zMo)T+HO`v^`)qJK%!Cqhj>%8gNX&jjCYW;Yb>ogs9#FpxfGZ`;2N>Gnf0zK)k&NdP z2@zTmVUZcqp!8GQ7TB+(RvuG&Zk=gA1+SKE1}HAXR?*FmbTs$;;T5JMm?8+=cT+dt z&ky7fx-&xWjPQKR#zghqbjKw7;3jE*6syAp zg;qL*#^r7uA{qd)A`6vA?{2v{#C4l&R9OvDAT%#wxVn>-#+*fU0;b@+KW(D9j0;)*Xlz0dRvYKiJQHK zC9{<=7@Y3r&jjh*T!R1FnW*C>GQjauOEfl{vvN02D3p@-CIJG)I z58d$8W{9&*=CR-U*swEZ3F;VKLXk17zOy}-D~g#Cf2UhLTgRNZ+jP?U88vYpyS1oLxYDf&+zxb77JppEmlypai2GUUyG=RMDXCvnlTECi z!|rrQ+IFl39H6Yb4JhJKzxGj{7ylF_VI#TI=4fg-Lqj(lDa9Jo7_=9`D<(qdSZCtl zpYzObNP#Pslx~B1EjMuBqYknTmqu@KJ!jg>f3*j4DhDaoHyKh2>9@mT^$HA(aD(nw zf1XP_H?^nSYgc`3jALs4!PSl0v01Psp#Y9bRTIh#1NP69TubfQ;1G)nrxHc+r={cE zezh?hn5of;Kg-gZrV}HRDc-jeZ2q!mQPY!>bZQ&F6O$Y)%%NJpt}mpl6M7$nAE1`|2O-4m`Xh{0M!cmpxQK5Am8lIsSf6%EE7QjvmJ%DeuYWW#L(qZbRWb`1Ib$>1YXBHB?4a)UDCJk%LA>o_BG2G7)ju5F|nMVf9|G`ks;%?>= zA0ipagdWN!g^iL~I?V|u=$tDOzAU>!x@qstpQ!}w3Q7%8gYpO4f>1|pf|Ks_f9}9h z$y2K)1{~UG1buVr6~8vnDSOvGrdL77W`FCeUZE<_(0$DzZ6|O#|C_<&SsPF@`%|%` zC=fUB<7&c+9DIntLh8igq#toN$p8>%p;2U$ zgkt`(ujKe|JA}`?Pb2S2EmSJZUox{}UACS7fUsJU+cdt}9TNQB@sH$##p7e@+KA5l zA~rSZ;=B^QQk__I$!13_v09j?-IuontqyK0b_< zZ`r4}*_G~_ma&n?ZQ)s5DkaY;sg+P_92{$y6V!iUGNP;TQgM9{!u%egq*4+A_rcF5 zpuY8hF_404sDi!XQEUYcf9km;XDBF%5j(L-6Eo1Q;A?ixqDU(Whc|XF8cB#mf$w?t z+bEKacS&n|&w)@f1;Fp^V)t3^|C>mEX|9(6AAaNOa30(V0tv>!hId}j4|g8IAS#3; zk2$?NwSwnQ%Ru;vGiITHXnA5P3hxBuuf!7Z^rS~X8t}qaCgncRe@BW3V`e2KkY#*( zEI6F0wj7}K;5-4ZXJU_u|AfE+Q^6aV-)4UQ>3H}dvgMt3JloXw$todj>i!|M@fxMd z0_u){C}&zCJm#8l=tWo`>Tt+su;Nnj#`S*blq9j1N4(K85|ER4J{}AAjx8K`L`N(0 zh+{5r7>zP6NUyp!f4z0ASOO_8NRL}6_(94_w0@DSpe{PIO2&)1juaL^iQf|Gv zVd%R|PP_)rdm>T}d{MzCw=&kLU9ph0grFp5H7Y4Dk)R`u>~B_9f1Of*r0_+8zQG#Bmt17)yJ z(>dm|spzw>V6YE9)3Znq=mLm}1h&Qy=lKT)(7m8ODcztoF`dA8SSP`*WI`MON%{Dt1%hW11gS^iN`l64)!DM4y z;fI5vA@hn0RfkWyu-sGAX2IbG^MhoX`iYn+e^9jRvy5%QaUC@AB=OBSLg2J=g@Y7M zUEmRRktH70F3!g3s;zC)o)kFwYx9!+Tm;)}Gx)Tq35nSyJM%dRQILHOW)a9Vz!Ac| z{o6xJUTxbT_pbv(p(>Q;*F?LHc>dq*x-~?E2aTssWNOT!&uNd*3f56(vwM{Cc|0a3K_7~j*P{oZ-Z=?|T+&i5J zeDrs2%^N#AUmkZWNE@&$NTcfruK9LFAT>BTdJ6{}$zuYIPm4iKEjuV>y6-^^Tm5^Z z{vTs(KRSk)S&2+zv&ei~Zgzf`weq5-s>)QI?G~(YMrif8+{7AcTO{=Zo z8Z}?nA~>TPy`wEkl=o_pi`OP(M)bVhn?muy(^vvl?DF;?l*2|5q1>WaM28zHzB=f@ zi3dXX-JH+#*a-Fp zD91tKr9VxHeXUfSAu3nAoUI+f93o?4d~55u#b4MH0@$jXVWq|6c1ai&e;FGj?U)y< zN+DOP4?a#k3aVs-n{KWeD_sgj@`h6zI;(V0dYOa%cx{}0&FrO#%m9|;X$QSbqpH<) zuW}ytM7$vyHs!WP)HoP3Z2OA5OoXeCG+NZklLe<^J)Tf1#Y8RaR0^_kN!AxuJYF*o*+y{ZN+}56nW%1J#M7w3n~MvFmV=Oi zV6VeEi@rQHMM^YH46AqSNouz31Ey_=sCyM`&|(rne*+1Q`D>YXWSxdhK(htD>nxt^ z=Z%Me9JOi_UZ+SoXG>b6y0S16JscffZwfe0vE2<)BZMWG#u(!We`}Ua;%w+`^AVwj z8}C?1htvoVIsfnI8$r@*y(>fY1_{7Ge#epO`rW>6`F8US#M;@9q;7+Pu}{4lX8|w> z8TkV$zIIVDkq3QEhjSZIdD&2C(EU#p%zyNqIOJ2cKfnP?Hsvd9 z*0RmqcL@AJSVI*ke<{V~eNb&DLmL4fj?E|Ef1*+1WU2w4^|7Zb5wY`wnkhnS%~9Y# zOFKp}m7?S$5`<%8UWc3@7{(v=jUzI}9o@UM0d!$q|>fqN&&)>AkymyIm3f~7O%k-fAY!gEirPgFp^16_~W&6 zFvTPUygT=$2Cw10_X2}QD)mWq=kW;{$g}U|uWE@Th;FuL!4m9o3I`EQtBGhetAZ1o zHV<8LV6xf`443^;t?OKWeZ?t(zn{vRf(HIQkEua*(8<>z5-|W36U$z_bCi|F5*^l} z;yOhJocaOCe+~B$pk8u%xUV|&dIWGZG@)AK$`3F3TrxacJQ;zY7^ImcWGfbyJKYMF zc)wHM@R2r1$nd+~M7d(e_?%gP8e#!tE)h$3%Oa46`v$M zTFaQiqa?9Js;Ntovt{gJJ~CNik1|se(11A(dr#=P>Oikj?HZc~%XGRoZjJ!LRBB$R ziINx*!R?b{%-pK?s;S*fpQXCi2NpsNQdjHjYbPs8tam6_w) z#Z`V^)vM1|=+biVmH1tNRz!brl1DXW)=2fh$SFdV-ZVY9H(=N;#Ye**m$AZ@%!+W@fA}Pe+8;U5j@RtX-;=P7%)N{^JyOT0*|HGNkxXkCCia!V`0lDDUDtVQ5Hq^9(dh^ ze_>gD=KE|~)6mU|NCcK40$)?TgcA$9oPR{escA>q(>(e3@UhFc;xDEWL95>0^h^U7 zOxt**RwYe!ht+#3K5bNyxaKp?o9fhylrbhD!L{M!rsjAp!L z%tCF>vit1sqhHpyLT)gf0n7fDlXOj6RxW?r0)}wYItAlhJHKGhkJpRFQrLB6e_PXA zIr$aWxUm0N`w{NUK$CqE7k7z%Cp-xyu-bOxgeAG{c5N@fW=I6*3Q$KknSl)2%-8!O z`JHzpCdEc1-#w+u02}0Q+`l_BEf%I-Sfz0?7)7DtsD-bDxxh?ns<^skjOVTQIv-u8 z&S(up6GOPK2(U}_bZX}-@ig@xf9&jG7@rRInm1ywf%4&s=>*JNC46>_lY>146Ub%k zqpfTCQeJ5BCG;lwu*p)BlJ5npF;D0q{jj={&{`$$Z;InoBWme+x{t0#zjRSFYVvC9 z)FdT@HQaqjSzL$A(eys_;j1YyxFyGNSBPLVGxN#|c; z=}5U|#$IGAgt=m5xNclj-31XEH2T)o5c${Axhxp2>1w}tpU7hdF;RE(<@1h*oy3r1 zIrXB-Nk?F1q6lZ);(g{IufevZAK~?aW6wVfdlZjX(_gLe+2fS0A1L5JmhAsDnhC5` z2fux9wY8E7v8ck8e^)c|9UrhoFw0q6K)iw1TxUCO(TB|f*i(^~%*X&UPP8D|G9IHS1afA%wG0+XW+!}vqg3m*xv zyJz%H76uMvya)+<`>v9)_kyb9;`y$@RfGZ_`r*Z|^CU-M+udoII{lOyIRYF2gmxN(V@ZyZpWTzB&P$|0gUp2YOO3q?YA=j7>d=G7EdStU7s(AEBD+PE7ZJ^Q!8b z*7)d{g}1jsy0876+b-Kk6mUN&%d&#Zo*iFRPl@t>5_bleG{O!O%gt-|ss8uts?;9w zf7B?*^=g=?>CM4!4Tdi)x_P@3nfo@nv7b`&|FYN}F*raI_kC?Towu)s?qn_YJT*TG z7I3+juWgPJnrUB=P6_mB$ZQZ*i@pEap2{am+7MNfsi)QNX1Z42)nGtv|k%anzyN5P>nL{Zqek?Xx* z-{SsO8qPIJx{Fd6M8~kh^ao8t&90fH|Fk+E2W-Z2+3ts9Av4cRNXmYrw&WZX@H+2} zBJcm5fqg#I5S6t z6JPeOl@^8C$WqnJ9s#oL%~?CCUGG1k3qs)6T+CRCF8^nl3f_V)64dbwiUTvD0Jen> z`j>cbQm30PY2NQln)0L*WmI3U2m&vPRoTk+xsthoKE(!$W|^O-WY6!ZisnX6Nw+j+ zi}8&pQ&`}{_IwxWL4ljs&*~52>-iw`!>g(!9|jsxXByl5 z=7nu>z0D?OexnoGOMQ`jl&VF#?GQ3=Xk#NzY(hKz5e6$IEK?Qlt2EO!cC{E?J|6t z^9PNZ>lOqi!PCuypzV!da1<5S^(VqpnTbEo`}fWeht3lo@X8O@!C^zXnNR4DP> zZqKTE4X(z>tI5}z2e;WWe*zz}y{EneAgd7EI(a*E^rKs`5 zX{B;}=!G*BTb?4jENkKJ(B=`0?SgAOD4oU;Il+4?@&V@9yDJuD&8O%_OJ{)zLZal1 z3ff1&SF>KEJWZ36#ET0Wu02=x1cl0;WsMUImR~A##Q~ismDIbGU`8q+h7SWP zaM4&Muj&Ss#XL*@f4b(p{W0CZXAc`ZSUL17)EW%#a$AWA!RA9C z@m((c#=x&rX!XsC;dcRcI2a`v4Kb6bV2XeSYX+rhu1gXRA}KZsJwtbc$d>`DEYqfD^K}jv#+n&e)@IAH^)Yu~ZMN zpu&`5;j)^Y6K_mSMXi=B+Bvl(fsvvA1y0LqQPyZeC^HS%D!u$4z<`$z;sL2b5O_)* zh`6k}Ai3y+e?;p5NQ8s|UH|o#pBDEP16xd6RaSS3&=|O_gb`_RdQp)p*=m2AmK=aqoB&-W>eX_}Q@!F>CaS2ZA zsIb2of9^_|h@AoT|LB;OmjTbPI6D$ zj{Uom^E4^~0?;`J2*qgTXAFWVi=zy7AX%RoB0}=Dvb%7iLpczBT~OP~+~UY7bm})~ z4Lo@_5|!#ELV{jW%e`Emw&GwClNk08%cm`df62hcf`O5q-5q4<=VV&)8<|u~3+tk4 z7vN6VDXi;C5!FQ%u|LaOHC5Z55JjIJc*>3xRsE2M((0y^#a@Bzr?nM>KYrcdTjwzk zXtbMj=eb0Fhbf^LLJ?nlA;4$6rRh0d?F~z~_~kR~8`j+9lWShoG-B~V>Jh+Mn!kb} ze<1?-#o!wde>vu{{05j|q}6KUmQ*=}CDr7gr7-zj*i3IDgN{Uf zaU?{5oD~YYE6qQxWb{M5`w_1W|3;R~=~n!J3Y)F1Fb)A1WOK_WQJ0y!qlT8qSLIC^ zj(a;`h*ssm-iF5ezIBf7RcsG-HSZ`Be{r5vlvn_{Row*Idj8jEr~IE1}_7?hH*=1cG)yt6%ua{;!20*Ttae_qXs zv&$*9dvV`!kLeVIRDzI?Wh}k|F0Y~F!ySletZY_fOC3fUaQj1yP>@PhSdzKw&_$3y z$ZjauB!M0nAe3K8arLbl^ft>*85CD6$^`jkYGTw4jq66`YhVq|d2SZeOa-ngnwGzg zP#TL{*6facp{ixZmz@f7{FKoo6iw=%dV&$X+#LwtnynpNbN)uy{Et8XLxL zTDM-(BiM3dWC!!s@-NG7#U`vFU+kL2HwKQmB#tGN$EAKr))eYj9Eo2q>d`R0+lnTE zdx54_P=tKf8NH>}FzcW;kK-i8iZQJ7NLJt9-T8GhLl_zu{T;QjqW5rHf0B9QtW&SU z9Mczoj9e7&%4|xFJSgUKdTUt&sJuDL_OM_gT>Ee?PsW0$T2|j>RQIO_c&(wU=$ZBP zV5VYDd%_nu=M)43eocPmru@v~0-QH(xi?5<)mMyx;s}vMc?F9CUpP$=kw4cI#Pc1n z-TirRK6}JtT7gb5uRZGoe`M?|LhM5v_O&H9`rYv2WEzC{3Ufi{L#M%d_%+icNlRS? ziV%s7Ifn;w`tvWgzPs)-v7@7c5y|}VuJOT>PQ&6}mkpcT7TV{pBv(dFP=3zM*I&a+ zI`~K~ytuy$88EmyT6?`-P76HZ(wa$dL{r+z>fpFLV*OtLp5QOee?sx%_sn1f#>uyl zSF8g5E7*#YK4V_788AUnuDN4dxF1UKQfW7|@_pz_BS5l~N;rkZ7*&FOf=`lPT=lcl zMy6q|Sffc$MwGw0Lk78Y)}40hT4ln(b?7r%(!ilMa?M-R9l+DkB#p4EN@?5sH$c3a zfk5+fxm!(GEfFg?e=50hIXCV2je+mr$B{=TG|@ms4~H~82T8D(Qgm1+ssH%FLG(_ob%Y{goPB`31iwwCNB z){O5p3=`hoT&`MG?S18lNX@)d($5Y|^cBjVxP9y(M*op)e}yo676_t&mR|r-E%?;9 zt1iu!$d;R{I+v+KMaE*8eY_Wu`SmlehihuNfOk(!kAw+XqP(E?1b8*VM8)jKN}OT= zXAins!z7Y;nmHww&DM9jgBesv)hd^ z#zleBfxhMoe=h%1*9+X95;W{xE06T{186Fg2Zl$KOT!8rEVfnvT$%nqJIHf0W| zdv;;gDoGzsz4;eakQp@}7$=U;q%l^trYuCpXwCfb3}LDf^}Q-U6T!+!UD(sUN)WlI z{x8P=FRYmEU}I6(3E9TCW8MTwV$IDQOGUK$%IEKT_Ocj(G^!FrFbHR?oRedbWYWxH zUSbasf0egOlH90j21KR*XXEA*$NQ-d%s8kF|M(_MZN~qwy2f$}`7S9w2{r9qhGnv; z?~|{2JIZPeR0NZ&cMN}|m`+;@5XtPP@A5x$qskkc$t#X^ylRNg#J{B)Zb#h5WJ0fBq0PBhP zOiX5s(AlM)D>BbVe;&)X#1sfSTOI5bNW5cq6>E$Q>I&oU!vAq)J3~+*Md$!6PcXmP ze{Z#BR$xMwf8|mON1N7Qr(^t78S-C^BL77z&^TIWQv2Wvp^3Yp|Fh6OYqazj3u zVeb+&eiioQUKtyIAizh9BWS|(?Yra+m?HR@X?Xc_9AJ?_R**5UanVd{R=lL`AP*zv zM=0Q*L*RwNfd<}x{_G-QDHc|-DOvS?f1du`S2Doq015fSlQ*|JK;D^WQYCUUGd8GGkJQ1fTCpv5br5pXr&w7#yc=A3Y=SHa~Bb?e~zvw zZZnrt9$2l;V2j+|JbWUqbOA_pw{!p1^$@W@YNo{G)zF=R>^Ez-#MveM z`9rqafM`-$%HCwlbc9qkf$RYk;psSt`(w?@WqdU6G)Tt4O7Ws5;PsJp6kMw>RRMlO zEr)a?ZGBCyl$2p)%%~_a@}r>mf8}@j36Fo;>-b^2MAE~pKnn~Rpa*f zF9KGdS}dCUMn8!HJt6)3lE2*MCRhZy%Zrb;rmq(!WpvOnaiNP!V#qGlfTDxt;ZCdUv25PZ9)8{UBK>0lgb1CKb?Y)AZmp z(1oc^#SOb21h*tbf)XMBgyUL?y;c*FQZzQ%M4oMzoquI13pK6u4b?%DccKGqtw75{VVWOf@_owfjerz==C|LmOp@yi&Vwfu!CXb=A6e7_6v*)w?Fn&!Onbdlz`!<}3P&9PxXgO*0V$@zUe|^Z;pRNngfmq95b@}ba zaY%EG*g2^`c6?H}g24G(?fC2>C+N;ZmHQImnIkKTyAtJS4+UOD5(|3skl`as0383r z$U%QNbi*|mF^zCocJW-$%QWg{rA%B3jv{IPxp1ilIM zT}gmBwh;c#e+I5UxaCN*ieQ(%O!hVU1R1f!Tl0tUd(ecg|5T-Au?JiKqE6 z(5;F#%dq_~FUf`CD-D`Z+2=hr26^h(#*+&bRPj}>&wz*k->-@_f{e;Y|>N(n)N*7)M&UU;NlNCid? z6iV0})lA$cM%y9)!hFV~*-MmkEulCUi~`W+yf#+}_Aw%My%J1^G>#VwnCn{JMGTSn zBJ^Iz$K`lH-h>C#*WrC)`&SW?PT4B*4z_?M#uvikIk3uwGZ@Pu(H|eAiE2->s`Ic5 z67Tkce}5;y>bgs{=iPv525$q7RUoj~iUZ8;b~d`bSu-?)urpG^mQ2}{3XQoWppC>s zGBE&69n|q@wViZenGfOv{bVx5QozY@mX(&oN7*O9G|+5XNHptn{o_j|A(l$2ada| zyNCR$JH%Z37H$mfHETM_YN66}F4i{9wX&iBTE0K)2sGzlpRC7_nu7J$BC3UQMYHPs zf5ZC^@slk1^zGBNwEH9>lu%tLUEo^XrcJ*z z^DAIH1Xb8zpV%+3#HlxB`*Nf<>7Jwp90zgGw<+dgK`dY8Qe*XKEafkFQp+Z+Sx=ka_~L>6DfW}#NV@|p$R9R#zJcyl0Fmt~ z58tN@38n7_iQ93e74eH|7k>ZTq1BJ@>HY--Y^cn&*r!=MyK~;?Q7m87K8z+VPnqaY zRR5RG_a4kFmE&_95jiRT^ia-!65XJ3PkcdLA}0#ojl_6i4|e|y1JZ;V4L${&r}w_FIaU!P$gg!zGE?BGp6LrxIeWSVn* z2c0%a?mdiraCUG&LIAq%GO!q=hFu~eI=Ul6@Z^8L*^lx+ zBMO@RP9_{>W^&NoJn9wYGBr1eU2luVbanhGJw|!mFn)X25ECNCf9-&(E<4pQ{cN^8 z7cz)93IH*|1s}3!yEr>|um>LzVp<3fd*g`*68!3CAupsH;^%dN^~P@HX6#puT40ZR7Lj#boqDfos%a)psh(-kMl1K|iLviW0o~JMNox{W9Bx~3bSw+8JE7^z%`IuRE{#Q`O0}QUE z1TR=hGI{td%vW*|%rCVLo|@i=21nOn$oJ_ zh!8wIVC<(0LKF1%c}JH}BZ0^UZe|!=d|4-0xxV3tb)1*DTM1-Qugc`WlsQn&U++_a z?#1n0sEy)K2eR4kGK~xNZ19^&pM+&j%90^4xjc$GA*cqa@O-@k+n{l?;P@QOXV_1_ zg}R{c?DcS`ea$S4Csz&a`bk=KYM`gn#0&V^z`MZM(+e7*LVx>c#@jSarCiF`LCC& zT4UB#hs>3{#1#26<)xnsL?^Q-q{?3?dKagj@Ur# zh%`VJ*4aGjULH?5LyF&(kELgMv(s;sO?v&?kH4W)@l*OFXO}Cli*&)cO9o;P14`X#Nz*NnN~aoE8m}* z(S|g%3Pv}HBiGSyqmvv}Lqsj>O)zEiHa)%i<1>2Gl@RStN3hO`vYdDpb`v%&)lPjT z!gM`K7Ni(Z`9Jzj^L-X+7to8;4h+! z@Fg9VT}P(rX6yDnp#9Y=lKs$z^7b~De;+Np0CORcUb5m-LuywBekDRnZqIP~RxMRu zoW}ARuv0pk&K}h1^0}@CT>80Oc4vnx;vHeKMX2Ml0b?n9-wx9p<&)sgY7nz4b*gOf zzs;#-;vnt-R>QJ;w@2Nq<&$|nsglimY(b3B>rG?8RS;mZvoKV;2e8C|nCd&Jf2IvW zm?L4q=zJU+Pw4`;{e2LBw#@J`S=piMpwnz{4b;V$NJvc?x6ERf3!Z)bK(}B~xXAX@ zY`c_|<9qWK&q>n@cSxi28=r*TnZTV*iav<_nzhmybax!AKbl2H+*2c0PQZt0_ut-d zyv-qVP>9JfKyByP&P-48_&hzUf9xjLo$~=Y*Ga&a?E^&|zW=s4E)(MprfMI4`KwFy zLZ*P%I^J^ssHNmQWuoMC%p)d0$m;15;$;vLb?259X&65^;|<$WNNIu%6_g4cUvIoS zc0wC%R-P|TC^m~|X|~k*_Vde$4c4UfN|o3$a+;VXk1Wab{KwgF_NLM^e<)QfO8Dtb zt(q_kvSk1Qv-Bd@x#A^L_cPhsDq{`wH$y~Q3aK&Ei5*`#)7nxS+`%rjr9oo_u* zqVi1?BKf@Idw_*UjbzD%A^BLc?9*nMX(aI|rq$MhOBO>G>gISzVWDbU3u{a9OY_g% zi*(J_`cZM3fnq1De?zK9YQZIl%Z0&C*}xDp?7b*p&`=4Ul$AwW%NYZ&mbGb7h9MqyZo>H@M0%AXkDV$xUJO&3dHng3!YE3N zNdTGC$8+_*psJ*U)wX&R9|yv%mWvxAH;)N{G3GJKYgwu`ouWU8G77{)4dDxbLtOo7 zH@v>5D5^NC5#pIza)oJV8Ff-C#hNm6X&meoV%dLkfAThwDrC9WoG?g9g^exG_!i$M zj_rxv9&5zLbBi~<8Y1x_49H6V^)lR%$1ko}n?BvKe=Ce-ghZrv2 zz~Y+XE9Yp);Eu&As?$PFzSWgrn`+EqdBAl%IZb8JKG0z%^~gyvcCs&wGLgS|mg-{; z$QuvRe{pp3SJciK-3G2L=MKdO&2lF`P)8< zLj#7Y^h@@5Avbo%Q8&7?r?dKnfz{0eE!|!Ie*yqDK*_(jrOFif2#MKVpo`K>YYDYc zo<8U_4|}WbO^mwq{S2v?I^3S4XNTY${Fjf5gIIt7JButefezR*I9;?PR)IM7A&2Nz zeUVx&@uZn*vxAe;Ijf-Efl^1V((F#k4}zPS=;U4Ktpeq&ah%9CBCh(8qXKkgcRB1j zJ$xGaaevnnMAG5V(KS$=PauLi@+cWxJYg4(Q$l&irkSo?x@j(h3Q&56mqxli#9CO4 z#;owOZ5IdN%Bw6fQ^rEVDp~)ph1fCFlU?}rwA04R>*>db^u;!{!g;NW5`sGzIB_g< z^8VA5Nz~=EZL~Sa0C)|6$iQ=V-ZzR#VOQ=Lz<(NE{TNS5L5z2HG3Oqfa<8Fu>8}Qq zva8Z|?lc}vNsc8rS`m(ioF28TNKdf_DAaEklOAv{swE6p7%kVl+EjMdMscXW8JWBB zHYeE_%i0szFQ4}>*3@ejUc!B3>&UX+fC={lZFl??9!+g(wt#_7#gUMDDhj`*)84IS zl7Hhq1n2XE;n(1LzF*_4I%#+9ULr8OHC{?=NQBG{2I71QsiI$vEkK)J@oAAW0K`uc zFUhLbD6nXu`Q9?zA7t3HJ~EsJIS>o=S%Ff_9Rsi=Y8BGZl`<4*aBSV)la4zuGwa21 z6{&9|I{Eu4>q*NwmTqJ;8qM3J;|pIC-G8_%rs2Jk!D8RT$-q-k)K69%Mkzxa&jo7u zvSEe_0d|tVcGjvuSjT*bHCa(YjkDQ_P^hZ|e!aFVBvV-!pfx^{XTEmzFsE%AD)HLg zX25<#(g;?(b5tS8(ke zqwn-Mxp)qCC_WWA*`$8J;Kpop4u)7ZW=h!s@Sn8hQOXyT*b(IQp_II9LOF{K0&a;_ zsVd7}+&{9oU)MKzay85w<8R6=blAB%y9LdOT(gwbbwOJP_VY!zv(@)f{pX;Iq7!9H ze#|)6DvDI>7Ol6RC<1i}IKL8-xqo~$*$FdT!LXiUb1fno-kKj>GeyN2PG|I*JUToJ zrVF8;_x^C8;X;-+=-7FZV;-0znWZO)WKx!U=kKk7)p}d2;tiUDfkL$N3^>4g^HP$j z!tnolS3&j@3I$R~t~uTPj>E>wreXeNnmFj5yf|=6(GIBF0Pw4tJQ3JmD1R;MIZ~)p zNUm!aIbFnuHzRpdL%=^qf>xN%A|fx8d(e?JZgIQj6B_Ha2o^CrCm%hm_v6`78=~Qh zEwBbX$okRy(I$gGmOsH!rN*{Ll^7wPE*>MFL}mn4re9o>`yc`zR(VTJabqVR)(vjj zv{!eO9Xy?LYXqZ+s8p;}+JBY^byJ6`!qs!wv1j&7BK6IgoBC)XT*2jS@*74nBRq2e zzOth?@8+x8D#{E$*2#AdX1mm1_8UjYXu?PSeO-{H%v(miB!|0^@y;r*WY}ggFlC!9 zqc&T*skGuR{}9h7k_#vp;tBO|BN zO3P(m^S@a&$v1&Pcf4|iZ@5O}DXI|u`0fzROR%Xq_^oA*l^SgSTd zMKIL@O-=`2EhA8`p5sEkk=@dRma*kU+H|_Ajy{6*} zTx+brxJ{1wVWTMeylaPsj(I{5y3v{#ovJ|+CzrE3iTHym(SI@}U5^H;mm!Cf`W&8H zPT1FP8rG(xvEV(XnVNA;6uYE1OTM|CN7tqJ?s~vmxkq$qRWHYZI**kLFD@@5sKq_f z(q6~EoTxJNuH=pyK-xIs#`-c1erEsQ7wcaFXd znh(3rZe{e@V}CBN(VU;T0Ez~=5V`bkPS5g)t1>Rl@GA z)CdJ#gOC3^>~lpn_h7l%Y8IiJrIPrR6#=PUT-FqvAAj=i<`QH&wwm$~^Q4pY!^XS* z>p=wzVza?fcg&oz^4WrXKchkGSI?f|CuYA9FW*$&7w`Zeje%eYmoZNnAD)KjnK)J# zPtnY>K6CyaLH==O&fbAlm0Fk=61(>*6drm0hvzL{J1lJ@9ahQV(5jFK<~9}aaUQCz zt;&Q_*M9@y!Upx$K4(Ovv03F&f993NA4elf%=6#?vmBC$yXzG1@YCJuL;kuS>Zcsg z4za0=KKqI+uAcEI!nowAW$ZHmGrz}Iy~fRBuKIp$v1GNCDOr;XzG`*8R;qk2gXei? zlzNX`ro&0*e-BS3Hy*Pfb#=AOWo;dw8h`qyF@L_U_Uo+=Frhy045S#~!0Xq3Z^$sN zA25?%37Wd-lzL&j%p(9EEHxp5;NBuU5?aWV&slGQF|e06TH<@14-n) z9cwcRjFrd5EsV6~$K}M+X9GbJy$*Tdrm|Z&Bg;h4{mp;HemzNY4m{;9hP(==-`_I) z7k|VKf*uc)7F_r0w8>O>z`y`0U~?3i)!srXb0?!j@?l3Qmi7}06funt$Z7>D82A_# zC;+Nzqy>^YK_+(EXh{MK=Sr1ZYBF~YNX6WPB3-|bWM!Rhfh{oZ8pcl0)L^B_g|_zo zTkCEe5*|obJZ-+gJ*?>Hdn)6x&5`%|0e^P|3n0>N_L?A826^&D3V^===qZ!CT}SM; zYv{SZ?Z?R3i*lc-MWr0V8QJdPqjC?x5$Ojp=9{@qG0d8LI?R~Ft}%NMS=?)l{>!=W z8B2VV+df5F*+ga5P3HrF*?a9Q;OSf#3Al=Qv5Xe7nisjN3s`88p$Ar&J=aUWynoBZ z6)USmSK{MwG<Fcd$%2iMHY^%Tau>Ca?A8U{X?XI6XsaqVj_STxA zJbVzLOJl-MW2uE9h8_Oc<@^n1klI4r+GlRS$~7lP#jQYhOOl`Lw&x9|Aa)sukGumvO=Nde$I%Y z6tg<0=>;sS+P~C4hqgexj7c>Ot0|WE+2iikq_1^hL+}LkHz+;|@PZj5fbN3o97l6*UM+f(dJz zw*+=(O!UZd7+O7&cO(UP%KO08l9L_Y0W*b#|1ymoyT}uW+`d!Ss|WmY7{6h74KDdC zTuYcMKN{-b`ZZFO!!yYV4u1jh{?`H*fBj0)(_d&2`;Cr2{4$q$>C?HbjEztodm_>Euxf0wM@<{fcaoh3oq5jmK-VWANqF@ulQTJY3 zL?oZ4jbGEPx*7(Xj9)=Y6mx%UB^mf|I@iHGJgWD1tQ#B57HgkD=6{WBI}zklLvxWa zXqhCBWOAM%L?)QxonWY;#O^EjLzxD?#o4Eb49s-R(Kag0k1#O3CY`Gqoj5AW1RH5= zIaixYaK!WZ5^6eX{}0tuf(BpkT?QBxtCBAG-hA!|p~;(4TL3D{4ck0OtlmJv@FDRas*c`HvjU7d2?hOZ(Fs)`%5V)frm@Sy=cki=km zy0y4dSw12=a3NX|yp5b*Z;r{lg@&BRCjC+DXJJymU97hSv5+OmUucD8)+5~U)S@VZ z=rz3rj9MZKsej@tD`IUcb}Lyc+@@`2O-J$wVc9z3W_r^Sjj!5<>%(;aRB(11Z-5swgNS;oY$>-D8<`Hn!xx3Kxq6jTKlsXg`t>gDwzgkQ zQkbL^7$har^E?L)f-=-s+~uB42>aO@Vhq7LaQKR)IeI@Qo96E`h$o^BS#j;jd&rC#2!hH?< zm6pKFpCC933IM7$} z6MxK$oa{DE^YvQ$CIe5(g+WN^gZT2LP}f=DEu-ITY*+n$btQjIU~faamoR{^lGJdn ztQb)AL@@eVKg%~P&no$$D=$>zYd5M%uUq*I1&ikVqij7%vz(E$w0kb#S%g0FFNnfp zFs9m4QY`gV+3VXds5@NsRngy^ObvR|n170r{6AC10g}B*{_EK7=E$x_eJ6V&6`rv*`#!gfKt`lo_~x> z7-U&jDcye{mfckfjB1ipHbI5FF;L^ALggz#@4b=1%E)nK7lGSgM-OjQ@KDiUezP%a z4u3{jae)C$`+kbTVljvBboQ!bqW;LUSb}*an;4f{K{9Eh@?5Jki`C7=~&RN zgtGrm@dJ1Y)12E1q3oOk3!8Iu7k@W@LB=H!fiByuEJ21QX=BFcklS`XkSvIHQY>Ns zOpa2C0}z{{!}OYKW4u<_um*JNtAhea#(bc7py;(`D(>%R?Kv9qO^G*kknRgwe(f3=e@B2_^@N&fiWER<@`Z*G)U=qKAe ziQr+II>D95Ck=DtoCl%0ite>VDQS2pO|7(+LQZOzGVX{)DK47a&{xBcP*&9&LUGI! zs;gr^a*75IfE9nL!gF{p+a%QK?@%+6zbCBc^>~B95NHYlb}}{@)-_b3p?ZEiYHXQn zgV;~89g#$R3XkxujepJXT<-iL6aLUD^xEh-;pZ!2#oK_D53S=hg=uJHrc%BZXL~9) z&4Y;gr;+>~aYa&jheR$GOjxePKz8QDYxNLse^!GhuiMm!>D8QAiIqXyjH&C-bKGfj z#u0T>NZMP&l;WrsJh?`=V{xC=cC$SgoSD@Zl0&Dc(Nnj8n4M|zf$7rZ&Ojfbd#5J^hd%T ze06FoQcBKhp$Y7$T#IUk3l0;VZWHAqn+px{%IF>%f&cq<;&;cOq`4pW97+x+wIz%( z;DLF2EWM5Fl7Ab}B!_YZoE%uygj1rXp1xI%N0tMk?ZOR)&Pg1%K#wPV3r&I})0d}Q zJ&W*`sVU9Pie^Qsw^Z(&I8-C@c{BewY5#SN`Qz?SEjW&a3he!@I6c60isvjDPfW&u z%HZsLD#4@_#mk*{{-Ft8KG0_16WXZM^ErDN@L!x=?|*n$Gw}(OJExf8T5>G7waXeh z=f43Ew8?k<>@_J)405*<#*-U~$Q5;d`u(o>d5+m12nTeLU??b2(p}$GZpTO)oHD=| z;C#;A`t^8-pazWTP?JB=`;*%xe57n_HOC zi#Ck=$gHP= z$bX8J)tvmUy&)QSEAUf3K_N();Z5p8MsI*-35mr-GUDLj=jyeHc1dvjwALkAt;S2u z5!QQF|FE*&VfFPC!fdyhs`0|TF#UnAg4;Q93|Y{GvZ%=1x{zy*ZZY6KWn8_^wGyW4 z%JFv;_!|kv-#VL=m{Mu->X=8XwABpRU4QGUux826MWrWPVYWSPrU}HW)+t4InPZnj zrBKceFZ4}a)J zYdrcfREO`i7=8P73Ofrd3qx)I)yHLn{mn1G@w97`tK)5-_zPe4R)B_Wq1k zOxLF9Mo&fm!g&F7m-yzCfaEaBdBS8~MogJ!^8@&{cxLUt>&rwpk}q{EM3p;%Nqjhv z{4mE+GdzbSVTbRedHM~qInv_k-G9iS6UgN*9qCJul|P>|6!9Rd#)CMB`Y6v6okxd&+C<-m6!nTMpFu3r+A2I}3#!GRl~Dpj^z`_zcb4 zEzf2w#LExQ8ut*xvI9Zo;*G9|f9RM>WMddZuQ*Lc1HHTbHA5_^W`1jqb$>)tPZt?z zNa0e*O6?|ze)z?A$s**jN5Y>uS?NQ46cQ#1_;$;suaH-N_cDD%p(VmrCC8eK&{#4# zReus~e6AOmeu)n_OLs7Kpf1K>Yy8LX9}E}Awj#uU$=?RmM)P8QZ=xivlLW5I`mdx2 zf5jcB{o{vq8ipUXA9?UxVSjPp3bjnMfOQg6RJ@^b2)h)==aH|QHn`Xw};yf%4-`N~S2Z>O781I^&^lu)@rcb(TdHmW{b$k);2^VjeGS?;0{DjsG zO>w}j`;d6fqUKk~YS`-7!=xIH@Rhl+FP1B!wH1f(dZnF+oF2`8!gqtCoAQ-s5pZ_~ z7FKytdZAv?mZeETGk-AxF1mR?&Kq)i@3XuWed^QbHkphGD$&Wqho==(TvOc0Yv<5{1O7PC(Fh3Wjm6?T7LdSWRC`;Dqv_sIZ zbGE2}t7-+~g?(uD9o=DE0IbrM+;?EMX+=>w4PmzQ9lNK#!ha!$kylnV(O!7fb3&(x zIkla(8CtClB>3@%08z7WE`DP_Dn)ISTs_OzMpky{q$Ak)1HVan&PUVdnS9F;JbQ2%%f`UsZxhN;2V_XzfVq>ZFC%Pf+(ClE@RPs=_EQF_e2 zd{fwbubci!z2hkESXZx6`WDE}<96iC@?C7D*-4*U8h^U`GiZ%s>X_iAKol$*4y^>a zSpm4|`zs-0SQ{qYa=J?yep}`^ZRkKD!Z!bRFg+5l$3feHc{)3ptJs&HiP^L3XrOKK|wf4KQ{a^mBgO?H-glFA%#=+`v_uyNkYjyTewR9_;L%g~NDOew&%olvDT z6gK+A;eUd;k!2tMJduBrGYd0%#C$iR!bh!dl;K`bGSg=Ze<`E;nLN*=*iRz`Ysl900snV$5 z*ncg2Ps`a5T%}-s55)0sEuqui^`r3Tf0PPX*5iy4JZf7}6d9}TI>w<5SyyaZzwBw@#}O(su#)&;eUmlA_9PHw$?$qmhLLFa`Zw|!awwcl(QrL zRF1Zs^64K)2Ed(=$&f`1S72aGfqmkQc%$ELY6b9f@$V85Q@rWT^Jn_n<-}dpJU6^= zjM3^F0C-E1WbRy8GE;ok%lUG7#QLQrp0&K)hG}5TYpAvXl4|OgHcr*^je8`Gg@0v^ zuLA3rshxq~__4mgAa*G)XHsq$Y_;^Usu=y6cp<)%yIe1CmC**4O$R33sXdE}6ZVc4 zu9AoMu;6p)`ztn59(w0G9+?57Ptndyw8x8};G!YaQ;279>d$=AlU~{&%uwWsK9>eH zl7JoYa6@?{dGO|kSMP2PNo5WhE;u{9;urgmPgO)44 zOXLw_!=sH^h2c*{2#2ke#BH``PG$lB2}!o6vfAR96Zc)b{O+Gfyd_X#prvasd6cFn?Fia*_~y z0Y8~?{JRKTK76>-^PC;sct)emjTcx8x%gpvM*`Xli^$*$cZpH6YDLR=L{NY}yMQrt zIA0oR{udQp^LXyjLR*&&35+S%c7hT=R>miooH*>!!9YY_BQR4(b@3XEN6qqE#~}KZ z1hU5iVkCf+f!M%i>|1*q6o0%R&%P9XP8!`OEG%siz6LQax)bT6Cg$-?KrNQdW%Me; zj6J{5mW-Fh^*0o_S4?Rv_S$_nt*Q#87HdlM5bf`=?P* z1G+6H@$OIn;uEs#EHD)>yTVut;riuC4Po|Ps4rvIdzYo)2pzsa7k^n(6H0gT_gb9TW%F;>&U(d%J0whKUxd!iypQgbN(T-?`Y$8t zRI6&_-}F`vA{f4r$?q2Afr$JWr9{Qy=f89=!RhF?D@a%a!>Vx;BoSlgP9_{>t<+IRboW8&_OIZdp=DzFhJ&ejA=3K}K#C<>w)rgblSL>A z?!uy2&yGSECAgq7)n)B0VE|7SBbZxXbF`h~_D2(!;^++}B%)0I0$@MPbCppDm{oaq zodx?~c#*Nsr+-=q7mBxQTy4-w5y<7p43q~94>z77qLBX456>g4(m1Px87h4{wZyjWt*hrig_g8)49Mc-i zGLDc>I@k6>yh5MTi|){RaW`EcovyLTX{=O?7MIj$V*mQQKQFhw$#~jS^hP4Po?T%P zOF*#AE`KieqVDjzV$=Ph68p=DfKoJ8$gkE2MF|ffNnQ@BI!>FjRjxN6h(re<6mKpp z-{EDQ5kkgKl~Ckg*v>Sn<&O_91J8}d)71{)v>Jr;nS2<%cL|@;AkT=bm4~g>`Vt4f z1U6o@t;qKrs-M>8M#-hq#(dN5Pu^keciOu*Lx0?OJS~LN4LQU5DUA6h;Q7DE$r7ACbXBjFf>m z^XN#MaE*bQ@b5Bzz9pw9&lw%I5`1z$D{d)M5#E(>kBOsF`6QFi=_q?5IB)u^k+C%l z`hU$Ymg_}sQz9Mt%alc!**%Y6M|L|mfMg7*q5lrV#UrDbP8 z_XIJ*ykl%FH>3<)7pyd=4siD=wG(%UV1Jg)Zfpv@>LB-6c1_>-jPJKB>XPHl!z)ML z=Vr-#W4aT>udYjm?8m(hx;r+3?+>MYuE~&ik#OBnS9b^hH;}w~inG`siza?^>V9y2 z=6Qr54Y0&KMY)C_EYti4i zD?%(4x&*cRWPt_-L(S--2ar|YFMs0iveeAJ+cX2uy?=Z`VwS?+MuJnUKvt;+#jXK4 zE-EonNWqipG%?g3xNKAGh~1l}+#9WPt=N#6ivaWs_QCvnVI$IE8#qv?5}T+VA;mn0 zI>$UpR*QC?j00q{9L)E~VPg@FB4wXLw?`G>nN{#&5+ zQ^&qEsa)}kAFBvSMteKLPJi#t8@t4lG~rb)xw!5^{E@HBEtk9s*jBFnLPDA-I-9eN zso^Y!ZtYLk0A@#NvqF@7chT_!Hd-I~GRs2YyKz-6GRbiNK2=e}R}4wb_Fc*MH;+i( z56A?5%UPqp{J^ZkFtF@ircFhj$>N_m$&^5C-cE)Pp?HG!zm%c;)%=h>V!GfN6O~^^dDBipsKa-dMdDm1E)?(> zku{SVAl0bwLQrC<_@NNAm4-mRNZ6l)k5!=U3z9zs82rS) z6~X=DD^VwDG zb8YBga|}Yps1q;T6VSvHWvlzdEP%1bJ4C0PciS+wwnNsCZGY0#V$CqZXw(SS1eK|j z!NZr&$}NebRgaA*leu-hK7T>51{8voLa-98&dzx4blLMB%^UgG$qK-VX9>3Pu$c@V zyVw;7Yz&Z|26bt0K5^=Ks$1(ffcx_{|LHgX>h(fhi2OjVTiBRAkPYm=!C3sH5y;uE z-rW5x03qad+<)N?5^GLJ!3?VAVAmxh7{Urk>^Yr?|4AOo@CV?oD^rTX68jc6?OOGf zg?9q>&DM>oQej5xL#fQ3;D@mM*U${G)w?OhfV=`HNGb?73mN4g;GpsWiCOs=(r*lX z<9+G)(K!3+06UV=8Vca?HtjI45mTf(S^M6xXkyMl`>_J4wjBFmqHD~fM z6pS%@vXqUJLSHFD%m4@OKpk6kq~z5(6RPeHW}505a+Q0#F#v#1T5AN`bPbDL;T|)Q zCXWtn${l6^NvKvC0n61^T|W}MhFvpVbnk2VZQ8f7*HPSOp!->=-#m;0AD2@A7qs?7-@Wa>U1f_^%OYCYk%(U7QSgDBC(M;-fKllsE12ghk_gX zdA8Iy{`oIhN~y9*6i5-rilI{v%;)ig$6QO;g9!m;sR;d-%MMhjK_ndw&j5useR%Pgrv@BDW3+OcP#r{2 zAf0#{K)+#0B{5i=f9~n6KNooyK3i>37fYs+l-cG7M6zcNIP2EZg{3(SvEg37RfSzG znsl!*unUCroVtB-+gz=J|%E=N9Ov|K1jPN zGrx}zI;+rlUO7pqQCu^^cmB(2#rtBa-AgsIsF$SSTS}C!%jZ=I;Glj!pl@bPmrT>$JC zn2ERl>Ou>Tm3rq3@sS$LPy#DyaeuiewKn9Cw@6MKjsyJVQueNSr4u2L1Xocj^ z&^WKRZSuX`O~N2u45eI~qg zRZFiOxbV#5P}cSzAC`?us(*3192(Fd^MzP~m_G`5Ma08Pj0*w$OC`@UR8=%POPpt8 zX?nN0pYrTVdLOKDYm}`(DftML-t@Tshk65B2$53emR^W4uS?_M7;%_r_1{v!mp7pJ z({m5gwq*-3c$A)d2Pi+G@9`iqKr#E3FMTu#cJ811)9>je77^3YNYIrrbiwu9uEYLc*Uvu(;#9A1z6NTNcjltW6~K#YZO9ZZieH*o$DNHliB&mg ziawzf=>M2(ouCORj|GhFVz>Q>wg}oOxJ@aA9LAv=N$-n!da7X;W?bPkGcef|h0*Tt zn}BN{@GH7sc4`m-gMZAycDj|LE8(}I!vrFkGK^2*1P+OUl9FQ%;yRLGn7A6?<%=-y zVg0dX4_L>g=N02*_JL-XjKJFh)x!CK{`|eS(6G`T7Rw6-z8l1dRUR6b@V>HqOL+ST`paON{0_c#9Df^?r#X84r$LC`$he@J zF4k6Jyf&yR0iXFxj)~r+ACbCd2k7r2xH6pU0(_mYU*7b|Jis@me40;&xLN)X(%uex zFCB8ttrOk^&0Uo#aLRd(uk1#EC9^INKR{T){%qgy5Ls96hXB#0M<2!!`p>z;$u&qz z(6~in0D~A)FMraw+XwoQ0juGlWY|b}JFW2?$g8)v?4S@~WF1c}{8O#t+)uf;*BwWS zwIYrcIgCSN9HXMWtt5&3YypdzC*x9ou)UETVNJzdeRWe`(y3aL@6d{pTt0H$fqfL7 zu!ns!z<94I0*s=-9o$=GA3hZMk_8jvqEd%~LvBVsSAR!I6;^e8A0Fnc!i7~5aIG$T zI*oJ#p-INW@O%{XZO^5@2(*I#1}XgOMO#Kp1Y2z$e(VjOyop6C0?c<0t!^bE4j>%H z0DHY6S}$cLU{TfY+=;>M$cQ1L&~6FJ-&GNE;=yqRno1Vdz>i8GM(rOQ@?YjJ?Jwo# z3EvI7^najL+jsbnEbpN9!SQo-ATuscXOAEn?6w)^cHCF7;Ju8K{cG779~oOx)X3W` zvv#&?bK0B#x=F!QUyQtnt30!urPrRmmvNEd;N5G5&fE$<2>@K!}d$jB!XaLKl^IS zE5HH>$|i@8+=(yavD3k} zQh&U)UV1{V8&^s_%V(LUQ>x3E?mN1)fkYy81JZVM|LVuYIUT16VS zE|geT2ud1J2M-&b88EC6|YyEwCLhcv44W* zYd9N5Vrxvn*1Q81;S!I+wyfL9cc_I0hrc&;RkA_I=CCT_A*BhIrjrnV&k{ZWSTj(4 zAt(Y_33gf|xWlgDO_kgxEUCgM5L^|M9imd>HC?TuuXCf?7?$gr-J2}9pf`*WxiP<& zjfI%1M|`WhHV^5r1#h^l9?sZzF;cJtuS~#phc}u*j5Z5_; zlk((v(mrvx~>W%@FQ;Q({ zF!=oxNjaS{Y=uSO$;)ab+dyG*0@0PfDiZ2Tbj#2mEI-Qpx=nx?e}B-Hm$OPqu3@J~ zTn)Z@>o?4a6Gq*(??mSEq@q+d;c>#2rPgS!RjnhisIWy#tWB$Irc4mpmh6Y!uz@T3@H4= zGIt4fdJSWt3(xBSEs#un5hodz@+UlwjmXyPq{r0HN_E#N+ApuKQUUWoAQe4~)ri;G zp4wXfOm=;oGQw7N?SH>iDi0bOaJ)q**Zy?zVGd9{Cs%48D1Ym5FvLq-%1!3$#g@Uc znvVG)-kLf7ibqvdNAqGRnbUEoww8#>C!sIR@((cDq2zX@=bwRkXJ`}XH_siIn5_JbXw6r%nzafn(UJs^i;_Dr!-Q)W3Ubo7p9$G@4 z`-59IWGr~LaDPe~?55-{^;GS$E@FB~1+`IKfZmKHuQyNhBE#TU2iYxID$~s|JQdUWHAX*@PwQQFye_N;~cCJ@W4RU2RiwNu2Mxncl^RyupLypyhactBr2DCt$g6z68 zYk&5J%waV5FcwC(;~lhsdFUqH<)bS{sA={Nn?S?gLFEMU4NV^e1rQ7#^fm(*h}%`W z3u_7KKyop?@}%;9%d`TqB;V?N-&es)Cbv4jw`WS~K@2Vu)KchhLyHt`TLxlnW6@O$ zZakSROM|}2sdg`ctMYNo!V)q|&h0Yy%zt{CRFP6meDjps%YyFo0r8pz0Uu={_uq`# z*}8N9CqQ3%C0!wx<5SAa&^E*VdobIud9{d{#YPl+G!XuXb=s5UfZFS&7%s~vCy;eh z4udjuH}u--eR}XbmlBqQT4}`^;~4Eg9sfxr$T-rEW_&9mSJwDf66`DAKT2HWfq!!F zxW-Z&pG37~MdGIRGE#yzdWTQLk@n1SjIn(DR@D4D98-8;pj``Zf#hj9Et3A*0d>L( zJ%);+Ph5Tr5DSmmuQ59>Ax3q-j(I8bIs|} zFQ!cpP>XRlThn1HD^M^W`D02V8qCdNVwG~!eaqN_0ucRW=Ei-uO|eNXKc@9 zm~g}JDN*-nc=OiI$Rt3C?+tret@yWONZKmlBMRgvU*UYJKVB{9_K>vKsz4-9r~tmF z(4}j>I<@G%iX?Djx(ntc#nxa_5;hnE6l(v0%XsY$2ri1TxxI!L_+|663{FXO-uV?Z0<&)2m2Z9aIjP}1Ucg1V>tI`Dl2WhMMBBm zsNq&y_MDFKCIek6M}ppBh<}@tDH1DrB!YL`(@r_{4Q$w98t3Qgp__X<65*z4iPo&Q zFtxm-EiNvLG+|SR8~xz$#=mMNC~}r1j_u62QV5K~W{`(2(7Wo^(=tjf^=hdoC}{k% zik|QV(!)L7O@pPkY5;^=#kei7gUhe-%~;x|-sKIl*m5vE8gZuU8-Kp1;)YRv=gIeLO9tuDgc!Mq_@0@DDj2z0pA4C z8dzD^Lb!hbQuAvZkbjV$b(|ivAxUO?9Z4@4r>MU&9(bc-;hkRz*>k;z19mRAOly6-s`JBfWesV!k^$cTV{XFu8Yt1)Im%(q{Ju9eHXZD zh3rJUAI6R1vM=IWCKe=w>UFU_I)t za&B|P$UxHK!ZL&o)I5ODeYLo>XOANNLsPh4Br6JyeT<0m-gN2;N5Ub$vfiqL^{T{7 z3&irx)q~Nq08J4n&gy$sSu@{_O1>Gr$<8RASrXsn|gx%TZNtG9GPVn6LyrGHWgKU&$l$j^iLf302y%GTF zwUIgLnUhJ^d6Arr{>zUNoeYVrc|@d~X<8w}+I_?3lfosht|Ygz4FG^H(Wj>SkaJUf zi1Y(Hi+{*jkpM+e%Ue*ETgVa`DDG&r_3viq+)*0uc_ujSO!5RlD*aAaN_Bgl9pJaE zShlG*da01l7u}tmI%s$OWG_kGLJ0Yr9iRI}vIanHyLYE0*0ib{=Npj&lZlk2GT2TJ zdePd~Pv%lqBnw(7=_4dfRAImzNGS55KmHg*w11+t^qwmEzb8%`LG@axmK)ct1U$3|XSd$1 zevKP86p?yj96NkPE0St-B4wSos`v@;cM+i*wN^&A7<2?Z(x?qqr#D7Mrlx4>&+qeF z>u+T_ohZS$TauDWV&s%l$}a3?zgG^f!0sB^L^+MemW#?iASRsJ-@VR^SOZZ*=> zn%@mT(%s&_+JCx6=*8s1e2Ri-2ndt^@*ewT(N{o@al>oDLg zRiChXya9_iC)tU&j2!HUY z(g7$9a&e-G&`*p>ioDiyTb73TL7t<#3LY06=#GWn(=1g8x$j$neu09I8qLy0l! zD|^iHc;(@0BCgED4^iZt$PvLHw(RZyrZ}*~fh+5VkOr@eH3>6<3F8$YsCa>D>R@}l z?+~k1dJ_8Lnel7MHuMr3wj+PprUqb zk@>>ur#S-16#>mmQ0pInXtSuaE-A&7Q^67jAyZ8Ufi*}%<$6WZ=e}orw7;~9ppqCp zHGO29K`!~+9e(Jbw#xzwjs+THMMrL6GgJs%V}31V_4;BeVLE;6jrYJoKL!yo^;U3i z>m9DRcl|}Cc&zUjUh;LoR)6?Nfd6tVILn1?pg6{w_hoGUxOjxU&vSyJj^mYuUF|~5 zxCfRmz_LA8+;^)Z!p~98x08Y^?<0B*uB0wrR>1h9NUxKM!OFEY{CvGbwkZctZ&)+v z^(%^b)LKjl%9NiG&nTtfB}sE7h>fD^|3ec96G32cYwJlCP_hC;+<&5Y_)c;0UiV4H zN*CVYndYHrhOTo`6+LPiSPKMBKVW`BncSQva8K~w8Ber!YpDQ4?IRRc=^OO^6sk?T z?T5Y(0Nf3pvKJ@qCj;qRHx`PQ{ECD|wSsUpW&*b&D!vOHP=;uV6Ysg&%|t(g_)nZ2 z8vCY-mKG)Jgwebyr$YtAF;Ad|KhTT(R&J56Q0z zZx=y}N{BBJZpGwC9?QIHyX!rzI*3r7--e@sX`aieAnh8&qDjp_=>Z-I;r6Qrt}voY zW5GdKe_=LjjrWA?x^bX7s-E9l*VCwYKdGGmhEen8p_87@+s&Oavy`L-Tl+{9)#{f- z`sCC0?H8LmJpB_EO<`L_NL7Rd?+v^L5IDFBUOum(kUXp*nIfbXiEBm!3H87 z+`o@kJ2+enh!fX&^}CO8_trL^&tv%c197M}gQ$)`sIS@N%L(hK1~>ytEPl^kELJkD zzpfjs3un<}&lq|L)dG)GBEzO1N1*X(F3(*6xmy~V2<)R2qGTWcA)H$_yMA_U$AjZw z(TseV;+cQ_RfE=CPjbb}wN$DtSHt<181NJr$~ ziZgFMT!Q&u_!L(S8~$Zo1TKYc2z#4l%9ElmzsiRi4zeWmuUvGk;m#chh-}-(VgTKV z+8y-j4$S&s@AG(r)62bAh`_i{urt(0Rwwl5nm~UYtF4g4ag!;YG15NmOkDlZ3K~c# zDOMV%^4ZlTxO*N`%FTiTnZh)a? z*~tyA#*NcMI)QPhy>q)0cflL!Z({Q8QP)V_5x!wtPVIHE`yM{w{xoSKYJwz?86CxL zj;w#*I4U~GL7NY;Ckvr~moFrvt{7vcjj(LSLl@;-hjWT=`LS6iMU2N5I>TPI-yc6s z(PM)_ByG@lfelZXPeYOEgIyrT?ziti`u6HQVVjrE`}FYN1%n5_!OR*u5C0ARx7r{Q z#^oQb5>`Y7k)~0v0yYQ_K(bCg>8tfKZWVvPYWRZ6j1VldwZ85w?%kST;qRW z-Z7^YgNWWoLIEf(#dP2V8t4CAE5aAA)FO(@Z0Zgns05qd7dUhE*Z_C_hCgCV_-aWT zFm$yDOW(6W#h83D05?IwH||nyj|t|NOo?^;9urfDc;8<2CGs`Pr5g* zO{3-uTs-o2=EF`1Mzvfi46{F#Ok{shF}rOZ=n8XGXREU{fLI5tNE=^|CPHV@y?(8B z8#L?+44(0!O-T?PGGG^nhoGA)H6iR8l4QI-9oZ`Gyf5bvD5J#ID?BI z%N4(yI}xmhCXa~k0RW@@-N%@=dI*qNU%Vw-x@=CjJc&$F4}RQNZ}Zo< zh@(16$LVS6umMqRGjeyQTSkARv1t?VXzmZ_cGF$4&CGo|VgXX_ON|W(A*+YZMHfG% zYq^)_ak!(IqNOiE)p)$9-{zj+2Q5W3Bp?;!*Q0-m<3zNO{>cZT*cL18ZA)=CEM(%N z?0rwV9cqOAECMgn<1HUlBsuyJuW(G)XcLNo!R_AoQ1f3fIB1YJEHi(a(Pzm>x@iqS z6Nk<{NF?98`Mcp&wH`+KxbtO6#R&bXK#!)*piG+JgOuQRs-P{7;VC}XX2?MmEj zVL$8yqrb~I(qPLYDRhJqGjp~8t4{R9@Ce4`cHzJG0WyZ{LzG7ApyMXdyPno=q6ZZfkg7(&;D`n_NCppGxL7ln^t(1p z>@6|;3)B*Zvj<}P-ABH4?9LLu9y(=Qz2@>3CoM38iNK!|q3l0= zo@YQ7$Pid&KUQ`Z3MjSeZh8Ph_IXF`05s8q(&mR{MwUpr92I}13u*zo>B#n7T0YQI zjVNP`rf;2D@hQTa**R<8{Paf-P&ndNL$M0(8knG^8_VVf&;u|feZ??r>%OH3==mf9 z@>cj>bIrI2E}u6fSfwVxDJgd-nIp}?>0C82xwI{fl;ZpOSETvGER)>}WOH1kjr-)t z7_K(+T&CP$o8Eu^ZSm58S_MowOjq5uin;Sy7)BQ-{?i=UjtOW6x9yGVI7`;z)HEhM%d{PSNmMKVxj-P+~N3Z7ds$J!Ahb#WAHFnkl zH@O+h2s9q=i2@pE_=(z){kh=Z0N7lQ4VLNY4(l@pDP}PQxEkM}9WznC8#83~X8!>R zExJ*L&7I5DSm&zof;Z=#3@3)p?XyUcmA=s#^rW6Oj{>G~IUdR3>QWi(An4T*FQJ+2unk zeWf2~H_z;DAGeTF+O(y$)W79cdhEQw*FaTF=ab!~#Vtk&4d({~%wjGx3<-eW7?I>R zhis|y{9vhgKBHFX-^}FsM_F8c_4WIkIEnHSg`ULVP^veRPEaYaR8K5Bs9$t>l?#Hq zE;N{Eyf7H(1?4=W(wX5*KBrKF%gbE;%1rb^pLO&yYPtTsf4F+~w8yt{ZA*LK@Io7B z0r%UPDE`Lc@<}G7H=G>^1gIE?OUhEJY&BR|*cuEZx69U|k}{*oyewmAyXHF-36`P} zg+g&Ng~%z^@rPCt%Y7g~|8&;ri-Licw${xX+o_bM){Ra4w=J|KyisRbyeL=-Tx@U= zzBm|YZfk1avayA-w={*ev~S!ZA2q6Yaj;Z2QS(3rHneTt+#Hr<+P1W`hc|`@r%?Y= z@?R31iCl8G?imelJXqUu1DRYVMXf-vnDaI?V3e|4@?RP(MJ_cs?z$91B$bILawFVV z=`kP65okbjJOxzc(#BHc{V#E^Y3%s>S*lryQX#3DtFYm0vz6jQnS3eqCWBhXn}UIX z%=SU_(^Sf7tc-lp)W+WwEX|py13*cDtPPXwkz-4v0+$C%otGQ5`Y#U#hzQ25>Is>` z$adMUHL46$)kG};wV@}Gin$#2B$(xt(-zC6$Q8j-_6md6*cBLsnSoe=X+DHf+(gnY7wZw zRR*o_Rlz_en_x{bm>kHaNQT7hpn)o0g^p>W=7CcAMgef^gg4Nlwq7au-~6F7mY4gM zrM_O;>I^04uV!lg&D71C+Bdcm;imA$X8AX~xyc<;{%z=>+YHXTwgm&5o76bmyrq5f z#x{cCsU0Y0VWl*+ZT-ytZO2>JaRPOJ77X#6lH*~hk5GjasS*MaS3GIx9GsU0Bw@pD zdk3yY-@4jhs{d*<0*W5MB4>2D^_3KiqbnOH|pY7N*zcj-1s^Y$(|eM9d$S}{nlfw zn^o~(xGBWi6Hm?hDXHoY(s#Lc|O#xLgQ42shsj=xTlug}nO7HS5+7>uWflYP?OQ-jq z@T#WJW|uLf`Qs*Iabm2cRZjb@E#Yv>#xOM!9vOvRSIWlQXZFUAwq8x60ab_1MOjL7 zJ*OQbd*#Xs(q!FcVxK*ZtQ40sP2Jy%PSVTN35J2++g=jAMP)MvS;J*v7pSg}r({My z4;!Pn52LtGR)Y$f8S6VmS&03%wOpF|-btIt{!FrIOMi!?zFJvfmAXoo(C?*6(h$o+ zGC0$C%Q_mbryPRz{m6&u-&gc(A*+NMbZiecG;iF@BeWEI%UPv8+cO)MS7KReTB)&! zLHb7+sv-SU3Z)!sR7fglhu&%_BX@S-Kez-k=_ zT|-WBSQIr51sgZOj&YYj`ekq?n^J=6`jr%d>g_9~z({bWb7U>`A=xw#QK^44Xl)VJzguTh zr{6!Cr9W6NQQz-P=7wYG9n|6Tu|5oW?!7Q?=~)%KT#DWX6YDmk^3%7$nqyUzPbA|R z7)$A7TAH4u)u|y?W)^Q#LI}U}U}@{e*YLbgy>V137pE%f70L}&W157Hyz5-ci^Y&Q zbhq_-;@IB#m-A%FC_vh)_}kBhcx-e4?MhS$Pc(ALe6Ca}8ayu))9eVzDgVrQasE}hN6Qv|CPVmGi)UQ;%{RM8k7XJ5BJzk`7S=H|jnO%3lJh;Q4 z(t(7+9nBEw%-%Z|9rK`c;C;_JE0)-3N~%EoB}>4R>nNJ3RJ~J|hw*u5a3(m$eGV!( zt0xDCfl|j^Ecn(CbQWp(CTZTbHf`SAr25KAY5cBDrTuq(=O#{|=0wiesA}dsFD>z^ z8XJ>lhQ@IXV?4AZEI}F4F;z&$wfZan9^CbQhj$3G@%_P>O4dhn2UGzqZ}Cqv-t_^j za9btUEiIe3IQ(N7>YC$IAAmja0Vk=9Oqxa;$u7+bxA0+-fNp{K}aW8|h6BqrRH&;=M2s?=|?Izt>SfOn{M6|Mb#A zf&Z2K6PWuaGzxS7MDR%PG&)42#6{EAUsy|)-Yd>oC!GnKx4;;wiRCY!9E(;8W_j674e+WD?@&$D4B0+vBWl1zI-V?be$wE+|C7OElzA*=9fyrA z{`5QRxYC24JR<;YrL44gW^lk+OUH8#(bCc$L$KIVMg5=KHnZ<@bFK#XJXXys z-AStW>S9zg3>L$LE@@-)f05I<*_2)mBEm0-b`{{g91 zS#X6f?PrVKnVR8W?m@?z(S^c7nF-EJ&hQj+H0c>>`ob0@Z*S@O2ggmGhOnS1jel9f zSwBsG`3$zAW*Y3Bj-Y4eW}oMQGUyDH((_-PJDF4ydM(c*^f%$Cri^{{No!6dM15~( z_3K#0d_(iRTnc_87?3{9w$0K{)7CC^NE@$Wh_h1m8||gN-}wDyiV8d;WF2#VjCa>g ztmzoFjdU?`E~N|US@+n=H-o$OHHz@ptfNY&>^mbc)MpH*zJxR8`ZOTA4_$npVjCRI zOz%6MX1hAmbY(8M>s#c(+*G>kTh*H01Rj#<9wMbCB{w1ET8W(xV{&=eXqU-{PqEhY zYx%$UZPJcn?o_3A1f8_d#JroS1d z<$4dFRN@$k$(aM+<1vKVPG~2J63j}eVLn(2&$HIf%s*E8+b@rQ15LYihh#j_8-vd` zCyhAwjg2H-V)2pSO!*P6jca?)e?Mrom+o0+)BCI+96V}yWdj#L_F$>u(epx7Q7VIs zRt&e^oOEEsQcRO-OOJV1%+W{Dq>masar#jx$lgpU!@YWY!YKkzu8U<6sK5^!v4nr= z_yjeHv~^r#C-Nic-5*i0#1Vu)_M=UueLs5q0#v?7j+fpZ@X0^2%Oc*($@p2dK+VM7 zO-6oc?lFVW1CK!|qxPeYAR%$bN2|oRTnbdMgsI3*!IRu-MzcSL%i_mW6LgLrS4uk{ zJK;)fUtwiOJ)<|}^b5G!8A=R00`7^&dbC{?Ph|V0YciIi{-plx`YDW=pBij;{1kgP zv2Lt!n1bvK>d^s}#(|nMQ3rtHrcNaaN?%gL^P5Hmeg?Pc&kS1qKLf3l^pYbxCS_hY z(BrU1m4T|7s3o9KnOGVtSfyR)6?6?}Yvge>@Z$!pvB$w7JYGX6ovPE5!E!@Zk{X)- zl`4-1cm3P|HU1pCNL&dv7tqIIsSMn;GzDl-^ylcJCTbd}?qnv9wIWeUWs>l!bAy?_ zL!bgr7_`DqI7VJNkpU%w;;B}I#V0Tcny7i8;Qmix^`u;DSe&XR&>Z>?z%)Ey(CRwC ziz&=49dYp^s)<%P#s98r(!p6N(rb#*!q} zCnY+Z%nT=EX{TbP#iyQv52jD~VAlTEV!G&YPA@_8?Sk3%j)nKR4Gf@)e3=L@#Ze&I)4W~ey33@rAZ{r|L#RFW;o;yJ+luio_Ik% zS9eAR8;U)mm+wzvLmP@+3esV4*RyD_XEmkeQpdB<45$*efiao$s&gNy=$PFI-qK3A^UdjI)bkK8>KO#QU z^&IRacR<+x^V`#?AXb_2-cbf3ANP;mQS_5i`H!dh2}(ba0f7ZbZ>jo6qs~izbcQeS z0f&?viu|HEi98QY@w|Z=dtQzrsE1KF#5IWCHLCJ_aMz*%YFuO$nt@f#Rm~+pg_y;z z1A&OqQgrbpbYhJ8!>08=VNCu>7q?QHMZ&_Lcy+Vx&v(K*iqg7=>UUWAQz8d$rLHm) zT!#M~-1QfxK&-6HH2&pyk~a)bUT0)pxEo6|Ah9r5)vU-3?T78iKme}eqog~ zr%Z1Mms<+|ZEI=g-`LnC$1laDaH%tmFY+knWl{gqlQOC!uB@v>uOsGO_8QU~X*?>E zsvt|j(kc6QM@nR+{hgLtiX*vF{Ef*G%e{2qA3-ZDe*B<^?a=oBohz;X`-!h&1r5%6 zl6hED$2*P&PMHb5Bv+vBdh8d6mm6J%-e2Z6+PCcZKFF^uOQkuAI>108iM0(q(GDKg zi7cm;ne58(()~Sm=+R)JH<4}SzOCo5l|+`E7+AhayT2Fj_fA=7)L6~fU zoC8Q&*Df=Mo74+v#x}T*0`^v~wcxBvMRbkzu~X5<vI z87NsUb)CLohmN&mXRwRMS-YJ|imnqZ@<^yvBh@FD9JLouuy}<)5)$Ec)^23M(h8$A zk&ovxx5Rjq9zI(l$HYn2HgUsA)(@duVHR>f>6I=K{3>6QSl@{7$<}FRKLg9i?{qAB zbR>&s-9L&aqkoi7Hv7jslI*3ECCBVXmHv&@;|X0Ua0<|!r!bm@z9RZhu{PPePqC_6 zB(tYkf5hZ?!l{U@Sf!_=nt+okpA(h!k_j%yURY0!$I7lo^P=$@Pe&bL^Ma&1$kV`>}tOc>@Y$egHC_SC5TOT3}?`^WjF$U$EocmSp0@JTUSBkz)b|tjt z;bD2Acn)>IbIdL@e-5g8=p2j83Al)4AD1DQkcN64MVDVXx3|F80CX39pV;fLwc%}mZ``wRObLH=oqpL$&YM)Cj=Hr&EiYTA&Q@?+Y_-VUFZQ)sx1P-QM`m!fSxK^q zv?&EC#y49(!*rQxX;xBoB#P(`*_w!7!tjds;*Th_Tc^DpdYpGP^6Xl0@?+1p03||s z@syVHX8|*{TxroZ00q=iJ@LDmU)39doN`2^9g+*1J)kj+<^l_;7|V!qV+D`EC~_TX zTok$N@vwCSDYrU}0+l$u1qCth2o;qfBTY>q6?Cc#T0|}pIN#(Td_Hv;&~0mOLf9zp zJ+`$rZE2#JS_6y7CCUIo@2s;Ao^Nps8P6+o7g(P^5%rF1gN3CF`K+3v=ieYFV(s=5 z#R!!ekzMIv#Cn`Yo{arPqcCwasca+?znH(McH|*q19B$r@syWOEO^YMdI4?wFMips z6}ki*L@zM~QlO;iOQcRZc!^~@S{}>Zx;hD7)?`Y|{hM3Jia79ZXt9PjN)3ciyZ+_X z+Y_rTdl9}A4bi3=psl^7U4`)CQAP^W&=AGOa__^*V(BUifOTNYhN3J?HmR%IIV z8^3^662*!=b){_A!`J#^?kbeIc$HaZ!<(t2V>`XQO?m<7akC1kqP|9Diq1D%?e^Vo zHu`tA)1s&!;(9c5SO>*TX?lyX zVn-%~KRS+%thAm`m>qfx=4&2&lh?w8B_k*MG66AQ8=H^C>r6>ZUWd*(f1PC4UD=8C zH&}C}gFiUoTwpTFAETp(>TF8G`+@yof0r&B^$d2wO2YQuYhTu^$=-;jnYvMdSU9sc zLO6$Rv>t~gp3U&GF5atWUgup-A6b4?x$uYALRs=+Q&H58vL9zN!v9t#Lg^4%@U55_ z{<&S*^)_^oa2WO#m)hLcj3^9Ns^}|JH2o7($R#RolM3R9o3s&6Be5IK<+PZ(Ns9#e zXKzBO;55M^?a36Rp33ABsf-HKguVTC6dHQFbqM2{TekmZONg5FeM~RzQTkFZ0OC_N-UN`z>n-}L^B5 z9QInV8$GAotqiNf*EpzcC5}0+N6yt-d#v5Ezwa2TuRGB_@e@V7GjGnDvJF6&o6euG z&afP9^oCw&qdR-qW;x;1d=kzEB^3TcyviPs%ZO~B(ar3!J`}_9l0J!liAZ_9*w6BE zcIA8ZQ4=}zdIyKpOiu*d^5N)6J6klcN)hek3{}cQ|AhY*v})uQvo~}hDF9NmtpZmn zc2v~rpOiR(h=@IP3p(p+O+vpei}~#+pruLLbWP~3%~G9FZ*6v3TKH2iW-m+CbWR9+ za7a{BR^wVH-{25DfvKo2+b88GK(xAiH>8z zj&4_>xb!IJX>Jf|lQ{w|)&LuZk+id59l5SGEGL<8Xv^l%Mz-pxjYa3Mb(YvUY)$KZ zf0|5U!z1yS9lljhCUs`FXaQx97vvy&tYAF{`)hQy{goee?Jp>K6vN74{cYBraymow z{mTuVd_v6KMlGtEv^Nij0z4lw7WUa?WZb;Izj+GWRi_o~dv< z@*ecCmlG0mAPRS2n%pS9b%u9cDf^an;)y#fAvI+_*;`i}B*J8-cL)Ii#C4*8xHTF3 zpGL4hSBmt;dtnl}2KMax&`~N6dU&n2?oPJg@=2Zm3{SbV;PObG7_(|T7IsuJ>0`CI(MP?;x4t?+(n9Ld70Hvj@)2kx@4_C3tPZyK?vsNTD;zMdyUI-oACh;vhT2 zFx)$7EjMG36&(MD;%6Br$JD%y-64MJ&8hXkP;P^m`>?g4k=ljw)6WI?R7uC-)JcBg zBPN559|41IVRB0v-4BtO?s+*8MJ_R31DqxxNe~>kYi|S}(`v)vQ!ElN@KKXu_@gY# zR1!2~HL&eNMG&J32#W`~MERo@9j!HvOt}HXhpppgKgQ)YwWn|l!=cTguxu>dMB^W~)(iXN)_6_i5jq<-VfFe~t0z>=JqaYT z_krlteJ0UaB!TF59DI;y96e0tr6Dt*ncYpy?j{_MGz{C&dDaW0#_htCb&$LgY*y*u zYMyC!f6~fGoiw38#19P1kjbfR!5H z0+NoW;wfC#*?lJt#ZecnX%rWH!8%1mzhIIod;z2|c(@)JY!7n4qk7Y%=8#J))&Lvs z2XKTNga{z?LIsx)Rs%bcOBC-nDNYg)h6#j0JW3TrLL7j!G_XoQ{})YQ@QVN@aiCwS z918Z(a^b^;1QuE35>qw6SprgkEipAckQCtc0aU${e*>)m zK-$5HaRScO01pt5yn?FfxT`yF8W<=8*jY9y_9F=~M2TTKmO%_MQog&+mofpXHNYhT zBG{#mMMbfRP8S#vqMv*ci*$C**BvXSQ(uYDfW)fV?7rHbkj1 zO;~X7OpW6o@}HQaf)`ORT}{C%MKpXF%c!kihHsdx`hM*9)ZdGWVZ$#iq7Rv3C_DtB z@SP6f90+Q|9Yns2&}zaVid@Q9 zi3f9c3?V35B++k!!uYpMuBVa2vlI>y%5AzN{BR^$2v`Fb2^jc}2@HRSsw*>sGD*aJ z)4(EfiE<5ao`5JFpuVJ>6X|(7)Q+K0{oe&J@?Dc+7m}o%Lir177UyR-;7&{tuu=nD zAYgn1pzfHQSLs<5pji!l55Va6Oo|00F-7V)X?c&z_Cx|A#f+?ha|B$h0XFOhP+1lk zcx)g`DO9L&cYJmtmniNxDNYhlcOY&@qDErgF{CM03Fx0Ufx&qINfwlKkRJMmc&lg- zBsDOLTw=-v!gifSQUmo8>gFY@l(G`yrbn!QC7sIuMBxz>-R9gY(Hd$~26GZCy!s3rng}_hDDujPR zVntXwcXSYPciU5LLl%)slxu+V1VoS_Pli$*#B<5jea`<=03$y&DRv<#z~r{mLG`RW zf`exwty!HSV5J7QK)?+&ecX>a~Q|+ zjaOY*_2($e|Af_uB^B3TC6R+CYUYR8BjhS5d%)@?4++g<@D=IZde=j;^a~Ub{3Uxx z?3;fH{Y#SsPT0#h9sp(ICevzf94S3KC&uL-MNCcrM4tHKWfYk?-EyIZi5>`;c&Z@H zd-+Kau0Cl>a0y9)bUxP2iVv6V&|JaAY?p^(h=?6|iq=JRp32!L6`e17jOelAuTXON zS7yocND9z|tanN`W6ZKgqfI(PP_ppLJ^|S9Jc`WTyYu)EChy(EkwGDQie;CwQYtaZ)W;?DDTs zO~W&|`q}~*9M%7(=KqZ@8&wGY1`4YQt^m5s09P5T7dwB0ow`k5bmMWrP)2k z|7p09c-cJvTdU?|Iq^@PQ{$8%s*V)W+PW<(zk{9rjOGKZH9mtnIyVx@MLHbo7^HM= z(&?;r^cf462Jn2(Zh$=t*0dS~yebBzjEFwV1+!FE?837UivfA;_tt?L{|3&343mqO z1l&y~Un1=s0ZY5~PvsBb__-R6pQBbmz}NF6Ytb%8pkf=5lUh+Lvv1Dq$|U_O~(K8Y|q z(sbhuJra;)CH#N1p4Q`h;(3%3dR{t0`<_RP*0wKuPq_-!mF5io>TVpDBf7?dN^gfZ zR1$~{VOqe{5R;etbi2YCUj&i4MYE0vC}}$GIqG;KMV$ui?>0l=Px!g>PbQ)tNjMKf zRq27Lt3e!yrlnFQV6_IgL_pb72~77$sDr9_R6v;De+Dr7XX_yP8E#&29jAvav-uuiOrcEm4w_L12z z9;AA8tx*48!C&OBrbN1sM2u`V3xEwXfG9~ew0I0p{gw2^!1BQIRo9V{3Iv?LT4R!woN5V_M@i{@t>h*ow#6glbKzHhpqt@bIod>yeCD{JY6Qa*5(UOyDE|Arziq(DYhfC`if(eB0H3II2;45f@g4QA7Xu zUm`KSWR~59B(}ENn&kA{g6Y|bp>b5Wn0g6L)BP`5(_-yOYmVQDNr(-9`l|=X@ZnP6 z-^J9jAzXWQnf7+*P`YH(y{1gI2*&8*3fK%Bl2J|D4)LO}2aDaq4@AqEwP)CwNM$Y_ z9dZKU17_S477x)DxO0z;2w0wN;#SL3djK^Shc}h=R1Eq}-?uo7ZRR0Yu@^laC?AhG zyUrsC@ir0*N5Kg4<9;sruDhDw3t+@+0=tkDfP+YCWE0hslmQ$-izxzDYJdv_q^?N5 zAx(-8ll3?Qds&2h07iW##R4Tw`#dz(kDtI1P2;8k+5ackc(#gzYdrH?*yN@}s2%J$ zG_zZUp4!-yqbJ0<)UGQjwlps0USZNa@Cpy2xsLE~SUflWbGUf&y?^-esy>Rw4>x!a zCG3QFiw2Jq;w_^?3OxxCI@06rtnL^hPj0fHZW$sANCqc7w^d|c=`evRh_P3q$q&BL zvuJF0RbJ((u_tQo1!8GT91USycC^QaC!QTG^)D_`J{ZG0;-o-RIOE6;z1s6nk5Hhg zyVjyz(X7q5mXD3(W@kJ$Z)tUG1TnSNvq?O$*0W!{VY~O0=s+)f7gA56o0`M#NCHKO z1Ab4?hh2l@%%fSq9E`F(zIAwegpNgfGz+U)Ms44HtfwMpNt%bK|M7g})Ub}@1HY4B zOHWxEGdSqpt|-dKp;uOqbGd})2uYapFf~e}!` zBN{#Xshi+jTE72f3Z$RZ3Xc_y%*-i{o|rfZ{Dw|4h~g##_I|<*^%7gZdZS2AYAVtd zeDt3TY~@C&JNKXLDPP0&K#UB_9e;H|n!KW_#xSR&x!B(2tjGx~oR>4W%M{6u1PU_d z{-5jc1E-+dv^cjxiS|=H^KXJSkwQeLp;I3tYR0Issj${o^FLNPdZvr*7>dQ+eTC3z zsAcptr$tFc7LY{arYAE#3VLeGGh|cS%_lMqEp^6S+ij zy-9JBfLNbM4=zDcNn*2~q6(b06jcKH112yS01$3SY$4oj-9paG}#pf*nZWxnd~o8e78&ELn5fL9imm2{?DUXRou^aBhYZ z#SLa@lN(T)x@4)j*@;eQmfPrVy^%}!U*qAE375Ubv!sJ`s6!(1aUdo-&oImFKLh3J zB?fIK@`aUD$ArE)Sd@`VRBM1s1Z4k5?@+pr#wR;@_(dNh6p_~gn0>9M@kpm5CrS@I z{0Frdz|bk4$z68GDXi)2gJ*gQ+5j96dUpGXaa>@-!-M{oGN}`eq6*XU9@lMP0eN;! zh0X?F(geVd+i^9lY&*QT%_YjnC8{nEoGc-!flifE5E$*18Y|vsSE*?9l<+yA11UAP zsK|t7M7MF&WlP%@XUyTi2Br-A99DUWG`zxxT`$8Gfxi=B7m;(#igcX|0#XSRl6;KZ zDtI1r7CI|p3c2jcxgHL(cg0%W2(gBR606vHo@Yv||BFX2y%TAi*A|QCX@U?y!zK?d zxj+s@Qcgjc$Sj@IaJH$tm zhPu>MJl5(lJxw^;hwI5{&C3;a-dJP9R+nnb&bGmNU=P9EX3t*3tjM;LSwTi_-FcNJ zjHxgtj2FY6Z=9RMqR}Z*63DZ!o>V&#Qavm|`RvLT4~Lc`yyfsiITNo(R|>t}L+3o~ z%Y9UUDieMKuE|!+wDm<{}puhdx#|$#Km_3shsFZ}V5J7QK)?}D00C}++(@4c)&kQS z7@~v`T zM*g8QEiX^J5wOr3jTF&=B;{GgrUJDRd6wIph%8A_j1zFq1%loIB+>4{`b#|xdMhv5 z;n{ckat_Ca^U2}FAXkokny3|rwcYEWC)sp_?G>hy6xf>o~I2< zwT?4l@k$gOxXR=yd=-k`yro6%+P5}uMhFOa+{~moi48SJS1Lmk9BOMHwL|4|LhL^B+XsU1KU>}^E5O70=KTg6cWA0 z!{>ruzJ?@&vA58I^DUln$DqP!!eS#C7sYGMYENG439ic~;Tm#OK`KeF^lm?Pjjw^~ zVVD4`4)lW5#Py(b!}T7Dp5pV#1zZ7&voVpZv&&wnyCFI51rwHk;vC9 z$TH;rsfVG7_$N`h$*kDIO`gM#H8V;y-V6u9%{O}}D4a~s-uk_ZRxrI2QOy^o)y62Q z7njB=t_*Yn#kj)SoEK5#65}oq6`Dp;gLL6@Xo8HT^FkovKn&K_7RPk(*j7BalRQRBiy0 zGW`>g9ssjFiXsWq9_ztkzQ!(lBH?+aIZg_RrOmnx#mOT$snL2X$P|7T)n2nEOTAzS zUfWn&?SaH|BUyEYJG%%aLw&?hp9vg85;hfLY%ihQ?Fm%?p55*I3UW>Ko4Ce);Lvdg zN1!H|Y4{VJCnAP_D}_mh=n8^811)s{`Yz* z85~GT4aKEhhbO0{>n^cV@eJ;*r*4LeToB;kKDt-fitKjKoZ9Zt1ixYyNw_s^C<8h$ z{N>7q-g8Lc8iBKiQcwZD^m1C8);AA$_VCyk8c6J@t8e&j91%#H#KLJ18%Sc@6QiIq zfW@`k0qIRS#Oz`kP*0oxE-t8jh!G zBoGbyC;U4giO3F$W;q+mBzIXje7RU*#wcP%rE|qNHOD>ZXIJZju>p=zs;;g@HS7-pOkTj zs*Ikb2n~Bq5JR_lUL&Sza?c`n0IN#MIWPhzkL>OcEBcDV>cl%BtI#`4Dji4)NFuU7 zq+w4w6FcFkLB#kwJTLLIEbe`$=NvKrPF}N#Bi`kitKGNVPHQKnMG=dxZaAZ`^ghJ} zN?UxFC-{&bQ3~AIV1@L@rUT0nWQX-XSmG;xUcXK>zL3$8I+%b|DGQ5}eUtbtFTk)uX;^PD~N7QUhF| zr2oC$^U4z)d1G}6zBRGXdypae9+OxBNw{vEizmfQ`SlwEsgdU1<9XUSH2K9lJQvw7 z-r+ggIv4x3FoLKV`FvgP(4hK?3G6LOBRutW=;Ndayw9W?ejn({^Z5jWdl`i(&lS(8 zgtv?DgHq%9z}X@bE-MSn^FpZ)D=2*lP`yu5 zz~YHbe9+U_>9i2j?}mZrkf$-n@6y-S9UFxxWiCW+%1iM#U<%9Zpq%;^S`qyqT6!Es zyOC(qNW#pYA5o5k(UAce0!9x`D~iPrdR{Un;9qPtEl5n%jd!Eqj=QBZbLZVWpYjTy6r-)bt7m_7 zxF>V`UeK7k*Q9X(Nde`-*sKooG~{#{f*>ePn#TKcHxTr==#)fy1$NJKskM#Jh7 zV6pq-9w%yuO`U-uY>xA49p6+NfWk}R=6hy4;qEhM?}Id^?sEu3N@5mC0lp=lx*p=( zVfb<9fd@eA<%!+Eg?5{`4kQJLh?5;*51OhL|2P5XYJdj_NTlGxxK(v<+{Goq8W@-Y zuye|!*iT85Q@pWlEX>__MG1za#y=Rd*gW*+}&RroQs$3*s%X3=Ax1WyPo zQlkX7^uk{vqp4JIF11nRlO7c?7W%a3dB>(lk#Xc75TVbQMRt4!qoVK`!^oNctVeyd zp`Rnk>YBz#<~ z#e5?6dcO8{R0K?O=onwf2c4glzH54todVy^JKXN$pB>Me%$pdHc0p1eRzT5Wyo?&m zm1Pa;9~51904?64uI9se+a~3dLX=apdz>WnC5SHiB~v;DBn7rehh)oU+&m`ZDO;P` zv1O(kXpVr30E+RGJ#ar6d}4C>&qeds|CAMgFw!_KrqO6XtVw$^4UZJqeu zL!Ksa=poN!kXqd_MaXZDs}^AC$RNBNVrS#MK^;Icr*8X+v2~uEVU&BfbcgNyD_tD~+udRyBfjUq; zllpPrxOJVG++O@T`nfAc|2H8> zBw=!3Y6b>Tjpk;{6agzWzy$)*-ULZxU<3z=q}v1ce5-r>z^@2>2f*leOo|00spC(y zCP7T8YD;?4b(|yMVhyn2y8z;vK-CKP{-SOX_al6w6S+k3yC%g+0&*kfV)(dIS}shu zAk+IwK>znlVDNhY7Lw{C6dPh&)_ zwpNG&Z9F-;O)quTe$DE4UDOm6RY6hi%3uLWffgd#3@y#(WHT;^WOYrEto%=e9sw}= zhzTrE()1&q4a#JE>=9!h$^WRw7Kg-|qc%d_%8`M;ai;?H?tj5$+)1(cs7a#Xha^}6 zN-a%X>Q~KMCvu764^7}C0Vy{f#KzG!`N3U&alT>$MO#I#Qgnzv@O8M>mlY2_hLW1q zJx=YRaFdiw3*ypRH)$*Tj(2-^`qo&!Quj6Hzfu+m)1A*hC+G5 zu`3mFw%4;&CVm3L4d0kk!Du)C#PgCo*dqt?cAN*Hvgz*t?|E-mrw^PCgUOPA)P!YL zs6Fm}D$E2Tn))fGt;$c;q6OzqU&iGHrLp)k$RO~z*$m;wAv`eBjJ+)GS@^1#3g=T- zcc8MOh+LxV0zq~jN$a+>hDq@JJv5ex{GYw{=N=A8rs=JLqt13e;pwoSf5Hunu%~~4 z`R_{l2(dFIvcqtD-f@!Yu>(=yqN-7J6K)Uep^>U#F(e95%({&ie@XRwvZj7dQa8h$ zdAO8I?vT@Sa*!_q(7+;ciE<5ao`BRn6HqSdNC2+U86g*wq=>rO{-^%WFv;+*P>{OL z6@igz*kb#aE=W-vAfyMmaOj0iTl?Uzq!q;;#qvSVPQyZvVc$0)B2}}JT~%~}v8uFO z$Pct;t!j;MdmCN-K}Si>5(j_nDWfDGbzXb?zaf6_UVKh)?{7RUw2pk{H=c#lVaj5+ ziH`1IrXmeS1re8MgdQBD%!|dRP0|g&MeR(C^R)mf#c5c(^S2NaB4lt86TA9$|4uJY z$*-Kkg(CxYBwV~_s!a*s+4(>{|?(-?LDcZkX#%$hFzfqIg}VT(*!JX}UHq3(90 zdHFezjy`7s3rM1#1dQ5c%A*l6mr!AlEYV%D=bpoc60Pilt0N{?zpFlj;ru_K75Jk` zEBr^$3N@>{4)MV@d}EMfD(KN^4pIE0=PY~gA3ge@ls&iT5ze~E9{;oZBBC#Np17J? zAKjigroVc7R4J_**`?%nO{jLXS4aMDwHh@dX|jI>?^Ay@d7nj+6fjZ1=?E4!KfC8? zCjJIo=x@dj1h4qfQ4xLi9IuRJQ1we&R~;+sf02rB3Gr>GbUS2wNQDMskT|oRD8Gof zl7laLzHu!SErsN9>&X6+=Dj>@^I9GgO=9jP_taPwKl+N z;mP3CAZWu)X`C9A>f|NQk2k4m;j=UHJ{J0mp&%n=YQ}sw{IVGwjHqd-Ww62s-fUI7 zNw`jihK18RCsv@7LMuk}LH*Sf#!S~C2xaV$+*sIu$U`?%9)A@!sCkN{zuGEMrxi`X z)91kC2NNl$I?c);=R08#%$F-(<&=`*UHwG>aM9@T!gK2J^3}t4dc2NLiWC$DJfv_Q z!rLfj7plERiaALtEJoZY|Yxb31J~rX{ zNe;ZqyG?95%KM95Z}PPcV9v!_jlaC;s3MFc+z5d*)%T166{GwjbhJwbQaKt@p*fkp zD`ZEev5_Rd8ae)IZa4d}S9{&FP~(2@x8=wN5qWr={>uBl;gccaxz(2qP>!@H9>Zjb z9q8uCW4wGtW1TC+=8i=hFCObMxhxuvLnA1^3i&(m%^4y^kL^5CsZ7y%oENvx9_Q7O zqISm#-u)%xtSO-Ek9OrE;HFTdP?q26LgFpuoIFExlRIPB_S5jP#tnE-Es=-R2 zc#`+Ni_yq1rQ-GNU$_l1*-K+p9v9Vd>c%w`ohO5-;>o)9sMjQt8d%{=o&1uQK3V+O zX+HX7u~>VGw^|!sP0=kAr|J@DAf5{OIleQZP1o*lW8qm3t|)Se;ZwbSF?Fi9!5v}K zjHaVT1i^)CP=l;TviOdxMlTXNaGFUrd>WC3m8iUSSoGmpPV>Xg*b&9kyifDEJ#52k z-+FJ&L0wwtXT*5Gq%j=;4RX)0D}ikf{%|0%>W2O=B9{o9ZUV!n14y~xN5!tLbetfN z7*~l8xW1hta*1*caGrq3NL~kt=jT;UA^!#dBO6SLT}Yxc0|3g*XbDW^vKTGLDFRk% zfC~&HTF^Pz;8Y@%F9hW7A9{`VsWp9$3KHAS@T$W))F-8BgeOPr&bB2%sR*cKEY3*Z zvNj>SvQo0DDOoh|Gi8FxtyC+#-4tim!qp`I6rhQvYw0PftQD{D=XYT24JtK8J*IIMViWR=5GLBC@`zmwGmZ= z%|eaV14DprFW~1)I_-|QDdZBB8sGu}`{em-*c!BPFa5TNmT=>)LgxV(J zxEDZD+K!kx-US?>4JY+a%n@+02H3C(K&omMQvmS@*`b?dSet8LCvxG-2PVZy0%l>C zxz;Iym=PUBAyXPyC7?fK0)rs{GdKpq;-NiwI!&*_Ni{HwTw+$aG@rLAlgZEGio!8h8CEG<3*?}R2gSSEyc@(j+P&w9z3pE2E2oI>ltT@F z^@e?&o0|C?4bCeVwC&k2S$=fDLE4|I?_oel>iIN2`K!V9&F6bNtlGF1>eq5D62r>I ziLiq!ERl2PlgjJ8!HEkTy3}@!7ohbwfOBegR=qSI5F9UBv{B>|;}Xb{Mabj@-j~jx zOH7st!2>YeJ-9|rgs4R~gesfl4?v7LS4Jg#V z)$5*Hg?lznaX~odf)y%#Unm>#evfQKjDqd;KLmmeNZiTYd66lR{)-?H5(!S-$~B>y zSSUePs*GHA^&)8@gV$}T#5u#glElItv#VsR|{=yxobaJPdTQkmQc zFMd_+mPO~KkZ$o(Q!JB6I>sT0MU;FLu^)Jk6Hj02J;U~2CWV2!i%#wE8h00kJ0MU} z2)J~JgDP6^B?-QE7Z(vpl29i_8{zPPPFfw7&8tbneT& zjmJ2m!^XOdy_k96VedZ+YQ#8*TmkagE9A0j?-hF93!+ zUiTwfbDdtjP)4g`oi3e40|h4#qGq8?fiyW$zS=Bw{%Y0%3^h9>C#d@2qK|7pI&zJ% zCUjQHHL*Q7XZaSeJ@poo!Yq;kA?FJ~;ZPg=J=_(-;r0+wAaPAx>uncXul1JAbFBkI zbX3gg$&`(U{ftSwfyzbRSdBm5>tBY8pi+5fRHD10R z3l@C8%6{>BV_`Pih2{u?=J;y(Z;#=L~mc`^-S@%d3CO5Xf<;vKwaH_~9{BLuCxRB>pK7amy)<3i=pp0#`UvrtaAGe1^Yr%Pm5UG8F~?m8i@AvRFWpw04tey1fr}7J>2Y zkwJAM2LVGd0HZMzSU^%hbJOFvF2SSmZCo)&z{MJ1LpM>BoPiQdu7sqC!_MwB(}`U8 z#)L_6l7Mo>NimLzK4O%fKu|hZNrcsI?{n@a)a|uBUJf{reIwybV`fMr8f-9Gw{JkV zSV|#?Bq%{8OyBX^ET={ph*&s1~ z=4qa7CgWtEKMit`v?=p0BmsgkuAQ{FSdDInLRpTwx2Mu@7}5G8*vtQZuH)fWzmo{* zpQvOoXJk!MjaiVw6<*SB*|w!^^JaOE3q3ldL^SJ#cOzRfO~6$SZxq*!pU}9nrt~K1 zQ6Juc+C_JG8*LnYlm0cbRc3Q~^+Zz+#W&%kr8Ifdd?7gb@};P#ENTV2bI@6QmGjLD4(1tbjx`Vp1dZoK5S>i|8Gy$!rg-DXy57D)lhuDrYSC@(KS+_#d&^29qx81FD~9Y_i| zhaG@HfVZ;DP=bR)ggXhN26%vh#3+JW)JGra+!L#34Gg>!z|MD?6#J2cSbU{as5`{) z#&)D3{xSipHNYhTQrD3^5i+DmZ&=<)a@`q`cLA7vmq~F9N$}I~l#q?(7(|TI87=ox z%?ff&>@;zWJAq3MGC3$&%nMTA4wH|Esz?JtM0a{0G|uzYTsp&Y5TPPiiWX_TKnVOJ zk2OU(@bz_jie9?81f2q$)m6!u{c)Zv^lp>6j(3AO>L&ad4AMq&DDbP6|2T4qxfe6%zsT zg9rfEz{q<5%)ZB@IEEw@@$RwyWN^zi5hhkJ9{S#`NOpieic(=V5Bl8SGPyp<^8GJzC{&a zzevEq`@Qr{FJrvay8`0_)C!2QP*Eyje6y1yd1xn3N(CY>e!#oQ zwm;z7Hul(mc=_uKWa!va<6id$+43&$PRBA4{U7q)%7+{r4>JW;35G76Ane{ z2H^>>`j(BjN?_Sg6ox(tZH5^Qjl%k5zwnlip*BX8nw)p=H^!&koh2YC4TRN5Z)TEi zI#fy@oVW{^@+7#ZPC8sr>n|Y*=f#zENaf05MNj(FpdI-zCQ2h}dui*ci~4XA!bec{ z)JJ63ec~hDKd6sC(6JGcp*%h!pH@X4Bnpn8N2AI32LZM7#)J0SlBV7E%SQ1 z11AGN1x(~q(&@1CQ(n56jX#*}j}62yIq=0?IQ^`SowG!oh&n?in>!X32^g3*M9fv9F=v$? zbyWX}pM&bZ`Exva$Z;ZWtVOMmt8l3~4Q zlKaQdSt4{lOyzvS z3v>%7STbfSdDAZaN?&BeZiZZ+;Ow_<+_^8KjTXP`R0-*#;UP4x+=*f}A!%Wi{#O|vQokVN-pLg^@nG`_+Jk23A2yR&IvAAp_vOkh8foYf1$+!TacnhpfYf1*sl zY7KCSfE1D|X@Ff=F3u-BG%zv;V0O-=IEEw!O5r*8waIccu!39@-!gHH-vW*qLrdbq z6}HN9^nDg^pm9;;LOj0-oF<^uXE>+eY(@+Y;i7JMQ`A4PNWj3uCNTUkQOwbXGz@K4 zh}aibp=KIbL@vbho4|Pj(ndCg;89DmT=3-^de%Vyw*icNTLaOtyO30>WbZg7@y|Ru zf$sp=`5gu15z+r0?^b*7cicb^(f>U!efKUK8_dP9eWGu5XCGE*Ui&L(YnYY=2~nQ+ zx*zg{BNFH1ppqn>+-#evdDT2~ME+eYn*R>!M=liHWYT6g0d+i*7_ak^8 zqfA#n@&nW&`vVg=h9sUyvN4=+)kyi~n3tmR1MdsR^R7P4t@x*k#3uNoD6-*)(j?mY zLoWrQ^0W&^vp6-|JMkk)j%0>IU_XMP;$EpHZhZ`M$F@Iu*Wg>FtVQvG7hJBundznh zUT~U96(9V-7r7!8vkqMq)FG?S63g8uytBmxP9^E73T+FyHqx_O5moPAL<~R9k5Lu> zPq-@fWj`@gUE|NZHMg(#qmwCBt|GE%r(bTDyGI!Vk5iv{+$*D1k4Cu6iVR^~RIVZW z=e%=@l3>gm{l$&5>Nw!tX74^=_?4r-^zJb%7JQxohZ@yP)H6g~gU4$h4wbl5Md(Rz z5`EI>Yq*t;l!(3dVrz}`zt25Y(?17>5T7F=ztVE1q4F!*!mA+UmwWX5e|c{;TbmB? z+MNg8_ysXtt;s=`cBJgkuZJL)`Um8De?k?XP0Ix5qHJ?u#j@Hu;qUTDhH#RH z>>SNcWdU=1*%b(F(>hGQXrTW&03**iKvGCu&yiLjhw}9Q zc)!?;%CZRQ=4+{hc<(ox9IX?UfQyY&F$7&Z<$;cv{3962lHWv?Lq03#Q8Q9SF5!RP z1!6<$c@BYu%WgQ9Li@hN3PbJ~!rdUl>leMx$z31u`NuJhI2PoKs8gsIF3eImuwc}PWqY(a=WVEKY}=XE}H)wrJar17Av2jt6o zd|<%id zPsS{+@#%xP@I(5K0PV;TK8mujZ#}|ynI*p5;M>5n5eb^kiqNsO*-j`}A=)G6^+U?!1^tr*y(W89ocpkpKEL$0Wbs&5l zlZUowr;5l9nXVJU*T{aCA)cC7W?YUR`+)IetakIpk;)u0A zC-S&~Y`3AFOs_q@*2mF^jyd{}-*=HXgUw%b*1rX@nrNjb=w2 zLlVt}R6d5V3#1ectRUCKNhYrGB;c|mWUunn3BM$wU0A^nyL$~$N~vfPqs1>^#+^*pH+@w~p7%Asjr1GikC36h*{X zAeS{F?s?Yp2YEK2a+;6NbgW(PtD2SK;Kzx8qCmaDZVdR&kejp4ml@=Qdgtl7ACcBX z;Aj?2>@>IgD%CG{tQ9-30eXZ@hU{y62Wza?#CAj>i0Bz+?Fwh0b~v@|-m6OSsp?hB za}K%0B7l0kjSl+L1>Eq4zQDGC^lv#=xNSSrSF_g24Gkx3|5!~wzvjG zU{;Cap^{r2P1S zI(H8=n%d*Q)PtMT&jYRCCZ1Nr&6~7R z2a>26;QE0N5z>)G$X5p^#tAqlfy5+gc_8F_iF>NQ*+(CogMS18)`u-MQ5`Yag5lM! zFG+u~#n;Dx(IL95R{Jts)m?1!Z4*zlt+EgBK~!9W%Z?&?%=PicNDi?%;2W$mUv_n~ zQqFcb?7LNOaxHA}J*LJJ@@-EJ?tmVaK4%^Qa_~N-tl@PR_~uG$Z_^=yI1Pcj5aqgs zuBA!$>7{^iU*3fz-3yg;i5t7)LNH_aB=)?48;$oB8n7D+2YV`Jhqn6M7{Wrtx39GK z`ZZT#D@`8r&bc>^)w`LR&ouC|CPomNQK(n(i*CT|Mc{4fBA*+OiEDm_Fp~@otPaTh zwvN=%=<3Bl`!6y3P4E)*n>O6lC5>#13Y?OZ7E7}XBt`v2_7bQA`x0M8Jb$h4h|6W) zPvX>(Y^;@)I=9@w%|to44mnJ}J#v&_+CtSdOLPAQmKOibWU1keU`e(Sm5{=B*`z4w zO#?fTOBCN|0w)Owl7qDCOmqo=JBn*>L8%hZf2j!!UaAHU0)$}ZLn%o#y-8MC2$y1{ zkaNh3&96f8fKG>>?m0;A7)a%+HR@?8OdPzclvj@a4Wk zP8YYcSNhgDSAN@bZ}zR#FAZ1w&Lm$oib21vYgfe*0|*q7Q74$CboWjp%GQ;7^cu)u z{2DC-H1RZ&tTcC`S`V12q}X(=ul93&uvmJN%0o}j>XGWG?hc`$6S~f)j$fYrw!0tx zYw+u4w?qbzE?ke^weNc0B4p_}27BR5&WO1iG>g!22X2t<>jWecB^;rZZLK>-pbK^D z>~es_Lw^^B@5@bitZ>BCjZjrD-pF&k+%CkX0huX@0on@3s)Us|Ys$H|`sh@STrz~- z=1ld)n|u@+k5B$$YpZVKu(cqfZ+CbD&!X^lR7wsg26BtZ&XU1R4=f=Z5q~?n3M;tU z<^H;;&pfQkTSy24H3=+4K|r72!y-@b2Vj(FsfA*YS~O+?3rGrJ*Kkm70x(a*2+wv- zx-x6_Tnv^aAF`+)5Qz4zcGHN9%O%{_c#Tm)ap!{*Jtp189?(^WC4S_sEg46JH_0#x zjUtyA@A2udiw0~2C({CiLOOVq(*}t%B>VM7q|sY&NomcZ6piNZ zN0E_!S>(?Cni?U_G&3k7NnIr{+m(dL!W;B34|siJv?U^|*md*7ExubZxY6CPRH@s4 z;@}mAzjW*1u4*Y7ss%t=GR5s!>-sOo0a-Z{qjF*{h0%>K9jQA>)(`mTc6IEk;X^ca zNy+a`k)6xB#C;`CkM1>d1CYbwfT}8W2)iMTvF4fpp$x{=otc_mN}G9cJCc=#s38d) z&|yjJ*`aMBTDu`XJ|-Hx(JAf^U=<|P>j`|88j*Yc+LJMxf7=&g{5>$cdl zZ^-8;R-IdPW5pO81@=lcI%Pr^h&DfiE`o^K{SScP!Q)?c< zG%@)R1Gk+QifHGp@Al1}jou;4f+#2|(K+93dXf|Li}2s>N)O)6+kL?!;8TnB#pDJT z55dFM`XonC5XJXEM&Yo;veIJTlc%N+B zv+ndA*g`DPm(8V}GDto$DL{^;#XJ2%z8p%W-{|Bo81JzIW76QPx9^7IH+O+j_AaJm z@4d@c)fUG5`+fW9#jt4if6({SG+*MXMmODTIGA@XaUIOF5e3g6Ya49zI)9~fNkK~X zq=e~qP?mlSS7d4<1cAFa%%CM){SPqczuS~>@NQpl9lpaugGNagwCDqlBct?{i8bV9 zb+0+nMHR~ULn`y`NrjIVIq zr;J~b-R=A0HMom2-A5wCVHaN858@f26LrNI$EOBqQNWbq@Fbe=nrL(iM8~I0Zl{qH zfHm%5`|#aKsSpvrrGbkC41B@_hCcydPa>aZ?;t`Qu)#Qxk?RE4ZC6At1g)9Cc>k(fI}a$ zlE=c)1SiABWxZZdj6xxI18#N^$1_=8Rn50PG z(9Q%)5EoBEEN;+7bQ-l8pEg`$(5J}2A0CnJjfKzozIi#qe4O6ZgU^D&tS9E3f5Z?? z58Y~ek#v{y4T_X{pgi37KvkGgVVtM0KVpa-*HFtK+`qoNBTN4I%%}3L!)@c=f!YG;ND;P8pXc* zeJ6?P{YHDxxTZ-A{<<%4f2(t~6}N+!{~~(Q+P%KT5N$Qh_xblVKG6_j`SPFWL@rVM zl1XurfY|ep%9tC+g==7yfc_a{r>CcM&%}&-$ZpU22i>Wz>mlE&NQ`)V2v^bCCgFY? zg!xVyZWOFAMq^S>WAfL8%g80FHNYhTqN=#_AA?&pD!*X!O9Lab0A^=RiepHkD=e4_ zeM*4k%Y7oJU8bUfToYe0agARA4!xKbfU#~??0AOlPP3UN7)35IUIUyaARJTjj((~}*7T}X;&8rFnidndt`IUH;l0h~_&7n#)jpQ4CZ z;~2L8zoOa11(5KIPJK^^o2{ps`5sPPaxMMZ{Y~O6Y4X3LCvFI~t5Gg>Yi?H}|LD@= zVPmEqH;v)ic6?AM+6jde-UJuaH0^mMT1AXlXp;#z9Jp-*W21(eJh+e^W~bR(B8CxA0dTC7FSVgkIa zNasnRP72+t=YNb7_=cyVr`(%zzir6j(eMt(p2tlbsqA|I`RLRYLzv0&`7Hf3Xy%{B z$Z`5i3WqA>@%uPdpm}PZLO9cPkrxuL~TazM%(-bplh1AuzKT zWm?RcU=)_?U_|Lr1iiSUcLdH8&dGw}MI}*=>Hmpl6Ya&*4nzSKOIFsMOBZE1S@q)` zxAYvSPe13Vqr<9m&sn)!w>%$J6SE8#Bf^;jcPaqrPY?;9NZtX@cT}}XJ z2(;xVmLn=zoOVSozYsltdH+^7)Qzc$9E!VszN%xyP)etM5!N&F3y>3O*oe?ra?SqE z3j2DNkV{V|fO7HpNO|HUk*C#%5vJUjf+t zs}MMjB)F2t%K^5?p0hZG;2kqw66XnAP5_&K4PXgMH5p%UGHIGsxD>NT9=Y_yuS1Hb z3FInAqkel9ms1nI#1!iUrd|wznHK>h5wtU*WkNWRn3GG$rKc0XIRec{gNEHC(OQs? zpK4bw0GGWG66`_}^bVdHA&7EsdfAUgnZTzmAb4+raTb}}{F~^TSo(!2>%WN}O3YR~ zd4za2{o9b_+;2fr=x_{rpd-PsVCRuJ>qu5!VpU%Xaa~B_4i(HBz9Tj3nZxNaf%6IA zB7uAYVl1eH3B2~g1Jla@=9eQzp1FMT>B--%7UvMY$gVg&jAWGHEnjNs_b7Gx_hCEc zkd&sVY`AKW=W=v9J0lJbS9zK3e>uc;At{YOj?5?!8Y!ckM8D}Wf&ct+boF2OXa_K* zU}EzhqVs55V0yjd|DuJ&)Wl4(zE}`b0RO;rQpq0NT=*uX|A@l!e+;WuM3Rm2K-VZz zBhHon5~M>9oF%ZH05%8=kNT9iT?0KZcM-tSMQr!*qH$sM>q;ZRO*E+HX(X>_*s(hQ zimfU$R*SE=t!3f=qsQGz9zxHWA}qQWFYDlU$}CbRWCbXgk#p|B;8)~N*dSgFJEY}R zw2SSaM%*0xc+4?_?%UOkT)Lb9&Nv|BPaG43bO+Z2rz67+0DQ^bmYgp{U=tN{ODi4L2Wa^Dt19^laKtyAX0>Vr>hs&tJo-c?#=44!lgTlcwPx% zEQmc%dw6yWe;+b@1Iy^k&m6tuhXxV$MNa0Dm!>viTmdxeE*v-i7Uc}rk)W5~su-#D z$NzT4RxGO3{cls=X|isALvf-tF>^gFFBs+-16C2UXvl~OETwqdTqcCN4$2)?$F1=Ho(d(~K zS8p4X0Y3&i3h!BXjn3lJzd>BNsurkVq>U?dKJ@J;OR3;izwvJL&TbbX?!YFsApRdv zxR^HZcWl~_9FY}pA;Mww4peh#C06mlb?a*16&Q%pW{_(21_Wm}s~ItvhI>fcAXs|a zny$DjUo$px;v61=w-SiO!YQ;0w~iSFY&jPOyjw7V>RXhU(Y=0!ny(dh?abmXVyk#b z@4Hsb>;1Q>cWsBTW9cBmi0QqRHT++|&sYJbxbJmCh@92&_p0r@V??-$@PLgP>bdJM zx=Yt7u_(U&dbOOKnumv>tR&e(kVc^~k-dzcq06)l#GPygWt1|GB8#0u62h(GRlN~_ z?MKs7$RPEv)-uYzlrX2kTGA*5nRH_-*n0mBinsOdo{w%(5x3`tkYMvR5QNeW4;M@? zL439NM|A zw>5p#WayR661PCGDRRW!Z%zZ!W@l07$iB126Z~SHBbq*n^}*#VI&?l8wr>$hJQiRw z7Yj$N#e;hV$-?=g(>npo?+k%OB&7#&6ByHl^2^dSFaT!>tS5jC0*B>Yns9(TEVdU$ zvAQkS%CT<^DNZ5D-b4uI#BsPqHbsm$rdiQ7XubSVjUh*f&@eY-Evx$4OkxFM=YXq9@RGBNW;NvfF#a#VX z?G5WZy8J#BdaRZ(1UmKp7!LP9??)}&Ju&WIPYhEIIbi~S`fe^Em!3`l=Lp2W4jmsu zNFc)r42^~@Y0%%IRBi$;dy_)Y!kg9G^+#?}??@ZfJnZhNb~BQ^eDTD}1kD2!D=ik0 zgf=37frjml9uw|}*)M%Ffccw4U=c~6$k0J{LIXl_)IWKOvjo-?zy^ViYj|ZSav4N2 zcA^L7J^*0p1D+xVbP7q$TTCdvt+-(O7cWBU;$Ex?kL^_t!P*N|hvSDe#TzKf3$kS( zmN+hGDc`{g9STa$O;36{2hz2iCymLlge2JNV&k+&Cg~r`ciOHT zD6f~L7P0K^z{wHyt9)2ponqseUKs6@w>2W`2KFDr`_;ehu!}UHeU`WSdg0%gwnhAr zGF)8D9ZzlPNQR#qTmh70eP@K->mG-R>R40rk?iiUs23^)BzZddVx z#{=MdeL&Hm5+y*=UXw|Xj^#tRoM&kF*&ytwAolD*uy5(0kxF9rnfe%(<<=&7n0WqU zs*zO53}IQ)%YWxP5FOI|_uv6c3_K!<^%8XNnV4mHt>Emyfn6E7 z^n3t>rUOaMk_-AXR!9x_GvdB(MQ@hIUJ$DnOd9$}hpbf2Q%(Ai>O%&u1AOsbVN<2#MGTVgz@D%@NkbZ7e#)o%e@%u^S$bvdG~Cf!{Rjb7@YUZ490J3L>F>7 z-RMd_ZVY%!!mKc&AWCkngadS{5ADzOg&lVgNpRVSY&fxb0$4ox+42p1@)B4}0GB*a zL>n^;g&ZUu0;RFpB97g!Zz7uSCztexl{$^2^v*2e%!xD3HhgS1D-J&TO4SKW9SMP% zBLJe}?X8`=ZI~$pA@49DvTU7j0yv^JRrL`yjW2Lf{mVQrrpS;%L(8NfoK%;+|X8_U1S-2K@)==bD6;O(U4-tQ2?Pi z=<{8~Z5l@na=35e1aj%w1aN^sQZh#QsBSX15+aa=0-w_2ayDaInJWVe1axK z7~TV?39Kc6OH67xrbJ^MAH*+nIafc1e5uipW@Z#LTM^~V_%h#>-P39J%4|o>#3kg? z(+S`lfnuMwCySj%4AkHhy`3-r&^^L?E0r;|L2nvU7dKy8VJk+)&3R;pO#Nd+=9jcs z-*}h0W)*MR$qp`sYjiVmg+3WX-y5a7ShKsrCe0x!Z6NlTC0~q@xC2(kfy<7ExGp4t zr)f0nrvkr_Rbq8-nZS7f^R6iTH8wB7{^q|6Uz-GQu6e;IU&nf7mFz(@0(RN29Tn|1>031EXj(`5s_hzn#OFq*-QK}<1s0>ILVkm3}Q z&c)!mMY<#A`flXXNY$8If zIMDM1mkCVY9a8ML8$f@M#w2r_yc;j_pq{u}eMw{p{jQVHYUWRdMHEk>)YB)8R`cvh zRkQmfUqKXL-*%^-{Y;pD;WHqKp`Zsv91^?+VPFWRfWEG&dr)fbo)CBtNpQGs{Vtk? zVGP2wXe8Zi(bM;+wY)5%6|>MM>-vO9rF#9nimyp{aNt8wGu6!htONIW`BQ8-FP&=B z>;*Xsy_edbnsXkM{;WFlK8qHoG$>`v`wVoE7)S?1sLztWn*kd=I#&Is`<$6=aLhv-}fwM(JDmjA#2CL;1`+Z1%(Vqt&nPHL$A;wsUc;+jj44H>*6~Vt3pq z<={VEMlL;Hj(Y-6{|J;Dh4xk(N4LGz#L?Z-Zh`PA@&JJO2h>Iz^m_P#Kn0t5&}$|r zc0vJ(h0*Dk_|3dJkY@R+%s+?{mmg$R*d6$xqqB=5VN(FrZ$E`e+;vKng4M}Wfx^5? zt0%XE1}?A+QUud6bC7gQKtk+a9JhOP_Ox#@=yaV{nQzxhcp)0|?`1pa%$LzGS+m>0 zWe(1h=GtW^U-X(*pr~c!(&?|LEtJdmeMKcaICC>9=+sv&ZPvA#`6{&Va@RcdwfHR7 b%-8zNUQK=79ERjze()Qr&&q^tO|SkLe(UKg delta 62139 zcmafc3w&Hf_5c6wE;dD!6wz))=@OBqNMZBdfZ8ZRizqCL5}#y~>?TWgv)jD7$xkIB zNc4v`awQX=jnBqsqY-aVv5TS&%42;%10qC4nxCSLJbsPJZvWpi?@fchd_K^7XXnhE zIdkUBIcLtCyZpdQRt~&m{0+`^pSb9Zb@k`h)}LP=`NXbQe_}N7oo^j{-ph9UKkILY z^Z))I{(If)U;mbi-hRpJX2U1F+?jpz`k%aNL$RZ}Dwa<6#)|UK4K)PamWJw(DyWM0 z4#cyu{;G3ARb8?6_P&gGamN~}D^w+S22ceHDpZw?^~KV|9m!q-q?i6!s_Gm!*l0nu zGzQ(aM$;Fs*`JPg3Yh+00s*u;Z9^3RwJZus^ydbf4xgAU9^)^iF87KHYEIyTpWPlA zcicCKJ+?Dec=IAnXL2$O^ zf|DHgl27nQ?xN# z{koSqr=tI3rMMtP7wlzvxo43`_V|{JN&0T2qH3g_VFAxi3cIm=B7IW;sXi+YPOkYM# zpF4FifG##&#nYL-Y&W%^i1%i(6q2IAt=M6872XkaqdTfMQ!_LRNzTO?Fw|fl!Diz< zNldDH`2{P6I}hyq*Ji4WNyCcF(LB*4bqr<(G&+ly1aE$$!6u#Q=?9aVnahYdba%ed z!Y2F1pgV3s34p;gVG>Jca>-7y%G?DD>gG#>Zs=0e74?AyJfMJvdjwm%-IrQjjRR`N zf~x9_r@%`J!A_757^kY-6&ot_CPPz#r zDtZuXh{44=+~AunsFpWF;=I}P#U)c`AE+QCO{_moUG}=uHdFyn%NA578|Px8Kbg*^ zh=xR#en3Sov-)bgEa;A2rur(CWW5mpm_gyqoxkjpXVSb2#$4H6>=HAs7LEGX9lcz& zRxF09YMR6fsflc>B?M|Bk;a;B?)>Ez4$GGZ-O8whLLZGajbf=ZHa9hHYalQ@HEnZS zqnj)6J4a!5cl1^4*8sJC*GdF${OJERiJ;X8DOk8iIv3HPGYdPi(Y7e3AeRXLzUdo*5K?^>q*Xf z;BXV~(EZjsPIC+IFbzROiixb1(^yy6PzT}Z2H!~y3FO_Dcb+YYk$LC5k#@70cc0=Y zX%kCllS_Z;O5_hDSeOWQt&*g$NR);A;^yIxLf^RjeF6Jz86#aUIUd)CSrY3 z*kqGEaluXLtUG5zExtE+^VJ3jEvJ%LWW%afH!w6X7x1#sDcGWApL_%Vru-$@cX@_KM zH+_K^eC=UZmY{>FfxcL~J1wDzMce|QDqnl;rbO`?!Psh9sDItD4y%)y4xrXyI>DA3 zmRoO)kS2At+v-To>$IR+I)PeelUZM^^94>lx`%qg^-BCRNTY;`#Q*J&rG=P*%ER{$ z$symD++=cD8%XH`7*flCtvoyABwSE<6^ zR&5naZd-S7cC`CtmY#QCa;~}5(H}}=`a=D~{R44q>!HE^I9G76ygTVZEWZ-h2T`Q; zLAP)Xc9Ls&2fWT~uxF#Q=~zi(_32O1-)-A9^`oikN;UY}ZH=5N?j2WFiB;|HOJ&@` zmFvamvN0o_NU#XeOQn1V=0eA9O;>x1`uQ=b9K=zyboOXKDCTXB{4?>@nlB^`V6Ft&<+P?Bk#9OoZTN-6r47a?9}TB z%%xb3iUqG>c(Y^Ip5we2qcJ=1@fMnUbo8m$@(~wfBS|qGBVz5-e%lAZtmfUGqQ1cq z-K!h9&Kg|da&@MG^8xqX zpPnJsK`Ps=SDv*Fs93B649E?;1|jH6nsFgKxB^AO+0D7u5T{&NofcFq2d#wbiP*`z zQkixxQnN|7;*%N*!}w%yHu}i`7qUgcSx=F3fYV3MWA+vT5p(TM-Xa;tz3-OAGfKcH zxqA0Xp-@ebyEqZNnVHehSauBx4VGXr5dP}!WE!ucn`O|_EGSZ6pom~W(scL7vjbch z4!8>(N}zW0;dv5L#a`eF<(% zXL>D5mfqalSFFCK0F}3(sjY zm2Yjf6f?D+^g4>{2g-b2!I*9PB~!Y4_DeQPjtr*NRB7glbtK}#xrya65O;UZh;dUp zZgwW<^m@Bqe!}xC{0@F+OyHJ^TRz&h??MKC*Gz}fvf5K|v1@Uyx;^F2e^&}h<7e9P zy?N1MU#3$t)6KWSD7ux95ks2YdF#o}DMg`<-nFKSaqsuXMLUB7T0)fE7B4v4=ACKu zNWy)!_i*~h7NZn?3@zrznhGT{ zJVI3sjlvt!&?H=m4G}kTz%m9h2lS>0$3nZ>6nkTq3CH{Xe=yi;RQ67rxcZmra0Z)dD`w)@VPIWNF;cds=Y2YxoT zsfc#rkOAKbrYNNc(=<6WJACU+2zJqHV)UT3{qH~cAMB)#SbvsUk`0rc1i8zF8!wuj zncqzFKOvTo7Vb-T86I^jf1!l?j$hoz9^dM0;u5|ip3n?ggf1Z{&rA6mH}>4_Uz(O? z$A77m?YoV#-E@oNXkGiBM}4KD`{X_6o+8|`SdJLI_;bVeLSo&kNe-tOdW*+8QW@^< z?TC{;fERc2UW;AwfLfGLH0T6pkXUb~Pxxc|z%(4H^0h}d#MM5hi5)JO0|UV&kvgH{ zM5O0D(jZ*nkw&)skY7oteTDnqkm%$d%Z>!_lamXi6R}RL224de>G5iG!eK+?gPSzV z1q*+17k*_1bMvpkbid~BV*Ymi8d@anb-WpkboMubN>qu4+b9*Z#s;x?q3_nfAE9u4 z^fv|f$X`y`oJi$XaZ9YTBi5- zxdlZC(a=(HIH|dEBHr938>;dFtnvr!zNl7jTu>B`q|wl}n|r|OYYI?#3rg^W-g)_J zDxQN%cgTVY9|B_?GJQ#;vY9?ql@ckAXLr(u$^&ZAf{OKVOE3XXC7@`O3I5<#FIas= z7vQ&BFnys~PrL_$MQ~#ecmnWn?abLwiwnV#jc7JZxzoS5hE)L6vIPYqfOv*I6r3A*#DZ#j z1Zu-0rmsGET-Os%KsqJ$n>#O|Xqmdpj|80o7JJ-z1m2Y{Aueq1%9h3Z&%vUhIp|2> zgh&Y#anLBl-rVpXz}0^+XvkHU!Kx9PEUiJjxs!jekk12Z(Sqvcb@ZW>pa2vh zxB8D3RP>L*+3X)r;v3zXz9H{VguS48BHgxtZVh_#v~0#nNytEAb}RM0;PdAHE*xY{8qma@gu3 zv;>}AGE^n3vs7Ig1oVoxDtBzjf|>zTffw+>l-!l2qiZ|S&il&&j-ON>v1Sy0Zs@P* z`md&Inow+c*m~jAQF98R=#KqWc8$*5nZE{S3x5r8P3ZXTZRrWBDv_%Eo8IaFCa};u z{fNRM-kFj7pNNgn3%4qG zmQO!hFmo?Rt9qr1u>m48J+))NbOsx%a(Dhi_X-pE9}sx|Fa(mQ0a2>0nSR7wu%K>! z5(4i@3rO-o7vd`55#SwS<&L=BPwK8p?l_=kp5%vPG(P^Px8M9zra7S-)YaG5ZEGgn z;lXJNqtLB*+M;~;X|)$${WN#TD#EvGpEizzFb+lTL_1C@c!68}jKT}E9eoB1@tITQ zLQEVlMh^Th_d>5PLKfi^kZYMIJDZC4+)aNEOHW3rqz5y(vR%7u+(RqEP6CZOj7K*6 zPunAV;9n1mL(Ps(p_e82zDQzE$STr8;|XIGxrKj2%>KLDYny_@e3Nvl{ONe7N=wnG zjS=>%k7~V<6=@4NWpigQZ31QLuIz|&`0Qi}#-=p49z4GNg=3(kSPP|3I&wyCInNQc zrokCi255hx`Ao-?P<-eq3&S{d>ymS-vC7zaKIfiO6Y(tl-jTooAZHZtIXlzuoOuo* zOYS*D${0lu)stz?tg#$Da@cr+<@^qxXpW#a<#)I|T;-Qzg@9w24@}3SH0m0f8ta5@ zQx~agtYg6wL|Ysk)^dUqWNj$Yp%hJ`a-_DYR-8NGscu^XjH1(o9Q6*I;4B$~lRdi5 z`P}oNM-#HSY&zv#J>`3`1JC^PwMpz9Uhm8p5bwU{JJZ(d{uh+}%1*X_WxF>xHhpb%E(s;R|S9oS2f6khCfLQC z^BC}w2k1@B(u@jA9;*=!gh(yhRi{o}yd9gJMZ+BI>NA`p*0vbO;Sp~Zc(BnbC+JO8 z$+@2zFs2-a+%b_D-DP-8uvmEQBFNIJ*F}`Av1dZCr z$f=s^9`5Wz+?qGH#W_bF^+5Z!LXb~s>xcyBso!}<2ccVfK_2!L~xX`X$!E# z3IOz$!_G-^sjn8}m9=+_;37?e zhSWxhwKX}?q0jaYBP66?wc#%~HM1)%o zJG8WuR&Tega6YDR`FxAqq8-{op#P=KJhI3I_T0B!0KidM#E0TdU$Ew38JmB#4Y>Sj z09L-n>Jco9DV82pn&M`mEV5SAB5}+A*yw8j_`M6Am$Dzc#(7~A6;i*VZew$#S#WQ+4O~kifoG&E>!vvJ9eQ1 zSJ!}`8tFt5uVNK^?|i-nxTe%0svtbAUtmU4k;RU!#=$}tVNtYP^qh;L?P7~&kw`?k zp6RHzS%$^b*RyHVBARhjS>a+WlGg2Ty#Fkc;4b9{NrX|6E$^Ut+UdZal;ft+pvs6h zQ-z5>!yNyu;&3I1S@sgA`h~nTG||BQhU~kSI_J7qUT~IBq}b6*oKY^B2Vy;>aR>@~ zV{e3h#|b}kskL0g_Wrf*O=8o~f_(^Gad>a~P0nVA-Th`~JzIFQV>EcS@iOQBQxV@R z7LuhkuoExWk`SAlrH}HeSPn9HlNLM9-&yPBWxRPgh&6>GDGA|drCQxeOXhF<#ap^u z&+uvur{W5`&F~dyGm0W5T}#}2lER)WDJk#k+2j?DIehT$yP}N4_rKLKp*OJY`wf}f zuC&x>vxBnnx7kFy?`=XZiKESHETf$7k)R0l^rX=avPp03?bw}l*g89W)hhips}F@> zXCgLO5*e-pdW}Qsu$5Mek-gA6fGKf6d>&R6~8Vnp9W-gUv zOA5n`&_>Wktcp#(i@K6vUjAKci?PLb+f#wH(Ad}@0~8vYn`?zW$Ex3BldkJM&i(IB zWVs0l3n)Vt5cN|8c!wy?X85mJTRWAmJ5=lh8;O`>B6EhnifsnYIQ%4Z@Bg5LE?jN# z)I=LtD%55XmhEiQ65`r6Y3sG)bXw~sivQ8IdPE3Yu8KusR?Dm{hNeeRq$A02P)aW9 ztsDfwJ%9}N0Fp;B2|vXDYgyy8jIoph zFJiy+fg*-c5kl_m(z3~DLa?bc<|LmsY+HmILa8i>dc@hRblkCuUNe~`7VZUB(Ozwe ztrGAomr=DrOg5FFZZfvUc_d>DNqJEPHB(sIl85>S@oZ4R3%J^Adkf~o@XC>0PVRLj z93W+gSH!$2!-PWO#9HdhNblAFJj}5^-Y7hR(8+i(k~m1@dr6^RkpgW=BfqJxv0jGl z;1LU&1qZB=csm9hT<;+jU}?~{KbwY}$Ni*2pS{~TOPtq%Cj?f68Ee~33u3qG5xBw= zC;S=dOs9%Wfr&Zb&F|Lc+iFU$xC>CNl>uRtpg}f%Ev>R^!Ic!^xyq4c?Ouzc zWvlOlQp2F>p~g6F-pmJ~A{bU%_aS?Sg4f>|zCwK?V6(;1GYej?Net{-t_OB)*8@8` z?_SI8%l6;k{O(-%E=h<9G)PP2<`piBDPh(T?~EDmME=8=xy28gDK9142T88d4ibm6 zJt2=|l3w+VV52oiQ!HwYtZj@?<`e+Ri(@BPQ|*m8%$9Ehe2=EOEc+2B=yZ6m+jD{l zc45;Wwc9Ct)TqNBC3Sd2nk1H~32cSKTl_YV%M7i-@^FE40(!?NV7cetqs>TMFgMM)-|$)k2yQEFW1}ramR|dV@LKlyJrhmZW2p< z@)K6KEdL3;MIQYG95Y34@n%eOS?my7{+PNF!kRwmEUhmh2B|%ki;?)@4v|%Eau%K7 zeTd0mxe2{gya_2;zRsM@n-qP-kvZ<^X#y=X5U6s}8alT(=&%xZ`-nfpxn(TnwN7G# z5ni?9To|9S8o>1)I87r2i+eusEAU{K+6K0OT3VV+d>S2xKJ8R*;kaOOP`{y}rkM_$ z@Ca=P{ug?JErtl0ddqQo)D2E zEGylh#Uh1eQIBwAbiffS#*Y`a^Ya$wEcWfwv z>d**w4Cq4xy`dZeNmsG)jKTEGJOn|qtOMuynIU z_|R>3@T-owd_Yqr1w^St!Mn;uHAqK82pl35z1%*CL1TLyoOW)11B4_;KY=I(DgKI< z+61HAoR%x=pif;iMYr_K7QSYUdgALCbm;4jh>xK`_oJE!0~(5_RI~v-;s;_|t_PDM zk^P2fhk#0K@*8^PANqzPqV0*y!URQ)VRL#nkQpE+x|kO)_f1G4Jy7q!x139z*HW9M zVz=lvB@&PJOM7+fWQkhAykEe$}t7;SoL@99;4p{U=~HXN5p){ z2ptNL)Z`gvb7g>w0Gyb$;3&eC21N+R(+DM!pll~<8QNrL(c!oa$ZY|{C@6p`idR6_ zY{3Sc_#WUw-?KWTs2e$fd|jwF){R=G!*K$fu>q@6@gce+K?rh4@jk#-$^b*R0-iTHek#50oaBjJsFTe z+3taELs|LCrpo{e1h{MiD(q-Bb`2Ujv505)*yaIn6h$vq5_Ax~@j2{=myg}+Ih)u6 zp7T;Ox@7{XoU@R`0YgFr({keAj9+jLYeg*%h}GQ1M(3Ph2r_}6AwSo}U6!|7=2z8g z=-86RK^NWm_E5trZquWH^a>Hva?ND)|n7Km+}uHBdxLimEvoJWOx2KewWmq0s0L0XSs?3Pl%-gCrlUCfeJH z^Vm`uVC9bh82*vfqf!Do1srdOo>>mHOpj9pn708_@y>W3I8KV$G=|EbS;g%(VEA?b zMsIf>BfaW)H^R;z%gQ8=S@y@MJpNOCSVT=iDW4nIO{%OBQSmd zZO))bvpmAwiL9Bvguefg#YNLNTTy@0mNUH=D*z}zWRT_TbPS{4vcS^_S@x-e9xu{L(m00BGYDe^T|J?Db zJ*^|Dyg*`8BL_Ne9qOY(VfjOP()AFr5Zhyj^I-D_6)sq*Z22HYUpa4)4I~5QV&a%9 znZmF|32Q|y!zrWl0GzS`g)0VV5rfFXQF>!bWq_4;0Wf@*)g$^twXUSt&*-^_-&!7(;h2Dk{oiMuU0WK$4) z#HW!uBNTQGvYn`9Xp_Ag9gf?8L<*{ks8G;$kn5cN=#eehfD`usE_9D|s1Rdk^apyM zC;SZT_IsSu*dl({18Gp159-4W%|hR;sjF|S zL*y~`ygAfzL-)y`Jn!heP=od2^G^PivtYe${*C?0&b!}H0Y-3kQ5PL4p_-?x8*lB_ z{ZrQR05EHNz`{%lRVW%ey3%N7m0Fj3a)kK=ZO*Ca}3AGG0Djz}@;fD+$4=%5-Ylhv+ z0qL=Z3}2Re$l6fZzK0x{6Nuk)km>>p{|@a%f9F)cl9xd8!3>EF_Ngfuf`gXxet*0V z9--O4?K;u01v~Vx(`6hM*+)30Tzjtwb56ih zZyXDuMIhF)Xa>qpE3of&ntR0HI=r(n)KU~eR0jaP!Xm5^>*6V{2dWV-{{anG{?Te! zC@0Nzath$N5mUfgQA;&kWTSrs;M5;2x1RUtAIp}-k;k05OGO7 zg*SvABiq@WmskrfD`|);9yy0}+=ByqK&o#NA=mkscoL#!LMREO|t6X48~&SRASfK5Hce-p%J^G~UT z%#J+;euq2f9RH@xkPEB0I@a40w-)d-XtL!Q3m2LcX_~?{AulVzGr`7COW{&vGXz*D z14Liyx@JeF7nV)7o1*_%@PBQn7&`Q};zGjiOt&T2~j?jgD`+28SPXrxh{( zseT%L2x-OI>0gTsR3yEcpl8Pv&~-fOArBfi3Gmg0^)&L)>0uaNt1? zv`BF8Q@r-Z*)(dIrCA`rWgC#{!dx-E9}6ie>4EEj-`q>H8=7?7TKlAXDKDfBlut^}-@A@R>O0 z8Y|9u&kKAa&KV~(okB+hCL)a(Ws@VTgUk@I)9xB1A89ftVlB4H%K}emy+-knxW4@- z)Bo7XHb)#f*|&_dqe7*xOpo9fpE>PRI}@kagxY?J&*R>h8VYDZb~`~Oq8y2G+FbeK zb1TEGGbxku2)uAy@M1n`gmS6mRlbDoIp~!rX6+6`wU&+6tkv29nrx%5 zAojpus1qY!z3`Jz3luVJCJ6Q|1l0&p&esbh9!;&L8k%9jO=`gaKi0AdtGaEIPb9f` z?)_)VZoNP!DSt}lJhnhdI`Iq|4sUti2G)tIZ2!lGBluez6Zu6)4kPC+tfrXdZ zytC!yp!y?2K9N7E6IX%s$rr0U9Rm%YZb?{ZN9s$iraFqaKZqum6+*tClk+~&fwTx_ zj#bV<-9@m9C{7UgV=Yx$+GeVJ^P6n3fMl>*;v%Tx6(r1FVG%wBf3(_lJG%RZ`^gsr z(zAKgGU9WY04vY50HuEdVNGyG3mHR?-K-V04B+UQ0GzS`KEzV;6bGZ*kl=Co&Xm`k(`o>Ex!F*WrzhV9r>r`Z*>MSwzS1Yq_UcZ zUM-5m6t`CURBZg7YTpVM9th4$>*Gh{S|S|zIS95x6>5=Ub6f4E7q|L?6K7jPgqn#h zDFfY9-A_owI|gBz?nEs^)a=->GHY2wDLS_ zh=eIMZgwPki(}hGEwhS7&+{Esfq?&WoFc|1!>Shyp5?Y?=()4b#x+}~SNz^O-xSxaaLXpC ziN&Jz=rUVx0eRV*a4>x{am2`PIIe z^~D@+N({kE!Q(@Ws61{vtaz=x5nT0J-|a6OK;WYwFxUIzeXy$}S0k=*yN_qJSmpX+ zxfW}XY^p_tt9XyL_)c@q;_Vf=e>mPZtSlt*v6uN0!>`A*L|<=l0+^GuR%039^aK>> zW0R<57GRzL7j3{Q)PqG#8Xi{^=#@O_tolM5FnS>|0*bU$8>aJ_I2VdQ6?P?GAbmJy zEdyKx;KUm&I9f&+8o4ZS+#-SS%66ib!8H2@bU1DU!UGO>gW6@__d@>!&K7LIiHiUi zy2$Df-tNBPUdoKe$BA2t-V+P2ZEgQfw>qWlrkq;{IoSx13 zi|wYDFGkaqJ1m@JK360y&09skPWe{;}5dQ zH`+k?Hv(u8MVcLWB5!yOh2{k#vO&1pSoNhgVDwS|W>I8$-uGYXvyZ)wycr|RYzu6_ zS!?%dJ%>i9qt@B-WoWJP@-j520!6QL&cd@`YupsD(HOlPfKxUgPQodAMR>;b3&PTu z$^a{)01QX19tBrH7wkmdK+a(Zc}Bl1hgyccrU)=^1JYe3LK1c9kt2-f46C@p1`J;T zz$l6|sgX0UzXM)U2{MR<&rMfcK=3`reWTCi2Vj$Lv764n1x+uaNHtw*R8HXf+Q#}O zVTRBntA4A`+-+c2ztuN-3KH&g;{yS(@+Aij$UIys3%}R&Hea{39~^o+Y^WdK>}=v2 z4N?VL4$}NpgvwPu9h@(x=z-}nySxUh4o;hXK` zd+b_=-y=45p>!eSM{W(pA{;_W`nFTKI`(Fh@71$K%EEhLnk>E-cB|RMwzT=C&nP8Q zah^)ck_1$wxABP>h#QKjc}6wjyL21}K+^3Xp8JztcMPTvKR3{WS7Kna9j#2YuVIxO zZTFdrqp;eg8yb9(!#y49ix=WW1^0P#9q?%lnQg=1C6mrLQ@hVuPp(%ImyG)2j-sY~te@f|*YL`N9#sTvWdQ7K@d_L7ba4-}52 zD1)N%_P56d*iyS?U^&#Xq$2_5%K#I+BG)P?eR@o! zj!fZ>gbf((1z;3K`hFaSKyipETx@=HgGpYH|61pMKS{ zg^cYq*qrtKTk2=T&x4Y$2ZtrKI!rtUi|#@v*ExZOee^wv-7bFs#*>a^ zVB1H1dF&F1sHEZXDxd;c6|jAcuP*#S;2-^(sU8TrH#wv=a5i_H?^*7W%YVokDO>uG zvY^wV(jHilGY+A)V~Nqn*f`(j=8BMaUDm3Q=0fdJ1Ca*A9BNYK2-8S9=8`}m~{ zv3Dn-nW!}<6A{7tHj)&Ki#=#~B+0sOv4&Bjp6%*hM^7EpAeLbW%^wtvL8iJkTl-z!bMmXDxb+egYf zfa0YSP4vTcIfNs99EG5k0W1*U@<)7+$;);hwRUZ9^MCu0_Mg5rVR0J?Jj2OqGH~J` zzkmdZpX_A0n@le_X}t;SIDeB=7W9D;#>5+DGtK_s#K*N8R>ZJ0#z%(JA|i<%*v?P-#Me{S zR_C&}@MbwJ5wUWMb`Rcni`-^}3?f0H_-Ke@goxZkQh3AUJDZ!J#zb2sZ*c-nrwzsb zI`!K-{xI@e?Yv}s0}f7Fa?i@X>18H;S2`E*(aR|=c7geL7xLN(~R$7B?v$+`>6xrI1wwDEl5BQYHkrsYqMCupnt5s~S3~&*E6Q8r-Fr{#}5J{7^X=W{-pCn37mB5#Ac>#Hic#=gDMIO@X1WiBJB6|6wD#qo0S9zX6T=)N!b zrZ<(k`r@k-x>8Y$6~63$G5gpTeb4u%zUUKaVOCuawC=zyeaS*GV)C!D?O*nZcotkG z>C|gQY$7-nOlJ~T>QuqIsF>6WI1A*mN0SfdH3n zKa%OYR3du;nE07p@zdxYqqThF`2aR#181TdQ~16(G+%6;}+M)vt0Rdz1I z=2k0Yk!g!$wU$k?XWEzLHZ|M;<~wh!@@wcJ{51=;I3?lc_9aW#Z>qP5$PKi%3koBWtv9Uw|qQjJ_n`@4q9rkwr>-mzOAtlnjhI| z^ko3;6-N3RXxAku9D8|nDL3rJ9O>6TZt^Njq)2J ztpVJf!-5sq(u_Tr%J0~N@vi=^50{RWH-l~Yp4c_`*yupdczfr+2X8O88&__%_kkVX z_x(`Y43O&F4#bDVurET2QGs>>uoe&WY4dD+#ysG&M#7`HIZ=xbk1ftYa@?lrS}e*# z&q!DvBS(;kg_Z!@iCSh8$=-$zZ}=e&828=g+rZ077_e(^_iYS@0L#^3DiVL(|Kc6K zjSgM-1*#uXYw|~CZl8Jwf9RWB3+>$PHf;{x?wjPKB)>IRwW%q@=wrj@H_%rbZ}cM> zZ}SH%O@pn=`}Xsba4{{&$g5=rTg-zpci0rIz5^6B!dz{NS|4xwiN#)4=1#?4-cNjs zwWK*?fp-Y|07&aYFJ8*u#7+V&WC*!xd&NmCr`pn;Hr1>Mm+e0zogvxV%}o$VR<5MC zcUl*6!#@WJqCdB$o2HhyeE^QYz8-|D;#NPO?n%@#)14>4MH>)?IF4W8NEE^qs)=}I z)dy|B=s^HxQKThYC-o)dNE`{I;iIGeVC&750WJb?V%~=98|1>L8yAV-z9b;-uwXk; z%V3(FM~CA!Ad#B~p>V^Qs4Sq_f(=-GZPqtJBSa~l1!}nS}LX#n6anId&%L$U@P|NfbaQN%`dMFO(mp{Mt9SwFEPohw0I$SXMaz zkcr>qKxK=+!Gis*g%d$oXZre;?L;j@zU*&-)3^;tm{b02Tze9?x%mrjBrTv8j((1= z7VaPk7w(}4tnOZM>z8~X%+MTbz zH^cd-hfP0Z_2CsBBFm!dIS&z6erFRo^e~9r@~}l7;trhGaDKs8k7U#sax9FYmYJOy z0xY0tvl?APOmX$vA3W6dmpk-eD)C^GOayg`98fPkJtzM-o8cTRjnWB&@Iq5 zg;YOc8z(Br?;7BQh-8G=9&(VVtm2P0YT-WuwJ3`8D!`T4fs8uYrRQWng-e~oCd&Zx z1h{Ae62rw!XgH!%hsiC{>s9{=PC$MtrXmB6Q>>$pSr{lkFwQc?0>nussZVSYwLn$D zAuRuxayocN9)rGP^uz;?`$RG|1Qy7=DWC|89tO(U!(#Zn5pVJ^v=Mf9#=oBBm+T;r zBTE#Ukc#yW;e&(1jZv{*I;Plxzxe7@-nPH^md-$~RU}c4;r0-=8WKd9j85F7(=M=y zC(v`~2{lIaZ9}Ld8EV7pegec2nNzyONNr#1{=fM|%7PR!jFVX)h7tWcv|o|uZS;t( zn;keJeVFt`8*N6|AI9Q8$j=wC?q$gv)GQlc2G-SE0*@gZ$}0?Y5C6mWo7eJwi*)Om z7Gi2hr02l6V>tENMGQ!P@^e)kP{PFb=HQitdpf}?o+@L)r_fOpMVblGB$`&fAE8ab z5rjMI1`rtL0q8A0h2s@|U?$EdVYkUY`obHle8y@Q;nZZoBe1g$?f|Zn*M%GEYFR64 zi3Lj|AAJT0O+90s`g;eT@!7Z04jr{Q&fE7-`<3nfw{PK$5_liHV|FE?4(>o`r#2gX zmb!V?!VeHC$bq0UUE<&>#g3HY~Hu)z>tHk*R9I z@msN_n|=O_xDloe$HRXAuhl1pt8h9>+5!noI2iS8@SP=v%c#V4oT*U{CyK1%1c@}E z#=<8c6eB8&I5oW73I6|>|9JX&q5)o;6`to;iB3;m=jR#wHiRg(!YWpwuOAshsC|~nL7H1{_cgU%_x0#{zjW&0a9d9ljgyBOid*G8sFKRq+==#}7f*zb_xaXT z=;&(HP2-qQ8TV`_Y7w6b%4DDKU*~L5vqAvuekzCELalGK|IoWRq zGH&1CH+LQ2%x%|P!U`KO|H~WfQ3g-(%OssGFY;SgANIV+|6p}2O}XZTcV*QK^Pdz= z*wm?LIDe|&oTJiyirY#_Z}gi8_%k2Hn|O(uRd4%C{PvZYV;lYQGmwZa5VwHg>YzF5 z6FCBj>**J95d+kSb3>JiswKxG;rlbN?UsE4$6rK-cgk)o= zr6d+qzn5Zkcbx9u%#Ps6q@P-Mn%@do^bWktKTnQ})m=`VZV{Z#pRNeN)@}BS!$+ho z8We0zQ$D^KQ$Dj9LohD2qapuZlghOwxu7Lk!@7jA_;TLyc+D&8zM9JuxXm9FFi0xZ5g^+3+aEbu)D5@s5BRpX_sZRvL;KH+T zDj)(iOBdxRX(i6^#m2fq3z!dX^`X!9E&e?B{*a|@)=FhH;aP3r$$f&9xtv?t{8MU# zbqC9#mg1HonUtVnE_u3{BiZNTtW07g-yH3?KyS6c}P&&oGb z2AC(n#WFw&>5`Sf7%-%SY0s+9wtI}84ZtjlRF5TLsrKPsW=2vI2ZVTGb7%V>CJEHF zh6G~wy~?ldbVSfya+R#Wm+upLH!!|h%r=~Nf+ihtR?3s_ z5uJ6j$uht^0WR8rk`W~sXD>n$sesP4dyJk-#Nb7oPq0D|to-Pj-?(Akd3xz0=uXN( zT!IK=>9&Rawm00X@eB7lbxQojTlXThek*sOx2MkkO6O(JQ6dGG6rOd+1Ph8a33NdQuvCVNcD7Om7-|AwOOw@O z7D^bjPRtgK4pFoSfEhq4GB$=|4$L(^#R|Z|)}mxUM!L&hYALrES<0 zuB)*wBCze}`>hX6rojSSDMj?Yb^Z~(0R3ez(1=3%(IU|1R~(;h7VE;ByFl-Lt5bU} zzFId>ELK5h1pj@a;y#x~x_Vc`TM( zE{LRq7VV9;NX1a!CKG;j^KE-J|2mp8xhhR8k+=Ev{+&?K$TlHfR_%(L+GMV9Ucn@g ziq+S}CNH$-K7S!dx`-k@_f^1{CY>(`h)m9FcwyCVP=G*!Mc+Vk@dp31JWqwd7B>J_ z1?y|YaQq?;EYN3j7x~pCnj;tadEg`8ebBWPi#2{Rx|q3GZgw|&IMvi5P6@t%9(?OT$g%_|f)WSLw$a^!F zKqt0hyyYzp`+CK?OZ{EYDnx)8l7(bM8dRd&_@$)STw1Q!yvhIP0Ddg8#W(w3e3}sQ z$ZyPToLC3UFg2?zbQxiNnT0iGmS#y(fCEDOK8D2SK?M?P^K$i(ZuqSNJ3c1X`c|!3vbW0Z31NjM3pfj1Nff-&P>{QF zdgIikoOHyD48;ekys<0&b^^vjZ}Tq+Hbr78GpNGb(ctpiO@l?cnGViTt@Yvh1SOA5 zv&dBzu3ptW9dX1H+r?un37TJgPxkl@(kJ6=emr6d`eoq!WNG zovS7dCnh3;#Q&~gRgK1VH^>7{Q&fj52Rs_L4%wRcc}N|bk6W|j9gCM!rOW?=&0>&6 zg#1#x8Rxom!n*7~)eY40-MTaQ=b^Pyf1OAUq3jiUW)(?$OyMK|qbM@l3xKE}R7TVo zH6h;EWEo(d02ggQp(FPqS5ueR+j?U;@JEVOUt{+ey#|0;6qWUe^^%gYi+~Zhv$-M8cACWj z3~11rde$`PpXV(`dXG0ys7Sk&Fr|D5RK|B%E^crJ+d8DXAOm;^#GXRYRxU17P zbi^;?WDww^wu2HbDhtw4h%3KSDoE!|{#ThrbmV=~;-)M?Cap&P{lxe0R|5oDX@yW* zILAS-5%&@BcUJuYzex%)Oi5-+r^r~rJJ$@sW!L&gg#g6#DtoQS(W3wo+Oqh9MADeS z1PrKAoATLFAU2L7y{?3lwHG<{ko;T&BSdz=2AudH^qtTLr8a(i#>Ac1*}62l&VLV& zFXxdB^noZEz4*U;8Q|IBXk$!)Dr)}{OAf>6L7{r->q)Tr580zw{t!k{dA&6Xs*V5* z>Vh6Sy2UNb1ZzbtBb-OC2jG+qD3t{QLfA15=42CWsSL341^|X{uzKVb5&j|3q?G(w6t8)Vft+C4^Z1Yj0Ls>f2YpZA9q027%fx*8k;i}bR&8~yy=r@2+K zTAv#mlTGubH#3H&3uE?DK00Oz-dG2sJ`@vhLp7GNf>?=1a1nRq;#fm=TNQ{6>mSupIHvuqwlhq@15aMsar`WILYd@mJ?H;EH zFmD6W3RG+(Hf-_ADn4cdhCc?tD2g<3V3kpqe1!c7b|xvoBS$7b=Kqlhd2jo;-%6#k z_v8LKE}(GZCaGm&riaFyB#VGQ^^!9LQ_aTqnEv6Q-UC5X*aMB7juMX(G!viTm5He! z(W^h94bZDU;s1>eFzn?AN4+_If`gA{b#xW~WJ1qn!@^4J{;CDR#=nZLW>BO@Pv=PT>#%sNkspYyuVpJ=wX{+1ynQyOvF%@z zz8ayTq>+P84M*|{^8Z+(J&miAJHIY5;q#pRI*=d#x;&6RP6Dv$Z;0BQw5;$A?I}3< zoBpv)MF=MZ@eg+>9~(qaoVWv8w>bkfA!$lOJ@V&Z$C^zlF- zh?~K*On1Uo$^b(%0Bo7DdL))19O2H8OwHeV*%)f^9y#r22(U2Y|E-YgGvBf0`jPL5 z9eX{#f{R3Df~IhNkWoK5Yg6m+tRL4SR_DgU)iAzJx&6bT7H_q5-$pC7me=%szx>SA zf@in9WzN6MIg8>_wAzSa>ASd?ew^0w$;fy+Z-YbDO2LbT`dqHf$sbs_)LYjuj{Lws z&;3Q9SgIdW&l%5~{~-=NDu(45k{ye*<#xXelcN>N7pwdlOC~2iwkdWbqw$bef$Gsm z;&7ZGuR>-6I<-EN+ZN9_ao!F6|_{CjaAr)|WUE8SO zNlv2)tyHhxv7aGsz??|KcrgBDZ3C14u0JWl93Ws=>p{Dh(Sty53PpNmu-iZgNxuPn zh$=4^TPg#roCjcd-U5^c30T-pu7wM1In*-anj*lw4M-8HI&cIUi3%lQ6?fTy;ky7B zMUh680EOvZ0%K#SvIPpshF5XASzXQ_7$0;;ksR_0dwG3^tzeI=QHXt1v!^_J1 z;v>XoKd4`}U;|Fv4Y<(V{%Uu8$Bmof&nYUFP(}5IPbS_2sPH|Or1UcPl&M==?(@r! zdFe=~qXmDqrU*Ge;YC6ufj#93G9m^j0wFHHAcV&xiVz|qu7ijG!?|BuJ+h;}_D`uD z*PQ(KtDPd2rV|DI%I1G#Mu7aWzrhG9f9tPi^OyNgIu&*z&S3T2P-@~dYsJre%s>-? zdA|k3)NlPylafy7=v=O-y_8Mg&nr_^5)b!lT09@Nr9YEa(h-<8X{hh>yWH#kmz4T3HH9?blRzj`CJNOU1t zErv`nq4C+h*H+@=Q{s!8%WHam_B?7IUxxo+ZH(Tve<O=H5J zxbABFYx@q%^Bb@+zp5%~g_rD@0e0j6s8gO{T>n7JqE_W!%4&7}RUX~IAz<>Tv9>3G z#OM>2pdi}PK;cQEAQ!RlaVdz+qn28_V0;3s{M#x(u2CbyDs~pVzp_@;GJvChBmTDm z(OCvL`*4GrCsWAcvqE@-A-GfqSowDVhW~E$h?on}3+Ga}We^8KB`k+prpGA)%-eu` zfc?Y0DjhZ+c|)w?hz%G%0>CJWaM|F%iEC|uEVJx?hP&&A#7e=A%$*@2@!l)`84~F| zvd~ZX+~a>7g%1AJ6QQ$!YS>FsZ2liM3d{ch3YAYfh=!*Z?DMoy)K|1zN{}bXC2cShP3Rso5 zW`YyJyV@CEl#7WLuwV?qCRw)dFAL|1e*@*vzctD-tV13Mq6_#|#Jcpl{|(tfTgS1I z)Zz8kG4`z0B%65_Z5GOkqQ1ac?5v_+e#Z)pu$CffwH5v5n}Xi8MgJ59Fs^Psa?IB9 ztu!Ovo@4$>$0^=26^K-0Uj}W|$8$@i5ga}9I|U#)`N<)#i3B5Fg%eQ8n~v+r7ZA&r zc$c;LaPeu>7cgfT-acQzjv4I=1a|9S1Eh0IDc62!;)DRK`4a*ntv8E4FJJ|??tNZh zhFd3up*Dz+(wq8Q7ts8}6J7Pi@%cX?H{w}xU4sF=`E?irZL(`Fw9V@SB4#p+Pg-iF zomHNQ_QNLz%+W=!x9jC6PP`39mBxJSMpX&hsTB>Uj={r{#A zSQXM@TpZ%oU4CQ01arw7QVo~{nd3f!6ZnR0O;(14^MU~p(wiOZC;0TF`OfrN%q@Rv#xn`wz`1|u86oCyWyp&mm2S*0Gv`+E#03q1jL3p65F5`6Ec z+yQLt3_Xv~b7s!KJQh%-RmjRig7UaadaUA1>V_zVKkJs>zN^m+Ag&1_ES5l6j@qhO_LV?n{FN3W zIPvd@Nlf5u;2)SE0nHXrOKTnzX8|sBmIc>?lQ!%Hf^z)pbV9JRZq(9nY@7gRY(OM* zky}Y0PLca?HA}p*6#*#6650|tY@+Pl@z1Gy8kbi~S!Bl(Li}$9rP{VaK3d_m9 z_P&E>2eM(J4ZH||C!=z&v{bVXZr?+NDJc>^P*ua$xXH> zZG+tw`)B9=y%Yr{r@FQyeDAWRr)7~i@cPfLThqQhwScnja_f? zwU%gR=WUmqjt@V^%>Cg|3l>~Ui!E)vJ+BLt-Q2k_P*`8=N%rr;8KBsDm2La*nkzGN zQ9xW>z~umwZIQKHjN!LkZ0J@Jq(bx$MYM8_U1*rz^uQ&aFmW@;jx0A6Bz8cWVex{7V*CYP zostPvmD)hN9sOzEj=sr^wHT2f?W$?6K~~0k;z@i&KGMi0QOn|yHxV9hvKRU0HwOxQ z1go`)7<|mq@j~YNWq@qC%<2-!E8^*d_(C?Wwo3n80%;pi%XB$IfCU?nRt?6PraP=+ z8x^lCc)1POaybCoP^6`W*#A&DL&AlxKK{(6%K!@mxO{ow+439AQU)sencZUF_ABH* zNO>rXE)snUm^b?t(nXYWW8eO_2F%w+y~A${1g+Pm)tFUH--~_cR*&|_E z5rQL?eC=jEmI#Q*ap82-n?B|#gRc~&;?|u>urCFTvx;st0!%LpcVh(6Zm zXB9mfkPz%41bd(-5{V^Yi#jq-Eew`TSsN{4faxou6zi=v!-J`SaLrP9JsorLKYpsj z@yF)@fDPZr@yMpr8VO)uNYmovMRH}ZP>=s^*dujHFX8zld7B!gNJg~5L0DTRpcK8m znLvJhiNY$Ra7MhOotCn^nVDU7GYh+PGaLKlkPs(hhQxVxuq;ftk6zhIAGIU#_d@-F zb+9ijvxNU*JE1ZI!er-@-a(N^f@sAe!X>F2=zJ(v902}h)q_~^k&7H@iFOZJ+j5W3l+NA0GJ&QSeg`GDXnC3blYVr>z z@v(VJ!%!sEnE3}Kj~nyl{}m7sn1HmhTXR*Ot4_Qe(Zo>gkvDJUzicgm?RbAc#4h5R zSC?@k4v0%!{qYVu$>m-#dS)x{2elT*eJ49>dI9%!U2Dm0w)ca984(wY6V26;Em+(p zAsn~ZXo4^$JfKZr4ioG;!__#rxQ?XPby9lirFDGb!|QDZj9#x9aL@Gtek*2uu?wpw zj^qnmgZ$4FzV^d`B_T%O0TICym<8$1#HU1K{leEuOr4E+lQ#xLlH|Uk^i|kbSdNSZ z#!o5ICwB(mGEmGNllkfC1fy4a>&G~SI5)wq`!TI9dmjt@Qbxnj7jO8SWX0D$Xk*2ptI?rnJ`TPw zeBAIo@_q2n4OFTXZB}M^(y9gHn*vh0$mC&a^m6lIgULi^c2pKQ* zX=*=9C9vS|38E6nCKs%p)yYrW?d3m>_7+j3cQAaZnqOkTcN6fXYJQEO9uE;#{TTxY z2i#`>nEj09?gl&_nrSbaRQ1oC-8_-QMU`9=;I1S3ZYW0`WrT2^c%zpDAItP@qvMU zLKtBNILS+Agfpd|&6NQz0&wD+7F-6y69@{?o<%$$4CfKH6Sa(fn*AnCoeh|XVX@=t zk~Bp?WRwgeU-yCyIPopOg}!BV2o#~B;kJ#~%1GLB1Xwp}p+hP9#=jLfpi~*2q=1uF zuc+*|O_THm#Clwd5K9P`BKQJoXl`P2-?nx3qu&lJiv1$qr@yyaLM{-Qm=Njk=$dj) z%$8R%Lk9`U^zp9#PM|{GJ4NnaqrhNyA+jT6QruBPrbCdWicNl3(vJqj^54Y{x%gd5 z9j;nr8^0Ggz|Orlut7MP+DTB#zlmFkY`2;*7CVuB7c{1>FkPJ5{F!y5mYJt<0-Uh{ z5$2`CZq+mKB3mf~41FJfE#J3#Oe64Ej14DJ)S=+UJ~oD0rpFlqEZBfx1PRE|?8HTC z1i<31RM4{lTRZ@^p-A(v;6P#|4g(OmYNpEo3k0}~qH3ZRkrymQY=qQwBjN;mkWLDz zcMJfIDQNHem77du$u*W8tGLZ(lO4BVTE6|HT-FpWr%&-A8L^Uy?(LZ&P=`+kj&)h< z5A2bR{s0J0p-7KRj034kh!h0h8>b66F}73&SouQ$hJR=Qa!SZB9!*WWvm9!%N-yw| z6P0Y~A7ptOlvZXLMX3N=7OVJ?jcoWw=rf8UjV#dPUGcTe#TKU|9ByTRc>-Lt0ddfv zs^bc%0cX{>%O3e!h~5rBq=@lOT$1?^i4z5SLI9m_BIk1&`l>HfHXyu%>h> zJfZ+el8_#lBSPCbTR|REL%isV3N!Fy-%Tz6@}g04sl128dat8x01M z7qC{;GK3lZ833njKpGuiB?!<^_snpwv!5-Y7NRTI`tD-45cIYRe)#8sIUx$^yhw>c zHggc|7Y|U-gSXp6@EK$A0x%;+-uNY`lL3yubO+Kn1J*RUo7X z&A)=JL@UKVWN-@wD}r_Z$^vHN1U-Wy4G4+Gd4P{dc1hxutr$QIG4yKyw){HqG@ahB zmCa^f<~Nqm@%G)1lV_1-vE`7hZf6b!f>H^<{1|mleKapN4AlZRu=vK%9%pk4HvWqX zP`)0t(5Ll*#U<>BuGBCceRU%zCfkWxW`$)R1p4DPAU0!sf>d6QMA4*4v5%6dV}(UEt6L z66u^Lw5nG5ux&SA{cu2Mw&O=eFc)ETAPKh#$`FE-7YR9nEAm+F8J7FKjp)?xfoL8@ znjL6&#nF(Ic7`)p#Um1sFlFIK02qBFz=JZ6KQL~6)b3^UQB_oP2zP+>HAM9RR{(xTFP^5b0 zpT#0+g$zmrNRL=&v}u$976@?J2Bc5Lt7Sr&zBxDoHdy43c8_g;1mGx&c#lLUr92=X z1DwXxDRMJ*#QW(pS*OSpTU?u>$|YM)9R8E^C*l%CMw{FEbC_HoBqfh;5@|O7n2pHt zV?g9jj|EQk&ir$r($bf^9+&$APPO~APmF~RqkiLdOz;e_In**uFD_xF z|Br$Lb@-5T!2>`Dksrq9Wlu;#AkGZFD*4CS{zfzSH`ObO zg&rpq@L`JO#iHk%$vkQqY?leJ^6wTPi4@{6!7F%y3ym0nwW1aQ@+oJde-9j6PvPI< zb-7u6S;;$iB(P**eE1*I^ok+812BgoJ9({i<5t%WRUROz zh}mSm2$5I-;?{-IP4@nUQno6TVQ*e2JsUIUo<%2RAm+7_;tGq@&o5LzxhWz_2gC@B z31my2tF{@nR6oC3+FsS(U=x<;jA(qh{1nlvpB4 zXrPlE7$a#>WVy5RMZm-|QDT{&#Y47io0m(ku5RNzdL!DlFr&OxlsuQ@vO!`(o(dhf znK+X%aSzYrOvRbJiFw#vZzH<_k1S1`p44z(zb!9OFdLK@tl%i}%8n!_l`go_S+_ryoi*Xl`6xNfTPhfo!MCEd$u}T83ZAO%)nDlC?i|i9q z-8cq8z3!B`_CiHOFtlOkDon+P+l`p8e^t<~yv=AkXJi-%^i6ws{5GQvzmwlKc^l?R zH`kMCxxQz@0irY078`6&-!4ilSX2lij5N?gLT@X8%V zMfkP0(&V=+;i`m#gGYq#kc+`6uoxl%x*y3&F;%6;U@pSlht})^VKFY0J%|ZoQ-N1V(&X1T$*4aX-YwF82n!oR?HRF8JrAVLt z{tZ@#e8CEjOhl1B!B^Heu0ZEqtD8*Jp~;}mY%SqPVYVr$7v|BVndj_TWY#mn?*|s4 z6-R^uDuxv;#Cdu*|BYNMHpEBA@JfSusKi~LOIQfH>WOcK+aRGw#Ir5;5O3V0s0V#N zb}RN7X1XEHYzJST&!ASk#}^2gxK{zGQ=LeM6VI1!vc_z;&8QUvv-bj+(?EGU+DKHh zproBI0w(SQFt|^(h_i+uM4)$G$^%t4gIaNmIRfTUv^nB`1TRC!$SL{X6Knqd4Nkq6 z?^h3+*pKH_?l*BdgYf8nGZ`QK!sPc&A^vKQ{Lt-2V8VW{E)}^!uHT3~``vKb@&~vv zw=4t?7#%_K_>W9VG%Seq;hCQ;g?X4-d(-g6Vc`)cOIz_{)o~ciqUS9r@&XAg&v2f0 zm#%clCeRK$RRo+RU_k@1%{XlUWGh6g;AsYivGoUai!BEM%%aG*m`31PK|=6xcV_g- z&J+O)1WYs z|G0VWIvFt7h4_Vn$R&AJNDzj<1QeT8W+xxgJ<30X9?hZ1rlw1_Zlrf^M^GrTb;xb zoIzbhXOMdo0T$e<)Dtc~ip88Ijo`7bY15v3%tR4xoLB(EO1~(XLFC!LFIA3 zL%69E?GO`()krxDlAyL$1cjOgv5B^gs1*-!>M#g8?uwXl_QK(4KMSuO#*(~~ikC3* z?INj2^w4x4@;E_KXdOPv?kz0mu5QF}{AcDbK9Nbf=cr3$LZ9Muvrk~a#XdBH%{-wP zE6hECQC*pcQ3s5E(!Ct@*%qFpIrEfJeuT-VOh&ClSAR|?LW~(!bDZ!9g`Y5Wq-c!^ zTOc_tg$G(e4LK9FX|_J!X4n~#IRkRK2-rMDnPPO>g*%I*9>tcl-R;~@*W7qJHOKa4 z9g0utwM;=?{do~B)#M4SD<4RD1LFc@%zIV05-_c%^g?!$FpeFG4h=#G>8SZ%l z=l%VryP5<|)Xd0Uff0xdb-55=y$%DqT9U+t0@{V$bjTH3^Fs3Atu1UOr$|DHd>G;Lr}yn=7OTO;UXJL0{<&|j?K}d^LVu1 zl1a(M5A7Hxm9I>YAzUApKd1W?JO^MCiaZdaByzYB$MmullLQ6ogYKmWm?z+z1_A*^ zb{~sc1gDEfTxnn@EWeA^|KNWsSg^UhpLv9fji5;_^@Sv@}gPz0k&M!8_MwcDZPhP*6Duv18t#D zV~9fu!RU|HWMOj^x^es^^l17eH3Wnr7VdFDzxXq9XWK>8iie=`WdIMntbmRq5fy~e zO|ZPvMj^}W7;449X#&m`0ePro0#Gg+9!7k%6|ZREfmZ-*L6Ijt_6p3Kh|M~O`Vd!{ zW{90C0?rb!pn;At5!801GlGNNGPeFz-D1nD0A^9-TZAizOjEj9?Zq9ByeIA^i+}|J zCSFrOoHlr@pxPGuKe@I>93a$+iIaT|z?=qRe1|a+Fbiej;QK&ux1BEnCQbqvoK!6$ zB9p8Z)M0P+gxEA0)QVb!W}ATdljb)fwT#98Te9h_skGB$rjn}5beSEClts4emu6O^ zbQrmLt8!kI=zJJ&Or0ZG4sH1<{pjEnnr%XnCoKhH^c{xTlI&4PFEr_a=z`4?aPE}( za@BCAw(z==M5^GpO2UYeL=L{8M08Mf$X`1%@5Bdi{vXO<<^2YA+)coh(Rhyhn)OJ> z21iz?#DE`x{2;Kf{!J*VqGe{K7BD-mB)Z-9#lMzrgQL$Dmx=SzxQLD-KjEo9{-aI3 zg`Il*EeQJ(UU24Zy}gy4HgPciF0!8Wd&~4`5OMajI@aUT9*MVcM=B1LEW1>kQT<9P z-KQNq1Nmm@!wJ^LJW{gJR$A3^c*N?Xz1{O$bA5*pVu^Hsv=U(1QBbv>c)<-Xy;r0fee-ul!Y05^D7GcHiL-caaMpE*p5gTINIb@Z z8cz@U!qL7cz66tcEGNC=R_$~yQrv}~<%)FM=YMZLsX11h9(M$1VQ&#kiwpue;)LN- z$MaV^^9Qpl9QzwweO3|xrGxt;cyXoj^qzeJoC%VO~^{O6xccZt3C&!$G^ G#s2~N%{6-f diff --git a/data-raw/datasets/antimicrobials.txt b/data-raw/datasets/antimicrobials.txt index b807ee964..b2691f9d0 100644 --- a/data-raw/datasets/antimicrobials.txt +++ b/data-raw/datasets/antimicrobials.txt @@ -3,426 +3,426 @@ "ACM" 6450012 "Acetylmidecamycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA" "ASP" 49787020 "Acetylspiramycin" "Macrolides/lincosamides" "NA" "NA" "antibiotic,espiramicin,espiramicina,foromacidin,provamycin,rovamicina,rovamycin,rovamycine,selectomycin,sequamycin,spiramycine,spiramycinum" "NA" "ALS" 8954 "Aldesulfone sodium" "Other antibacterials" "J04BA03" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "adesulfone,aldapsone,aldesulfone,aldesulphone,diamidin,diason,diasone,diasoneenterab,diazon,didimethanesulfinate,novotrone,sulfoxone" 0.33 "g" "NA" -"AMK" 37768 "Amikacin" "Aminoglycosides" "D06AX12,J01GB06,QD06AX12,QJ01GB06,QS01AA21,S01AA21" "Aminoglycoside antibacterials" "Other aminoglycosides" "ak,ami,amik,amk,an" "amikacillin,amikacina,amikacine,amikacinum,amikavet,amikin,amikozit,amukin,arikace,briclin,butirosins,kaminax,lukadin,mikavir,potentox,prestwick" 1 "g" "101493-5,11-7,12-5,13-3,13546-7,14-1,15098-7,17798-0,18860-7,20373-7,23624-0,25174-4,25175-1,25176-9,25177-7,25178-5,25179-3,31097-9,31098-7,31099-5,3319-1,3320-9,3321-7,35669-1,42642-9,48169-7,50802-8,50803-6,56628-1,59378-0,60564-2,60565-9,6975-7,80972-3,89484-0" +"AMK" 37768 "Amikacin" "Aminoglycosides" "D06AX12,J01GB06,QD06AX12,QJ01GB06,QS01AA21,S01AA21" "Aminoglycoside antibacterials" "Other aminoglycosides" "ak,ami,amik,amikac,amk,an" "amikacillin,amikacina,amikacine,amikacinum,amikavet,amikin,amikozit,amukin,arikace,briclin,butirosins,kaminax,lukadin,mikavir,potentox,prestwick" 1 "g" "101493-5,11-7,12-5,13-3,13546-7,14-1,15098-7,17798-0,18860-7,20373-7,23624-0,25174-4,25175-1,25176-9,25177-7,25178-5,25179-3,31097-9,31098-7,31099-5,3319-1,3320-9,3321-7,35669-1,42642-9,48169-7,50802-8,50803-6,56628-1,59378-0,60564-2,60565-9,6975-7,80972-3,89484-0" "AKF" "Amikacin/fosfomycin" "Aminoglycosides" "NA" "NA" "NA" "NA" "AMO" 54260 "Amorolfine" "Antifungals/antimycotics" "D01AE16,QD01AE16" "Antifungals for topical use" "Other antifungals for topical use" "amor" "amorolfina,amorolfinum,bekiron,corbel,curanail,fenpropemorph,fenpropimorph,fenpropimorphe,forbel,funbas,loceryl,locetar,mildofix,mistral,morpholine,odenil,omicur,pekiron" "NA" -"AMX" 33613 "Amoxicillin" "Beta-lactams/penicillins" "J01CA04,QG51AA03,QJ01CA04" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "ac,amox,amx" "acuotricina,alfamox,alfida,amitron,amoclen,amodex,amoksicillin,amolin,amopen,amopenixin,amophar,amoran,amoxi,amoxicaps,amoxicilina,amoxicilline,amoxicillinum,amoxidal,amoxiden,amoxil,amoxillat,amoxina,amoxine,amoxipen,amoxivet,amoxycillin,amoxycillinsalt,amoxyke,anemolin,aspenil,atoksilin,bristamox,cemoxin,ciblor,clamoxyl,damoxy,danoxillin,delacillin,demoksil,dispermox,efpenix,eupen,flemoxin,flemoxine,galenamox,gramidil,hiconcil,himinomax,histocillin,ibiamox,imacillin,izoltil,kentrocyllin,lamoxy,largopen,larotid,matasedrin,metifarma,moksilin,moxacin,moxal,moxaline,moxatag,neotetranase,novabritine,ospamox,pacetocin,pamocil,paradroxil,pasetocin,penamox,piramox,promoxil,quimiopen,remoxil,riotapen,robamox,sawacillin,siganopen,simplamox,sintopen,sumox,topramoxin,trifamox,trimox,unicillin,utimox,velamox,vetramox,wymox,zamocillin,zamocilline,zimox" 1.5 "g" 3 "g" "101498-4,15-8,16-6,16365-9,17-4,18-2,18861-5,18862-3,19-0,20-8,21-6,22-4,25274-2,25310-4,3344-9,55614-2,55615-9,55616-7,6976-5,6977-3,80133-2" -"AMC" 23665637 "Amoxicillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/c,amcl,aml,aug,xl" "amocla,amoclan,amoclav,amoksiclav,amoxsiklav,amoxyclav,ancla,augmentan,augmentin,augmentine,auspilic,clamentin,clamobit,clavam,clavamox,clavinex,clavumox,coamoxiclav,curam,eumetinex,kesium,kmoxilin,spectramox,synulox,viaclav,xiclav" 1.5 "g" 3 "g" "NA" +"AMX" 33613 "Amoxicillin" "Beta-lactams/penicillins" "J01CA04,QG51AA03,QJ01CA04" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "ac,amox,amoxic,amx" "acuotricina,alfamox,alfida,amitron,amoclen,amodex,amoksicillin,amolin,amopen,amopenixin,amophar,amoran,amoxi,amoxicaps,amoxicilina,amoxicilline,amoxicillinum,amoxidal,amoxiden,amoxil,amoxillat,amoxina,amoxine,amoxipen,amoxivet,amoxycillin,amoxycillinsalt,amoxyke,anemolin,aspenil,atoksilin,bristamox,cemoxin,ciblor,clamoxyl,damoxy,danoxillin,delacillin,demoksil,dispermox,efpenix,eupen,flemoxin,flemoxine,galenamox,gramidil,hiconcil,himinomax,histocillin,ibiamox,imacillin,izoltil,kentrocyllin,lamoxy,largopen,larotid,matasedrin,metifarma,moksilin,moxacin,moxal,moxaline,moxatag,neotetranase,novabritine,ospamox,pacetocin,pamocil,paradroxil,pasetocin,penamox,piramox,promoxil,quimiopen,remoxil,riotapen,robamox,sawacillin,siganopen,simplamox,sintopen,sumox,topramoxin,trifamox,trimox,unicillin,utimox,velamox,vetramox,wymox,zamocillin,zamocilline,zimox" 1.5 "g" 3 "g" "101498-4,15-8,16-6,16365-9,17-4,18-2,18861-5,18862-3,19-0,20-8,21-6,22-4,25274-2,25310-4,3344-9,55614-2,55615-9,55616-7,6976-5,6977-3,80133-2" +"AMC" 23665637 "Amoxicillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/c,amcl,aml,amocla,aug,xl" "amocla,amoclan,amoclav,amoksiclav,amoxsiklav,amoxyclav,ancla,augmentan,augmentin,augmentine,auspilic,clamentin,clamobit,clavam,clavamox,clavinex,clavumox,coamoxiclav,curam,eumetinex,kesium,kmoxilin,spectramox,synulox,viaclav,xiclav" 1.5 "g" 3 "g" "NA" "AXS" 465441 "Amoxicillin/sulbactam" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "NA" "NA" 1.5 "g" 3 "g" "55614-2,55615-9,55616-7" -"AMB" 5280965 "Amphotericin B" "Antifungals/antimycotics" "A01AB04,A07AA07,G01AA03,J02AA01,QA01AB04,QA07AA07,QG01AA03,QJ02AA01" "Antimycotics for systemic use" "Antibiotics" "amf,amfb,amph" "abelcet,abelecet,ambil,ambisome,amphocin,amphomoronal,amphotec,amphotericin,amphotocerin,amphozone,funganiline,fungilin,fungisome,fungisone,fungizone,halizon,nystatine,nystatinum,terrastatin" 40 "mg" 210 "mg" "16370-9,18863-1,23-2,24-0,25-7,26-5,3353-0,3354-8,40707-2,40757-7,49859-2,6978-1" +"AMB" 5280965 "Amphotericin B" "Antifungals/antimycotics" "A01AB04,A07AA07,G01AA03,J02AA01,QA01AB04,QA07AA07,QG01AA03,QJ02AA01" "Antimycotics for systemic use" "Antibiotics" "amf,amfb,amph,amphot" "abelcet,abelecet,ambil,ambisome,amphocin,amphomoronal,amphotec,amphotericin,amphotocerin,amphozone,funganiline,fungilin,fungisome,fungisone,fungizone,halizon,nystatine,nystatinum,terrastatin" 40 "mg" 210 "mg" "16370-9,18863-1,23-2,24-0,25-7,26-5,3353-0,3354-8,40707-2,40757-7,49859-2,6978-1" "AMH" "Amphotericin B-high" "Antifungals/antimycotics" "NA" "amfo b high,amhl,ampho b high,amphotericin high" "NA" "NA" -"AMP" 6249 "Ampicillin" "Beta-lactams/penicillins" "J01CA01,QJ01CA01,QJ51CA01,QS01AA19,S01AA19" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "am,amp,ampi" "adobacillin,alpen,amblosin,amcap,amcill,amfipen,ampen,amperil,ampichel,ampicilina,ampicillina,ampicilline,ampicillinesalt,ampicillinsalt,ampicillinum,ampifarm,ampikel,ampimed,ampinova,ampipenin,ampiscel,ampisyn,ampivax,ampivet,amplacilina,amplin,amplipenyl,amplisom,amplital,austrapen,bayer,binotal,bonapicillin,britacil,cimex,citteral,copharcilin,cymbi,delcillin,deripen,divercillin,doktacillin,domicillin,duphacillin,grampenil,guicitrina,guicitrine,lifeampil,marcillin,morepen,norobrittin,nuvapen,omnipen,orbicilina,penbristol,penbritin,penbrock,penialmen,penicline,penimic,penizillin,pensyn,pentrex,pentrexl,pentrexyl,pentritin,ponecil,princillin,principen,racenacillin,redicilin,rosampline,roscillin,semicillin,servicillin,sumipanto,supen,synpenin,texcillin,tokiocillin,tolomol,totacillin,totalciclina,totapen,trafarbiot,trifacilina,ukapen,ultrabion,ultrabron,vampen,viccillin,vidocillin,wypicil" 2 "g" 6 "g" "101477-8,101478-6,18864-9,18865-6,20374-5,21066-6,23618-2,27-3,28-1,29-9,30-7,31-5,32-3,33-1,3355-5,33562-0,33919-2,34-9,43883-8,43884-6,6979-9,6980-7,87604-5" -"SAM" 119561 "Ampicillin/sulbactam" "Beta-lactams/penicillins" "J01CR01,QJ01CR01" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/s,ab,ams,amsu,apsu,sam" "sulacillin" 6 "g" "101478-6,18865-6,20374-5,23618-2,31-5,32-3,33-1,34-9,6980-7" +"AMP" 6249 "Ampicillin" "Beta-lactams/penicillins" "J01CA01,QJ01CA01,QJ51CA01,QS01AA19,S01AA19" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "am,amp,amp100,amp200,ampi,ampici" "adobacillin,alpen,amblosin,amcap,amcill,amfipen,ampen,amperil,ampichel,ampicilina,ampicillina,ampicilline,ampicillinesalt,ampicillinsalt,ampicillinum,ampifarm,ampikel,ampimed,ampinova,ampipenin,ampiscel,ampisyn,ampivax,ampivet,amplacilina,amplin,amplipenyl,amplisom,amplital,austrapen,bayer,binotal,bonapicillin,britacil,cimex,citteral,copharcilin,cymbi,delcillin,deripen,divercillin,doktacillin,domicillin,duphacillin,grampenil,guicitrina,guicitrine,lifeampil,marcillin,morepen,norobrittin,nuvapen,omnipen,orbicilina,penbristol,penbritin,penbrock,penialmen,penicline,penimic,penizillin,pensyn,pentrex,pentrexl,pentrexyl,pentritin,ponecil,princillin,principen,racenacillin,redicilin,rosampline,roscillin,semicillin,servicillin,sumipanto,supen,synpenin,texcillin,tokiocillin,tolomol,totacillin,totalciclina,totapen,trafarbiot,trifacilina,ukapen,ultrabion,ultrabron,vampen,viccillin,vidocillin,wypicil" 2 "g" 6 "g" "101477-8,101478-6,18864-9,18865-6,20374-5,21066-6,23618-2,27-3,28-1,29-9,30-7,31-5,32-3,33-1,3355-5,33562-0,33919-2,34-9,43883-8,43884-6,6979-9,6980-7,87604-5" +"SAM" 119561 "Ampicillin/sulbactam" "Beta-lactams/penicillins" "J01CR01,QJ01CR01" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/s,ab,ampsul,ams,amsu,apsu,sam" "sulacillin" 6 "g" "101478-6,18865-6,20374-5,23618-2,31-5,32-3,33-1,34-9,6980-7" "AMR" 73341 "Amprolium" "Other antibacterials" "QP51BX02" "NA" "amprol,amprolio,amprovine,anticoccid,cocciprol,corid,mepyrium,picolinium,pyridinium,thiacoccid" "NA" -"ANI" 166548 "Anidulafungin" "Antifungals/antimycotics" "J02AX06,QJ02AX06" "Antimycotics for systemic use" "Other antimycotics for systemic use" "anid" "anidulafungina,anidulafungine,anidulafunginum,biafungin,ecalta,eraxis" 0.1 "g" "55343-8,57095-2,58420-1,77162-6" -"APL" 6602341 "Apalcillin" "Beta-lactams/penicillins" "NA" "NA" "apalcilina,apalcilline,apalcillinsalt,apalcillinum,lumota" "NA" -"APR" 3081545 "Apramycin" "Aminoglycosides" "QA07AA92,QJ01GB90,QJ51GB90" "NA" "ambylan,apralan,apramicina,apramycine,apramycinum" "23659-6,73652-0,73653-8" -"ARB" 68682 "Arbekacin" "Aminoglycosides" "J01GB12,QJ01GB12" "NA" "arbekacina,arbekacine,arbekacinum,haberacin" 0.2 "g" "32373-3,53818-1,54173-0" -"APX" 71961 "Aspoxicillin" "Beta-lactams/penicillins" "J01CA19,QJ01CA19" "NA" "aspoxicilina,aspoxicillan,aspoxicilline,aspoxicillinum,doyle" 4 "g" "NA" -"AST" 5284517 "Astromicin" "Aminoglycosides" "NA" "NA" "abbott,astromicina,astromicine,astromicinum,fortimicin,istamycin,istamycins" "NA" +"ANI" 166548 "Anidulafungin" "Antifungals/antimycotics" "J02AX06,QJ02AX06" "Antimycotics for systemic use" "Other antimycotics for systemic use" "anid,anidul" "anidulafungina,anidulafungine,anidulafunginum,biafungin,ecalta,eraxis" 0.1 "g" "55343-8,57095-2,58420-1,77162-6" +"APL" 6602341 "Apalcillin" "Beta-lactams/penicillins" "NA" "apalci" "apalcilina,apalcilline,apalcillinsalt,apalcillinum,lumota" "NA" +"APR" 3081545 "Apramycin" "Aminoglycosides" "QA07AA92,QJ01GB90,QJ51GB90" "apramy" "ambylan,apralan,apramicina,apramycine,apramycinum" "23659-6,73652-0,73653-8" +"ARB" 68682 "Arbekacin" "Aminoglycosides" "J01GB12,QJ01GB12" "arbeka" "arbekacina,arbekacine,arbekacinum,haberacin" 0.2 "g" "32373-3,53818-1,54173-0" +"APX" 71961 "Aspoxicillin" "Beta-lactams/penicillins" "J01CA19,QJ01CA19" "apoxic,aspoxi" "aspoxicilina,aspoxicillan,aspoxicilline,aspoxicillinum,doyle" 4 "g" "NA" +"AST" 5284517 "Astromicin" "Aminoglycosides" "NA" "astrom" "abbott,astromicina,astromicine,astromicinum,fortimicin,istamycin,istamycins" "NA" "AVB" 9835049 "Avibactam" "Beta-lactams/penicillins" "NA" "NA" "avibactamfreeacid" "NA" -"AVI" 71674 "Avilamycin" "Other antibacterials" "QA07AA95" "NA" "avilamycina,avilamycine,avilamycinum,inteprity,kavault,surmax" "35754-1,35755-8,35756-6,55619-1" +"AVI" 71674 "Avilamycin" "Other antibacterials" "QA07AA95" "avilam" "avilamycina,avilamycine,avilamycinum,inteprity,kavault,surmax" "35754-1,35755-8,35756-6,55619-1" "AVO" 16131159 "Avoparcin" "Glycopeptides" "NA" "NA" "firvanq,tagocid,targocid,targosid,tecoplanina,tecoplanine,tecoplaninum,teichomycin,teicoplanina,teicoplanine,teicoplaninum,teikoplanin,ticocin" "NA" "AZD" 15574941 "Azidocillin" "Beta-lactams/penicillins" "J01CE04,QJ01CE04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "azidocilina,azidocillina,azidocilline,azidocillinum" 1.5 "g" "NA" -"AZM" 447043 "Azithromycin" "Macrolides/lincosamides" "J01FA10,QJ01FA10,QS01AA26,S01AA26" "Macrolides, lincosamides and streptogramins" "Macrolides" "az,azi,azit,azm" "aritromicina,aruzilina,azasite,azenil,azifast,azigram,azimakrol,azithramycine,azithrocin,azithromycine,azithromycinum,azitrocin,azitromax,azitromicina,azitromicine,azitromin,aziwin,aziwok,aztrin,azyter,hemomycin,macrozit,misultina,mixoterin,setron,sumamed,tobil,toraseptol,tromix,trozocina,trulimax,xithrone,zentavion,zifin,zithrax,zithromac,zithromax,zitrim,zitromax,zitrotek,zythromax" 0.3 "g" 0.5 "g" "100043-9,16420-2,16421-0,18866-4,23612-5,25233-8,35-6,36-4,37-2,38-0,6981-5,89480-8" +"AZM" 447043 "Azithromycin" "Macrolides/lincosamides" "J01FA10,QJ01FA10,QS01AA26,S01AA26" "Macrolides, lincosamides and streptogramins" "Macrolides" "az,azi,azit,azithr,azm" "aritromicina,aruzilina,azasite,azenil,azifast,azigram,azimakrol,azithramycine,azithrocin,azithromycine,azithromycinum,azitrocin,azitromax,azitromicina,azitromicine,azitromin,aziwin,aziwok,aztrin,azyter,hemomycin,macrozit,misultina,mixoterin,setron,sumamed,tobil,toraseptol,tromix,trozocina,trulimax,xithrone,zentavion,zifin,zithrax,zithromac,zithromax,zitrim,zitromax,zitrotek,zythromax" 0.3 "g" 0.5 "g" "100043-9,16420-2,16421-0,18866-4,23612-5,25233-8,35-6,36-4,37-2,38-0,6981-5,89480-8" "AFC" "Azithromycin/fluconazole/secnidazole" "Other antibacterials" "J01RA07,QJ01RA07" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"AZL" 6479523 "Azlocillin" "Beta-lactams/penicillins" "J01CA09,QJ01CA09" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "az,azl,azlo" "azlin,azlocilina,azlocilline,azlocillinsalt,azlocillinum,securopen" 12 "g" "16422-8,18867-2,3368-8,39-8,40-6,41-4,41661-0,42-2" -"ATM" 5742832 "Aztreonam" "Monobactams" "J01DF01,QJ01DF01" "Other beta-lactam antibacterials" "Monobactams" "at,atm,azm,azt,aztr" "azactam,azetreonam,azonam,azthreonam,aztreon,aztreonamum,cayston,dynabiotic,nebactam,primbactam,squibb" 4 "g" "101497-6,16423-6,18868-0,25234-6,3369-6,41662-8,41663-6,41664-4,41727-9,43-0,44-8,45-5,46-3,6982-3" +"AZL" 6479523 "Azlocillin" "Beta-lactams/penicillins" "J01CA09,QJ01CA09" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "az,azl,azlo,azloci" "azlin,azlocilina,azlocilline,azlocillinsalt,azlocillinum,securopen" 12 "g" "16422-8,18867-2,3368-8,39-8,40-6,41-4,41661-0,42-2" +"ATM" 5742832 "Aztreonam" "Monobactams" "J01DF01,QJ01DF01" "Other beta-lactam antibacterials" "Monobactams" "at,atm,azm,azt,azt1,aztr,aztreo" "azactam,azetreonam,azonam,azthreonam,aztreon,aztreonamum,cayston,dynabiotic,nebactam,primbactam,squibb" 4 "g" "101497-6,16423-6,18868-0,25234-6,3369-6,41662-8,41663-6,41664-4,41727-9,43-0,44-8,45-5,46-3,6982-3" "AZA" "Aztreonam/avibactam" "Monobactams" "J01DF51,QJ01DF51" "NA" "NA" "NA" "ANC" "Aztreonam/nacubactam" "Monobactams" "J01DF51,QJ01DF51" "NA" "NA" "NA" -"BAM" 441397 "Bacampicillin" "Beta-lactams/penicillins" "J01CA06,QJ01CA06" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "alphacilina,alphacillin,ambacamp,ambaxin,bacacil,bacampicilina,bacampicilline,bacampicillinum,bacampicine,berocillin,centurina,devonium,diancina,inacilin,maxifen,penglobe,pivatil,pondocil,pondocillin,pondocillina,sanguicillin,spectrobid,velbacil" 1.2 "g" "18869-8,47-1,48-9,49-7,50-5,55620-9" -"BAC" 78358334 "Bacitracin" "Other antibacterials" "D06AX05,J01XX10,QA07AA93,QD06AX05,QJ01XX10,QR02AB04,QS01AA32,R02AB04,S01AA32" "baci" "albac,altracin,ayfivin,baciferm,baciguent,baciim,baciliquin,bacilliquin,baciquent,bacitracina,bacitracine,bacitracinum,fortracin,mycitracin,parentracin,penitracin,septa,topitracin,topitrasin,tropitracin,zutracin" "10868-8,16428-5,18870-6,6827-0,6983-1,87603-7" +"BAM" 441397 "Bacampicillin" "Beta-lactams/penicillins" "J01CA06,QJ01CA06" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bacamp" "alphacilina,alphacillin,ambacamp,ambaxin,bacacil,bacampicilina,bacampicilline,bacampicillinum,bacampicine,berocillin,centurina,devonium,diancina,inacilin,maxifen,penglobe,pivatil,pondocil,pondocillin,pondocillina,sanguicillin,spectrobid,velbacil" 1.2 "g" "18869-8,47-1,48-9,49-7,50-5,55620-9" +"BAC" 78358334 "Bacitracin" "Other antibacterials" "D06AX05,J01XX10,QA07AA93,QD06AX05,QJ01XX10,QR02AB04,QS01AA32,R02AB04,S01AA32" "baci,bacitr" "albac,altracin,ayfivin,baciferm,baciguent,baciim,baciliquin,bacilliquin,baciquent,bacitracina,bacitracine,bacitracinum,fortracin,mycitracin,parentracin,penitracin,septa,topitracin,topitrasin,tropitracin,zutracin" "10868-8,16428-5,18870-6,6827-0,6983-1,87603-7" "BDQ" 5388906 "Bedaquiline" "Other antibacterials" "J04AK05,QJ04AK05" "NA" "NA" 86 "mg" "80637-2,88703-4,88704-2,94274-8,96107-8" "BEK" 439318 "Bekanamycin" "Aminoglycosides" "J01GB13,QJ01GB13" "NA" "aminodeoxykanamycin,becanamicina,bekanamicina,bekanamycine,bekanamycinum" 0.6 "g" "NA" "BNB" "Benzathine benzylpenicillin" "Beta-lactams/penicillins" "J01CE08,QJ01CE08" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "NA" 3.6 "g" "NA" "BNP" 64725 "Benzathine phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE10,QJ01CE10" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "bicillin,biphecillin" 2 "g" "NA" -"PEN" 5904 "Benzylpenicillin" "Beta-lactams/penicillins" "J01CE01,QJ01CE01,QJ51CE01,QS01AA14,S01AA14" "Combinations of antibacterials" "Combinations of antibacterials" "bepe,pen,peni,peni g,penicillin,penicillin g,pg" "bencilpenicilina,benzopenicillin,benzylpenicilline,benzylpenicillinum,capicillin,cillora,cilloral,cilopen,cintrisul,cosmopen,cristapen,crystapen,dropcillin,eskacillin,falapen,forpen,galofak,gelacillin,hipercilina,hyasorb,hylenta,lemopen,liquacillin,liquapen,monocillin,monopen,mycofarm,novocillin,penalev,penicillinum,penilaryn,penisem,pentid,pentids,pfizerpen,pharmacillin,pradupen,scotcil,sugracillin,sugracillinsalt,tabilin,ursopen,veticillin" 3.6 "g" "NA" +"PEN" 5904 "Benzylpenicillin" "Beta-lactams/penicillins" "J01CE01,QJ01CE01,QJ51CE01,QS01AA14,S01AA14" "Combinations of antibacterials" "Combinations of antibacterials" "bepe,pen,peni,peni g,penic8,penica,penici,penicillin,penicillin g,penora,pg" "bencilpenicilina,benzopenicillin,benzylpenicilline,benzylpenicillinum,capicillin,cillora,cilloral,cilopen,cintrisul,cosmopen,cristapen,crystapen,dropcillin,eskacillin,falapen,forpen,galofak,gelacillin,hipercilina,hyasorb,hylenta,lemopen,liquacillin,liquapen,monocillin,monopen,mycofarm,novocillin,penalev,penicillinum,penilaryn,penisem,pentid,pentids,pfizerpen,pharmacillin,pradupen,scotcil,sugracillin,sugracillinsalt,tabilin,ursopen,veticillin" 3.6 "g" "NA" "PEN-S" "Benzylpenicillin screening test" "Beta-lactams/penicillins" "NA" "pen screen" "NA" "NA" -"BES" 10178705 "Besifloxacin" "Fluoroquinolones" "QS01AE08,S01AE08" "NA" "besivance" "73606-6,73628-0,73651-2" +"BES" 10178705 "Besifloxacin" "Fluoroquinolones" "QS01AE08,S01AE08" "besifl" "besivance" "73606-6,73628-0,73651-2" "BLA-S" "Beta-lactamase screening test" "Other" "NA" "beta-lactamase,betalactamase,bl screen,blt screen" "NA" "NA" -"BIA" 71339 "Biapenem" "Carbapenems" "J01DH05,QJ01DH05" "NA" "biapenern,omegacin" 1.2 "g" "41665-1,41666-9,41667-7,41728-7" +"BIA" 71339 "Biapenem" "Carbapenems" "J01DH05,QJ01DH05" "biapen" "biapenern,omegacin" 1.2 "g" "41665-1,41666-9,41667-7,41728-7" "BCZ" 65807 "Bicyclomycin" "Other antibacterials" "NA" "bicozamycin" "aizumycin,bacfeed,bacteron,bicozamicina,bicozamycin,bicozamycine,bicozamycinum" "NA" "BLM" 5360373 "Bleomycin" "Glycopeptides" "L01DC01,QL01DC01" "NA" "blenamax,blenoxane,bleocin,bleomicin,bleomicina,bleomycine,bleomycins,bleomycinum,blexane,nbleomycinamide" "NA" "BDP" 68760 "Brodimoprim" "Trimethoprims" "J01EA02,QJ01EA02" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "NA" "brodimoprima,brodimoprime,brodimoprimum,bromdimoprim,hyprim,unitrim" 0.2 "g" "NA" "BUT" 47472 "Butoconazole" "Antifungals/antimycotics" "G01AF15,QG01AF15" "NA" "butaconazole,butoconazol,butoconazolum,gynofort" "NA" "CDZ" 44242317 "Cadazolid" "Oxazolidinones" "NA" "NA" "NA" "NA" "CLA" "Calcium aminosalicylate" "Antimycobacterials" "J04AA03,QJ04AA03" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "NA" 15 "g" "NA" -"CAP" 135565060 "Capreomycin" "Antimycobacterials" "J04AB30,QJ04AB30" "Drugs for treatment of tuberculosis" "Antibiotics" "capr" "NA" 1 "g" "16545-6,18872-2,23607-5,25210-6,25211-4,25212-2,42643-7,48170-5,55-4,55623-3,56-2,57-0,58-8,61355-4,89483-2" -"CRB" 20824 "Carbenicillin" "Beta-lactams/penicillins" "J01CA03,QJ01CA03" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bar,carb,cb" "anabactyl,carbecin,carbenicilina,carbenicillina,carbenicilline,carbenicillinum,dicarbenicillin,dipenicillin,fugacillin,geopen,gripenin,hyoper,microcillin,piopen,pyocianil,pyoclox,pyopan,pyopen,pyopene" 12 "g" "18873-0,3434-8,41668-5,59-6,60-4,61-2,62-0" +"CAP" 135565060 "Capreomycin" "Antimycobacterials" "J04AB30,QJ04AB30" "Drugs for treatment of tuberculosis" "Antibiotics" "capr,capreo" "NA" 1 "g" "16545-6,18872-2,23607-5,25210-6,25211-4,25212-2,42643-7,48170-5,55-4,55623-3,56-2,57-0,58-8,61355-4,89483-2" +"CRB" 20824 "Carbenicillin" "Beta-lactams/penicillins" "J01CA03,QJ01CA03" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bar,carb,carben,cb" "anabactyl,carbecin,carbenicilina,carbenicillina,carbenicilline,carbenicillinum,dicarbenicillin,dipenicillin,fugacillin,geopen,gripenin,hyoper,microcillin,piopen,pyocianil,pyoclox,pyopan,pyopen,pyopene" 12 "g" "18873-0,3434-8,41668-5,59-6,60-4,61-2,62-0" "CRN" 93184 "Carindacillin" "Beta-lactams/penicillins" "J01CA05,QJ01CA05" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "carindacilina,carindacilline,carindacillinsalt,carindacillinum,geocillin,indanylcarbinicillin,urobac" 4 "g" "NA" "CAR" 6540466 "Carumonam" "Monobactams" "J01DF02,QJ01DF02" "NA" "carumonamum" 2 "g" "51694-8" -"CAS" 2826718 "Caspofungin" "Antifungals/antimycotics" "J02AX04,QJ02AX04" "Antimycotics for systemic use" "Other antimycotics for systemic use" "casp" "cancidas,caspofungina" 50 "mg" "32378-2,54175-5,54176-3,54185-4,58419-3" -"CAC" 91562 "Cefacetrile" "Cephalosporins (1st gen.)" "J01DB10,QJ01DB10,QJ51DB10" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefacetril,cefacetrilo,cefacetrilum,celospor,cephacetrile,vetrimast" "55624-1,55625-8,55626-6,55627-4" -"CEC" 51039 "Cefaclor" "Cephalosporins (2nd gen.)" "J01DC04,QJ01DC04" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "ccl,cec,cf,cfac,cfc,cfcl,cfr,fac" "alenfral,alfacet,alfatil,ceclor,cefachlor,cefaclorum,cefeaclor,cephaclor,compound,distaclor,keflor,kefolor,kefral,keftab,keftid,lilly,lopac,panacef,panoral,raniclor" 1 "g" "16564-7,18874-8,21149-0,6986-4,83-6,84-4,85-1,86-9" -"CFR" 47965 "Cefadroxil" "Cephalosporins (1st gen.)" "J01DB05,QJ01DB05" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfdx,cfr,fad" "bidocel,cefadrops,cefadroxilo,cefadroxilum,cefradroxil,cefzil,cephadroxil,duracef,duricef,kefroxil,sumacef,ultracef" 2 "g" "16565-4,18875-5,55628-2,63-8,64-6,65-3,66-1" -"LEX" 27447 "Cefalexin" "Cephalosporins (1st gen.)" "J01DB01,QJ01DB01,QJ51DB01" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cflx" "adcadina,alcephin,alsporin,ambal,amplex,aristosporin,azabort,bactopenor,beliam,biocef,carnosporin,cefablan,cefacet,cefadal,cefadin,cefadina,cefalekey,cefaleksin,cefalessina,cefalexgobens,cefalexina,cefalexine,cefalexinum,cefalin,cefalival,cefaloto,cefanex,cefaseptin,cefax,ceffanex,cefibacter,ceflax,ceforal,cefovit,celexin,cepastar,cepexin,cephacillin,cephalexine,cephalexinum,cephalobene,cephanasten,cephaxin,cephin,cepol,ceporex,ceporexin,ceporexine,cerexin,cerexins,check,cophalexin,domucef,doriman,durantel,efemida,erocetin,factagard,felexin,fexin,ibilex,ibrexin,inphalex,karilexina,kefalospes,keflet,keflex,kefolan,keforal,kekrinal,kidolex,lafarine,larixin,lenocef,lexibiotico,loisine,lonflex,lopilexin,losporal,madlexin,maksipor,mamalexin,mamlexin,medolexin,medoxine,neokef,neolexina,noveol,novolexin,nufex,optocef,oracef,oriphex,oroxin,ortisporina,ospexin,palitrex,panixine,pectril,prindex,pyassan,rilexine,roceph,rogevil,sanaxin,sartosona,sencephalin,sepexin,servicef,servispor,sialexin,sinthecillin,sintolexyn,sporicef,sporidex,syncl,syncle,synecl,taicelexin,tepaxin,theratrex,tokiolexin,uphalexin,viosporine,voxxim,winlex,zabytrex,zozarine" 2 "g" "NA" -"RID" 5773 "Cefaloridine" "Cephalosporins (1st gen.)" "J01DB02,QJ01DB02" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefa" "aliporina,ampligram,cefaloridin,cefaloridina,cefaloridinum,cefalorizin,ceflorin,cepaloridin,cepalorin,cephalomycine,cephaloridin,cephaloridine,cephaloridinum,ceporan,ceporin,ceporine,cilifor,deflorin,faredina,floridin,glaxoridin,intrasporin,keflodin,keflordin,kefloridin,kefspor,lloncefal,sasperin,sefacin,verolgin,vioviantine" 3 "g" "NA" -"CEP" 6024 "Cefalotin" "Cephalosporins (1st gen.)" "J01DB03,QJ01DB03" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfal,cflt" "averon,cefalothin,cefalothine,cefalothinsalt,cefalotina,cefalotine,cefalotinsalt,cefalotinum,cemastin,cephalothin,cephalothinsalt,cephalothinum,cephalotin,cephalotinsalt,ceporacin,cepovenin,coaxin,keflin,lospoven,microtin,seffin,synclotin,toricelocin" 4 "g" "NA" -"MAN" 456255 "Cefamandole" "Cephalosporins (2nd gen.)" "J01DC03,QJ01DC03" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfam,cfmn" "cefadole,cefamandol,cefamandolum,cephadole,kefamandol,kefdole,mancef" 6 "g" "18876-3,3441-3,41669-3,55634-0,55635-7,55636-5,55637-3,67-9,68-7,69-5,70-3" -"HAP" 30699 "Cefapirin" "Cephalosporins (1st gen.)" "J01DB08,QG51AA05,QJ01DB08,QJ51DB08" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "ambrocef,brisfirina,brisporin,bristocef,cefadyl,cefalak,cefaloject,cefapirina,cefapirine,cefapirinsalt,cefapirinum,cefaprin,cefatrex,cefatrexyl,cephapirin,cephapirine,cephapirinsalt,cephatrexil,cephatrexyl,metricure" 4 "g" "NA" -"CTZ" 6410758 "Cefatrizine" "Cephalosporins (1st gen.)" "J01DB07,QJ01DB07" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "bricef,cefathiamidine,cefatrix,cefatrizino,cefatrizinum,cephatriazine,cepticol,cetrazil,latocef,orosporina,orotric,seapuron,trizina" 1 "g" "18877-1,55639-9,71-1,72-9,73-7,74-5" -"CZD" 71736 "Cefazedone" "Cephalosporins (1st gen.)" "J01DB06,QJ01DB06" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefazedon,cefazedona,cefazedonesalt,cefazedonum,refosporen,refosporene,refosporin,refosporinsalt" 3 "g" "NA" -"CZO" 33255 "Cefazolin" "Cephalosporins (1st gen.)" "J01DB04,QJ01DB04,QJ51DB04" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfz,cfzl,cz,czol,faz,kz" "ancef,atirin,biazolina,cefabiozim,cefacidal,cefalomicina,cefamedin,cefamezin,cefazil,cefazina,cefazolina,cefazoline,cefazolinsalt,cefazolinum,cephamezine,cephazolidin,cephazolin,cephazoline,elzogram,firmacef,gramaxin,kefzol,lampocef,liviclina,neofazol,oprea,recef,totacef,zolicef,zolisint" 3 "g" "16566-2,18878-9,25235-3,3442-1,3443-9,41670-1,75-2,76-0,77-8,78-6,80962-4,85422-4" -"CFB" 127527 "Cefbuperazone" "Other antibacterials" "J01DC13,QJ01DC13" "NA" "cefbuperazona,cefbuperazonesalt,cefbuperazonum,cefbuperzaone,cerbuperazone,keiperazon,tomiporan" 2 "g" "NA" -"CCP" 6436055 "Cefcapene" "Cephalosporins (3rd gen.)" "J01DD17,QJ01DD17" "NA" "flomox" 0.45 "g" "100044-7,76143-7" +"CAS" 2826718 "Caspofungin" "Antifungals/antimycotics" "J02AX04,QJ02AX04" "Antimycotics for systemic use" "Other antimycotics for systemic use" "casp,caspof" "cancidas,caspofungina" 50 "mg" "32378-2,54175-5,54176-3,54185-4,58419-3" +"CAC" 91562 "Cefacetrile" "Cephalosporins (1st gen.)" "J01DB10,QJ01DB10,QJ51DB10" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephac" "cefacetril,cefacetrilo,cefacetrilum,celospor,cephacetrile,vetrimast" "55624-1,55625-8,55626-6,55627-4" +"CEC" 51039 "Cefaclor" "Cephalosporins (2nd gen.)" "J01DC04,QJ01DC04" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "ccl,cec,cefacl,cf,cfac,cfc,cfcl,cfr,fac" "alenfral,alfacet,alfatil,ceclor,cefachlor,cefaclorum,cefeaclor,cephaclor,compound,distaclor,keflor,kefolor,kefral,keftab,keftid,lilly,lopac,panacef,panoral,raniclor" 1 "g" "16564-7,18874-8,21149-0,6986-4,83-6,84-4,85-1,86-9" +"CFR" 47965 "Cefadroxil" "Cephalosporins (1st gen.)" "J01DB05,QJ01DB05" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefadr,cfdx,cfr,fad" "bidocel,cefadrops,cefadroxilo,cefadroxilum,cefradroxil,cefzil,cephadroxil,duracef,duricef,kefroxil,sumacef,ultracef" 2 "g" "16565-4,18875-5,55628-2,63-8,64-6,65-3,66-1" +"LEX" 27447 "Cefalexin" "Cephalosporins (1st gen.)" "J01DB01,QJ01DB01,QJ51DB01" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cepale,cflx" "adcadina,alcephin,alsporin,ambal,amplex,aristosporin,azabort,bactopenor,beliam,biocef,carnosporin,cefablan,cefacet,cefadal,cefadin,cefadina,cefalekey,cefaleksin,cefalessina,cefalexgobens,cefalexina,cefalexine,cefalexinum,cefalin,cefalival,cefaloto,cefanex,cefaseptin,cefax,ceffanex,cefibacter,ceflax,ceforal,cefovit,celexin,cepastar,cepexin,cephacillin,cephalexine,cephalexinum,cephalobene,cephanasten,cephaxin,cephin,cepol,ceporex,ceporexin,ceporexine,cerexin,cerexins,check,cophalexin,domucef,doriman,durantel,efemida,erocetin,factagard,felexin,fexin,ibilex,ibrexin,inphalex,karilexina,kefalospes,keflet,keflex,kefolan,keforal,kekrinal,kidolex,lafarine,larixin,lenocef,lexibiotico,loisine,lonflex,lopilexin,losporal,madlexin,maksipor,mamalexin,mamlexin,medolexin,medoxine,neokef,neolexina,noveol,novolexin,nufex,optocef,oracef,oriphex,oroxin,ortisporina,ospexin,palitrex,panixine,pectril,prindex,pyassan,rilexine,roceph,rogevil,sanaxin,sartosona,sencephalin,sepexin,servicef,servispor,sialexin,sinthecillin,sintolexyn,sporicef,sporidex,syncl,syncle,synecl,taicelexin,tepaxin,theratrex,tokiolexin,uphalexin,viosporine,voxxim,winlex,zabytrex,zozarine" 2 "g" "NA" +"RID" 5773 "Cefaloridine" "Cephalosporins (1st gen.)" "J01DB02,QJ01DB02" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefa,ceplor" "aliporina,ampligram,cefaloridin,cefaloridina,cefaloridinum,cefalorizin,ceflorin,cepaloridin,cepalorin,cephalomycine,cephaloridin,cephaloridine,cephaloridinum,ceporan,ceporin,ceporine,cilifor,deflorin,faredina,floridin,glaxoridin,intrasporin,keflodin,keflordin,kefloridin,kefspor,lloncefal,sasperin,sefacin,verolgin,vioviantine" 3 "g" "NA" +"CEP" 6024 "Cefalotin" "Cephalosporins (1st gen.)" "J01DB03,QJ01DB03" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephal,cfal,cflt" "averon,cefalothin,cefalothine,cefalothinsalt,cefalotina,cefalotine,cefalotinsalt,cefalotinum,cemastin,cephalothin,cephalothinsalt,cephalothinum,cephalotin,cephalotinsalt,ceporacin,cepovenin,coaxin,keflin,lospoven,microtin,seffin,synclotin,toricelocin" 4 "g" "NA" +"MAN" 456255 "Cefamandole" "Cephalosporins (2nd gen.)" "J01DC03,QJ01DC03" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefama,cfam,cfmn" "cefadole,cefamandol,cefamandolum,cephadole,kefamandol,kefdole,mancef" 6 "g" "18876-3,3441-3,41669-3,55634-0,55635-7,55636-5,55637-3,67-9,68-7,69-5,70-3" +"HAP" 30699 "Cefapirin" "Cephalosporins (1st gen.)" "J01DB08,QG51AA05,QJ01DB08,QJ51DB08" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephap" "ambrocef,brisfirina,brisporin,bristocef,cefadyl,cefalak,cefaloject,cefapirina,cefapirine,cefapirinsalt,cefapirinum,cefaprin,cefatrex,cefatrexyl,cephapirin,cephapirine,cephapirinsalt,cephatrexil,cephatrexyl,metricure" 4 "g" "NA" +"CTZ" 6410758 "Cefatrizine" "Cephalosporins (1st gen.)" "J01DB07,QJ01DB07" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefatr" "bricef,cefathiamidine,cefatrix,cefatrizino,cefatrizinum,cephatriazine,cepticol,cetrazil,latocef,orosporina,orotric,seapuron,trizina" 1 "g" "18877-1,55639-9,71-1,72-9,73-7,74-5" +"CZD" 71736 "Cefazedone" "Cephalosporins (1st gen.)" "J01DB06,QJ01DB06" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefaze" "cefazedon,cefazedona,cefazedonesalt,cefazedonum,refosporen,refosporene,refosporin,refosporinsalt" 3 "g" "NA" +"CZO" 33255 "Cefazolin" "Cephalosporins (1st gen.)" "J01DB04,QJ01DB04,QJ51DB04" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefazo,cfz,cfzl,cz,czol,faz,kz" "ancef,atirin,biazolina,cefabiozim,cefacidal,cefalomicina,cefamedin,cefamezin,cefazil,cefazina,cefazolina,cefazoline,cefazolinsalt,cefazolinum,cephamezine,cephazolidin,cephazolin,cephazoline,elzogram,firmacef,gramaxin,kefzol,lampocef,liviclina,neofazol,oprea,recef,totacef,zolicef,zolisint" 3 "g" "16566-2,18878-9,25235-3,3442-1,3443-9,41670-1,75-2,76-0,77-8,78-6,80962-4,85422-4" +"CFB" 127527 "Cefbuperazone" "Other antibacterials" "J01DC13,QJ01DC13" "cefbup" "cefbuperazona,cefbuperazonesalt,cefbuperazonum,cefbuperzaone,cerbuperazone,keiperazon,tomiporan" 2 "g" "NA" +"CCP" 6436055 "Cefcapene" "Cephalosporins (3rd gen.)" "J01DD17,QJ01DD17" "cefcap" "flomox" 0.45 "g" "100044-7,76143-7" "CCX" 5282438 "Cefcapene pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefcamate,flumax" "NA" -"CDR" 6915944 "Cefdinir" "Cephalosporins (3rd gen.)" "J01DD15,QJ01DD15" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cd,cdn,cdr,cfd,din" "cefdinirum,cefdinyl,cefdirnir,ceftinex,cefzon,omnicef" 0.6 "g" "23636-4,23637-2,35757-4,35758-2" -"DIT" 9870843 "Cefditoren" "Cephalosporins (3rd gen.)" "J01DD16,QJ01DD16" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cdn" "cefditoreno,spectracef" 0.4 "g" "35759-0,35760-8,35761-6,35762-4" +"CDR" 6915944 "Cefdinir" "Cephalosporins (3rd gen.)" "J01DD15,QJ01DD15" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cd,cdn,cdr,cefdin,cfd,din" "cefdinirum,cefdinyl,cefdirnir,ceftinex,cefzon,omnicef" 0.6 "g" "23636-4,23637-2,35757-4,35758-2" +"DIT" 9870843 "Cefditoren" "Cephalosporins (3rd gen.)" "J01DD16,QJ01DD16" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cdn,cefdit" "cefditoreno,spectracef" 0.4 "g" "35759-0,35760-8,35761-6,35762-4" "DIX" 6437877 "Cefditoren pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefditorin,meiact,pivaloyloxymethyl" "NA" -"FEP" 5479537 "Cefepime" "Cephalosporins (4th gen.)" "J01DE01,QJ01DE01" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cfep,cfpi,cpe,cpm,fep,pm,xpm" "anticefepime,axepim,cefepima,cefepimum,maxipime,pyrrolidinium,renapime" 4 "g" "101502-3,18879-7,31142-3,31143-1,35763-2,38363-8,42350-9,42351-7,42353-3,50631-1,58412-8,6643-1,6644-9,6645-7,6646-5,6987-2,8272-7,8273-5" +"FEP" 5479537 "Cefepime" "Cephalosporins (4th gen.)" "J01DE01,QJ01DE01" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cefep4,cefepi,cfep,cfpi,cpe,cpm,fep,pm,xpm" "anticefepime,axepim,cefepima,cefepimum,maxipime,pyrrolidinium,renapime" 4 "g" "101502-3,18879-7,31142-3,31143-1,35763-2,38363-8,42350-9,42351-7,42353-3,50631-1,58412-8,6643-1,6644-9,6645-7,6646-5,6987-2,8272-7,8273-5" "CFA" "Cefepime/amikacin" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CPC" 9567559 "Cefepime/clavulanic acid" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "cicl,xpml" "NA" "NA" +"CPC" 9567559 "Cefepime/clavulanic acid" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "cefcla,cicl,xpml" "NA" "NA" "FPE" 23653540 "Cefepime/enmetazobactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" "FNC" "Cefepime/nacubactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" "FPT" 9567558 "Cefepime/tazobactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" "FPZ" "Cefepime/zidebactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA" -"CAT" 5487888 "Cefetamet" "Cephalosporins (3rd gen.)" "J01DD10,QJ01DD10" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefetametum,deacetoxycefotaxime,epocelin" 1 "g" "32377-4,35764-0,35765-7,55640-7" +"CAT" 5487888 "Cefetamet" "Cephalosporins (3rd gen.)" "J01DD10,QJ01DD10" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefeta,cefmtm" "cefetametum,deacetoxycefotaxime,epocelin" 1 "g" "32377-4,35764-0,35765-7,55640-7" "CPI" 5486182 "Cefetamet pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefetametpivoxil,cefyl,globocef" "NA" "CCL" 71719688 "Cefetecol" "Cephalosporins (4th gen.)" "NA" "cefcatacol" "NA" "NA" "CZL" 193956 "Cefetrizole" "Cephalosporins (unclassified gen.)" "NA" "NA" "cefetrizolum" "NA" "FDC" 77843966 "Cefiderocol" "Cephalosporins (unclassified gen.)" "J01DI04,QJ01DI04" "NA" "fetcroja" 6 "g" "95767-0,99280-0,99503-5" -"CFM" 5362065 "Cefixime" "Cephalosporins (3rd gen.)" "J01DD08,QJ01DD08" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfe,cfix,cfxm,dcfm,fix,ix" "cefixim,cefixima,cefiximum,cefixoral,cefspan,cephoral,citropen,denvar,necopen,oraken,oroken,suprax,tricef,unixime" 0.4 "g" "16567-0,18880-5,25236-1,35766-5,79-4,80-2,81-0,82-8" +"CFM" 5362065 "Cefixime" "Cephalosporins (3rd gen.)" "J01DD08,QJ01DD08" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefixi,cfe,cfix,cfxm,dcfm,fix,ix" "cefixim,cefixima,cefiximum,cefixoral,cefspan,cephoral,citropen,denvar,necopen,oraken,oroken,suprax,tricef,unixime" 0.4 "g" "16567-0,18880-5,25236-1,35766-5,79-4,80-2,81-0,82-8" "CEO" "Cefixime/ornidazole" "Other antibacterials" "J01DD58,QJ01DD58" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CMX" 9570757 "Cefmenoxime" "Cephalosporins (3rd gen.)" "J01DD05,QJ01DD05,QS01AA31,QS02AA18,S01AA31,S02AA18" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "bestron,cefmenoxima,cefmenoximum,tacef" 2 "g" "32375-8,54174-8,54203-5,55641-5" -"CMZ" 42008 "Cefmetazole" "Cephalosporins (2nd gen.)" "J01DC09,QJ01DC09" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "cefmetazol,cefmetazolo,cefmetazolum,cefmetazon,metafar,zefazone" 4 "g" "11575-8,18881-3,25222-1,87-7,88-5,89-3,90-1" -"CNX" 71141 "Cefminox" "Other antibacterials" "J01DC12,QJ01DC12" "NA" "alteporina,cefminoxhydrate,cefminoxum,meicelin,tencef" 4 "g" "54908-9" +"CMX" 9570757 "Cefmenoxime" "Cephalosporins (3rd gen.)" "J01DD05,QJ01DD05,QS01AA31,QS02AA18,S01AA31,S02AA18" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefmen" "bestron,cefmenoxima,cefmenoximum,tacef" 2 "g" "32375-8,54174-8,54203-5,55641-5" +"CMZ" 42008 "Cefmetazole" "Cephalosporins (2nd gen.)" "J01DC09,QJ01DC09" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefmet" "cefmetazol,cefmetazolo,cefmetazolum,cefmetazon,metafar,zefazone" 4 "g" "11575-8,18881-3,25222-1,87-7,88-5,89-3,90-1" +"CNX" 71141 "Cefminox" "Other antibacterials" "J01DC12,QJ01DC12" "cefmin" "alteporina,cefminoxhydrate,cefminoxum,meicelin,tencef" 4 "g" "54908-9" "DIZ" 5361871 "Cefodizime" "Cephalosporins (3rd gen.)" "J01DD09,QJ01DD09" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefodizima,cefodizimum,cefodizme,diezime,kenicef,modivid,neucef,timecef" 2 "g" "18882-1,6988-0,91-9,92-7,93-5,94-3" -"CID" 43594 "Cefonicid" "Cephalosporins (2nd gen.)" "J01DC06,QJ01DC06" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "cefonicide,cefonicido,cefonicidsalt,cefonicidum,monocef,monocid" 1 "g" "18883-9,25237-9,3444-7,55642-3,95-0,96-8,97-6,98-4" -"CFP" 44187 "Cefoperazone" "Cephalosporins (3rd gen.)" "J01DD12,QJ01DD12,QJ51DD12" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfp,cfpz,cp,cpz,fop,per" "bioperazone,cefob,cefobid,cefobis,cefoneg,cefoper,cefoperazin,cefoperazine,cefoperazon,cefoperazona,cefoperazonesalt,cefoperazono,cefoperazonum,cefozon,medocef,myticef,pathozone,peracef,tomabef" 4 "g" "100-8,101-6,102-4,18884-7,3445-4,35767-3,35768-1,54166-4,54167-2,54168-0,99-2" -"CSL" "Cefoperazone/sulbactam" "Cephalosporins (3rd gen.)" "J01DD62,QJ01DD62" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 4 "g" "35768-1,54166-4,54167-2,54168-0" -"CND" 43507 "Ceforanide" "Cephalosporins (2nd gen.)" "J01DC11,QJ01DC11" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "ceforanido,ceforanidum,precef" 4 "g" "103-2,104-0,105-7,106-5,18885-4,55643-1" -"CSE" 9830519 "Cefoselis" "Cephalosporins (4th gen.)" "NA" "NA" "winsef" "NA" -"CTX" 5742673 "Cefotaxime" "Cephalosporins (3rd gen.)" "J01DD01,QJ01DD01" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfot,cft,cftx,ct,ctx,fot,tax,xct" "anticefotaxime,cefotax,cefotaxim,cefotaxima,cefotaximesalt,cefotaximsalt,cefotaximum,cephotaxim,cephotaxime,claforan,kefotex,omnatax,pretor,ralopar,tolycar,tolycor,zariviz" 4 "g" "101479-4,101480-2,107-3,108-1,109-9,110-7,18886-2,25238-7,31138-1,31139-9,3446-2,35769-9,35770-7,35771-5,41671-9,50632-9,52128-6,54191-2,54192-0,54193-8,55189-5,55644-9,6989-8,80961-6" +"CID" 43594 "Cefonicid" "Cephalosporins (2nd gen.)" "J01DC06,QJ01DC06" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoni" "cefonicide,cefonicido,cefonicidsalt,cefonicidum,monocef,monocid" 1 "g" "18883-9,25237-9,3444-7,55642-3,95-0,96-8,97-6,98-4" +"CFP" 44187 "Cefoperazone" "Cephalosporins (3rd gen.)" "J01DD12,QJ01DD12,QJ51DD12" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefope,cfp,cfpz,cp,cpz,fop,per" "bioperazone,cefob,cefobid,cefobis,cefoneg,cefoper,cefoperazin,cefoperazine,cefoperazon,cefoperazona,cefoperazonesalt,cefoperazono,cefoperazonum,cefozon,medocef,myticef,pathozone,peracef,tomabef" 4 "g" "100-8,101-6,102-4,18884-7,3445-4,35767-3,35768-1,54166-4,54167-2,54168-0,99-2" +"CSL" "Cefoperazone/sulbactam" "Cephalosporins (3rd gen.)" "J01DD62,QJ01DD62" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "fopsul" "NA" 4 "g" "35768-1,54166-4,54167-2,54168-0" +"CND" 43507 "Ceforanide" "Cephalosporins (2nd gen.)" "J01DC11,QJ01DC11" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefora" "ceforanido,ceforanidum,precef" 4 "g" "103-2,104-0,105-7,106-5,18885-4,55643-1" +"CSE" 9830519 "Cefoselis" "Cephalosporins (4th gen.)" "NA" "cefose" "winsef" "NA" +"CTX" 5742673 "Cefotaxime" "Cephalosporins (3rd gen.)" "J01DD01,QJ01DD01" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefo32,cefota,cfot,cft,cftx,ct,ctx,fot,fot1,tax,taxmen,taxnme,xct" "anticefotaxime,cefotax,cefotaxim,cefotaxima,cefotaximesalt,cefotaximsalt,cefotaximum,cephotaxim,cephotaxime,claforan,kefotex,omnatax,pretor,ralopar,tolycar,tolycor,zariviz" 4 "g" "101479-4,101480-2,107-3,108-1,109-9,110-7,18886-2,25238-7,31138-1,31139-9,3446-2,35769-9,35770-7,35771-5,41671-9,50632-9,52128-6,54191-2,54192-0,54193-8,55189-5,55644-9,6989-8,80961-6" "CTX-S" "Cefotaxime screening test" "Cephalosporins (3rd gen.)" "NA" "ctx screen" "NA" "NA" -"CTC" 9575353 "Cefotaxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "cxcl,xctl" "NA" "NA" +"CTC" 9575353 "Cefotaxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "cxcl,taxcla,xctl" "NA" "NA" "CTS" 9574753 "Cefotaxime/sulbactam" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "NA" "NA" "54191-2,54192-0,54193-8,55644-9" -"CTT" 53025 "Cefotetan" "Cephalosporins (2nd gen.)" "J01DC05,QJ01DC05" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cftt,cn,cte,ctn,ctt,tans" "apacef,apatef,cefotetanum" 4 "g" "111-5,112-3,113-1,114-9,18887-0,25239-5,3447-0,41672-7,41673-5,41674-3,41729-5,6990-6" -"CTF" 43708 "Cefotiam" "Cephalosporins (2nd gen.)" "J01DC07,QJ01DC07" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "aspil,cefotiamum,ceradon,halospor,pansporin,pansporine,spizef" 1.2 "g" 4 "g" "32374-1,35772-3,35773-1,55645-6,55737-1,55738-9,55739-7,55740-5" +"CTT" 53025 "Cefotetan" "Cephalosporins (2nd gen.)" "J01DC05,QJ01DC05" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefote,cftt,cn,cte,ctn,ctt,tans" "apacef,apatef,cefotetanum" 4 "g" "111-5,112-3,113-1,114-9,18887-0,25239-5,3447-0,41672-7,41673-5,41674-3,41729-5,6990-6" +"CTF" 43708 "Cefotiam" "Cephalosporins (2nd gen.)" "J01DC07,QJ01DC07" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoti" "aspil,cefotiamum,ceradon,halospor,pansporin,pansporine,spizef" 1.2 "g" 4 "g" "32374-1,35772-3,35773-1,55645-6,55737-1,55738-9,55739-7,55740-5" "CHE" 125846 "Cefotiam hexetil" "Cephalosporins (3rd gen.)" "NA" "NA" "taketiam,texodil" "55737-1,55738-9,55739-7,55740-5" -"FOV" 9578573 "Cefovecin" "Cephalosporins (3rd gen.)" "QJ01DD91" "NA" "cefovecinsalt,convenia" "76147-8,87792-8" -"FOX" 441199 "Cefoxitin" "Cephalosporins (2nd gen.)" "J01DC01,QJ01DC01" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfox,cfx,cfxt,cx,fox,fx" "betacef,cefoxil,cefoxitina,cefoxitine,cefoxitinsalt,cefoxitinum,cefoxotin,cenomycin,farmoxin,mefoxin,mefoxithin,mefoxitin,merxin,rephoxitin" 6 "g" "101492-7,115-6,116-4,117-2,118-0,18888-8,25220-5,25240-3,25366-6,3448-8,41675-0,41676-8,41677-6,41730-3,6991-4" +"FOV" 9578573 "Cefovecin" "Cephalosporins (3rd gen.)" "QJ01DD91" "cefove" "cefovecinsalt,convenia" "76147-8,87792-8" +"FOX" 441199 "Cefoxitin" "Cephalosporins (2nd gen.)" "J01DC01,QJ01DC01" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefoxi,cfox,cfx,cfxt,cx,fox,fx" "betacef,cefoxil,cefoxitina,cefoxitine,cefoxitinsalt,cefoxitinum,cefoxotin,cenomycin,farmoxin,mefoxin,mefoxithin,mefoxitin,merxin,rephoxitin" 6 "g" "101492-7,115-6,116-4,117-2,118-0,18888-8,25220-5,25240-3,25366-6,3448-8,41675-0,41676-8,41677-6,41730-3,6991-4" "FOX-S" "Cefoxitin screening test" "Cephalosporins (2nd gen.)" "NA" "cfsc,fox1" "NA" "NA" -"ZOP" 9571080 "Cefozopran" "Cephalosporins (4th gen.)" "J01DE03,QJ01DE03" "NA" "firstcin,imidazo" 4 "g" "100045-4,53820-7" -"CFZ" 68597 "Cefpimizole" "Cephalosporins (3rd gen.)" "NA" "NA" "ajicef,cefpimizol,cefpimizolesalt,cefpimizolum,renilan" "NA" -"CPM" 636405 "Cefpiramide" "Cephalosporins (3rd gen.)" "J01DD11,QJ01DD11" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefpiramida,cefpiramidesalt,cefpiramido,cefpiramidum,sepatren,suncefal" 2 "g" "NA" -"CPO" 5479539 "Cefpirome" "Cephalosporins (4th gen.)" "J01DE02,QJ01DE02" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cfpr" "broact,cefir,cefpiroma,cefpiromum,cefrom,keiten,romecef" 4 "g" "18889-6,6647-3,6648-1,6649-9,6650-6,6992-2,8274-3,8275-0,8276-8" -"CPD" 6335986 "Cefpodoxime" "Cephalosporins (3rd gen.)" "J01DD13,QJ01DD13" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfpd,cfpo,cpd,pod,px" "cefpodoxima,cefpodoximum,epoxim" 0.4 "g" "119-8,120-6,121-4,122-2,18890-4,25241-1,41678-4,41679-2,41680-0,41731-1,6993-0,90849-1" +"ZOP" 9571080 "Cefozopran" "Cephalosporins (4th gen.)" "J01DE03,QJ01DE03" "cefozo" "firstcin,imidazo" 4 "g" "100045-4,53820-7" +"CFZ" 68597 "Cefpimizole" "Cephalosporins (3rd gen.)" "NA" "cefpim" "ajicef,cefpimizol,cefpimizolesalt,cefpimizolum,renilan" "NA" +"CPM" 636405 "Cefpiramide" "Cephalosporins (3rd gen.)" "J01DD11,QJ01DD11" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefpam" "cefpiramida,cefpiramidesalt,cefpiramido,cefpiramidum,sepatren,suncefal" 2 "g" "NA" +"CPO" 5479539 "Cefpirome" "Cephalosporins (4th gen.)" "J01DE02,QJ01DE02" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cefpom,cfpr" "broact,cefir,cefpiroma,cefpiromum,cefrom,keiten,romecef" 4 "g" "18889-6,6647-3,6648-1,6649-9,6650-6,6992-2,8274-3,8275-0,8276-8" +"CPD" 6335986 "Cefpodoxime" "Cephalosporins (3rd gen.)" "J01DD13,QJ01DD13" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefpod,cfpd,cfpo,cpd,pod,pod4,px" "cefpodoxima,cefpodoximum,epoxim" 0.4 "g" "119-8,120-6,121-4,122-2,18890-4,25241-1,41678-4,41679-2,41680-0,41731-1,6993-0,90849-1" "CPX" 6526396 "Cefpodoxime proxetil" "Cephalosporins (3rd gen.)" "NA" "NA" "banan,cefodox,cefoprox,cefpoderm,cefpodoximproxetil,cepodem,doxef,orelox,otreon,podomexef,simplicef,vantin" "NA" -"CDC" "Cefpodoxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD64,QJ01DD64" "cecl" "NA" 0.4 "g" "NA" -"CPR" 5281006 "Cefprozil" "Cephalosporins (2nd gen.)" "J01DC10,QJ01DC10" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cpr,cpz,fp" "arzimol,brisoral,cefprozilo,cefprozilum,cronocef,procef,serozil" 1 "g" "123-0,124-8,125-5,126-3,18891-2,6994-8" -"CEQ" 5464355 "Cefquinome" "Cephalosporins (4th gen.)" "QG51AA07,QJ01DE90,QJ51DE90" "NA" "cefquinoma,cefquinomum,cobactan,quinolinium" "100046-2,76150-2" -"CRD" 5284529 "Cefroxadine" "Cephalosporins (1st gen.)" "J01DB11,QJ01DB11" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefroxadin,cefroxadino,cefroxadinum,oraspor" 2.1 "g" "NA" -"CFS" 656575 "Cefsulodin" "Cephalosporins (3rd gen.)" "J01DD03,QJ01DD03" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfsl,cfsu" "cefomonil,cefonomil,cefsulodine,cefsulodinhydrate,cefsulodino,cefsulodinum,pseudocef,pseudomonil,pyocefal,sulcephalosporin,takesulin,tilmapor,ulfaret" 4 "g" "127-1,128-9,129-7,130-5,131-3,18892-0,25242-9,55647-2" +"CDC" "Cefpodoxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD64,QJ01DD64" "cecl,podcla" "NA" 0.4 "g" "NA" +"CPR" 5281006 "Cefprozil" "Cephalosporins (2nd gen.)" "J01DC10,QJ01DC10" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefpro,cpr,cpz,fp" "arzimol,brisoral,cefprozilo,cefprozilum,cronocef,procef,serozil" 1 "g" "123-0,124-8,125-5,126-3,18891-2,6994-8" +"CEQ" 5464355 "Cefquinome" "Cephalosporins (4th gen.)" "QG51AA07,QJ01DE90,QJ51DE90" "cefqui" "cefquinoma,cefquinomum,cobactan,quinolinium" "100046-2,76150-2" +"CRD" 5284529 "Cefroxadine" "Cephalosporins (1st gen.)" "J01DB11,QJ01DB11" "Other beta-lactam antibacterials" "First-generation cephalosporins" "ceftix" "cefroxadin,cefroxadino,cefroxadinum,oraspor" 2.1 "g" "NA" +"CFS" 656575 "Cefsulodin" "Cephalosporins (3rd gen.)" "J01DD03,QJ01DD03" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cefsul,cfsl,cfsu" "cefomonil,cefonomil,cefsulodine,cefsulodinhydrate,cefsulodino,cefsulodinum,pseudocef,pseudomonil,pyocefal,sulcephalosporin,takesulin,tilmapor,ulfaret" 4 "g" "127-1,128-9,129-7,130-5,131-3,18892-0,25242-9,55647-2" "CSU" 68718 "Cefsumide" "Cephalosporins (unclassified gen.)" "NA" "NA" "cefsulmid,cefsumido,cefsumidum" "NA" -"CPT" 56841980 "Ceftaroline" "Cephalosporins (5th gen.)" "NA" "cfro" "ceftaroine,teflaro,zinforo" "73604-1,73605-8,73626-4,73627-2,73649-6,73650-4,74170-2" +"CPT" 56841980 "Ceftaroline" "Cephalosporins (5th gen.)" "NA" "ceftar,cfro" "ceftaroine,teflaro,zinforo" "73604-1,73605-8,73626-4,73627-2,73649-6,73650-4,74170-2" "CPA" "Ceftaroline/avibactam" "Cephalosporins (5th gen.)" "NA" "NA" "NA" "73604-1,73626-4,73649-6" -"CAZ" 5481173 "Ceftazidime" "Cephalosporins (3rd gen.)" "J01DD02,QJ01DD02" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "caz,cefta,cfta,cftz,taz,tz,xtz" "ceftazimide,ceptaz,fortam,fortaz,fortum,glazidim,kefazim,modacin,pentacef,tazicef,tizime" 4 "g" "101481-0,101482-8,101483-6,132-1,133-9,134-7,135-4,18893-8,21151-6,3449-6,35774-9,35775-6,35776-4,42352-5,55648-0,55649-8,55650-6,55651-4,58705-5,6995-5,73603-3,73625-6,73648-8,80960-8,87734-0,90850-9" +"CAZ" 5481173 "Ceftazidime" "Cephalosporins (3rd gen.)" "J01DD02,QJ01DD02" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "caz,cefta,ceftaz,cfta,cftz,taz,tz,xtz" "ceftazimide,ceptaz,fortam,fortaz,fortum,glazidim,kefazim,modacin,pentacef,tazicef,tizime" 4 "g" "101481-0,101482-8,101483-6,132-1,133-9,134-7,135-4,18893-8,21151-6,3449-6,35774-9,35775-6,35776-4,42352-5,55648-0,55649-8,55650-6,55651-4,58705-5,6995-5,73603-3,73625-6,73648-8,80960-8,87734-0,90850-9" "CZA" 90643431 "Ceftazidime/avibactam" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "cfav" "avycaz,zavicefta" 6 "g" "101483-6,73603-3,73625-6,73648-8,87734-0" -"CCV" 9575352 "Ceftazidime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "czcl,xtzl" "NA" 6 "g" "NA" -"CEM" 6537431 "Cefteram" "Cephalosporins (3rd gen.)" "J01DD18,QJ01DD18" "NA" "cefterame,cefteramum,ceftetrame" 0.4 "g" "100047-0,76144-5" +"CCV" 9575352 "Ceftazidime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "czcl,tazcla,xtzl" "NA" 6 "g" "NA" +"CEM" 6537431 "Cefteram" "Cephalosporins (3rd gen.)" "J01DD18,QJ01DD18" "cefter" "cefterame,cefteramum,ceftetrame" 0.4 "g" "100047-0,76144-5" "CPL" 5362114 "Cefteram pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefterampivoxil,tomiron" "NA" -"CTL" 65755 "Ceftezole" "Cephalosporins (1st gen.)" "J01DB12,QJ01DB12" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "alomen,ceftezol,ceftezolesalt,ceftezolo,ceftezolum,celoslin,demethylcefazolin,falomesin" 3 "g" "NA" -"CTB" 5282242 "Ceftibuten" "Cephalosporins (3rd gen.)" "J01DD14,QJ01DD14" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cb,cfbu,ctb,tib" "cedax,ceftem,ceftibutene,ceftibuteno,ceftibutenum,ceftibutin,ceprifran,isocef,keimax,seftem" 0.4 "g" "35777-2,35778-0,35779-8,6996-3" -"TIO" 6328657 "Ceftiofur" "Cephalosporins (3rd gen.)" "QJ01DD90,QJ51DD90" "NA" "ceftiofurum,excenel,naxcel" "23709-9,35780-6,35781-4,55652-2" -"CZX" 6533629 "Ceftizoxime" "Cephalosporins (3rd gen.)" "J01DD07,QJ01DD07" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfzx,ctz,cz,czx,tiz,zox" "cefizox,ceftix,ceftizoxima,ceftizoximesalt,ceftizoximum,eposerin" 4 "g" "136-2,137-0,138-8,139-6,18894-6,20378-6,23622-4,25243-7,3450-4,6997-1" +"CTL" 65755 "Ceftezole" "Cephalosporins (1st gen.)" "J01DB12,QJ01DB12" "Other beta-lactam antibacterials" "First-generation cephalosporins" "ceftez" "alomen,ceftezol,ceftezolesalt,ceftezolo,ceftezolum,celoslin,demethylcefazolin,falomesin" 3 "g" "NA" +"CTB" 5282242 "Ceftibuten" "Cephalosporins (3rd gen.)" "J01DD14,QJ01DD14" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cb,ceftib,cfbu,ctb,tib" "cedax,ceftem,ceftibutene,ceftibuteno,ceftibutenum,ceftibutin,ceprifran,isocef,keimax,seftem" 0.4 "g" "35777-2,35778-0,35779-8,6996-3" +"TIO" 6328657 "Ceftiofur" "Cephalosporins (3rd gen.)" "QJ01DD90,QJ51DD90" "ceftif" "ceftiofurum,excenel,naxcel" "23709-9,35780-6,35781-4,55652-2" +"CZX" 6533629 "Ceftizoxime" "Cephalosporins (3rd gen.)" "J01DD07,QJ01DD07" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "ceftiz,cfzx,ctz,cz,czx,tiz,zox" "cefizox,ceftix,ceftizoxima,ceftizoximesalt,ceftizoximum,eposerin" 4 "g" "136-2,137-0,138-8,139-6,18894-6,20378-6,23622-4,25243-7,3450-4,6997-1" "CZP" 9578661 "Ceftizoxime alapivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "NA" "NA" -"BPR" 135413542 "Ceftobiprole" "Cephalosporins (5th gen.)" "NA" "NA" "NA" "43269-0,43270-8,43271-6,43272-4,85052-9" +"BPR" 135413542 "Ceftobiprole" "Cephalosporins (5th gen.)" "NA" "ceftob" "NA" "43269-0,43270-8,43271-6,43272-4,85052-9" "CFM1" 135413544 "Ceftobiprole medocaril" "Cephalosporins (5th gen.)" "J01DI01,QJ01DI01" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "zevtera" 1.5 "g" "NA" "CZT" 86291594 "Ceftolozane/tazobactam" "Cephalosporins (5th gen.)" "J01DI54,QJ01DI54" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "cei" "zerbaxa" 3 "g" "101484-4,73602-5,73624-9,73647-0,87735-7" -"CRO" 5479530 "Ceftriaxone" "Cephalosporins (3rd gen.)" "J01DD04,QJ01DD04" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "axo,cax,cftr,cro,ctr,frx,tx" "biotrakson,ceftriaxon,ceftriaxona,ceftriaxonum,ceftriazone,rocefin,rocephalin,rocephin,rocephine,rophex" 2 "g" "101485-1,140-4,141-2,142-0,143-8,18895-3,25244-5,25367-4,31140-7,31141-5,3451-2,41681-8,41682-6,41683-4,41732-9,50633-7,55190-3,6998-9,80957-4" +"CRO" 5479530 "Ceftriaxone" "Cephalosporins (3rd gen.)" "J01DD04,QJ01DD04" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "axo,cax,ceftri,cftr,cro,ctr,frx,trimen,trinme,tx" "biotrakson,ceftriaxon,ceftriaxona,ceftriaxonum,ceftriazone,rocefin,rocephalin,rocephin,rocephine,rophex" 2 "g" "101485-1,140-4,141-2,142-0,143-8,18895-3,25244-5,25367-4,31140-7,31141-5,3451-2,41681-8,41682-6,41683-4,41732-9,50633-7,55190-3,6998-9,80957-4" "CEB" "Ceftriaxone/beta-lactamase inhibitor" "Cephalosporins (3rd gen.)" "J01DD63,QJ01DD63" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 2 "g" "NA" -"CXM" 5479529 "Cefuroxime" "Cephalosporins (2nd gen.)" "J01DC02,QJ01DC02,QJ51DC02,QS01AA27,S01AA27" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfrx,cfur,cfx,crm,cxm,fur,rox,xm" "anaptivan,biociclin,biofuroksym,bioxima,cefofix,cefumax,cefurex,cefuril,cefurox,cefuroxim,cefuroxima,cefuroximesalt,cefuroximine,cefuroximo,cefuroximum,cephuroxime,cetroxil,colifossim,curoxim,curoxima,curoxime,froxal,furoxil,kefurox,kesint,ketocef,lifurox,medoxim,sharox,spectrazolr,ultroxim,zinacef,zinnat" 0.5 "g" 3 "g" "101503-1,144-6,145-3,146-1,147-9,18896-1,20460-2,25245-2,3452-0,35782-2,35783-0,51724-3,51774-8,55653-0,55654-8,6999-7,74699-0,80608-3,80617-4" +"CXM" 5479529 "Cefuroxime" "Cephalosporins (2nd gen.)" "J01DC02,QJ01DC02,QJ51DC02,QS01AA27,S01AA27" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cefaxe,cefrox,cefuro,cfrx,cfur,cfx,crm,cxm,fur,rox,xm" "anaptivan,biociclin,biofuroksym,bioxima,cefofix,cefumax,cefurex,cefuril,cefurox,cefuroxim,cefuroxima,cefuroximesalt,cefuroximine,cefuroximo,cefuroximum,cephuroxime,cetroxil,colifossim,curoxim,curoxima,curoxime,froxal,furoxil,kefurox,kesint,ketocef,lifurox,medoxim,sharox,spectrazolr,ultroxim,zinacef,zinnat" 0.5 "g" 3 "g" "101503-1,144-6,145-3,146-1,147-9,18896-1,20460-2,25245-2,3452-0,35782-2,35783-0,51724-3,51774-8,55653-0,55654-8,6999-7,74699-0,80608-3,80617-4" "CXA" 6321416 "Cefuroxime axetil" "Cephalosporins (2nd gen.)" "NA" "cfax" "bioracef,ceftin,cefurax,cefuroximaxetil,celocid,cepazine,cethixim,cetoxil,coliofossim,curocef,elobact,kalcef,maxitil,medoxm,nivador,novador,novocef,oraxim,zinat,zoref" "NA" "CFM2" "Cefuroxime/metronidazole" "Other antibacterials" "J01DC52,QJ01DC52" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" 0.5 "g" "NA" -"ZON" 6336505 "Cefuzonam" "Other antibacterials" "NA" "NA" "cefuzoname,cefuzonamum,cefzoname,cosmosin" "NA" -"CED" 38103 "Cephradine" "Cephalosporins (1st gen.)" "NA" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfra,cfrd" "anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef" "168-5,169-3,170-1,171-9,18902-7,55646-4" +"ZON" 6336505 "Cefuzonam" "Other antibacterials" "NA" "cefuzo" "cefuzoname,cefuzonamum,cefzoname,cosmosin" "NA" +"CED" 38103 "Cephradine" "Cephalosporins (1st gen.)" "NA" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cephra,cfra,cfrd" "anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef" "168-5,169-3,170-1,171-9,18902-7,55646-4" "CTO" 71402 "Cetocycline" "Tetracyclines" "NA" "NA" "cetocyline,cetotetrine,chelocardin" "NA" -"CHL" 5959 "Chloramphenicol" "Phenicols" "D06AX02,D10AF03,G01AA05,J01BA01,QD06AX02,QD10AF03,QG01AA05,QJ01BA01,QJ51BA01,QS01AA01,QS02AA01,QS03AA08,S01AA01,S02AA01,S03AA08" "Amphenicols" "Amphenicols" "c,chl,chlo,cl" "alficetyn,ambofen,amphicol,amseclor,anacetin,aquamycetin,austracil,austracol,biocetin,biophenicol,catilan,chemicetin,chemicetina,chlomin,chlomycol,chloramex,chloramfenikol,chloramficin,chloramfilin,chloramphenicole,chloramphenicolum,chloramsaar,chlorasol,chlorbiotic,chloricol,chlornitromycin,chloroamphenicol,chlorocaps,chlorocid,chlorocide,chlorocin,chlorocol,chlorofair,chloromax,chloromycetin,chloromycetny,chloromyxin,chloronitrin,chloroptic,chlorovules,cidocetine,ciplamycetin,cloramfen,cloramfenicol,cloramfenicolo,cloramficin,cloramicol,cloramidina,cloranfenicol,cloroamfenicolo,clorocyn,cloromisan,clorosintex,comycetin,cylphenicol,desphen,detreomycin,detreomycine,dextramycin,dextromycetin,doctamicina,econochlor,embacetin,emetren,enteromycetin,erbaplast,ertilen,farmicetina,globenicol,glorous,gloveticol,halcetin,halomycetin,hortfenicol,intramycetin,isicetin,ismicetina,isophenicol,juvamycetin,kamaver,kemicetina,kemicetine,kloramfenikol,klorita,laevomycetinum,leukamycin,leukomyan,leukomycin,levocin,levomicetina,levomitsetin,levomycetin,levoplast,levosin,levovetin,loromisan,loromisin,mastiphen,maybridge,mediamycetine,medichol,micloretin,micochlorine,micoclorina,microcetina,mychel,mycinol,myclocin,mycochlorin,novochlorocap,novomycetin,novophenicol,ocuphenicol,oftalent,oleomycetin,opclor,opelor,ophthochlor,ophthocort,ophtochlor,optomycin,otachron,otophen,pantovernil,paraxin,pentamycetin,petnamycetin,quemicetina,rivomycin,romphenil,ronphenil,septicol,sificetina,sintomicetin,sintomicetina,soluthor,stanomycetin,synthomycetin,synthomycetine,synthomycine,syntomycin,tevcocin,tevcosin,tifomycin,tifomycine,tiromycetin,treomicetina,tyfomycine,unimycetin,veticol,viceton" 3 "g" 3 "g" "15101-9,16603-3,16604-1,172-7,173-5,174-3,175-0,18903-5,25247-8,29214-4,29346-4,29347-2,3455-3,7001-1" -"CTE" 54675777 "Chlortetracycline" "Tetracyclines" "A01AB21,D06AA02,J01AA03,QA01AB21,QD06AA02,QG51AA08,QJ01AA03,QJ51AA03,QS01AA02,S01AA02" "Tetracyclines" "Tetracyclines" "NA" "acronize,alexomycin,aueromycin,aureocarmyl,aureociclina,aureocina,aureocycline,aureomycin,aureomykoin,aurofac,auxeomycin,biomitsin,biomycin,chlormax,chlorotetracycline,chlortetracyclinum,chrysomykine,clorocipan,clortetraciclina,clortetrin,declomycin,declostatin,deganol,demeclor,demeplus,demetraciclina,demetraclin,detracin,detravis,diuciclin,duomycin,elkamicina,flamycin,isphamycin,ledermicina,ledermycin,ledermycine,mexocine,novotriclina,pennchlor,perciclina,periciclina,sumaclina,uromycin,veraciclina" 1 "g" "176-8,177-6,178-4,179-2,18904-3,55655-5,87600-3" -"CIC" 19003 "Ciclacillin" "Beta-lactams/penicillins" "NA" "NA" "bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital" "NA" +"CHL" 5959 "Chloramphenicol" "Phenicols" "D06AX02,D10AF03,G01AA05,J01BA01,QD06AX02,QD10AF03,QG01AA05,QJ01BA01,QJ51BA01,QS01AA01,QS02AA01,QS03AA08,S01AA01,S02AA01,S03AA08" "Amphenicols" "Amphenicols" "c,chl,chlo,chlora,cl" "alficetyn,ambofen,amphicol,amseclor,anacetin,aquamycetin,austracil,austracol,biocetin,biophenicol,catilan,chemicetin,chemicetina,chlomin,chlomycol,chloramex,chloramfenikol,chloramficin,chloramfilin,chloramphenicole,chloramphenicolum,chloramsaar,chlorasol,chlorbiotic,chloricol,chlornitromycin,chloroamphenicol,chlorocaps,chlorocid,chlorocide,chlorocin,chlorocol,chlorofair,chloromax,chloromycetin,chloromycetny,chloromyxin,chloronitrin,chloroptic,chlorovules,cidocetine,ciplamycetin,cloramfen,cloramfenicol,cloramfenicolo,cloramficin,cloramicol,cloramidina,cloranfenicol,cloroamfenicolo,clorocyn,cloromisan,clorosintex,comycetin,cylphenicol,desphen,detreomycin,detreomycine,dextramycin,dextromycetin,doctamicina,econochlor,embacetin,emetren,enteromycetin,erbaplast,ertilen,farmicetina,globenicol,glorous,gloveticol,halcetin,halomycetin,hortfenicol,intramycetin,isicetin,ismicetina,isophenicol,juvamycetin,kamaver,kemicetina,kemicetine,kloramfenikol,klorita,laevomycetinum,leukamycin,leukomyan,leukomycin,levocin,levomicetina,levomitsetin,levomycetin,levoplast,levosin,levovetin,loromisan,loromisin,mastiphen,maybridge,mediamycetine,medichol,micloretin,micochlorine,micoclorina,microcetina,mychel,mycinol,myclocin,mycochlorin,novochlorocap,novomycetin,novophenicol,ocuphenicol,oftalent,oleomycetin,opclor,opelor,ophthochlor,ophthocort,ophtochlor,optomycin,otachron,otophen,pantovernil,paraxin,pentamycetin,petnamycetin,quemicetina,rivomycin,romphenil,ronphenil,septicol,sificetina,sintomicetin,sintomicetina,soluthor,stanomycetin,synthomycetin,synthomycetine,synthomycine,syntomycin,tevcocin,tevcosin,tifomycin,tifomycine,tiromycetin,treomicetina,tyfomycine,unimycetin,veticol,viceton" 3 "g" 3 "g" "15101-9,16603-3,16604-1,172-7,173-5,174-3,175-0,18903-5,25247-8,29214-4,29346-4,29347-2,3455-3,7001-1" +"CTE" 54675777 "Chlortetracycline" "Tetracyclines" "A01AB21,D06AA02,J01AA03,QA01AB21,QD06AA02,QG51AA08,QJ01AA03,QJ51AA03,QS01AA02,S01AA02" "Tetracyclines" "Tetracyclines" "chltet" "acronize,alexomycin,aueromycin,aureocarmyl,aureociclina,aureocina,aureocycline,aureomycin,aureomykoin,aurofac,auxeomycin,biomitsin,biomycin,chlormax,chlorotetracycline,chlortetracyclinum,chrysomykine,clorocipan,clortetraciclina,clortetrin,declomycin,declostatin,deganol,demeclor,demeplus,demetraciclina,demetraclin,detracin,detravis,diuciclin,duomycin,elkamicina,flamycin,isphamycin,ledermicina,ledermycin,ledermycine,mexocine,novotriclina,pennchlor,perciclina,periciclina,sumaclina,uromycin,veraciclina" 1 "g" "176-8,177-6,178-4,179-2,18904-3,55655-5,87600-3" +"CIC" 19003 "Ciclacillin" "Beta-lactams/penicillins" "NA" "cyclac" "bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital" "NA" "CIX" 47472 "Ciclopirox" "Antifungals/antimycotics" "D01AE14,G01AX12,QD01AE14,QG01AX12" "Antifungals for topical use" "Other antifungals for topical use" "cipx" "NA" "NA" -"CIN" 2762 "Cinoxacin" "Quinolones" "J01MB06,QJ01MB06" "Quinolone antibacterials" "Other quinolones" "cino,cnox" "cinobac,cinobactin,cinoxacine,cinoxacino,cinoxacinum,clinoxacin,noxigram,uronorm" 1 "g" "180-0,181-8,182-6,183-4,18905-0,55656-3" -"CIP" 2764 "Ciprofloxacin" "Fluoroquinolones" "J01MA02,QJ01MA02,QS01AE03,QS02AA15,QS03AA07,S01AE03,S02AA15,S03AA07" "Quinolone antibacterials" "Fluoroquinolones" "ci,cip,cipr,cp" "alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox" 1 "g" 0.8 "g" "101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9" +"CIN" 2762 "Cinoxacin" "Quinolones" "J01MB06,QJ01MB06" "Quinolone antibacterials" "Other quinolones" "cino,cinoxa,cnox" "cinobac,cinobactin,cinoxacine,cinoxacino,cinoxacinum,clinoxacin,noxigram,uronorm" 1 "g" "180-0,181-8,182-6,183-4,18905-0,55656-3" +"CIP" 2764 "Ciprofloxacin" "Fluoroquinolones" "J01MA02,QJ01MA02,QS01AE03,QS02AA15,QS03AA07,S01AE03,S02AA15,S03AA07" "Quinolone antibacterials" "Fluoroquinolones" "ci,cip,cipr,ciprof,cp" "alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox" 1 "g" 0.8 "g" "101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9" "CIM" "Ciprofloxacin/metronidazole" "Fluoroquinolones" "J01RA10,QJ01RA10" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "CIO" "Ciprofloxacin/ornidazole" "Fluoroquinolones" "J01RA12,QJ01RA12" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "CIT" "Ciprofloxacin/tinidazole" "Fluoroquinolones" "J01RA11,QJ01RA11" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"CLR" 84029 "Clarithromycin" "Macrolides/lincosamides" "J01FA09,QJ01FA09" "Macrolides, lincosamides and streptogramins" "Macrolides" "ch,cla,clar,clm,clr" "abbotic,abboticine,astromen,biaxin,bicrolid,bristamycin,clacee,clacid,clacine,clambiotic,clarem,claribid,claricide,claridar,claripen,clarith,clarithromycine,clarithromycinum,claritromicina,clarosip,clathromycin,crixan,cyllid,cyllind,eratrex,esinol,fromilid,gallimycin,helas,heliclar,klabax,klacid,klaciped,klaricid,klarid,klarin,kofron,mabicrol,macladin,maclar,mavid,meberyt,pediamycin,qidmycin,veclam,wyamycin,zeclar" 0.5 "g" 1 "g" "100048-8,16619-9,16620-7,188-3,189-1,18907-6,190-9,191-7,20375-2,23619-0,25190-0,25191-8,25192-6,25253-6,34638-7,43987-7,43990-1,43991-9,7003-7,80559-8,89485-7" +"CLR" 84029 "Clarithromycin" "Macrolides/lincosamides" "J01FA09,QJ01FA09" "Macrolides, lincosamides and streptogramins" "Macrolides" "ch,cla,clar,claryt,clm,clr" "abbotic,abboticine,astromen,biaxin,bicrolid,bristamycin,clacee,clacid,clacine,clambiotic,clarem,claribid,claricide,claridar,claripen,clarith,clarithromycine,clarithromycinum,claritromicina,clarosip,clathromycin,crixan,cyllid,cyllind,eratrex,esinol,fromilid,gallimycin,helas,heliclar,klabax,klacid,klaciped,klaricid,klarid,klarin,kofron,mabicrol,macladin,maclar,mavid,meberyt,pediamycin,qidmycin,veclam,wyamycin,zeclar" 0.5 "g" 1 "g" "100048-8,16619-9,16620-7,188-3,189-1,18907-6,190-9,191-7,20375-2,23619-0,25190-0,25191-8,25192-6,25253-6,34638-7,43987-7,43990-1,43991-9,7003-7,80559-8,89485-7" "CLA1" 5280980 "Clavulanic acid" "Other antibacterials" "NA" "NA" "amonate,clavulanate,clavulanateacid,clavulansaeure,clavulansaure,clavulox,serdaxin" "NA" -"CLX" 60063 "Clinafloxacin" "Fluoroquinolones" "NA" "NA" "NA" "32376-6,33284-1,35785-5,35786-3,7004-5" -"CLI" 446598 "Clindamycin" "Macrolides/lincosamides" "D10AF01,G01AA10,J01FF01,QD10AF01,QG01AA10,QJ01FF01" "Macrolides, lincosamides and streptogramins" "Lincosamides" "cc,cd,cli,clin,cm,da" "antirobe,chlolincocin,chlorlincocin,cleocin,clindamicina,clindamycine,clindamycinum,clinimycin,clinsol,clintabs,dalacine,klimicin,klindan,sobelin" 1.2 "g" 1.8 "g" "16621-5,16622-3,18908-4,192-5,193-3,194-1,195-8,25249-4,3486-8,42720-3,55657-1,55658-9,55659-7,55660-5,61188-9,7005-2" +"CLX" 60063 "Clinafloxacin" "Fluoroquinolones" "NA" "clinaf" "NA" "32376-6,33284-1,35785-5,35786-3,7004-5" +"CLI" 446598 "Clindamycin" "Macrolides/lincosamides" "D10AF01,G01AA10,J01FF01,QD10AF01,QG01AA10,QJ01FF01" "Macrolides, lincosamides and streptogramins" "Lincosamides" "cc,cd,cli,clin,clin32,clinda,cm,da" "antirobe,chlolincocin,chlorlincocin,cleocin,clindamicina,clindamycine,clindamycinum,clinimycin,clinsol,clintabs,dalacine,klimicin,klindan,sobelin" 1.2 "g" 1.8 "g" "16621-5,16622-3,18908-4,192-5,193-3,194-1,195-8,25249-4,3486-8,42720-3,55657-1,55658-9,55659-7,55660-5,61188-9,7005-2" "CLI-S" "Clindamycin inducible screening test" "Macrolides/lincosamides" "NA" "clin inducible,clinda inducible,clindamycin inducible" "NA" "NA" -"CLF" 2794 "Clofazimine" "Antimycobacterials" "J04BA01,QJ04BA01" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "clof" "chlofazimine,clofazimina,clofaziminum,colfazimine,lampren,lamprene,phenazine,riminophenazine" 0.1 "g" "16623-1,20376-0,23620-8,23627-3,43986-9,43988-5,43989-3,55661-3,55662-1,96108-6" +"CLF" 2794 "Clofazimine" "Antimycobacterials" "J04BA01,QJ04BA01" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "clof,clofam" "chlofazimine,clofazimina,clofaziminum,colfazimine,lampren,lamprene,phenazine,riminophenazine" 0.1 "g" "16623-1,20376-0,23620-8,23627-3,43986-9,43988-5,43989-3,55661-3,55662-1,96108-6" "CLF1" 2799 "Clofoctol" "Other antibacterials" "J01XX03,QJ01XX03" "Other antibacterials" "Other antibacterials" "NA" "clofoctolo,clofoctolum,gramplus,octofene,phenol" "NA" "CLM" 71807 "Clometocillin" "Beta-lactams/penicillins" "J01CE07,QJ01CE07" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "chlomethocillin,clometacillin,clomethacillin,clomethocillin,clometocilina,clometocilline,clometocillinsalt,clometocillinum,penicilline,rixapen" 1 "g" "NA" "CLM1" 54680675 "Clomocycline" "Tetracyclines" "J01AA11,QJ01AA11" "Tetracyclines" "Tetracyclines" "NA" "clomociclina,clomocyclinum,megaclor" 1 "g" "NA" "CTR" 2812 "Clotrimazole" "Antifungals/antimycotics" "A01AB18,D01AC01,G01AF02,QA01AB18,QD01AC01,QG01AF02,QJ02AB90" "clot" "alevazol,bisphenyl,canesten,canestene,canestine,canifug,chlotrimazole,clomatin,clotrimaderm,clotrimazol,clotrimazolum,coltrimazole,cutistad,diphenylmethane,empecid,esparol,femmesil,footlogix,fortinia,gynix,imidazole,jidesheng,klotrimazole,lakesia,lombazol,lombazole,lombazolum,lotrimax,lotrimin,monobaycuten,mycelax,mycelex,mycofug,mycosporin,mykosporin,nalbix,otomax,pedesil,pedisafe,ringworm,stiemazol,tibatin,trimysten,trivagizole" "10653-4,10654-2,18909-2,54177-1,55663-9" -"CLO" 6098 "Cloxacillin" "Beta-lactams/penicillins" "J01CF02,QJ01CF02,QJ51CF02,QS01AA90" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox" "ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen" 2 "g" 2 "g" "16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7" -"COL" 5311054 "Colistin" "Polymyxins" "A07AA10,J01XB01,QA07AA10,QJ01XB01,QJ51XB01" "Other antibacterials" "Polymyxins" "cl,coli,cs,cst,ct" "colimycin,colisticin,colisticina,colistina,colistine,colistinum,colobreathe,colomycin,kangdisu,kolimitsin,kolimycin,promixin,sogecoli,totazina" 9 "MU" 9 "MU" "16645-4,18912-6,204-8,205-5,206-3,207-1,29493-4,33333-6" +"CLO" 6098 "Cloxacillin" "Beta-lactams/penicillins" "J01CF02,QJ01CF02,QJ51CF02,QS01AA90" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,cloxac" "ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen" 2 "g" 2 "g" "16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7" +"COL" 5311054 "Colistin" "Polymyxins" "A07AA10,J01XB01,QA07AA10,QJ01XB01,QJ51XB01" "Other antibacterials" "Polymyxins" "cl,coli,colist,cs,cst,ct" "colimycin,colisticin,colisticina,colistina,colistine,colistinum,colobreathe,colomycin,kangdisu,kolimitsin,kolimycin,promixin,sogecoli,totazina" 9 "MU" 9 "MU" "16645-4,18912-6,204-8,205-5,206-3,207-1,29493-4,33333-6" "COP" "Colistin/polysorbate" "Other antibacterials" "NA" "NA" "NA" "NA" -"CYC" 6234 "Cycloserine" "Oxazolidinones" "J04AB01,QJ04AB01" "Drugs for treatment of tuberculosis" "Antibiotics" "cycl" "cicloserina,closina,cyclorin,cycloserin,cycloserinum,farmiserina,levcicloserina,levcycloserine,levcycloserinum,micoserina,miroserina,miroseryn,novoserin,oxamicina,oxamycin,seromycin,tebemicina,wasserina" 0.75 "g" "16702-3,18914-2,212-1,213-9,214-7,215-4,23608-3,25207-2,25208-0,25209-8,25251-0,3519-6,55667-0" -"DAL" 23724878 "Dalbavancin" "Glycopeptides" "J01XA04,QJ01XA04" "Other antibacterials" "Glycopeptide antibacterials" "dalb" "dalbavancina,dalvance,xydalba,zeven" 1.5 "g" "41688-3,41689-1,41690-9,41734-5" -"DAN" 71335 "Danofloxacin" "Fluoroquinolones" "QJ01MA92" "NA" "advocin,danofloxacine,danofloxacino,danofloxacinum" "73601-7,73623-1,73646-2" +"CYC" 6234 "Cycloserine" "Oxazolidinones" "J04AB01,QJ04AB01" "Drugs for treatment of tuberculosis" "Antibiotics" "cycl,cyclos" "cicloserina,closina,cyclorin,cycloserin,cycloserinum,farmiserina,levcicloserina,levcycloserine,levcycloserinum,micoserina,miroserina,miroseryn,novoserin,oxamicina,oxamycin,seromycin,tebemicina,wasserina" 0.75 "g" "16702-3,18914-2,212-1,213-9,214-7,215-4,23608-3,25207-2,25208-0,25209-8,25251-0,3519-6,55667-0" +"DAL" 23724878 "Dalbavancin" "Glycopeptides" "J01XA04,QJ01XA04" "Other antibacterials" "Glycopeptide antibacterials" "dalb,dalbav" "dalbavancina,dalvance,xydalba,zeven" 1.5 "g" "41688-3,41689-1,41690-9,41734-5" +"DAN" 71335 "Danofloxacin" "Fluoroquinolones" "QJ01MA92" "danofl" "advocin,danofloxacine,danofloxacino,danofloxacinum" "73601-7,73623-1,73646-2" "DPS" 2955 "Dapsone" "Other antibacterials" "D10AX05,J04BA02,QD10AX05,QJ04BA02" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "aczone,atrisone,avlosulfon,avlosulfone,avlosulphone,benzenamide,benzenamine,bissulfone,bissulphone,croysulfone,croysulphone,dapson,dapsona,dapsonum,daspone,diaphenylsulfon,diaphenylsulfone,diaphenylsulphon,diaphenylsulphone,diphenasone,diphone,disulfone,disulone,disulphone,dubronax,dumitone,eporal,medapsol,novophone,servidapson,sulfadione,sulfona,sulfonyldianiline,sulphadione,sulphonyldianiline,tarimyl,udolac,undolac" 50 "mg" "51698-9,9747-7" -"DAP" 16134395 "Daptomycin" "Other antibacterials" "J01XX09,QJ01XX09" "Other antibacterials" "Other antibacterials" "dap,dapt" "cidecin,cubicin,dapcin,daptomicina,daptomycine,daptomycinum,deptomycin" 0.28 "g" "35787-1,35788-9,35789-7,41691-7" +"DAP" 16134395 "Daptomycin" "Other antibacterials" "J01XX09,QJ01XX09" "Other antibacterials" "Other antibacterials" "dap,dapt,dapt25,dapt50,daptom" "cidecin,cubicin,dapcin,daptomicina,daptomycine,daptomycinum,deptomycin" 0.28 "g" "35787-1,35788-9,35789-7,41691-7" "DFX" 487101 "Delafloxacin" "Fluoroquinolones" "J01MA23,QJ01MA23" "NA" "baxdela,delafloxacinum,quofenix" 0.9 "g" 0.6 "g" "88885-9,90447-4,93790-4" "DLM" 6480466 "Delamanid" "Antimycobacterials" "J04AK06,QJ04AK06" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "dela" "deltyba" 0.2 "g" "93851-4,96109-4" -"DEM" 54680690 "Demeclocycline" "Tetracyclines" "D06AA01,J01AA01,QD06AA01,QJ01AA01" "Tetracyclines" "Tetracyclines" "NA" "demeclociclina,demeclocyclinum" 0.6 "g" "10982-7,18915-9,216-2,217-0,218-8,219-6,29494-2,7006-0" -"DKB" 470999 "Dibekacin" "Aminoglycosides" "J01GB09,QJ01GB09,QS01AA29,S01AA29" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "debecacin,dibekacina,dibekacine,dibekacinum,kappati,panamicin" 0.14 "g" "55669-6,55670-4,55671-2,55672-0" -"DIC" 18381 "Dicloxacillin" "Beta-lactams/penicillins" "J01CF01,QJ01CF01,QJ51CF01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "dicl" "dichloroxacillin,diclossacillina,dicloxaciclin,dicloxacilin,dicloxacilina,dicloxacillina,dicloxacilline,dicloxacillinum,dicloxacycline,maclicine" 2 "g" 2 "g" "10984-3,16769-2,18916-7,220-4,221-2,222-0,223-8,25252-8,32380-8,55668-8" -"DIF" 56206 "Difloxacin" "Fluoroquinolones" "QJ01MA94" "NA" "dicural,difloxacine,pulsaflox" "35790-5,35791-3,35792-1" -"DIR" 6473883 "Dirithromycin" "Macrolides/lincosamides" "J01FA13,QJ01FA13" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "dirithromycine,dirithromycinum,diritromicina,divitross,dynabac,noriclan,valodin" 0.5 "g" "35793-9,35794-7,35795-4,7007-8" -"DOR" 73303 "Doripenem" "Carbapenems" "J01DH04,QJ01DH04" "Other beta-lactam antibacterials" "Carbapenems" "dori" "doribax,dripenem,finibax" 1.5 "g" "56031-8,58711-3,60535-2,72893-1" -"DOX" 54671203 "Doxycycline" "Tetracyclines" "A01AB22,J01AA02,QA01AB22,QJ01AA02" "Tetracyclines" "Tetracyclines" "dox,doxy" "abbocin,alamycin,aquacycline,biosolvomycin,biotet,bisolvomycin,chrysocin,dalimycin,dalinmycin,deoxymykoin,dossiciclina,doxiciclina,doxirobe,doxitard,doxivetin,doxycen,doxychel,doxycin,doxycyclin,doxycyclinum,doxylin,doxysol,doxytetracycline,elinton,engemycin,hydrocyclin,imperacin,intaloxin,investin,jenacyclin,liquachel,liviatin,macodyn,mepatar,microdox,mondoxyne,monodox,morgidox,ocudox,okebo,oracea,otetryn,oxacycline,oxamycen,oxatet,oxlopar,oxybiocycline,oxydon,oxyject,oxymykoin,oxysteclin,oxytet,oxytetral,oxytetrin,oxytracyl,oxyvet,stecsolin,supracyclin,terraject,terramycin,toxinal,unimycin,vendarcin,vibramycin,vibramycine,vivox,zenavod" 0.1 "g" 0.1 "g" "10986-8,18917-5,20379-4,21250-6,224-6,225-3,226-1,227-9,23623-2,25223-9,26902-7,7008-6" +"DEM" 54680690 "Demeclocycline" "Tetracyclines" "D06AA01,J01AA01,QD06AA01,QJ01AA01" "Tetracyclines" "Tetracyclines" "demecy" "demeclociclina,demeclocyclinum" 0.6 "g" "10982-7,18915-9,216-2,217-0,218-8,219-6,29494-2,7006-0" +"DKB" 470999 "Dibekacin" "Aminoglycosides" "J01GB09,QJ01GB09,QS01AA29,S01AA29" "Aminoglycoside antibacterials" "Other aminoglycosides" "dibeka" "debecacin,dibekacina,dibekacine,dibekacinum,kappati,panamicin" 0.14 "g" "55669-6,55670-4,55671-2,55672-0" +"DIC" 18381 "Dicloxacillin" "Beta-lactams/penicillins" "J01CF01,QJ01CF01,QJ51CF01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "dicl,diclox" "dichloroxacillin,diclossacillina,dicloxaciclin,dicloxacilin,dicloxacilina,dicloxacillina,dicloxacilline,dicloxacillinum,dicloxacycline,maclicine" 2 "g" 2 "g" "10984-3,16769-2,18916-7,220-4,221-2,222-0,223-8,25252-8,32380-8,55668-8" +"DIF" 56206 "Difloxacin" "Fluoroquinolones" "QJ01MA94" "diflox" "dicural,difloxacine,pulsaflox" "35790-5,35791-3,35792-1" +"DIR" 6473883 "Dirithromycin" "Macrolides/lincosamides" "J01FA13,QJ01FA13" "Macrolides, lincosamides and streptogramins" "Macrolides" "dirith" "dirithromycine,dirithromycinum,diritromicina,divitross,dynabac,noriclan,valodin" 0.5 "g" "35793-9,35794-7,35795-4,7007-8" +"DOR" 73303 "Doripenem" "Carbapenems" "J01DH04,QJ01DH04" "Other beta-lactam antibacterials" "Carbapenems" "dori,doripe" "doribax,dripenem,finibax" 1.5 "g" "56031-8,58711-3,60535-2,72893-1" +"DOX" 54671203 "Doxycycline" "Tetracyclines" "A01AB22,J01AA02,QA01AB22,QJ01AA02" "Tetracyclines" "Tetracyclines" "dox,doxy,doxycy" "abbocin,alamycin,aquacycline,biosolvomycin,biotet,bisolvomycin,chrysocin,dalimycin,dalinmycin,deoxymykoin,dossiciclina,doxiciclina,doxirobe,doxitard,doxivetin,doxycen,doxychel,doxycin,doxycyclin,doxycyclinum,doxylin,doxysol,doxytetracycline,elinton,engemycin,hydrocyclin,imperacin,intaloxin,investin,jenacyclin,liquachel,liviatin,macodyn,mepatar,microdox,mondoxyne,monodox,morgidox,ocudox,okebo,oracea,otetryn,oxacycline,oxamycen,oxatet,oxlopar,oxybiocycline,oxydon,oxyject,oxymykoin,oxysteclin,oxytet,oxytetral,oxytetrin,oxytracyl,oxyvet,stecsolin,supracyclin,terraject,terramycin,toxinal,unimycin,vendarcin,vibramycin,vibramycine,vivox,zenavod" 0.1 "g" 0.1 "g" "10986-8,18917-5,20379-4,21250-6,224-6,225-3,226-1,227-9,23623-2,25223-9,26902-7,7008-6" "ECO" 3198 "Econazole" "Antifungals/antimycotics" "D01AC03,G01AF05,QD01AC03,QG01AF05" "Antifungals for topical use" "Imidazole and triazole derivatives" "econ" "bromazil,chloramizol,clinafarm,deccosil,deccozil,econazolum,ecostatin,ekonazole,enilconazol,enilconazole,eniloconazol,fecundal,florasan,freshgard,freshguard,fungaflor,fungazil,imaverol,imaversol,imazalil,magnate,spectazole" "25595-0,25637-0,54178-9,55673-8" "EFF" "Efflux" "Other" "NA" "effflux pump" "NA" "NA" -"ENX" 3229 "Enoxacin" "Fluoroquinolones" "J01MA04,QJ01MA04" "Quinolone antibacterials" "Fluoroquinolones" "enox" "abenox,almitil,bactidan,bactidron,comprecin,enofloxacine,enoksetin,enoram,enoxacina,enoxacine,enoxacino,enoxacinum,enoxen,enoxin,enoxor,flumark,penetrex" 0.8 "g" "16816-1,18918-3,228-7,229-5,230-3,231-1,3590-7,41692-5" -"ENR" 71188 "Enrofloxacin" "Fluoroquinolones" "QJ01MA90" "NA" "baytril,enroflox,enrofloxacine,enrofloxacino,enrofloxacinum,enroquin,enrosite,enroxil,quellaxcin,tenotryl,zobuxa" "23712-3,35796-2,35797-0,35798-8" +"ENX" 3229 "Enoxacin" "Fluoroquinolones" "J01MA04,QJ01MA04" "Quinolone antibacterials" "Fluoroquinolones" "enox,enoxa" "abenox,almitil,bactidan,bactidron,comprecin,enofloxacine,enoksetin,enoram,enoxacina,enoxacine,enoxacino,enoxacinum,enoxen,enoxin,enoxor,flumark,penetrex" 0.8 "g" "16816-1,18918-3,228-7,229-5,230-3,231-1,3590-7,41692-5" +"ENR" 71188 "Enrofloxacin" "Fluoroquinolones" "QJ01MA90" "enrofl" "baytril,enroflox,enrofloxacine,enrofloxacino,enrofloxacinum,enroquin,enrosite,enroxil,quellaxcin,tenotryl,zobuxa" "23712-3,35796-2,35797-0,35798-8" "ENV" 135565326 "Enviomycin" "Antimycobacterials" "J04AB06,QJ04AB06" "tuberactinomycin" "enviomicina,enviomycina,enviomycine,enviomycinum,tuberactin" 1 "g" "NA" "EPE" "Eperozolid" "Other antibacterials" "NA" "NA" "NA" "NA" "EPC" 71392 "Epicillin" "Beta-lactams/penicillins" "J01CA07,QJ01CA07" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "dexacillin,dihydroampicillin,epicilina,epicilline,epicillinum,spectacillin" 2 "g" 2 "g" "NA" "EPP" 68916 "Epiroprim" "Other antibacterials" "NA" "NA" "epiroprima,epiroprime,epiroprimum" "NA" "ERV" 54726192 "Eravacycline" "Tetracyclines" "J01AA13,QJ01AA13" "Tetracyclines" "Tetracyclines" "erav" "xerava" 0.14 "g" "100049-6,85423-2,93767-2" -"ETP" 150610 "Ertapenem" "Carbapenems" "J01DH03,QJ01DH03" "Other beta-lactam antibacterials" "Carbapenems" "erta,etp" "ertapenemsalt,invanz" 1 "g" "101486-9,35799-6,35800-2,35801-0,35802-8" -"ERY" 12560 "Erythromycin" "Macrolides/lincosamides" "D10AF02,J01FA01,QD10AF02,QJ01FA01,QJ51FA01,QS01AA17,S01AA17" "Macrolides, lincosamides and streptogramins" "Macrolides" "e,em,ery,eryt" "abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid" 2 "g" 1 "g" "100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4" -"ETH" 14052 "Ethambutol" "Antimycobacterials" "J04AK02,QJ04AK02" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "etha" "aethambutolum,dadibutol,diambutol,etambutol,etambutolo,ethambutolum,myambutol,purderal,servambutol,tibutol" 1.2 "g" 1.2 "g" "100051-2,16841-9,18921-7,20381-0,23625-7,240-2,241-0,242-8,243-6,25187-6,25194-2,25195-9,25230-4,25404-5,3607-9,42645-2,42646-0,55154-9,55674-6,56025-0,7010-2,89491-5" +"ETP" 150610 "Ertapenem" "Carbapenems" "J01DH03,QJ01DH03" "Other beta-lactam antibacterials" "Carbapenems" "erta,ertape,etp" "ertapenemsalt,invanz" 1 "g" "101486-9,35799-6,35800-2,35801-0,35802-8" +"ERY" 12560 "Erythromycin" "Macrolides/lincosamides" "D10AF02,J01FA01,QD10AF02,QJ01FA01,QJ51FA01,QS01AA17,S01AA17" "Macrolides, lincosamides and streptogramins" "Macrolides" "e,em,ery,ery32,eryt,eryth" "abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid" 2 "g" 1 "g" "100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4" +"ETH" 14052 "Ethambutol" "Antimycobacterials" "J04AK02,QJ04AK02" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "etha,ethamb" "aethambutolum,dadibutol,diambutol,etambutol,etambutolo,ethambutolum,myambutol,purderal,servambutol,tibutol" 1.2 "g" 1.2 "g" "100051-2,16841-9,18921-7,20381-0,23625-7,240-2,241-0,242-8,243-6,25187-6,25194-2,25195-9,25230-4,25404-5,3607-9,42645-2,42646-0,55154-9,55674-6,56025-0,7010-2,89491-5" "ETI" 456476 "Ethambutol/isoniazid" "Antimycobacterials" "J04AM03,QJ04AM03" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"ETI1" 2761171 "Ethionamide" "Antimycobacterials" "J04AD03,QJ04AD03" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "ethi" "aethionamidum,aetina,aetiva,amidazin,amidazine,atina,ethimide,ethina,ethinamide,ethionamidum,ethioniamide,ethylisothiamide,ethyonomide,etimid,etiocidan,etionamid,etionamida,etionamide,etioniamid,etionid,etionizin,etionizina,etionizine,fatoliamid,iridocin,iridozin,isothin,isotiamida,itiocide,nicotion,nisotin,nizotin,rigenicid,sertinon,teberus,thianid,thianide,thioamide,thiodine,thiomid,thioniden,tianid,tiomid,trecator,trekator,trescatyl,trescazide,tubenamide,tubermin,tuberoid,tuberoson" 0.75 "g" "16099-4,16845-0,18922-5,20382-8,23617-4,25183-5,25196-7,25198-3,25231-2,41693-3,42647-8,42648-6,7011-0,96110-2" +"ETI1" 2761171 "Ethionamide" "Antimycobacterials" "J04AD03,QJ04AD03" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "ethi,ethion" "aethionamidum,aetina,aetiva,amidazin,amidazine,atina,ethimide,ethina,ethinamide,ethionamidum,ethioniamide,ethylisothiamide,ethyonomide,etimid,etiocidan,etionamid,etionamida,etionamide,etioniamid,etionid,etionizin,etionizina,etionizine,fatoliamid,iridocin,iridozin,isothin,isotiamida,itiocide,nicotion,nisotin,nizotin,rigenicid,sertinon,teberus,thianid,thianide,thioamide,thiodine,thiomid,thioniden,tianid,tiomid,trecator,trekator,trescatyl,trescazide,tubenamide,tubermin,tuberoid,tuberoson" 0.75 "g" "16099-4,16845-0,18922-5,20382-8,23617-4,25183-5,25196-7,25198-3,25231-2,41693-3,42647-8,42648-6,7011-0,96110-2" "ETO" 6034 "Ethopabate" "Other antibacterials" "QP51AX17" "NA" "ethopabat" "NA" "EXE" "Exebacase" "NA" "NA" "NA" "NA" -"FAR" 65894 "Faropenem" "Other antibacterials" "J01DI03,QJ01DI03" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "farom,faropenemhydrate,faropenemsalt,fropenem,fropenum,furopenem" 0.75 "g" "73600-9,73622-3,73645-4" +"FAR" 65894 "Faropenem" "Other antibacterials" "J01DI03,QJ01DI03" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "farope" "farom,faropenemhydrate,faropenemsalt,fropenem,fropenum,furopenem" 0.75 "g" "73600-9,73622-3,73645-4" "FDX" 10034073 "Fidaxomicin" "Other antibacterials" "A07AA12,QA07AA12" "NA" "dificid,dificlir,difimicin,fidaxomicina,lipiarmicin,lipiarmycin,lipiarrmycin" 0.4 "g" "73599-3,73621-5,73644-7" "FIN" 11567473 "Finafloxacin" "Fluoroquinolones" "NA" "NA" "xtoro" "73598-5,73620-7,73643-9" -"FLA" 46783781 "Flavomycin" "Other antibacterials" "NA" "NA" "bambermicina,bambermycine,bambermycinum,flavofosfolipol,flavophospholipol,gainpro,menomycin" "NA" -"FLE" 3357 "Fleroxacin" "Fluoroquinolones" "J01MA08,QJ01MA08" "Quinolone antibacterials" "Fluoroquinolones" "fler" "fleroxacine,fleroxacino,fleroxacinum,fleroxicin,megalocin,megalone,megalosin,quinodis" 0.4 "g" 0.4 "g" "25411-0,32372-5,35806-9,7012-8" -"FLO" 65864 "Flomoxef" "Other antibacterials" "J01DC14,QJ01DC14" "NA" "flomoxefo,flomoxefsalt,flomoxefum,flumarin" 2 "g" "100052-0,53822-3" -"FLR" 114811 "Florfenicol" "Phenicols" "QJ01BA90,QJ51BA90" "NA" "aquafen,descocin,dexawin,efnicol,fricol,hyrazin,loncor,macphenicol,masatirin,neomyson,norfenicol,nuflor,racephenicol,rincrol,thiamcol,urfamicina,urophenyl" "23740-4,35807-7,35808-5,87599-7" -"FLC" 21319 "Flucloxacillin" "Beta-lactams/penicillins" "J01CF05,QJ01CF05,QJ51CF05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,flux" "bactopen,cloxacap,cloxacillinhydrate,cloxypen,floxacillin,floxacillinanhydrous,floxapen,floxapensalt,fluclomix,flucloxacilina,flucloxacilline,flucloxacillinum,flucloxin,fluorochloroxacillin,galfloxin,latocillin,orbeninhydrate,rimaflox,staphobristol,zoxin" 2 "g" 2 "g" "NA" -"FLU" 3365 "Fluconazole" "Antifungals/antimycotics" "D01AC15,J02AC01,QD01AC15,QJ02AC01" "Antimycotics for systemic use" "Triazole derivatives" "fluc,fluz,flz" "alflucoz,alkanazole,baten,biocanol,biozole,biozolene,canzol,cryptal,diflazon,diflucan,dimycon,elazor,flucazol,fluconazoli,fluconazolum,flucoral,flucostat,flukezol,flunazol,flunizol,fluzon,forcan,fuconal,fungata,loitin,mutum,oxifugol,pritenzol,syscan,trican,triconal,triflucan,zemyc,zoltec,zonal" 0.2 "g" 0.2 "g" "10987-6,16870-8,18924-1,248-5,249-3,250-1,251-9,25255-1,7013-6,80530-9" -"FCT" 3366 "Flucytosine" "Antifungals/antimycotics" "D01AE21,J02AX01,QD01AE21,QJ02AX01" "Antifungals for topical use" "Other antifungals for topical use" "5flc,fcu,fluo,fluy" "alcobon,ancoban,ancobon,ancotil,ancotyl,flourocytosine,flucitosina,flucytosin,flucytosinum,flucytosone,fluocytosine,fluorcytosine,fluorocytosine" 10 "g" 10 "g" "NA" -"FLM" 3374 "Flumequine" "Quinolones" "J01MB07,QJ01MB07" "Quinolone antibacterials" "Other quinolones" "NA" "apurone,fantacin,flumequina,flumequino,flumequinum,flumigal,flumiquil,flumisol,flumix,imequyl" 1.2 "g" "55675-3,55676-1,55677-9,55678-7" +"FLA" 46783781 "Flavomycin" "Other antibacterials" "NA" "flavom" "bambermicina,bambermycine,bambermycinum,flavofosfolipol,flavophospholipol,gainpro,menomycin" "NA" +"FLE" 3357 "Fleroxacin" "Fluoroquinolones" "J01MA08,QJ01MA08" "Quinolone antibacterials" "Fluoroquinolones" "fler,flerox" "fleroxacine,fleroxacino,fleroxacinum,fleroxicin,megalocin,megalone,megalosin,quinodis" 0.4 "g" 0.4 "g" "25411-0,32372-5,35806-9,7012-8" +"FLO" 65864 "Flomoxef" "Other antibacterials" "J01DC14,QJ01DC14" "flomox" "flomoxefo,flomoxefsalt,flomoxefum,flumarin" 2 "g" "100052-0,53822-3" +"FLR" 114811 "Florfenicol" "Phenicols" "QJ01BA90,QJ51BA90" "florfe" "aquafen,descocin,dexawin,efnicol,fricol,hyrazin,loncor,macphenicol,masatirin,neomyson,norfenicol,nuflor,racephenicol,rincrol,thiamcol,urfamicina,urophenyl" "23740-4,35807-7,35808-5,87599-7" +"FLC" 21319 "Flucloxacillin" "Beta-lactams/penicillins" "J01CF05,QJ01CF05,QJ51CF05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,fluclo,flux" "bactopen,cloxacap,cloxacillinhydrate,cloxypen,floxacillin,floxacillinanhydrous,floxapen,floxapensalt,fluclomix,flucloxacilina,flucloxacilline,flucloxacillinum,flucloxin,fluorochloroxacillin,galfloxin,latocillin,orbeninhydrate,rimaflox,staphobristol,zoxin" 2 "g" 2 "g" "NA" +"FLU" 3365 "Fluconazole" "Antifungals/antimycotics" "D01AC15,J02AC01,QD01AC15,QJ02AC01" "Antimycotics for systemic use" "Triazole derivatives" "fluc,flucon,fluz,flz" "alflucoz,alkanazole,baten,biocanol,biozole,biozolene,canzol,cryptal,diflazon,diflucan,dimycon,elazor,flucazol,fluconazoli,fluconazolum,flucoral,flucostat,flukezol,flunazol,flunizol,fluzon,forcan,fuconal,fungata,loitin,mutum,oxifugol,pritenzol,syscan,trican,triconal,triflucan,zemyc,zoltec,zonal" 0.2 "g" 0.2 "g" "10987-6,16870-8,18924-1,248-5,249-3,250-1,251-9,25255-1,7013-6,80530-9" +"FCT" 3366 "Flucytosine" "Antifungals/antimycotics" "D01AE21,J02AX01,QD01AE21,QJ02AX01" "Antifungals for topical use" "Other antifungals for topical use" "5flc,fcu,flucyt,fluo,fluy" "alcobon,ancoban,ancobon,ancotil,ancotyl,flourocytosine,flucitosina,flucytosin,flucytosinum,flucytosone,fluocytosine,fluorcytosine,fluorocytosine" 10 "g" 10 "g" "NA" +"FLM" 3374 "Flumequine" "Quinolones" "J01MB07,QJ01MB07" "Quinolone antibacterials" "Other quinolones" "flumeq" "apurone,fantacin,flumequina,flumequino,flumequinum,flumigal,flumiquil,flumisol,flumix,imequyl" 1.2 "g" "55675-3,55676-1,55677-9,55678-7" "FLR1" 71260 "Flurithromycin" "Macrolides/lincosamides" "J01FA14,QJ01FA14" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "abbot,beritromicina,berythromycin,berythromycine,berythromycinum,flurithromycine,flurithromycinum,fluritromicina,fluritromycinum,flurizic,mizar" 0.75 "g" "NA" "FFL" 214356 "Fosfluconazole" "Antifungals/antimycotics" "NA" "NA" "fosfluconazol,procif,prodif" "NA" -"FOS" 446987 "Fosfomycin" "Other antibacterials" "J01XX01,QJ01XX01,QS02AA17,S02AA17" "Other antibacterials" "Other antibacterials" "ff,fm,fo,fof,fos,fosf" "fosfocina,fosfomicin,fosfomicina,fosfomycine,fosfomycinum,fosfonomycin,infectophos,phosphonemycin,phosphonomycin,veramina" 3 "g" 8 "g" "25596-8,25653-7,35809-3,35810-1" +"FOS" 446987 "Fosfomycin" "Other antibacterials" "J01XX01,QJ01XX01,QS02AA17,S02AA17" "Other antibacterials" "Other antibacterials" "ff,fm,fo,fof,fos,fosf,fosfom,fosmyc" "fosfocina,fosfomicin,fosfomicina,fosfomycine,fosfomycinum,fosfonomycin,infectophos,phosphonemycin,phosphonomycin,veramina" 3 "g" 8 "g" "25596-8,25653-7,35809-3,35810-1" "FMD" 572 "Fosmidomycin" "Other antibacterials" "NA" "NA" "fosmidomicina,fosmidomycina,fosmidomycine,fosmidomycinsalt,fosmidomycinum" "NA" -"FRM" 8378 "Framycetin" "Aminoglycosides" "D09AA01,QD09AA01,QJ01GB91,QR01AX08,QS01AA07,R01AX08,S01AA07" "fram" "actilin,actiline,antibiotique,bycomycin,enterfram,fradiomycin,fradiomycinum,framicetina,framidal,framycetine,framycetinum,framycin,framygen,francetin,jernadex,myacyne,mycerin,mycifradin,neobrettin,neolate,neomas,neomcin,neomicina,neomin,neomycine,neomycinum,nivemycin,soframycin,soframycine" "18926-6,257-6,258-4,259-2,260-0,55679-5" +"FRM" 8378 "Framycetin" "Aminoglycosides" "D09AA01,QD09AA01,QJ01GB91,QR01AX08,QS01AA07,R01AX08,S01AA07" "fram,framyc" "actilin,actiline,antibiotique,bycomycin,enterfram,fradiomycin,fradiomycinum,framicetina,framidal,framycetine,framycetinum,framycin,framygen,francetin,jernadex,myacyne,mycerin,mycifradin,neobrettin,neolate,neomas,neomcin,neomicina,neomin,neomycine,neomycinum,nivemycin,soframycin,soframycine" "18926-6,257-6,258-4,259-2,260-0,55679-5" "FUR" 6870646 "Furazidin" "Other antibacterials" "J01XE03,QJ01XE03" "Other antibacterials" "Nitrofuran derivatives" "NA" "akritoin,furagin,furaginum,furamag,furazidine,hydantoin" 0.3 "g" "NA" -"FRZ" 5323714 "Furazolidone" "Other antibacterials" "G01AX06,QG01AX06,QJ01XE90" "NA" "bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn" "69574-2,87794-4" -"FUS" 3000226 "Fusidic acid" "Other antibacterials" "D06AX01,D09AA02,J01XC01,QD06AX01,QD09AA02,QJ01XC01,QS01AA13,S01AA13" "Other antibacterials" "Steroid antibacterials" "fa,fusi" "flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta" 1.5 "g" 1.5 "g" "NA" +"FRZ" 5323714 "Furazolidone" "Other antibacterials" "G01AX06,QG01AX06,QJ01XE90" "furazo" "bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn" "69574-2,87794-4" +"FUS" 3000226 "Fusidic acid" "Other antibacterials" "D06AX01,D09AA02,J01XC01,QD06AX01,QD09AA02,QJ01XC01,QS01AA13,S01AA13" "Other antibacterials" "Steroid antibacterials" "fa,fusaci,fusi" "flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta" 1.5 "g" 1.5 "g" "NA" "GAM" 59364992 "Gamithromycin" "Macrolides/lincosamides" "QJ01FA95" "NA" "zactran" "100054-6,88376-9,88378-5" -"GRN" 124093 "Garenoxacin" "Fluoroquinolones" "J01MA19,QJ01MA19" "NA" "ganefloxacin,garenfloxacin" 0.4 "g" "35811-9,35812-7,35813-5" -"GAT" 5379 "Gatifloxacin" "Fluoroquinolones" "J01MA16,QJ01MA16,QS01AE06,S01AE06" "Quinolone antibacterials" "Fluoroquinolones" "gati" "acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer" 0.4 "g" 0.4 "g" "31036-7,31038-3,31040-9,31042-5,41494-6" -"GEM" 9571107 "Gemifloxacin" "Fluoroquinolones" "J01MA15,QJ01MA15" "Quinolone antibacterials" "Fluoroquinolones" "NA" "factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum" 0.32 "g" 0.2 "g" "35814-3,35815-0,35816-8,41697-4" -"GEN" 3467 "Gentamicin" "Aminoglycosides" "D06AX07,J01GB03,QA07AA91,QD06AX07,QG01AA91,QG51AA04,QJ01GB03,QJ51GB03,QS01AA11,QS02AA14,QS03AA06,S01AA11,S02AA14,S03AA06" "Aminoglycoside antibacterials" "Other aminoglycosides" "cn,gen,gent,gm" "centicin,cidomycin,garamicin,garamycin,gentacycol,gentamicina,gentamicine,gentamicins,gentamicinum,gentamycins,gentamycinum,gentocin,lyramycin,oksitselanim,septigen,septocin" 0.24 "g" "101494-3,13561-6,13562-4,15106-8,18928-2,18929-0,22746-2,22747-0,266-7,267-5,268-3,269-1,31091-2,31092-0,31093-8,35668-3,35817-6,3663-2,3664-0,3665-7,39082-3,47109-4,50630-3,59379-8,7016-9,7017-7,7018-5,80971-5,88111-0,89481-6" +"GRN" 124093 "Garenoxacin" "Fluoroquinolones" "J01MA19,QJ01MA19" "gareno" "ganefloxacin,garenfloxacin" 0.4 "g" "35811-9,35812-7,35813-5" +"GAT" 5379 "Gatifloxacin" "Fluoroquinolones" "J01MA16,QJ01MA16,QS01AE06,S01AE06" "Quinolone antibacterials" "Fluoroquinolones" "gati,gatifl" "acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer" 0.4 "g" 0.4 "g" "31036-7,31038-3,31040-9,31042-5,41494-6" +"GEM" 9571107 "Gemifloxacin" "Fluoroquinolones" "J01MA15,QJ01MA15" "Quinolone antibacterials" "Fluoroquinolones" "gemifl" "factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum" 0.32 "g" 0.2 "g" "35814-3,35815-0,35816-8,41697-4" +"GEN" 3467 "Gentamicin" "Aminoglycosides" "D06AX07,J01GB03,QA07AA91,QD06AX07,QG01AA91,QG51AA04,QJ01GB03,QJ51GB03,QS01AA11,QS02AA14,QS03AA06,S01AA11,S02AA14,S03AA06" "Aminoglycoside antibacterials" "Other aminoglycosides" "cn,ge1000,ge2000,gen,gen128,gen500,gent,genta1,gentam,gm" "centicin,cidomycin,garamicin,garamycin,gentacycol,gentamicina,gentamicine,gentamicins,gentamicinum,gentamycins,gentamycinum,gentocin,lyramycin,oksitselanim,septigen,septocin" 0.24 "g" "101494-3,13561-6,13562-4,15106-8,18928-2,18929-0,22746-2,22747-0,266-7,267-5,268-3,269-1,31091-2,31092-0,31093-8,35668-3,35817-6,3663-2,3664-0,3665-7,39082-3,47109-4,50630-3,59379-8,7016-9,7017-7,7018-5,80971-5,88111-0,89481-6" "GEH" "Gentamicin-high" "Aminoglycosides" "NA" "gehi,gehl,genta high,gentamicin high" "NA" "18929-0,35817-6,7017-7,7018-5" "GEP" 25101874 "Gepotidacin" "Other antibacterials" "J01XX13,QJ01XX13" "NA" "gepotidacina,gepotidacine" "NA" -"GRX" 72474 "Grepafloxacin" "Fluoroquinolones" "J01MA11,QJ01MA11" "Quinolone antibacterials" "Fluoroquinolones" "grep" "grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar" 0.4 "g" "21316-5,23638-0,23639-8,35818-4" +"GRX" 72474 "Grepafloxacin" "Fluoroquinolones" "J01MA11,QJ01MA11" "Quinolone antibacterials" "Fluoroquinolones" "grep,grepaf" "grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar" 0.4 "g" "21316-5,23638-0,23639-8,35818-4" "GRI" 441140 "Griseofulvin" "Antifungals/antimycotics" "D01AA08,D01BA01,QD01AA08,QD01BA01" "NA" "amudane,delmofulvina,epigriseofulvin,fulcin,fulcine,fulvicin,fulvidex,fulvina,fulvinil,fulvistatin,fungivin,greosin,gresfeed,gricin,grifulin,grifulvin,grisactin,griscofulvin,grisefuline,griseo,griseofulviin,griseofulvina,griseofulvine,griseofulvinum,griseomix,griseostatin,grisetin,grisofulvin,grisovin,grisowen,grizeofulvin,grysio,guservin,lamoryl,likuden,likunden,murfulvin,poncyl,spiro,spirofulvin,xuanjing" 0.5 "g" "12402-4,54200-1,54201-9,54202-7" "HAB" 175989 "Habekacin" "Aminoglycosides" "NA" "NA" "amikafur,amikan,amitrex,arikayce,biklin,biodacyn,chemacin,fabianol,habekacinxsulfate,likacin,pierami" "NA" "HCH" 11979956 "Hachimycin" "Antifungals/antimycotics" "D01AA03,G01AA06,J02AA02,QD01AA03,QG01AA06,QJ02AA02" "Antimycotics for systemic use" "Antibiotics" "NA" "cabimicina,hachimicina,hachimycine,hachimycinum,trichomycinum,trichonat" "NA" -"HET" 443387 "Hetacillin" "Beta-lactams/penicillins" "J01CA18,QJ01CA18" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "etacillina,hetacilina,hetacilline,hetacillinum,natacillin,phenazacillin,versapen,versatrex" 2 "g" "18931-6,274-1,275-8,276-6,277-4" +"HET" 443387 "Hetacillin" "Beta-lactams/penicillins" "J01CA18,QJ01CA18" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "hetaci" "etacillina,hetacilina,hetacilline,hetacillinum,natacillin,phenazacillin,versapen,versatrex" 2 "g" "18931-6,274-1,275-8,276-6,277-4" "HYG" 56928061 "Hygromycin" "Aminoglycosides" "NA" "NA" "antihelmycin,destomysin,hyanthelmix,hygromix,hygrovectine,hygrovetine" "NA" "IBX" "Ibrexafungerp" "Antifungals" "J02AX07,QJ02AX07" "NA" "NA" "NA" -"ICL" 213043 "Iclaprim" "Other antibacterials" "J01EA03,QJ01EA03" "NA" "iclaprime,mersarex" "73597-7,73619-9,73642-1" -"IPM" 104838 "Imipenem" "Carbapenems" "J01DH51,QJ01DH51" "Other beta-lactam antibacterials" "Carbapenems" "imci,imi,imip,imp" "imipemide,imipenemum,imipenen,primaxin,recarbrio,tienam,tienamycin" 2 "g" "101487-7,17010-0,18932-4,18933-2,23613-3,25221-3,25257-7,27331-8,278-2,279-0,280-8,281-6,282-4,283-2,284-0,285-7,35819-2,3688-9,54170-6,54171-4,54172-2,7019-3,85424-0,93232-7,96372-8" +"ICL" 213043 "Iclaprim" "Other antibacterials" "J01EA03,QJ01EA03" "iclapr" "iclaprime,mersarex" "73597-7,73619-9,73642-1" +"IPM" 104838 "Imipenem" "Carbapenems" "J01DH51,QJ01DH51" "Other beta-lactam antibacterials" "Carbapenems" "imci,imi,imip,imip32,imipen,imp" "imipemide,imipenemum,imipenen,primaxin,recarbrio,tienam,tienamycin" 2 "g" "101487-7,17010-0,18932-4,18933-2,23613-3,25221-3,25257-7,27331-8,278-2,279-0,280-8,281-6,282-4,283-2,284-0,285-7,35819-2,3688-9,54170-6,54171-4,54172-2,7019-3,85424-0,93232-7,96372-8" "IPE" "Imipenem/EDTA" "Carbapenems" "NA" "NA" "NA" "35819-2,54170-6,54171-4,54172-2" "IMR" "Imipenem/relebactam" "Carbapenems" "J01DH56,QJ01DH56" "NA" "NA" 2 "g" "85424-0,93232-7,96372-8" "ISV" 6918485 "Isavuconazole" "Antifungals/antimycotics" "J02AC05,QJ02AC05" "isav" "benzonitrile,ravuconazole" 0.2 "g" 0.2 "g" "85381-2,88887-5" -"ISE" 3037209 "Isepamicin" "Aminoglycosides" "J01GB11,QJ01GB11" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "isepacin,isepalline,isepamicina,isepamicine,isepamicinsulphate,isepamicinum" 0.4 "g" "32381-6,35820-0,35821-8,55680-3" +"ISE" 3037209 "Isepamicin" "Aminoglycosides" "J01GB11,QJ01GB11" "Aminoglycoside antibacterials" "Other aminoglycosides" "isepam" "isepacin,isepalline,isepamicina,isepamicine,isepamicinsulphate,isepamicinum" 0.4 "g" "32381-6,35820-0,35821-8,55680-3" "ISO" 3760 "Isoconazole" "Antifungals/antimycotics" "D01AC05,G01AF07,QD01AC05,QG01AF07" "Antimycotics for topic use" "Triazole derivatives" "NA" "isoconazol,isoconazolum,travogen" "55681-1,55682-9,55683-7,55684-5" -"INH" 3767 "Isoniazid" "Antimycobacterials" "J04AC01,QJ04AC01" "Drugs for treatment of tuberculosis" "Hydrazides" "inh" "abdizide,acetylisoniazide,andrazide,anidrasona,antimicina,antituberkulosum,armacide,armazid,armazide,atcotibine,azuren,cedin,cemidon,chemiazid,chemidon,continazine,cortinazine,cotinazin,cotinizin,defonin,dianicotyl,dibutin,diforin,dinacrin,dinocrin,ditubin,ebidene,eralon,ertuban,eutizon,evalon,fetefu,fimalene,hidranizil,hidrasonil,hidrulta,hidrun,hycozid,hydra,hydrazid,hyozid,hyzyd,idrazil,inizid,ipcazide,iscotin,isidrina,ismazide,isobicina,isocid,isocidene,isocotin,isohydrazide,isokin,isolyn,isonerit,isonex,isoniacid,isoniazida,isoniazide,isoniazidum,isonicazide,isonicid,isonico,isonicotan,isonicotil,isonicotinhydrazid,isonicotinohydrazide,isonide,isonidrin,isonikazid,isonilex,isonin,isonindon,isonirit,isoniton,isonizida,isonizide,isotamine,isotebe,isotebezid,isotinyl,isozid,isozide,isozyd,laniazid,laniozid,mayambutol,mybasan,neoteben,neoxin,neumandin,nevin,niadrin,nicazide,nicetal,nicizina,niconyl,nicotibina,nicotibine,nicotisan,nicozide,nidaton,nidrazid,nikozid,niplen,nitadon,niteban,nitebannsc,nydrazid,nyscozid,pelazid,percin,phthisen,preparation,pycazide,pyreazid,pyricidin,pyridicin,pyrizidin,raumanon,razide,retozide,rifater,rimicid,rimifon,rimiphone,rimitsid,robiselin,robisellin,roxifen,sanohidrazina,sauterazid,sauterzid,stanozide,tebecid,tebenic,tebexin,tebilon,tebos,teebaconin,tekazin,tibazide,tibemid,tibiazide,tibinide,tibison,tibivis,tibizide,tibusan,tisin,tisiodrazida,tizide,tubazid,tubazide,tubeco,tubecotubercid,tuberian,tubicon,tubilysin,tubizid,tubomel,tyvid,unicocyde,unicozyde,vazadrine,vederon,zidafimia,zinadon,zonazide" 0.3 "g" 0.3 "g" "18934-0,20383-6,23947-5,25217-1,25218-9,25219-7,25451-6,26756-7,286-5,287-3,288-1,289-9,29315-9,3697-0,40371-7,42649-4,42650-2,42651-0,45215-1,48171-3,48172-1,55685-2,7020-1,89488-1" +"INH" 3767 "Isoniazid" "Antimycobacterials" "J04AC01,QJ04AC01" "Drugs for treatment of tuberculosis" "Hydrazides" "inh,isonia" "abdizide,acetylisoniazide,andrazide,anidrasona,antimicina,antituberkulosum,armacide,armazid,armazide,atcotibine,azuren,cedin,cemidon,chemiazid,chemidon,continazine,cortinazine,cotinazin,cotinizin,defonin,dianicotyl,dibutin,diforin,dinacrin,dinocrin,ditubin,ebidene,eralon,ertuban,eutizon,evalon,fetefu,fimalene,hidranizil,hidrasonil,hidrulta,hidrun,hycozid,hydra,hydrazid,hyozid,hyzyd,idrazil,inizid,ipcazide,iscotin,isidrina,ismazide,isobicina,isocid,isocidene,isocotin,isohydrazide,isokin,isolyn,isonerit,isonex,isoniacid,isoniazida,isoniazide,isoniazidum,isonicazide,isonicid,isonico,isonicotan,isonicotil,isonicotinhydrazid,isonicotinohydrazide,isonide,isonidrin,isonikazid,isonilex,isonin,isonindon,isonirit,isoniton,isonizida,isonizide,isotamine,isotebe,isotebezid,isotinyl,isozid,isozide,isozyd,laniazid,laniozid,mayambutol,mybasan,neoteben,neoxin,neumandin,nevin,niadrin,nicazide,nicetal,nicizina,niconyl,nicotibina,nicotibine,nicotisan,nicozide,nidaton,nidrazid,nikozid,niplen,nitadon,niteban,nitebannsc,nydrazid,nyscozid,pelazid,percin,phthisen,preparation,pycazide,pyreazid,pyricidin,pyridicin,pyrizidin,raumanon,razide,retozide,rifater,rimicid,rimifon,rimiphone,rimitsid,robiselin,robisellin,roxifen,sanohidrazina,sauterazid,sauterzid,stanozide,tebecid,tebenic,tebexin,tebilon,tebos,teebaconin,tekazin,tibazide,tibemid,tibiazide,tibinide,tibison,tibivis,tibizide,tibusan,tisin,tisiodrazida,tizide,tubazid,tubazide,tubeco,tubecotubercid,tuberian,tubicon,tubilysin,tubizid,tubomel,tyvid,unicocyde,unicozyde,vazadrine,vederon,zidafimia,zinadon,zonazide" 0.3 "g" 0.3 "g" "18934-0,20383-6,23947-5,25217-1,25218-9,25219-7,25451-6,26756-7,286-5,287-3,288-1,289-9,29315-9,3697-0,40371-7,42649-4,42650-2,42651-0,45215-1,48171-3,48172-1,55685-2,7020-1,89488-1" "IST" "Isoniazid/sulfamethoxazole/trimethoprim/pyridoxine" "Antimycobacterials" "NA" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"ITR" 3793 "Itraconazole" "Antifungals/antimycotics" "J02AC02,QJ02AC02" "Antimycotics for systemic use" "Triazole derivatives" "itra" "candistat,canditral,cladosal,fungitraxx,intraconazole,itraconazol,itraconazolo,itraconazolum,itraconzaole,itrafungol,itralek,itrizole,lozanoc,onmel,sempera,sporamelt,sporanox,sporonox,traconal,triasporin" 0.2 "g" 0.2 "g" "10989-2,12392-7,25258-5,25452-4,27081-9,32184-4,32185-1,32603-3,54179-7,7021-9,80531-7" -"JOS" 5282165 "Josamycin" "Macrolides/lincosamides" "J01FA07,QJ01FA07" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "jomybel,josamicina,josamycine,josamycinum" 2 "g" "25597-6,25702-2,41698-2,41699-0" -"KAN" 6032 "Kanamycin" "Aminoglycosides" "A07AA08,J01GB04,QA07AA08,QJ01GB04,QS01AA24,S01AA24" "Aminoglycoside antibacterials" "Other aminoglycosides" "hlk,k,kan,kana,km" "kanamicina,kanamycine,kanamycins,kanamycinum,kantrex,klebcil" 3 "g" 1 "g" "18935-7,18936-5,23609-1,23889-9,25182-7,25213-0,25214-8,290-7,291-5,292-3,293-1,3698-8,3699-6,3700-2,42652-8,47395-9,49080-5,7022-7,7023-5,7024-3,88002-1,88705-9,89482-4" +"ITR" 3793 "Itraconazole" "Antifungals/antimycotics" "J02AC02,QJ02AC02" "Antimycotics for systemic use" "Triazole derivatives" "itra,itraco" "candistat,canditral,cladosal,fungitraxx,intraconazole,itraconazol,itraconazolo,itraconazolum,itraconzaole,itrafungol,itralek,itrizole,lozanoc,onmel,sempera,sporamelt,sporanox,sporonox,traconal,triasporin" 0.2 "g" 0.2 "g" "10989-2,12392-7,25258-5,25452-4,27081-9,32184-4,32185-1,32603-3,54179-7,7021-9,80531-7" +"JOS" 5282165 "Josamycin" "Macrolides/lincosamides" "J01FA07,QJ01FA07" "Macrolides, lincosamides and streptogramins" "Macrolides" "josamy" "jomybel,josamicina,josamycine,josamycinum" 2 "g" "25597-6,25702-2,41698-2,41699-0" +"KAN" 6032 "Kanamycin" "Aminoglycosides" "A07AA08,J01GB04,QA07AA08,QJ01GB04,QS01AA24,S01AA24" "Aminoglycoside antibacterials" "Other aminoglycosides" "hlk,k,kan,kana,kanamy,km" "kanamicina,kanamycine,kanamycins,kanamycinum,kantrex,klebcil" 3 "g" 1 "g" "18935-7,18936-5,23609-1,23889-9,25182-7,25213-0,25214-8,290-7,291-5,292-3,293-1,3698-8,3699-6,3700-2,42652-8,47395-9,49080-5,7022-7,7023-5,7024-3,88002-1,88705-9,89482-4" "KAH" "Kanamycin-high" "Aminoglycosides" "NA" "k_h,kahl" "NA" "18936-5,7023-5,7024-3" "KAC" "Kanamycin/cephalexin" "Aminoglycosides" "NA" "NA" "NA" "NA" -"KET" 456201 "Ketoconazole" "Antifungals/antimycotics" "D01AC08,G01AF11,H02CA03,J02AB02,QD01AC08,QG01AF11,QH02CA03,QJ02AB02" "Antimycotics for systemic use" "Imidazole derivatives" "keto,ktc" "brizoral,ethanone,extina,fungarest,fungoral,ketaconazole,ketocanazole,ketoconazol,ketoconazolum,ketodan,ketoderm,ketoisdin,ketozole,kuric,levoketoconazole,nizoral,normocort,panfungol,piperazine,recorlev,sebazole,teryzolin,terzolin,tocris,xolegel" 0.6 "g" "10990-0,12393-5,18937-3,25259-3,294-9,295-6,296-4,297-2,60091-6,60092-4,7025-0" +"KET" 456201 "Ketoconazole" "Antifungals/antimycotics" "D01AC08,G01AF11,H02CA03,J02AB02,QD01AC08,QG01AF11,QH02CA03,QJ02AB02" "Antimycotics for systemic use" "Imidazole derivatives" "keto,ketoco,ktc" "brizoral,ethanone,extina,fungarest,fungoral,ketaconazole,ketocanazole,ketoconazol,ketoconazolum,ketodan,ketoderm,ketoisdin,ketozole,kuric,levoketoconazole,nizoral,normocort,panfungol,piperazine,recorlev,sebazole,teryzolin,terzolin,tocris,xolegel" 0.6 "g" "10990-0,12393-5,18937-3,25259-3,294-9,295-6,296-4,297-2,60091-6,60092-4,7025-0" "KIT" "Kitasamycin" "Macrolides/lincosamides" "QJ01FA93" "leucomycin" "NA" "NA" "LAS" 5360807 "Lasalocid" "Other antibacterials" "QP51BB02" "NA" "avatec,bovate,bovatec,lasalocide,lasalocido,lasalocidsalt,lasalocidum" "87598-9" "LSC" 71528768 "Lascufloxacin" "Fluoroquinolones" "J01MA25,QJ01MA25" "Quinolone antibacterials" "Fluoroquinolones" "NA" "lasvic" 75 "mg" "NA" "LTM" 47499 "Latamoxef" "Cephalosporins (3rd gen.)" "J01DD06,QJ01DD06" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "mox,moxa,moxalactam" "dilatamoxef,festamoxin,lamoxactam,latamoxefum,morrhuate,moxalactamsalt,moxam,shiomarin" 4 "g" "NA" "LMU" 25185057 "Lefamulin" "Other antibacterials" "J01XX12,QJ01XX12" "NA" "lefamulinacetate,xenleta" "85425-7,99281-8" "LEN" 65646 "Lenampicillin" "Beta-lactams/penicillins" "NA" "NA" "lenampicilina,lenampicilline,lenampicillinum,takacillin,valacillin,varacillin" "NA" -"LVX" 149096 "Levofloxacin" "Fluoroquinolones" "J01MA12,QJ01MA12,QS01AE05,S01AE05" "Quinolone antibacterials" "Fluoroquinolones" "le,lev,levo,lvx" "aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan" 0.5 "g" 0.5 "g" "101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1" +"LVX" 149096 "Levofloxacin" "Fluoroquinolones" "J01MA12,QJ01MA12,QS01AE05,S01AE05" "Quinolone antibacterials" "Fluoroquinolones" "le,lev,levo,levofl,lvx" "aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan" 0.5 "g" 0.5 "g" "101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1" "LEO" "Levofloxacin/ornidazole" "Fluoroquinolones" "J01RA05,QJ01RA05" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "LND" 9850038 "Levonadifloxacin" "Fluoroquinolones" "J01MA24,QJ01MA24" "NA" "NA" "NA" "LSP" "Linco-spectin" "Other antibacterials" "NA" "lincomycin/spectinomycin" "NA" "NA" -"LIN" 3000540 "Lincomycin" "Macrolides/lincosamides" "J01FF02,QJ01FF02,QJ51FF02" "Macrolides, lincosamides and streptogramins" "Lincosamides" "linc" "albiotic,bactramycin,cillimycin,frademicina,jiemycin,lincocin,lincogap,lincolcina,lincolnensin,lincomicina,lincomix,lincomycine,lincomycinum,lincomyocin,lincorex,linocin,mycivin" 1.8 "g" 1.8 "g" "18938-1,298-0,299-8,300-4,301-2,41700-6,87597-1" -"LNZ" 441401 "Linezolid" "Oxazolidinones" "J01XX08,QJ01XX08" "Other antibacterials" "Other antibacterials" "line,lnz,lz,lzd" "desfluorolinezolid,linezoid,linezolidum,zivoxid,zyvox,zyvoxa,zyvoxam,zyvoxid" 1.2 "g" 1.2 "g" "29254-0,29255-7,29258-1,33332-8,34202-2,41500-0,80609-1,88706-7,96111-0" -"LFE" "Linoprist-flopristin" "Other antibacterials" "NA" "NA" "NA" "NA" -"LOM" 3948 "Lomefloxacin" "Fluoroquinolones" "J01MA07,QJ01MA07,QS01AE04,S01AE04" "Quinolone antibacterials" "Fluoroquinolones" "lmf,lom,lome" "bareon,logiflox,lomebact,lomefloxacine,lomefloxacino,lomefloxacinum,maxaquin,maxaquine,mazaquin,okacin,okacyn,uniquin" 0.4 "g" "18939-9,302-0,303-8,304-6,305-3,41701-4" -"LOR" 5284585 "Loracarbef" "Cephalosporins (2nd gen.)" "J01DC08,QJ01DC08" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "lora" "carbac,lorabid,loracarbefum,lorafem,lorbef,loribid" 0.6 "g" "18940-7,306-1,307-9,308-7,309-5,7027-6" +"LIN" 3000540 "Lincomycin" "Macrolides/lincosamides" "J01FF02,QJ01FF02,QJ51FF02" "Macrolides, lincosamides and streptogramins" "Lincosamides" "linc,lincom" "albiotic,bactramycin,cillimycin,frademicina,jiemycin,lincocin,lincogap,lincolcina,lincolnensin,lincomicina,lincomix,lincomycine,lincomycinum,lincomyocin,lincorex,linocin,mycivin" 1.8 "g" 1.8 "g" "18938-1,298-0,299-8,300-4,301-2,41700-6,87597-1" +"LNZ" 441401 "Linezolid" "Oxazolidinones" "J01XX08,QJ01XX08" "Other antibacterials" "Other antibacterials" "line,linezo,lnz,lz,lzd" "desfluorolinezolid,linezoid,linezolidum,zivoxid,zyvox,zyvoxa,zyvoxam,zyvoxid" 1.2 "g" 1.2 "g" "29254-0,29255-7,29258-1,33332-8,34202-2,41500-0,80609-1,88706-7,96111-0" +"LFE" "Linoprist-flopristin" "Other antibacterials" "NA" "linflo" "NA" "NA" +"LOM" 3948 "Lomefloxacin" "Fluoroquinolones" "J01MA07,QJ01MA07,QS01AE04,S01AE04" "Quinolone antibacterials" "Fluoroquinolones" "lmf,lom,lome,lomefl" "bareon,logiflox,lomebact,lomefloxacine,lomefloxacino,lomefloxacinum,maxaquin,maxaquine,mazaquin,okacin,okacyn,uniquin" 0.4 "g" "18939-9,302-0,303-8,304-6,305-3,41701-4" +"LOR" 5284585 "Loracarbef" "Cephalosporins (2nd gen.)" "J01DC08,QJ01DC08" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "lora,loraca" "carbac,lorabid,loracarbefum,lorafem,lorbef,loribid" 0.6 "g" "18940-7,306-1,307-9,308-7,309-5,7027-6" "LYM" 54707177 "Lymecycline" "Tetracyclines" "J01AA04,QJ01AA04" "Tetracyclines" "Tetracyclines" "NA" "armyl,chlortetracyclin,ciclisin,ciclolysal,ciclolysine,eficiclina,infaciclina,limeciclina,lisinbiotic,lymecyclinum,mucomycin,ntetracycline,tetralisal,tetralysal,vebicyclysal" 0.6 "g" 0.6 "g" "18941-5,310-3,311-1,312-9,313-7" "MNA" 1292 "Mandelic acid" "Other antibacterials" "B05CA06,J01XX06,QB05CA06,QJ01XX06" "Other antibacterials" "Other antibacterials" "NA" "amygdalate,mandelsaeure,paramandelate,phenylglycolate,phenylhydroxyacetate,uromaline" 12 "g" "NA" "MGX" "Manogepix" "Antifungals" "NA" "NA" "NA" "NA" -"MAR" 60651 "Marbofloxacin" "Fluoroquinolones" "QJ01MA93" "NA" "marbocyl,marbofloxacine,marbofloxacino,marbofloxacinum,marboquin,zeniquin" "73596-9,73618-1,73641-3" -"MEC" 36273 "Mecillinam" "Beta-lactams/penicillins" "J01CA11,QJ01CA11" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "amdinocillin" "amdinocillin,coactin,hexacillin,mecilinamo,mecillinamum,selexidin" 1.2 "g" "NA" +"MAR" 60651 "Marbofloxacin" "Fluoroquinolones" "QJ01MA93" "marbof" "marbocyl,marbofloxacine,marbofloxacino,marbofloxacinum,marboquin,zeniquin" "73596-9,73618-1,73641-3" +"MEC" 36273 "Mecillinam" "Beta-lactams/penicillins" "J01CA11,QJ01CA11" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "amdinocillin,mecill" "amdinocillin,coactin,hexacillin,mecilinamo,mecillinamum,selexidin" 1.2 "g" "NA" "MEL" 71306732 "Meleumycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA" -"MEM" 441130 "Meropenem" "Carbapenems" "J01DH02,QJ01DH02" "Other beta-lactam antibacterials" "Carbapenems" "mem,mer,mero,mp,mrp" "meronem,meropen,meropenemum,merrem" 3 "g" "101222-8,101488-5,101489-3,18943-1,41406-0,6651-4,6652-2,6653-0,6654-8,7029-2,85426-5,85427-3,88892-5,90980-4" +"MEM" 441130 "Meropenem" "Carbapenems" "J01DH02,QJ01DH02" "Other beta-lactam antibacterials" "Carbapenems" "mem,mer,mero,merope,mp,mrp" "meronem,meropen,meropenemum,merrem" 3 "g" "101222-8,101488-5,101489-3,18943-1,41406-0,6651-4,6652-2,6653-0,6654-8,7029-2,85426-5,85427-3,88892-5,90980-4" "MNC" "Meropenem/nacubactam" "Carbapenems" "NA" "NA" "NA" "NA" "MEV" "Meropenem/vaborbactam" "Carbapenems" "J01DH52,QJ01DH52" "Other beta-lactam antibacterials" "Carbapenems" "NA" "NA" 3 "g" "101222-8,101489-3,85427-3,88892-5,90980-4" "MES" 176886 "Mesulfamide" "Other antibacterials" "NA" "NA" "mesulfamida,mesulfamido,mesulfamidum" "NA" -"MTC" 54675785 "Metacycline" "Tetracyclines" "J01AA05,QJ01AA05" "Tetracyclines" "Tetracyclines" "NA" "bialatan,metaciclina,metacyclinum,methacyclin,methacycline,methacyclinum,methylenecycline,physiomycine,rondomycin" 0.6 "g" "NA" +"MTC" 54675785 "Metacycline" "Tetracyclines" "J01AA05,QJ01AA05" "Tetracyclines" "Tetracyclines" "methcy" "bialatan,metaciclina,metacyclinum,methacyclin,methacycline,methacyclinum,methylenecycline,physiomycine,rondomycin" 0.6 "g" "NA" "MTM" 6713928 "Metampicillin" "Beta-lactams/penicillins" "J01CA14,QJ01CA14" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "blomopen,bonopen,celinmicina,elatocilline,filorex,magnipen,metambac,metampen,metampicilina,metampicillina,metampicilline,metampicillinsalt,metampicillinum,micinovo,ocelina,pangocilin,probiotic,relyothenate,ruticina,rutizina,sedomycin,serfabiotic,suvipen,viderpen,viderpin,vioplex" 1.5 "g" 1.5 "g" "NA" "MTH" 4101 "Methenamine" "Other antibacterials" "J01XX05,QJ01XX05" "Other antibacterials" "Other antibacterials" "NA" "aminoform,aminoformaldehyde,ammoform,ammonioformaldehyde,antihydral,carin,cystamin,cystex,cystogen,duirexol,esametilentetramina,formamine,formin,grasselerator,heterin,hexaform,hexaloids,hexamethylamine,hexamethylenamine,hexamethyleneamine,hexamethylentetramin,hexamine,hexaminum,hexasan,hexilmethylenamine,metenamina,metenamine,methamin,methamine,methenamin,methenaminum,metramine,naphthamine,pellurin,resotropin,uramin,urasal,uratrine,urisol,uritone,urodeine,urotropin,urotropine,vesaloin,xametrin" 3 "g" "NA" -"MET" 6087 "Meticillin" "Beta-lactams/penicillins" "J01CF03,QJ01CF03,QJ51CF03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "meti" "belfacillin,celbenin,celpilline,cinopenil,dimocillin,estafcilina,flabelline,lucopenin,metacillin,methcillin,methicillin,methicillinanhydrous,methicillinhydrate,methicillinsalt,methicillinum,methycillin,meticilina,meticillina,meticilline,meticillinsalt,meticillinum,penaureus,penysol,staficyn,staphcillin,synticillin" 4 "g" "NA" +"MET" 6087 "Meticillin" "Beta-lactams/penicillins" "J01CF03,QJ01CF03,QJ51CF03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "methic,meti" "belfacillin,celbenin,celpilline,cinopenil,dimocillin,estafcilina,flabelline,lucopenin,metacillin,methcillin,methicillin,methicillinanhydrous,methicillinhydrate,methicillinsalt,methicillinum,methycillin,meticilina,meticillina,meticilline,meticillinsalt,meticillinum,penaureus,penysol,staficyn,staphcillin,synticillin" 4 "g" "NA" "MTP" 68590 "Metioprim" "Other antibacterials" "NA" "NA" "methioprim,metioprima,metioprime,metioprimum" "NA" "MXT" 3047729 "Metioxate" "Fluoroquinolones" "NA" "NA" "metioxato,metioxatum" "NA" -"MTR" 4173 "Metronidazole" "Other antibacterials" "A01AB17,D06BX01,G01AF01,J01XD01,P01AB01,QA01AB17,QD06BX01,QG01AF01,QJ01XD01,QP51CA01" "Other antibacterials" "Imidazole derivatives" "metr,mnz" "acromona,anagiardil,arilin,atrivyl,bexon,clont,danizol,deflamon,donnan,efloran,elyzol,entizol,eumin,flagemona,flagesol,flagil,flagyl,flazol,flegyl,florazole,fossyol,giatricol,gineflavir,givagil,hydroxydimetridazole,hydroxymetronidazole,izoklion,klion,klont,mepagyl,meronidal,metric,metrolag,metrolyl,metromidol,metronidazolo,metronidazolum,metroplex,metrotop,mexibol,monagyl,monasin,nalox,nidagyl,noritate,novonidazol,nuvessa,orvagil,polibiotic,protostat,rathimed,rosaced,rosased,sanatrichom,satric,takimetol,trichazol,trichex,trichobrol,trichocide,trichomol,trichopal,trichopol,tricocet,tricom,trikacide,trikamon,trikhopol,trikojol,trikozol,trimeks,trivazol,vagilen,vagimid,vandazole,vertisal,wagitran,zadstat,zidoval" 2 "g" 1.5 "g" "10991-8,18946-4,326-9,327-7,328-5,329-3,7031-8" -"MEZ" 656511 "Mezlocillin" "Beta-lactams/penicillins" "J01CA10,QJ01CA10" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "mez,mezl,mz" "baycipen,baypen,mezlin,mezlocilina,mezlocilline,mezlocillinsalt,mezlocillinum,multocillin" 6 "g" "18947-2,330-1,331-9,332-7,333-5,3820-8,41702-2,54194-6,54195-3,54196-1" -"MSU" "Mezlocillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "54194-6,54195-3,54196-1" -"MIF" 477468 "Micafungin" "Antifungals/antimycotics" "J02AX05,QJ02AX05" "Antimycotics for systemic use" "Other antimycotics for systemic use" "mica" "fungard,funguard,micafungina,micafunginsalt,mycamine" 0.1 "g" "53812-4,58418-5,65340-2,85048-7" +"MTR" 4173 "Metronidazole" "Other antibacterials" "A01AB17,D06BX01,G01AF01,J01XD01,P01AB01,QA01AB17,QD06BX01,QG01AF01,QJ01XD01,QP51CA01" "Other antibacterials" "Imidazole derivatives" "metr,metron,mnz" "acromona,anagiardil,arilin,atrivyl,bexon,clont,danizol,deflamon,donnan,efloran,elyzol,entizol,eumin,flagemona,flagesol,flagil,flagyl,flazol,flegyl,florazole,fossyol,giatricol,gineflavir,givagil,hydroxydimetridazole,hydroxymetronidazole,izoklion,klion,klont,mepagyl,meronidal,metric,metrolag,metrolyl,metromidol,metronidazolo,metronidazolum,metroplex,metrotop,mexibol,monagyl,monasin,nalox,nidagyl,noritate,novonidazol,nuvessa,orvagil,polibiotic,protostat,rathimed,rosaced,rosased,sanatrichom,satric,takimetol,trichazol,trichex,trichobrol,trichocide,trichomol,trichopal,trichopol,tricocet,tricom,trikacide,trikamon,trikhopol,trikojol,trikozol,trimeks,trivazol,vagilen,vagimid,vandazole,vertisal,wagitran,zadstat,zidoval" 2 "g" 1.5 "g" "10991-8,18946-4,326-9,327-7,328-5,329-3,7031-8" +"MEZ" 656511 "Mezlocillin" "Beta-lactams/penicillins" "J01CA10,QJ01CA10" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "mez,mezl,mezlo,mz" "baycipen,baypen,mezlin,mezlocilina,mezlocilline,mezlocillinsalt,mezlocillinum,multocillin" 6 "g" "18947-2,330-1,331-9,332-7,333-5,3820-8,41702-2,54194-6,54195-3,54196-1" +"MSU" "Mezlocillin/sulbactam" "Beta-lactams/penicillins" "NA" "mezsul" "NA" "54194-6,54195-3,54196-1" +"MIF" 477468 "Micafungin" "Antifungals/antimycotics" "J02AX05,QJ02AX05" "Antimycotics for systemic use" "Other antimycotics for systemic use" "mica,micafu" "fungard,funguard,micafungina,micafunginsalt,mycamine" 0.1 "g" "53812-4,58418-5,65340-2,85048-7" "MCZ" 4189 "Miconazole" "Antifungals/antimycotics" "A01AB09,A07AC01,D01AC02,G01AF04,J02AB01,QA01AB09,QA07AC01,QD01AC02,QG01AF04,QJ02AB01,QS02AA13,S02AA13" "Antimycotics for systemic use" "Imidazole derivatives" "mico" "aflorix,albistat,andergin,brentan,conofite,dactarin,florid,micantin,miconazol,miconazolo,miconazolum,micozole,minostate,monazole,monista,monistat,oravig,vusion,zimybase,zimycan" 0.2 "g" 1 "g" "17278-3,25607-3,25722-0,54180-5,55686-0" -"MCR" 3037206 "Micronomicin" "Aminoglycosides" "QS01AA22,S01AA22" "NA" "micromicin,micromycin,micronomicina,micronomicine,micronomicinum,sagamicin,santemycin" "NA" -"MID" 5282169 "Midecamycin" "Macrolides/lincosamides" "J01FA03,QJ01FA03" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "macropen,madecacine,medemycin,midecamicina,midecamycine,midecamycinum,midecin,momicine,myoxam,normicina,rubimycin" 1.2 "g" 1 "g" "NA" -"MIL" 37614 "Miloxacin" "Fluoroquinolones" "NA" "NA" "miloxacine,miloxacino,miloxacinum" "NA" -"MNO" 54675783 "Minocycline" "Tetracyclines" "A01AB23,D10AF07,J01AA08,QA01AB23,QD10AF07,QJ01AA08" "Tetracyclines" "Tetracyclines" "mc,mh,mi,min,mino,mn,mno" "acnez,arestin,borymycin,dynacin,lederderm,minociclina,minocin,minocline,minocyclin,minocyclinum,minocyn,minomax,minomycin,mynocine,periocline,solodyn,vectrin,ximino" 1 "mg" 0.2 "g" "18948-0,25225-4,334-3,335-0,336-8,337-6,34606-4,3822-4,49757-8,55156-4,7032-6" +"MCR" 3037206 "Micronomicin" "Aminoglycosides" "QS01AA22,S01AA22" "micron" "micromicin,micromycin,micronomicina,micronomicine,micronomicinum,sagamicin,santemycin" "NA" +"MID" 5282169 "Midecamycin" "Macrolides/lincosamides" "J01FA03,QJ01FA03" "Macrolides, lincosamides and streptogramins" "Macrolides" "mideka" "macropen,madecacine,medemycin,midecamicina,midecamycine,midecamycinum,midecin,momicine,myoxam,normicina,rubimycin" 1.2 "g" 1 "g" "NA" +"MIL" 37614 "Miloxacin" "Fluoroquinolones" "NA" "amiflo" "miloxacine,miloxacino,miloxacinum" "NA" +"MNO" 54675783 "Minocycline" "Tetracyclines" "A01AB23,D10AF07,J01AA08,QA01AB23,QD10AF07,QJ01AA08" "Tetracyclines" "Tetracyclines" "mc,mh,mi,min,mino,minocy,mn,mno" "acnez,arestin,borymycin,dynacin,lederderm,minociclina,minocin,minocline,minocyclin,minocyclinum,minocyn,minomax,minomycin,mynocine,periocline,solodyn,vectrin,ximino" 1 "mg" 0.2 "g" "18948-0,25225-4,334-3,335-0,336-8,337-6,34606-4,3822-4,49757-8,55156-4,7032-6" "MCM" 5282188 "Miocamycin" "Macrolides/lincosamides" "J01FA11,QJ01FA11" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "acecamycin,macroral,miocamen,miocamycine,miokamycin,mosil,myocamicin,ponsinomycin" 1.2 "g" "18949-8,338-4,339-2,340-0,341-8,55687-8" "MON" 23667299 "Monensin sodium" "Other antibacterials" "NA" "NA" "coban,elancoban,monelan,monensin,monensina,monensine,monensinum,monovet,romensin,rumensin" "NA" "MRN" 70374 "Morinamide" "Antimycobacterials" "J04AK04,QJ04AK04" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "morfazinamide,morfazinammide,morfgazinamide,morinamida,morinamidum,morphazinamid,morphazinamide,piazofolina,piazolin,piazolina" "NA" -"MFX" 152946 "Moxifloxacin" "Fluoroquinolones" "J01MA14,QJ01MA14,QS01AE07,S01AE07" "Quinolone antibacterials" "Fluoroquinolones" "mox,moxi,mxf" "actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin" 0.4 "g" 0.4 "g" "31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8" -"MUP" 446596 "Mupirocin" "Other antibacterials" "D06AX09,QD06AX09,QR01AX06,R01AX06" "mup,mupi" "bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin" "20389-3,35822-6,35823-4,60542-8,60543-6,7033-4" +"MFX" 152946 "Moxifloxacin" "Fluoroquinolones" "J01MA14,QJ01MA14,QS01AE07,S01AE07" "Quinolone antibacterials" "Fluoroquinolones" "mox,moxi,moxifl,mxf" "actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin" 0.4 "g" 0.4 "g" "31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8" +"MUP" 446596 "Mupirocin" "Other antibacterials" "D06AX09,QD06AX09,QR01AX06,R01AX06" "mup,mupi,mupiro" "bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin" "20389-3,35822-6,35823-4,60542-8,60543-6,7033-4" "NAC" 73386748 "Nacubactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA" "NAD" 4410 "Nadifloxacin" "Fluoroquinolones" "D10AF05,QD10AF05" "NA" "acuatim,nadifloxacine,nadifloxacino,nadifloxacinum,nadixa,nadoxin" "NA" -"NAF" 8982 "Nafcillin" "Beta-lactams/penicillins" "J01CF06,QJ01CF06" "NA" "nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen" 3 "g" "10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8" +"NAF" 8982 "Nafcillin" "Beta-lactams/penicillins" "J01CF06,QJ01CF06" "nafcil" "nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen" 3 "g" "10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8" "ZWK" 117587595 "Nafithromycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA" -"NAL" 4421 "Nalidixic acid" "Quinolones" "J01MB02,QJ01MB02" "Quinolone antibacterials" "Other quinolones" "na,nal,nali" "amfonelinsaeure,baktogram,betaxina,chemiurin,cybis,dixiben,dixilina,dixinal,eucisten,eucistin,innoxalomn,innoxalon,jicsron,kusnarin,nalidicron,nalidixan,nalidixane,nalidixate,nalidixateanhydrous,nalidixic,nalidixin,nalidixinsaure,nalitucsan,nalix,nalurin,narigix,naxuril,negram,nevigramon,nicelate,nogram,poleon,sicmylon,specifen,specifin,unaserus,uralgin,uriben,uriclar,urisal,urodixin,uroman,uroneg,uronidix,uropan,wintomylon,wintron" 4 "g" "NA" +"NAL" 4421 "Nalidixic acid" "Quinolones" "J01MB02,QJ01MB02" "Quinolone antibacterials" "Other quinolones" "na,nal,nalac,nali" "amfonelinsaeure,baktogram,betaxina,chemiurin,cybis,dixiben,dixilina,dixinal,eucisten,eucistin,innoxalomn,innoxalon,jicsron,kusnarin,nalidicron,nalidixan,nalidixane,nalidixate,nalidixateanhydrous,nalidixic,nalidixin,nalidixinsaure,nalitucsan,nalix,nalurin,narigix,naxuril,negram,nevigramon,nicelate,nogram,poleon,sicmylon,specifen,specifin,unaserus,uralgin,uriben,uriclar,urisal,urodixin,uroman,uroneg,uronidix,uropan,wintomylon,wintron" 4 "g" "NA" "NAL-S" "Nalidixic acid screening test" "Quinolones" "NA" "nal screen" "NA" "NA" -"NAR" 65452 "Narasin" "Other antibacterials" "QP51BB04" "NA" "monteban,narasine,narasino,narasinum,skycis" "87570-8" +"NAR" 65452 "Narasin" "Other antibacterials" "QP51BB04" "narasi" "monteban,narasine,narasino,narasinum,skycis" "87570-8" "NEM" 11993740 "Nemonoxacin" "Fluoroquinolones" "J01MB08,QJ01MB08" "Quinolone antibacterials" "Other quinolones" "NA" "NA" "NA" -"NEO" 8378 "Neomycin" "Aminoglycosides" "A01AB08,A07AA01,B05CA09,D06AX04,J01GB05,QA01AB08,QA07AA01,QB05CA09,QD06AX04,QJ01GB05,QR02AB01,QS01AA03,QS02AA07,QS03AA01,R02AB01,S01AA03,S02AA07,S03AA01" "Aminoglycoside antibacterials" "Other aminoglycosides" "neom" "NA" 5 "g" 1 "g" "10995-9,18953-0,25262-7,354-1,355-8,356-6,357-4,41705-5" -"NET" 441306 "Netilmicin" "Aminoglycosides" "J01GB07,QJ01GB07,QS01AA23,S01AA23" "Aminoglycoside antibacterials" "Other aminoglycosides" "neti" "netillin,netilmicina,netilmicine,netilmicinum,netilyn,netira,netromicine,netromycin,nettacin,ntromicine,ntromycin,vectacin,zetamicin" 0.35 "g" 0.35 "g" "18954-8,25263-5,358-2,359-0,360-8,361-6,3848-9,3849-7,3850-5,47385-0,59565-2,59566-0,59567-8,7035-9" +"NEO" 8378 "Neomycin" "Aminoglycosides" "A01AB08,A07AA01,B05CA09,D06AX04,J01GB05,QA01AB08,QA07AA01,QB05CA09,QD06AX04,QJ01GB05,QR02AB01,QS01AA03,QS02AA07,QS03AA01,R02AB01,S01AA03,S02AA07,S03AA01" "Aminoglycoside antibacterials" "Other aminoglycosides" "neom,neomyc" "NA" 5 "g" 1 "g" "10995-9,18953-0,25262-7,354-1,355-8,356-6,357-4,41705-5" +"NET" 441306 "Netilmicin" "Aminoglycosides" "J01GB07,QJ01GB07,QS01AA23,S01AA23" "Aminoglycoside antibacterials" "Other aminoglycosides" "neti,netilm" "netillin,netilmicina,netilmicine,netilmicinum,netilyn,netira,netromicine,netromycin,nettacin,ntromicine,ntromycin,vectacin,zetamicin" 0.35 "g" 0.35 "g" "18954-8,25263-5,358-2,359-0,360-8,361-6,3848-9,3849-7,3850-5,47385-0,59565-2,59566-0,59567-8,7035-9" "NIC" 9507 "Nicarbazin" "Other antibacterials" "NA" "NA" "nicarb,nicarbasin,nicarbazine,nicarmix,nicoxin,nicrazin,nicrazine,nirazin" "NA" "NIF" 71946 "Nifuroquine" "Fluoroquinolones" "NA" "NA" "abimasten,nifuroquina,nifuroquinum,quinaldofur" "NA" "NFR" 9571062 "Nifurtoinol" "Other antibacterials" "J01XE02,QJ01XE02" "Other antibacterials" "Nitrofuran derivatives" "NA" "levantin,nifurmazol,nifurmazole,nifurmazolo,nifurmazolum,nifurtoinolo,nifurtoinolum,urfadin,urfadine,urfadyn" 0.16 "g" "NA" "NTZ" 41684 "Nitazoxanide" "Other antibacterials" "P01AX11" "NA" "alinia,benzamide,colufase,cryptaz,daxon,dexidex,heliton,kidonax,nitax,nitaxozanid,nitaxozanide,nitazox,nitazoxamide,nitazoxanid,nitazoxanida,nitazoxanidum,nitrazoxanide,pacovanton,paramix,phavic" 1 "g" "73595-1,73617-3,73640-5" -"NIT" 6604200 "Nitrofurantoin" "Other antibacterials" "J01XE01,QJ01XE01" "Other antibacterials" "Nitrofuran derivatives" "f,f/m,fd,ft,ni,nit,nitr" "alfuran,benkfuran,berkfuran,berkfurin,ceduran,chemiofuran,cistofuran,cyantin,cystit,dantafur,fuamed,furabid,furachel,furadantin,furadantine,furadantoin,furadoin,furadoine,furadonin,furadonine,furadoninum,furadontin,furalan,furaloid,furantoina,furatoin,furedan,furina,furobactina,furodantin,gerofuran,ituran,macpac,macrobid,macrodantin,macrodantina,macrofuran,macrofurin,nierofu,nifuraden,nifuradene,nifuradeno,nifuradenum,nifuradine,nifurantin,nifuretten,nitoin,nitrex,nitrofuradantin,nitrofurantoina,nitrofurantoine,nitrofurantoinum,novofuran,orafuran,oxafuradene,oxafurandene,oxifuradene,oxyfuradene,parfuran,phenurin,renafur,siraliden,trantoin,uerineks,urizept,urodin,urofuran,urofurin,urolisa,urolong,uvamin,welfurin,zoofurin" 0.2 "g" "18955-5,362-4,363-2,364-0,365-7,3860-4,7036-7" -"NIZ" 5447130 "Nitrofurazone" "Other antibacterials" "NA" "NA" "acutol,aldomycin,alfucin,amifur,babrocid,becafurazone,biofuracina,biofurea,chemofuran,chixin,cocafurin,coxistat,dermofural,dymazone,dynazone,eldezol,fedacin,flavazone,fracine,furacilin,furacilinum,furacillin,furacin,furacine,furacinetten,furacoccid,furacort,furacycline,furaderm,furagent,furalcyn,furaldon,furalone,furametral,furaplast,furaseptyl,furaskin,furatsilin,furaziline,furazin,furazina,furazyme,furesol,furosem,fuvacillin,hemofuran,hydrazinecarboxamide,ibiofural,mammex,mastofuran,monafuracin,monafuracis,monofuracin,nefco,nifucin,nifurid,nifuzon,nitrofural,nitrofuralum,nitrofuran,nitrofurane,nitrofurazan,nitrofurazonum,nitrofurol,nitrozone,otofural,otofuran,rivafurazon,rivopon,sanfuran,semioxamazide,vabrocid,vadrocid,yatrocin" "20388-5,87793-6" +"NIT" 6604200 "Nitrofurantoin" "Other antibacterials" "J01XE01,QJ01XE01" "Other antibacterials" "Nitrofuran derivatives" "f,f/m,fd,ft,ni,nit,nit16,nitr,nitro" "alfuran,benkfuran,berkfuran,berkfurin,ceduran,chemiofuran,cistofuran,cyantin,cystit,dantafur,fuamed,furabid,furachel,furadantin,furadantine,furadantoin,furadoin,furadoine,furadonin,furadonine,furadoninum,furadontin,furalan,furaloid,furantoina,furatoin,furedan,furina,furobactina,furodantin,gerofuran,ituran,macpac,macrobid,macrodantin,macrodantina,macrofuran,macrofurin,nierofu,nifuraden,nifuradene,nifuradeno,nifuradenum,nifuradine,nifurantin,nifuretten,nitoin,nitrex,nitrofuradantin,nitrofurantoina,nitrofurantoine,nitrofurantoinum,novofuran,orafuran,oxafuradene,oxafurandene,oxifuradene,oxyfuradene,parfuran,phenurin,renafur,siraliden,trantoin,uerineks,urizept,urodin,urofuran,urofurin,urolisa,urolong,uvamin,welfurin,zoofurin" 0.2 "g" "18955-5,362-4,363-2,364-0,365-7,3860-4,7036-7" +"NIZ" 5447130 "Nitrofurazone" "Other antibacterials" "NA" "nitfur" "acutol,aldomycin,alfucin,amifur,babrocid,becafurazone,biofuracina,biofurea,chemofuran,chixin,cocafurin,coxistat,dermofural,dymazone,dynazone,eldezol,fedacin,flavazone,fracine,furacilin,furacilinum,furacillin,furacin,furacine,furacinetten,furacoccid,furacort,furacycline,furaderm,furagent,furalcyn,furaldon,furalone,furametral,furaplast,furaseptyl,furaskin,furatsilin,furaziline,furazin,furazina,furazyme,furesol,furosem,fuvacillin,hemofuran,hydrazinecarboxamide,ibiofural,mammex,mastofuran,monafuracin,monafuracis,monofuracin,nefco,nifucin,nifurid,nifuzon,nitrofural,nitrofuralum,nitrofuran,nitrofurane,nitrofurazan,nitrofurazonum,nitrofurol,nitrozone,otofural,otofuran,rivafurazon,rivopon,sanfuran,semioxamazide,vabrocid,vadrocid,yatrocin" "20388-5,87793-6" "NTR" 19910 "Nitroxoline" "Fluoroquinolones" "J01XX07,QJ01XX07" "Other antibacterials" "Other antibacterials" "NA" "galinok,isinok,nibiol,nicene,nitroxlina,nitroxolin,nitroxolina,nitroxolinum,noxibiol,noxin" 1 "g" "25608-1,25723-8,32382-4,54181-3,55688-6" -"NOR" 4539 "Norfloxacin" "Fluoroquinolones" "J01MA06,QJ01MA06,QS01AE02,S01AE02" "Quinolone antibacterials" "Fluoroquinolones" "nor,norf,nx,nxn" "baccidal,barazan,chibroxin,chibroxine,chibroxol,fulgram,gonorcin,lexinor,nolicin,noracin,noraxin,norflo,norfloxacine,norfloxacino,norfloxacinum,norocin,noroxin,noroxine,norxacin,sebercim,uroxacin,utinor,zoroxin" 0.8 "g" "18956-3,366-5,367-3,368-1,369-9,3867-9,41504-2,7037-5" +"NOR" 4539 "Norfloxacin" "Fluoroquinolones" "J01MA06,QJ01MA06,QS01AE02,S01AE02" "Quinolone antibacterials" "Fluoroquinolones" "nor,norf,norflo,nx,nxn" "baccidal,barazan,chibroxin,chibroxine,chibroxol,fulgram,gonorcin,lexinor,nolicin,noracin,noraxin,norflo,norfloxacine,norfloxacino,norfloxacinum,norocin,noroxin,noroxine,norxacin,sebercim,uroxacin,utinor,zoroxin" 0.8 "g" "18956-3,366-5,367-3,368-1,369-9,3867-9,41504-2,7037-5" "NOR-S" "Norfloxacin screening test" "Fluoroquinolones" "NA" "nor screen" "NA" "NA" "NME" "Norfloxacin/metronidazole" "Fluoroquinolones" "J01RA14,QJ01RA14" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "NTI" "Norfloxacin/tinidazole" "Fluoroquinolones" "J01RA13,QJ01RA13" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "NVA" 10419027 "Norvancomycin" "Glycopeptides" "NA" "NA" "NA" "NA" -"NOV" 54675769 "Novobiocin" "Other antibacterials" "QJ01XX95" "novo" "albadry,albamix,albamycin,biotexin,cardelmycin,cardelmycinsalt,cathocin,cathomycin,inabiocin,novobiocina,novobiocine,novobiocinsalt,novobiocinum,robiocina,sirbiocina,spheromycin,stilbiocina,streptonivicin,streptonivicinsalt,vulcamicina,vulcamycin,vulkamycin" "17378-1,18957-1,370-7,371-5,372-3,373-1,41706-3" -"NYS" 6433272 "Nystatin" "Antifungals/antimycotics" "A07AA02,D01AA01,G01AA01,QA07AA02,QD01AA01,QG01AA01" "nyst" "biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex" 1.5 "MU" "10697-1,10698-9,18958-9,35824-2,55689-4" -"OFX" 4583 "Ofloxacin" "Fluoroquinolones" "J01MA01,QJ01MA01,QS01AE01,QS02AA16,S01AE01,S02AA16" "Quinolone antibacterials" "Fluoroquinolones" "of,ofl,oflo,ofx" "exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin" 0.4 "g" 0.4 "g" "18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8" +"NOV" 54675769 "Novobiocin" "Other antibacterials" "QJ01XX95" "novo,novobi" "albadry,albamix,albamycin,biotexin,cardelmycin,cardelmycinsalt,cathocin,cathomycin,inabiocin,novobiocina,novobiocine,novobiocinsalt,novobiocinum,robiocina,sirbiocina,spheromycin,stilbiocina,streptonivicin,streptonivicinsalt,vulcamicina,vulcamycin,vulkamycin" "17378-1,18957-1,370-7,371-5,372-3,373-1,41706-3" +"NYS" 6433272 "Nystatin" "Antifungals/antimycotics" "A07AA02,D01AA01,G01AA01,QA07AA02,QD01AA01,QG01AA01" "nyst,nystan" "biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex" 1.5 "MU" "10697-1,10698-9,18958-9,35824-2,55689-4" +"OFX" 4583 "Ofloxacin" "Fluoroquinolones" "J01MA01,QJ01MA01,QS01AE01,QS02AA16,S01AE01,S02AA16" "Quinolone antibacterials" "Fluoroquinolones" "of,ofl,oflo,ofloxa,ofx" "exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin" 0.4 "g" 0.4 "g" "18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8" "OOR" "Ofloxacin/ornidazole" "Fluoroquinolones" "J01RA09,QJ01RA09" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" -"OLE" 72493 "Oleandomycin" "Macrolides/lincosamides" "J01FA05,QJ01FA05" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil" 1 "g" "18960-5,378-0,379-8,380-6,381-4,55690-2" +"OLE" 72493 "Oleandomycin" "Macrolides/lincosamides" "J01FA05,QJ01FA05" "Macrolides, lincosamides and streptogramins" "Macrolides" "oleand" "amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil" 1 "g" "18960-5,378-0,379-8,380-6,381-4,55690-2" "OMC" 54697325 "Omadacycline" "Tetracyclines" "J01AA15,QJ01AA15" "NA" "amadacycline" 0.3 "g" 0.1 "g" "73594-4,73616-5,73639-7" "OPT" 87880 "Optochin" "Other antibacterials" "NA" "NA" "aflukin,auriquin,biquinate,chinidin,chinidine,chinimetten,chinin,chinine,conchinin,conchinine,conquinine,dentojel,dihydrochinidin,dihydroquinidine,dihydroquinine,hydroconchinine,hydroconquinine,hydroquinidine,kinidin,numoquin,optochine,optoquine,pitayine,qualaquin,quinaglute,quinicardine,quinidex,quinidine,quiniduran,quinindine,quinine,quinineanhydrous,quinora,quinsan,rezquin" "100055-3,73665-2" -"ORB" 60605 "Orbifloxacin" "Fluoroquinolones" "QJ01MA95" "NA" "orbax" "35825-9,35826-7,35827-5" -"ORI" 16136912 "Oritavancin" "Glycopeptides" "J01XA05,QJ01XA05" "Other antibacterials" "Glycopeptide antibacterials" "orit" "NA" "41707-1,41708-9,41709-7,41736-0" +"ORB" 60605 "Orbifloxacin" "Fluoroquinolones" "QJ01MA95" "orbifl" "orbax" "35825-9,35826-7,35827-5" +"ORI" 16136912 "Oritavancin" "Glycopeptides" "J01XA05,QJ01XA05" "Other antibacterials" "Glycopeptide antibacterials" "orit,oritav" "NA" "41707-1,41708-9,41709-7,41736-0" "ORS" "Ormetroprim/sulfamethoxazole" "Other antibacterials" "NA" "NA" "NA" "73593-6,73615-7,73638-9" "ORN" 28061 "Ornidazole" "Other antibacterials" "G01AF06,J01XD03,P01AB03,QG01AF06,QJ01XD03,QP51AA03" "Other antibacterials" "Imidazole derivatives" "NA" "levornidazole,madelen,ornidal,ornidazolum,tiberal" 1.5 "g" 1 "g" "55691-0,55692-8,55693-6,55694-4" "OTE" 77050711 "Oteseconazole" "Antifungals/antimycotics" "J02AC06,QJ02AC06" "Antimycotics for systemic use" "Triazole derivatives" "NA" "quilseconazole,vivijoa" 21 "mg" "NA" -"OXA" 6196 "Oxacillin" "Beta-lactams/penicillins" "J01CF04,QJ01CF04,QJ51CF04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "ox,oxa,oxac,oxal,oxs" "bactocill,bristopen,cryptocillin,micropenin,ossacillina,oxabel,oxabelsalt,oxacilina,oxacillinanhydrous,oxacilline,oxacillinhydrate,oxacillinsalt,oxacillinum,oxazocillin,oxazocilline,penstapho,prostaphlin,prostaphlyn,resistopen,stapenor" 2 "g" 2 "g" "18961-3,25265-0,382-2,383-0,384-8,385-5,3882-8,7039-1" +"OXA" 6196 "Oxacillin" "Beta-lactams/penicillins" "J01CF04,QJ01CF04,QJ51CF04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "ox,oxa,oxac,oxacil,oxal,oxs" "bactocill,bristopen,cryptocillin,micropenin,ossacillina,oxabel,oxabelsalt,oxacilina,oxacillinanhydrous,oxacilline,oxacillinhydrate,oxacillinsalt,oxacillinum,oxazocillin,oxazocilline,penstapho,prostaphlin,prostaphlyn,resistopen,stapenor" 2 "g" 2 "g" "18961-3,25265-0,382-2,383-0,384-8,385-5,3882-8,7039-1" "OXA-S" "Oxacillin screening test" "Beta-lactams/penicillins" "NA" "oxa screen" "NA" "NA" -"OXO" 4628 "Oxolinic acid" "Quinolones" "J01MB05,QJ01MB05" "Quinolone antibacterials" "Other quinolones" "NA" "aqualinic,cistopax,dioxacin,emyrenil,gramurin,inoxyl,nidantin,oksaren,orthurine,ossian,oxoboi,oxolinic,pietil,prodoxal,prodoxol,starner,tiurasin,ultibid,urinox,uritrate,urotrate,uroxol,utibid" 1 "g" "NA" -"OXY" 54675779 "Oxytetracycline" "Tetracyclines" "A01AB25,D06AA03,G01AA07,J01AA06,QA01AB25,QD06AA03,QG01AA07,QG51AA01,QJ01AA06,QJ51AA06,QS01AA04,S01AA04" "Tetracyclines" "Tetracyclines" "NA" "achromycin,actisite,adamycin,artomycin,berkmycen,biostat,bristacycline,cancycline,cyclopar,dabicycline,diacycine,dumocyclin,embryostat,fanterrin,galsenomycin,geomycin,geotilin,hostacycline,hydroxytetracyclinum,lenocycline,macocyn,medamycin,mephacyclin,nitox,oksisyklin,ossitetraciclina,oxitetraciclina,oxitetracyclin,oxitetracycline,oxitetracyclinum,oxymycin,oxypam,oxyterracin,oxyterracine,oxyterracyne,oxytetracid,oxytetracyclin,oxytetracyclinum,paltet,partrex,pennox,piracaps,proteroxyna,qidtet,quadracycline,quatrex,remicyclin,retet,ricycline,riomitsin,ryomycin,solkaciclina,stevacin,stilciclina,subamycin,sumycin,supramycin,sustamycin,tarocyn,tarosin,tefilin,teline,telotrex,teravit,terrafungine,terramitsin,terramycine,tetrabakat,tetrabid,tetrablet,tetracaps,tetracompren,tetrakap,tetralution,tetramavan,tetramed,tetran,tetrosol,topicycline,triphacyclin,unicin,ursocyclin,ursocycline,vetquamycin" 1 "g" 1 "g" "17396-3,18962-1,25266-8,386-3,387-1,388-9,389-7,55699-3,87595-5" +"OXO" 4628 "Oxolinic acid" "Quinolones" "J01MB05,QJ01MB05" "Quinolone antibacterials" "Other quinolones" "oxoaci" "aqualinic,cistopax,dioxacin,emyrenil,gramurin,inoxyl,nidantin,oksaren,orthurine,ossian,oxoboi,oxolinic,pietil,prodoxal,prodoxol,starner,tiurasin,ultibid,urinox,uritrate,urotrate,uroxol,utibid" 1 "g" "NA" +"OXY" 54675779 "Oxytetracycline" "Tetracyclines" "A01AB25,D06AA03,G01AA07,J01AA06,QA01AB25,QD06AA03,QG01AA07,QG51AA01,QJ01AA06,QJ51AA06,QS01AA04,S01AA04" "Tetracyclines" "Tetracyclines" "oxytet" "achromycin,actisite,adamycin,artomycin,berkmycen,biostat,bristacycline,cancycline,cyclopar,dabicycline,diacycine,dumocyclin,embryostat,fanterrin,galsenomycin,geomycin,geotilin,hostacycline,hydroxytetracyclinum,lenocycline,macocyn,medamycin,mephacyclin,nitox,oksisyklin,ossitetraciclina,oxitetraciclina,oxitetracyclin,oxitetracycline,oxitetracyclinum,oxymycin,oxypam,oxyterracin,oxyterracine,oxyterracyne,oxytetracid,oxytetracyclin,oxytetracyclinum,paltet,partrex,pennox,piracaps,proteroxyna,qidtet,quadracycline,quatrex,remicyclin,retet,ricycline,riomitsin,ryomycin,solkaciclina,stevacin,stilciclina,subamycin,sumycin,supramycin,sustamycin,tarocyn,tarosin,tefilin,teline,telotrex,teravit,terrafungine,terramitsin,terramycine,tetrabakat,tetrabid,tetrablet,tetracaps,tetracompren,tetrakap,tetralution,tetramavan,tetramed,tetran,tetrosol,topicycline,triphacyclin,unicin,ursocyclin,ursocycline,vetquamycin" 1 "g" 1 "g" "17396-3,18962-1,25266-8,386-3,387-1,388-9,389-7,55699-3,87595-5" "OZN" "Ozenoxacin" "D06AX14,QD06AX14" "NA" "NA" "NA" -"PAS" 4649 "P-aminosalicylic acid" "Antimycobacterials" "NA" "NA" "NA" "NA" +"PAS" 4649 "P-aminosalicylic acid" "Antimycobacterials" "NA" "pasraa" "NA" "NA" "PAN" 72015 "Panipenem" "Carbapenems" "NA" "NA" "carbenin,panipenemum,penipanem" "100056-1,53823-1" "PAR" 165580 "Paromomycin" "Other antibacterials" "A07AA06,QA07AA06,QJ01GB92" "NA" "aminosidin,amminosidin,crestomycin,estomycin,gabbromycin,gabromycin,humatin,humycin,hydroxymycin,monomycin,paramomycin,paromomicina,paromomycine,paromomycinum,paucimycin,paucimycinum" 3 "g" "51719-3,53824-9,55700-9,55701-7,55702-5" "PAZ" 65957 "Pazufloxacin" "Fluoroquinolones" "J01MA18,QJ01MA18" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pazufloxacine,pazufloxacino,pazufloxacinum" 1 "g" "NA" -"PEF" 51081 "Pefloxacin" "Fluoroquinolones" "J01MA03,QJ01MA03" "Quinolone antibacterials" "Fluoroquinolones" "pefl" "labocton,pefbid,pefloxacine,pefloxacinium,pefloxacino,pefloxacinum,pefocin,pefran,pelox" 0.8 "g" 0.8 "g" "18963-9,35828-3,390-5,3906-5,7040-9" +"PEF" 51081 "Pefloxacin" "Fluoroquinolones" "J01MA03,QJ01MA03" "Quinolone antibacterials" "Fluoroquinolones" "pefl,perflo" "labocton,pefbid,pefloxacine,pefloxacinium,pefloxacino,pefloxacinum,pefocin,pefran,pelox" 0.8 "g" 0.8 "g" "18963-9,35828-3,390-5,3906-5,7040-9" "PEF-S" "Pefloxacin screening test" "Fluoroquinolones" "NA" "pef screen" "NA" "NA" "PNM" 10250769 "Penamecillin" "Beta-lactams/penicillins" "J01CE06,QJ01CE06" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "havapen,hydroxymethyl,penamecilina,penamecillina,penamecilline,penamecillinum" 1.05 "g" "NA" -"PNO" "Penicillin/novobiocin" "Beta-lactams/penicillins" "NA" "NA" "NA" "35872-1,35873-9,35874-7" +"PNO" "Penicillin/novobiocin" "Beta-lactams/penicillins" "NA" "pennov" "NA" "35872-1,35873-9,35874-7" "PSU" "Penicillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA" "PNM1" 54686187 "Penimepicycline" "Tetracyclines" "J01AA10,QJ01AA10" "Tetracyclines" "Tetracyclines" "NA" "criseocil,duamine,geotricyn,hydrocycline,penetracyne,penimepiciclina,penimepicyclinum" "NA" "PIM" 65453 "Pentisomicin" "Aminoglycosides" "NA" "NA" "mutamicin,mutamycin,pentisomicina,pentisomicine,pentisomicinum" "NA" "PTZ" 55250256 "Pentizidone" "Other antibacterials" "NA" "NA" "pentizidona,pentizidonum" "NA" "PEX" 16132253 "Pexiganan" "Other antibacterials" "NA" "NA" "cytolex,mangainin" "NA" "PHE" 272833 "Pheneticillin" "Beta-lactams/penicillins" "J01CE05,QJ01CE05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fene" "alfacillin,alticina,antibiocin,arcacil,arcasin,astracillin,bendralan,beromycin,brocsil,broxil,chemipen,cliacil,darcil,feneticilina,feneticillin,feneticillina,feneticilline,fenocin,icipen,isocillin,ispenoral,kavepenin,maxipen,optipen,oralopen,orapen,ospeneff,pedipen,penagen,pencompren,penemve,peniplus,penova,pensig,penvikal,phenethicilin,phenethicillin,phenethicillinum,pheneticilline,pheneticillinum,primcillin,priospen,roscopenin,semopen,suspen,synapen,syncillin,synerpenin,synthecillin,synthecilline,synthepen,triospen,vamosyn,veetids,vepen" 1 "g" "NA" -"PHN" 6869 "Phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE02,QJ01CE02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fepe,peni v,penicillin v,pnv,pv" "apopen,calcipen,fenacilin,fenospen,meropenin,oracillin,oracilline,oratren,orocillin,ospen,phenocillin,phenomycilline,phenopenicillin,rocilin,stabicillin,vebecillin" 2 "g" "NA" +"PHN" 6869 "Phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE02,QJ01CE02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fepe,peni v,penicillin v,phepen,pnv,pv" "apopen,calcipen,fenacilin,fenospen,meropenin,oracillin,oracilline,oratren,orocillin,ospen,phenocillin,phenomycilline,phenopenicillin,rocilin,stabicillin,vebecillin" 2 "g" "NA" "PMR" 5284447 "Pimaricin" "Antifungals/antimycotics" "NA" "natamycin" "delvocid,delvolan,delvopos,mycophyt,myprozine,natacyn,natafucin,natajen,natamatrix,natamax,natamicina,natamycin,natamycine,natamycinum,pimafucin,pimaracin,pimaricine,pimarizin,synogil,tennecetin" "NA" -"PPA" 4831 "Pipemidic acid" "Quinolones" "J01MB04,QJ01MB04" "Quinolone antibacterials" "Other quinolones" "pipz,pizu" "deblaston,dolcol,filtrax,karunomazin,memento,nuril,palin,pipedac,pipemid,pipemidate,pipemidic,pipemidicacid,pipram,pipurin,tractur,uromidin,urosten,uroval" 0.8 "g" "NA" -"PIP" 43672 "Piperacillin" "Beta-lactams/penicillins" "J01CA12,QJ01CA12" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pi,pip,pipc,pipe,pp" "penmalin,pentcillin,peperacillin,peracin,piperacilina,piperacillina,piperacilline,piperacillinhydrate,piperacillinum,pipercillin,pipracil,tazocin" 14 "g" "101490-1,101491-9,18969-6,18970-4,25268-4,3972-7,407-7,408-5,409-3,410-1,411-9,412-7,413-5,414-3,54197-9,54198-7,54199-5,55704-1,7043-3,7044-1" +"PPA" 4831 "Pipemidic acid" "Quinolones" "J01MB04,QJ01MB04" "Quinolone antibacterials" "Other quinolones" "pipaci,pipz,pizu" "deblaston,dolcol,filtrax,karunomazin,memento,nuril,palin,pipedac,pipemid,pipemidate,pipemidic,pipemidicacid,pipram,pipurin,tractur,uromidin,urosten,uroval" 0.8 "g" "NA" +"PIP" 43672 "Piperacillin" "Beta-lactams/penicillins" "J01CA12,QJ01CA12" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pi,pip,pipc,pipe,pipera,pp" "penmalin,pentcillin,peperacillin,peracin,piperacilina,piperacillina,piperacilline,piperacillinhydrate,piperacillinum,pipercillin,pipracil,tazocin" 14 "g" "101490-1,101491-9,18969-6,18970-4,25268-4,3972-7,407-7,408-5,409-3,410-1,411-9,412-7,413-5,414-3,54197-9,54198-7,54199-5,55704-1,7043-3,7044-1" "PIS" "Piperacillin/sulbactam" "Beta-lactams/penicillins" "J01CR05,QJ01CR05" "NA" "NA" 14 "g" "54197-9,54198-7,54199-5,55704-1" "TZP" 461573 "Piperacillin/tazobactam" "Beta-lactams/penicillins" "J01CR05,QJ01CR05" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "p/t,piptaz,piptazo,pit,pita,pt,ptc,ptz,tzp" "piptazobactam,tazonam,zobactin,zosyn" 14 "g" "101491-9,18970-4,411-9,412-7,413-5,414-3,7044-1" "PRC" 71978 "Piridicillin" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA" -"PRL" 157385 "Pirlimycin" "Macrolides/lincosamides" "QJ51FF90" "NA" "pirlimycina,pirlimycine,pirlimycinum,pirsue" "35829-1,35830-9,35831-7" +"PRL" 157385 "Pirlimycin" "Macrolides/lincosamides" "QJ51FF90" "pirlim" "pirlimycina,pirlimycine,pirlimycinum,pirsue" "35829-1,35830-9,35831-7" "PIR" 4855 "Piromidic acid" "Quinolones" "J01MB03,QJ01MB03" "Quinolone antibacterials" "Other quinolones" "NA" "bactramyl,enterol,gastrurol,panacid,pirodal,piromidate,reelon,septural,urisept,uropir,zaomeal" 2 "g" "NA" "PVM" 33478 "Pivampicillin" "Beta-lactams/penicillins" "J01CA02,QJ01CA02" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "pivaloylampicillin,pivampicilina,pivampicilline,pivampicillinum" 1.05 "g" "18971-2,415-0,416-8,417-6,418-4" -"PME" 115163 "Pivmecillinam" "Beta-lactams/penicillins" "J01CA08,QJ01CA08" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "coactabs,melysin,pivamdinocillin,pivmecilinamo,pivmecillinamum,selexid" 0.6 "g" "NA" +"PME" 115163 "Pivmecillinam" "Beta-lactams/penicillins" "J01CA08,QJ01CA08" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pivmec" "coactabs,melysin,pivamdinocillin,pivmecilinamo,pivmecillinamum,selexid" 0.6 "g" "NA" "PLZ" 42613186 "Plazomicin" "Aminoglycosides" "J01GB14,QJ01GB14" "NA" "zemdri" "73592-8,73614-0,73637-1,92024-9,94719-2" -"PLB" 49800004 "Polymyxin B" "Polymyxins" "A07AA05,J01XB02,QA07AA05,QJ01XB02,QJ51XB02,QS01AA18,QS02AA11,QS03AA03,S01AA18,S02AA11,S03AA03" "Other antibacterials" "Polymyxins" "pb,pol,polb,poly,poly b,polymixin,polymixin b" "aerosporin" 3 "MU" 0.15 "g" "17473-0,18972-0,25269-2,35832-5,419-2,420-0,421-8,422-6" +"PLB" 49800004 "Polymyxin B" "Polymyxins" "A07AA05,J01XB02,QA07AA05,QJ01XB02,QJ51XB02,QS01AA18,QS02AA11,QS03AA03,S01AA18,S02AA11,S03AA03" "Other antibacterials" "Polymyxins" "pb,pol,polb,poly,poly b,polyb,polymixin,polymixin b" "aerosporin" 3 "MU" 0.15 "g" "17473-0,18972-0,25269-2,35832-5,419-2,420-0,421-8,422-6" "POP" "Polymyxin B/polysorbate 80" "Polymyxins" "NA" "NA" "NA" "NA" -"POS" 468595 "Posaconazole" "Antifungals/antimycotics" "J02AC04,QJ02AC04" "Antimycotics for systemic use" "Triazole derivatives" "posa" "noxafil,schering,spriafil" 0.3 "g" 0.3 "g" "53731-6,54186-2,54187-0,54188-8,54189-6,80545-7" +"POS" 468595 "Posaconazole" "Antifungals/antimycotics" "J02AC04,QJ02AC04" "Antimycotics for systemic use" "Triazole derivatives" "posa,posaco" "noxafil,schering,spriafil" 0.3 "g" 0.3 "g" "53731-6,54186-2,54187-0,54188-8,54189-6,80545-7" "PRA" 9802884 "Pradofloxacin" "Fluoroquinolones" "QJ01MA97" "NA" "pudofloxacin,veraflox" "76148-6,87800-9" -"PRX" 71455 "Premafloxacin" "Fluoroquinolones" "NA" "NA" "premafloxacine,premafloxacino" "73591-0,73613-2,73636-3" +"PRX" 71455 "Premafloxacin" "Fluoroquinolones" "NA" "premaf" "premafloxacine,premafloxacino" "73591-0,73613-2,73636-3" "PMD" 456199 "Pretomanid" "Antimycobacterials" "J04AK08,QJ04AK08" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" 0.2 "g" "93850-6" "PRM" 6446787 "Primycin" "Macrolides/lincosamides" "NA" "NA" "chinopricin,debrycin,primicina,primycine" "NA" -"PRI" 11979535 "Pristinamycin" "Macrolides/lincosamides" "J01FG01,QJ01FG01" "Macrolides, lincosamides and streptogramins" "Streptogramins" "pris" "eskalin,micamicina,mikamycin,mikamycine,mikamycinum,ostreogricina,ostreogrycin,ostreogrycine,ostreogrycinum,pristinamicina,pristinamycine,pristinamycinum,pyostacine,stafac,stafytracine,stajac,staphylomycin,stapyocine,starfac,virgimycin,virgimycine,virginiamicina,virginiamycin,virginiamycina,virginiamycinum" 2 "g" "32383-2,35833-3,35834-1,55709-0" +"PRI" 11979535 "Pristinamycin" "Macrolides/lincosamides" "J01FG01,QJ01FG01" "Macrolides, lincosamides and streptogramins" "Streptogramins" "pris,pristi" "eskalin,micamicina,mikamycin,mikamycine,mikamycinum,ostreogricina,ostreogrycin,ostreogrycine,ostreogrycinum,pristinamicina,pristinamycine,pristinamycinum,pyostacine,stafac,stafytracine,stajac,staphylomycin,stapyocine,starfac,virgimycin,virgimycine,virginiamicina,virginiamycin,virginiamycina,virginiamycinum" 2 "g" "32383-2,35833-3,35834-1,55709-0" "PRB" 5903 "Procaine benzylpenicillin" "Beta-lactams/penicillins" "J01CE09,QJ01CE09,QJ51CE09" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "afsillin,aquacilina,aquacillin,aquasuspen,avloprocil,cilicaine,crysticillin,depocillin,despacilina,distaquaine,duphapen,duracillin,hostacillin,hydracillin,kabipenin,ledercillin,millicillin,mylipen,neoproc,nopcaine,parencillin,premocillin,procanodia,prostabillin,retardillin,sharcillin,vetspen,vitablend,wycillin" 0.6 "g" "NA" "PRP" 92879 "Propicillin" "Beta-lactams/penicillins" "J01CE03,QJ01CE03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "baycillin,propicilina,propicilline,propicillinum" 0.9 "g" "NA" "PKA" 9872451 "Propikacin" "Aminoglycosides" "NA" "NA" "propikacina,propikacine,propikacinum" "NA" "PTH" 666418 "Protionamide" "Antimycobacterials" "J04AD01,QJ04AD01" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "prot" "ektebin,peteha,prothionamide,prothionamidum,protion,protionamid,protionamida,protionamidum,protionizina,tebeform,trevintix,tuberex" 0.75 "g" "NA" "PRU" 65947 "Prulifloxacin" "Fluoroquinolones" "J01MA17,QJ01MA17" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pruvel,quisnon,sword" 0.6 "g" "100058-7,76145-2" "PZA" 1046 "Pyrazinamide" "Antimycobacterials" "J04AK01,QJ04AK01" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "pyra" "aldinamid,aldinamide,eprazin,farmizina,isopas,novamid,pezetamid,piraldina,pirazimida,pirazinamid,pirazinamida,pirazinamide,pirazinecarboxamide,pyrafat,pyrazide,pyrazinamdie,pyrazinamidum,pyrazineamide,pyrizinamide,rifafour,rozide,tebrazid,tisamid,unipyranamide" 1.5 "g" "11001-5,18973-8,20461-0,23632-3,25186-8,25229-6,25270-0,423-4,424-2,425-9,426-7,42935-7,55710-8,55711-6,56026-8,92242-7" -"QDA" 11979418 "Quinupristin/dalfopristin" "Macrolides/lincosamides" "QJ01FG02" "Macrolides, lincosamides and streptogramins" "Streptogramins" "q/d,qda,qida,quda,rp,syn" "synercid" "23640-6,23641-4,33334-4,35835-8,58712-1" +"QDA" 11979418 "Quinupristin/dalfopristin" "Macrolides/lincosamides" "QJ01FG02" "Macrolides, lincosamides and streptogramins" "Streptogramins" "q/d,qda,qida,quda,rp,syn,synerc" "synercid" "23640-6,23641-4,33334-4,35835-8,58712-1" "RAC" 56052 "Ractopamine" "Other antibacterials" "NA" "NA" "bufenina,bufenine,buphenin,buphenine,bupheninum,luteonin,nilidrine,nylidrinum,optaflexx,paylean,prepar,ractopamina,ractopaminum,ritodrina,ritodrine,ritodrinium,tomax,utopar,yutopar" "NA" -"RAM" 16132338 "Ramoplanin" "Glycopeptides" "NA" "NA" "NA" "41710-5,41711-3,41712-1,41737-8" -"RZM" 10993211 "Razupenem" "Carbapenems" "NA" "NA" "NA" "73590-2,73612-4,73635-5" +"RAM" 16132338 "Ramoplanin" "Glycopeptides" "NA" "ramopl" "NA" "41710-5,41711-3,41712-1,41737-8" +"RZM" 10993211 "Razupenem" "Carbapenems" "NA" "razupe" "NA" "73590-2,73612-4,73635-5" "RTP" 6918462 "Retapamulin" "Other antibacterials" "D06AX13,QD06AX13" "Antibiotics for topical use" "Other antibiotics for topical use" "ret" "altabax,altargo,rebapamulin,retapamulina" "NA" "RZF" "Rezafungin" "Antifungals" "NA" "NA" "NA" "NA" "RBC" 44631912 "Ribociclib" "Antifungals/antimycotics" "L01EF02,QL01EF02" "Antimycotics for systemic use" "Triazole derivatives" "ribo" "kisqali" 0.45 "g" "NA" "RST" 33042 "Ribostamycin" "Aminoglycosides" "J01GB10,QJ01GB10" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "exaluren,hetangmycin,ribastamin,ribostamicina,ribostamycine,ribostamycinum,vistamycin,xylostatin" 1 "g" "NA" "RID1" 16659285 "Ridinilazole" "Other antibacterials" "NA" "NA" "ridinilazol" "NA" -"RIB" 135398743 "Rifabutin" "Antimycobacterials" "J04AB04,QJ04AB04" "Drugs for treatment of tuberculosis" "Antibiotics" "rifb" "alfacid,ansamicin,ansamycins,ansatipin,ansatipine,assatipin,mycobutin,rifabutinum" 0.15 "g" "100699-8,16100-0,16386-5,16387-3,19149-4,20386-9,23630-7,24032-5,25199-1,25200-7,25201-5,42655-1,42656-9,54183-9,96113-6" -"RIF" 135398735 "Rifampicin" "Antimycobacterials" "J04AB02,QJ04AB02,QJ54AB02" "Drugs for treatment of tuberculosis" "Antibiotics" "rifa" "abrifam,archidyn,arficin,arzide,benemicin,doloresum,eremfat,famcin,fenampicin,rifadin,rifadine,rifagen,rifaldazin,rifaldazine,rifaldin,rifam,rifamor,rifampicina,rifampicine,rifampicinum,rifampin,rifamsolin,rifapiam,rifaprodin,rifcin,rifinah,rifobac,rifoldin,rifoldine,riforal,rimactan,rimactane,rimactazid,rimactizid,rimazid,sinerdol,tubocin" 0.6 "g" 0.6 "g" "NA" +"RIB" 135398743 "Rifabutin" "Antimycobacterials" "J04AB04,QJ04AB04" "Drugs for treatment of tuberculosis" "Antibiotics" "ansamy,rifb" "alfacid,ansamicin,ansamycins,ansatipin,ansatipine,assatipin,mycobutin,rifabutinum" 0.15 "g" "100699-8,16100-0,16386-5,16387-3,19149-4,20386-9,23630-7,24032-5,25199-1,25200-7,25201-5,42655-1,42656-9,54183-9,96113-6" +"RIF" 135398735 "Rifampicin" "Antimycobacterials" "J04AB02,QJ04AB02,QJ54AB02" "Drugs for treatment of tuberculosis" "Antibiotics" "rifa,rifamp" "abrifam,archidyn,arficin,arzide,benemicin,doloresum,eremfat,famcin,fenampicin,rifadin,rifadine,rifagen,rifaldazin,rifaldazine,rifaldin,rifam,rifamor,rifampicina,rifampicine,rifampicinum,rifampin,rifamsolin,rifapiam,rifaprodin,rifcin,rifinah,rifobac,rifoldin,rifoldine,riforal,rimactan,rimactane,rimactazid,rimactizid,rimazid,sinerdol,tubocin" 0.6 "g" 0.6 "g" "NA" "REI" 135483893 "Rifampicin/ethambutol/isoniazid" "Antimycobacterials" "J04AM07,QJ04AM07" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "isonarif,rifamate,rifamazid" "NA" "RFI" "Rifampicin/isoniazid" "Antimycobacterials" "J04AM02,QJ04AM02" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" "RPEI" "Rifampicin/pyrazinamide/ethambutol/isoniazid" "Antimycobacterials" "J04AM06,QJ04AM06" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" "RPI" "Rifampicin/pyrazinamide/isoniazid" "Antimycobacterials" "J04AM05,QJ04AM05" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"RFM" 6324616 "Rifamycin" "Antimycobacterials" "A07AA13,D06AX15,J04AB03,QA07AA13,QD06AX15,QJ04AB03,QJ54AB03,QS01AA16,QS02AA12,S01AA16,S02AA12" "Drugs for treatment of tuberculosis" "Antibiotics" "NA" "aemcolo,nacimycin,nancimycin,otofa,rifamastene,rifamicina,rifamycine,rifamycinum,rifocin,rifocyn,tuborin" 0.8 "g" 0.6 "g" "NA" +"RFM" 6324616 "Rifamycin" "Antimycobacterials" "A07AA13,D06AX15,J04AB03,QA07AA13,QD06AX15,QJ04AB03,QJ54AB03,QS01AA16,QS02AA12,S01AA16,S02AA12" "Drugs for treatment of tuberculosis" "Antibiotics" "rifmyc" "aemcolo,nacimycin,nancimycin,otofa,rifamastene,rifamicina,rifamycine,rifamycinum,rifocin,rifocyn,tuborin" 0.8 "g" 0.6 "g" "NA" "RFP" 135403821 "Rifapentine" "Antimycobacterials" "J04AB05,QJ04AB05" "Drugs for treatment of tuberculosis" "Antibiotics" "rifp,rpt" "prifitin,priftin,rifapentin,rifapentina,rifapentinum" 0.11 "g" "100059-5,76627-9" "RFX" 6436173 "Rifaximin" "Other antibacterials" "A07AA11,D06AX11,QA07AA11,QD06AX11,QG51AA06,QJ51XX01" "Intestinal antiinfectives" "Antibiotics" "NA" "fatroximin,flonorm,lormyx,lumenax,normix,rifacol,rifamixin,rifaxidin,rifaximina,rifaximine,rifaximinum,rifaxin,ritacol,spiraxin,xifaxan,xifaxsan" 0.6 "g" "73589-4,73611-6,73634-8" "RIT" 65633 "Ritipenem" "Carbapenems" "NA" "NA" "ritipenemsalt" "NA" "RIA" 163692 "Ritipenem acoxil" "Carbapenems" "NA" "NA" "penemac" "NA" -"ROK" 5282211 "Rokitamycin" "Macrolides/lincosamides" "J01FA12,QJ01FA12" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "propionylleucomycin,ricamycin,rokicid,rokital,rokitamicina,rokitamycine,rokitamycinum" 0.8 "g" "NA" +"ROK" 5282211 "Rokitamycin" "Macrolides/lincosamides" "J01FA12,QJ01FA12" "Macrolides, lincosamides and streptogramins" "Macrolides" "rokita" "propionylleucomycin,ricamycin,rokicid,rokital,rokitamicina,rokitamycine,rokitamycinum" 0.8 "g" "NA" "RLT" 54682938 "Rolitetracycline" "Tetracyclines" "J01AA09,QJ01AA09" "Tetracyclines" "Tetracyclines" "NA" "bristacin,colbiocin,kinteto,reverin,revrin,rolitetraciclina,rolitetracyclinum,solvocillin,superciclin,synotodecin,synterin,syntetrex,syntetrin,tetraverin,transcycline,velacicline,velacycline" 0.35 "g" "18976-1,435-8,436-6,437-4,438-2" "ROS" 287180 "Rosoxacin" "Quinolones" "J01MB01,QJ01MB01" "Quinolone antibacterials" "Other quinolones" "NA" "acrosoxacin,eracine,eradacil,eradacin,eradicin,rosoxacine,rosoxacino,rosoxacinum,roxadyl,winoxacin,winuron" 0.3 "g" "18977-9,439-0,440-8,441-6,442-4,55713-2" -"RXT" "Roxithromycin" "Macrolides/lincosamides" "J01FA06,QJ01FA06" "Macrolides, lincosamides and streptogramins" "Macrolides" "roxi" "NA" 0.3 "g" "18978-7,443-2,444-0,445-7,446-5,7046-6" +"RXT" "Roxithromycin" "Macrolides/lincosamides" "J01FA06,QJ01FA06" "Macrolides, lincosamides and streptogramins" "Macrolides" "roxi,roxith" "NA" 0.3 "g" "18978-7,443-2,444-0,445-7,446-5,7046-6" "RFL" 58258 "Rufloxacin" "Fluoroquinolones" "J01MA10,QJ01MA10" "Quinolone antibacterials" "Fluoroquinolones" "NA" "monos,rufloxacine,rufloxacino,rufloxacinum,tebraxin,uroflox" 0.2 "g" "NA" -"SAL" 3085092 "Salinomycin" "Other antibacterials" "QP51BB01" "NA" "coxistac,procoxacin,salinomicina,salinomycine,salinomycinum" "35836-6,35837-4,35838-2,87593-0" -"SAR" 56208 "Sarafloxacin" "Fluoroquinolones" "QJ01MA98" "NA" "difloxacino,difloxacinum,difloxcine,sarafin,saraflox,sarafloxacine,sarafloxacino,sarafloxacinum" "73588-6,73610-8,73633-0" +"SAL" 3085092 "Salinomycin" "Other antibacterials" "QP51BB01" "salino" "coxistac,procoxacin,salinomicina,salinomycine,salinomycinum" "35836-6,35837-4,35838-2,87593-0" +"SAR" 56208 "Sarafloxacin" "Fluoroquinolones" "QJ01MA98" "sarafl" "difloxacino,difloxacinum,difloxcine,sarafin,saraflox,sarafloxacine,sarafloxacino,sarafloxacinum" "73588-6,73610-8,73633-0" "SRC" 54681908 "Sarecycline" "Tetracyclines" "J01AA14,QJ01AA14" "Tetracyclines" "Tetracyclines" "NA" "sareciclina,seysara" 0.1 "g" "NA" "SRX" 9933415 "Sarmoxicillin" "Beta-lactams/penicillins" "NA" "NA" "sarmoxillina,sarmoxilline,sarmoxillinum" "NA" "SEC" 71815 "Secnidazole" "Other antibacterials" "P01AB07" "NA" "flagentyl,secnidal,secnidazolum,secnil,sindose,solosec" 2 "g" "NA" "SMF" "Simvastatin/fenofibrate" "Antimycobacterials" "C10BA04,QC10BA04" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "simv" "NA" "NA" -"SIS" 36119 "Sisomicin" "Aminoglycosides" "J01GB08,QJ01GB08" "Aminoglycoside antibacterials" "Other aminoglycosides" "siso" "rickamicin,salvamina,sisomicina,sisomicine,sisomicinum,sisomin,sisomycin,sissomicin,sizomycin" 0.24 "g" "18979-5,447-3,448-1,449-9,450-7,55714-0" -"SIT" 461399 "Sitafloxacin" "Fluoroquinolones" "J01MA21,QJ01MA21" "NA" "gracevit" 0.1 "g" "NA" +"SIS" 36119 "Sisomicin" "Aminoglycosides" "J01GB08,QJ01GB08" "Aminoglycoside antibacterials" "Other aminoglycosides" "siso,sisomy" "rickamicin,salvamina,sisomicina,sisomicine,sisomicinum,sisomin,sisomycin,sissomicin,sizomycin" 0.24 "g" "18979-5,447-3,448-1,449-9,450-7,55714-0" +"SIT" 461399 "Sitafloxacin" "Fluoroquinolones" "J01MA21,QJ01MA21" "sitafl" "gracevit" 0.1 "g" "NA" "SDA" 2724368 "Sodium aminosalicylate" "Antimycobacterials" "J04AA02,QJ04AA02" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "bactylan,lepasen,monopas,tubersan" 14 "g" 14 "g" "NA" "SOL" 25242512 "Solithromycin" "Macrolides/lincosamides" "J01FA16,QJ01FA16" "NA" "solithera" "73587-8,73609-0,73632-2" -"SPX" 60464 "Sparfloxacin" "Fluoroquinolones" "J01MA09,QJ01MA09" "Quinolone antibacterials" "Fluoroquinolones" "spa,spar" "esparfloxacino,parox,spara,sparfloxacine,sparfloxacinum,zagam" 0.2 "g" "20397-6,23610-9,23628-1,35839-0,7047-4" -"SPT" 15541 "Spectinomycin" "Other antibacterials" "J01XX04,QJ01XX04" "Other antibacterials" "Other antibacterials" "sc,spe,spec,spt" "actinospectacina,adspec,espectinomicina,prospec,spectam,spectinomicina,spectinomycine,spectinomycinhydrate,spectinomycinum,spectogard,stanilo,togamycin,trobicin" 3 "g" "18980-3,35840-8,451-5,452-3,453-1,454-9" -"SPI" 6419898 "Spiramycin" "Macrolides/lincosamides" "J01FA02,QJ01FA02,QJ51FA02" "Macrolides, lincosamides and streptogramins" "Macrolides" "spir" "formacidine" 3 "g" "18981-1,455-6,456-4,457-2,458-0,55715-7" +"SPX" 60464 "Sparfloxacin" "Fluoroquinolones" "J01MA09,QJ01MA09" "Quinolone antibacterials" "Fluoroquinolones" "spa,spar,sparfl" "esparfloxacino,parox,spara,sparfloxacine,sparfloxacinum,zagam" 0.2 "g" "20397-6,23610-9,23628-1,35839-0,7047-4" +"SPT" 15541 "Spectinomycin" "Other antibacterials" "J01XX04,QJ01XX04" "Other antibacterials" "Other antibacterials" "sc,spe,spec,spect,spt" "actinospectacina,adspec,espectinomicina,prospec,spectam,spectinomicina,spectinomycine,spectinomycinhydrate,spectinomycinum,spectogard,stanilo,togamycin,trobicin" 3 "g" "18980-3,35840-8,451-5,452-3,453-1,454-9" +"SPI" 6419898 "Spiramycin" "Macrolides/lincosamides" "J01FA02,QJ01FA02,QJ51FA02" "Macrolides, lincosamides and streptogramins" "Macrolides" "sipram,spir,spiram" "formacidine" 3 "g" "18981-1,455-6,456-4,457-2,458-0,55715-7" "SPM" "Spiramycin/metronidazole" "Other antibacterials" "J01RA04,QJ01RA04" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "STR" "Streptoduocin" "Aminoglycosides" "J01GA02,QJ01GA02" "Aminoglycoside antibacterials" "Streptomycins" "NA" "NA" 1 "g" "NA" -"STR1" 19649 "Streptomycin" "Aminoglycosides" "A07AA04,J01GA01,QA07AA04,QJ01GA01" "Aminoglycoside antibacterials" "Streptomycins" "s,stm,str,stre" "agrept,agrimycin,chemform,estreptomicina,gerox,neodiestreptopab,strepcen,streptomicina,streptomycine,streptomycinum,streptomyzin" 1 "g" "18982-9,18983-7,20462-8,23626-5,25185-0,25205-6,25206-4,35841-6,4039-4,42658-5,42659-3,459-8,460-6,461-4,462-2,46719-1,48177-0,6933-6,7048-2,7049-0,96114-4" +"STR1" 19649 "Streptomycin" "Aminoglycosides" "A07AA04,J01GA01,QA07AA04,QJ01GA01" "Aminoglycoside antibacterials" "Streptomycins" "s,st1000,st2000,stm,str,stre,strept" "agrept,agrimycin,chemform,estreptomicina,gerox,neodiestreptopab,strepcen,streptomicina,streptomycine,streptomycinum,streptomyzin" 1 "g" "18982-9,18983-7,20462-8,23626-5,25185-0,25205-6,25206-4,35841-6,4039-4,42658-5,42659-3,459-8,460-6,461-4,462-2,46719-1,48177-0,6933-6,7048-2,7049-0,96114-4" "STH" "Streptomycin-high" "Aminoglycosides" "NA" "sthi,sthl,strepto high,streptomycin high" "NA" "18983-7,35841-6,6933-6,7049-0" "STI" "Streptomycin/isoniazid" "Antimycobacterials" "J04AM01,QJ04AM01" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"SUL" 130313 "Sulbactam" "Beta-lactams/penicillins" "J01CG01,QJ01CG01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "NA" "betamaze,sulbactamum" 1 "g" "41716-2,41717-0,41718-8,41739-4" -"SBC" 20055036 "Sulbenicillin" "Beta-lactams/penicillins" "J01CA16,QJ01CA16" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "kedacillin,kedacillina,sulbenicilina,sulbenicilline,sulbenicillinum,sulpelin" 15 "g" "NA" +"SUL" 130313 "Sulbactam" "Beta-lactams/penicillins" "J01CG01,QJ01CG01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "sulbac" "betamaze,sulbactamum" 1 "g" "41716-2,41717-0,41718-8,41739-4" +"SBC" 20055036 "Sulbenicillin" "Beta-lactams/penicillins" "J01CA16,QJ01CA16" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "sulben" "kedacillin,kedacillina,sulbenicilina,sulbenicilline,sulbenicillinum,sulpelin" 15 "g" "NA" "SUC" 5318 "Sulconazole" "Antifungals/antimycotics" "D01AC09,QD01AC09" "NA" "sulconazol,sulconazolum" "NA" -"SUP" 6634 "Sulfachlorpyridazine" "Other antibacterials" "QJ01EQ12" "NA" "cluricol,cosulid,cosumix,durasulf,nefrosul,nsulfanilamide,prinzone,solfaclorpiridazina,sonilyn,sulfacloropiridazina,sulfaclorpiridazina,vetisulid" "NA" -"SDI" 5215 "Sulfadiazine" "Trimethoprims" "J01EC02,QJ01EQ10" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "NA" "codiazine,cremodiazine,cremotres,debenal,deltazina,dermazin,dermazine,diazolone,diazovit,eskadiazine,flamazine,geben,liquadiazine,microsulfon,neazine,neotrizine,palatrize,piridisir,pirimal,pyrimal,quadetts,quadramoid,sanodiazine,silbertone,sildaflo,silvadene,silvazine,silver,silveramide,sliverex,solfadiazina,spofadrizine,sterazine,sulfacombin,sulfadiazene,sulfadiazin,sulfadiazina,sulfadiazinum,sulfapirimidin,sulfapyrimidin,sulfapyrimidine,sulfatryl,sulfazine,sulfolex,sulfonsol,sulfose,sulphadiazine,terfonyl,theradiazine,thermazene,trifonamide,trisem,truozine" 0.6 "g" "18984-5,27216-1,463-0,464-8,465-5,466-3,59742-7,6907-0,7050-8" +"SUP" 6634 "Sulfachlorpyridazine" "Other antibacterials" "QJ01EQ12" "sulchl" "cluricol,cosulid,cosumix,durasulf,nefrosul,nsulfanilamide,prinzone,solfaclorpiridazina,sonilyn,sulfacloropiridazina,sulfaclorpiridazina,vetisulid" "NA" +"SDI" 5215 "Sulfadiazine" "Trimethoprims" "J01EC02,QJ01EQ10" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "suldia" "codiazine,cremodiazine,cremotres,debenal,deltazina,dermazin,dermazine,diazolone,diazovit,eskadiazine,flamazine,geben,liquadiazine,microsulfon,neazine,neotrizine,palatrize,piridisir,pirimal,pyrimal,quadetts,quadramoid,sanodiazine,silbertone,sildaflo,silvadene,silvazine,silver,silveramide,sliverex,solfadiazina,spofadrizine,sterazine,sulfacombin,sulfadiazene,sulfadiazin,sulfadiazina,sulfadiazinum,sulfapirimidin,sulfapyrimidin,sulfapyrimidine,sulfatryl,sulfazine,sulfolex,sulfonsol,sulfose,sulphadiazine,terfonyl,theradiazine,thermazene,trifonamide,trisem,truozine" 0.6 "g" "18984-5,27216-1,463-0,464-8,465-5,466-3,59742-7,6907-0,7050-8" "SLT" 122284 "Sulfadiazine/tetroxoprim" "Trimethoprims" "J01EE06" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "berlocombin,cotetroxazine,potesept,trimerazine" "NA" "SLT1" 64932 "Sulfadiazine/trimethoprim" "Trimethoprims" "J01EE02,QJ01EW10,QJ51RE01" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "antastmon,astra,ditrim,ditrivet,sultrisan,triglobe,trimin,tucoprim,uniprim" "NA" -"SUD" 5323 "Sulfadimethoxine" "Trimethoprims" "J01ED01,QJ01EQ09,QP51BA01" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "abcid,agribon,albon,arnosulfan,bactotril,bactrovet,deposul,diasulfa,diasulfyl,dimetazina,dinosol,dorisul,fuxal,lasibon,madribon,madrigid,madriqid,madroxin,madroxine,maxulvet,mecozine,memcozine,metoxidon,neostrepal,neostreptal,nsulfanilamidesalt,omnibon,persulfen,radonin,redifal,rofenaid,roscosulf,scandisil,solfadimetossina,sudine,suldixine,sulfabon,sulfadimethoxin,sulfadimethoxinesalt,sulfadimethoxinum,sulfadimetossina,sulfadimetoxin,sulfadimetoxina,sulfadimetoxine,sulfadimoxine,sulfastop,sulfoplan,sulforal,sulphadimethoxine,sulxin,sumbio,symbio,theracanzan,ultrasulfon" 0.5 "g" "87799-3,87803-3" -"SDM" 5327 "Sulfadimidine" "Trimethoprims" "J01EB03,QJ01EQ03,QP51AG01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "azolmetazin,bovibol,calfspan,cremomethazine,diazil,diazilsulfadine,diazyl,dimezathine,intradine,kelametazine,mermeth,neasina,neazina,panazin,pirmazin,primazin,solfadimidina,spanbolet,sulfadimerazine,sulfadimesin,sulfadimesine,sulfadimethyldiazine,sulfadimezin,sulfadimezine,sulfadimezinum,sulfadimidin,sulfadimidina,sulfadimidinum,sulfadimidinun,sulfadine,sulfametazina,sulfametazyny,sulfamethiazine,sulfamezathine,sulfamidine,sulfodimesin,sulfodimezine,sulmet,sulphadimidine,sulphamethasine,sulphamethazine,sulphamezathine,sulphamidine,sulphodimezine,superseptil,superseptyl,vertolan,vesadin" 4 "g" "NA" +"SUD" 5323 "Sulfadimethoxine" "Trimethoprims" "J01ED01,QJ01EQ09,QP51BA01" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "sdimet" "abcid,agribon,albon,arnosulfan,bactotril,bactrovet,deposul,diasulfa,diasulfyl,dimetazina,dinosol,dorisul,fuxal,lasibon,madribon,madrigid,madriqid,madroxin,madroxine,maxulvet,mecozine,memcozine,metoxidon,neostrepal,neostreptal,nsulfanilamidesalt,omnibon,persulfen,radonin,redifal,rofenaid,roscosulf,scandisil,solfadimetossina,sudine,suldixine,sulfabon,sulfadimethoxin,sulfadimethoxinesalt,sulfadimethoxinum,sulfadimetossina,sulfadimetoxin,sulfadimetoxina,sulfadimetoxine,sulfadimoxine,sulfastop,sulfoplan,sulforal,sulphadimethoxine,sulxin,sumbio,symbio,theracanzan,ultrasulfon" 0.5 "g" "87799-3,87803-3" +"SDM" 5327 "Sulfadimidine" "Trimethoprims" "J01EB03,QJ01EQ03,QP51AG01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "suldim" "azolmetazin,bovibol,calfspan,cremomethazine,diazil,diazilsulfadine,diazyl,dimezathine,intradine,kelametazine,mermeth,neasina,neazina,panazin,pirmazin,primazin,solfadimidina,spanbolet,sulfadimerazine,sulfadimesin,sulfadimesine,sulfadimethyldiazine,sulfadimezin,sulfadimezine,sulfadimezinum,sulfadimidin,sulfadimidina,sulfadimidinum,sulfadimidinun,sulfadine,sulfametazina,sulfametazyny,sulfamethiazine,sulfamezathine,sulfamidine,sulfodimesin,sulfodimezine,sulmet,sulphadimidine,sulphamethasine,sulphamethazine,sulphamezathine,sulphamidine,sulphodimezine,superseptil,superseptyl,vertolan,vesadin" 4 "g" "NA" "SLT2" "Sulfadimidine/trimethoprim" "Trimethoprims" "J01EE05,QJ01EW03" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA" "SLF" 5344 "Sulfafurazole" "Trimethoprims" "J01EB05,QJ01EQ05,QS01AB02,S01AB02" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfsz" "accuzole,alphazole,amidoxal,astrazolo,azosulfizin,bactesulf,barazae,chemouag,cosoxazole,dorsulfan,entusil,entusul,ganda,gantrisin,gantrisine,gantrisona,gantrizin,gantrosan,isoxamin,neazolin,neoxazol,novazolo,novosaxazole,nsulphanilamide,pancid,pediazole,renosulfan,resoxol,roxosul,roxoxol,saxosozine,sodizole,solfafurazolo,sosol,soxamide,soxisol,soxitabs,soxomide,stansin,sulbio,sulfafurazol,sulfafurazolum,sulfagan,sulfagen,sulfaisoxazole,sulfalar,sulfapolar,sulfasol,sulfasoxazole,sulfasoxizole,sulfazin,sulfisin,sulfisonazole,sulfisoxasole,sulfisoxazol,sulfisoxazolum,sulfizin,sulfizol,sulfizole,sulfofurazole,sulfoxol,suloxsol,sulphafuraz,sulphafurazol,sulphafurazole,sulphafurazolum,sulphaisoxazole,sulphisoxazol,sulphisoxazole,sulphofurazole,sulsoxin,thiasin,unisulf,urisoxin,uritrisin,urogan" 4 "g" 4 "g" "NA" "SLF1" 5343 "Sulfaisodimidine" "Trimethoprims" "J01EB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "aristamid,aristamide,aristogyn,domain,domian,elcosin,elcosine,elkosil,elkosin,elkosine,erycon,isosulf,mefenal,solfisomidina,sulfadimetine,sulfaisodimerazine,sulfaisodimidinum,sulfaisomidine,sulfasomidine,sulfisomidin,sulfisomidina,sulfisomidine,sulfisomidinum,sulphasomidine" 4 "g" 4 "g" "NA" "SLF2" 9047 "Sulfalene" "Trimethoprims" "J01ED02,QJ01EQ19" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "dalysep,farmitalia,kelfizin,kelfizina,kelfizine,policydal,solfametopirazina,sulfalen,sulfaleno,sulfalenum,sulfamethopyrazine,sulfamethoxypyrazine,sulfametopyrazine,sulfametoxypyridazin,sulphalene,sulphametopyrazine,vetkelfizina" 0.1 "g" "NA" "SZO" 187764 "Sulfamazone" "Trimethoprims" "J01ED09" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "sulfamazona,sulfamazonum,sulfenazone" 1.5 "g" "NA" -"SLF3" 5325 "Sulfamerazine" "Trimethoprims" "D06BA06,J01ED07,QD06BA06,QJ01EQ17" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "cremomerazine,kelamerazine,mebacid,mesulfa,methylpyrimal,methylsulfazin,methylsulfazine,metilsulfadiazin,metilsulfazin,percoccide,pyralcid,romezin,septacil,septosyl,solfamerazina,solumedin,solumedine,sulfameradine,sulfamerazin,sulfamerazina,sulfamerazinum,sulfamethyldiazine,sulphamerazine,sumedine" 3 "g" "NA" +"SLF3" 5325 "Sulfamerazine" "Trimethoprims" "D06BA06,J01ED07,QD06BA06,QJ01EQ17" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "sulmet" "cremomerazine,kelamerazine,mebacid,mesulfa,methylpyrimal,methylsulfazin,methylsulfazine,metilsulfadiazin,metilsulfazin,percoccide,pyralcid,romezin,septacil,septosyl,solfamerazina,solumedin,solumedine,sulfameradine,sulfamerazin,sulfamerazina,sulfamerazinum,sulfamethyldiazine,sulphamerazine,sumedine" 3 "g" "NA" "SLT3" "Sulfamerazine/trimethoprim" "Trimethoprims" "J01EE07,QJ01EW18" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA" "SUM" 5327 "Sulfamethazine" "Other antibacterials" "NA" "NA" "NA" "87592-2" "SLF4" 5328 "Sulfamethizole" "Trimethoprims" "B05CA04,D06BA04,J01EB02,QB05CA04,QD06BA04,QJ01EQ02,QS01AB01,S01AB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfmz" "aethazolum,ayerlucil,berlophen,gliprotiazol,globucid,globucin,globuzid,glyprothiazol,glyprothiazole,glyprothiazolum,glyprothizolum,lucosil,microsul,proklar,renasul,rufol,salimol,sethadil,solfametizolo,solfetidolo,sulfaethidiole,sulfaethidol,sulfaethidole,sulfaethidolum,sulfaetidol,sulfamethizol,sulfamethizolum,sulfametizol,sulfapyelon,sulfstat,sulfurine,sulphaethidole,sulphamethizole,tardipyrine,tetracid,thidicur,thiosulfil,ultrasul,urocydal,urodiaton,urolucosil,urosulfin" 4 "g" "60175-7,60176-5,60177-3" -"SMX" 5329 "Sulfamethoxazole" "Trimethoprims" "J01EC01,QJ01EQ11" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "sfmx,sulf" "septran,septrin,simsinomin,sinomin,solfametossazolo,sulfamethalazole,sulfamethoxazolum,sulfamethoxizole,sulfamethylisoxazole,sulfametoxazol,sulfiodizole,sulfisomezole,sulphisomezole,urobak" 2 "g" "10342-4,11577-4,18985-2,25271-8,39772-9,467-1,468-9,469-7,470-5,59971-2,59972-0,60333-2,72674-5,80549-9,80974-9" +"SMX" 5329 "Sulfamethoxazole" "Trimethoprims" "J01EC01,QJ01EQ11" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "sfmx,sulf,sulfam" "septran,septrin,simsinomin,sinomin,solfametossazolo,sulfamethalazole,sulfamethoxazolum,sulfamethoxizole,sulfamethylisoxazole,sulfametoxazol,sulfiodizole,sulfisomezole,sulphisomezole,urobak" 2 "g" "10342-4,11577-4,18985-2,25271-8,39772-9,467-1,468-9,469-7,470-5,59971-2,59972-0,60333-2,72674-5,80549-9,80974-9" "SLF5" 5330 "Sulfamethoxypyridazine" "Trimethoprims" "J01ED05,QJ01EQ15" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "altezol,cysul,davosin,depovernil,durox,kineks,kinex,kynex,lederkyn,lentac,lisulfen,longin,medicel,midicel,midikel,myasul,opinsul,paramid,petrisul,piridolo,quinoseptyl,retamid,retasulfin,retasulphine,slosul,spofadazine,succinylsulfathi,sulfalex,sulfapiridazin,sulfapyridazine,sulfdurazin,sulfozona,sultirene,vinces" 0.5 "g" "NA" "SLF6" 19596 "Sulfametomidine" "Trimethoprims" "J01ED03" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "duroprocin,methofadin,methofazine,solfametomidina,sulfametomidin,sulfametomidina,sulfametomidinum,telemid" "NA" "SLF7" 5326 "Sulfametoxydiazine" "Trimethoprims" "J01ED04" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "bayrena,berlicid,dairena,durenat,juvoxin,kinecid,kirocid,kiron,longasulf,methoxypyrimal,solfametossidiazina,sulfameter,sulfametersalt,sulfamethorine,sulfamethoxine,sulfamethoxydiazin,sulfamethoxydiazine,sulfamethoxydin,sulfamethoxydine,sulfametin,sulfametinum,sulfametorine,sulfametorinum,sulfametoxidiazina,sulfametoxidine,sulfametoxydiazinum,sulla,sulphameter,sulphamethoxydiazine,supramid,ultrax" 0.5 "g" "NA" @@ -434,65 +434,65 @@ "SLF11" 5335 "Sulfaphenazole" "Trimethoprims" "J01ED08,QJ01EQ08" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "depocid,depotsulfonamide,eftolon,firmazolo,inamil,isarol,merian,orisul,orisulf,paidazolo,phenylsulfapyrazole,plisulfan,raziosulfa,solfafenazolo,sulfabid,sulfafenazol,sulfafenazolo,sulfaphenazol,sulfaphenazolum,sulfaphenazon,sulfaphenylpipazol,sulfaphenylpyrazol,sulfaphenylpyrazole,sulfonylpyrazol,sulphaphenazole,sulphenazole" 1 "g" "NA" "SLF12" 5336 "Sulfapyridine" "Trimethoprims" "J01EB04,QJ01EQ04" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "adiplon,coccoclase,dagenan,eubasin,eubasinum,haptocil,piridazol,plurazol,pyriamid,pyridazol,relbapiridina,ronin,septipulmon,solfapiridina,soludagenan,streptosilpyridine,sulfapiridina,sulfapyridin,sulfapyridinum,sulfidin,sulfidine,sulphapyridin,sulphapyridine,thioseptal,trianon" 1 "g" "14075-6,55580-5" "SNA" 60582 "Sulfasuccinamide" "Other antibacterials" "NA" "NA" "sulfasuccinamid,sulfasuccinamida,sulfasuccinamidum" "NA" -"SUT" 5340 "Sulfathiazole" "Trimethoprims" "D06BA02,J01EB07,QD06BA02,QJ01EQ07" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "azoquimiol,azoseptale,cerazol,cerazole,chemosept,cibazol,duatok,dulana,eleudron,enterobiocine,estafilol,formosulfathiazole,neostrepsan,norsulfasol,norsulfazol,norsulfazole,norsulfazolum,planomide,poliseptil,sanotiazol,septozol,solfatiazolo,soluthiazomide,streptosilthiazole,sulfamul,sulfaplex,sulfathiazol,sulfathiazolesalt,sulfathiazolum,sulfatiazol,sulfavitina,sulfocerol,sulphathiazole,sulzol,thiacoccine,thiasulfol,thiazamide,thiozamide,wintrazole" "87591-4,87796-9,87797-7" +"SUT" 5340 "Sulfathiazole" "Trimethoprims" "D06BA02,J01EB07,QD06BA02,QJ01EQ07" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sulthi" "azoquimiol,azoseptale,cerazol,cerazole,chemosept,cibazol,duatok,dulana,eleudron,enterobiocine,estafilol,formosulfathiazole,neostrepsan,norsulfasol,norsulfazol,norsulfazole,norsulfazolum,planomide,poliseptil,sanotiazol,septozol,solfatiazolo,soluthiazomide,streptosilthiazole,sulfamul,sulfaplex,sulfathiazol,sulfathiazolesalt,sulfathiazolum,sulfatiazol,sulfavitina,sulfocerol,sulphathiazole,sulzol,thiacoccine,thiasulfol,thiazamide,thiozamide,wintrazole" "87591-4,87796-9,87797-7" "SLF13" 3000579 "Sulfathiourea" "Trimethoprims" "J01EB08" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "badional,baldinol,fontamide,salvoseptyl,solfatiourea,solufontamide,sulfanilthiourea,sulfathiocarbamid,sulfathiocarbamide,sulfathiocarbamidum,sulfathioureasalt,sulfathiouree,sulfatiourea,sulphathiourea" 6 "g" "NA" -"SOX" 5344 "Sulfisoxazole" "Other antibacterials" "NA" "NA" "NA" "11578-2,18986-0,25226-2,471-3,472-1,473-9,474-7,9701-4" -"SSS" 86225 "Sulfonamide" "Other antibacterials" "NA" "sfna" "NA" "17674-3,17675-0,18987-8,35842-4,4040-2,4041-0,4042-8,475-4,476-2,477-0,478-8,75650-2" -"SLP" 9950244 "Sulopenem" "Other antibacterials" "NA" "NA" "orlynvah" "55289-3,55290-1,55291-9" -"SLT6" 444022 "Sultamicillin" "Beta-lactams/penicillins" "J01CR04,QJ01CR04" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "NA" "combisid,sultamicilina,sultamicilline,sultamicillinum,unacid" 1.5 "g" "NA" +"SOX" 5344 "Sulfisoxazole" "Other antibacterials" "NA" "sulfiz" "NA" "11578-2,18986-0,25226-2,471-3,472-1,473-9,474-7,9701-4" +"SSS" 86225 "Sulfonamide" "Other antibacterials" "NA" "sfna,sulami" "NA" "17674-3,17675-0,18987-8,35842-4,4040-2,4041-0,4042-8,475-4,476-2,477-0,478-8,75650-2" +"SLP" 9950244 "Sulopenem" "Other antibacterials" "NA" "sulope" "orlynvah" "55289-3,55290-1,55291-9" +"SLT6" 444022 "Sultamicillin" "Beta-lactams/penicillins" "J01CR04,QJ01CR04" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "sultos" "combisid,sultamicilina,sultamicilline,sultamicillinum,unacid" 1.5 "g" "NA" "SUR" 46700778 "Surotomycin" "Other antibacterials" "NA" "NA" "surotomicina,surotomycine" "NA" "TAL" 71447 "Talampicillin" "Beta-lactams/penicillins" "J01CA15,QJ01CA15" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "aseocillin,phthalidyl,talampicilina,talampicilline,talampicillinum,talpen,yamacillin" 2 "g" "18988-6,479-6,480-4,481-2,482-0" "TLP" 163307 "Talmetoprim" "Other antibacterials" "NA" "NA" "NA" "NA" -"TAZ" 123630 "Tazobactam" "Beta-lactams/penicillins" "J01CG02,QJ01CG02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "tazo" "exblifep,tazobactamsalt,tazobactamum,tazobactum" "41719-6,41720-4,41721-2,41740-2" +"TAZ" 123630 "Tazobactam" "Beta-lactams/penicillins" "J01CG02,QJ01CG02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "tazo,tazoba" "exblifep,tazobactamsalt,tazobactamum,tazobactum" "41719-6,41720-4,41721-2,41740-2" "TBP" 9800194 "Tebipenem" "Carbapenems" "NA" "NA" "NA" "NA" "TZD" 11234049 "Tedizolid" "Oxazolidinones" "J01XX11,QJ01XX11" "Other antibacterials" "Other antibacterials" "tedi" "torezolid" 0.2 "g" 0.2 "g" "73586-0,73608-2,73631-4" -"TEC" 16131923 "Teicoplanin" "Glycopeptides" "J01XA02,QJ01XA02" "Other antibacterials" "Glycopeptide antibacterials" "tec,tei,teic,tp,tpl,tpn" "NA" 0.4 "g" "18989-4,25534-9,25535-6,34378-0,34379-8,4043-6,483-8,484-6,485-3,486-1,7051-6,80968-1" +"TEC" 16131923 "Teicoplanin" "Glycopeptides" "J01XA02,QJ01XA02" "Other antibacterials" "Glycopeptide antibacterials" "tec,tei,teic,teicop,tp,tpl,tpn" "NA" 0.4 "g" "18989-4,25534-9,25535-6,34378-0,34379-8,4043-6,483-8,484-6,485-3,486-1,7051-6,80968-1" "TCM" "Teicoplanin-macromethod" "Glycopeptides" "NA" "NA" "NA" "NA" -"TLV" 3081362 "Telavancin" "Glycopeptides" "J01XA03,QJ01XA03" "Other antibacterials" "Glycopeptide antibacterials" "tela" "arbelic,nvancomycin,televancin" "72894-9,73630-6,85051-1,88886-7" -"TLT" 3002190 "Telithromycin" "Macrolides/lincosamides" "J01FA15,QJ01FA15" "Macrolides, lincosamides and streptogramins" "Macrolides" "teli" "ketek,levviax" 0.8 "g" "35843-2,35844-0,35845-7,41722-0" -"TMX" 60021 "Temafloxacin" "Fluoroquinolones" "J01MA05,QJ01MA05" "Quinolone antibacterials" "Fluoroquinolones" "tema" "omniflox,temafloxacina,temafloxacine,temafloxacino,temafloxacinum" 0.8 "g" "18990-2,487-9,488-7,489-5,490-3" -"TEM" 171758 "Temocillin" "Beta-lactams/penicillins" "J01CA17,QJ01CA17" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "temo" "negaban,temocilina,temocillina,temocilline,temocillinum" 4 "g" "18991-0,491-1,492-9,493-7,494-5,54190-4" +"TLV" 3081362 "Telavancin" "Glycopeptides" "J01XA03,QJ01XA03" "Other antibacterials" "Glycopeptide antibacterials" "tela,telava" "arbelic,nvancomycin,televancin" "72894-9,73630-6,85051-1,88886-7" +"TLT" 3002190 "Telithromycin" "Macrolides/lincosamides" "J01FA15,QJ01FA15" "Macrolides, lincosamides and streptogramins" "Macrolides" "teli,telith" "ketek,levviax" 0.8 "g" "35843-2,35844-0,35845-7,41722-0" +"TMX" 60021 "Temafloxacin" "Fluoroquinolones" "J01MA05,QJ01MA05" "Quinolone antibacterials" "Fluoroquinolones" "tema,temafl" "omniflox,temafloxacina,temafloxacine,temafloxacino,temafloxacinum" 0.8 "g" "18990-2,487-9,488-7,489-5,490-3" +"TEM" 171758 "Temocillin" "Beta-lactams/penicillins" "J01CA17,QJ01CA17" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "temo,temoci" "negaban,temocilina,temocillina,temocilline,temocillinum" 4 "g" "18991-0,491-1,492-9,493-7,494-5,54190-4" "TRB" 1549008 "Terbinafine" "Antifungals/antimycotics" "D01AE15,D01BA02,QD01AE15,QD01BA02" "Antifungals for systemic use" "Antifungals for systemic use" "terb" "afogan,bramazil,bramizil,corbinal,lamasil,lamisil,muzonal,shoprite,terbina,terbinafina,terbinafinum,terbine,terbinex,terbisil,zabel" 0.25 "g" "10720-1,10721-9,18992-8" "TRC" 441383 "Terconazole" "Antifungals/antimycotics" "G01AG02,QG01AG02" "NA" "fungistat,panlomyc,terazol,terconazol,terconazolum,tercospor,tetrazol,triaconazole,zazole" "55196-0" "TRZ" 65720 "Terizidone" "Antimycobacterials" "J04AK03,QJ04AK03" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "terivalidin,terizidona,terizidonum" "NA" -"TCY" 54675776 "Tetracycline" "Tetracyclines" "A01AB13,D06AA04,J01AA07,QA01AB13,QD06AA04,QG01AA90,QG51AA02,QJ01AA07,QJ51AA07,QS01AA09,QS02AA08,QS03AA02,S01AA09,S02AA08,S03AA02" "Tetracyclines" "Tetracyclines" "tc,te,tet,tetr" "abramycin,abricycline,agromicina,ambramicina,ambramycin,biocycline,brodspec,cefracycline,centet,ciclibion,copharlan,criseociclina,democracin,deschlorobiomycin,economycin,hostacyclin,lexacycline,limecycline,liquamycin,mericycline,micycline,neocycline,omegamycin,orlycycline,panmycin,purocyclina,roviciclina,solvocin,tetrabon,tetraciclina,tetracyclinehydrate,tetracyclinum,tetracyn,tetradecin,tetrafil,tetraverine,tetrazyklin,tsiklomistsin,tsiklomitsin,veracin,vetacyclinum" 1 "g" 1 "g" "101504-9,18993-6,25272-6,4045-1,495-2,496-0,497-8,498-6,7052-4,87590-6" +"TCY" 54675776 "Tetracycline" "Tetracyclines" "A01AB13,D06AA04,J01AA07,QA01AB13,QD06AA04,QG01AA90,QG51AA02,QJ01AA07,QJ51AA07,QS01AA09,QS02AA08,QS03AA02,S01AA09,S02AA08,S03AA02" "Tetracyclines" "Tetracyclines" "tc,te,tet,tetcyc,tetr,tetra" "abramycin,abricycline,agromicina,ambramicina,ambramycin,biocycline,brodspec,cefracycline,centet,ciclibion,copharlan,criseociclina,democracin,deschlorobiomycin,economycin,hostacyclin,lexacycline,limecycline,liquamycin,mericycline,micycline,neocycline,omegamycin,orlycycline,panmycin,purocyclina,roviciclina,solvocin,tetrabon,tetraciclina,tetracyclinehydrate,tetracyclinum,tetracyn,tetradecin,tetrafil,tetraverine,tetrazyklin,tsiklomistsin,tsiklomitsin,veracin,vetacyclinum" 1 "g" 1 "g" "101504-9,18993-6,25272-6,4045-1,495-2,496-0,497-8,498-6,7052-4,87590-6" "TCY-S" "Tetracycline screening test" "Tetracyclines" "NA" "tcy screen" "NA" "NA" "TOL" 54691494 "Tetracycline/oleandomycin" "Other antibacterials" "J01RA08,QJ01RA08" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA" "TET" 65450 "Tetroxoprim" "Other antibacterials" "NA" "NA" "primsol,tetroxoprima,tetroxoprime,tetroxoprimum,trimpex,trimplex" "NA" "THA" 9568512 "Thiacetazone" "Oxazolidinones" "NA" "NA" "acetanilide,aktivan,ambathizon,amitiozon,antib,benthiozone,benzothiozane,benzothiozon,berkazon,citazone,conteben,diasan,domakol,ilbion,livazone,mivizon,myvizone,neotibil,neustab,novakol,panrone,parazone,seroden,siocarbazone,tebalon,tebecure,tebemar,tebethion,tebethione,tebezon,thiacetone,thiacetozone,thibon,thibone,thioacetazon,thioacetazonum,thioazetazone,thiocarbazil,thiomicid,thionicid,thioparamizon,thioparamizone,thiosemicarbarzone,thiosemicarbazone,thiotebesin,thiotebezin,thiotebicina,thizone,tiacetazon,tibicur,tibion,tibione,tibizan,tibon,tibone,tioacetazon,tioacetazona,tioatsetazon,tiobicina,tiocarone,tiosecolo,tubercazon,tubigal,tubin" "32384-0,54184-7,54204-3" -"THI" 27200 "Thiamphenicol" "Phenicols" "J01BA02,QJ01BA02,QJ51BA02" "Amphenicols" "Amphenicols" "NA" "armai,dextrosulfenidol,dextrosulphenidol,igralin,racefenicol,racefenicolo,racefenicolum,raceophenidol,thiamphenicolum,thiocymetin,thiophenicol,tiamfenicol,tiamfenicolo,urfamycine" 1.5 "g" 1.5 "g" "41723-8,41724-6,41725-3,54169-8" +"THI" 27200 "Thiamphenicol" "Phenicols" "J01BA02,QJ01BA02,QJ51BA02" "Amphenicols" "Amphenicols" "thiaph" "armai,dextrosulfenidol,dextrosulphenidol,igralin,racefenicol,racefenicolo,racefenicolum,raceophenidol,thiamphenicolum,thiocymetin,thiophenicol,tiamfenicol,tiamfenicolo,urfamycine" 1.5 "g" 1.5 "g" "41723-8,41724-6,41725-3,54169-8" "TAT" 9568512 "Thioacetazone" "Antimycobacterials" "J04AK07,QJ04AK07" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" "NA" "THI1" "Thioacetazone/isoniazid" "Antimycobacterials" "J04AM04,QJ04AM04" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA" -"TIA" 656958 "Tiamulin" "Other antibacterials" "QJ01XQ01" "NA" "denagard,thiamutilin,tiamulina,tiamuline,tiamulinum" "35846-5,35847-3,35848-1,87589-8" -"TIC" 36921 "Ticarcillin" "Beta-lactams/penicillins" "J01CA13,QJ01CA13" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "tc,ti,tic,tica" "ticar,ticarcilina,ticarcilline,ticarcillinum,timentin" 15 "g" "18994-4,18995-1,25254-4,4054-3,4055-0,499-4,500-9,501-7,502-5,503-3,504-1,505-8,506-6,55716-5,55717-3,55718-1,55719-9,7053-2,7054-0" -"TCC" 6437075 "Ticarcillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR03,QJ01CR03" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "t/c,tcc,ticl,tim,tlc" "augpenin" 15 "g" "NA" -"TGC" 54686904 "Tigecycline" "Tetracyclines" "J01AA12,QJ01AA12" "Tetracyclines" "Tetracyclines" "tgc,tig,tige" "tigeciclina,tigecyclin,tigecyclinehydrate,tigilcycline,tygacil" 0.1 "g" "101499-2,42354-1,42355-8,42356-6,42357-4,55158-0" +"TIA" 656958 "Tiamulin" "Other antibacterials" "QJ01XQ01" "tiamul" "denagard,thiamutilin,tiamulina,tiamuline,tiamulinum" "35846-5,35847-3,35848-1,87589-8" +"TIC" 36921 "Ticarcillin" "Beta-lactams/penicillins" "J01CA13,QJ01CA13" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "tc,ti,tic,tica,ticarc" "ticar,ticarcilina,ticarcilline,ticarcillinum,timentin" 15 "g" "18994-4,18995-1,25254-4,4054-3,4055-0,499-4,500-9,501-7,502-5,503-3,504-1,505-8,506-6,55716-5,55717-3,55718-1,55719-9,7053-2,7054-0" +"TCC" 6437075 "Ticarcillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR03,QJ01CR03" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "t/c,tcc,ticcla,ticl,tim,tlc" "augpenin" 15 "g" "NA" +"TGC" 54686904 "Tigecycline" "Tetracyclines" "J01AA12,QJ01AA12" "Tetracyclines" "Tetracyclines" "tgc,tig,tige,tigecy" "tigeciclina,tigecyclin,tigecyclinehydrate,tigilcycline,tygacil" 0.1 "g" "101499-2,42354-1,42355-8,42356-6,42357-4,55158-0" "TMN" "Tigemonam" "Monobactams" "NA" "NA" "NA" "NA" "TBQ" 65592 "Tilbroquinol" "Fluoroquinolones" "P01AA05" "NA" "tilbroquinolum" "NA" "TIP" 24860548 "Tildipirosin" "Macrolides/lincosamides" "QJ01FA96" "NA" "zuprevo" "100060-3,88375-1,88377-7" -"TIL" 5282521 "Tilmicosin" "Macrolides/lincosamides" "QJ01FA91" "NA" "micotil,pulmotil,tilmicosina,tilmicosine,tilmicosinum,tilmovet" "35849-9,35850-7,35851-5,87588-0" +"TIL" 5282521 "Tilmicosin" "Macrolides/lincosamides" "QJ01FA91" "tilmic" "micotil,pulmotil,tilmicosina,tilmicosine,tilmicosinum,tilmovet" "35849-9,35850-7,35851-5,87588-0" "TIN" 5479 "Tinidazole" "Other antibacterials" "G01AF21,J01XD02,P01AB02,QG01AF21,QJ01XD02,QP51AA02" "Other antibacterials" "Imidazole derivatives" "tini" "amtiba,bioshik,fasigin,fasigyn,glongyn,haisigyn,isotinidazole,pletil,protozol,simplotan,sorquetan,symplotan,tindamax,tindazole,tinidazolum,tricolam,trimonase" 2 "g" 1.5 "g" "54928-7,55720-7,55721-5,55722-3" "TCR" 3001386 "Tiocarlide" "Antimycobacterials" "J04AD02,QJ04AD02" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "NA" "aethoksid,aethoxydum,amixyl,datanil,disocarban,disoxyl,ethoxide,etocarlid,etocarlida,etocarlide,etocarlidum,etoksid,thiocarlide,tiocarlid,tiocarlida,tiocarlidum" 7 "g" "NA" "TDC" 10247721 "Tiodonium chloride" "Other antibacterials" "NA" "NA" "tiodonium" "NA" "TXC" 65788 "Tioxacin" "Fluoroquinolones" "NA" "NA" "tioxacine,tioxacino,tioxacinum" "NA" "TIZ" 394397 "Tizoxanide" "Other antibacterials" "NA" "NA" "NA" "73585-2,73607-4,73629-8" -"TOB" 36294 "Tobramycin" "Aminoglycosides" "J01GB01,QJ01GB01,QS01AA12,S01AA12" "Aminoglycoside antibacterials" "Other aminoglycosides" "nn,tm,to,tob,tobr" "aktob,bethkis,distobram,gotabiotic,kitabis,nebcin,nebicin,nebramycin,tenebrimycin,tenemycin,tobacin,tobracin,tobradex,tobradistin,tobralex,tobramaxin,tobramicin,tobramicina,tobramitsetin,tobramycetin,tobramycine,tobramycinum,tobrased,tobrex" 0.24 "g" "101496-8,13584-8,17808-7,18996-9,22750-4,22751-2,22752-0,25227-0,25800-4,31094-6,31095-3,31096-1,35239-3,35670-9,4057-6,4058-4,4059-2,507-4,508-2,509-0,50927-3,510-8,52962-8,59380-6,7055-7,80966-5" +"TOB" 36294 "Tobramycin" "Aminoglycosides" "J01GB01,QJ01GB01,QS01AA12,S01AA12" "Aminoglycoside antibacterials" "Other aminoglycosides" "nn,tm,to,tob,tobr,tobram" "aktob,bethkis,distobram,gotabiotic,kitabis,nebcin,nebicin,nebramycin,tenebrimycin,tenemycin,tobacin,tobracin,tobradex,tobradistin,tobralex,tobramaxin,tobramicin,tobramicina,tobramitsetin,tobramycetin,tobramycine,tobramycinum,tobrased,tobrex" 0.24 "g" "101496-8,13584-8,17808-7,18996-9,22750-4,22751-2,22752-0,25227-0,25800-4,31094-6,31095-3,31096-1,35239-3,35670-9,4057-6,4058-4,4059-2,507-4,508-2,509-0,50927-3,510-8,52962-8,59380-6,7055-7,80966-5" "TOH" "Tobramycin-high" "Aminoglycosides" "NA" "tobra high,tobramycin high,tohl" "NA" "NA" -"TFX" 5517 "Tosufloxacin" "Fluoroquinolones" "J01MA22,QJ01MA22,QS01AE09,S01AE09" "NA" "NA" 0.45 "g" "100061-1,76146-0" +"TFX" 5517 "Tosufloxacin" "Fluoroquinolones" "J01MA22,QJ01MA22,QS01AE09,S01AE09" "tosufl" "NA" 0.45 "g" "100061-1,76146-0" "TMP" 5578 "Trimethoprim" "Trimethoprims" "J01EA01,QJ01EA01,QJ51EA01" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "t,tmp,tr,tri,trim,w" "abaprim,anitrim,antrima,antrimox,bacdan,bacidal,bacide,bacin,bacterial,bacticel,bactifor,bactoprim,bactramin,bencole,bethaprim,biosulten,briscotrim,chemotrin,colizole,conprim,cotrimel,deprim,dosulfin,duocide,esbesul,espectrin,euctrim,exbesul,fermagex,fortrim,futin,ikaprim,infectotrimet,instalac,kombinax,lagatrim,lastrim,lescot,monoprim,monotrim,monotrimin,novotrimel,omstat,pancidim,proloprim,protrin,purbal,resprim,roubac,roubal,salvatrim,setprin,sinotrim,stopan,streptoplus,sugaprim,sulfamar,sulfoxaprim,sulthrim,sultrex,syraprim,tiempe,trimethioprim,trimethoprime,trimethoprimum,trimethopriom,trimetoprim,trimetoprima,trimexol,trimezol,trimogal,trimono,trimopan,triprim,trisul,trisulcom,trisulfam,trisural,uretrim,urobactrim,utetrin,velaten,wellcoprim,wellcoprin,xeroprim,zamboprim" 0.4 "g" 0.4 "g" "101495-0,11005-6,17747-7,18997-7,18998-5,20387-7,23614-1,23631-5,25273-4,32342-8,4079-0,4080-8,4081-6,511-6,512-4,513-2,514-0,515-7,516-5,517-3,518-1,55584-7,7056-5,7057-3,80552-3,80973-1" -"SXT" 358641 "Trimethoprim/sulfamethoxazole" "Trimethoprims" "J01EE01" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "cot,cotrim,sxt,t/s,tms,trsu,trsx,ts" "abacin,abactrim,agoprim,alfatrim,aposulfatrim,bacteral,bactilen,bactiver,bacton,bactoreduct,bactrim,bactrizol,bactromin,bactropin,baktar,benzenesulfonamide,berlocid,bibacrim,biseptol,centran,centrin,chemitrim,chemotrim,ciplin,comox,cotribene,cotrim,cotrimhexal,cotrimoxazol,cotrimoxazole,cotrimstada,cotriver,dibaprim,drylin,duratrimet,eltrianyl,escoprim,eslectin,esteprim,eusaprim,fectrim,gamazole,gantanol,gantaprim,gantaprin,gantrim,groprim,helveprim,imexim,insozalin,jenamoxazol,kemoprim,kepinol,laratrim,linaris,maxtrim,metoxal,microtrim,mikrosid,momentol,nopil,oecotrim,omsat,oriprim,oxaprim,pantoprim,potrox,primazole,radonil,septra,septrim,servitrim,sigaprim,sigaprin,sulfatrim,sulfotrim,sulfotrimin,sulmeprim,sulprim,sumetrolim,supracombin,suprim,tacumil,teleprim,teleprin,thiocuran,tribakin,trifen,trigonyl,trimedin,trimesulf,trimethoprimsulfa,trimetoger,trimexazol,trimezole,trimforte,trimosulfa,uroplus" "101495-0,18998-5,20387-7,23631-5,25273-4,32342-8,4081-6,515-7,516-5,517-3,518-1,7057-3" +"SXT" 358641 "Trimethoprim/sulfamethoxazole" "Trimethoprims" "J01EE01" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "cot,cotrim,sxt,t/s,tms,trisul,trsu,trsx,ts" "abacin,abactrim,agoprim,alfatrim,aposulfatrim,bacteral,bactilen,bactiver,bacton,bactoreduct,bactrim,bactrizol,bactromin,bactropin,baktar,benzenesulfonamide,berlocid,bibacrim,biseptol,centran,centrin,chemitrim,chemotrim,ciplin,comox,cotribene,cotrim,cotrimhexal,cotrimoxazol,cotrimoxazole,cotrimstada,cotriver,dibaprim,drylin,duratrimet,eltrianyl,escoprim,eslectin,esteprim,eusaprim,fectrim,gamazole,gantanol,gantaprim,gantaprin,gantrim,groprim,helveprim,imexim,insozalin,jenamoxazol,kemoprim,kepinol,laratrim,linaris,maxtrim,metoxal,microtrim,mikrosid,momentol,nopil,oecotrim,omsat,oriprim,oxaprim,pantoprim,potrox,primazole,radonil,septra,septrim,servitrim,sigaprim,sigaprin,sulfatrim,sulfotrim,sulfotrimin,sulmeprim,sulprim,sumetrolim,supracombin,suprim,tacumil,teleprim,teleprin,thiocuran,tribakin,trifen,trigonyl,trimedin,trimesulf,trimethoprimsulfa,trimetoger,trimexazol,trimezole,trimforte,trimosulfa,uroplus" "101495-0,18998-5,20387-7,23631-5,25273-4,32342-8,4081-6,515-7,516-5,517-3,518-1,7057-3" "TRL" 202225 "Troleandomycin" "Macrolides/lincosamides" "J01FA08,QJ01FA08" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "aovine,cyclamycin,evramicina,matromicina,oleandocetin,oleandocetine,tekmisin,treolmicina,tribiocillina,triocetin,triolan,troleandomicina,troleandomycine,troleandomycinum,viamicina,wytrion" 1 "g" "18999-3,519-9,520-7,521-5,522-3" -"TRO" 55886 "Trospectomycin" "Other antibacterials" "NA" "NA" "trospectinomycin,trospectomicina,trospectomycine,trospectomycinum" "NA" -"TVA" 62959 "Trovafloxacin" "Fluoroquinolones" "J01MA13,QJ01MA13" "Quinolone antibacterials" "Fluoroquinolones" "trov" "trovan,turvel" 0.2 "g" 0.2 "g" "23642-2,23643-0,35855-6,7058-1" -"TUL" 9832301 "Tulathromycin" "Macrolides/lincosamides" "QJ01FA94" "NA" "arovyn,draxxin,increxxa,macrosyn,tulieve,tulissin" "76149-4,87798-5" -"TYL" 5280440 "Tylosin" "Macrolides/lincosamides" "QJ01FA90,QJ51FA90" "NA" "fradizine,tilosina,tylan,tylocine,tylosine,tylosinum,vubityl" "35856-4,35857-2,35858-0,87587-2" +"TRO" 55886 "Trospectomycin" "Other antibacterials" "NA" "trospe" "trospectinomycin,trospectomicina,trospectomycine,trospectomycinum" "NA" +"TVA" 62959 "Trovafloxacin" "Fluoroquinolones" "J01MA13,QJ01MA13" "Quinolone antibacterials" "Fluoroquinolones" "trov,trovaf" "trovan,turvel" 0.2 "g" 0.2 "g" "23642-2,23643-0,35855-6,7058-1" +"TUL" 9832301 "Tulathromycin" "Macrolides/lincosamides" "QJ01FA94" "tulath" "arovyn,draxxin,increxxa,macrosyn,tulieve,tulissin" "76149-4,87798-5" +"TYL" 5280440 "Tylosin" "Macrolides/lincosamides" "QJ01FA90,QJ51FA90" "tylo" "fradizine,tilosina,tylan,tylocine,tylosine,tylosinum,vubityl" "35856-4,35857-2,35858-0,87587-2" "TYL1" 6441094 "Tylvalosin" "Macrolides/lincosamides" "QJ01FA92" "tvn" "aivlosin" "101526-2,87586-4" "PRU1" 124225 "Ulifloxacin (Prulifloxacin)" "Other antibacterials" "NA" "NA" "NA" "NA" -"VAN" 14969 "Vancomycin" "Glycopeptides" "A07AA09,J01XA01,QA07AA09,QJ01XA01,QS01AA28,S01AA28" "Other antibacterials" "Glycopeptide antibacterials" "va,van,vanc" "vancocin,vancoled,vancomicina,vancomycine,vancomycinum" 2 "g" 2 "g" "13586-3,13587-1,19000-9,20578-1,23615-8,25228-8,31012-8,39092-2,39796-8,39797-6,4089-9,4090-7,4091-5,4092-3,50938-0,523-1,524-9,525-6,526-4,59381-4,7059-9,92241-9,97657-1" +"VAN" 14969 "Vancomycin" "Glycopeptides" "A07AA09,J01XA01,QA07AA09,QJ01XA01,QS01AA28,S01AA28" "Other antibacterials" "Glycopeptide antibacterials" "va,van,vanc,vancom" "vancocin,vancoled,vancomicina,vancomycine,vancomycinum" 2 "g" 2 "g" "13586-3,13587-1,19000-9,20578-1,23615-8,25228-8,31012-8,39092-2,39796-8,39797-6,4089-9,4090-7,4091-5,4092-3,50938-0,523-1,524-9,525-6,526-4,59381-4,7059-9,92241-9,97657-1" "VAM" "Vancomycin-macromethod" "Glycopeptides" "NA" "NA" "NA" "NA" "VIO" 135398671 "Viomycin" "Antimycobacterials" "NA" "NA" "florimycin,floromycin,vioactane,viocin,viomicin,viomicina,viomycine,viomycinum" "19001-7,23616-6,527-2,528-0,529-8,530-6" "VIR" 11979535 "Virginiamycine" "Other antibacterials" "NA" "NA" "NA" "NA" -"VOR" 71616 "Voriconazole" "Antifungals/antimycotics" "J02AC03,QJ02AC03" "Antimycotics for systemic use" "Triazole derivatives" "vori,vrc" "vfend,voriconazol,voriconazolum,voriconzole,vorikonazole" 0.4 "g" 0.4 "g" "32379-0,35862-2,35863-0,38370-3,41199-1,41200-7,53902-3,73676-9,80553-1,80651-3" +"VOR" 71616 "Voriconazole" "Antifungals/antimycotics" "J02AC03,QJ02AC03" "Antimycotics for systemic use" "Triazole derivatives" "vori,vorico,vrc" "vfend,voriconazol,voriconazolum,voriconzole,vorikonazole" 0.4 "g" 0.4 "g" "32379-0,35862-2,35863-0,38370-3,41199-1,41200-7,53902-3,73676-9,80553-1,80651-3" "XBR" 72144 "Xibornol" "Other antibacterials" "J01XX02,QJ01XX02" "Other antibacterials" "Other antibacterials" "NA" "bactacine,bracen,nanbacine,xibornolo,xibornolum" "NA" "ZID" 77846445 "Zidebactam" "Other antibacterials" "NA" "NA" "zidebactamsalt" "NA" "ZFD" "Zoliflodacin" "NA" "NA" "NA" "NA" diff --git a/data-raw/datasets/antimicrobials.xlsx b/data-raw/datasets/antimicrobials.xlsx index d6dad6733113db1544182a4e14819c14cc2ee2b2..5e6cc3c3256d53edbc1463ef4a3f48c5914879ea 100644 GIT binary patch delta 75439 zcmY(pWmsLovaXA}I|K{v?ixI}ySoRU!3XXV+#$g|xVuAecXtWycF8_xt$psV@ys9H zHM_gIy6Ua(Wglwv3<^m}77_{z3=R$sY#^u_=`%RQKu|3+xW~V5LMg=2zn@8v6yPwd zpX9ZaeG@vNDDi}-ClF}B!N80mz`*|B;k7SNxc@UA8wLU5-@wmsmoWdnSf~yEGv6p0 zJ@9Jla?%jbg7BWC?$Md4+HZ#5=3--^;GyrMs1cu*uwOEI#~C1InQX!^L&xrY2D zmy&~YB)#@~@)U(1l{jc;dI5L`3~+8k4{CJP?XO9M!wp|@gc8TnLTW3+t$*V}_SPLn?1jv>;X&Nh&p}zf6*M>gY*=_EihOnfXzr6- zb9cJ13R)ON=6dNc12BEE4^9cCl~2ggmqncz2`=J@+g z5#pu8y>j;J4SH$u44}EUQT7h3c9Uqto^5Qj+JJO9DSvc4g#Ue6e|v4NVBS*hl6P%n zrUDY(c+dXe>yyvOE#JY%>2))1)-N>Zzpyf1$RccnTE0CGcC*icb)Xx+%=@Hbm0@IG zzH8LJT?+d`jAtfYo9N$P9R8{CbUy`0RD$z)1~TkB63b|--~|p-jP3!K4lJL`ocHy5 z06271dw)Dvg<^7Sd%skLUzm7*d~bbszdR?&F=kO!f0fqIlt=D-jO_@tz-~);6E2!N z-4MQ;#9(e56LuNPFi|F02DX-kUC%tN4=<8Vlx|eTt{sy1-$S!MBei$%dqIa7q}cr) zhB{JE&ytgHX`h zFGIzVZ!MK8>gEL9-$5^-!taoFXhv+urItVc9!v-QjTigw@Wi00XX||rEwGpuTgAYq z2q62M_tPh{6fS2Zft7>#ZRkSm3X;M$K)FfON^Vw{mzi@0c7Rz|b=T(y*XWph`Vxbx zhl8lEK~KjY6ah$zW>`~x#*1L0CkzS6(2hjbs1j0AF8fp2WwH!Pu!)!~*I}+=*xNvP zXBxrBLH=dHStXdKV6U%~g1wsBuzpqT7rYIBIX%J9R_R@FLESZD)Ex-nt1{QENM2lq z7SM5{pdqVO(sJ9w@#iZQdbci4^On$bp!FMEIpSzm`xEe{b?m`T8?++*dDrUkI?GxG z&Kge|>-p_1_H8sbJ^8iJK&{r9uB4lT+A-@KVX=upu7SAk&9KT`Ql8 zjkCFwylgkl(%bsiDek*tU9a1ZxrGFR({mX)B?#ePE;GW@$(s9it&^YpJEaujk}@^A zDg`(t&ViyrD=bb4kWG!IVT|WI_Ckx*#h2MT7Tx5lTQ#0rl+B*N`bz!H9 zb^CQFGZPcUR>^dq_0=Y%Fa0M+dPIT$SY zxf@zSY!4^EUci6CT+z>Fy+gyjz3>Dj14v%aFDnfDR`b``tD`hM>0X>V3-`ByF!oS# zP)Wedmla6n9$MIZowB!cnb?$yr7{P~_6Wgb8Of>x!38ZpJr-0TM)0$*f*?96 z)*E3@4v)-*!cFak_~`+@K|XC_2Xzg@p z&4Z|si-W#E3lW&JZ2>u_s&EqOsR{5T)*D%8Jl$jSi$k!1AA8C$rj2s!N1$|R-jJ3@ zi*yT>6V2C5zWwyrYY?Zy(wK$k6Hu2Bvuw5u41D*x-7B`#kGAo#2X3O zDr#5PFw&ZzM%>uZq4yjK~d`3~HVHggLSFPRTiGTU3`s_S}r0@qD&v}p6$ z(vMKK(mTJ*O3K@h2+Rzihw}E#1Gj%+q%)D+s+%{_UE&4nZ*lwYcbBbLFZpjG{vn2P zh%C*nzdnZcQ%B7;jrFYO5%`^zge*`NJTp%)&%ld?DQgZ&uF>3BE;~P+yI-PZNOI7o zv(!Fj#+2Q2#>AsCaoBj~1rD^23*tW^V=6kW33V?#;!_0rRBQP_&E<+3@0Mf=GK5dy z`tH6y5ch&6P_4z#{Zt8HM0ao0eFTT$S`_dR1@pI5yk}z!lkwy7r z|E^>t$4n4`i@9;xzTmhTw;hz5Ei2dM&AyDZEdqzGcoILNEj{6(1E{Z5n3hGDmqZ>* zta(s$bJ3U)@bYkq^YqcearDG*a0Vy#A})LOU|XGGE76G`x4>jI2XWv;8b*#CFCv)Dn#%-53;73if7bB($8hSyahVw<+1w zcV(z^#+y%mLQVC#HOYWeBHT?sq!ob?_r^|NTkehvxI=l-Bj8e>FXB&?*B6&tYBXiz z)>EFx9DWS0UgFC>TzF_VITHK&oAbqjz(I3_pY-M&u>~A~#;%p_ZC==0U9c;(YecUA4!@c?&hFue+>^b&x zYBC(JQ-tAmJ5c|bgq%sK_Iw?J6{g?k8~?PKBN93*A)+{hB}80M-90Yt`uHY?pA?>d zC=tyi9vCbNPv^rVILfDRTqxHlcohL&C{{wbO+KVNxF3B^WEWh?)hz>g7=#QMU2qZ+ z2MC5iTND1~dl+w^BZwcmtwI^|Ovg_zIgWp2wkhQ9=K*Hom2Z+ya18Hll_F<-^m5t) zrWzbL@JvRX&no%;ep7N?!tW{r+b^q3R5UzdE?`)&C>QP|U+fIuuZ(NF7%uo$y@QrY z9r*Jm1AUY((H9zM6<+K0;*G`)h25F!rx3ai?$c%y5b7JSCp?u^H~*A+PH#%C+s$4p zorb?sr~$~NTH^Dhny@~!6-YJ7^KcLKaDG7s*iFe`U_KOI5~k~tY)OPr?wb*{NF3P) zBo+4%uuBy=p5quu?%|znRycmXhCG(g6_@oH)zw_2@rL-r{|lw0Bu5 zAL~7zVWu(jzAC0lD@KtCR&v&gFCDTjPLVrQUk`tcohJB<@+CjH?-^=Xx1wta>%eZ2 z+2_G5zi$&s6oD8Xj#{WY{J2MP>r0a7hL1;8%N=Ch!KLpZjIe7YNy{+m+`!j1CVFy0 z8fk!BBSYP=$0IYrUW-*axXfc|OWtk23Tc%30#+Omx*Z@FtAhLTz|yZe1a({EN|-hY zZlO}KEJ3TRaAXAm79m8ycRm@KZR6L`)ba&Bq{Cf80^4W4Fc+Dor%oL0i=xtx%6z8S zs$eN>Ey(lQpZ&68Rij-yEuseaY1-NukIz8cXnR0#S{h~gmxt$50fY&`6~epUv=Kc{ zjRd(yf_?TSSj~BQf}ekR5cVL`kS+F0`W_ce!j0fboL7;@xFiM~kYeFBgd17rlWWbS zx61B_8#P`%jP7``P4({DK)87?elP>R zTV6<}-aB#rEz;u;@!ToyberAaJwET3)(|qW+$Yys$>h(=iv1BH^fP0*k#difF&PJ* zWW|1Vou+2wAqeN}Ga9{LVjJ1Lnl;5N`2g2bF;0mCsl0ZWr&~sl6XQn)rV{K01 zi?f8p=#dmvp1fTPPcTOYhQa@WSlAku@hg+yM&KE5v z%E=v!HiK?-L|{LEF)<5va24lV(a3+^RD8=w5!9lJhnu-oO3Wy?8K0kX!{Gq5_}3Fl z1n7nvNu4{w^d8@|-<530ASrMC?Be{X%n|`nV0UGVd`tQ}fTRXm_IKqz<(tNjNo)c} zJ8BtkHOLhNLONpUj9d2CQqa^S%aDa;2Tl`(wWTh7Rf8&JFFchQ{Q+ISuP=?(6!kZIkv0&{>!oWwoTptjG>s&XA`gzLp2F?% zd=UCz+S?$N5!AU8U18<3mJrY4S+tSK9LnCVF0Azfo5Gx@`;ejGrl%ob*nPt+&D``_ zQg-a{nSKI~;@-{{i!k66#ViEQjD|btRU`jSpEUyd6^$Z*bqMYiYA=G+kKEeC4@0tZ++oZFm67fFoGBFwZ|7Se3)OJ!Y>6i~S7m*#E@v{4d-W<)zkY}Ywf z>2B1(`M%&pDgvw+O?^&>(uASeW|>eiji+DnSRa3eR05bzKY%~g6a6?Fao0#UPH@I{bNe5dcpy7rafXh(G($Mhtuo^-|;!& z?fvQRz%jOB7!2lMjMzf0o;sV)^G24<7*!2aou86|{neVOwd2qDuda$)q=!8>F4|Y~ z3AF4~JAmbu6}TNLZ8r<}S!G~YsO@KtEt!%OuJjKAfZ;poXiDtQx|7uJ?q_(%(Rptg zK5FkNMjPSYiImVQd`OcM6gS%}n7hm9@J$Vmc2NA+5q_NE4`WuigkQ(J>8>FC;bLv- z>(XIh4_Hd!>?E;^i5`A|k=OG@(GlLJoc2Z*)Xf!e8&T*q6!}__}LaRefg?Q~-+ zU6rrR0+Pa#gNjWbD=bANIh(nlNr>9ivW;)tB{&^QQh$EGEQ-@>oX1sWxMKwOFe~dI zUusL!3;aG>lD8e*UWnJV2L?kIlwe>et@ypB zWWCKlYLIqNvH8OcOl25RoE6%cD3=IL$|!O%qFmzl`XuY z)4vX;fkB~Qf=RvZH4W-lk0HLA?CWc@akVbQbg%OK$GbNvD1j=~E7)?Ix6WvYa#EE) zZt;Hy1vixiH93I?<5nVi7jyJtOeMQ~HYo;FsaMM9$pGK-xam`UE@zn49$*hF1iz|> zM&al4s=H!8yJS0LzgZ(q6cc1j_r`yWc-^IhI1%K9vL_!h`ccx|O&YN^E=xo6XX$nw z55KJ(j^fi~>5_?l-VO|p>%WV-tmnzy^Yj^<^VDYY0(Hj>j)hbQDwx7%#UK`TbLD8R zxlFzMIf)F#nFA99_#o{4u^}j59B&-IxZUG0!Ls1PY0OAr8^dgg#M&$tc&;2s>wDyf z7%8Zutfl3>%_{>3#hs`M2&L$!b%x+&HBW=MkN$RvgLf^Qq%0~R=NL-i z>ddT;+@#+SQ4~NQ+yGr%Y$Jg|(sfepVKj;rY@nIvY<-(~I-1O>*1P&Gh%z z(udzg!m&gE*8Uh;WNsPELHD=UQja{a0da*N3Jt&K2vNecwkLX>l?CGN(urHwM28jS zsV)M48+0`5sJ{Cyl#?@SLzl#zGL4);*T3mvpJ8GNE-iF^Gcvd${u8Wog!904nZ;0w zeY%Rak?Z+6(6o+^-0*15Q~9UA$wqD*umNHrVw}nbVzPq_3eRk1#g1Ct^tZqa52=5i z)3hWD=B?qi;oQ&{XkKiWY-q_fqOF~j1~nzy>DEM_otGGya9GK$up(j+Dea zS7gXjOSH4ydS*fW39TK_GVCYwOZ1T9(3F4*%auATkR>0P=2S?m9Dd4MI3JG7BLu{N zS2EBD{Mq|%Gv+rZ?#u3(2m`8^w|>Kb>!V%vEH7litzaF9dCc5b8s$57z)lN?+*>HNg0ZvJV`b^Uuf(gP z2$Bv#lu$4*sL~OK(1`p>0bfb4Y!uCl_Lrmaa~aR;3}K))-Q%VmuGy9dngxJ^fBHp6 z3nOY;uVF!drA}qu8l~B8YQ^`lP%Z$SlMnE-vQg6YXYRq>scJIG;`^X}RYj%S2RL zYV{ROozt0zbi=b`f4cSh*Ei~d#(X&*PEYG`vqdiG*=aWy>U{%jWRF~#B3aJ_Qm_o; z3l3*`E;h&Fpta}q=+iQGggjAA3}j6lKWQ~F8F)Y=E6jj|j|bfrW$;eo0X;59hjvE(+!Fjd_3L%H#mF5?nI$nyQ2-8ar9ut-blm1B4NDbu8{G8 zg=(bqJ6cAe)e!$S^u^OwBLK+zjFb0#YbJiRJ)f5QF~>GWGd!*5fBr>jJJcU-CJqs0 zx6h*NIBOWPBZoD>*{Q)SAbS`7L(DXWclQDPBfaywb4ttkaSSfa8Z^U{j3>(w%R*qW zzZZU?T1G&&nuZosp8j0M$}UASH=vvvYO+BTH>fUz9Zfm7z>nb?gafqtpXZ1d3qpyK z6Y;HD{g0O>`C3W;n5wJA=!HDFhvF}#?NLeLiDSMP>zA}|YrwS-?A+o0_W;kq-UCbD z(NU!e8sQYDuS59-fg$S)p|wx;x?)n!u*8N-Z8)#wtI*1(*DWRAp8@jA!ULXJE!X#) z&Zo2n-{B}V?>+!dlEfyai+ALSk}$=>MDN;maPVKg6{7NokQn2UhVgnT&sTPrzrb3R>tTc zZP?O&g8gI>f)EDDn;3dmcQw~1w{o|`XrkNuEosjkN1%usMf+@j!HaxJHrOEZ8J2o} zRrFSYKsfZ6XS71Kc~Z4Gg81GIS5P5KE_kXhPJ(}(c>5#bYO5tUOM|x_{`?9E2@EM2 zq%k09tF8ZaL;14Q)GybGD%r7>6ItDkMb@lsW3bZAewT7{wTV))&>*r<)#X%-5%_x! zYmJ0U5AX>c&?Y`rFqes-HFx+iDJjCv15U5DXOjVKZ!oKdcwoms9MO`6tGM3Fl+L+4(zO`Vhv?cb0kI~)&3FP@v?>Z5C&Ch2Vkcdn;rk!ZuyR;O}B!i#Xcs8NY3+} zm?PO8SgWvdoiI1lrs4_xyYZ3P7b5hI2+2H7G&E3mt;K6LpARV*-Rouoq{{E^N36y%r7Mi-dK@=ke@Lls zF_m-ZXjEkh;jW2;*cAbsr27=vf*aAUuK_3rR{xUF3;0(Ra{Z-NAdv_Liiw2B{D-Od zM`&LOQ@&f5FimX#sDkU*dUu<(Os@18XahRG8hh4R`{!oma+#=?<-8l`OJHkpkH7c? zA`z=|uF2W1+tPae&Q6x-8Vx}?EB(i@2*1iMYie{l_TSN$F4V_2;Ldnxj|)6{=_a>^FBH}hv;OnxOok#R8P+w6>T#&>(4U@ zf<;T&jVy+~lEaY@QM1QNDtyPxc}_Ai4Ua)r>^RKC5LMlhHGvBfbz#3NJRz|$)OJg{ z=TO9Zvsx%P#_p(^!3d5Pw#d%@LwWKN0KNRYEMImLw|K)SjN7lJtr%)Y=c>$+rM8yX zVP-8OZKp1;Z$T)eo<%VhPxUn1od(4W`fzwhDJL(3E!mA@T_?39QN0u_0>`juRC3&Y zAiW6-=1Hr}jzoK*rFO@k_iGZoZC^ysmxDW?j_|QhLRRsk`zqD5p0{tT5@lU?0mpFA z?1mI|iA-KrDThhY_jmIsC2ZQ1L#)}a&m0rEI`GMl$gE|7gd{OD9-!*+DPPHYH#?ARQFV6t;5mEhEXWie)PY~yh)!@_>Eu9lxjHI zs$Vi6kxPou6Zq3wpaBS2)gBvGSu*JC7*Zhh-`-W+A-k818ETJt`r{PaO0e*B z<$VU1bl%|uj^c0D$dBx0>ilq(i~Q~%V_F&&@;@_bop25>aaMa(IMZ005g<6MMd zGLu{meDM;j)EaDIqgOv@TwcPB*rkFnR;_d_bJX*!7Ud%H4o~=NU^`uGr4}f;7H8$0 zhcCtlkqAKWksbs~Jxo3GCL_`XA}NKbS5Rkrh>k<>xhLE+Eoebj$sgA;9pa9LlXx#+ zxBGhc^8Z!B*#+h1_~sMj4wF!~7wXS& zHW+yVA!|Ujh7!a0hQgJR$&@^TS>GD8Y5~VP7NPjKwZ&ur%a<2aHV_P*nz3!N6lx{O(`;$kWc>9_@iFYfObu6i~Gy(?pdlIs->r!9XSO-;-gqV^P{94Qn(PM5>BDG@<)pfU1HSkqslY@#v z+Ez07xZ*obaal|Is;?HKI>du4{{ri=3z6J<-c6F-i57*2*)43uch6xS6WTGWa`dwD zU)n$NVNpZ`*yQlLEU8VOqtS^6ya_DjWN?m7%_LoPPv9iYsUz29=9QO#VJ&Y}_oDSg zgYvkBM_**Z-N>Y4`h-OMlGR^-TxU1vRKj0<*bXEcSY~)X(ec5lj?#t?OR=mXCgWW~ zk3=buYg0Je9;Ub#-A64E=2}P{YaI)^fJ8w9>@xEww?Pb1gMUQ8&pZ0oI&zrML z;fCi@h5V|aw&;na&be(01|#)NPYEuS3?VDlXIOD#4gNA&FQSOy&00Tj*e4Ixz&IH0Q09q6=(sMo zHH;F`?$Bz9*4|KAc`A%17iNXMxXH}S$ad0}Wdv+zk+jT&yp-km*x6{yq6exj3iLK7 zxvdL+;kM68Yt>j3RigP8K)_Uf8=EJp#!JLb9!gO2cPhCYNY719bRnN8D8!tQ7og*E zJyo*hKR#b7`aH1}gYLnk@!8$cGR+9=5DF4a)a{TmoD*ESZ3Y<39KXIRW9`>3U*(&j zSq3zHYm0v@9bX0WDw|tw)sK$Yie9HHc}dqA>t|*q9M!P1=?|P!Zp}e-&M`|`n9l5v z7xv4+Z1fbFg5~H4<&ZfjZ@WI28TiKpR#bX0QrS!Sdp;$%k+w@~YeHLue2e@21#jwb zV5kanbf}1{Bt8(af1?x}*;r=xQtcZ@oeEIz)~s_z&?ZnvifMRMCIStA%t2EWnmf<) z<()o9yRkh}lHfsK%fy{@F5;V=?QEz-RkHeYC&tJD0stonS46m|iCZT;$=%>Ty30Lh zI>Uk-BgFNBr9K4~ui`eTWi~ZkHxJ^VqnmqG*qLiA4${2VQphn%$R#-#TkcP{=mBt0 z!I8(J+V>1be0k}sDIpwO^vlRKY6%3As&Ct540g8QRl>HyjR=24Cv^= zY}Z4ZtF&T=%1MvFZKe(=5-P!cP!lq~;RG`(9fWaXm9n;h|DyTXvyQy~lFXt6*4}tU zt)f_d1x;g7a+umH-W+TrH+7gl5&{T=o%j-IqI{@}2%UJN1U-dlH-a+|68uCf|BS@q zkvCE}Mqm)Qz~n`sLBD|Qp7uwoExJr*$Cyu8`X)H^_f{~O%A9&E2}*+pwqPX1Qn8=N zC98&A#2kV_jAwK~sG-RtT))_3lr1(IjEN355sOje*4~IDMl6!O#DsRz8aq(o1T}f- zpk88#;!v?b{N(E2X&o4Mq|?lV;b*FCPq3&xvw?xQi0$R0Y%O~3KUw14hmQ!TZwRR$ zBUd!`-RaS;hpJjWU#T#*bsBH`&$HOu6|dMn%WSMP{Y~G2?#tVT?n6N&m3sB@j)zui zs|AbTwT;~P9pw>gg3U}SSOt8wWSz2!AQ^ul>(t_l(N=Of2_QIxo?{@Km}rjKx73qz z`LmB*q;V~B8gT|YTFgU&E0@-3-tzoKtO?Jc{QH=Jd96-G`X3QP_>+F|mGQDN`@FOM z6}sm6uEc`*C>z~mJi4C&yh|BJ2R#CM(|892myirT2z~Al!8-FtP5i*jm&QOk=xIW= zUNiYl)I#P|baR_jUg#CC5XvIoA2aw-UVjNGA@e+zpBYhGm(EQ zXPJVp-Gm=^Vz;0GlnKPnp)tT#sZpIcXr6XC!*uU{tk-%1{iZ7NUQNVCK{Ya=4^ zsHr2_WfHW_R6R?EM!MjygQwtUmhpu{xz~Kt!HYd2bp+0Iz`i!(;K_H>n8*-PsekN> zgu%0uX}mIydiYo_LQ;Y;7Cg;lE}fLVd1es$va~3^DU=lrCaph$Di*J?P9#Mjffcb= ziNl;FRd-A?4}h5{TkGRQc4i?eJbXXL!9cfLVLr!dYv!2D$yQYvmv+D7#lXY_GTD%e z%#ErRiQmj@!^w1-L$WI?WJM5Iffko1A}XgQwMf^jikL6g(`KQ4_Nt^qHJ22MOD0T?5r8$~_4|H8e>Z7jIp^hHI)Bu{ z{>>6oDhxsD)gB`ix5o%;BFF43>9o8ZWB$vDVqT+KZh1S|R?%e#GD>Vz2OM$KD7~>e zjxTb>OS%mg=RTMje@}z8BLTLN-1%GOJgOim9jiIoi`Aadqo+>vC3VxtK4nr1#L{z zYdNL;z)*9go%=YNicJ|lK5RLK|Hx2tv1Dt#3$S~or15cJsC_tJYtR(sg(mE_D|i6uEEFT?&v#uKr8S3rO2z`-m<9SkN7Ds+Um4ZVvsj20l1-|CrkWT;K+ z`Gr~OapI06*3@SMS0wLE@r7S9uR_sTL9A&vD#S5-tn>^UC-#y4Ef5<*##K19b$zA` zhzsRWbDh6360dVA-^ESPgYwK@koop9nXX0;sV;}XH<6^H)=HDa(crFL2>RVJ1xD__ zhqCHKV{nB1!?9#6?`nHpAE|qq{zP-c?r%4-mJZEkQgYuWeThgL1E(qWp_diK&-z^I z08lAC;-*LW-<9kqaufaB<3S!+p7M7>;3FB&xI6H3pCv@oWgwd5Ma5N<;}3$zG4)_T zHj)k|OGK~S%!jA9Lz3TGJoc)3vLL?s+BQ0o;5Qn}f>=6c#j=EtOjSO$&Yj0@m@8Ko zz=3jyOokCTw`qoK;v`pMZQywZ^7{Lr89ryDWW^iH`zXHsRcPy<5J0G4!`=+A^TK^B z4SNPLE7Y#t#R#lV?b%MrKtERUR;d&i86`+al%kUx@?5EWRNdIpr_XW}c{M5&)WJH^ zAPrY|+upk+1`X*sWk$J|-nl6gDQ-r*g>L5IY719mOHA$M(ZdcnH>GE?QCLo?Vr;2b zbCYUN2HP}BC8E_Z&RJyK_AbzR4}{;DLQ~|8juUq7f3S!NA^C?6l3x{;>0v|JigZg$ z$&}^R3zm8I+GO%z+oXuO7hiOKG=IJ5t?}Gv;7d4V$md~Nme~$#*e>oQyl*O_sGT~_ zJ(QjNTWPFoOd%q5`eFC~6xTVKW*%{;49pnwr(2OzHau}pTND7U6EP8uF5>`hRcu+* z-J7&84#A&_8U6Ai{=7LyXN6uwoTZ#tb#4ujUIK&Bwj(4^FFRXfp5PVX*vVKrLF6Nh z4^A^Am=Z#yr8+D(x@bFHc)8=P1Fn33iG?#K=6R8ptR%F(G@*#@zxL%!09rj0I!yad zIa}k*0a`uNG(a0tBcDGnC=uDx**vNzS%%UsyTBLcY=yR9A2+C=yl?79*V*7tRXT3*Xo=zhTw-_h~S0 zh8g(16~ay6p{7=)NSks2`-?J+Aepp1@RL#-1Fj^OQT^t{b>Xq8M?YfnF@B^dWL33@ z2Pvoaw-$vFO!{dU4(RK&->RY0AA~+5J!$-irht7#=Yi}F67A?$7-~X9sHnJmG$j@D zfVNF|! zZv=wN!|cpLoipcSsv2q9UxQaj1w)<04LB15_lc>&r~FWtBo9uGsgv)Tzf0+9`mw`;lb!D?`~A2v5xMyyLwg_@Wq!$LO)9-*XpFVH!18nB zjo|LSQXlU>!@Q^;B>n%`{l9DYXLz?kwZ6cv%6}s&q}h5ub(0OZzg?qtTGVMtn}*2? zwV$`n;bSjcGw=^>L;R#yQ)WNh1-Rd+u-Kt7tDH2RD;9MZ#kgU4o)zjF8Hb*&d1IEe-(|;(! z2JKve!8mJEOY-yS=~;5+h^9j4c(U|^#Vi#WdrKBb$dVNpCRdVdDY$Hob@Yd_fj4)OP-M4Pf167D!y=q3C3S2X(KnCtU%gZck|NZ0hr8`E;Xhp_&CJWW4wlxG%ldLDBqi~x zX@Bg;Xl_P2PAc&qnp%AB5!*qU|58^UQ2YQLBIu_7IP%T7khz2h%>xcL-RHQ5wtVtD z)X8r=W=^}}6Y!(CLSwFt&c1e~$$Ke{+^`|<&3SdFk}U&8rh~$z%VCh`|D7??xIwkn ztekrlH?NpVwWMl>0pU6@>?%!S7y>r6a*wL^qOH$jrdH1yHI}~CRB9iN^Sroobii7C zasP|^Oy#SkF$I69LEi_=?%3{-_2Qxf#syaRLSG5@ABL|R>5N#(#$HLzeNQy7)Zm%`Bn~+D z5}AHog-75-&Ur3jGap_?pzxoBkO$gIXnphsmhgVJu8jTybDrI(RTPUQ+GSHZuvyOBrIw+}!gmNnkQX&K;mz6dXby7gIbZ;>Yz;Qpmf~lKaMgM( zH@Ca6Wt1MumTR+e)spc)P1)Q7*S}gu2WWr(yAa+}{{@XXS^0h=AcW#5^@mk_dldE~ zF(|~8oPlR5!!(KKx-PlXRlfL4b0X>TlQ1qNsZCTvJ-r|Z|IKYtv+RyvmC?IC<3Da0 zYE(4{A|sc3taiQoL1~F)1`_b9B;|NrRi!tX!Qb|kqCO-_0DG;A4%Y~8w0(2{$H)R2 zJOVt46!^EguRo|xKUHQOGnm$^f0xvkEZpvd?EpxJzuIR`U$ehdBe2_6Rg4z0Jf9x$ zEoyw*4RnF=`=~N7?C53fql`G@zq@|s-v38xntS7Mt*BN_hm6jXGAqXX$=O4hCO*!8 z*g8jSTA2{&@th7%<$>as#xp?Vk_LZbx1>!cH#zP>%Cq0=;Pmrqn0YZTFFadst1*+g zp(d-IV8kgPq0;hYt&zD~ANwIce6J0)tiFV2&E-P#_#wDS>$m)73=%bI#d0$&b>~vO z?IGr_MS1;u!$NwdGG@QYL&4@>tpg(C(4@zYO<19OxgVm z(+;lmNU|l8i6@IBWEaOvHNUO6;BXpSsAC=vzaX-w<*3T1W+}_3M*s24)^-iNLPR^0 zRZ>`k3v_nWNP6&TD~k6%Z-ZV1DlHtT3c+p#XPs6z;h;`GOj5X2?cig>rP@bd^Nepu zqW}rqUz7VLnp5(uJz}1-1!^QkM!zrjW~wixL53dCvDn}pJdc+(OMG86F;U6G|K?jh zKH0K2>~oS#J*7*WCuZQQ5GsJPM5~*1-WDo}f^!SHA4yi4us3P0oQtor#{tH{aeFdXYLA=4p`aE9HK30g zIi)qS0l%mJ!sL^;<{eG5l@%NCoZZ^xQ5K|6@ z#RNR*7cKK9A6q<~iAT|#>*#^DM_$OkHA4!^1Uh7Yd-yr0o7!db?gOEK9-W%grds8{ zO06Gy2+oSrgm;>H{(tLgr}yS4!4e`+LmRctOou(W)fG zt(}bR@7OW0*zcX#xzV_~m2vnHdKvl7=2M4WBhIe4U-&}Mhz!F2 zt6vZvrf1y%j#6DTu%C*Qqta!6_whsr?2>-h{HDx8Z);8NLv#{qwIQRG^oNhG7uQ8C zydY=z|_pNNl;TxT(P;%Fl>^b!1Lm)C`&pT-&VyMH=zBut+&vua)k z*}=}}G?zg}8~x8+3W8ky+}C8}cJ?N0~( z-}EebuCTCSp6qj!tAm7I6LV#8@;JDNVM5Va zbnJWjO{Ti(yLDZ`SUsiw$Fd8 z_FgGR%>1L*H#+!O5M%3m=Kl1*V?FBG8@XoE?EvzDEIvL<^=^P5OT(oi<}T1j_U~$8 z)L-KqJEWCFlCsE#NEPR@WX5?NF4L&Rm&_I`oF(a8tPBu-1YHbDj z0(NAXR{ShcgaH+IJjtI^`2>E~iGO@X81{Kjxy7=f9<3=2JHVtE9?63W>YJj|_o$FX zpoxFLp8hoC661S&aoPZzTI*&Q+e?9n!mlakjg|~(|M%pC4>W$15uRjbnJ8NbYvGAw z_TWQzt@rJOGa${KBR*VZOnw0D+WTB}F?1g@??&IeH!bt?~>vZFpk=DI8{YiA;|S9bU)i6#-bwb#_TI($)t=} z+AboNzT>y386~P$8L?6I0CNSpzZ_Q;7QY>*iK?*5#wcf@tESd^oyX0vVm<(6o&uPD*0H3vO%$^MZH zkht19gq~ZP8PYTBmZj{9^~hA`OruZ)O>i8J=vJF#lU))&SI@ib$Wkk5WoK6ZBEyvC zgNxKK^>n_OQ++Mij|k!!!XGsi13bM;JY$F_aKO!@7vjc1(W zEiGgX(jHL5@cM5q&ihB{^|(#GVdNj;>SH!L1DgM(S{@BXIs9 z2%!Dp0E#M_Pgw7>w9|8c2>f&_I$M&P2})axKnUTHMwqzWRFxj=PGcFv*4Gw% zKNU3E?^m+Y_|(^jS;Ai)`~*}#d4N(AvOiDU2<%!<2$oBxr=4cpJqc{h zAm@$TVmn`LERd5>6RzF}vvt|&9qJH6*vB!_Ql!YaG5pt+p)AIS#z*k&E_N_$-Y*t^ zc&|WvmbzNJZSpC!;3Vi8=l@h-6=|hu_#qGi;fEjLwF&nEfK(MMvYYY9Tv){iPHk(P zkh(bsuT4;3J1N2^-4P??sCI^F@fA-^^--i0MtTAfXlP6j;DTVK=(+bGznO5Bbo#Km zB*;AAhd5;u$^2nFUNz@8H7#A_i_x(@RSpwtpJw5|c`1KM%yB6gwm;<%1LX==34r;1 z-!$B1#25Ji5Up^-1g8N}BPO8L( zNqPd7;@`kUW{tGpA?hRxv!J!F6iZAc6mF_A5)Dm=n_HHY15UCm_cs`i#sivUW|6@f zTLm+vPXuEhR*uS>JHbZ_#P~ZI!!q1%G|xDOs0V!oSe)B*-o^a=aF>uvn{T*Xo)j|p z(1SIWvS#w-^+`TgopqK`pb4=kse#`1aH{7oVqN1RNO}7e`=Oz8hi*ktwx<8ekJrch}#aa2p8`oyvXf*aS^jBogIV-~74 z42Zx$6!hXRDHLAwPSCllMY?TKyMnAmpS*!CMuY}=gJww;MJ zac;izoqO)OYjt&X_mA$iYE^aBv-h)iskf|$ZVntTy=s?gJliT%_x%&FQXMq;Dcw#% zU!m<;TbF)TME5o?cVNpnd)2HHfNeFePDh}o=3nX#y&sqlP*o<`MZ~O3ddpbJ6!`<{ z197lASPYHH$j|&HgtEIW27zMdX2Na_hYG|_u@x}BM_p5dGRY&vtTKQ4i^K*OdY+vl zX6#EGjEebj)4QxbNYFH-&FXq*>F*mqG!)9I_?G#`$_)WxZV#)^=6#wu#{jGEiDE9& z`p;^SM=MAQu)-RxelVAlsj`_Fxn8V=!8lY=_}@SBfmBmGqLdZsZWo>wjYr-idX@dH z$30L(%=<2We^*F^oE}zj6&JIy!dU8`7D1`jBj}^C_Xy!UddPr_UHYzDx7=S-d_HLmQT9@oKt)920Q|7ih{6kHU zx~D%|<%f8cLbh}^;q(?}^IvQIR<_|b$?PGt@6pEZ*sK(;+!^&;1@9p9e#p3vnPkmiw4L;gi5_yY`c|7~^Qvb{ z=FncuWxDb45Az9UtLM;8mn#6w66K>cc77_Ld=t}`~z4RDn0n92+ zRwiz-e0Y$?_+{K|mfrDZjDDMAwqUYqpd;GnBlD(MaKAo~IUh$~>-Azr$%zgYp69zM zV~XyuW>@u&glD?4P{A}-UXkwi(WQfT%)LyXL$XG?zIt@8Qz{_%E? zm}(T=Re^$LG-G~yKkEW`a^6vI6nbtGpY#s+khyc*Y3!=3LopUtzcxV|Q1^2q>9)M2 zC2Q%VvD+4J1^RRCqU~q;VS<;7r{p^XfzM+|CS0+MZ|(ApZwYlp2h8A5XO6g!-wl&y z^{80pXu?)6^e&q-;*|3u>TP!hPWWghPLUW!IQcqd?sLOHq0ay+Yj*sG~tJDIoHZkJ_vrw;xI#H{K;>57A z5*Tgp+ttRtcdO_b#a!(un^o@&wG0Zo&F8h$U<8bRI;kqs9O=n_?nT%SVM{?Vey#K! zeN~h(@EOIjoNxN{vT^EB7fH_(^~2lfZxTQ)qEd_a&hqp@Az@U8*j9XHeALJRsmD?!q$#8u=e)RJ%3_LSZ>M80OHLV&w(q_?)a1fE(GmTiz z593?!Rb0n{#`*>ZgI8TqVU%Zupapp%I9Wq1Trrbg=OkDs4`&;-e4hHR6?Xby4Nr^T zr&;|7i}KXaQDbI%H#@gGP@X|IUuPEs`~W=Qt2<9>+sAH-(}q*;IrdPk77(>keV_X2 zzp<6tl{T$K=ZP{oJyr~Zs28={m)(*6MKC!XDZhbV)jcQ#kgO_Xw~|Q+=!I0vqTC0O3FV zvvAvT)F$HiiHItpTkuFAUZhke^o!CurKU>c?SNAr0!f>C9rJy~bO?Hcm4OqcsRSl*2yp3iuMR!#+{OUIJ0M zFbUYu!alV}*_vobYh53D=_p?fJ(p((5p5k>2?HFTKo{SR2D;#WNOp8KTpCVTpey38 z5xbUih^FhPCXX}S3Vehgpl9t_F_!NMnc*~4^aC>FaYV~~#*I7}5F3SbZ%BYEmo{@L zM8buDWu1r1d~PJ*#$u{weNq>Q5#@bj1s%bvL=w;Sq4iU^$VW9@sKM*QV|<=zM5eG zdOwHI5QDh0Jd5FXtdb(nfSSTZibF$|_ZBZr zo(xYewq4(v~$3Il@uEY_)RCKP}SjEm4-@@HA(@u)ms9HINl)5+R1*Ks&s9_d4SLsynqqmQVktqn#+G1c5eure%j$Xx|KVz!`w z(Lm;?KY9pPQ$X*j1Y|tp1iS3SY;TW))0-t+?-!9W`%pt|u5dk+&0bUHJ})PLB=#Fn zU#CajJ|@nQ{c-87T-KjbQDx1+%`cVOrzY|ZSjjjanNc(Y?h3X7X;aJ3!5w$T@-Ff? zf45d*n5-zS35d2*I-IO0mszt@lm_zW7j%agP<@aP7i@U)O7c~XfH7%Kpt@t0{g!N< zG7vauwjO=PA1`6CaZWOYnXNze@iDvJc^-(HGY+yzz9`eGMmZ$89DM0~g z^ZSP;I4I@kPpW70+UHOF3*#RE$S^8;G)Vwe2hIayjy62ab0yk8f(QpVxR-OgIE(M!1;}g;#VKrF}UFq}Xu=!bQ)k^Uggkt4>DU7kilE@^QKH+xi+>WS^ z37S7ax_j!-JAwvY4HyN4U-!UG$|bgOc0?vK2{1ac+EW|wk~vw_j}|YtcljT&%&yl~ z&kM3?oW0jtVxbiwXr*Zqt-mP4eXKd^-?g>LU$&7CCUH;ND6!fjIIkgxFyaN>u!mnb z8c`xUcPs$jy&X#I3BK_7Es?6|M5BRyxQGwgo2-6Z4Dqgi5cL6ZtN9ZsKbxpGR^;L! zB!5e2=g2C_h&*h$H(T=H4bK)wBI##7&mJWabm%q2e}eclanI(3S9QEr@?@(}bDSDe zzJtdv&z8JhJ!{GA)$_V^<~wk!SPpeo8dSeR43#PFjkqss8P z*#*;(DB0#a!=V7^_?jDlufBxYphtCZwR-$>jOEtH#gib9N~6p^E_@vP2Ujo$MFok> zt@=(th!Do)fLSwC=z_0{jAG#Vgj5R#707I=zJtWMxBsD6jtQAV=x;n zMD6`Jp!>(z5Qi_q<+{v_^cUlWL+*zv_OS7b!*v=Yzox=MU_yQI{X`cqB-IHR$TH* zaRnfLAq&&2?nz-v-xaQuxgtik5Bu2QhhT=D*uIh13t-)TtV2?L&zxP(EXog20;oe$e;;K7f3Mr^_%>It*9{p~ zyI0-LJl?llqFHX|P9TbPZItNNJ>+gPgBhs%?JbGFR7rx88>IiGdMrQ=$uxl*%bKZX zY(+}M`iO#3zP>@BH$)Smb34&qwiB!ia&&=_r+ZC_HeoxfSQCvTt(Ex_@#63cxg7)y z<`Wrv2<+{v_~J_AeBrH>16Ku{{oQ*TdMjOc$?Lpo&nP~OoK!k7dw-%RU1 ziZ_1bRLX;M#cCd1sTh{cJsjOPZGq9jqVcS_;nIR`I^j7r5X$tfwP9AadpNMl0d1@Latt}xB@shg z5*{NjmeY<^zGl=g{b}@ZEPVt#dOZ{LrVW)#cOlXJ#8xN|%YVyu8qW|F=~xQFg z)>W@ic9A%1yz?`uH~7H~4>6Fo?37E+yHV(_w~cwa`p$$5 zQ8rsEgQmr^?C^dJzJV)bEL-F!9e8Np&R zbo^ix;uSO;{8yn#q^uIJ3s~h~^+jpeCwBr}BA0lD8w@(d6I>)<+rVcjL%MHy19|&| zrG6RoR?p-D%U1;udGK|}5)xF!ng>T%78M&GHn7L&rG+KZ&C4G~xuWHm|H4LyfhSw; zxE`;Hja6ffWalZe#l*^%H*}0QqO`5qKpMZ9Z}@2#Exxx!C76Fn4`x2@Ch&;etof@| z;642kOYg3`G^ILVJCn-}d&kDc0lT$S29@rNN$INZ8vz99DF21i!ZN6UPAK0^D-WzL z1Ada3r?XGfGddTeN9xgtuR_DhIM9r;>L=)T5LdcxQVfkJO`*h);bv5bS2?Ywu5Iu} zag^eF8r-(cwmKSYw1xhCtu`3k{xU?&tru%+?^M!gL+wM`(e#3V=DGJJkPNTPS$BnU%RvUr#M`8cD$a49XsbNc`@cV2SIJ@A?Ym4BlY@|h7+}~e@Rz~D-+{Ye{=+Za9Z!_qutYOyJIl_gjTx(yCX^g zy)N+R{ElvI09p;U_yfDYL@i#k5w%~IU+!g$;=Q%TZ!W^HftoGrAn`nn;Wt zcVVE~EoEiTLFdg&a_|O9V=wNki+n6|4!T!)@dHl```6$8W^aAjSHx}9q8_{MGZs7I z%m|+c>0)0@h7mf&Zr}Lrp(d5cRhUYdF-|f-9<)IKDl~j13b8qoWn*7w$ZaZl8&g&f zaXABXDC%}W5=_3v{6&y#XmT;#($O9qEk_BD1j5{8- zb^lo=e+C_6XB?OQGZ3Z^V3?HEous!r7?2g`RZw@YD~X-h9pt3Sa(Ea4E4PtqP^Sh5 zcoA3}E*y>UFa)7QLYp+~O4W&{6?9>wiJ(&$X`v?7n?T6JE219k)0ByIX_=$fKzLJc z+{P57Qjx5ugr9EUcq=C)bYj1H8UJ9_4krSz*ZIV1B~Q{d_R1cz`W&$!T2zqH8)}P< zFmzy6uIw!e<-km23JP;_gAdGh_#QSj6s+yA z(?XmxS);=78%x9#`=m~b0Khxr67;K_n~5ui8iW`pcq(%Wml{2c_V-a}P(%hlRGc$F#qJ-_iYIBrIj z0_{^b8};MYbB9gH+hMW(b2LC{Jg82Q|77h|xq#Kf>;y|6Vr0u&H8UTK`L?vB65UIR1W#%~n<$Lejq%RR>0{@Q*IE_^2x#U6%! zK^~~SEmN(6B}EUSJwo#E#uOYcLz%rk$~yMdAKWS0p%6%o9XQQRuO7E;pdL;}u(VqB z9wkrd#W}%rN9kwmWpR#WMd4%%ozDe(1=v+U^k}$ zbCh%~&{OfyCE`w_Gq8eR#<^H}##5fzKMS5gX1#Uf&+i7U*Hg=qe7{BgmD_w)AtxE^ z5+!|6`ZRSWny~awky7uSTzMHsyTjYjtc|x)jrpr)oamjCVJ7KoN*AnnQHpGMQPAe1 zEH>vZZ&Pwj>$a!N@C@;l_B6VVLt0aSMgpc3jO@P!~V5add4~yKa zui;@8QwnETzib8yyY^LsKicq3H&DB4V-7J+kUj;rC552Nz;Q(gl*{`S3&;bMkzh}* zA=1F;=VA#b^cYDZl_*Mrr_n&^5;?$q`09kBOmojNz}q;5$B{x(_*kFoE}Ja6G7g@% zPVA$9%o_q;SX;iC+Zvyf``%u>L5ldmpCcofHAR~8gaxR7Y|l<}quu#EO>4BvII^@x zYVtJe=}y%zV7)OqgA9gBzx^GfpvS*5mgIIaQ@`rrqf(+K1#gD;6O9c7n&^$YkydL8 zyO2zxhrjMMQ-8vMvc(dygz@t}3ao}dd{7r*@3^aTR#w#J%0dsz5|WKTMViI-qeoS{ zE9Fh>Pc0p6A8oW$KSg8v@7!G$$0+f1fmgM>#kTQw=jnz3Cz5{0PznQX+d%Z{CrC-$ zwaNdKei!iQ5bh)GSZ#@45H;K~tb)==B96B(dv?0u4R!om{_*ugV0$8!HcZ@Zmt#nu z{@yFHJ#-^1G`)`W>w$*9{U?Ox&?Cz1r)be0Nsz|42_%OZ=|Wb`LXm%)haw|YA)9E( zewJ#R;Z3aS3sWNUVF5h#I9_oXJ+r`DPN-|~3E^JPqb5ZyvS(y!o)D@V-TpJaOm*EZ zp|O5v&_~tNDQjHFqzoZqL`+|}PCQYc-{I`gQ)|-94ndI>fLuS6A*c(L=gElN$Ph_k zwtUcveTKpw3wz92xcc1E7CKpK<*GyFtngR3SZr4%k>wRb0dmzD(~>f!p|Y|5D`>huZH`iK~J7(S1NH zcGg7k)OddT^Y1WpF?jYC`)an8C)EE4FgcS2dC=oigNN4Zq(1(?WRYAdmOax&lZ3|? z>}D`CdEv)<^I@CVx7pO{z}-r*B~tt+ixv<(QYZj#7ms9 zCY%$h0)YkVo1&MDv3@UkgehvXx(ujc36Z=8Y&RXhKRgDp4Z$5$Ot{l$mNsOm@m`?8 zo4!cx-jHy{A^tE>c%;F&nVQXW@u%;cU`}V|hov zu{uHz(|P-E%+4Am<>X&Ned@*VfEVgKu7YiS&~Xrgv19tuT4z{TTExc^-lUI(&u}6D zjG2DtJ~H`G|HbGAkJ+c+iZP7(kz&V1GLvpb(t3^UY8Hr4_96kCG?Gd!DBQp;_`Q^l z#L)ROUC+HN3fltOM8bs&af*Kje@FrtV@o>9!Js(0OGaS^vG(_5ev&MLMdYV~LgJPH z8P2K&c@_Uq?Xi?cB|moWyQg+J3m1G_$=bmW3N;v`FVwE z^W-~nY4I@f7wO|>ptx>Ad-30A>NtFpH?wqoZ3Od&^dBDR^4hO&S~rp1FW(Ld4TDx{ z4?W~8%gIxFNwlYHtS>F_3Yh9&_YrwuWgc62l0MC&(05!9Px2Std7>U?h_NjPoYL)B z$UbpxeWWKcO?h5P?6;q6fSXFxKfq)BQaqA8L=PVS?2}Xn>>k*Yj27a1ppkseFt*A= zK~ev(VY{nbb74n8L?DV+_S=n@C7#BZY-4uHdQt1rjLV8)my*_lqKTX!Hv8uFBwBji z5qAHtL;WZFC{dT07{Im6eh8Q})=eE=7%}v>IjTLB}1Vh$}dv;zKr~+w;U`7us)(8GbztlQwRrooG zk&1_dr9?u%6U4lr3M0AnLt#@C-?RNK!GTFRO-dYBUVbqia`D# z-&24EII)155u5!9+{*qf^IKXlx$~!Bx;bTi-k+afY<~{SnLgH9Szr3>$&C-%^q8~w zQ&;Haf~jSZ6aa;M0>~ujGpBtMw$I-dGd9T5^mE1OY%tRF+EDnUE%Ap^zDL|MK;d;okwo%_}AL; z#M*J@OF~XJh7l*D1zTQ_+0My?>s}VB1n);F$=6-h+UR$i<9Yc?Rnpg(wC~@cQ(d=g z>=Mzv1EPDWZ}@O!%RTP_W6bxiBXWbcZFaa00&a|Q>3oz|0sRu8Ko#0OuwN&1V7bPs z%{3=>Y#^G7VR1NAEnByVE`G5;!4?U{tveAk=t{0#dWOeECuqC`?{nnaPI6|xKJDSt`Jjlsf34pz2zlX`)}O8O4vB{&wcn`k*qUx4wEgJ}pY7EhRX_ zq@U9x^2qvDYJr;qL)g@w@1`#J(xlMf0NkcO4Dp!}q7hO$p6rf02i(XpO@W=!#A?Pn zV2x8|`{R1)ZLBL4WC(_72=kca|$&DF~laPx#! z*O963f|eyciDLdDZI1G_HQJU7krB!9v-NoHS<9n6&6v!emaHiesYgVRz?oo_m>c1O5eUQ9&V;2@P zb_P6p9#Qdz%17n0z2~r;kWhFB_?=7j{N8>{x|S)2;57Gcc`Dy9ZV0^md-4mq-OKvh zMQb3Toz6mke_T8L#+djnCg?tJmz&bqNo4;3J#+x;OTD(S}Bk$~I zscmjsmZF5cRIvt!%*Xre&yW!f`Ee@u^rSnhO(VcvfXNaD9isV9@b>SGbBdlGQHe#1 zh`$Y_e}#~ZI8Vk2x?!Vm12!q*O(d8WM~Qujl*;7HrV&1Pq6oCEgjR9+F(%CBG&7u} zD=cH)lRHHCi)xgRqO#u&#hPYV&)VQcY+ck6snw-nJ4tCno06r$p-bTxZ)r+RJ_d@~ zrPM_d=qC}~ANU&bf20Dn0c|yf7tdPs^S+9fKLzqHpC>1VS%PuwdOYCgosNCzC7QHU z&27vL8eDyCfRa*B%bvQrZD%bS+9%!Z)Z4gI|6@{f8&h4QZbCG!!d8u4DkUBW?bGI} zCxgqD+395Y-3QwSl)-Ar<<$gm1N+T`LDo26610Pf`yLTPPE`PqxI#Ek#$lhyqq}v8 zIygMo%&e7Xy{tb;N>zICsR99xt9yy+%fUPw*Ja-)-7~;s#mr)A6{QX?@tw#o}EH0HRcsvtgLm*qkobL|?8BBZ1|y zsz$QE*^{iaD8LOyaghEe4ELYHO1*lB1s5?pDF&HW2P{&xdWcYMSJywt3UG(c5GMCv z1J;{oZka!Jwk`0=ucs*FZwI;k8qaZRHRxC~hfi-2ju(d#zGlR?oUPh0+^`Eai}%{b zb}+a|-G*X~h$8S&WpHfbpqRA^e!yoNsf@S^D4mv8Ap$-%!<KC!c+xg(h$$1eE)q1bVPVw%dD%VKkhs3seZ z&n{2DnyQ3y$dKML14-zB2SFFdj?tWF=_mVcf2W|tC*w-6J3l>qR6#@*F;m=MePB=G zCPqjJ4FKN1hEvv|?8^<6Y7kJ)7Prkzcv-tqm#3I|_4;N($~jJIKk1+XG4+55U@z1LL!ZqNdPDOOd{A;p^yTu*aKFh zAT($R$&VoPql#Yz;!v%iI7dNML`OAscuo)-($G(+G^JXfuWJ|QK$#qOYD9g0FTI79 zJ->-H`$FFdZTfi^J~e@(dUpz>W;!q1+>&_gMP(c!Z86RD#LQ{1KJhyfjRG=O2>_+B zxig|64+o_}@4kb*a-O`6vjVc0ZvnqSj*1(=!P1} ziH?Ap8cifRTmP%w!S+g|!+?u-5~y7{=Bu$KTK}7+?V0lOhij#+w-ZH)a-N3T z4t!Zww+kEidQSd>+{=2}5Pljr+1h$0{dlB57hf6_lL4x+(APjP&-6D9A%~~z_*=dp zVky$CTNY~i)h8fPktnUf2k{jK#iW4q*k6gn)Z_K7;mSWb8)~0Jx&snijS!QL z>7iNo$*kBCOg6W{F@Gg;#JyM9&K#^VxBdm6tmm5Fc@eMxmL9wduL>lCP4l(U zsa#vbS&kD?A`lp$K$krv!BkZkZ~{PWzjV^w^t%93;R7Y13woE`Ey<73Yd2%J$qsr5 z_WB4{dI(o9T<9UhL&_D9>|p(@6o!559@Kpefm4#ljpScD5=k>fNd_UneS#@XVAQ_ls4pY@aCS%pKw3*4VZL|7`S2GrghvZjW);c1+Ul?mn+gxBpfBb> zyyx4&&N^W_JUwPZ!VzktjaCUg=4{tVfUHQaYzL;xc2+yN?>_)JA8WVRu?$mU`@C$7 z&pyUZ&th#@gvz(FvT)i=Cpp|j;mzmzc_8@)MFG5aOdC)f2f3Pxt9sql`H?mL2Nkf}MJbw9pM-_+us zhBSnolGn(XsmTWHoM--3!w#QGj%ewd&C7AHR8Cq@MGm0;C8UFNF!@jVIpKvBSsBV( zrSrx(k9bO}`1tzEw8ZO32~j6oG|3{-4X-niY{Mlckt|xQq?$}M%>k>E&pmKDkG}ex zLTH+r^ij>q9P^*0Vq-WTSUu2AtGZk>h`nZGx0m^b+L-B+B}=NovV|tK+XPHzi6(L= z+A8>VPzC^|r2D-u*tjhOF?$qE)`|#T=dO8Kp>rhfN=y2`6}S}8q#M6mrJyFKdjAqQ zuUcR;MW!KX)vpIyZ0PN68M9Fl7ZCevI`%E7kuup1mL>5W)lgJDcRX0W8X0UBA@&;k zdl+a`FlJaTOo|edZ6$bn-_jwmp7olgVu?^@-zR`MT7CL3pR<9eJQD@cBNIn+H~;)VQTW2#X63cZzFc%K9OQlPk^xv zbOZk%9m}g442o)$3aCyB`~*4NtOV5ftR^8gZKrDhOA8ngKf||zQ7DZy1Ch6{O!r39 zEHmw;N@Uyta@~E>Iy56V!Pdc~sYAM6&J>^{d#Bbx%Zu;P7)U5!+I$T7?mvjBEu?n` zgO>u)RnV{5RqbLLw!Nm}%jM#~{Kzz6z$X8K;KA&RF+EONt2;KN^G0JXkb6>eo7@NW zxzUebdgSMcHAWf1vyxwfErXXmZa?VQx<(&$1ZzW4YR2FcIXq$fTdQp?ay>=*9SeYi z>L=;I3qQ?uP>_pbRPCEYDRGdb)UeuP%b%Yf@+3f!m2_ni39lfArD5PBPN(2OHh;^=e^T!9Ob1CmSn<c9O_1%8xSj|&0g1| z);6jZQ%${5|GkY0m_|uKQN)`TpQvzJm1l)ANEk%X0pvrz5CEpk2IKV_f!9mf&W4ji z&f3wzqtH$VQqvXU)affmLk0#Vli=IPNF`{groZLSt$n@;blNsPB53o4irZ35%MyeU z77w$w#+_9vzT8L41_c12q*KXR^y7Z+&-e+E%U&0xo24UM8-f&}*o{#jD%T+<6wM8z)f~epHA27> zqm>g2$CuPzCC{4PEIoWeaO>hm9bp0lki!%S`(chYHIo*9fQ;VX0{mlu(kis-5Py;X zkys{#j?Fs-C#aY|kPj4s+QK;gO&o+c-Y_e9>GPzpu#^8}$6Gy_cPF_;8eF_@dmVAt zuG2=o^Du{g88>~t)um_rH2EXcK4C)Pp;p+XL!!_tLS>u%qgjpUIG7qX4Uww za-SwnX3jC~g@j(foy(@Za^Ge-6RrBdsKt^>>F>Ec1b6 z4G85Vb7ODpnz#{7tQkxOpUHN}H4OC#3}T2{yLi>cXev_5Mo`N`<~?8C)1Xbhpl6W=m+$41*L2LAEHrS`MC!C(Hx( zJN$x9r-<*EFi)P0MJs}489?o;cU;(xAvJ=pq5dMomD}j_34}lJs)z@U?Xe^);?6Rz zr#sspr$21DbW?2grO${!4!+V)PXB42@ZtCHs%@P4y>QKm*4eGdBYBsW!1q}WSK#V8 zdqnA+4)D3UbI>$=7MjV9Utl}Y;Aew6iV?<#4;P>-M`Z8d`CH>R0gw`7ZKjE1b!ubV z%jw-fO#Uf{BZ}B^;1J({C0bZD!8?0g8ofz1(W96>VVBz;!R~@$HH?P;Zp4<@&~yH! zgXI!)3L%4l!(HJ^^C=-eoxKeTLsRCt=~|Q!#N!Ejo*>SmU(pJ21Dm31>9CYi$I^c& zJM}c>GnFY4XT)4=2SBonZV4?a(B6%8<65EApoY!QRyHqjr15b{Z{YIypDNuiof#l$ zNf?OcDKiJpM$~$v9c3Z)26W2%F|93mquY3`U4!0FiVjUe;vB8nPB+cI;gJHaGyON1 zrNXu9KyHM0x{1ek_8V5YjCB8oRh&w+W1btF2Eyk}MF3rTx81jr-_}dXJ5^fV!SSU- zF`hQTvB#YqBzj5{n65>xE*q#I&8&N;n5l#(oI;Q92-PV*E6yZYsnXh!(jv) zdK!g1WgTnod3;+4gmye*Cq&z9_+FF*T{oBnkA`iJEMH@mPQZB8-n6E-G9v*AhREUyT!7>uTU@v~`=pbq&z!q%Fu)DyYR;`Fh zO<1*V#0u1c1LDw5+XQi>AfMWF%Y3a;Ykjtn1Ym@a3bIQVgh6nvs+Lg>kJmyGY7IhX zUxFSDk(bIYqF8*sc)BfL4C0I5<>$MaeY42=M+<3Sucg2;<}V>KIMd7ulBM68`b}jW zmoM|h@*txq#v%a-$E#-3NSIaLl`MVUJUgDH0k@pypI*BI-#*g+PWEwoKUA%pb6x?g za>mH{bFLv-p~T~3&I2Pq>k~B6onnBdeu2Y4AW?XaIx_aN33H_*?xe%-FZLN)kr~>t z{wh-X#_^I7RUWp=h{j3U0oF=i1c)hGz?n9r!@H8lWaBtWFfS!BNxY@U6+ht?MLc8f z3Uj~Q%Aa&R6Pa~c+sVclBMYF_&wfBi1H$@Uxr)AN7cDIpy1Zj-qSlc|akvHqmNf`@ z=vtulabL7X3t$1~IGjtfI@F|w1LNwAd;3N(+Sr0Ex6{eTpfQY*VN%EpV@ts6nTUsdhpu0pinLJ>VCD)g0*^4pl=0#XK>dude}LQtJhn#U zl~OG*iv(lS1y#@ecK^#EL|c!%q(?O*XJvggM^)iU4NxY7&{(d?S4t~k?B!M?d{J&& zkpD!8&;{Ls!;3?xgU!Z3TET!x?@xqx$37|&CPGwmiNvTwH3(?L0!-V-^+f34>z@PS zDUzfMhGM)(62HuIzKZ#<0VBkm_jBC$U_Jaip5Dn^+sVoK*Lxe4--PjD8J9Nuwt)kl zZK4BH_)_iCqOMx4xWzHAUB07{_uv;}*rf>8Mkr$ooT6@E0jNbiC&-TdR15~qmeL#P8q7eFD0F=3mg{$6v)?6Qo)--(naQC)uudHsXV_W0_A ze)!nJX7qx;Z|4eMLv3MW5W0l@LSdHF9dU=eUXy#P4}B{B+a*RSKi-npQ*Hjp&}A?R zXZEqHKGg*fD?cTJm&TDfH3E5USUN+pB%zOgGzv9RSW0!FMH`}}^)_|;+5-x}W8f67Wszem~} zE9$WUSe=g*Jd)kx0Ui%STY?%Nn*KOYdl<$^t;b;^5RKHBL;w4sH z2HEpCuA+C_vg~vhDy3(X0jPW%7&OFvUS7dTyFzQ1-bn%upN43y@EafleQ8zn7k<_e9d|SbNy1m(Vt-{!K z`T(Q=qs)JXtlYgUsd-DH%0)7^7}ntT+3@Q`{;Kz){$cs+CIgVBuNvTuR|q0U^M&Lp z+RX8k7oG&=GoR|m)Q^jyTDHijp(d9ar`y0NEORFRUO|E_34RWa;as#8X9dm5TDv&Z zSsv}7igjJWxNR28FC>$rBnN_nLrm5yC1ISD2k&KM&VXlkU?yl@@{hHVtwpB9#+u9sJ14dIdEC7}p zeTA;7aE7nHn3FrzWJfH~sS$^I+haGCy%(IpcHg(qXN;c}D%D9Fg+3@uYr)U5F7w!N zCpuC)ml^Dd#Z0S#uG-+yusLae5?HtgRq6=(l!iVj+4@OIp!u$&o(B6!&^O|{K_Od ziyl-AHpZOW(`=kd=`^e;uweZJby122m`NMrelj$5iA}ZCtA0{`8fJ)rAp%nPIlUn5pf*`8y_@ z^at4^`0QD~f;N#1*YWty6jBlPJN)E4(14cX&eBf%aNY;z?I6jg_fHsuN&&3Y)(>ro0^^Y`XN4J$Wlg8 zY3lUnfrW-+p{&uLeXFIcV*02mMAVDz8&h_slmB-)^`x#3Z%YSJivHIcvW9nv07uQrcRGqUNCOTmc>o_qwO26oH66fvjx0q8c}HBPNJW}Q0@L7 zm5P)tcgCWj1BD9j`uT0lPgE+#oF}G0_4e`4hmC^P&l&l}%Tp+vzNLVUq5SYUZp2gW zwtGxj=5X9p=FprKUhfxn+i1d4(ZUR8GU*PqyT&-l3K<0EzfGGDe#DPddPU}$c*c(& z$FqNH0O*1;ZKaE8IS3U91`+63#D`bXUly{B6qztfIMh=})G0%dCwf^#>^t||s0h{M znU<*XhlmGs*+FVnCEAEv)PouS-iu^={(*PNTnBEK0w1)e1a#u2-JdDz{ggN#C^!C#*uTbNv+tF8LS2OrI+ApaM_nM|4TepcpijVYs2x zWw^<{8$B{Er^X}4E;%qa-=3K(4R>1g%Xy&9HDK*h`3I1p@xtcFEcW* zoZ}>;5AJqj5Ft>Y_auQ)Pg&o%DPg-fYPCl_xXt$!?fx#HWL2%&ncKEy@Wt!l}P6*IE*{@!a zJ&~--zf4R)3~{VG%V0>hqN2U>&S{5IllJJ>D}hcjAp!#GsBwoc0Iw-uu31IV=1&mT zm}0QsuE-1A+sUoc%@ORM9!SnV-R%LD30*s@9R2@IE6DU=U+Bu$r4K;?j*EznDjz$T zBdF!01*C|%AItab(Wfy|J6J63K83b#v&4hvOM`_4Wa#QGlJuIr_weT?b=3Ayxc@@X z$hinvSrlrvB?=z-@WGJeX!-)d~&2EM9CeWvtg zSpnn_5wVWOPie*d#VJCzWmY`G3*Bzx7vV)u{IV|tr9i|BJ8AHaPk%&O^ZDoN*c95Q zu(0O5>o(>S2?A+pG0poF{i#I_!bOzs@NQ*Pyn^*uh&e*|dF(2orQQfdQ>rdVX4SU^vlUJi z%i7-i_S;_-o?5sQ0+ok7-$BQ+;9;3_zUxrCtnz4pJ*Y=enRsuZGGPx39^c{eITL{)k{^C4^dl(|2Iks+$O&zMZJJ;Ow~jL)l~cEOY{n&of!o~v;Lg<^e|1Js+m#yuF(vIxYibsSKgI-&EZ9} ze=}TD0D&hrUnKBPqNO(Ne8Wp6v#NP~tYG;%JB`}t7&c~0=9s|<1*i|%ZrFwuV%|oP zFZX>}sQQBp(a43=Co&{Jth1s+o(a5p9~5QZt2HF8MId*U47l4)F4gyAPZ=?|E49$25e8M-^OMx-eu%Vf+k4NC1n{ z@O#j8r;pSY2Ls5P$0j7ZNk#H#nVLMKG7HO1%j+~|WWljr@icDg+9RF9M1pH&ON-+(h z66&@x`Nf}6Y$CJ|RHVGd`^rp&)!aebR-7Rn2ghSrqPQ7P8Xu_yoqn=_?Lz7}KnN#3 zNQk%evHD-klefK3On@!qf^RqNV>N$PkPeh`DO@j;053CWzgF%H0y8el>U;wP4IyI) z`h`21iv-SAI{+|_((51O>nhl?qvrO>wFW5x*Ng_tac$GQxgE>Hi2l8G+lp5%aUSg= zbI#bNK{)?->=8^OaP+RJ+!`NL1&xATNoaX)kB*z@sM~#H53PY8jA0^BgQCq)HN`_?8@6=GCQBuyAk-3VtgYjn z9FZp9i-e-M8FV=WDl^$10shG4GTg=_!-HPtuh?JQ)>-Zoqtnghov3sG?+Ng zYISEW4+;_Rf4@Bn$%va%dGSn+eabqM@b&nom#a*;_@xK=e;v%xP!(-5nH>EEvg;Ul zX?0sGTiY;fM${uK?uDCKjFzO4Jg17GI~}z7VhZI9eZ&eOaQddN^Iyy3siR|-FH&(C zQN(PxeCFfdb7HbeTMkQQgCRHUyUYEnKb{@fSfm@(5~CPKQFfE=j@1Y1`CN4!KcOh` zIw)?r?{AV-D$z}ENOJX9NpGQeX~kfx@dFSlxYEPzMjm!- zPgvm7>4gIf!zYk8zwVm1C&WQ%2+yBNtnivZX&hs73Phw=ve0TnxQPYPvx0(H4B;*E0ApJ#!|tlc@TgkNibC_jB!6*WTx50VTf zd<)3?O2d@gy>u%Vd9%VSX4FGD?WiUX%aZ)cmv*+@Qq+PPOo)G`1tQZ8(15A^xxM`J>PmmxfjPZHYqkx9p z(AkNHr<+wxsE`xTu+~z)SkJ2rKi4^RNqT< zd%9Xvf~kR3GozqRusUN4#rq!tF+b!#<7h-waBWe+T<59QkDYkax4l)`tG~(4s2VFq z(@F><0N%s+SGwUTz%$OVgzO_l5g?B@zp_(c`| zOD^!Nm5DMyy4otLEAp0Wr0Z6B!*64}J<`56I%s*@nJ486>F1lbc3*yoZX<4MNzQRd z`v4wA9gP)-gWE54f!Is_5ub<9NEpaSnQbwpm|hA2{~hFGL&Sm_l%139kEXST1v3M7 zotg>{!}|C4HXR4pmGjYRpt9r-cRp)AO|=Em9JC^!+``$nHj?~=Lf8mj5kH=lR0JL* zGZ7KBrB+OTQrF!AAyPqPoPiQeFh3*xu8AT|Y^-gx8T4ymaMUG4L(;$>w63Z`T~=?8 z1kp>H^P1$yxLCRfuw+}~qFc(g6hhw09Cp~DS~Dulv=7=lW{q{az)>1CKA67Vx@@eq zIxV>labSdbeIizCf4_vPJ1eK-U$`|vtkGWmnxFw(G)6A#^D*Rcw|VcN(28ez^vr}A zI$^AKlvu526m6(79gRoleZ3HO2ci--3W#3k*b7CRXz)n*Qw>e%qE0%SNLR6VCtxh{sUXzCDOI`hekN$M5JD8Qw!ki$RWgFJv9FmH zj&DpXs+if?HC0U>72=TTbLeA7)?&r>wS&K4wyG0>IxnY)&GC$j!TM>gg;4g1A-a;L z9M$&75R$a2i$&5Bl17%eW)}}x7R}le`JXv~@p&4-KcY0qfg%CY%WB{_gz&P~YCAjM zM4fx?mAFyv%)dTIz;olpvJvk5r`?g5;f3#iXYNZ@6iS!acf*4vFK$-?4Vxa)pos>S z@x>Zrlz+97<&VVIdh5$4=)WNq3nRuqZ3_I3#R7vOm}|KewJpey=Y>Uy{z@#2|K>m;dP+0wGA>5YBmOw`7p5PM26&xoR65y&;6CC z(@;}-bTs*>m1v~WEjT=+m;mE`VzEfS&UyQtK+SCXmgHee*gJIrVPTU^t`TnKJ_`wu z_~`xTXPWZA590JENuVJUW*u;m5tvE!VN^6p9>$XGsq463PckxGy(Wl!r6lm|qlyts1a`+;s^{ z{0?S})&&*=k}f!@J%NUnwYsnF`O5u%d%epfpCP)pxm7^1pPGu;Ke+Zxi#DM!%k${w+e4}lmI;VPyU4Clm0#fxO#m;B`(89au7a2XcY_9J z7Obw)66fK9^aqHskH-cR>(Z=9MsKdUU&bcw=NF8~{6~%8&~rD+nM75BrP>&zJ1*=M z0`62d{&b@YtF1}$We)_XX`>B>{8GVe){>b}(`H-d8J$V_Y{|OgQ`Z_yfm|+}My7Vm zT4bF2d=DfBosvu_ZTBV|s^*Vn)467-gaBMBrp@HBwSla0XcX;a()2gT(Ph2SRGm}i zyDs=jH+UR3e%YyccGXHypFv6Ie3a=iltO72s>gLX2okIEAry9{!vDF{%V!bRu#El} zHp&VTu{@s5q{Zkvp$PUnxje+*ZrrFLm_+lpn|FpsB_sQVG7IHGK(NONZ0-ybxWZj7 zuz`e`^EqGV&$OI>8K*h##FWRbMa&qp&%Bd_Kgs}RyZ=>0C+KND>(00~=d0)SU_HMi zj*<^pW(#h{GJ=4NMzwcf*$8H<=xLGwUk#o<4NEuJpdOm;gyUL>*~-Y51q5syxRFhp zX&Xe4E_DnY( z!|u4PJ=1t#nPhQYz?_sj-hGAyESAP^-9)^mwV4kWhES5OfnChs&!W{>I0^J2V(hbu zQFaF1b*l0mQc=ZphMkMQey)QqfG9=hd296I(O4~2E#zq&8vAvJk-Cez=Tno+!JiRm zDY`-6EzT7)YXakIuab0TD&UE8>^zQDdpFpXC#wYBOx_xkQNx*ciRGzy`gi=D}jar|+2;H_kghi7VZe9Icy&i*e#~t)1k&U~O3e zZep&P_TLGP2Px!19zIV7<|PRgB3NmI{=Us3MmL`+m!KV(317?(pD^PQnVTg8@@a5j zMouJsw&*^>SM(U9uRTq_9-@Trw2P+G>dIxP|LW``u%fpF%8FK#0x=WlhoRnNrnykW zF1=!_htzYME%VxAxZRc+laR<0BikuCO_>i9@`Il1>O>oj+hQZF2aJuNq7vvAMfW2) zST6qsmiB&&R7_V!HPC!{#NZ>2EVUD)%~s@Cz5(@B>vjFN3UsMaq81X`rk^&){_h%L z{8we*C}0}(AdGU%81f|1Zz{XpW-5F6aoidvB|x?lyOL6OoSK(sjQW*G;3V-X#+;Yb zUc`&&J!47#{g1IZDvE^C=#kG{wP&@r1B~*JkaYD*32j+x6|Iu`i4nn1T;J?=g{hy? zE3L%7Yqt|>Z-)rn$a(IUGdZ*mc1M0fW#|{ciZWiPVMToT4$J0td)037EBxlikdghe z@L4o;E`rk0gZ~`=xSipCv%{}Ou~MQC0`Sx8aIU|lB9|1+%hDe9m=(>!o0>8tMeeN; zR1zd(7~B;wWiPN*BB+0B@)pd9LaNy&*U_i0956YT8+%1VYCkW#$0W9Al?L4d_2xiS zLA_VFvng3%Y)|z<9FMjJaT$=4p=XIh1B|g0YMlu(2VYuL|EEaAdBqjLzHWr8tZ!@r zSyURL>*M?Ky9JPH`U@eQ?ISbzjP&lS8ITe<5Jk|el;T%7X`D~IDAIm#5tJXrh@bxR z@ITLd7GUArefx~y)R%**QOxxnke)XdI6O@_1N884-yFpGwkQXSB@<`WWdYU zM1YjGV%e7M+}u7zIg^Ky!DRt|S_O-9IYAupoz7_#>}gNB%EP*T##DAKiaiLv1oh9O zm+P8?QBm77VMWg}#{TXa*9mzZC>@MKjF=^L4k#OT!4&q_EX`MeF!bxmy5xfGP=WfF zJ@{hoG!~1KZn_>Xjd5u^ZQYbxYCcQE?^rVM^YhYyaw}D?kPCV}Oq;PJW8l$We7tH! zVoK6Dyh-|yZSThk3$a-u4eIdW03M-0|UI%f`S zD3blIs$2X>24f~a1uYJ_dIqnr%G|8&U3$~ucxUuddAXCa zQI&cEF5T-P2VwK-YS3}SqzpU1FYE5~aG~<1D7zo`6P8qDwB9^-^v}+i}n6Zql)8?FWHAuK+On9Hh-Q zfhdV`jjk5|c@K>snU4rZWPzn|)IxEu3xfVn=KH^q@9#Gzn-ncT5H**1%CD|Wj+WZ_ z(hx6K$NPP!#;95Eb5kE;xASO`wOW-IJ1IeFB?>Azj$9Ef*TSOms~4#>-z#qx*m6o~ zYFw&!qq?$sIBGGCrkWEg5=jg}?(0$-Q=Qu5?Fv7a5IQ|H+eBS8$hr zM!?c-r>m`eSi8r?79((@)Y0%q3yl=o2;r)_Vh*|nUi^08MQ7)ni&!pz{kYY#D?($g z&(K5Vn{^Ewc$DC=%c^a{WN0GLuhN)X6 z`U@}}TKWZ7qC7Y9zS}x*=(kq#+ys_GRz~RAvqgmbLEYDSK`p{4CV($3?q@ zWWmu4z!W2@vi7NIPY|OSq~ew zlSBec9r=4*mg^~SkL>o$mG#!)A-J^_vy(W~%|czNYG6xj{uzJmbx*4<)^aJ0DiS&J zMKc6`oRg#F9=V!@RrjrK#$DyCS`TY{+^d5k7V;6l^gI@GDKn*cvC3p?gV+WMh&9bp zdeio1&nXz8hhRx;GSh&1Q0L9U273l`J`95$=L#OH2k5RH`vg{(!^cWk2b!c&bGuvp zPuZJe@3|4gBy_3hXhS@7CFSUe$n6gcRKvly{dUnLchi>KZR_BLV6k3ooOa9QP77Q) z0vy9;!B4Ehs^~F=IshwueO5Xw~q#dAypHP<9)25f$kr1t!l{S2-XLTqH1uNGkh zYfgC7?7Cem16w^jQN)gyc2CAHhy4RdbqBuk>D^lXIZd+Ih;G|9hgckG_ohci@2>TF zpRo1X)O7c`|9~{Bnb35I@5b8nlWqxS|9`>?k~`uQWUQtL!}4(kA*m(=oxFNT0ux|u zir$#TwMkpcEr1Hg?jlXb%or4qG2G7+68-gG^UFPme*dVtJ|N?}Rxh#12_vt|EkEK9 z6i!pbkb)VigKNlU`p$FmC6G3rr(lA$b;OXAm_a2HG35YU_sIXpi#v-y1`;=& z;Q+-UpZxCZ+%4Wi*q>#rxkjp5{HUH0LyCp^2pPVt=K1;&N#L4kku|4NxjAOq{}vuO zjw~eAda2>bwZmYu2>NLDI42pisez&kTT`4L(&n53Yh#*Idn`b8!rmbSWyt;r!?fs^GH*E|e4^3>7K5QP?1Pz3u(9b_1QScev} zD9hvs_$jqyw3aVOxGNh&<#c-Kp{95@TzQPT7^7_`T1PRYCY9K|jgZsjuZ@sF&1k-l zm*@)NBOpA+!vu2nUgnN_SGz?^5tN2`dl8d__SYTbCC#}-N9YaV*$@@3gwgQm4W(yS zo0zs4?*^9h2(zqNDCYwTyE`1Z)Nlb!Oxc{h?}h3DDBI4S`I&aiaq-pq{DIQSS?GQI zK8v>})tKrU>Cto8)BuOI{sX(L>_fXOr27E)$~Kc-Umzu2Hj5<9?RK|dv;=JK$R*jN zI}z243`V6W(<}yGJ^4pEOLXdSt)xQoF%`u^knNk)2H=>1$Lb4RY5IwT)^eeJ&BDjY zT?O^qi`dPy>g_$e1H^u;veT%W5tUmseE5Tq;8uwByCqeUAlS!nTBA4~X_ z-~Fnhra+A8l!ua#g*G8%v)`8o!|3t&5z+%gU~YH9ZrVR{PriQd6VG1*KQ=IEltGir zY|*#kMt%26a-x$*nc3hLeHu#YA-+Rp&w;N@`!h%Qkj@*lE=idAa@Q>VDvanZCcD+a zRL{K>SRk-S05mu9{a;Fl$w_j`2;|y0aLs~DnrRyN$RExip?bBb zrF8x{21fJZ_O7!sQdz=K@cV7zcSk^3;_h4!^DV;$vrCGM#gAs!!x1aqJJUQi1x*ev z%zEw_-n;W|_V^*S$HfjQ_tcIE;DFcb9T&c@CL{~^Aw2!t)^ZUcs6jJ@Bp{oGR&nkd zv;Hk!f)Cv)kLuw_%o#WBS&KTLw+ZYH4x>hO4Pl*iyNvn$SeTxg#d}5fLi*5+g;uRU z=OKCZv`_SB91>&=Z!qF$!AiA8UlzN=05830MObwIc zYuurLnS7g=^i%WJbg;e_|U&~d?`>1 z{Kvy9KfAB|=PO_Uxa$n`SJ0ij8nGhy>za3?pe6TaaCktsFnOhv2?LwY=H>d#Yhbv_ zl1RRGK?C{AwWvVAjrLU~tw4aN{P@%SJ#S;hhs?5{+N%1uT;?J7KjlZss{(Ar-(|7T9T+I9_`7_-4*Rm^)8)@bK49!XgHz33Z|}gMK++V-7`>FPXj5 zvn2d%uaKQrTB+tUk%IPoMp=TGCT=?&50NOKO`g z-xI`!%K@Zc@~i@tpi=P#ldh+bDvlV74A5^d9AM`aoFm=2H?9goBOwj4QkC_570@6G zmeHczFcL0R$pY+84upUqQ`FEE|J6VPRQcFp2EK|RDJ;a?cS^@lv)=Yu3 zCX8t^C|>j*L}H z*WQ%W<*~BJJHC#Qph7OcY{uV<*xj&RXiKIR+W#-TZ;HiWh{S{qEHT_kb2w!AcE8IB zw@+H~Z;ufd(CGq09ES8_hT`cY*2WP;0}vi^zO}^vIQ%XXCde&-gXzUOc10+McG89c zCD`kG(`}7?Nxh^3)^7bX&H?>6#V?L`kW^U4 zNz3J@fiRtNj)_y5;V&I(_HEmU%HiXe)ILPF$#wmtEWM52shFmxb$wEL?%bJ3sLgh| z1h4anq5QqUTt>$#s;JUQUyMJxnfrrzjBuXQO%#WV@|-B0@81VmQ!`xd`iXhI65#>w zi>h8GNDjfa%g6GZqUQ|9j&C0+l-ayV4DeOC^_}*kKz0%f#y~B{Ps-jckUc5`z zEgN+-HvgmbXZRp#`#!pGDa1n_@Y;EzXwoe?V%0pk#4e`W_$?$7oT2n>B6)6H@9e8) zdY{=_(y1W~Y=-5WQ~Auwp;J1%tRap?LU)G>Mp%M^d$)h`%0~Vi$WL)}_0HG4Nuick z+#-xTEBy#dM_IIKi(5Xz?#NQ$iTUT91vlatVK|6aL4uB_fL}tSkEHbgh`MnfX8&fg z_KXS!5IruR9rwR^S!VM83;*p9f0B?p@a`Tp&h%gq>H41{t z7TTf%A5c$3l$0N}KLSHkf|E((uGj`yOdC8N8IG`_#xz$|79CzT6r$65zVi%MdI)>v z)zMpjMc=*wPlyJe&YCa^RI!_K^>ih$m?}aes(Wo7hP8D`fUy#9LB=#V>$W}O5+8*6DGt@sjWwRY_?KlR^4YX@^xQp< zjsF!)-2LhydndxXE~=WDNa3mTq(g@MjJ_6iZg#Fc4)`cZWytm&Lca_tABaB68l8{{ z$VlE0;b!c;L=T@hlO0ulsq&>8&+d8bv6%7d>}Ddf>dH>Z6gj@Lgjw;gboLaIf!8&9 zV|=rvNdB zC3DLF6jeVXl+$+#duJ{P^VVofYKa8-xKt;pY6BT*eg}&n6Gx%)JuuqC+e-Y_fmlnK zL>D^tL+2+XP*(8%YI+&~{x6uVvo5m)`gbqOErl!Z5f8n9$z$~6ISLU$smf=2AzIkK zEd5iVis_uBm&H}5o|cwvG1=2B8ws+eP)G2iiSnp3094*co>b+?w)b{O$DiJI`x9a} z9pE7-b~m{Tz3ZcncWTyzhboDobPt_Vu$(}pj*Vi zWM^jfNW+yjFvRh=7^7KMEy7&unMsgxvbuB5 z&Ia3|B4|Eb@~!6NpWFv_!rIR@k-%is`^_TnP-^T|%Umo9PDGU>Gi-`yOxd;6Ijz8b zn!ThC>(oaWtl-F{`OwV!4Ufa(l(`LSB+*c*w5&DE%psFfqd7!g7P9#%RVucarGT^B z%x}zbzfv-&_^Vd68ae3|>O8(QnHJVn|4R(?u5~zi$N$fa(drwSOub=u~5H| ze|mTN&|>HE+@aaks6o8e9WGoBCn|WxZ&I}vL}fN$4i&J+$A6Y;ONT1=*YOmg`!}Y; z;b;a3B+4ahVk{emA0wXCo&d9%f&smU$Xjq<;TP>PSi54lAo_cf3z=o{-i$-=y9J*- zqI?W?^7PrwabDZiK%lMeD#XA4O8ed^c2|%U3Wf2A1rBCc(x#A^F@^idt`LM+ML$t+ zLx<3D(U;f{u=dXXRNOtG>4UPZG3&eM4Cg}KA%%KpnULFF?nRbGWnI+#3{Tj^%V6aT zPkd$$V~exvsA^3$Tk(MXW60urlN8mZDAo$?59>ZaGgkp*um4F;EO{6S+lyjZtM7gN zt3V(}3!%q-@b`3LG6>`MjJkvL>sUvBU-*>tZEkS;Zb@#aH#FH{XDqmT#P-rnV|hazojD`Zo){%ndM;yV01s6HMXD-v97rQVIp!HdiAl7 zA7oWNPAq71`q9>Gb5R29+zw~eEdX}Fe`={!Wj&~gcW=SXJg8r`0>1wHH@M)jJ#vSw zOp3XC2A6y>mG_q{X_n8F!az1+ww& z?hz)^55+#QW#=*S*ncxgx{dZ!J5^`O3|~s<&EOa9VRQzYt`|6~hJL^}5RYyr7HBYz zl4BElN!*+UMn((G1kEQZnK4K%OM)-n;1f4p4d1kib;kZcF(mJk*EPvawJ-3o^@UAA z>b()oD%#2jl{~8!4pdw5QCm-`J6Y#a_C>s+o-K{{n@f59|IZ|%7}<3J|LTif6EJz$ zxp4{(Fuxh=ySQ ztK!5ss0)U#qr$5kT)Qq(ZKbDMFj!4M5st*$KvDLrpfFtk3$iT5r1)N171%vj-kncT z6TAl0klPxSAhT?$Y~N&E@A<mW=Zh> z9S3b7Cr<%+eu1&;gd8cqWcMriI!f*&VC&TyyDPo4aZED6AOWvWFbf;T^t_MOi#^P9 z*QTd9lJLJ=<=MSD3ny`OR4POMgqhxagXb)yXX9&a7-^Bo%5M9ojDK)1dzE(jCFR0G z7MMO*%KFEBSIqL|_9>bHrH2iLffF()6F2Pvm6U&cuet1I?SN!k1F!3lxahv!=KEIT zTh#0Mna{GZDck@kw!2hbJ^U>GnX{ZEGMVl)3)o>wHYh0gsymnqq)kFSGgBwq@C;rmVoX z_|`M())4!=(}_RM>-5}_R_87F2uI&K_LbPL@jF60i!(yRy*dEw@=;#4;1*kOqg zUbqMBh_(BLS!fKE7_g-8=7T?BpXe1%dw3ToyTQpyw5x@Inlv9gP0rhb;92!#cNuvZ zE$ZFIyS0$SrnN?YG&bvFE6X%9!G-jo14$4T|&R~Vt*i4*tP7)Wb?o0AMo8Zg1tRs)r-a1j{yQ*)IJ#F-p zfgDTx+dE_mv167~#-C=plh07u^YE3Tcp}>GlG*tzHra*!oI+#a%;>|(_~AfX7Y1k3 zRR(d`c^YUiBIP^o2$poX^1_!ep&?~ovT9AhMgA-t3$m^V>zvIA3O+_~R zZj{CG&t?6vWTVri@|Pn(qZ7Zf-FTD3@rGwzyiDQgb@F(e zWZfmanm75el;c2;=ww~c)4?#yKDbu?XmlKt4F?=JUn&ER{!>b6)9ygdJQmo!TX;Qk z6(wV;&m;NA)Qt(oTjW9+Qa2kXNX|OELBFJxK)`?u?ya23?%O$|i!cKN_DRw&FT=qw zwr{PzsZOlnCAh5WyEqK6j^6^D!s_4TFRmdf7B||{6Q*-Ul_9>E|BzoO5h2`v8yVu^ zJF2#PZK2Qf_s{Hd;h)Amsv^HuaLLQk4SB|qa^KGBrl|COM#^j6`GdLqW5@+Q41BNW zV*uz`cmOc_dYL9kdbk`adUXL-Z~H0G0(i7+~rd~GF3D0$bGo^XRkMFs@)5f zGDbD#uc+|79B|xymZ7(x1f6V(->S?9QAs!we}gQg@9Gw3%!c$ICH)t$X(*E1pU^_4@fiqCJoJX zT0o#`+r%teRd;lY?jI!kWgbndY8x&hRRvE^%kPq-M6p+Mbo#nc_i;8dAR3l3vC-ep zrlD0ETeWE-=(m3flqfK*u?lEsCUPe`*?hQljnq4S0PqQ1H&ck$$$k@31|k?|Lis(4 zpsfVdP)A5=VkQ~Fm~!s7=W3dOhki`ngBjU}a@i-CS|E+07nAaBWbH5>vr~069hxw1 zJuJg--a78hsQX44h)-yjViDp>#+U7y z6Yi3BATQNR43KV4#*y_#0QysAWm(Di!Fea_+)cxW5-e=m*2gb1u;h1c$}2O6>`fGOand><3U5}iD~G6^9M{>ei}px`XG!59 zTK>z*%WET%?D_+kYMa(WJP~*LkUQ8(dcy(TOVdG%_? zhcFTp2XOz_dg}QjV<0t1ZpNkBW(fdj`(GdCQO2izhI!sPwZzLZCIaKtnE7YjAoHOt z)#tK|>QTDki})&_^^9mJhcJcDUhEh zuX|umOq#jQ<1_X1IYfu2Wl6&EP;vxuYjhR36VNE~qj92Xq7~6*&9_j=@b2kAcTJ)g;zsA{#+AMkb151qZ>oHva00LuwLJ?U9qD(*$|eW%>_Se!5uRzSdjBd$iW7=7x?PsFERUL2#?7y-#oESA61G&% zpaqzzMPZ^L*)u00SuK}SMsQJsGoHX{y4KgFa=|hWsHNk)15N1Z!Q$-QhV^5(i|Vpn)n1E8=-~xihlxye6$>{#vD839vEC4+FK~sr_Q{y@&tQlgFW>G zYHy-`>5=UIFYN8dUsG~qmG5Y~N-P6GMyG{?wAh}8vXI}IOY#wp!6c;UJA2z{i;DCtRJzlCC8hcb14v6PoFXb#g;=V7Vh(iPu@$nsIq`yXeLRE&-f zXGA5i;ZnFz*lu5VK9?HC#_39^I(@n~1u79<0)^;jIj~3m;MUyq@%q}tc>i^+h0cXr zj}K^|PDz$M7oAms7hEVQZfJJ)t&8_V^9E=D@!Demqn|N0v=lk-l)t(DT(!P2eTo@e zZZr;enJy!G6`c3!8Q2bJML3_FaPr2X56W9O2y~8*AUlm?)W$)gW){h%#6?;)+jTN3 zcOFFW&Xw$HmR1$hv-5WDP5pCR^Nkr0mwgFWe<3%+U{Fl&_r#Nxz+h#DB6MdPg2Fag z>2hr4(SAg4kZOk1w z0;8Vh6sU$AHH>cK&sk`QLlRV;L^(vX?8GC#5QZbaZrXRiVHxLVuY6YjUv?{jLq2EX z<8kQ9s}7DRn-JBc5}{<0D(&xetqhqNVhG)jgy_pr66E!*13=!6te0u`Ps-;gg)@>d z8??*2ws)2}-QjEZ^**R<(;v=3$(D~%=K-|;QcmPs{b^pyS*uaAGe-~)0}P%_hscBh zba`DLK{X|m{5iSIW(w)b>Ivgt!(@U~a%+ zYoBojs%rL^fV)1tcQ!YAv{tF%YL5&(*K*t36g>aQIjFzkU*eZEj&GpYc?w@M{i7QPuaJk8>F zcJY4JKgq%?KgR}`{rcpZe0Ic<4hG|A9IN~|XVt*ocU;MpVY#}mcL>oPi?-lyHe`0} z@QcvA7woUGp~uw5B91U$Zys~0A|Yv1H*nfoOWg0{caWQte|m5~JY>D? zYdl>`gGxB6`d#&E9Ms*lD5j^#_PT)j(8>fantPaG3xXTNb$Eh%~vt z2Lv+!np90ZYq{rt{^SZh{=K@8%lg8V+Az~K%aVKf37$2fwMF-!7QXaLu>I|K=sn35 z&LD*cfv1yb?gtNWD)OsHm1xe3V8lv z&fe|x=!eGSuaZ8`6K%}TZY9R!en!2&8=XR2{mwpDMX9HYoIs} zhQl=T?owFwJ1kd_2r`apEm3jEQvN#6ai^*q12R8Baa`I+Py;COQzqQ0Y8&sww_4it znx+K3d0MDRg!QnGB$!pDFIfwRQV1uuI3$*g>>IpKF+9i%+c&G|7Td7NLz`2zhY3T) zujWZjit*DpA@uXfd`YUyRAvJz8_BA1px)o)p0J}eD2eM#h@OYYjFRQ=0IX3Y2io(LDOZFP@*le&)4yU(|Z(M7-hGRC}2tB+6N_<~_N2T5a(+rtdqsz!yu(dp&|e@O7An%r<^6A+Tarp7{eJCc6? z1UjadSgiuDd?LG0rOX!7(I=4D(4355$N}SEUJ~28v|YKD)bWH)g3kTmBj~V{5`^)D zIiCe3o-kqgD!1!-MZqM5JmwaCFQFk>;7at8xb?(!6{$4`1uu7b_{N_P4Y;JjNjlST z#bL4{+GJ1s#Z%8;pK8Zgb$c&s5fsvNK+z352n1KDeqxlg=@6XO5&IqB&v!Y)u_oGV zb=g*@_LlO2LNA%^PKVu8(qdmBX2MUg4UI>I2m79q`RbZq?$qwURTr``A#Y}^d2a3L zw}3z~+dXkTT^V7q#3=&)08z@3^;3@c4ID5B_^uPPLnhLQ&|>ABwDx7!`?sTfMbvyJ}W~7EFHK3Q?N>n96Wd%lF;42*x>e7Y2N*icLu!&oE z+Z}h&;kD`at>UqoW_sITOQp60aV-%8h0y!VGJ;LC5#(84V?$g+>e@FI4d^ZJezLOD z$EQa9TlGxMMs^#WU0qCW{*Wand?%c8vdX~^Re=D_()bM_3gaP_8te1C7^tTFAG=CCx z>gjNtRSe~0ccwZuTb{n{6bA@z=Qr5n^$p~>5uCU`Hrs{CT%)_8i#t4oT!;TYK8Sgp z>`;9Q6)Aj$RZ!vw`<}mvVJ-ImG4&QefdfzWFz)USi@Q54EDnpiySuvtcbCQ8VR2`1 zhsE99-EEPNyWjoqyGl>qBvnbJDl?Tyzt`ROH4K23@{(tEIZ%%-uV&G(hJkck>@t_r#ujZGfLAE(bjJo=J4Saon z6vJL7RQskZAy}M#tB}r$?(6$)xDANWMs$b}>>#rnrr1Fe_Q>`MmOA{RK{ZcD zn`o4YFbgFP=Z236Z;1bYFbOY+!o!J*8shrtC3GGrtCgq{jV(rA)j|sneaveRUPjeI z7O2?ES|-K*cju$9O0d@)$kK)I9JXC)GCetJN;d>0{YqrI8%_E@P;l1=CK~%Lk{sV5 z9<8_f@hvLQ!2}RNr&D#ZYI|hEIpL4h{T+w;nat{Jt&hl< zz73bY4nm4##E%M%$Y<1HAC4!72W{&E3MJVAXrGOpK1< zx3sDa*Op(tlwjhNB%!gepO|mAEukb+-a+2NbaaD5H7`Y(XjCRSJ9`nrmHBlhg4-CH zz2QUnv*qBy)th>4cf+o#lW#(4?L2BcwzTdK4JPZm!jOD%)pJYO73BtcQ};3h-P!<_ zd+@PE34p69lQbpwTZ0EYDx9sB#6B%pGdxNjgZLgsI*}e`oJA#Sjy^n1tlZcE)wD?C zrSMK1k5Jz5gfB8$2%Rq1Ey*m!Ez5Qi9QAh@Ej1Db_ipao}+@$LT?3cHss&d;Oy;XH^b}_2c z=YkQHlcy)@)nxzsPAljB`HXwkfu9d!u>U(t;bLpCi_UK^Aio|^DmWQMq!y-%26oj! zZ}(vB@7#&U(TL&o9{Gxq8*Kdmxo?r2g8l{|i3;B(7Z0g&PJHARyTK_qR=by*y3em3 zxh2x%i+{aLy7LJnNth4Z4%Pn^3`|I%UZMN+CvrA}VKEOy$^B}4W-yMDU$y8EzJ0~) zW|VL<_sVCUaGQ`vcqXDx;#Z_o{Tonymf2DSRq}IB^z3{abKS*P-{Aw)cM>Zd#GY`~ zkTi?xO^?zwrA&-gVYy-n%!;;C^nuUPTwJnPT(TV8Kf1nE8e>yYGnLmy>`B->R5xkP zXmRGe5mS|)DQ7)g)qU>OeH7|Dr}qMa#yrr9QN~_vD6gKAMGe@NIiW9-0Yd1>$MyXF zMSf<5cz3_PnJ5!Rk<-j_ot>s|- zUHw?$m*`8Jg)$6vh(H|28OLzkF!;t3$MD=Bm<9IirD5lEi1{m8+czpPVGl|cS^osR z#Ev3#7rUJn$fHqs8~ql_5{5IxhALA3;pV{;imsZz%a24C&GVc2u(mI)A5Pxy);#Md zFNh`L$oD#|FdAUs#TioE$HkQLx~*$x;G$q5@4_LBHgBgJCP2V(W;WnQhax{?dh%7S zWOvD2L+ej{#*Mwxi{-gGNCRIoLek-TNyuf%3d$TLpMO}n^2NoMIG`WfWBHRXf9Wux zEK5^SufDQtk`!4nKwI%f1X_A;*i~=}QNV_&iZO_Pk_||7O*4$W4w+ffpXp7#o`SlD zU)Sr>Vsr5qn3}IVh|G>zw`rar^e&0q+mD+qs~*pm7?oD&43E`SRbymhqEs-emKZ{% z2+i(97bflHlIN7m^+FcGN~6w|ohD~~MCMIw%qSCP z?@rk^HOsF3bakHL+?Z_zb91WlJ##xvwd<-U`0pFG2wl8$m?=!jeMH{<=>^{NBFWbbmza7=3ElTWB&TgZ~nRr>SB!M(|Nx(Ik?Kl z9pUtCKtozQv2xK=`V79ztf4@3fQ@B6t>3{Ish{GimBxGaWe0x4hT;r5rTYh_!?!%R zwG!n~_-6NiL~v`(y}?uP9k5n?*A}cCBEShyEMTOvb~=MGp;#jxI!XBRR$%}ZUEmjG zIK{8N!ej;4NnMMO@9ra2YW3PIKy)`;YlB2)5vK_GW9>pQuXEc-|F8?A9+U zyMVYR+SJol@gOo^QNi`9_t>yRC(j_ZadLR*1J>xMPrs#twM(t^A){({1OV=&Zy7# zV?)dWD*`(oNbvYcY{rBJ8Mo$c|DpTfZof~)y!o?wvj@*=rA4o4+dN}aZIt+9j=$!k zv9@LHwb&6%Mc?`a%(Eei+w<86UUwbmb@8qLrDxdu_IO;}%CV-L#y;vL1+XStI87C+ z>1%vGV(;B~2<$&YBn~U=_+}JK_JOJU9YI(Tg0>DBLpXbdiea1#I_PzZfR!e;hnl6T&^!VX0 z1a4GvZiK zjS*HzgB7D6BDRNJXYuAfZh$d!bmBlD9L2R@run%y@lZzzF$5?K0FScLznRMUY=Kip zEq^8hB*Y;Pb;nI?ZSF_rg9rJjkBGE0Bd-mw=L)N?l^#WX|MX+ng)l#m(ax|nHJdV)Qf*79)}f9MX?12<*K%k zflEASo)hQYtFjx$&Pr85Q4!i zLl2?uBsNzmHs8$ASM6s?*M=HoVzW9zfutO^tT@UzdDwqkhJ{0M-vbBuHS`>6JGKox zZ$n#~kyz5L!}DFl(kg;$(tkc>$V)_HBbhNtW&!WB_6_7RMrX{hb2o0BrDEm|Go+k# zHGvCJK1wc5bi95wz>T}X!#y95vWt@z#x~)+fKc`2fO^OI@}IzBsUjVer#rjPMH#xIAJd% z(Lj2MdJv;OXD!uQwvho7rmFVt>COUPVi9vD(}>3MJKrC7~il> zV%{q>85oo`>Ss(zfVs*qCj^RCCc}**RT~b5*;+0AOOn z?J?7IKse_UX1TCvZ+!i&i>U{ilrTDFsURl;D$vn>z7N*i%X61nW$X&g`}HBO8CnhM zb&Y~|?}wQG+?3Hj4ZbUus6E?GZw0k%0yuag3mb^Uajw=D9`I;76`$6D6T83l5 zp@U1c^Y|BYze?tsSWC#{I!gJ$g!^OBrQBhNTnUWsB$W1LZ%?>AMk2Ox zJE&oThRj~nD%4vN)X~OvHpjfBUeY$2W3s| zlYV;SGzE=_AQ4J-q?0E)8G0m|AuIO`4Z5WRcJwal3l~;&e;IBN)*TSZ+gR;~GC!;= zJ7<{N!yHaOKyCkeG`OD%9Vu6a+b7Y7U>zsaO9bZGqlh!~WX&Uyf^eGko8i#kC%<3w zdBu{mwKy-E)AL#@TxU)qJwHtTpd0&AxzJiU-pJBjsq{|eshmAsT&mTey{i5Cj(1lu zA=&-s*M*aMP*?Eslq_F#%_Ql+bV})%KDIgKOnLk_V<7lEJ~`YKEX^@PsBi zQ}Ya@SG#RrU}4;jNq@#V+;~xZ4!*mV<3_#;?#D$(GMAbB0%&s?Nu2XxY(X+SY8v`_ z(uiT80T6dKS}IJ;HXAiSG-{<#}PG-)!{-VZigpXV$U%2jyI<7!ND; z>|T9g-p;^GO^MX^bZYKXk$--fqRPwM?pma!{=|8c$S^8`%0|AUEG+2i>RsYY$wPH} zEaOdob|nC_5P-OUL$j!6Su!v0&_R=WT6+bo?W}&DTCe@_wRI-wUFoXpZdpFgx3ZUI zz86tEy)CKt#g#+GyjW=GROa2rH)~D9Lb0qxJ0P?lURUvJQVd^AL4*V@GA& zgi0z54l1W4-+c;F_?t;GC&nzSVyR`@K);Tt^2Z{AXsO8I-hz5C*(-EJU${dkWD#O|OQ6Ek zrL1x=l7d8RprOJ1{_#1b=L)+VrZJ=U${i;k{0r(Jh)zM$|JhD8AFYL>#we}?Ff-k` z_X%ynLVHpjd1{s-Wn?ElpKx`1aUn)~aYc!;IyIJz?s#`nEm)cSQKqM#P1kH!W|Vdx zGd;<1A7*lSzqr;yAl}qo$Y4O%NppJnqs$1nkF}ANX7M?B(!kbUGTAt`nw{kaLfO+@GO!{hEd5vjY@$G|Pvh>rw0-=aWGJI=P@RtX$ z2j07Ed+$5r{92-4*+8xGb)1cfYsRGXbhZ<>+t|+Xi6^%k9?z~Q>69Swmfx+6C|x4O z63ZxpZtd>M5s?@#D=#cH3){W%H;TDIv*<0JaK-CaSf6yxHrqx<2C-z?pN;P$UZ5>! zoX1YrS0xYlekC&iN@(s0e;)6_ZbYdLzvFEv?H-92C>d0mjP`ml5=3@l+D&&jN2Fsj z!oUbba!Hdt%k{_r25L9p5E)Jt@M{{3;lGX^F;G7le!xq)!Cx&+{Zomm*E_kY!};m- zt>u)B!EVg0O5&};y4kd)rzg~^AYQ(HskmYRQT3#JR#}3>$E?NYKB$ojt@J0(;XQ|k ze`dYGZ7_tXBEH1shJjDjWfu zEfr4Tl@odLfk7bAxMJj2L#5)aG{VW_fG0?4lExF2EDa|`mDO%4iscddY1r4@NfnCW z*n{CiC(pui0-Q&~y_BkIZm}N@2o8m-_h27)S?Kg$^}6&`P4#0+_EBxanXGmDX)%0& zmA}J_J=GAtS+?L1%Ss?W{4bM2!(Z6gxM?bnp(`L`3A-O%_k2-D{&H4P97da!f%Y~6nH%dbq1B^ z0kE%=*+L|Fl*5y{$Ji1aev`~5W59M}ik=QM#O>XP3eD0jO*Aud&5!?R`WM_@$AD0D z@54Oz_U&MtSZVStpu@P5XqE}J!RsaEY~X)=K#`XXFpepKL@2F4BNkYc@;mFfy))%m zbB$l(mC{b)0Mv1Fdg8!>@InXRcQ(aIiaZ}C{rZ%*N`rful+p#vfVl%n6`Ei=Cl2U>Uxkp@EJaF5;Fa%V|vc|00A^ffi_sM}ves4R&LrUnf z9Wc%bu}dK2Jj;c>$qj|mEcH7l)*z96|42HY*&s~DG2XJ$koYmWb5Ro4rViN(9ZItV9mihKOW9_YJs-NA2%m>k zpC?sY_i1&qH;;@r#{dEYj>4WgV!?k;O6iX1Se67>I~LT%C#p*^KfBy74(RJQ=u=q} z$DT;uu2BgCWqbd+B>AQtDTycYt`tWXP4`9JJ29{9cAb9ET6atPn7!K%N=m0rMB!&U z{;(YaZCdgCVS5PDgbOM6{``(C$Y*WB5DU(7c;FD2`p2&iBo(mnjLiPQiOTpoH$~Y- zh4m)mvsxt&nkuPerr0C!*E|D)1up5~z*zH&xpJ6L<~38>)&j0TVb^_H>_MvWyVaQw ziKh!xdqCJ&4n5Hm$A@q+^$2&%PP8*V=Q(DqiJ>0*(K-J(M-;(m-gY&y{^mdDEwcng zRFHGLn11Y82o}J^S9R{P|I3H0KCv>6@D~@GoM$hP+?*|6sou}qgU>H#uYkf_r*S_z zNSqA`@B52kZe1pLs2R(sogd%Pc%GOe8n!2;_|PP~(2t60cMO$;P86hxl5K?~A`#3t zpQlxaGAD+O6g_1NvWAtFxYDQEAIku@e zQw4V1mds9cg(yxuZZpm>^o#gYv_`H2wb4+1I4Zn@vj2X!4 z4sx24EFiiNw6Ifl0mkf0Ms$`^@5qf&Op_U9{SLHzrG;N^N@tKR?a*FBpKG?ZQeIaJ zoo%*7u$s8T`eBj(1!bRN}&h`CWUnm_-oMiV__SdTh!q=kHRjY^7MIL1y5U zfdew(TRnn)9n(?#nYX0f2&~`ze)J03bTni0NL_m(1vyV-)u($fX%Y)c!|oQDDvM#O zg;4boeA_cvhz?R^LsFaI*5KenR+}Ku;2<-cjtgcliaty!@j!tVhnmG6`@u^Co{$1+ zbSk5-4K>@X4Q0mLX3mDX87<<$hO{%m9Sm^op=_S>KRt|tI)3T7-c#^i*kYI1a+U~# zM0t#fM)at`SBemd)S#5Q5lm_rz*n{yz}ZBs%-QM=qx&=1kgO-UfAj3s9wz;JlYt`8 z;30F|)`vwM;XxfSj|Ay|dVzlt$ld=paN8*uhraS^(>3*J*Ohxx^1bFm{qi5MM+^8I z(dsy1R?A)8v30qF97YER3BDqFuwLk73?)eRC)|O_BBkd*$wp$ca;*^Ufrs4)YbzOS z8>k=-P&!=q4w2TK1}#@08{rFaH=za>hIATCz9%YmG#6nU(c-{q^@3c@GeN3kDpjZE zv1=HNp=Q!~8Ar)(X{3lnj9N`#^#UvRSIFKU@3jZ^<9c1aMGLJPC8S8^i}{|(+nkw4 z)BGrS_AN&!?FE(c(t4LYS3Iz(z&$?eL2vB_l&%qbeRd&i0T|?R73p~T-L~m$Ds)ms zn^5zcGW^P`PC&X(7EQpY<@&qXABz^hf5lmkSx_9RHHC&78X+woNOE;9V?Zz|KQWkT z*wl+)F7*5nfkLkHkMEu$2fSesYz^!&^(VFIZQyH1%{f>t+83Y{% z!&b5~KRln6bP|j5%rmBCgz~e!g!vwR>?niXMXq|0@8kk#AFlg|T{d3jyMhZ9xeJHl zj5K?R^62mTMaGml@{7=}&cIrkd|hjKCStpA5T{ospfk^ha(n9-uv8&Ifs^K|D^D3G zZbMYLprEDwqA2D`jh9_-H%CWH*gn1!BJq~bK3sh-&*Ld+>2c?&x5RVgn(eH&w2ugy zJqm9tRLMUvov0?WW_Of8=Gmy}zhywVqz39QF=*UYC=2!)$+=FM2{?wXy~wcnXR(2g z@UZ#&l;Hl5%LGm1noV)NGXKggO>%?)>hvGDz5D78qmYy$g1#|Ex3NG-?lt11o6O9g z|MLNN`Zz{R`pB`HVAbMJnrZb|=fRHi-X!dveppaWkrs?{L~V6u1aqGZIOTz^$bHM3 z(ijhDaYl;)J`OT-2idoOiF)ok3g(Y;JS`+I=zrkZ)$t%Yh7mh{zGTuo<6d1k#eEN` z1$uvgt)H5{dZr_tZ`cS?G}c(RX>%?@Iao%&#FOF`S&TLDtRf!otVuluYuUnEHKb4V zyE#u*avpV9-QE4zSO;}=MhkkElerx-R4ejSiS7gkEWLVQI|pzI|C!2OvX?Ic+zhZg zc{kcR{AVOd8rSf{ZCoG!&F(8(kyH8F&5-FAtNN#W{Rh;!==ZjFOSGgx%b*8JxZ-qy zYpv5g3cfO@<aj0ExppNq}^eg8c&+{ z^_ci(U5(S}NutZ*#?m2VTEU;DrZnf(rvL}}%LI|F5+Soz`b;0Xwg{Tk7ptMmNhQB_ zBKOdS2uM%}?%60uIlhQcR5TKIBCz14a@-e;IEfM| zv5c&BKfYQuGfH^Et6RAH@*Zlz7Qy>DzWy<)%>A*cxD31HQV$54t=8wp~b7~ zPCQoys;7}jKg#C3qmjwHG-xj@f@4jGJafmKHD^>F8~g;Dvle=4_AX5fNBX{mJ$%_} zn!ivUNa+SsBKT^Mw*Iz}~bkVtj=$Fcn(2-aK z)LP>ZVxzBI9K0-#c`j%7fAHY0XBBv2sW{p}t25*ZstJ(%5Egv$XP|zk9cAk{{IKc; zEg$s!VFm1fltbczKh0iI>A;B3h%5hIL@q|^yqSwxXXnDSarX|?*FWZvX$G*N1oiWf zyJ?pE*Novi|1D-r&&_`pJ&pRRCo3}o8D@kfqG!gE z816}J#u8#wU|NlW6E7T2fGVp<@-qp7(x}s*IS463v#1E=g(Y2hPmL6D4{%g-%+Ok3 z%ZR-f%ZR1XxFcn)JrvttTEf(U*bR*OA+y=7Jau92gLW8{UF1{twiqn-^YZktHxv>Y zAB(_7BkL=6iaXpuh!T|YmK1}s+Xf5NPjFEzem_ICN&74S0W<5buPmdI-f^OqOk0tj zM$0*TAHyFH+f{Pxow3Zs*C*~8mznOQ`F!6jAP=rYO>s&z z-3cEGW-$Ey2s8{L`>&@tYG!ccCU+zhvYdAEge<{<=xDrY|1B2njQbud_*?JflOj;Ni%28m(CLU6_xQSKf zI}1#nfm1GLcJOEVG7&T7>c{5R6?NxXPn!m@=Ats&3XJRe`!l$|f9H;^B~G7e%8%DQ zn&e2E_kspNLL(${0nuPMm9Cd~{<12^%`i)oFetRJum(a5ln|m2&^{=Cll?tXC)!!Y zxui&Q@GIm|)(Y;HAO>W)zN7#AvRSj4A z^=sCsWD8WT^f?wao&TngQt|z>q|KCha>#V*^mueW@{{!R0VZeTol+SetRSujM;gs%04+?f*(iHJ;0 zGpOK97-%h)9Vl8WhY^;*lR}s!z7pXQZ<(tdiSi+jBj>s2%|aQvKB%P12yZ5D^dsYC zFQ9#fOuG832{eb4qC85|M3}3ssY%H!ShY+x>5EDs&zI=#T@J>v0Zm)HM6kW|81rgW zrC$$%=_`^Ps&L~ISkfdFNqHg_sum`Nq>NtSk~nG-L>f+DNm4hV&-6aa9Fx|Wna2$? zAaDJnCzGZ%vc&0Cha;ibyJ@cz za-|a@UETLJSN(<->-rbTWnPDo1+|9>w39F%m|Isl_7#Y8Yo1E+3){DlZgNKw-W#=Z z2L{LCr-ky~W$>p=Ry`=^h6w)4@ILoYYbHTmYUHk-*(NcOj^Hw!MFh_>S|`M4BT<(k z(E)*sT+2b}v|l#SsLTfE3;fn1Mrpk`HP3At9YokscWr3{T80xbLJHd`C*Z#oUa>w$ zL-Z(KR-?f=A&C7Ur=(k}T;Al#!u$Kd=_HEwPN=+!Dexp-kpT zV`t`BQ7l9dpyx3RrrmnW;Ls#qrA%Jpru=r~TRrJ`0(Q1GRa@LY3`smknVFfE7@h#; z+*Y{U6F#?hT}XaEb!~AVD9(o*!ah9p+Vs%b=b-&1rt&(w(qUA!wcwvkalg}hfNhi% zxdudee<``!Kj^v$IUWI7`R%z}N;1<~cDbOv<44{fW)@_oXbtmp5>h3wT}nkVuTb;t z^w~7fG*th;nS)M|jt~H5R0+F)-xJ%PUidu{q&?Kaq)+?k8X3U(j1$@Uf}W_S4K?+oq8+rFxaQxl*l~yRx|k2`1eU zTcRsUY1`M)d)Lt#7!!fNPEOM{c?K8Y2)-Os!vsrghM|?&Qntk;U@tyMfG6VMXn$Ud}sH$v;UF4H8QMcr-tTI zTlQq%IsTGfvQ+MVjtyHe(W%mlWECyQit$&B%cpv;LCcn9U3uO3{Iu$K`McO;gwkY0 zqFLLK_+9F~2r5vYoXcg35!)Ki{3rJx>r5Pc#>J#+P5GcQLWf zW-k>5+BN)kw+(TWGCb=5N01?8IX$sj`sHu{g~7|k@X@@yP1Dx~=hpAgmsx67=%c)y zvWH(YjvrQs?I!*}w8xvih4(bP(b^kyPPYJB0})KXNZ{1Uto+|vvu&fHKfCq5FGkMpx6>bZ= ztNVdJys)JOC@t2oQ(J#q#-Mf|Wsl;Ys%0gurqQThC?db;;qkxv^xAC#0s(}MEgDi9 zVaXf>XL@X(aP7a*R#pOaeyb#24*epkAeslNo*w@&+MUj-bck6+wZB?(y}{tAQPf>e zlXSk~m6`4oSL`@w*Vf z<@UGOy8zoWtqYmxXNdJ;srP63x7C(^TB)H#JsF3J*qqrpwf4!%M88R{LR*l0yLw0B z;Y~ewbUKxDG5)L@$AV6TYFzH)A^kaw2>cYGePo;P_5=5iX9I!Z0rz(p1No81$rmMz zna>#GsGSN|TqLL9m|c?BEEg#wns+1(M3E>{T1zqGe$xt0V6#ai=@RrPvO}=GqK>@1 znf=CVxcvre49^)i4|1PV;?zgNYY2b66C}91=u%@In_a2};-XxHod>SD___W2^5hRH zomss=G?%M!DA@A1va3Q<8+dag5#rl_V8`~ot3p$@D=ZzC+FMt?1APT;jC`(z9E>JmeGD!_ zm>;Z=`(gPYl@GU$>U&j7PAkU`e3Wgh#YD7K^SoV(*UalfSS)?dH#r1sJoFh4;u}76 z+Ha_Arl~)KLd^6GozBJ94E$^{OFNX;J~G8xg6$Fb0#>WXzCyiAvFF`vJ1U66R9QFk z`3`T6j@tRA0LE30mm9)R_+gXl`Phe)wf~c?=8dYK{;BW&I&fo7JREd0gQD@AtvOkF989WR0L^Dw^I^UWr&94IFc6E1PtaL~ zTxx^E7I>{qld+_Jb2~D@pQlgDw{b+Q2(ecAOnH!Pf&5VSg7YZ}A}Xku=#|WAvk4t2 zt?%xaUMR7Dh5=J?TJu4(Dz28k^8rp%*_k_SbIYCJli!$Uwi^xpUM~o)!#&h8Cy46%#JD{0WEn+#0y(u8 zKc|T4=SFSSjhc0Z&WXw9mhj2sIT*aMHx_013LQ$azplm&$@*XL$jMebUd9b6GM#>k z^ZPY5ZuBEs)oul&VGCqdv~S2{4*i)gQwM?EjV1mVLT(ee`29@3KJnw5+kG zSX8+(uxra`j{i7E81ys)kh8fbcmKi2VtNh7DT!y2P|Je%7z{G)zl!}N8D~WtF2N6N zbgkm06^yIIp$w1N-&vcg!1q<3F_?$ht*J}l;lMR4MEr9$6`w7;@_RTLxCE7(r=ztS zI}Wn~cE!$n#T?$o31;#Pf>_iS_oZ6L6~^`lrJ_CGK!*E#g$&IJn6x3jh&VCkP{5-_ zP{E_ydOcTEw;+;5-svxcvwL~Qp1XIjigv$@-Rggwyx7?pXSCMQ%3ihD1w+UsaM6oQ za368u-S#zYbz0(Vp{VN_4TqHDv=7*$aOQ~{$JEWny&=1vI37-RtZbtJjeu(8>d|BUeRV)Wrf0sD$Qpm6#fO{Tp zPJ=40&H*n&A01@xpI832T{Sevh34eC>F}0Yf2awz{t}Q-B!B z&}x>^&kSp+2uH^*9PFgmi{9A*`(v(^t@K-+jz}%#s7!YOINrqTY+{G4}F1Pw8x)|8sRGTS1ep;bt2C)OoUpKEFiNlob0 zYUhm*K?kM*p-1V$;;}R)q8UsdXV^71;*>DR7H$%T z6_jP=$chCiIqCwVp&dTry+uB+gHH8@cLRy!9MbfK200qy=q0I#vf8G^zhW>(5g%Z? zkciz7s6>0|yJES)hr`(%q9?x^0r)U=5mojwFtwZ?f+CI;J5v<07o0!r-F^ZaEz99c zTqJ00#6Pi(tCevEZ$>%xM*r!>8Ao33NiS%4CJFl61RoqLO-SeLUAywBduW-{LFKk~ zy4}NCzicX0_V}i}?>ls3uUZ+>0*ks$gHA;!|2Rq0WSb4fKbUAEQW<*o4ZpPK^P;eS zfJECYcMu~Yo0>LJF5-{g{3hqa$pi`Npp5mL-}LrzcEySYR|MYye@~30uO`p-2lV<4;bYc?mK~CmTX?`kX@}M)$8(s8 z?F=~Jz5YLc0nt3~B|)o^BXt^45S_o#{KWBP7R8Bt61H)wNN3WHeS$dZX-HVEn2%%i zgO;9My=KnRn`es5PVNCo){TkPxTSc8pBzNgsvd2r zww?W$arN<=o4uhQ&DG7eb95fY0iij3I;81+;@CO!Dc=|WG+<`4dHTR{;Y~i!tSgs8 zRkgs1qjgHWflenY2~qvQhs>H^z>8bnQ+1sdQGwzJcvnQ0RJKh<9sw$?{Hf>52U*8Q zZ{*!@OUeQ6Ax!zHsVvB~o#6|;#i3t_NucFm$Dd&-S>E!-Qu%c;T{h~N)#fQz(3CSl z*cH6p>rEQd8k*lVlE0Ak8O^+k1;_WMaLX-&DL=-$Xk+(XN~jR%a2bX1U@DWlE?f z(gbczByf_jJ3Gkxz<7b{RFRwvt>6sehUh~QS1aZW=j5fk`7cDJ!Gs-c){|2n)%*^_ zky9SnN9-rTn$fO<=_mi%j=NJjVwhhwu(~F&9TQA(nq-R7Zx6>*+j{12G(m*3F(Buo z=2`lfjfDt|6JO|mvfYFK4H7lI9}OZk?jw`&FYUO$!o9ja z_Gze~&i>N;G$b+K#DUhBtBECMlrm*lG6G_YOlL%p7Io`;I<2(C749?J)=aQi)fFP3c-C)4FO9jixrFpyIrbd-_o2Zszs58z4zI5phdx&W2bq;+lqs8;TQ>dp@x*Qi)<#Q+8T z8JOY+1|+LnF0LRyr>8bQ7B$`-^_yUl`Frd({%Lk;eLSV*OPqA{hO%)+aT_-r^BXse zuy96EMo%bpzhz2_i77?*y@=wnfv}^OK+n8DnJaSAy!i2r9Y2hZNh;kz2xQV+tN13H zFQe1P__ZkhnrXJ6FJHfMWKMEJ@dIAX(@wlK|8k(RlI{i?is>-Zm;5J+M*T&Gm7p-o zqK}&DPCArhEMh1y!8!1zH8+v~HQW9d`ax3tPMkMUXO1S)m*&c5ym9Q?nSQGGI%Oq; zcL@IQS4ags3A@8F_U9jOg%S&H zGa9%HHjhu9)hlr=?)LkR)jM7}$fFjr>;30LkHe2=ZZ9O)ljZTAm?wqQu&Q=HlLlMC z(>t{q$ob8;8A1R3eFVNKO6svTNAjbgguC$o(qRJXf{B0+5|waB=qZeG3$XSW<>~ah znBW2q`xYq*Cv|_dEpGmadEN>?iul!kTre&;RSjHP(wGJj>wDI~rgAd-hd3 zEBw~TL>FCNdnr$-0ceh%YN?J0lKP&QTer8=Q2k9RyI3I7Tx%u%fnu{0^uY@DuCU%T zWMiYyab8V%>!NyHqlwigvl`z;d=dXz^0Tn=&p{zT9O^luRh3!LX@_`7RIw&5U){>e z0U9_S$H%68anCa;7HOLNp)n!UyxoFY`};))W6$$Y$d5JkZbT>hgCpwvJV%R>XoapGP_Q_vW3Nn9l-;|nsVpdaIJ`@iCk$R%yq5R zS*Ux-k~2GLMU+kNniIv<+k}$=_l9@|8z@A>mCHYH@6WbhwI3B3_Y0NmIoH~~bk^Db zxRL!Oq_hzVs~KcKKx2mP#R$VCG|b%ZXclW~OOUKl+w^|uvQ9q9MxqH9JC@jU0r8&i z*H$2USAZB7OW`G~9Y~guU7(5P^~hUIIUQP!mA`oq=Aw>~A{Ger#NkN>Xwl^yu5W@$ zmrPWqF}$VhW&#wt({G#WUbv7rybm-iA~zI-d@Dp0c@IRIGfZ{e!t^tCUgKZP_|~;S zyGowtxd*>t%2{7F%+-O|NcKI{-ZbGGc`!{lTqrmy6T(U6@$=4s5^+i_g^I~GHM`sW z3L=ujo-mzuO>Is*)9`cwtlsTH2-p{K}c@|yCo_VlQn zyiTAfsltEXbrOG7h5u6FfuruMJ9JAdVNH#CK5eMwq5zX-Oae?jI_GI;gXo7|`CCbx z&5vF;BZ#CxPUDh@Gt+7^g}{~`Qw|by>RL+9)-8|U_q{*Qs=H$eDrNcp6>NqU$smda#5Lc7M zKtomrkF*;G=Vs=if^>vCZ@d<5Zq6VSqmt5%L2!Q{a_Ui^wwkm2{lFAI>aktA)EZ1? zmOxZ5}3Kaugyfn?6R~j@Z}F=y@s)sUuZx4svdTX3IAo`;YB}tN55+{Ny>Og zzdM2-N;<;)X_iRtdCi%gY(H$oKzY&FF@E0w*df5bk&H@wOWTu*;;_|Y&)>?|$~}Ka zovOciwK$vGB$f%8V!L_{soo;&&L3>JyM2MQ0v&_Ah-}N#Wigk)baqp@@pMzEGnT-d z8wGt&xZV3^u{09Rn$uWNuLtHA%fA&GX;Xn2oiM|VblJj*BD(F~9iuyvge$u)8z+p`Cyd-X2z23@_}om#^Y zsI)fmQmtlLYVATCp?BF`Wd@zum%XdNOkZy_my5K0rMp`QFOH!WacW^0H%>1>ht7Su z@=N~d#r{eUJ|R}~B|{x+jy6R}Bz*|t{Q*@aXeFNVTTA4xpEbcedrfIe`5leS-2ovK@|BS_vdQ!Sxcd#D{vKK72)}V~ z&aoui_T~(?aj*v6oHoaD25Sz>mJS40I=WcT*u#Z@os)7MV`L?$sfP3RcUMHBd1=Os z_?kRtxLE`J+FAeorC!3GbPx(YtAtXlx=m)kZX>s{&+P*1HZ`g|{}dYiA$_mWBpSWI zSJ&;UJNt2h-Cd|^12hQ5f_o1sH>(8I#OU8gV%KPyYjXKEK2WJu={yd5kY?`59=PvB zo39!SW+AGLulzqq@D*>#f3q!G51nlRZATQN&9%qsirKLbmJ`v8mJ><$$YhA5hbf(V zg&Ve$j)#)z{=7Vp$&b;xWyh0n(g;`DHcN_~3V^u=$dn+CYbvrJJyQ9tmNtF8atXRY2hE)>8*#fHP>! zeIZ0c8um%qclG?eESQrMjYNJ%l8l0q-qoRrGXXW*hL?`4Jq@Pg?lNrVyK(PS3e~-# zo4AXk6%0{WJV*H-fpzT0L5G{_cA(m88Pyy6U_V`&Rn#Je;E9)zR;%d5X(ZJxY zgL{Ak3lf~*?(R;I-~=69!k~jo&fURwwL@-qVwh9R}|cRQNkOE5jz4fht#E#_a6uRB#)dz1+WK%WnZgR zN6xMLdiIlj<+IkHz-e#8Y;s~Jdu(TaN+ir>ygw@1%th3RU!}fV{5g)0Bzl|tI5v5$ ze4Y(es28Q|EQ2I;N_Ia{{FI?Qz3$7D;n-h2LkP8||2D}s<_>^pSxGKnAx%L3Pl^n` zr4Pd+X3;S!AVU3e0eH8$!&r~l6u|01FEB5|#l9;KhYH@>E5)o_V-U41U&6K}mnwi; z^`#r{?mH<#v0wrXd%P`xP%PUodI@5(0)uDHg|Pq0=2_uwaSkWblRsa0WyuHiv8xY( zq?H}t7xJ~~_vIJ#%otEsv010JKiEpW;kq??1s5GWB#!;u;0+zVIyWcp2>20F3#A$z zI%;iAF@YI&SkAK3sn0o9YhZpfazAg_*s$yA`57LOIf6lAMOIlaG{*SmzE>-u%ZgPP zH#R~Xo9GIjO%e9y#&k!TAaV7TljlV%C}%2Eb9{~AZQ(K@W6C(tkKgUrc#DUhePP1? z&ewGa+TDl>@85sg)mY#XFeL8n#(vvLXsQT*#@CMQ@l3XvvMW*Z`LH`emWuA z$d-VVCR!qIjIXe89{o0L(8s;Kquy%6K4GrGieaaK2II>1;n|y{_qP>m@7@WF8)|{Y z2}3tEobw{kC2h!G+aK$+h7f@u^`twV(?7AED^N7eu5Kk=7MiIg_amV1UT(#I;d z42LsEs`zV`-mSPRYZGCRs}4(HojqDLL!2-VR?!9`s@tOye5!!ERL@{3qRm~_>^K5e zpiGuKrWGImi+6m)6sp3OJe#3Ck*F_-@hCv56WHp>!aU|OgGjee>mmC59KdifFpLl^ z1A+M5g*vgr-|;P-qRnHm#q2ENjXY5>D&5X7+?CcA@G(Oo13vmu+~b-T7Wh;|*P$lA z!P%w`x-{;pmKjc=+p7BVre_{#o8_Kt)hivnb7@Oa`{IR-=|?o-YF6R)=y>3hN*M_E zB6WDvpHHIOuWQofB18+=m2 z`>~*n4Z6G7)jftFK+HJ{uvcM?AOZB2=Yoe8y;f=?c5_H8uxCGk7~@Grk8PO}#BduLBjwkjgpv|J7}JZ}`6yB7*vfDFRP#d;iC zeegfHO;;`K?Ri#OHLmI2j;h(fPk;X7YcLPYCqxwVWM#4WT;kb_oD9H_0;LK?HU$(N z=Uw37{y{QBt_YnAY#?wC=A#E~6+!?2_7Hmg)xltX>_%I(c-ZVtYj!s)#Gr>2;^e~D zxLCR#$9yMRH?osnuarvb-em3i@n;C2n96O()!)obb!AyG>CVs%aZXisL;Idc^y}?t zF4A`DX(uQqS9K#fiVvF$GXlx1Md=yA3{+%7*k7JSoNu94S8SB$*CUja zW29YD`BN1_LTV4t6~Audxr^~yNC-y&i*kXJGX3;INDsqm#0MUb)8kg_09T=24WdwQ zM#8<}b+J5GmG+SG?$nYv$2x-D4!UC3tb~fM0Wuik#34W7lozw!!3!^`z_=XWN~Sb|NM+fNw5TvQm8^WdvWQsHa1t zDcRXjJ|yGr#nFJ|c8L|U!<`V!u3cWHTd)5CD}RUg$o*}9y7E_qtoO|+Qi?@-l9^Oq@$D)BfQYAa z6B=eJJvCy25<*c})_ZK!*-xXyYRzptz_G<|%-+^$9-u#JN2Lhi;83ZGdt2LFiKt80 z&k$}Q@tpOWHs_6evsG`>`m0gabknNF;SlJE_Dt$DzxuW2VX|5WoNu>Cv8GhLw=1CJS@k?% z-jz*I)QB&p!eZzmT}WeBc|E)svoP6`1{ZoTYC)`XYi7n#M*zO4Bd_Up zy5*9dwvnm$^NZoR!^TuatOdL-zED%78 zly--~ZVUEAThMY=83_Kke4XzFRWED~2*huobK9bWgXe}Er*a(xH`x9q6~u9RnF;L8 z;x#$!&EpAJaixOes5MlFSl#20K+}P0B#yM$!%n3^r^Jg

4;1jZHGimErx3-?QWB zm*7IDw_|^xCe1`7l({QH9iZcY=X2vc$@U3vxSH_7dZZVe?m}$9#2t8_&I`( zL+xE7CGm(OzdUi@m`KvMBw^Mrj(?s|&kc=!k($w^->Yo3KA8!h^RI%#~x^wCCAjpnS z`&(3kgnsFG_jtQy@_s8ecntT6R zyDven!{@rtt$nSkWSPD@!HS_XB}-xtQGZdcDx>bTBXyIcqYq5Iw^PBI)}BUR!7MV@ zy3Sv0bhlQI9Es0$j3B7}c^F$TY;v816d5Y?%Mn9?0S3|K~0qv=5V#IPM7l zGX~Va2}0PWnf9#wO$yS5S*USZPl0lIHYmb@IWjWa@0qjXix&EgFWM1O#%T6KlP)Ww zC8*1S9eP0OkaSp*MmU)HS3eok8x{FMq)7`( zf1l+gRdQ1BwKn5oC8rI~=!!P-kIiHtt;mvn$rrDCiz_!gzsE?*+=G}qP?fwvoDY}p ziTQCIPEtJa_Bi(3Lp%!#>YHr(QdqA_w=}ksS-}@z)`Nx{jjRj+%>R}Ke`Y62^|LC^ z-Iv6g608tb4fEU)5QLbN(xLG|72~frG$L?Rq@^qm0ZTfidE#;bpCbYfv(!sV>-)&9 z9~@vS2Vv3SmyRG=~%d#Yy!0fz%1 zU62nN0lHN9N7)^M(0}Xs zRA%YQ8B1FREEZaR(nKC?FVaMU2w9TYcf|{G(L&h**2*-H#5BPJdfC~26EY7n+mfkT zfggPsPfkXe_!O(1#+?j|OC4o^apGmb8R*GR5l(@=$lbQ_6gZ!tZ!u(@F0p_-+v(iU8L?kV zbA2;^pNiin49=Xx=E|CE^{%dgLbs5_JsdRc2`T!fX%u<+R|oBm$hOx!m>z3!WQ?DP z^Q_Key>MtfGJ0&HFSUtS@2theFDGo_uD~Q1>U~QEFtq>!pom*Mq}g*aIcTsRMsca6`yhJFT@su7_sup!78* z#+(CCw;&$@DSd9t%})b#T--3tVCD;wj5Q`#Y_+eI26N3QkCBU@7W=Q8UK&Kxoi|aE z7T$x>e&yJpU3j@_FW$D zQWhVE@VH|2W&FD4YgnN!(Qe%)@Ib@SQx6wObUf;hv%8hpcvQ%o#h_fzL<{@kPH^D$ zRET=%@`g#TspCt~DjV7T=J3^^7D|t65Z~#bIAK1Fz8vuD_bLltprqR_rMw zs1v^!U438D1Vid^Q|RI6hpzV@2qnLE)x{JzVp+`po&&WTas2(#89?7`!VJ(Hyfd2} zA={-A1wT=(n)!6KaELC-yIy&88U5x>M zNSshEG6lp$d??t)-ttYk&2BR5CjvOyLLj0w*Hs#ipKUoEJmCsh*n-lgMFr zGCCY*^&w+pt_UK|udx*ZDx%3(KIUk;ziHnm8~J7Z4~QP<60iJth{F*B~tYWS3vZk;T_(ISzi3} zzrr|J-(rS9Ov`=Sgxi@zN+jf?y4>Sa#qwxKHpOQWg;}E)FQg}Bae3oL0m*3SZ=2BM zO2JOONVu-Wj00nhN`!l1z9&Q7Unoe#gL73Alzv1+{r(nn?QoWr=4HsP=3$xf-EZzB z-_M(ox`6NPF2B}v-a9!jJW`gka@$Q@2`CfO&Ev!e&|vmtq^cJl-?+%Iz#cs;FGBV5 zk{h3f(*GU0ixv9>7cM$64|fu< zmN{h#q$1gnqY%wG^uyH2c;9JleOlt4t%=#tlQHBj2D?$0KT4MLv06B#=k5irN%Y1p z{HibL?THl$hx(?X_Muf#vzcXDS+h3P)j$`#TK(SKB6Bew-DNo-_*l;oDcFUUyl%qS zN>g3n1-El>8a5)OHKV*zm-`DxsI@-nENW#c2-nTl+_w-u-wbEvD>`VLp_VpZ9IA} zy-ufJX;O_R1?{A({`x((eLw4dC18QOb+snsWsnL>Yn~0VJ$hh$S0lP%H;N&}ce|0FTQqwtq`%Ds;BwWakZufOA z$5FX6X_j#aBTns(2(u~zfL?zn*-I3CGsXzG$^4YD7VuNP5*0gGi@3OFX7BsW$82RJ<1ILh4K7|VpU9v}Kqu_4pfoN-G<>o(m z@X`%1YX6AiGX=-fY=iJ`ZddE5$-jl*%8c-kCz!mdVUbdZ|TkW$()RifKTj z?x+NP%i>|dXtdZZySCOPzj!-`M@%$^#v9W=9`V_e@|c>-o+#yt-K(ttVo zpm@3l?rZ7s<&%h~P&2zdd$UC@yvMSZ?UquIg^H+G?lx74AZV_#1zjyGRZnj)uF>># z-Vwm!ygEkW-5$MLI|t$7vHyZ4q)p>S{aAe{`t=Imd7xH7r}MBXf8~Rnv%N3%2jlUR zfRxamTxK&U(Ov?t)E_Uo96Zy#SPew}g&hjdETbWQc3!WXA2X6{hf40AGhSRxo-?h7 zG3#4ALLgRtX%aam3!WU~pYo{8D-*nL$Jn&vgT5gnOKKw{BaDjt51{Jw#|2aN(b4or znd7K0bEdxxly~p;6@D?#gcC$81hLkX_-gP(&Wit5kXlMtbA9uRTV9WG)y^pp9nzl!~5PWCPCBo-jS0*97#uP|=US9Nj{={=>IGI2L) zam~v!f+l$b`lp62yWYQ3EgmnjDbSTAniq=WdIX|GS2+Htnty8e-FTcUfw+Smwngf! zrx?l3Uf#<&w&K2$b7|<^{DND3(k^>hfacuoZwD{05!*2hDyKh*ifsRn4I$o1Jk`tB>v@`yNi6=LAxG`-iWe zS0$fvE)9?i@~Fe(zw6ol*c^33!nmh5)_g_NY& zDV3t)35OPqtR4L!MNYQy%BPqOeMk?}C@O>eCWVvdLyk8)BlY+eEGS06${bzc~#*R&HvMc1~q;BI)- z9!{s{zc5@jU?n&}!v*BeXCb2*Pd6aU)9`GtxlJb*V0&Qd-d!GLAw^MBl&?0Os(#c| zclY{3^~+S%t8sl6#JQ)JiaN$9ho zed>us5z7+UH;Ww}1;GwXzH~xtahCME$d2j_2TT_VQl;ULelYfSM2$EV( zu=m2kg|zCHX5d!+{uT9m;Sx%pCY}{mWB!ICSBe0C7Ga3>kiViJvTZ|-^2XX78I>;D*C`vf3DG}#f~NJ+3R*1HH?>_KAl?=~(7 zlT!Mrz^c3{Rqa`y65Ks&FTxX(3C!AITAF%2lU}AlFWSFirA?i*(Ry9CFZnaM1Qjd6 zkr_R;Ly1y*QQJocA_5BHF&Kq;S8wIr^r1}?ey3?#3((254nW4)!H1hU&+wtd#w_xV zP)2W&q$yG}8Ujo^zc}n;MNrk2c2wk!M|4;f8aM}iFczmoN_xJobWqQetc>#BrO1_~ z7II0i*6T#khVc6cm$7|%%qDo1fNrP7E*~J8W9YN`O_!%@Ye1Ud6X4_dq@FF6**1Sfm)t_2;y_os*)ic-DSr#(_9 z*Pi4jDF{^fQ{O%o9;k%V{)ImKKV3MlX2ZQXyl)8$&q4IZWKMj@;c4mddS>vQ#WUUV z!A+M-(-Pd(q^1)!?o{#_mBgcO>8xQ0TT=SuLf<^2h2wB-_Tt4WjAtY~x2hFUlhfRq zmpuX7tp^YGu9K&>08UY{2-ht&*wsz{R8-q>^M~eL{pK!X1C0yBX5CbV4kKz`^H82H zC7bsZ_4LJ)-%mZ!gp{v;sCs@(5=Lsek8t4)>)*smh99h}1%9Qy>3YJ~RKdXfazHog z$%Kpql6rxpse+6`j!J@riHV6c7?~-^i!6kKzz@90lK)^GFR~csU}UMW1luH5=GA|n sa`Pd}|MS#`4_V|ttN8w1{f7@(6z`wa|L+Z%Z~2kMUVIclMnXdRKi9J=Q~&?~ delta 74583 zcmZ6y18^o$w*?y8b~3ST+qP|El8JkgOl*7NOl;4@wkNi2>t*h(`~UB~s;{c+>*_w| z^gg}UUVH7`V`mVr`w$4qa^MgcATTg6AUJNd2wy6_RIL4kws=%q#t3IbvR1_JW`zPu~jps?Z-3HhFdhBlX8_UXGD%Jo+Wi*R=g>c&lR~i53%ybZP zT~V<73cufWxH4!UG_2@i{yeV-ABL01k*ReCn&YpX{%D<#LIz1UE^MXyu^)G{8y~OF zZuhhOb#(iQ`HuU0z*_@Ns?gg-=i7mi0`T(3mv;0VY7T;oD<`Wp-5r5xNwsL%UB=(@l>xG%-PV`V!I z<|x|v6;LMgaBCzKV6He~Q(MN@a;KpqAm}~??+oMj@{wjQm^#W52D^F)q#8fC31S;u zHGkM=b~5VvmVIsuPPm-!`p0wWkDb)cHz8zV#*dp`c>XbMgLi5sts6Z58)5_ad0J1Z zwT*%KT_K^b%IL_=^Fl832mKZ7b01^#fPLnC&(tRTLhj)}$gvT_{0GyT7>=%=TN4~Y zW!0i)0qS)&K?MS0b!!MPI{qi!$+DP}OCKMH`1pe_Jxy?;vT@wj(7l*%&84yodtdM& z1#8uSsD;yAZTz9*6nb-ufeczt5-E*{@q!7F>lFuOP)a7LbMH|}Uub%=zaoQcG{0&9 z|M8njn#CsD3&~AYhQq*k$@loY%82D#(hlcJr`N;l8LrwBt*T+*z~ipv&-bIf{Gj-n z-qM@=bi=RZDoZh1?)4S&N|(`o@4YzyC_DsC)bcT8%S#cv`?r4g2jge@1$_tK2gudM zg4h~rT_pg~&+!Zs-m`c)Gf9{};QNLi*q%T>1gCgozi)7#nvPbaEto^V%r3z}0@R3Y zfP1dnpRN3~qdHwcb%|7CjG_@&DM9-MTaan~!(pI(7 zQak0^DH5>SgNWpDZ_nzzj>6+`7g0!YHeL0M`~^lCVRf47Z@JaDXBR94dJct7gmIZz zhUJf^;t-6{Q1q=%ze|3;%CcBR5-uEOJz|LAA)ZKKN6Hw;Ha6wkvGFmTvsg7?(OhaZUq~S5$Q%u;zw-iy#mLcM;Qw9D%$VnNh@1I` z*zTd7wO{4NX=*jp+KIRF8U9P9(^=}pY3jx2*ga}3G|R4PeYIW0o#`z!32O2`ElY_X zeNHiSmTUmn?GZP%TYtw0C>J&J1Im}Za*>C&eOqj|RTK`wsFWgK0ZgQJfwoKIDmzPV z77cc+j*_i(Y8|r+a@C^d!g+79Nv2VtT0MD9i`u8btE8bbNbhBj?`6;DWiRv)qba7@ zp3tqr^C2|6(#$)GKDIz0#qy;z09LDJGCLKU`wYM_+O(>=t6o!EGMrjyX3R46-@3h; zK~}IQMAqY;-^*u^rz>W=bHhYN!>ID8^;Ah2*-pQHbd67X#& z(uw%3@1;t~cjM<%FLr8bz@@qkTEPy{7(>qn+6&6&Yqpj?bU)iU>LoGS<>YN(HM;*r z05Rk}tees_bE0+Gs%nit)pgNnnDTt)0vr&l^>x*Beg?mB9_KfHC9ifWQ~A@3Pcg&9 za=F$d3kPuMh0R8 zzW6H&ppsy|6ZGV8%U;Ug)?bRB9^euc(j;|I)zM#VabNbb_p!H^qMYtWwSvyw1xoIt-~Kk= zkAAx!eYhV*KB7_6XtF4Z$}aQgs8yAWMFqdOa8h54v8-7fp!lv*o2ipzJUjo2YWW>G zST(FWVSPvfm(MPIlqt}Xj#QrCz3*+Wr$R?PH?&imK|yFoZ(l!&Xk$rZU;+gXiyzU6e>OoY)d#BHd&Ex}JcaiDNLSLePB9N-ES!@0X6J}dEMnI0L3d$j zU`wWtEEyy`em#;}e{f={xOt7!{O&nGt}n$uv~D~3yGCe%t7>$^W1R85tnF8%E8=LL z3{Pv#AwzY`y08Nr8hFO`(lWWTZ#|~Hb0Jt>$*(&2xHi~IFqe~{wHV+eVMHdJ%lc>P zyvO)riK)tQzHT|2QsD>`ObF6K@+)76LuNh*cuHWEPQfYhR0ets$S*DNQeM?Tj@;dZ znf5~@thQqPYR;4Kb1x1=ICJ+iT-|^`{r7~uz{2*!ORX8+rr<9D>!U4&KAtRgpv zRizx(d!;{26_JDS6+wW@!HmKO$VS@3wtoK+ns$n6{Vg{|yZK5=*{S2+mtsA^riNfh z13~NF12aLvqW^*p~ymc-*P* z-qc-;vc9Si(3a6qD3lC-G7u1R5_g$0_!60clK!Va^(NQsO;Zs+xb1sYE;igE{F{&Vhp}uCl1Ot;+&3LXF9X~`{^6NI}g4JB#PIwEJ$)L8$VVB-8tZPihcAH%Ofs(PKc`fV~ zRQ%mS1AMAatk7OateCY4J*(CKp$H8ew!q{&@Xix;cB96IpI3%}2%-$Scry4KM8fZF zwBP!hUYtAk6GVZ=LW3j+v`@h{xT3Qe!SmL}@wDE8WDt0ckxtJ-VxmqSW#hKQq-BIY zQ@NFb<1R4F)2J(uAA-IjQ+BMv>{B5ej5I~90DDcVfON?g4`T6$))@^HY*{)`vcQFm zO5hJ+mAw@+%O-VH^3PEU(_fS9r}4`~T2QX?D`TLCApxbdC8ej`*2-IKLC7z4Q3bKb zmcS$K+%UM_N}DpKKmpN2*7kL%N|BPnG#+UTX)VBXvkj9D-G335wm^NhO)$f_PIl%& z_sc2fMC){XTsFjH-f3=ytL7(8pLfrgw<*erOJjQL@IY*L46)ZvR;;9dQV6sQh-?G- zx|Q_0Fr-HTw|1}S(RM*RdJtO)#iODy;T7t=a;iU^Udi0c{%GY~G;!`x%!7f}W0jrn zf(Fo0&MUd^j*GDsl<;oSs^dX%+Qs7#(nu9vnQ?%>PHP1>+w~O!z*3TwG1d$GX%h7k zgKApc0E#=EVxi8EsUt%;6POA!=Q?H+DrV$a0sB0643dobyouRO{rvMLA|*?Dc2yW+ zO+@9Hl*21fg0Dy4%`+ZyTsI@|3DR)^>lzrM?jOk?+rTzG#~d3|rT-24qmyYc=-JD- zyf=bF;?rG~#OCrsTTqgh-PQA`3W;OIxIrZ#PW}!lyp|C`HufB;SshWGP2T47mFVS8gAC^qz~#g=5u5}9WM8&dCNm$&#Huj7r{O>Bn7Qj z6sDN9Xu51m@$vJb>CtjydOMvle*t_&JhOmaM)RhgP;$f+E#KSQ%h#n}$=(XY7la9p zP9hPMq(3!2tT7`f%HqSiw3H@Q83xOc?0rjoY5vv~(s+pAaoq{4&O<}8Q<3SCm{=x> zht{9j!md!irWcs1H4&Yf;PVRwwrUHJ*}n6#{wC~o>lUm$o-&3&l4+Frb^{FHr~Osg zXx4aWyhWnA)UFg<;QyxQPSOJtp)bM}At{if&M#QC$xB_Z8EQW~Q(kTp-ibNq6nu`Q ziA1q(i$n+GtG?)nxH^0e zfx$D+H~9eq&FBLxIpR`QT?eo;EudcFqUV!dg6kpyjx+RA+D0bZe{0Agqp`E8X0jF6VeO(pUy2yIQt1!$IFo z8>*Fd`v3{JGoQ|i-x!#i1|Cd;hD!@+VuM*qp&7+1Bn07Zga9WjBvSOndO=zPCzm(Y z9yXBR48@mKrRxrx7O6K*9%EaZaY#5ljIK_9bB3<(ynuOBR6j=qSERXyXmt3Uq&KFH z{c5YY>B!j%jGDW*1Q2434w(_fbAyfV<#Yx_qq5QS#f(sL%xt47pTY9(Aom%xUWJ%J z2R;BBXr10JT0))48_utmIiEjS7yeaxAf2103-1x*PKB=i{j7UFt!H#;1g@om`v4U0HY5b@9zE)) z3?!_il?T<^!#XK&=pMnU@F8dWIJw7SZMx6cq;<%{n$pC5PR6Ck>C1CluPm6HY2p4KU!LiKFmJi0psT;(yTM zf6?;Z^*+O_X!ccN0Il++R=fh~jKHltS*<2$8Vu|CIduAjRhe0rRP@VskVyR586=sp z3&LpQb4dMdzW&!!aYAH#STpF@0VEiNKm z%&7c3m`j%AQ^0lN#hJSuy7BJmF2Ssy=@PY{$d3M}>%NCk;Y7d_&r$_;$RTJ(sN53} z8bbC?u{U|=bwEYG{bst^&pjn(X4%DHA^^0Tp~bf4Rw0oJKj-^2FAcnhv`!bP_y>E2 zGz8jQSpHn>J>mDK4#V>E(mgZQ8bs(H?{J=3^1kgDf->L9&8JeuApsUJD=Gf?Z_@yI z1TJhQRazL{^{RPa&suf-lg{M{rVi#u_s{cr>zl4-hw^pG8iRJ*JZfQ56^KGE;M9&I z*x*ab|HL((Yy5n#tnkX62Ip1zX^Qh`E!YHVFK#=_S>N76I4Eg$i&EXK+x=$C3bbs8!8Od3eYe(mqsYUb9OEaW=)FElVCF-&pB zoc}n_9k&yUooOs@>w(svRT8FB0=`1}h~P7OG8}@)RvVv{ZfHj}V`STvr#HVPi+|m# zhel>7$AQL*#ycNOgqslok36SbCsu(9h_!dvdSM31<pME2NkPM{c0mZvESLi!ReBqv)!f0K)p`zK4aK6##kGo5OLx z-%c%+IAsq<*djkVD4nk@#LO=Fifrj(*Qfwyr>mc1y?M}eu#(qEORJl?;j8u?{vcJy zf3OKgF;F0g@D#TuZAU1Y#FxZml3dm;uF5aOlFz5oVRXu^Zwux$fV-h%o$KV}0~*X3 z;vl-K+e7MxSuq@NH#4{HFi@D)Zr4lr+b&U3T!h+nk5a6H^FtHoec%t9n{m}YT<`1y zZQ`I_2hqd-1&1IIq6Rq*X_Byo5TB@pC66Be-G&rRCJfy4_@8YbnzcfAF^EicO~9eL{MjiV3gK=Ayr3pX#rtTk>ho}hd(pD z@FfhwB0eWh?D8NTE>9(v^VmFOeu8H#5}k z9-i0e8#(Vy#Blh&Jx$-jb8EtlD)Niebjo8^FJngCe}RJaHR^Av@tz7f5C)bMcdz-TPn-+RPtvGx+K{YX_#Fs| zkmUEedd3@Xdy~FgdI+XNG9nfBo|SZIn|OvHMHieM^imeQ57KWCi!3E>iCD9SWFdcL7Y}Y~g|H^~@7J&cuEPK6F!lsch>A8<8FLgvy0(LIYC= zLjJi`dihs*5dlbA9ZpPd=g_Q<@JHRfU9(hkwJ!F~B>!T@X%Lweo4svHlZS8(E% zCyIMKTcRm>upKOzCw<#-vAlM)fH_Lb6@%^lpXh*c{oajxw(Rl{Kiu`5=6o#?!2`2! zS;9!{>jGk>f5_Iv1c~{Znh?M>Qry56)=NM7W^TmpWwjs!YDA=jZ*kL(%O@%~5;Lkt z6CjSWHwu{eZMOJhBGn7xXue6dU(zpGiB{peF_R3&w)~?VPN`3@0q{c+U+i6K`wk7g zegx34F)97X(G3W3wjxBSgSp2x(~VLl?NLb!HQfk}yD0Z%+)shfyBLZ=)s+Y9@WaS! zx<-!nJ-qb$#0$94yt_OKnf^cNNjRliomASgKy-YH^_Fx;7Z)^sd5~*L-4+G=h=YTW%n{}7r@jd=eC_EhEZ+U`kvzPm6 zHn0xpNZ>}Y~30aAsUYYN2h>HX0>&(h?NI!e{+u2=BQ@y zUu1vbpCZ%G)TdmHjJlF2soS}Teh$C6EVnX9%Iyyt-iL|W3!wsba`=+*&tzHK7u zWJy6ckl9a{o@O@As1yw3x&jSWw{GqH>nfH0e9GAlI0R4*03Xr) zf7vB3>~f69lt-Uv+kzy1wscQGDNL{5gFr_)oR)FXw0@w&ZK<_XUAos{{pMm$HAY78 zk9bHz!SVlDY+QP!U;`*9epF`Hu3l^5I*1RWMm6uh)Vf&^X1|mKzVO;6XGo}yU z)DQM*dJpIECc3hPcYK3)K7)6m zhvbv{)}aQH^y`mHB@D6TNy#Moos;eMS`KWb!kDv~`!qRr4^-?Rjl3M}H`S0WudYC; ztLYb$U8AZi;&SihF`tPHg9{${k*)%Nkh>oNAJg0?{ilC$5qm|Kjtkb{q5U@qlitA1 zZ=2GO#HKP-YBLhq^5d5{qFSqIW1+lQrI3_97xTFc9QNhzTvYh6w>2DPTGgLpG{WL9 z{F5Gy$9QMZ*5=P{;;$Bb-3_`%5&->;9jM7JAhqoE8HBBI@P;*sE89M^CZ`4;2R}T| zI~O*mslt(=G^E3s|L}2M*!n1sG>bl7Wq;0U4+?Wk2@#AR&@2;=>u|1;90%kUdT(th z(ZV-D$<6C9N6AMpKr`qY+g z@J0aMLTRn675;z=+6%OuM#pc{Y2ABW``enDfVgh zeBXnjkutBCscAffWj?ve^Xx^fHUCh0LM1~2cSI4g1)eby+2ZgoR_|cpa!dMPc^Ae@ zZwzvku;ps`!Wn2##(Xlc{!;~JJRx0?L2KYkHp%aN4qGCNdxV24q?QOC>Fq?GuCMd~ zlK_8n7uJ#A0ad!4U#quXNHr?Y-(p7118bq;u){tupHG&6RC>*6ze*tJ?95(i;Ts`0iSf zpe{sUDD?QSWQcUyeYOeFaHZ&f;VQ71CfBmTC){?mhh89S6gEP9B|1+(NZ;NApE z@QS2Od;Wcf2txbO@2Ksr9LU_%$?`{yOzj47zs8CwW!>|E1CGpx&sgpg9{S0y{9}CX zhsSu%myXlWA#Qj~8Bq}C11SJWy8zaLHz};}RlFvOb&)KV%$C_x7(%%)Htd?=B`ct* z+*LP94uoiI*;Vd$zZxjts>JLz{rg9R#kVW%3E;^{^1ZoG{OwhxRgs#MvWFVRqj}PV zC24V@L-VZe$ub6D6%}(0+vWQ1jJ# zggh?hkd<~V`~i_0w@c9nR^tC&7$`<&f)TZw71*6$Phl*Y7?9BI&PhZT8{2+`@lID$ z2spbgd#mj{15X)e6(yrj7zV@<8RWquF@-Rl85p_07$6~FXBz0|ERx9cGnVpo#;IyR zjXbXB+;}u33S|GFVi>UG=Vy3wRJ?K-BEFo|Li^Zz{-8xFrI0JrNnkZ~jnQ$yKWrrstSB7p`xqGYrIc)_o{*)Kfoyr9m z%{DvDU~v9lKahO73mvX(0-^oO-!*;4f@N6Qi-syj7{j`T2|p8*JJcV=4kfw&cA>T9 z0+<1Uwb5LZLdE`^3bVb_S|K_4jAMC;svJ}8L-~1E6*fnuCF%!yYt@1h6n`>)xxONd zqWSST&5UWXLvXgN=gh`&Ul@N4o*zT-m?9crrsKQbgz)#LUk>Ne5OR_QK#j!(OC+x~ z=k@Q;1h88YbE_}qnXuJs<#gY>eifTC09qo>3s!evIipqx2~ZGGSK4`u#U%_30oHV< zL=0kAUbR-?_MA1!Whv^v($%VKoD;s?7gh)Z^`@kgV{pbqtLI}8I(bUt7%DRgm=a9R zhMbr7+9f%xPKMtpJ5_buI|3IrIU-|-%Hz@D{*3jb{~S0nKQ~bn7`_b-tu|4(0t$}H zdXb^we@C24WY|JzD+@$nbN0K!GD)=$%=9wVdIoOS`gY5};eh+-VlluN2dQk1w3-v) zhDDs$)30D>tcK-guh*$|60Ga~dOJD-0cN4Vhd5kC$-#0gTGM-VGu~6QyLcB*B4pXT zp`#S{(2+DA%iH!_Rh_IGEt*ngfnh;==FGdc3@@O&3%t=}aZ$N`VL!Q}*`U2c7(805YhSYx*G=w58B0>o|tkWI~NR1cG|bSCMZe zoN}2^gC+qg2T#)G*^k+=TbbIeL7s+k9e#}Cu7H5bkoNU_OnCD$?%QWNM~ZnK`A+ij z_(;xIVr~VUToWQ^6y>1|gv(N$6XW}g$b-I z!4`n5Ea2c`|DB<1Kjc^`^ZcSj*Erx?_H4dXK*3)jq+3fiO8C@-B*S`a^X5HY@y+2Lb5uw8dF!1s?LOC1|BWWOVg2t6^;cBe9bSI7aQM0ktfhJ z`D7E}JbnJGL$vffG$X=wY=31J<8D$V*R7j;v%7||A%C{j>JJgL1f!2ubZyh^epmI3n+)_C1wW{E~L z%5-Vg7O;6Urn^cQ3$)Y1hhIGlZY${nZ64Mulf$cFkgQ(I< zjGNXlc{8^dsUPA#5~g=9STl`7Zybl7YRj?aCp{LOKGWz#lqFw8&VBrZx$=HsUwmuV zr>IZiC&n^6x zA1>v+T+lIRtMa6Gf%I&Clzc~5g!EuM4bXk|IY^)AT_(@v3Z#T-L2@Grz~-ual@iWg zt^+X{95t9#@j2B_g*n0r-Z1I<$3y$AjUIPIdWiMpv8OVTtW?IHgIW>ITA>k*iGoR! zYD<1f2%o=HvUZ5!ffV1C2Hk4$Pey?E>Cq&9FhrMGKQFS0 zU-=pD!^7*#fCuY+Q5J-w5dnpouJOYg$D$`5x98KhYI{3!#8|1B#9dW|lgzE)Q)^PJ zbH<(%)z3zI`h>F382&o%1iCx`FIfb32-r=WMTO%y=k?0J>n3~t(78c~yXbeyhCqs& zl!HHV*!`7sOuSh8pjdv`SAtrK zY50%Z9TNEbOJRn%*2N1`m3C*&bQupUP68}s3YR{y&!O==e%m!Y<7`X;6^F7Q4q7!? z%yqeByb+(G$juR~s9$^VROSC%L1=a-V*P!$#&sGnq4&VK71(V+E>wqB zD#KDF4R)rXDRv%lvb+HzzztnFATF#p<)Hf2WC*U*2^NSKe?xvTrA7S|eITq%vIb}f z%+htlWDEJof|8=yT^$hOQe^EpCRK$Z?-65EHz>&nZNJE?COjX+CCoL;%H$XIm59nt z+E{macmyWZ_yvTe^#xXUzClEfe2gqrmMbC1#R_yNg@PP@D16Z$2 zq(Y0j=I)i3x!jJBvXvl59|nS@X>WPCA?MEoH{hu@Ry0XVx#2&M;YL0<+;>4fD{P;p zJW=OoDgd1vH2dypFnjsf{kV#*m=Mi-3qZ z7jgt(#GW5(L6(b^s4F-h?(yIx*Q0V4?HT%U&{z4ywOp}$ZnN1kI&l3R8}1}QVlNsy zS62JGC6c0Wt>IWy)THS0WzfL!jb}feoDv~+#&-^cF#5KXzEwkgf;Y=H?PtRW!nW_;TGlYRRJ2X74!_DK3 zOvRVL%>CI)!$k~^6m%ovVBT(xbHd}S{eLM;=q))6=bA_j4LrvCegBX*8egD+1Hr(w zKl>!R$CV*Zs0LXHaAToONp{k2WzzmAP;oF+@~K8ABf*2P{{LzbQbOl?KUYNDX`mB* z{g{!zg`3SN>g#hc4bZ_4Qdn)Z>f_b`%x$<~IH_>9@}R6vm{Lz-DI%(^Be` z{}y?DS92UzNwHk&2C)L2HNJv^=O#2x;9LN_hH30vNt+Ts9=fXoyA01OaZ@KT!x+JLkPI zurD)2p_KFv^uk^23gXBbj+r5^W)(-`Ox&pD6!L-nOxy^vH1DP&WAF|C?_ z%d(gctE_I~W{J6k)=gOBQ;AH6^ufbUOBg9B!M#u7iuv_V%>UmWh9O1K!aCzYBYL7+ zB{o1NO?daqDPVfvItnG7w}P}&lSLRQQ@NjOrq5Vzqp>X6Z1PmfCguN`l$Dz_|F--T zDVT-{Tvx6L{;R_-$*cz~A*l~*OEpbOzR4G>D*e*I*oS6WV}maQ`<>FX1yz6fXUtMe zqpC4+pmB+d%nicllZ=jpY!TbL8~<@xc?HUu>$1TiKOtGo$Yldv03YKhyE41i8)^1r z*DLNxeV~JIZ`9*adLSRwD7w{;4RfAP9_)ie+S;;Ps*EFOz-n;&%l%#!BJz{G;cf!+ z^(N2T;o^ki;%bc_C=RkVe_OiZLX8ow(zKH0nZ|&0NP2%el2GKY5m9tHciGT$J%G`i zzmUo+|5$g#{7l+AgqooHEPjirhB>)~GIH(I{R*z7pB!pui^jYCuVs5edClq4;xBFyB zF)*`^a5bs+a-w}YjXAMOnAz;f=8w~8vQAAgZn3}tW!x@3y0mGwa6=^z8t}M%&59un zk(x?+a|`QkZ+_th6=TK6XAyx5_h)X9)|-8d8X&at$mAhm9=!WKc50M@ zc+F&HS8yN2N+}*_T0f}ry_|05C+rKY9dv>PJ)^smI0GwYn84*5_??7pVnPh@T5Rw@ z1!^rTKKuRfq`P>-TiPNIY$iB*9O5kbzhpUBr3ia1-|W^nxX3>ex!dIfGKu z$*B2J?`3)2ubH!h)_HoG5aFH%!~M=~{Fk4lsBGZ*5AZq%O(|A^6Cx2%=2r(qLk%oeu? zK*fWwnk$JWbYK{xxx-WS?Rp5WlzBrWm?v^FeaG{F*475+;HBeNDqgt0%&qF+p=N5%Y-P;ZX;P7*AVSy}gK*(17(0b@-BLU+PB4GZaDMy|Yze!6 zbLJ|j`X?gq?H3+Cj5ReerEqr(&mtWb*2!KZL%Wy%r(${j zuVP7*R%8~}Oscoieaq>;(Y?k4&n}df8klDY_YCcp33)Owq)~&yQuk1+-0a7Iqsw(C z>U11^-}=NuwpEv%-GD_9l3hPP_>4ZJ^FumK42z)|b%gMH+rRg3Khf_mF+@rI=hGOr z^hlY>Y!#FiUZNiL9tE(<4emPIp$8Cl{j9&dCzfQY(dQwt%p;EUgYH`etKpKH>Zgxp zb;gSA^^JR3Us&BTJ8bdiIQ3Ytzx({=jz#{^nfdE~uwTiQdF&gA>%?{zfahM+`jt6q zmRcIg6|mgHy47A1#`ikWP8EH*?v5Zh(T2+zuf@1_ll*4!2^vpbQr{emuLOz!J7lq2 zv4De30iTmvmSDw+P_Lro)+RNr!e)WSf(XJ^y^qnspa6rH+4-MBJO{1Tof}qe@32THZoU}+ zf$IfB+zin(*cgAw64Hv&F}9XvVy~%=Y|h#u7Uo_vR@6okUt5O88#RlOX#&ek3h5vb zj6dMf<$UNu0*0^%H_D*gH(dw+)kQG*3xzYbPL;8A#B*G)iR6`miI5q-kjJ6l&&wTP za1y|gLJ9qC{gWFyK60;xfyHNLM*=#o)KV+M0q z82^odPcrBEPe`znIylct1)%m-YZ9~EQONrhbHk2<;^sq>XsH~{0~YgwzB%K9zOB7> zb1rWY?N6T3sJH{!(^G&D@jm~tXPDl9NZTvo2dCQT7{&qc1lWj{Eg? zh7)L^9Fyz49!P(dT;6DjL%5L3{dZbk{^8jFW-Svt1FMDdiM7$V-#lF>Oj`lGH(9r6 zs+aDLHFrm`L_X~gJTcn6!N6gUd1=SsVN=9J0N1Qx{{SL!X+lvoy5{n-A*hJe`tLMW zelJ?;*??lzl41m8=|tY4Ioy}0`9 z7Ku19Vb2`6V`fx0d5a8fnUIjj9aXOMAsfj_h2rU_8}&PR#%#FPLlwq=26EJ&4Lm!kL!x4hzvYnz z50@^=lP`dj#ymyaVNbGYoIybkGEPSaxU(fY=A|+38wFfUO*YG!EL{>nvSGIAWs!De zxOb1XOZ8K;mxfpVdUqX%T@3tzpSxSaj4$t*@8UDOx%<7{+PAP9kYALJV>BCm;^Jt4 zd9IInZh%SjXmm-`gy3yIJizsKM{L=IaN8yjiHwo$`)w$di30um%wKyHG1s*rz}=g1 z%pSL8k=41@f;o*9^T(u+@JhZRl^S+%lTxx z8W+3l;UC|9RL+n-{#v3Ms{tvjK*3^~plYRTcA8+BzVrf?1+xgtV4k9LQ+4<*J}cw)kEm!A%nvNzWPDd57{(G1?%bZM2Aw87JpPQ z1%w~M;NV|a_Z-p#zUGSsT(|w80VhQ0A@5FmQ2CMS@`6(CAdw$4{fg9t4t&uJJ^N9E zw+%Y7l6V%D>QFDL&t<}~?VFb-j zdq>b*1^2BA?x6|}c~Izv2z)>QYS+00c>nxN`pvX`22^}RXj1^c_+^=X40c0sWf_qf zXY+S_z?B%`7a{f=!_)2dMWElOH|yKev)b5cc+gi4vJV?J_yI<&CeMMcYT2pSis9X zJr?Z>`Q9SWYN4fOD`0IIrJhB>&bSe+&kx~^iJDeK%2%#lGaafl)X@9D`IAw%-q@Kz z(jf@9kl9wLyrnZ8Q&0AsC!njalQ0a-zk%f!=A?c?Tr2q(Gc496W|_^hoqgs|1H%My z>nKPG%A1Ydqz}sbD_x`)Ia%MJOEe4?$b)W!e2u8j@q zajeG5J-`}zatOR`C3a90VW^W>eDM~3!X5fKPHGrNWKZ{K++#^t7Wb%&1}&3D43l!X z7U*7UjZb8cW(7+#_O17n;Rjhs&Hn*`RR5p2^T0$&JmejCHGZR}dZLFDuJDv@XNUc6 zoy8P(2OY6Us1)7r!=`IG;RmTx`Nh$r@JI;zZ$Q{i=z1INYAfyPZ(4qW55@w*IV(|@N)u$rGADdRnEBgYUfM74t94KRJBcU&ASpG>Bs_8!=g zHbfEdI)dS~F&T~T4y87BhH?kv>204@E-Yh`7HtU3a~XLFY#A15qTs7nAHC^4Y_*Kw zGlA42s_gE~M4lkfjpss4gq0N;Pt27S&uQ75>)`a(CGyNOI}UKf>5|G6-l$)%!s9W0 z4kG2-tX;VDDHIQwPV9DJ;H@wr!@=;gn2hqN?RhZH9HfC^SX?Z4#gO4+EizDG2ZIez%6$y*O7U#Vd~;lsxa2E+kr3% z@SiV~{xHI!xCFu;AKL#}P2(d{wlgSrt`7)l~ra{pZ)1{@wzW~HovjI|p|bbX&u*ZQHhOPHfvYCcoIWCeFmR?POxxw*BR~&wcBDRj0dZ z_o+I6^x4(jd+)VY^PHzo?+rj9!Q{SW`|0i~VCjnLg5{S}*Ie13&h~>SP3bgp{DS+V~!~PvGQhL z#lDwNu3sPeOMC$&6#O=IeLo|I`in$uu>s^VUgNRRGN!E4{z0L3lA9r2lZmMg3j(!a zQQV&+>%=c}z@Tv%jW}~BT(PuRmFV(~)LAt~3EC$2kGE#Mq0)xnmpz6;40*{Opx4-d zjN{aFm&b`N(O35kwp;Mm<$hpt2&^&&D6v^{_rXU79IJRu<*M>V!5BC`ET$`+?o6Gd z@W>w9iRMF|NuTHlAQM}u-^VFYoJ6p(2^r(2l~!9flx4${&J%Av?fF!QLQYREy*)i% z+{$Rz$Xpb*I_erq@~k?0Nyxhfu;{ziXs&|0+ix8LTk-#Xq%01Fz?-#UM1Dd(+)O*N zY@aN!?R58rJ32=<&+4!sTei^qLSk6Syufh#q@-3# z?JBW6TT2wt84!6`q0)*ad^_L|Wtu%k1&eGC&pcWW#hh9RMXIeo!tz4Kod8+Of;rcZ zUjps=7^T{qu8Ch*DhAutn2Z9u}F zGugp1@E!c;_|okS zT_!*A&W(sU5Mcvgcj0xR7=6BP8$FrFsn!cTSMx@D`h7^9*vHj(M2tZ(Q7Qy31FnCF zeb}j0-6>?LY2=7HUM-Mo5We184L(Lh$RgND6kLXSPGIK*K`Ri)!nUBd3=jeqZ06l9 zDo53kgA^dtoHcUvS@FI{tXTkUQRLkqbw!`SHK#RTLr4S54?2f?Y zlHWJ{2p7Voz_5B>V~&PJp<@q7PlzPA-*s2N`n-1Ldl7OWa0JZEzZ?2X`nY%J4T*fm z0ZU=;ljCi8jwuQ$A9QOK!Lgb2;z6u@xFiBe&g$+8S>AHc8`jSI!&j-%874cP75alyl?m90UQw7L9kqfK4b@deVlO8_#pGVXP~eHuVI9(u>)jp#732 zA*H{d>Mxc=t2WBao31+RiM{k@1~{epGOwuOG_T$!OV42SYe)yNwYf6(9;bK=Txw|o z@RY3a)F1Ld0wJ8*HocmuZk+%SsR1Hc1n0B6%>+&Mc{Q8V@_VlJ`pr^9&hdo{0IP{L zMyvl^FL*KpXuw=ANb>k{NH^g*bFKH~6fDu?-^2h|GI(7gs~r$&P)w=uuT&zr-{?U+ z_r)^Is4O+WrD#=BsxzXBpct(mC96@SQjg{+>SvIl<^k|RRr+4fr8|6EEdh(~>RFP0 z<|H@Z7LVQV|4x77-f&&gO5{Q!0f4@B3Wqm+>?R461Hjvd;z&n4)H?0)|2~ARR~H}D zx#ns2;~FkWGx&2l0(S;*U($c`rn{kJy>N)l%OUT5VSsi81qzC}@mt@LQh^G}G5h%d zRT5BzmB%Z~BA>vzh*&?T!FZ=T^!8VLvxR{}HwQ#Dka4T7o7zivP@VO+0~r7PBXtEu z-tG-~fnXTq#0r0b_&>{$xH|y$mj5l|S+g4Q3IebGG2s>$nydgqQ$6?_VfmTEvjtl% zDs>Z@FzR|O1~$-_sN#@8eL}A?716Zm$7nO0=>-phU_hMjJv15@a6yBRj?F1BiYKWJ zC-2YH-1CP5+>p?5R05f-fMSVaOuc(EM#EvhIbhuhF=D+*G97>)3esttqrrVP)S6ok zVAZ(cb=y!N72m+cg6b{$uJgTXN^JydNj3n)xLW@T3(>tS^q5lzQA>_z@vaB#dJcjpr)@JobTFdWI_}K+P zzVa!lhUz;@j}#V5&u|(D*!U1XaMwWS0lyjvHH@G3VWx2`GcGU5#t6e%5Gw%tZwD=a zp9m^(U#^~$F44&oryTD|@i1Q86_6g|&~M3^g?}ddvt4&ud%0P8<|y{(!)tyOO%;

k+C+B+rcG_f>tg-&Qq^YIN6@tkL9VQ7kZ>(jNL zf!{EvKMgNpl~f`JAWq#ovx<6WO}PMQ+^Q=wg7?+!%Err6%^H@9<-lpmj3w>e8t!Tn ziE{WX-HT*k%GZE4n^>N>d$;Dz+XlBD^_rh&n#NGuo=i2^*Zk&#_(>JFglCcApzvp{ zHe5^uCrUsN)1pvP;lpbREzBsdZ?&h!wDHEhjGh`*_x7)^&+K109fsjVAzT26VMbTB zZt2}7xh$08r92qOzZOYkPUL7@s1H5SUX=DG@Cp?vdrx`dg-kG{c9;iVFzcj1;k+Tu zaHx}R6f?s|62Qo2D_CRvd&S#wU$BQq?@@O%yM0~&qafFUlN8(e&W#A5nzndisn90J zj_yh~$esN!e1&Uy@v{bQzx4sqSnYwTVV#t&eRPQ?ehC|AonR;yVVoKd2R$=R9oAUt zGlwopoibk6IW*h?t~&Yl-pVn5L`d;$yN*Go^!QFH`~OL4T5RDBS4hu$-<#_w(|VH7 zSL6H3(xbYtxO$0)G1Q#QfM0|$7=E8P^iZPm-v}I#nr%ax=S%6@tPKLFF$vANu%@Zm zxC=!sd=eVUT_`^LpM~Z-IY_?;(-ZD{3Nm8iISnE7_1WeNj~*Hx-G-irstm%4&r>Fi za)J_#T;eD2h+H#3gG*lJ!uSUT4`yb5B5=badwhG`-+G92q@u8UJ%L@kB{6c_Qxl-S zi$&9FTu<&&2;4_(y1xLLJvePLq{=jW53AT7@j_4#5m|Q$U;c!0kaZmH6v=I|dw~If| zxf>rnMsGqYsY}9{HpbWoi`5m6(~Gm*Y>Zl;b$Hc|Bu(ph9^L^mQY99BwZ|`H;zFW5 zIESj{U>PEq#Hh8OoNdrB>j~TAKW9RIX3sSDw?*p$X^&9c9{4KJDz`W@^Zh9i`vhX|ju<7y$o zsZP@xMGYjArlrWf-G-H(#_c6h^Zl`IVGiP#~~ef`5%v;KMrN5LS0kMWM8}@0TNg39qm9+OHn8m$J*J zDGk7c4C?w<#o;fuuO{!+rQZ-zm&LZi`5jg5V`<5^ zFru#Chf|(Sg(Z5xxjpxWgDXq+7;H!EQOXz!n@M}L;sYZT&OXg5H7%!+x2RCmNUnl% zMO%HaHq;Qt0pon=<>K2mz|P(LFVEJ`hwEqJZZHmMIV}*@)um=_@f+c@kE*cA%%1?I zZM*Dx^ceX+1(~Q$?R&8iPn-y;%+cWkzw+^O!qZMGY2&a_4j=c<7xDXje(VbkR}k z)0FB~p*8Ypm31UPHt0vn*{}nCl-TN5|Ba+WN$97!UN_<)8TG9r1>B>5K)n(%8B89E zHBhbJK9T9FKcMW`NLM|K1XD|XBi(D#41Expy0OtoN*;{QBDXoa)^egH$7?I{SPM%h zgB2_G?RjO8dk$U&1X$z88qMB+$S)KbOFfx3}zV>7%m z=kBf1q3U+X&I~AM+;p8CLN1K$ClabhMau#(JS3(r# zEE*1Gp6g{XFH04>NF|B>Gk*`{KgC&wG#@_7{9W=v1K+XNln%88ctF)2CNVnFJ=Ti@ zZYAm9-tDpL*@<-E|Jw-cGOV?>21l@>LVlX?P{HV7+Cb`*So#Po2X%gioJ`gFD|6s& ze)0vmfepv}5u*)I?&f1No6|mSpMaeC>h& ze@I&lVWaq^dxqFidwnq2=B-J;FYtRC!Ke-_udPS*sWGvaehahh7!eK^lJH{rSL$(%jHM1#CD5dE)X?Nqr7KCM!@oZ zW9+!Z@H!G;iI)G=A@xtz&4(Qixoaklx~Hk=dro7yec!E#G?G39F*+8z6@`IX9=|di zv);jatx?viVzE9c*iIR9f2*xs&>~3 zKOZe>pV?JN&(8W`Z6lu8(9X>SuBkgCmTH;FYNGUuauDEEEH~x-91Vne))%r6R37qA zTO@N;t&L|%I`0-Ho=^0mX;WUJz165^D8yWeU={a3K_NgUFMu5|JX5`W$@MP1=h2ID z!Sex%*4n{A@z!M13=tmcf5Mo6J|_-C7fNNi$gLdTvsdLgsUV+tEqw9=I$VqOVcEtD-f4 zf&QibAdoA345V{t@rqienG6t{K}-myIofhz9r}G$8DBFY8lFsH>A%`RIpo~*v1e-OXepEg zS=u!JCmSt^Re6_2*8qO3zUH<#c4y#aC&5sGmRdqo?nA+$ih41Aic|pb<$NHQ>U%BR znz#|dI}eS^Mvqa%JLgKc5md}%oCzFC_90f^01h_gm6r5KrP=*vF*lxe|+Iv>@q6%D;y$UqYf?P53mKT&QxR9_~%&;;86XKOA_oXsqOw#+uc&z4FDW5LCu4OEijGFAR+JLT4hOI>csW|Z6Q-o-7tXP`4u)X0+ zg9^N<>B#nMD(RIc3e@O7+4Z=s3M%f{6>F5OWQWy9no@{b#NYzuD`<1!cAeo6sGRE={*5(r z#aY3li*bjNN3o~|NDAY;j4LCk%$a12{m5N2{Ki3*lgowD?VL@dX%4H2^WhM68jS-L z{5B$h)&(AY5%7?60$#AzjXAsf53OB{fRM2r;Jlg<7IA|&FxY#cQb+r)dND3Aw1u1j zc!o%>#miptQ8H&HutY@bxCk&#<5#?>hm6#F61uf|5^|a*pfb1fyz0)(P+ted9}Ycy zFUKAKr^9T1V>=*gwsoX^eV;0v;Ov?loWb9=l)JuI$RcPnQ2?4E9LCdz8%6perjo!H!&wliHp5fGK4erv_gl?qqqdz ziG#?B9jQklS~p=D-bMV2m^h@jzbQ|lwzOtv7R~9`iun(R)i5IGM)Sz|N-CI!`Pw-L zDm}20``>%IkmK$Y;0_^WlIp{U+o|C$E@oGj5>NppxRKip;{fSrkbyI zZFwu?)d=04uLZ=j3HBrvdIn%eW5^@)^=8I7_>tT&3*nADoId=kgpuYqB8oWyKyVNH z>1E+Z#B{EukY@;~al*N~vi+>s^}%!Kc{D=UIKza=&8Sch;iT5n<)P8zrP;oaAOCH; z#n*?5RQ74wzx2|N^xrQVS63!kt-GYz14;r6E?Rdjyg`Pjpcl5NpjHbfq>|23=K1jG zY;;NKBg#|Z6S{6u&-JBr8e7>G0Hld+9aHOq;{`e7NRIEmLkVZsUY0XT(jDqZ<*C={ zX$u^ld|mL_aCCGjqSxr~DHDgg7WNeLb_hxbBq^Lz1x zn`_?=W+gS~!}djg=3L#Bpncg_nWnME(!Gk&clkdeCYvvPhmsT#Mi&4XE%Xj$^}0A1 zx#f(uboes0G{zTmVA0}ublhk=kotMzld^DSrIezb6oEt(+jq6_PgwNSpnnCBCr>+S z!;3SG8x;>YH9TT=lv_oK3PLLI8x`5~GGemhhXq2t&f5Q&k{FQW=NG3;njp%>gOd7v zHYRtGo;c>72H!Ey1o8kalF_tv9U6Lu;k*4o$M~}@Rs|c%SS}*XnzSIqa}b}b943=` zk;pheVR{qwMfH6ifyHo)NBQTqBtKb+@|nyu<3gZH8A0IPMKk6hY=^HG4NwQzEeGmt zbOsvJWZ)gmHx!{Rv^aE9U`~eEw*M={Y014{*XzzanFa^M55uwy|-Y3Yf1bfGIPx$tm}YZi-wWq2P26*{OnD+_sT*Uwc}3E zFstZq*dg{$HlmiY3A-o1RBWS+zjT`mWhCtb-x+hLjFZ@AC4G=swuy2-9^F4-8aTWe z@(6(d@bVMI?P9F2?JM+VZdt}(jTwqN*;`}vfV}1A^BfCCg4xe3ZhoBTYShLlAy>?S z;a-*9SCrq%6e->WB(98}8e;L3mO^nU1h;8pSqdC3XI;L2vppAem502&wG(qDo_f)F zwrj|3jdU<=_9Ly-td&H$vKfPhs>ub#^O*&J+{KhQ_zt?XJvS%;xQ2Ts4;R78EXZ!2 zvnUqqY_a$Tt(+_E`qhWklg}Orf9O1 z3c{hveq#0v;RlccdoKZT=Rrhq&boqt;1|J;zZ|DpsbrPRqc!G~Gh$r5eBF|d0fKb? zv}sHW{o!^Pinsbxb}Tb!PCnM}h~FL7`(k+Q_eTpi zoGi(#yAU&iB%qlQ4nJSP(xr4G$eu-*;+VM+ngjjO$quC_$0r`y?m|6A=a!vDs+Lbwi?1=G*b>bIj`IA@sofEk<9 zaX9IG*6wD?${94{O>DK5L<_=FhNB!nnXOx7mL`<}OSK$CAkU~VnUe_fGM#H+l-5iN zmv!mPAX6?i#3JZL^R*b-Adm~P^GXh2Sl5P_9i0-0mp;(u6R#dpVRO74{Og}J%G8py ziiPa{zm)+%N&zh~4I_sV{TDx-jH_<_nw)<=I#{$<@Y}q3OE%d| zf`IUjdR?PV(^)GZ$z$E@rUm`$5HS)yPF<0P>;n-SI_F>dD6H*A4kW*3YsIV(Fh4>~z{J3DqKd2V8@KlpLC_QB9hFJyusIFDXCinmGUVmS1^6TF61I-uqvP23l z2|$FxVY^$Zj(K_JNB(;E{?!a1EWViKqDfAzaVxyG%1F`^W<&X-%D`2-p%98S!gsSc z+eD#O%|V5wSun=WKocS=;_c1|ZQ*kBTCuuGo3MmZ8-~)&6_41=*=uoGG3Ft@Bt_@W z_?#wOD$)RMem^#t!pGo59w!U2R$KchIphseGoJOZg~@c$qhWccnL!F*EMwgJb}ls{ zFz>6sq~bPQbH$o>USxeC3{@Hbq!P)dL{wP;)^gD&=RZ#k7Ht${eTt80w3jZJj7tm( zZua%Kd9q+i$oyl4n&mcu{P$7XeD-{EJTFTuJ%gRMMSnV{+TK~YMZ>pcbj>`!w(*36 zRKhIvG~vnrwZUley1oS)XpRybzaq>?5!5d!_UwXw4MR3Sn15p@6n?=R*CVh( zBaP2IL27P2_PV_w4moj(qE+(SYkm^swhlW@?kc*>IHhV((->*FTv}y$njKu_*JYu0 zw`|}=MBs)>u@Y3QZ>kB#Q`rDn@9Tc`3j@}!;kg1374`%f)|(0%Z~aC>Etxk1MpQus z(`Q1kesq0Odmsy-s5%cWGUdZStdWu7wANL?)-6~74J@(WI$VaBUVpBan4I62|Bz{Z zT5c;s)$C-n|H6=b+GB|`lm!-M*)^V;U_Gj_7j+Fy!BU0q-qmSx0Is>0_wT$BhNo?u zrH?rViELEMu$yW35^L#tWk|@ybMZ{GcqQMLc|X$0Qnk{f z)>1Z%JdFAOZG*pTk|k)RQB$xb42f2Vgt*~BlIMt^91}so+XmS{sRoE9XP%MCaVZ2V zz##dd&6(eA8jc-lfcLqeKY}*lx3$bRBN{Ga*CHCK(5p>`SyVLE(ic)VDDcxcLaPvM zJ4FEKmqly&JW*<02c(20)o}D>w4$>(SwPFY4oW9{B1gGL8~el z7(E>CNk#c^Tr{j4@U7#$JH8i3oMYC;@w)|ZS(_T zH*haQhwwRM88hqHR65N9dRSWxI|sgMx-rlIw;2sTr-r&P9t~n42p33 z;47UP{|IH#7tryeR1FqwmBu@>u~6iAnAPqvox2~t)c&b)>g(;=^h1^#d6NMggjays znM6TW5F=sWjw6-yZwn_gxdp)O6EoX*<^|NH*!I!Urw>bSaax_UJd@j9MLGVyWfUh^ zNgv;!vYoeU_0s2QJT$E>t;sPdJ$T>OI7g>EWQ}OdraWxi*?GPdFJvmG-LTJcd;Wmd zw3NTFWiSf-xZ!r}ggJ?1GCBduC>h#^27jfR?xkl@)M8w#@U=ibK?L#Oh4eEcyc`$H zgc10f=8d=|T4S%m+#Y&0Mt+kXVuXAe%WR_DN#9mlayK$_0#VWT}bXA=se%MuN(< zTZbSLX@QSTzx0l9$|iJ4-NcEc^^m1ju8{|w2$B|kP)M)>1(s+;jB$9H(fC)wiqL(d<9 zwB2rFhm2-Ac@Er_g^}LsZcM?-Fe=d+w9s;#O!iD*#AZp?I@JSx_lc=1Cm;HgwTjRH zxCyVCL>4Py0TU6X8nC2L{yns0Ta41lq9Nja4B2|Q^-WtNl#KYY=2rfz;4nLf)ET$2oj&lx!aIp5;{GoXRZ>}}?q3uWBD1aQxgbIx|Rnd5d( zrr?pfkdGK%E4X_lw`6`kF8iJ*ZfO@w{QiXa(c~`-c=u>wy>mTc=^52M!psDI(&EN7 z_euDZibZ;!p<#+A^>Nt3XujnZ!norzSX6mHU~j(V0ZBg!0YN{iD-6q`F%xKO_}?~( z-bmyE{-0sM|BPQW=7DR?nAH25u{6LdV3a-zr4xeP?DOiVV!Y!wuM)lgiH_4J63{!d ztkFHYH_0)oT}4Go}o8Zq0V6uKj zbS6^agkY}MR_dS(8a!D z@<1peJ18!)W7_W2lIizA><4ubFs;r;%%D9M<(Sd;uQE8(5S61IbCzTYoy?e!6m)q# zv0yk6bP@iR>iY=BSH=}%Dk+h*N4G<7;APF&CLKm>H#dI zGNomcPmXbZ{r40@Cu}eYH`%0Vf_g7N=VJ7d0Xs0=yo!S$7usM%B%t#rk*r|K5koQ< z>(D5($bI>vGHlBN&-w9C!5l0lJtO>649_$5rmIP>Z@sj3N|%EsgIuTom^OtT7@GBd ztq=sRQHlFjQuh{K*3(LVHNy?Cu%v!xk41<=bY}czedM5FA3T|YD}3J%?1Ct&z)HZ6 zj$8~QdVMnI5Rhjn!QZD;O&2#%09MO@SHrwO+MoOIne z{HKeM!lNQc2+h=M}AepKecij9y@i{9|$PYhqi8Y5Bi?` zbznPh2V+u$1#Hhl@#(>wW8zwq2n9wKb=+1D2MlwmKmKZyf2rkoIIr9$q}gb^?aa;(OA36ZOm=4xCSRb2=x zBfDx(1=32h8xc@&Yz^R4sC_2_889+YGCtdf2Ok*L(2gzz+FB~Ug0Xs8xTo);IsPM% zjy{2}C*NE&NAehZa1VU)OS~d`pKmZNY6wNvn^mzqJx9u}NFIS-M$h%7nNnY`{}zNa zAT5gWF=A(Ayw_F*YZh4aD)oeQVT_QtEOqbZU&}TA8VD#K2Mb_@veLO2or})CLLv#D zpH|g!0^z)AN-CqBj@jV?tJzG^;u5*wR|#{rC;JwaOy-y>>|3|~a${30(KDtht4?pJ z)2SmVC*7_@D%1XR?F^W$n{M{t2@$cFoRu(mFFAIqG)5jaTylQR2DK{3F%YN`xInwS zA;htNv=P&%vp*oeZl`Aaf(}(SB-s)M$W4whgddVPV|mb0Gs!q(m<@1H=E~vPx@pc| z%5M^ID_Aqx5He1P{Cc~)mUCGN`h{238m(;GVe&X%CNB7!)&iVl(nJt9%lE$>lnnaT!LAJ) zWFw3Z7sxb2-j9Vz38qyyHBcUnlhXrYBHYqB9Mx}$<(7+7-3UIGG&_-_dU>uN+~`WD zg+=@!Usl$#Q^AUQ9;qnvu3A|@KIT7oD!JCc_BP_V?LIzRH+Gi z%C)@5UEZ4h>HFT@nAN8KOtp56* zRDgVWbLNalCX_7+p@K^-&|RQ(Mj2_(?Ol#I|T@7J$HgSZ;-#5ZVMBkuXu!L4%NaG&(gsn2=uF zvB@NSqH-CDOjs+Bunw)9Vk~V?a(x0NvOR<$xxY;;o&>{oHOiDvGc~u3%w5T4X{5VYI`mL7uEe|-qf z;sRbpQT8}7SJ(jq)qode{gD4YDSN8J(eBrGd__D62)a2$xB0thiE!4k&{s7a(rca^ z+zhmdl?QP7% z0zkC8{O=lv(29N9B{JzGLA=dESXC;7f5enJ?sMbu4`R=v-s`w*OM@cpT}GfBz-qH} zxIjmB+5zb)E8st!8w_LoD4nhs=#qx$eRU^14S59mlX+P55m`!2-ncFU-E($rJd|)q z3;TJisA2F7B>yigf2<8%ei$edzg@sqt-Qzbo2xK8 zu8{EQK{ExCHIImXx|)r+9jTPUHj{Ll2c1Pt9b7p_G5LZ1iM3{d{Gl1!ttw>}#?I{K zK;dr+?#lt#(5b1?5YElKlF!U6wENs>_2gG3|AmdI&suwem$RiQfc(yNylfG70H>M% zHx=&w5yk4XqxmUpcQW}N=C-5MAY(Ts%ndoywz1=@GzDw|Wp@QDMShE5vL6!5yQZ-i zU%E(Zx`D3-fB^e2>KZr%==B@@E8Ul)`t>gr;f!xIYHH6ItngI0L8Qve_Hvh zZcC0vWbb;P%}ADfS*~^{*tyX2x+)sK)1vSQ(ct_dskUk}`Uj0Iya7y>TWz%>I6I^W z|0gYuM$pHyUIe%<8$75s6ap*ct;0GOQtkhGeC#e5K*dV%&l^jnAyPiLYw$!6(fAlu z{|IYcd}^{&^sDyo0En~gJlIkW*BOISki$Z7jo*Z>HO|j7WS_} ztx!}W>|fnrfuTu+-dugC+l$!uj?ROk_^3kh*On~<{M{Y2-5s9V1EVbZvlo#7j-%b5 zD_tg90oX=gOWZg|Wy<&_p42p)Xip9y#43l7#Y%Z3+6=%4uLNbGaD0}gpPVs9hMq19 znwp0a4cpy1d-UH8Slk>xC6>yc5=*;@1fn;|=-%y-m`6Qxq#+J|cpiD~K&99rCTT!` ztl8*jHuzl6cPWS8~1}zt>ra)vxk79)-Vp zAyxdZjNnj?r(&n5AT@?$Nk1fobFzryRS1is$uOOX%kj5H2;^6&Woul3L*3x0wdUXP zJi!Kg7f`{AF{x1-|DSvq8CQ1XPH)xxoKBZ>(chhQ1jma5-UMuFl0TUwEKyV6iq?@P z03MDBMJ~nA*0+O#)0nLn!PvL0Acwf|mN4alEwUC*pU$eta=feloA#p1Mun=&>vSjn!<)kkT5Nr zlebFmMYUb)9sHWtxA`yLyHPFINO0Rlz-0DGt)S!o;|Fqmja)k!ZtM#!vF$7iPU4ly z!54tJ%Ru5`>2S?(RQD{;_+JZC*kJP5@V*{Ej#CQm_}*=Q3TYG zd1W#Ox|PkLSaKNS~g zaNp}-?w8bakN>7R0RN>Omp`qrUDi?CDBbWju%-fWXy@VIP_JW}kyG==%4!|^dQcd4 z-&zPRTh-p%;aoTnx)Aw69xfoV-RAq#*M=p!tl?$3T5Xr-7CwjhR`F~ zP&K7kvOu>l^KzS3vwi?~K0ryRwa%wECMqJ5b-hHx6&zqH#>0UkA3@oiTX`{C-h5@+ z>_r!mJ|V^UO|$L=?9c9f6-P~o$RM6sWtZ+?6Pb8~7n8OX)?hHkH$rZG52Kx0@*5NB!_lZfK=Avdy zNl@CQf)e1jW5GXWZpZZX)uB~iEDm`#m~`T}-sj#TA{z`%xxU(AK_tr)NNA8O3yWf2 z_WSs==a!#ur`jE+$L}h%ygtAM$A;i8dN*3}ZKpe~L)p6&i0ey={C6A*s)G?40jqsQ zPs{hjZltYZGmzdU32KHcMg2TQedowkrP0v!Hyfa#V=&8v?HV;qduwC(sk8F8T}4r zN>zTj5_fFDO@2tX$A)JPbNLNSuj&o5JhUL{D*y!ryslbX&nr}*{#<0c*egMKp%Pkr zNEx7~*y8YTnRR(dSW)oD-yVAc$9!FjoBBp$YNG5RjF40n?$EW^4pZ!nFL-{6Fa2Uo`!9th8f6b!j0{j5Q zcVhX_UVnZ1gGEf*gUTfcv3hC>j@!YY>2lKkXq6PaoDy~Ykp7~NxUXfD2!|T}VsgnF`1~3BFJ=o60C21i9mzAtKB1lQ0G*iZ4nq-+L*<@)T)##%|E22b zg!Jm=*&Al-Ag-f**LDjZck8;RlN6LRno^Q9I%SL1y29jGw=49LTlEcf&U7hs&cDao z&^o_$;^1^*ZQ2&(W$SA6+#j;pz$sQ-pEsJB0aaA56^!t8Ve~{|Dk%eKu*!g1{7X57 z*qU?+%hAlyW7d7>bb+nC$~t?IF={r1x$;yxH(8_W5d^2db)QuIvJ`hiGsQRE|7Z!> zZuYiUyh1K}FCpIL0aS6LblaXdHh2z`VnGUI@fGv0Y;)Kr*+4mMd{==`x(wtu$wMHy znUSb*oBwAot9fr=6BIUJ$#WCJgrLXXJmjMz)NO(`hgH^iRA!HfEBAk=`%&?QczC!U z#l%Dy+h_)kZWfve1=$t}rNaLy571}Svfa%jiw*rb;4TLB4div$L2H449kWGVn4l(M zLSHy3L%|azC2@^17Jva}`$=8CVbCe*yPJ{|#_jox z-;H|l*}@5eu8Y|`g(S$Vt&piJ5N@j_+~2uJURrJw^$bUglRBwU2&9H6v$f|7D@{R> zdc38YQJ=e=T$3~+E6(8uR4*jar~%!miV#??EEs-(0$(Z?>>zDd92{Msbw;qtHu_K}^W|BtJ;3X7{tqjhn2cXubayAy&t!HWtfd7B@SC~x4`HCRbZFwl|XVXm*l zF-hO5QUtLQbPbXp~$z9nVqC}Ct?{{HaK7RDof2a=SPTxo-0D~4|va^p{r6T zKM(aQcR#Ua`e1x8ax>Wj@i)V0x8pL0KV=T*Wf$FIbxCC7xAy#tqq!pKXtA{=ua0SF`3zl<-vieMn-hRy_P^NWiV{k?_;sE&$ttU ztI&0s{tnBG2+99>>75qyj>hz)L!dIBw-N(KGEg3JhoTq`yDTI{^maauY&1NMRHT#V z@`-`S`5JGl$0vn+dT=+NFh6IeM%%H5Z+tEWmfU#KV%W1WKeH_45V`eqfzT#(6T3Nf zptnAV0vK#N(C=61ZpvH>0mK6+i@c1CBsxNrp}P*1$qy3M4zK5nAjX&^L^T>|=ij=0 z_Y2x%SQtxBLGe%qWxn}8-lR+ z$D8w2+psQ0s?THVd*ikKa(bpkWZ_(#HY*=b=jX4HpdZWyNDt0tq7qL6f;&)vosLr#ad z(iq&ORm-BQU+(as`ZD`znCqKX^F@*lNb1w zu`oHMaC~Uqq5oe(3*LQ76Z}3r39skvNc(#c_iFR-tgx6fu=C73_z5?97v2id7X#t= z1mB}z6`GYaScD>-zPhl)qX3&;SzINUaELibC|h{P>83lXsjB76Tf<>=hjBJW5zjoS{v^uvzV)2CS^ z=~n9DkP7X#M8IrDp`0yoy^F)OxAD)a>2vr@v3g-re3JPtpf@GRd=g; z=PPwxC6)^P2?k3ZW+0iIG==@D0$-2s$-@xJ9SfLYyR4>@JCSutPzit3J z^=G+p>3v|&jAX*4J@c zblj4)BcFsIc(fre`?~OPpmw0?DezHdnMBk0A(-IrU#28+2rQ6n{qr`uQq_;6=;m!= z?K;Q39x~K7*5A>D1l8OjIw}IZ%(qvj>t(|N!RgY}65X(h;O!Ov@al37#$u*sFTy7u zJX43+EFE$j48KYZ4r1I*ZW{ z`(+M17g3AQ$M5cS;D7Dwpz&N38-4d*@Z|6$9IoE>cP8i`@XsyTHf+X-u035~xm+!Z zolHQPLRccMDW?x4VkiHSae*lEI={auEf1XEFUI0aM5|u$2PFX4j8Fg+o zBDg9sr{PLx=mnn`9#5VgsX4kE;H_6=xZ;oBLf0>ShJ%)xv z{eeg?NCGd*KaKON9PgSkk)X~jk|{@)sAtNER;D;jAUMTyfOn_pbUHji^HyR+f{C13vku>3ER(-cgCSyN6lUG>4S1ehobU9qfO0-fFlSa1%|h1S-7@mW zOXOce@CH~s&hpWof11Vzf3mfib<&o5$W1hL0j@``Q{Sy?Mekh6E*_3E zMjN%+M+pQSfD3~n?=wSzhD4Y3^W8pyR82{ZG#MMi0k&wM7Zp%D$@9hKA2P%C2$Yt zI2Vc_9~OI_^%AT4skVX<3Rf-8P$%UUmqF?gTy;-!wSQlu(&}0YnV}UAux%$(Blip^7KbKKEFO?ek9)% zrP?p~4xC^8!QzS48UCLy6iighkVN+8ljf0 zqVFIE=0MfJ*vE9o9`uuE)X|{$kXngYADv?iMCYg694HXQpPR}K{;iIOBNZ;0$dw7k z(2fbAlEnvZOzt`mTza6&qOdE0dpK%guCgiGf6?{-ts!6#ygIsya z(=i3X5B6qlDH7B^W7bjX5(qkHdPRFYyov9ZFg=l0y~oNzReC9VdC0%Obk{^Lw+EgB zhRvw;PNv7%?V3A+@2a9h{UD`Nn8-(!)}HxpV>glN*Pjuv|GV|>i!7X{_6Jr#j%9;* z0D{tw!=|CMo$O1;%lF$>3O_MrwJX2oG?amkjgPrd>Rv6|1byzuZy~}Ldcj?W5u9up z3=x!Sq#$0BMGgU0tt>!NxFNXVcl&)}`&ZYg;`CR@DwDlwo7`2CkTL}$QFA>t;KwzR zQb^4r*ipqOiA$HLhsu1qo&#xqQ&wQEpt0$??e@U^+Z5R2;iYM5Y7! zsWXy{kKWw`Gon+&VU=&c;9OKGjNkI;i$9)r-7GS=(iHne0UwB%Li(Hn1KFTUrYs?F zS7ri+A5JKsngJFZg{;yKZ_7=Jl9L!ryI_TH?BkFQlGcMz>TVdDap&bJtNp)4VyPeA z=}d!@nt#*f2f8k~NO$SfYwY}oH462_qdc4QF*0^v5YQF}G+s`6-Z({x+HKC4N!o+$ zqJAdC2p`*Poel3r1%{!0xf1rQ8k=tZ@P}E`(5X39DHs@uu5A^i3xxp!4NgOWJ!=CSfCs8B6oF!sDIKWY_j)TKc_fJRS05ao`|Gcx1<}m zFVXXlMg*`s>2nqNr?i=zmlcE93>fdCCg1K6n_o+Lk>|xDN~bJ2aa&o6B$Ed;4{B48 zSX;#8F*Y~~6CXWX)J+FJY|?XGx11C_knvo56C^`0EtWWN)tTIp;ep|5bH;?3oKxk3 zpvUuj{r1&z|Gli@$IoS+7?^&KZ(55`10^wank|-VxKg;IR4Pz!-7Vqgs5hf`<4=0Z zIlXI08CF>Q_`Pjc0iO=O_JMtFYK)ZqJfNnTE2d10< z`sE|C)mO6^xaa9pvH2y~c0fJ!mX9SDE#mp%K3ZHCW%7iIctn_0&A~)`l^}pN!^z3A z&*eOTldYv>VdhKGfvySA#zf#{>)-Uve56OVS=8n-qngwq=!ArQ$hii!?3n zUs7L@a^Y@L`&#nSLaaK3V)>p*%iQs`(a2OC;Keex!g_AD8vfL4nzQL7<+77u3#cBp z#K3DYQ)IaEqe4$v~i(^VKjMu!Me6DQ2Y5#CqIc;v>(5^H+{vf2hMcilA-^tet+-4c+Uo3^Cj6wjUU! z(o@;&hlz)vqJw$&ZI2~lf$NQHaVP3n*NMIi)>0T*5_c6=%wx8Pyi ztoQzswxMsQ9%3fK8B;t{tM|D{F7&G$IGK;Lwxp@T*6EV@aMgokT0zz?f4x! z1^Y^8XeA$BWV0v#HxdJZiw~y=YtH;#^**td7^}VGgu3|)|mk#@^*<~PY zha7`l$u4UAr%HiyapmB>xKNdV?tC&BGDnB?^_R_YNoqgIx%fdJuVzWpXXfGolmNK2 zJvxtjq=7hw?ICnb;J~c|tT=#6K;;A*90~^)Y;wH#B$JEF>U7YWu}B*q#Of3j5o)+a zMWxdmI*iNa|3Z6kAKZE;EZ1aK-eoWs@Rb@3qRspRw=`C(l9|+%Nhg={>u1fRB~9B| ziJHpdA%82)c~UK=kk8&*P^5 z^*unGbl=vRWD=X&RD9=_3PwvU z;LudEoM%HhYp6}7Tz#R+lf2=5D%dUng$Z4j>fsDhwoA9xQC(a*tu4`~8O9)NZ2OYZ zo>uM_v4I?VoTgAv(mahZ#Y+UY@t=DEn-}JDV9%3j)QA|A7$SpO2SPkfbS@Yp>~@Dk z)iSiPK2=`ISqDiYRvrZ}y%-UoTMjRkj@M@)m9Wesdmt)2(X_nVi!l8Co@JzYFC~jXzA>BEB&U zdqwsF_9R)Ca;8QrYx8`t-Ty);Oc}E73lPwUoue(ee^x#z-N|#c{1ggQEMxo2ANztq z;<3ofKMjY!abqn1grjQv_i9(tg&Mz>I5YS}R>XpDR4+4Mz)CrxZBVsQPFl;Sh`*d< zXzzR@1Wgg?V*b{qvxUj<(v=27VMV!Q(-!*6mET%&TQj?>V>YsRq#?o1^yJ^9=WQ}J zg6{;A>kaO8gvUTAZp!9kH)Zzuw`bN!FZ^t1>`2yF=1!kPHi)#)Fb=0(%t@!Tpz4>s zi>{M!`><$J3#&#MwQ}6cQ1ys0x0-sH#NB#UxT4^eD+yFg3h_ZZ70s%D<4%DHBVn4A0n*j!m+Gi@MLhI8 ze#}56)z)d$eCPSg);aPAW7+(XeyI|s2KJ5}vRa}#)q_5YKO|JJ21NRiT($_k_2H)sFkb6XZ1RRBX zMwP}L^rZl+TKwCC&F#$a?xgByR}d4ZmfNSEcpPDS$|~5KPSz#m-?ne`D+;aC zG1+Xwt)L4rZVoiYOyp6FicZel0`|((=_LMKdGmxXGfWy1pNe#w@5%+dG)VZ9%)Fv0 z2qPNxUBvp(d=b8ZP&V4ABH$@Yjg7>P(#wH=k<8I6fE^EC1Dzltoqq-xAv@Xb(d!<* zc3`uLt~AJ1-CmF>8L2JzV`rM4^}0nZYxIi6V6I(!X+{kVWny8hdRm%mrmbs0Lecr7 zf{xd*2QMrs%@L(lVQO?sQhpvQvFlAi0dN6f<`^{Ah*9=lRXh8*sch(2KLX( zUj^3m7>==IQY*4AL_K$RasuCgeJMNYrH!LtN6#qtrayRO>wUr0hP-xND7grBoUEmR z*t!t1-4zM-8W(;7j>6zJeiuJ*4YCEu9-$X2*G3xwnM{}9kr7cv*2?K{DsDx?c1Ywz z0JOFJ1}dW2qa!KwVVZ&dj?mdPUO{3%=(fVbYS<^Hbc34wzAubylY0T~he{pvSRh1! z+rdp0dyfIWJ#A&fm%L27ul9doY}ZfEkchn)lES|np|-x+U|GdE>8s(Q1oC9#rNI@7 zx8&y*&5+Km{tCg4=k>bV?=Z+i6dQyrxzLU)XzNVKN3!|tr*~kceGuG2^&gv0RBecf zAp^&)HvMRp(u}@CymFD~PR+Q*v=P~xzX#2(;&vR&RPgisuFZ2wP+MGw*YktPBA6oK1)v%0e z8F;)WFS5FoQp{~N;^RM`6HvGD9RK7E)o&QDFp-@|C;bkPgidmB2&ou;*WOO6i}H5$ z%$tTzF-Mzjdk_1ugc(6_ZJKl1la0wV@FK$>FCEJ-;h;Mo{WMbPs2MBeBMZG5gpS=< z3c49&E8ugX?5IIL{P{`BV~1>p`1{oQ3vC^1jJ*9e{blZJ!YN8prb~X|gAoP$s{UCU zp;*Zh?Aai|=Dxqd9(ctnNy2F136NkTC=Z<>lkso2k083DV zLM^Ph-z1t_JtE`;R7L)&q6bLonCW?f59(TMvKp z1*lS>E2}U7FUfcgvD4c~JxwHMb>;*=z4@;hcCvAWSzJJM=Lm;$V&(gW2!oKXP9+j4 zBM$>dDLxJt>?&#Q2a|AtDEs>-P%Yk!8?KtwKc$*uDvfM$D9Zsgty3Zi}umLWIyk$9BNuDDi7V{D6n>zpF50 zkB^2^Hcmu0X*W5GG#2o--&Jb*ac@%39mg!$2TH8%Z1J*2K>)Aoa=9-0Z%!`X?0KWR z{(nMJyZo*u;Qju+hP38(?f4kN=n(hH+WF0>A;F-7shau_FFMSzJs_pU5b874$J&!_ z_K5S!ge~xR?3viRvr(Ice!AOnZf_#3c}*|g@2tZ1W%+IoXCvyH2RF73wPQ;o9oynU ze~=&@+uY>=&{RDXAR^6a+PD2W0{%m!raZ$h61e&J%2AsLtEQ|Xhl4GYM_?m8eS(>g z5ye1POdUQVE*)DbR)*2Q;IO`G=hw4*XE{sN>^UQD9?kX)U$z3r^?EQCK@UORV8l^T zLywyMQ_xhc$AW+Zl-6fEBlQ;xuh3i)_(8)2$5}#q^}G8a;v7vhetjg} zPEa05rqO;eD!6q84ZoyV5ma=U3yG)!$tW;T%TM{OsneoPbKp`Ea}_en577)J`9|Pk zt&eb*b=!`gM>6T#5xH$C%{)QJd7{U_*+1RuxhQwjVgXp;=+o`opQR=>O{zPGf(7sK zQn-Q8?zhGYK2-49_kOBXE&6N{#8jaYO(zshAy&=&y`vzXUSt-m6;eO8E3G;R?*hFe z+$8sd)N~YRu9ko8j1I!YCx`(0tgIS{gE5Ga-?AYqPtPrebh1>Qt!!hy$rQAS!~^{J;C)})d>dsA*} zNUZKAid@L|()**LG?uWq>ss3`A#L#WzOuWUqFA7CONU|~qIya-@@Sb4u*yuLP`ecS zwS!}}JoJ>&y+v+xK$_VGj0~=(JCxB|Wd2)f*J3NUXnR3` zy&n5IiwVr|y_U;DgMv#E&=59&`ZTLU$ghjdiMbES{G6>@Kr(Gz!@};H$r&-({{0^i zM`%E>yXKC5YG`C1?j4qSDTJyV`qyrB;_lx`H=L8}gU&lv+Gr?(BqNM!B04Yb0r zs>CEb7joKPzM}U_z6I}rzM1|ZetADXcqFs>$JGQ>Tc6NdEN~PHRMLyA1_bipKg^!g zXUQw`k8JCw>QF><_J;Tk9;5p(N^6NWlUsNpaGDvRO zp%B{iWe)bZm`zuV6ydn;*6OH%JFAGmMaf7UID&f8z@N%)^?kkJ&JjC>d|^Z$=OV<` zfW3*3if8U**EQo^fRHXXF9hja7je6e z(>8z1pSQBX4ZS*#(D;7ZJnb33bMT@IPJn-DTSy-_9^dYkT_$VFS<4MP8!*?Z$JQn3 z=|t0kZ$5Qfp4&ihajcH?pU%0aOSvOS!j5+echomcUIhP1;qVSuQ6vyY{Z8RlJ(l-% z4~g%C>Mc-Hkd6^FhDpPuXItV{7+)ytU&T<^Td&9V&buZ<$+A?QBRT)8-XPwoNo$Rn>&~V|2{WVXoCC7>)9kE1jR<@Grr`BrsHKQ3dJ2yfQgZhuP zb^&!Ekr@nyG8;VcigL`xfF^O*0IW=deON&qGYvpk$lk<01X)JYy7aaE5lPon&+Q{K zaGqECBeWUTMWy9~srw@gJA?*^J)(w5;#ZJf?curz4_D4%$d3W8&hlV&t*Gn+I_X3k zJ>Gon?6}wkE%?>=2s5S9?>RolG@N}=G1>}Iv7eURxlKcdJz4j=KnwH;nKjO0&)?Ysbyv89u{s38DV$k0{7fbW z3Qx~w)LIw6oZgvqDQmjlx<0=Xl?=vCIRz%?jm($1i`YEV=Pd2>2`|Jaf@woOv5ss} zgFj&hi^}ZhkTg>6KO#$k?Xf|A(Jc@`;1xnSDmk5REas^Tyq``??Ps#KR7TU5{{p5_ ziI1}LseY{3dU-SsC?#&_fYzhM%7q03RE`@iHf=r?dNhuLH!on@tI zRo8p>!^%Q;BbT5uPVc?;PsU1KKJ*M)SC6k_nN>L?RA4W+&b7nRRrN3OAv#_mQzabN z{EL!w8tJM`4Y*i!r$8~IM?J|7pE;UG+q7%7e9%}m{k$V0+Dv~@UtD6{{0;|piUrFA zm7h`}4H|WJq}K~W-Fw-u$WC?w&%$GWMUq*A(FB?n7biPaV`PwRn<*96>fM;nnQ86b zr|Lh6h)B>4_EDPqk{!mu;hR6k&s&dNjqaZtugJv>!>8V-r@-0v^@!2m*Gy-ylD>Ho zH*YZHnO=EANG_7KnE%-{>u?g^S5tPwoI32B3S8S$I{v1{dgfp{b-F(Xa6GfhHTh|z zjCQ0J`;yYO$(hPQd9`>{s>sF8%RS#Pc}Jo*#=eFbtn0Y7Q7@rmaf1BAi&snz9g4ZZ zCJH~C8IJn=34rQ(8KMHhJ#uBQ)DR9-jx#iHNJ70pR6I+~kgAer(MLv`h?}tKn9}}b zpA@)PziGxzBiPoY78D-qr007YJuBjJoFhNQ+;5E~D%gvoERL06IDO)p_v38Z0j+!7 zn(atS)aY1*M`$e`$<81OV+PdRBR}#B?&}ND6X5dmJGZ#rlk7ro!-AY=r_tq>{7Wb{V3qLoNI%mxNVUt_Wq6 zRMAibhxwD#KefG7i8vMN+wG3%)g%>W(DTm0r;#=$9>M-@hC4&~JxXv2)A1wdb{z0e zPM1A37<)F8eOqgvZT{nFHu$!dw_W&q&k>^^p)e40Pzc!^Ws=a0ESE!>Q`jou0j9wM zk_kPJga(;yuqG6HR5yw-%oZy1mPP2p0?tnSvK-a5D{{?=c;BEaeD*{w+SmkUGi9A6 z-PGmBPN&O{QEq{=3#M|;wh0HeIgbE>0eQF9?U{&vTrTBJWG8&pcq2JnP@Ve%uIZ}w zj=B=-G(_(J7#eRg7yM^IZ@Jn6GIb1w_IqlMMG^}nrX?H#7Z%4&iCiKvf-a4Ga2!iR zUxMDG3az=Fk`GVu?J!OSF`WVtNfGq^vyH`eNQ5QVJEq!=#Hcqgt z>Obx~dpGKk^HJCCGVI4eWnz)3DiCsUtJ#)1DXA50xL>QgklC(VdW#E&an!XkA4u;b z3C6a>)mT+ooXB;xirk@koQ!R6cX6FCOQ@un&IH)OY!VJq?XM>-yXbcvndy@mMYGu# zwk9KRA%CwFYbuv3T?m5gJOF$N1(hKeD`hQ(KF@OqehBCgiS6Dk`1b4Jn}CEVJ#t)2ApI2M-z@YfEvnT8Fr9;!;Hy|enw6wHVx_;i|fWV60IrfKtuqBU?wTnhd%ML z52yv8M?s|`zx%%h%$*IRaOgt$w{t8qlx=xOWsMg(x~7+sc#Z=~j1h3-2W2{Q2qtfP z%zNp-Jk;<#Kl9UtI+kHw1K+N6Z{`n{dKk2qro5J&P4jtQiM6#iN$Ubmx9YMDU&Se$mHwhR zg`4JTStse}$VY>5X9B!)mcMTGh}C)GtRewEQXa6Q1+qXy8)r{E@zKu>yBg{-(lAk( zA2k)jR+umiWgQG_Ejt!&l5b*R|H1;0biq$0;m82UQ95K&~_LL5fQ?SX@X zQ>CHngoQ#skKN0twDAlT9qIvtlE?%vhvkZJe*ah!9WS|b4FB3vcz_qOXUDGgN2lGD zaKg);qsCS>_M+y+mF_ACAaM*HhSMOqb+e@P9;0?+&Dp{4l?JH zhSSen<|zT5uil(vPE~?}-+l{1Y3AWLL;h%v4r%8Mk$Q4GS9E9*3oq*B)@yb`vt#KE~FyYOu$hs z{67H7tp}@(oq95w%*(TJka;M}I}!JHw?^oBc{g{Pje!|?S*8Qp0ZK-op+wv+0M= zNyT~+Jys;Vh9Wf!;XWM5v;4j>o^Q9=t&9mQ-=~xfTj?480P~@1cAj-7k{M3YMIR*) zXb(yFBTV9Xe@#9ZOV@l>+)EWz)y?-UoH5~ zw+30%$D+GsEr|UO8{j2C9?D*KYYILc#YCOE$x{5tohD9wW~J-THr{?98TlRGETau$ zXDx`JP7G~fwbb5t<&Q)(rCvp(LSHQWS8H^kC~iU3lZzKq2)KyPA$D#FpXt#nj;oY^ zwSi@Q-X*r@? z#VdmM_}2MrrWVrDfOLnZkB?5LDbj1(_s*hmaxLB${i#39o?K0=l-XyIr|YS)(_#?DkfkLG8m4-H=O<3DhXq~0}~@hhh_W`4ylC#g6{e}p==+fw?hxW^{Mi){y_ z;4yz(n_g5L?E~F^D9GU^_H$*BaiE98^>b8LvgqF10HZLl+$+_frQPW{sqP-#a)6O;FLGMFPK!1V0vpOxOL`lX1ctcc9 zbWF_&qr(`DN*gVOKWPC^U9RG=W<&QO&ViFsqy)o&Hh*3 zC7+S^0K_V;RdSjQ-`RyKLC9XRm1isY!Ys5g=^jR%NG^%GZZy9X_B_AbxUD}3-IPj| zh)Z>RUw4B0jpdwI&pb6%zaIQ$g_uuvO~ph3}D%c$2N?8 zVZz~jHe~@<)6qw9<k|>bB}f|IH=_+=cMX=}4;zGl z7^?V$=RcLjS;mAsAIpNrG#^HC^XM9C%oZu6QuQv^8R4A_M*Y~4V#IsF8RsejCXa_4 z_kF+E_b2!XAH{LfDvgubKg_{i-YCoRt;JbJzfa(*99%X_56Qa=wS-vd3e1Xu+JydK z!eWhv0}OZp_bb!au@>fS@3U~X?Cky4jC+Tz4A{S~+(Ts}THN1aE#O7ry{xq0vms50 zCXRjW+}jfzL`)7A$Rnfm&Y*(6<1=KS!vrlqL2!V}p)Tql%j?(3q3u;TH%6P+S$^NT z$3vNysBnb+Xt~RRh&sj~FQ-EVeyexSWWKJpZ%3TX(vr6G+8B)*fL*f-KjFVXV`WyY z`-s}BMG_}SG~efm^R+cJxiNh%tI;#8&5k_Fa_3dnez&5ZNj82r5Pj0!&&4M|gu9-8 zj$-|Rem0>;bDXxUUY>FhMh^R$d&T35*2w=YHRxbHck6mha2`Qqo?|8f=<+NZndF#v z@K)|P3`yn7bel!fC2C3IUu7v`!TLO_k&_{6Q|7It))|VJNvUcm+7x2aM91fZ)+fw| z3oCtw)V%#s2X=6CKrvr2X-ev2zclZ1>|WBhn@7=HHooiAmdEsXipB7S^*n$q@n3=iO8mN`YU?e=IkQO41E9H~w$ z4@k4y#WMYavcI)p|Kp@^mV}bio5Oa1zje=Ut(w4>br9~Y$9xwx*72?hUFVUtTO-R< zM4W0cc~qg5y@w={f_pR@4TXE`V-CIc`|*^Pc=NPy2F10rJ%fPKpB&qqnqI8ES=^I?EK zjwTnP$7V=Q5hUzKtXO|KI!lxT>tR%}n&1oMmrO^ z8;-fg`FwFwY}UfGMvBigB7a3=WyYIxd8I2Y`-Plsa}^u-mcbVG1Zn}HwOI)`W@K0kwbvTf&GdK7Ss0<5+?oS9dm(X z9UGKc37E*euMj$kj7BLLqEpwh3&y<;HL>)`lSg{3dv~SA<)B6?2~tLv?z zf5*aHCTK)+XG4S6G$mGDJXiyx6mOHJ0TP`J%1M&4sbiaHaC6tsziWYO4FJ8BBjEU&v{{$G0R}(H1C`Cys_l zBmwdsB-njq{emxLb2J}2c=QOxdUuybzZk0qWaSk778l2FH5_va|2nz;=Uo=CuZj_# znUmi0&`~EYgRUcn8!l0GWioIF%A>M=YiaY0IpnxtFZ>0lU(to^V*K}g5lPr4cDh3wydb=-_|Jy6)2=#5xM5fQXy%%Qe09)Ru%^j zktn3-76)z=fYcCMaFh`WX&Zr{3#YRekrcg1Fle0Y)zKRC#acK3)5}Rr9(_q*YxxmY z>biz*#%tF8OHVTdDV9~PbqjMH-g}FdUw;FhJY22LhnNm5d{0`oJ4M5j#O5Vtfu9{S zWS%wqP+hNm;Ll9MVz3b^XibT>07OW)Pu5=LeOmtoAR_;wM3zp-`h!#d$c&qpAL_3e zS9u{z3_q0CZ@AeGj9?Yo!)8uSD+SN4yv&3K;pKcr$=>FJEFyPE1U+~-%f|)8=s1gi zQemupEVk&Tvy0yhAU5i0AtPt*I()SjR zRy{!xip`E_R87gKM6yxhsL;^tgh!BJ5#*N%N`d2UAGS0@Z%K9~4ChT!q7O5Pz z(tOSWno3LFRJ?8Dgs4p z;AlqsJeA)gPCiALR;2U^D=N$vUAxzb+=FEh!UC1Qglr)7NkHMyX;GJTWx7veNdB(T zL*qxWry!}nkIbf#L{4i5p28o!UjX{&cQ2$|Z-9^qPHd-fY5_HiI1 zu=hIb<&@K(<61p6X6j!Zt}=y9%4^v7LSJ_Pqn{gFY>GiHkG{HDk%E(SqvNGy_4H0! z-K)o{QT#?rkcvnmL?su*{Q61~56=>BU_A5F=lPX=3o-<)4`?C{gI*w+nSMVtXF@sj z1gJnFz(^79yIiYHLwmpyV{J8wjYpOOl7Gk7<#j^>nCOt31EoqJP{xzh6Dmx$xA zmwfo%nAG6K{q`F>%FWB<_ztsurSv=(i$#6DdoMoe{Xo`$$h;-GJypsZ#$GT0G>vK` zwl~Z3*h+|Aj)pwu6Q%Q_ucQ~c(Z(8@+JXv(UDQPT&rYh=24?eV?F>}IFt1mxa24u) zw{bXc^-jH4VBxc&7+p~Ed5J|8?x43G8d$c6lpyo2^_`QCe_-pwrSaJ&pAfdS$_a1y zO4Q$W@x8HOj)NoI8MB2(#7W@^5D!eR+x|F#9y5`?@9A}8iCsF`t4 z^D<^24VKOe@j~WB>pKVS8k9I6g(1Wnk{m=nzUmWbynB|L*+mKIaPSJALpGTIn%pCu zM@nCwHp_{9%_gpE*GttJHKS-}HN0qa=vnQBwMWKp9~b4yBQ2E_`S9TMEmfe%j`|C-+RT)y_YQ`Wmv& zcct}$->$CVLKNkzt_l0z*qZg4fA8l5uVk+GF%~^}U1DH3cS%@R40y&v7Vk=AQDoFj zTX{Sppc6mUi*82mOU%33uI?Tay^in96aUWY*+sMXy-M`U810G-SV%5f$18fA2-Dy% zAKd}oE6aFZ_pSKj`NhUY$$&3fN=z_RJ@+WQOE4qS1*GYjF57%^p+VHBKCT6YjHidU zoft52r`baNqb%bz>@#0Of1x94c~-t$0H`Db=u0;c=Gn-z3+-hx@CZ0cFMJhntAbgN z((9xRfQR1}L22dv4+|IyRT6TZz#r4-5+eyMEDFITCkIjwZ&*I^ak7_}2}T4$@ZwR; z&v6IQ5QBTO__cG0|FXIRg^0!94-y(mr`xw1m&3P%+M#AVm7V~B5T0$A-$4Qx^h5rD zW*Fn>Kx9F3L$Tv4;|~1&3K9!LkyVHx&B7-H~#01}X#&7w&o8hUd1+*nLqg)EnTWJ0Zga!2#Yomu0^X( z2^yL$1ez}pbD>YS_8?XhwGwHpgujAolDN8BOSO$&S>Ux&vsV?_?x|@&m_TsbkjZa#BejTnRCs-3r_(jZ3;=}4E$GUbjBjE!RgR`z+d-Q} z$Uy=---hrW#*-e#@g7g(xf9lNFLbQ2R&YBw*bZMJM(W7_%sy&~&1#iaDfO-^5$~ey zMClm8WzZ<*76>GPw#2Rw2Nn-utaF{aqG2Yy(7s$ya(Q}=y2 ztmEJ|Z1P-RK}CVJjL3&Rvo~EYV)ry4!|HH4b6Vur(K-fG#|G?C9|#c{nEcH8Vq(G0~cLy#?j}QSem}qXRNZ~lEXd&`n@W1wqzv)$0Gepjp z_pwT;XxTdA|N1qZr27ufH8S8iE*mn%?M&j#`*QTWRp<-%JGZ(Bw{Ikq2jtC(B(cJ2}W5o<1y^xF!RaoHlS!K`prh>o+- z8h(dDZ^T?!D|hkS>U1fnW8hHE@+_iK1!BpNXMdNdhB}_*qmtle4l-rRMX>99)4W8d z3$dkkt&I@#WeCjy`6$_EQ9Eg~!QYoK+|icX_WMqsxpbTzfo?e`XC7bAM0o+UusG>c zKJ7_+QB-ZAJNGfM zAnAWk4+KQF9_TTL#KJ&VpYl>WVW^_uF&%|NLw6*kNzkbTCzHi@ImoGy=3j69mtN8s zsKN-?Lx&qTfHGggoE=}vysWig1ld2M-89oIY`t;@K9UpscT(K(FBs$X=h6H}QvGV= zR8dbDj&mUg!q2b6rUKG&30!8oGb|z8NWGYS!QU!WP4mYZjGN_|-6H?y9AT={S}7*( z7AQKY^UMxsu|$hLCqR9-F-B!e{*AKR@#~P;_4{Ts6tLL>m2Bw8{N#?)$LzPP=}*J~ zy75AzrBsxEye3YQ9wZTqbyD6bFbIHM^YBk4??~|$Z_KG=$F>PhP5G_RvI(ivAB#m5 zm4Go$LmRVqyOzTcJMa_(_tDgf?{mnUoul_U*$l6HlYveC$2u^tCsp05^@)n2fPh%R zrG|CZD{yzQuE>{vhu3ClS-!Lzbs(t!MK+n{dr@PDgTr zHAaeg30{#k1}Cz5h!JL?Mbp*u!cT6TtnOOZ-EIGG6>cjZvFJzA=rQT@!*WQH@pHqp z5fOn;ipDY_kN)%z%8Nx$R9ZgA?bas@5E+N0&>_SP4zvH-IPc_$m>m;Wgg@kp-Kt zqBT~A0GJ+_pRzy-Lj!fLwVGmDH{=9+lEL4??!T8{IvcA>C5w-fo_v$3Qaq*xW`hTp zy%7kqo2h_sJkO-axHHP`EjMgkKTm{Mea90Itn&!coLh7-+FN7B1BE0fYt2!}ZJ5pB zsGu{n;8f@C4oD;DH89E?K2tej!mftGvv!%@@E&Iwv~&9hIB?h|)Y|6L+D@W(a(@vJ z!sLM!jW+WsM|=4;8Ipzj2^_6R+lp{$7gF8?M!kf_0u|$P!Xp){gTluC$WQ^^e2;y3 zlQl0H)v}{B8UZVs29YVtgErwW{i@F7Xur6|z@nLp{&aA~1pRs^fyvn-@+Yx5J#zY; z-v4Zhaum&z%`Av|6#XTenX0ahc>rNWn_G@lD%bjWNLE|J0~wp;L%`q`0=v7#>eou5 zX6d!O6Tp1f)0GbSxSO#}q!Z9})&w~bDr;?De_J0_r0<)9cgO8c==;7zeh$MO7SKCJEbqI!@@GrD*!)tuSmY=QQnyha3B=7C%vMp?su4uT3j zZpei&xnUWiW&F-QCEC7nmX27b44OHU>vi;VC~=e&%Nl))PFAEVFV;|fF8^1y-tR}b z0Kmsis;jCnZl-K{?;{!%{dBZ*8Z5lHuc{$Zetl+IrTnOhlRjW*4~XFKHgM47{dsx6 z-A5RV=7GIhP3!rSj=!$nxRQQh5`mzCrLP1X2K#9yF{WtzT8Z*-UZEG>4l|9cRCR&Y zx4zJD9T&BvIaUuhzCyj>{2skuGc$zO7|6Lfgt16Vr3)lz(erQYRFhEfp0>TS?>b|d z;r}`Mv(n-EN_nHGDH!8|?_JozAzPy7@Zz{UuKvkY@0a~TvuaD5RhEOb-AB92uh?Uc z(;p7qwBs}CLFy}+^{>cCOX0U-rR;6L5T0$BZj`GCxx2h*c04pUM7w1EO&<-4bptc1 zl0U!jD4nt%$p{Fds>FT~=b#dqo(e$Gw#zQEBtrJ*WPL%F-4?rih!0+=j0s-Z=f+!c zo>m&*IUqXx&rp0YJ`ak6dyW5XEjN2m2J)Nl6>6fo*`Oxj4o(x1r!ii=h}TYKMRfxc zZ1TE^7f6+o%GX|!18=IrX8E2FuuNADJ~mOeLTUM}%z>RqtiW~G7Jic{>Hk|-Ki~7Rh_e}nbJrc)fvNpJ`XYHaR?Yat35~PD5^QMoCLI)#-Haal zaqt#a*!3i>bu0nv!>iEhX1X(2>=0o}C+K{PwNf>7xMt5+B8;`>Ua$#7pcAg5=gNwV zUhMQU6cT4{S}2mqEHVs3;_{SE4X2n)xvFyuPM&iT_fgBe+erR74z!|GVvB@v7L5Zg_*sQi6?>43mLl!>zgN8DfUrwsJ(*$VB7J%SU7mk5jI&s#*L{k8zZ6Z3`u z`wcy2>^)$qP~$?E)tHrr?}at=Q}Cv6WF$G zy;K~+5mX$ib3Go~CT~=8&>g5GnKAAA`mrHll@^Ly0O)xA5g0ebK_Du*+j(U*qOPlHsPGOqh3f4@s^Ed2Kz~{ zyz_Ujg~{f@y_4STgNE6AxJkasevNrZgiOj~5>Ke;UeRmoktV)|*z?Pm8&T#7QUBJ5 z2OzWBMPQl4sia(|lYR%q@w`QeyMW(sJI0`RLz0&M;t<~lkf11{{tZr%V}Y0h9cB{2 z!|+KAL-9$d{06#TO%^PK;F>bFy&!`2;3G2l!C8~3Nw{+ZKL=znI&(~Oo0xR66IWzt z-G4#_LG}Gpkk`tTAxTm$CHH4qSxpStbz-M1ysnI}dLu)R{TEdpZFA?%LReNXm}S#Y z_3z{GMf(H*-xE64e=VidOqow@7P{wV?7?LThv{mhS2~Yo1o@_)y_8A(6CZbH?NSx+ z)8N>$+y1H4BYzi?DGDg<{e%xHqQd)rch~4;s1#jRO3Zflb0sWOQZbzv#2HKi4=422 zD;i?KRy=(vWte68uK>x=_6tb+!!{O-ry*fq)#&56SP*~)Z) z#y--oa7kWQgEe*7ku##BbtzPhDV*6jbUbQ^sq!`jrj?;LS>@MS0y2oHozjRL$*3Y} z!yV$Vg7<~uTFUuAy9CH9yxhKy)uyOfglkdnUBZccEsb&=1eT_!Owy~wS1i?+33Vz` zKBzWRB_|u4@>GDxI%Tfo1clg(&M*LYLm}>+-SGxY!nS_-{lMe`@B4vs1MG+OT5+t&m8Bh0F@!Un`Ago;$*~K_PPh^ZPu7 ziK$BXSNS2mm6!|OU~HVa@BY}*hUUoz)C~s1jx)?32-3L$)RrDO87MoWH)Alw#{^dc z^_!l}dte{aAl{^=B0VlK#cw7P3#snU(q5?8i#|N~?)lz5t=oalz2JMh{Kop+J*^~( ze=h?{>sbm$iYQ|G?FQ6K*D6H-SYg-WQJ*rWLOV|I{JmlEV(?mJ5BA=f#xb=BvblL}_@arB4Tx9qudf>YMLq1)YCmAd@b6>V?fh|-QQgvIXy<&gHBVQk z1#BMQwfFtJ7dxG3YJp5tz^&~%ZdQ;p){|6}td1FZVET9RrM*PrXI_W%XOWv5di>E{ z6FOBSm_XYCxVQ+b13WSSta&DJmgSI6**}oJm}UT56{|~usv|vERt|&XeX!>6M|KnY z#%@9KdkArJe?o-+GZo^SKNEk$)aRx&EjzJsKc@IVp4^&ePFmMRx@tc`dlX+rZc_SX z-#38DCXw8RLiRbD_%Vfm4pWBeHjydZ0og4ydFRI`kzv_0Ns<>}Jx!|J`SE5OJL;Q` z8xU!Cx_>2Sj;QCA8USBvldrXrRbl8Rm#$thabCFAXRwauygdQ?FtCz#%TJ<)Y%pni z9L2=6ht-${Us$dK0m($979$HYj8v4=iyjH9LlT<3=pYOGEtP`lrGKg}nP5H$S~2C@ z9yH2|zFt+PjHNzczL1;^m)NA>wK>0q$SpOJ2UP;V;(KodjZ` zdEO(-fRmFjNFZ%in{vt2nET6HmyN8E`v6(7sc zF50h^95sn`p<0wq+iI_YVfS)qzK$k^6_Z5?O93I#^56kUexP;OFrR<0EMCPA-$&QH zR6$?tRFkZB4}811ZR}J>D8{80+1+gISGdkh#YhCryD&H0<#-($Tc1kr-RO336)PTI zJv=La!1(Lo2qd{D63kv!k9o9JiU^3>ZIvqYXjyW+W;mpsLa>R+W+@TA`9tj{FrwQ+ zq3ouB24nz37Fcn9;|G0|Vpvc%1e&4+w8++X<1)1Nl9>QG83e zNp8JKDDuy5kPlC%<YdosCi=alqwaE$0&Cc3$q%r@07Wr;g?|4u9K_xu|0+~P13@7C8ti>wA0$lwVm~Ur><)q{`PyAA`V;2 zTY5m%opMvlP{uQ<&gorg{o_}2RA~E)m3SyO8{S?o!OZY1Sro2Rkb|rtOB_q!&qZ`H zp)c{$T2cs3ADrnRBG9^e($7s)(RYVz@uOZij*>N-tZ(2)oBBVps26|g{6+|(D~ru^ zwVlsCBk51LLd651Q|OE~+I1$O)JAUx6)XXM{p2zxP1mQD3ZW@ z*F%8vJzlU~gYKK9kcm1Yn*(&BGd&yx@Vi)uq~MkpRUi$;he4+C5%xQo)g5uWGyMU`M}#_E;3k`ngURKnW&jlfGC<%ASab7opW=2GQ5;AAkewQqLTQ^ zR`1a#v8dQOvU*$n6w1{7#V|Ut-?vh&!CDjnlj+c-Z*X0an{O|qflYDpvw_69NS)^Z zzlZ2N&N=xc@euMtnho8xe4V6K_~!#=zl;|Kcq?4AEH4A^8xbyjJ^yh=>JF!S~J9)-F#FS zw&^H4YwjTom&KroFP#fEHBW}6Vz{9JC8_aQb3^0v5V2pFC{2o!V!x6{P82C7-})~H z`DV1u$!_bq@!IP=w6v0^0XUs|3M-0?+Oe)qI5k4(Kk;*kO_n;Oo%`^Db4}&X-=Uh; zHpFz8w_P@1CJ;X68UunXG2UZIyr^!cPeNRgbDgStM-eL`zFQqc_vB?;EK;IeWG4t; zcSmwWv6dnYM4ZaBG&#-`jSOI+cRNKzP@|_!lQI0qdB8&dM+pZYuKdN>tTB2hCy?lx z{mgYO{v*+*k!S6!)@UoRt7Xu@*beG8t#Xs$AcW@_?`TGC{y*o2K$`!9#6EQ=+kX_a{dvtXmj2OR$r_9na% z!ph{NCwH{V?)W31%FEE`sP;Xi|6vp{YB}SB%Geq{2O4G1B zwLA_akf9g{IUdkbQRU>Qkp63=JIxw0e>02mf;RsC8y7&PdHR*2*m~z32(fYn9|)oI zIF+XvEmW}d5oz!^_2tdF1+m-x1GgRffWu8DU7iADNxH+02tTYN%{>X>eKZ{_9=HJ$ zN7^3q{T~#Oh&NN6uemjzg5EVXN;qjj&n_`;0R6{6Yk(32kISPt7Yrsv%)(jJ)oX6& z@}=+Bxl6#eFGGVmTgUxtvWjq8_vS{vY^!#CB==4KCCkJh@_QSZW&Y@~mEY)l`{?d3A>nOOe2)QDe*az*IU_3_*;Q?0Mh0t{>st zv?l%|pnt`aI@{l~FOe7{?#<~&%X^U$v?-R9U;y+@`AUQG?wt8^Nk<-{+#7yHBXdwH z-wPI~+98tD2%wKs@Kb-!f?#nt|C6T~cupI5eYv;Awa|j<=_Wl%3 zj3gIBeZ@a6{x$b?^w3xhMr|T4sDC7?Z0cPd@iKUSHy$mYCHYFugtM-ryBdWGMPOG< zLP3{1`-X&?>oLOtCBdNEDLK#!S({lN*zvM+Bn%9zImcCDsguF|VCo_5fe#0x&fanA z!$+Y$66ubFe5c~!X?`J(q}EqAZy&rV7k&lFZYo_>oa5eR#5H10Ds%53g(hcQo&7(L zCnsQPxIUFv+D5j(L@40lvOv}BAAJ({c>j#DY>Sow7oF24(4ckequpp~5+#AQtT#Z^UCXuo6imVGmezCQtT_}3h@hn&OR+m+EtmKwoxD50)%VosQ zhv;h-?}(jjfr?PTzi^{$juf2X?|5S_+@xa$LLyC+wz;B6($pX!;AI8sa3I7eLaF19 z)(T@KMF*=En7YYu2*L{;y*V&bxnyA({v!X9r8mJ4TCKe8IW2Q9!w%l$E~xCC0-4hz z_Khui*gv*gSp`OQl8*bJDk#<~wCFd>lz^+xCo@%2aVr1n7qQXi>)v8%q6#wDBth&u z`Ydwc?Q=!xui(!^;hN03jG08W$us9a-U5o2rbXt@pXbjWZ(oPogcNxmhiSt@OF=k3 zH~oT`T(Ix*W~%FN1BdfHVs$aM4A|rzY#SuPYD;_wS<*%kK&jeOS)@||MnIdd{hRBJ z^Ek?c5ZZ7t|K`&dpqRbSyXXxLCu?$`Sc4X%%$NGN@)u9J>OtZ0Uzz)%YcpDLl@hp$ z^u+KwU@PA7E(aYE6NOoxr<0{*0~1yz7t#g%We)6n4@)FCNy=$@5GQil2$>Z1GkES4 zb^;z430|ad8xFWItJG8u7zNBJKL|Y#>PcC4zOR>cCU>X-uj`e<1Wzfew*K~=j8~7{ zB{-{Mz1lNqS~a5>A>3fp3tccOT2v$4;c%Zz`%?A&PqRKbBiQKCE>W$*URvGD0hTD26ys(H4H!bLe!4&>>NQFX?5&k zDE0~5Sd@Aw&!<2M3OzAmsaX%hB@XHc=9W|PNxrE+cn%VT{VNSy1VHDJSA4*&${&TocWp9RBRI(S{$Df^xH5yc~RTt$j{~n`zXN7Mr>oKB5_M2~QBd!qpT0E6AMUsGAzjH8 z@oST$c`^|542fHJ8I$VrlJ?p5G38BvqECK1i@_-6jFJWk2ajU_#&dJoe2$CD!qUh% zL8n2$iSzBXKL8N2dn9a#cVzj)?$AX0*jwJDMFd@{aI`{?iX7Xr3b+!q^S*ZxJ+_a7 zud!i({vDSwe(SAWfPpq;HyxcpF1&#f|3xM}rgK%F`vW@prM1B5xeUAhp)KdzjdLll zoMh2ot~H5{`-ar7t1JZS>Rk^m?q*HvFMQmieKMGrvm;{2bFTFp>b=>A zPW=WN>XJ{UkS#MXu>eq{^AcNMq`K+H$J3Rfx#5SuGoKu8GYVCP(HIe=jmUjM{Xt` zh%Bsgo~ki8oLU5@P3A`$UJ~QpqwsoPxAwR$6rJMXaTq93#RH{l{F;@dP0jC8lw)GE z$I0$FhE1~t5};hK0b&H#zX<ab4C zPLh=!%}{^|2~f>}z`zQ2ox6+R!TcrE8b@tF5`0_PvHGWP z_my)kFx2~j55T@!g8t^^e0C^*^JZ$hw?tXlY5@%D=ZHXw7K^PT!sDZO!=0gbx5XuKm0zP(NxOHfj-v-Ha->WlmUNS=?J^w{Y4v&3f| z^sj%&;tSw6^j(bt&|(KmJP#2ZA?B1VO;)9>|Eo*C-r05?ZuoXB2ttJC5KIqS|P-jU(c zCo~UyV)L{o)W2+ImJLH?0yP*Irdi#MdNaGFAk$%yUcXDZNi z2;$GyVLrH~K~v`(R(QrX0Bs0TjI^sR9@heE11#yzQPp2|?N)E)4vk0fBcCu-yuMZZCjH{r2w^MwJ8t}E#f{})8b*!EqpAi&p2t^(<-m^WO)hP?ZL)J$!Wu-` z?;J{`VlVn$KRZsV*UC?kC5G`>mY{onHV9P2TH~m8G?P9QMPfgx7-it<@$5|>#)tt~ zqll*QGBX=8*+qm{-xU=@dUDFqtd=5CluS#HxD(tYcZUJAIoxpRImW)<1>Lq;kDY`_xqJKOomg%g_{Umytn zJ5x_6n(RXfZ}8tO_P~A$87^0r;}}3ZMkwGBvFjQc(WIAFKNCI-MY1t+vp}ynKA`#0j|#a{CaR_P0>yZk8=biAsfqpyFgG%7ZtIQ0KO| zH?ztf0{$iV+d=m0NjBgrlr!Zfq>yH$5e|Nz5C*Pc8PnOvr;hP!>mY#!MF=&vl}EJQ zb<)*+(z|++hlKMeQ2Qp7gf7LJUAhflTsJM>BPa+17or$bO* zhAW(9K(2%<5sxWhqUl)~`aZ$<_$@ci&PZddL$%csiB0GBJu);NzJ zTVAAN(gELllnvweaQPF9pNXkrg03jf<2?IpM+sAJ{QGR42~*jk%>n;}kqQZ(p;Ggt zK2rkz9FzjOGo|<5Z?o=MUv8{QlU(3O1zveD&q3$4j@Q#vu>O%QCD zHU-c$YQ^R`{84aK>*Z{r-oFp^=rw=$G`YHk&O8FLLX7N;)bbr&zC2*vV@$i?x(~b`oXdzr3BEUg@l#7T~ZIx?ACQYL6>=c5D#y6 z4JcMs7y;gb=d)#2b1p-b*YLlA5h~&FccQ8h0{45gjak#1}Ve+9TiQV&{}0W)*s z^+`kv;^XZ!Z_x)Lp_e4v5LpTn{y2EW7R~z@A9C+RA2WoW&IqJHZ}ewuH=ZK}?xRll zBeor>dj4&$v73UMTj<-6^*_J_B&;h6Xq?B1MQ93(!_%od8)-`pigQFEaG4z#h zB+FKF!Qqz_^Sl+)BS+g;?}A=y!Ea7JCb8Aba7AZtO~{HT!_J!$O@6_-{#X$s&(!0V z1nEf!*8+W(J+*~vh4fsA;>s+XQ9e{rRrXLMSmf7v;TRa_`jfUtr+2{8brmKzx3OX` zefPiJVM!NcWQngBiJ*?%;x)0TX^J}q%^XPoBh375sc*)X7#~Cl&XCSS$OCMo0`-1n zn_4oo3*6Du*$r?LJmySC2|PE8Ds0&{u`FRFnwdLRnemByP6mp*w%r(XoMu!AV6Awg zNz|H40lmLyV8Ajonr#;m39c4+a%d)4dl;C8dW!8X1)Kbf=kCR8rX>V)e6K2WgkVehU~<*CQvnz2 zO4>x08eaDwE2BBqg>8(h3lMi!`PFtf=?i+xzwN8x5BjxU+4s!{u%8?b?(knvlLC}B z@6ilE4^=u~9e~EMMkQE@9)V2j5{SSe3aJGtBtnng-_`F zH4kS);s?l4(5m(VmjI%BT1?7^<&?n_yN(3UiJ`PLLPh!WvE2*e-t*) zXC+1-Wp%Zln2aa}+hrWaYZF*#5-lz-o$TmJkHeuEKLYfXZ!xUDy^PO{)3VK1Hr;19 zjCIpy=zP#WdUyZt_`PiFmaQ)COC1&XH1Kv6?LHpKvGS=fso4<*THm|ncyartzP}~{ zykqjD<$0VW7pHrJuYPYZvf9fKC7i-qO~?E+T{B7kqy--3^MwILi;xoIDw9~aqW zwDB$-_oT1l=MYd!dH=DQyn)US3Mx$zbi2N5yrL~vWjqNyZG6sy$cN}$8Kh2zBH>fv zF_A*=j@5QJ&Re=&7l>%8b0z^TLO8b}CJdyn(TQ0FQ0$0ul@!P`6YV2?0DGuKGJjkm zGd>&zct1Ec*s-1g3jx@Pn;Qnv$FLx|kq)WK&SVedt^xH2|ybAMzH?j~M*1F*QKkwmAU~SW+AMeZ2sB48j;l=`xfJSt4c*uVoYBIsrKd+1J?@)K?_a)URd9x*$hSby|MJX> zA?2ic!wBdT;Ma3x+?3y%ElVbVhI>S|;;cNYaMTq|1LiX7^~3OND5OnTh${Gq3L9|#rQP`RO48{S4%Z^{ z#3wV!c;MUqWj4?%IxU`#4Jam_hIrM2jwqD)-dei|!UJsdD;C{kDz`v7w_$qqH zz|?^$d>l;sa~6v=gN?>Df4!3t1w(HnBP8l@wZ#(RfLq_M4NX?~<_LbJHF6^)IsrPD zs|a1;eIDMh`Dwg`jYhlg+ zu7}t?kpN4^7Qy52Mr)tgiq{u;U1Lm;8Ux*=pW0?)a|krFVZ_zGux%r{_wN z7nMggU!7N1z?W0obBk1JJ$NGft#FWDV5XmkdrEepni4+^2Arm4#X?R!Oy+oLQSPMF zYW0p0}Wg%2R~xHucN=|RmZc{LSEohVk{C%AP=`M1$76l zX_y?^73x>1PyZb%C8{8ruY7#SVsbd`!|EJd#Bskra(F^#uc&D0gA|)uI1)xiWLBqa zkuWeOP+fkksJ79tL4FJgrX;Fss=wq*1w(4=4Rju~@XD+Xl2Bjc;%yW40Qjhg^3w$G zSyFsy^jxRSB(<~>Bt2~>NQ$KitVzr+YJ)E=Pb*DCt+Ct)#(q4&8muVbI!H2Ku(T5K zr?~vAYVZXX*;iX$b<4u|0-MH*6zzBgRJLg3c(r*pksZHWJj1+mF=08oaQl`C(r&uM ztAI7anYPm}IW2Q2Vbv3>0-G7uE4OB^q~Yh`pk`u4lUInQC2K4?As3k#y*6>0l16a} z_oTo~-NW(-;hG=&A{FVDU(@e)82U!=zsmS+Uhb-Bg>iUdNvwE{qUEqyeS{E!Wl7mw zc`LQJ^nvk$-vUqDkI@|dOKigvYQ66c6(`Wg{Au@FJd6DP95(u~fb@ct9+w48V9xg! z!S;B2(j`)=l8YL~W1>M7Xwf)2G#B;n2}KAYN1t9e9omo^a0OXi022-F5L=`IL@1r2 z&Z*w#Ivj?epeuR6H55MmOI2gU|9BFn0iz~1x4@13SL2bGVGdc(Z>Na>=3%lLE{1p( zh2SVfZ0sD1iK7VcL#xtNuC=#mVxq4iK6I4)KG-NF+x(;DyAgTOpNNzGA9ifz+}1+F z#oiURD2DRCBVXW>^`ddls+hTKZ8k@0w2!pY!}Btgz|$OJ|&bCoc?~- zS!=Ik>7ahb))PtOo2meoZaIfvQND3&j6xym)m|6(kd8L{S#0}Lv)#2+jER9T;verD zgnmutRTzNWh+b(oXZ2!>p`FstXc>CmLn2P=g10NZ`D|C?p1UgH8eyZ(PiX3F&D&$P zdN{s@C7as;reO*oN_)4ZUiz%e$UNF&rB<{ zboWZz3jH26aM86L6zkW(U$(Z3xtG5^Byt+0lL;J3BaO~7L~IQu2N(9A!^uz$`3hBX zrg$jJO9dC2!$?F;yyaH=^hI#*NN)$nd6r2IXvaq2V#RQK-?B-G*Ozyco+}Y!9E_7D z(!~=%v&Ar0i3orIwjC`m*S*0A?Gq{4P?BRr7|rZlRSe!g(F_WnMaZC)$~Lx`LXP zWp>mTMN;r@6AE^B6rRHLtm&5soKgh(v?gloe__GX!QGiJ;)xcB(Bjj>hqlY_8sXTA zD@t+bBz;VX3p|2fHqkbPspnqA7jT!pP!YV#8QG1yRX-3b5_A7qJ{bJ90!-w43g!F^ zd#tQ?pCN!N!cW4*3cA6XRPOk{BB0XFG(j9)D;~O5HZLrvC?{1SEiOAyTGVM+)vRN=~U2~V3 z_{U&v9cKW7ni7Zmq!T)>1;`llp3t8e%s}5VnGVGl*u^~EA4hpM3)SZ2*w=v7b(O(xb z;9n$Z@4miFE(y8HOvr&#`APqD#7c`5D|8WP;ayxsdL?*2h;Md+1x#wmbL~y=8nd(C z&uP>^2XTlfMWOEtTUl&{T$Z;!u9A0$-W1(e{7FW~32%Mb7ZU@y5)E%RpK5W9jOqLhri$@x(x#VcF(gCuL~e`HxhlzBNykx zX%aGy&hyMAegl%d=KtR#;o&LCj z5Snz#C3Gp97;aTFH==S@7wK3PX(iq|qgpXU;u!7N8H!5hpzZ6=Us8~?BV}2Xm02=Ho^|4|7*G{frSkJyxV$&oe`S$R z|C&bg?g54Kw#B{4KFd&q5Rt<3!YR@mgD}TS)$&36ViL#A<-i$-iGAN4r@DMTXt58< z;QJ=|1DLdIfpPLiEQG?TO{`QWu&3cZEus#?`n^j9l}61T3zY__vS!~$Ik;3Q{Ghcby0 z$-jj!grRbfj?u1> z;v&!D9V3dfLxy3pM>-(x8nLP6utn_BvejV8bT9LRF`EVbDy=_5YUE`Iwt*ev_ZuU( zFF|xVJzrsKRkx->l|Bpv4hhEd`5~|raCnd1oi8tQba9GQF0-ZFqPPpy2GDax5W_?m z3R_Ik!@drp^;lI=Zb=^NG9YhRL~|>txyeu^sb@HRqsuWN* zV}0`_prj@6|Mp$Iz_Xr22_JSSvA-h9N^?Q#^PeAqyM<0!-K|^Zb-E@^M%?zkmAv6^=e2qVCnW&Q}(vSQbiQlqA>Dx{y) z-s}SS7m;9}S3R@TA^!z3-W#wrw@b@sn}e->zW5~XVB}$zXznl_H==$97d(p@sD6g) zM_@0C=Ew7hky6T6NMW{Ku82v?42cu-smEmMqNTm0M1_en;EL^wTH-;SP``z-HC9J# zq1ak+fl}MnUQeutvHy!@`pIiO(^80IM8vHJw)1B7|Jsil9W>uyL}mwr$f>CXkXs@&^}+FUuUh3lFbQJ zgbWY32D&?72Zj2*(SYunTI!Rc+^0rD97~=CkHq)t%D8pnp0;}TBv>Q>J1~K{8 z8YwuktQXs9yi*(hwO{Z3Qw$X|S{KQ{9)jNyg1!rMwPN>?nNIu{Sq0FvtHojJ{jxH1 zAp^0B&91d9a(()H!#6*{5-JobZ0UgBIHPz~F;4fiO`2SpU!-F{yzXJ{Dxk;Xqk0fJ zfDS3Mj9;a{*9_|FUd*334Y-bDs^GU1KcsLy=cI&?ZWBr>vWf*9bzD#v?2D+i^fL$? zg%5{wGRi%8<6RRm@JqNgT@w_ZM!_}N^E?N=h^R-l#t%9zsulmGO!<_FAw^l6P7A%Y z=W?4{6msu(&_4z75-!{_Wv+YeE+X0S_TpE1SzVS z2p$HA#8;`hnv0_=B^g%Lg!jB)pcs&saaTJwy_&Ys`iW=@k(YG#$^5`$A{GqtPIr;k81mdUUWQew$x<;? z{afx5tr`3>fz=X=Tg;*bz(5Qnn>~R+92nCvJf%H2vmK4BqzF^|&=Ab>VZtHts!E?Oh zHk%D&;A!$HyOJWMV{6Cu#3f!sr{|^p6vEQ~Boz>chT|Gin@%1w2qI+=j7P)a`}7`$ z9%jyyCrPEq_AY{ccj ztBuZ*0A`pj>AE&*Wze3W?Z9}ULZ|<>*)&u3>Dt;#+9fTsDtBn%cN|Po)?{KbnJw># z5|2y`TV{*K&8d95jH%VKy)@RFZ#o@;GjBQ;tXM#uNzIxJRHYFQP5$Knf5A64u5f#{ zxXP>G6WDbreXJyKcsYjci)~8`h_7bM#q7A~02l>l-g)W`{c^e5mUm7DG5Ncu9R&&X z3Jv+|{UfL&eMW8zc^Iyr#k;&#v-B;rd;Y1!%zob)5#DSQ!b*4h5SzM;3$R}g1hS>WI% z34rBvIAeWTO&X!&s&@9S=gSuSlm1mxHO@6y%sgicnN}_ei;)T!!&OINfnejb5co>_9#Lc$41W(^gB?u@CI_{T}2Gl+H2*SI7OklLg4J?UTU zLkQ^?;u*hqX(@_v-(X#y<@@N*z6sYakNo8$x3t$P*($~URp4Uw7SEY=I3k)y5(Ien zDnrr2ETyPg^y=}fbblGrmA`51?7M5IMnZfOwjc+_t|`nE=AxlAQKX-4v)a&|-qE1GDfR?B0 z?Q&c3q8Mr&^+o<3=ENh{pCc8zy#OA5?4Gf!ZI=*KK-SvR{j$dOnb&EQ-`0il&U&EI#OrJ=$y{mZBhuT z2i_et#GGUHsYhnm=am8 zpMy@-bJWi&b1cO_kk2&bsy|;^d-}{Rvg!XrgZY^MA2{@TRas40|e@k z+c2{i&Kyu4h*OXMKvJH!v-9YS|L)}<+4X|UsINx>rF&FZ3OeHbxg;u6HvcAn2 z5|?^B%JT?vxS7t4t1u6UvDWp>dMe z%Z%O@HR_NbxgYlNm9Brn@DTz_V@92(IfHgDR%1$4+HF^H*YYh2*YXz{y_zyhKY|choUQM(iw=9j*#rQQR?}d?0$s(TX3<(ruW|& zm!MKBcO2#`8W9E+eziu^QOork&vS4d7 zzn$rHCv6ns|`ayy-|3 z#n-*7y%_kh5?F<=yatmLLztRVMR6mJ7C6b&qPZm^+1*V_i3Ue!~zHYSZ+r8 zor21WrRjg-MjO(V|R$P6<5rz z`QKO|!~yxvY{{ne7E$|#&g?#fEy*(v$tMiHdxR1g)b0ccMdu zHNc^$dSzq1vvK2@3L*g!YR*oiE-i%o39bMhP*}k<;*Swe#=*G`VAfLzoh(he{y&N2 z$@H+;SQHqKj=)hV8wby=xrG1~Wtf}XOa+;dMJTeTVd8>^ zr_X5=e`D5@_w#W^%savH@v;uErnF_Zm+3mJdDw#nh-(0iBT^f6u^+bt?S;{0`O=cD z<40_aVq0 zU!%w=ZoC1}T&2HbF4|b)7|MpiS62}sBiaLj(NL%9F@iFLa!Y8FrK=VRJP^kz7j4v$^(rAar}*Y?Vbr6@)f12&6;%U0j29Nced$x3%fJ z&vmz&$+>v%xYLWHF^}#M(w1V^p^>R6!KL@=VYYRtJILfm$x7F9 zSvLP{*ROvhjjvx^{m!9w{6}iRr`|JfxI4h3$qFrdED9_~mZ~1%UVDQHG9>Wg)CnX( zR$i6EDuxmDBL3>RZ@Q(8xn2N}oU0;k$^)$gn@u$H0EZ}^Ii6(t@l3~x_d*2S1wKT- zwA7JfOHim_P@0P>1gc$jH~7>YDFe4&-&5cq3Mqrm8&A+|>n$pB2Y01W)SBS} zo0ggRa&fF4x1DS;n>$dhdz`tR$O{}KO~}K;$>jQ>%p}=x*)v8v7&$kcIZiB?LTi(fGeHZyg7ic`EAwZSWtZf$GH~<}-pc*aX zO*{$}`pwYb-{)bsS}($q@X#SgFT9Pt6)xzX2uflTX3=xeEZxb~z0gx6+ry}%cc#%% zGKWY!zDFvdos*RoA`j=oNo(YhtSDZZwCup5@4?oQn{~$N9}ueW)W+xnB@%c1Inj?j zsh;C{aBuk?4`{BQR!VtzxX9k}Z)75pV>5lc@o|TcSkj)h)=e+uE)Tu^)>@_nySY2*q^;s8W zU$fv$*_}8;k6Zpl$;mz}ZFaR@+rj?MKahB=QJZ7p`wB^3TO*_Vxy+Qq`bDKe(GFm!7*K{-|$mgaai4-<`u z1T}wJtcvR1__aa(Z0dhdbS}Bq)o7uoT4#FR#T=~H9jM$wGD`F&=Z%tOj7aM>8L38P z-1>@OV&cv}^==Oe>W|(q7x8Mo>*xptYN@%lsL!w?E%+xV3J~uyTOf<$M8=}n(q!m$ zNpdd;ExyZz`Jv_(^mj0!Y7#WF`FGj)F}dutAkmPss(4{gOj)|zxq*>+i$bTGy8fbR za%m#3L+L@ETdj<~&6>OZg>tuTNaXMB#}@P9crbpfW)}`LzKDRie5U##Avn@LN+URusz{8bBi7o5Q8|a^QFn7Af}S({vT073lHk`YIj#Dns8}NjI_P`8>A4A{<_aG;Z z1%@Vpn-OIF%(!FoEGHCF12|IIS_JG2=(mojvabi#&8mUf*DayRT!tT7v}~`md)o_p zCz2dd7wMgr^5wB(t7|VJnL{_3K_NL#q<+0-cg$URAGgSax0JRHbGRS3N_y7bGo@oI zKnPofuQYV&g0q&`;{`N+bu!JUE=Pg?HHa;*N{RuumCnMb)-&Mya`gu1gbkBujUtgK zYJ@G=*v%OyGptRy%{KH(r=UZGayOTUh5RI$d%^0viLkw(>8*3LUtSqfmUT~*!J14? zv0Vd6$!2fqTC2Av$%oSgEeE_`z14U>lSt3@$UEMYWmI$9P&7!`xGz)&`D%p6CpPeb z-0`_0PBzcqa(Mz3B8X=;WiemcGG&yX!wgOv>iGxLiI{R!_uf7GIMhZbmlj}qn2(E- zg&Sd0d22?-q`O~nFs_ZVkQZYKK zP~*|VSQp5p_d0GU@M>lW!6Q>IUhU>va4^c9M9_!rMt2Gbtv8dAitsFACx5*~&Iqt- zS)5^50Gs*sig$F96=e=ocCa$3jz_=sf`Aw40IlgL>B}$kCzd8?%>7IWu z1)LNY)F{vVqu<)V3woXwqg=_h;^Or}?m;0(l0$l2?{qOD;rBa&5C%$;KwE zZvE}`|HyU`2r~FFS8+~-p+WRw44~fuK8l4F%%8vKTNPFR>b3}x$0!+Z4i1$GQB-{D zC6Q=hp0NxAj|^Sex4vEjh}505Mk4B(i!mm`B{A*nTZ;YE`&n;!G9#4*y_rao?O!5p zU_K4?)t=pw)N=Vz>Qyxq&cj7Q*Ri>7*dYSN6R(F-6~UcBud1BdO*Qs8mrAz6NHMz+ z&cifmX+pJGx{~nM^?Rk*rtv1Yt?&>ASpxBzW~G9X7H9?s#OzA}nLBo~P3}Nhxl%=$ zgXJL(mtRE~Bij%LVE6UH`maYk8`zL zRMQx~4L&k=xnDKl3DhR_w0*d42**Cp=4r*U$&67Q!J-zo2an>1l4lI>Gwo~hH9i@j zEcIzabymQm>C0C@7Hy&#H^Z5dzd+4gVU*onK`-LqUEyE_c2n1YOKyx06S-f>o@cgGC_n92Xm((Y*8DUN%1D z!dvpa`zDW16WY;(3Un%_HDcPO(|`1?OIP#}67jyyUkOC*jmX#6_?*1lg18*O@4Ni1 z>Xyy%T)*15E3-`^j7zR2Y{S2sJChVBKSJ>`kOojhTFS68gedQJ(5k2ND3t_8Lm43V z15*Pk0yhi=*o|rQdT{cH9&(7firFK%HmQb6o=IP-3ssrUq=mZ(!9K&-HbpOj726XN z)5B&3k$S7!tg<`eck0m%?skaLQIhMYESHdd){kG*#ktvTHKP#}$ozScVrh#hG?#}s zu>i`X*NkR8-2JuFLEXgLEGBM73-Y0A*Qd$a=h`s-Wu$kWK2g&A2>07!xsTxVXM44W zv(TT%++DEJKN62FPrYv*Wt+~d96n5BCi5yDmZ6!)$_XNt3U$4~ua&PEq>y)wI;m_m zStF#h&l7xT{>kBJmL4?JmOsmkAaWG?xfxjc@%_;Dfat@(FBw$RIScz$D9qKMbbcc{ zFoIpvU-U4@&eTTb5a3IO~k z$J>=+8fU za!l)=nN^;OM4^S3Z}_on-5L8Xbh>T@z2Gwp4bjsHDKV{EqDMDLfgg2nv(={H1}$4n zN%FeG#3YTJc}t36cD^p80C5GdUa&7+e~7NtqyM`anYZF*9e0p~Y^#G?sP^$&z2*Hz zCw9OZ#^B?=uS+Lk5-=bA*h1FxMgo zaFTR6l{LwKuWqaBdM2lb<5yg&M6Jt;W&#EIq`T~Guzozr%7%9lpxI0r$=Bo&7gw8L zN{GZ+9CJvjNnfmIbuF&I=w@q%Gn3VajQL;VD>$8mv+CLc{x2T)dk)rSvcVux24vZ_rXD^1lA& z5R22%Oak3V-Li1aAnlkq^MX8jT4?18IrfL1q=`9H#8MU06ZEh|h0o3}tAo*;CT6&r zSbbl=pQM7sY`Da~5{%t-oT@-3V1{kGR%Z?c*bUgE(mKC`ex$j)wXmxhwAqQ_%t8}{ zCYo9x{W1?bWDtcK`nMSr_L}~>V^L-dq3fZCcMD58tfIp-l)JAWRAHC(^RV}xqWNv- zZ{?jUi*1x5`pI4)c!UeyBN(%N!=cO4j^@<9KS`B}8Dx{9Vx3earO9C$CBVjDzXStV z^&{fmlycO2BSyjkq*k~H88az!IURvogNV6s;lS$ljxxv7_C9>W`y?~gOpIV_5MhS1 zCX1Kc0?EcN3lZP`y;Hl>;rNMuB|co{2{43z+i5ncPpR(GX?DCvi4T9}@!eri zx1ROuFeL#DXUG}&X|uO{N>#cv2#%VSW?!|rT3P=h0prP0|4O<*SY*XubO@NaH=_6o zmyRc|_?%OB6(`=zFQRM=AbHqzh~JE^nNVjAp_JF?9~cqbXUkQ@?n+m+hq#w0>y6Da zNK%yHA0p~0w^%A<9x<}PoW+W{Bdhx=Lj=~5h`&&Fdwg+$gUnwCbLAW=_q-UhE*L$+ zXC&t=eN-mn&EGFFE^sVAt^`!TC<<~(@-H>pzS}kU%y+FN{b_9uMxkB%{;+8s%HDqX z;ipzZOF+Z}uh@=A)CoqJ?!>vz`}qNfywU}^qFBa_TOAta4+)%jVRMiJ7bk8}|1qv0vM5rdb4(t>!*KT?XnpOdP#oiiye&smx z;jHPp(#WmN2&Q|Ng2_)m^kN+S#uE5QQ2hm^5W3KHrPs2Nf&lvqV1L^--;)u+puN%#o))m!dJF=stzM92?ATW>v*Zxs5b7D)p@XM1-A} za8M}i)liB>SpA$NFs~1A;*Lyg)!1LR6q);~x$jnaR8yc_-^<@}nC~!?w?Y=DiHzTK z?!ecl(3+Ux1Dlr^hwLs<3CG02LDigzBEF-yUY@8FWLGNRh@es9;>#?(ep+NLYGUu`;+qx~Lu9IAFqtq$$Bz)gij zNhJx}M@C`qz(Rjg3C`JLVdFB%M|jr?c&0rmsX)FN+1x!8Lc@N4>J^3cq1n|&n0&6y z&+wjfJcVX7`gnRs7gUDGl%%7!Dx|IZ9h!y&0uD`m64lYCj|A^kHJnz2^T>!JjC>1F zeAIo-%l7cHX83@Ntm#ATDd#g%Yw5XrD5n8W8Hau5Ls&t&vcM-kq2B3y?OU;^_5-IE zZX}aOGEMXX>P9>`(#~Sk9$+}7<*!*}CGL3`AMJSf!pt#xiJeiI68^sJ_3SV5@4mhd zP6pz{4N9Lz#7389d6*H`ie~T1%SJh{^#63~*L^ZdBdY<*XV}kB^M)p|i>wU#lEQTy z7LROO*4$g4)JlF%b9(O$j;;6h=KC85tJ`0H7HQC8bsvlx@w9^FQuG_js7)GQ7QQEV z{ETrrEjlgMj;D9nxwaL90^R#DK10*YBgY~6r=SR)S2*+a?=2EYbaRg_>?9ihfleu7 zl{ScI=b#K+lACpg{BC{i8lNR%=Epm?+9+iJmpSVwVSX{86KKlmH{3XlCSct3@&VZ+ zIV;KCybe5^lMu6=^yF*2!nz7tJor|kKf+nurOT{m3wa&6>loc$RQqE=Rr-zT+mm-< zZQo4w*_?Gs`y2vu^nCY|pUf)yuWc#~Zta+_S8D|Toz`oT3MTgsk?!kc_20N5iF}pH zj|3bF)uZ5VdV{aZd1FlFVrWBI-9_E;b)e}Cu*AG<7}Li$p{dF7?@Ouu9L=oJd8G*D z=-+U+Hl(=!QTUN1!#&Pq{>`U;117G$0aI@dzNC}MnyvP`bFCQXRUl+IBH1);7+M<>Q+l zt=x9vO&(!7$)XXYKMD_tgIb3559XH_$R+TXSDU} zNhpb6Si>dK*hep<%PH_80olGc-FCAY*^tBNn7^69*nx-<&>Fd03zEF+ic*0@;AB%CKXq4}56N*I#!txp} zzj7ii|43;av9d1xAiOkyILkIzpKPdR)Y_$d_yQ&DfJ!jd;XJJPjVLz@8MX6kWbQnf z=j*msHfm+}W077Kv27azG6kS*6uhE0I8!;SAREVMAik}$Myje@+SfCx_+$PVFTqaQ zQPz;Ae>k0PeXWzpA$VB1&XPYfWkxc9GwlqEeQ0D9tgbJZm?)RhB{evl$n@gJpsr0- z%Fx&O85Y-zl{B2+FDirJWwm!6UB+r!cw;7#o$V{5EL`I?B9ZOCQRo9;s7Mt1yEyhl z+F^~+n!dwPmv=ERsx{sTOQj&mjA6w%*LQK$5g3M(CNe3PwuU#C&AeR4QiH)_G*zn- zciWV4L=lGp-U=oyfB(NjLeCi5H~BAKyh7ngk9kOYqnZuLH-CKC&hbMWcgG9j!Kd0q zUtW_q8s)MFem+WcHMYszJYQp4K5fyU->ZJmm^}A(iCIjXa&wNGDm>W%xijw*1sxTjK0x!v+#eZ!ND`)ofF5|h+;(|JRYyd{Y@98 zTAEK$F0uNbz8#D7rzFnt8SXG{?5wlj^`UPVcTj=lX_=bt34+JVHjRv8^c=YXWj4ZO zv+o4*17|!w^|ML@r6}~o1rvtivC2FDEgD`J$dt>_XAxm0eJOb_7AYB;Wjha+&EZ!> zp7=%Dry0X`27c+XHap-|YV-Zeyw4Pe!SNJm!NEz=H?zC;K$tVunTW1{ly+N@r2zmr zzHoNIi?}AEy9JHp-_ym?1-w$ZxH_{a)-nEkEBE6Dk_(I6WwB))cjlXmg?Fwbxf-o+$^fhz6 zu)i81o0a^9oi}JdZVV#B<%-(^XZR-g_<<^9`p&hoS?JgP1dvNb*9!CgwqW{Ud?Fd& zLW8pMIU<_^k0ofvWN`ahaQVZ+hJI!QF7jD+<<|#%z-T<_Q_o1luN`lux8VO}|F2!~ z8X(f5PuEzq)`PfWFIcHZNSEIR!oxlDh<)b%)_seJ{raDQ2U}S;mZkW9>D%pGzuc4m z20H${CN2NCRm@B$c=>Tcm&yRB7WH2%3~y+v#iK;LB=}h13o&<6&ue9%dzxa ziNR_*-@Q8H;lK2nL@y5E+81z>BSEW|dd=o+MQOWhl&=}fp+19_?7zvY;2CR1$f8RA zW42jTeVai}g~L*93rQFYpG*NQC#*$x%@-K(2$ z{Nyuc+X1bmx;mMN6P(bGN#LA9+3mV08X$caF1TZ3!W`WDKy~}0C_Hn8{BxJE{Ngk= zsM!jF8em_eRk}x{RAQR(Bq^k(L>M}<3t~#0>fgCY_rrI=H5?PRj{;-nfCVU@^*MmuA8&b2jXUm!;Se} z90=|cF8-Q6(Bvt&E@YJa?RwCC?sj5j?_?Ay#Vsumwy8FEC1|k{Tz1^}xpAP;9;nJ5 zeSVSB!swriaq6_~+-c=LaK@KOHR3{`EuOCN}@yIUwWa zgV-_fOs%PchHl*3;7Uh>h+rgwilC{2h(v-+h=7j%0v&6qE-{Agp{(lRkMhGH`qO!b3 IL_k3J51_@SF#rGn diff --git a/data-raw/sensititre_ab.R b/data-raw/sensititre_ab.R new file mode 100644 index 000000000..87c64a1ed --- /dev/null +++ b/data-raw/sensititre_ab.R @@ -0,0 +1,498 @@ +codes <- tibble::tribble( + ~code, ~name, + "ABT773", "Abbott 773", + "AESCUL", "Aesculin", + "AGMATI", "Agmatine", + "AMDPEN", "Amidinopenicillin subclass", + "AMICYC", "Aminocyclitol class", + "AMIFLO", "Amifloxacin", + "AMIGLY", "Aminoglycoside class", + "AMIKAC", "Amikacin", + "AMIPEN", "Aminopenicillin subclass", + "AMOCL2", "Amoxicillin/ Clav.Acid */2", + "AMOCL4", "Amoxicillin/ Clav. Acid 4:1", + "AMOCLA", "Amoxicillin/ Clavulanic Acid", + "AMOXIC", "Amoxicillin", + "AMP100", "Ampicillin 100 ug/ml", + "AMP200", "Ampicillin 200 ug/ml", + "AMPHOT", "Amphotericin B", + "AMPICI", "Ampicillin", + "AMPSUL", "Ampicillin/ Sulbactam", + "ANIDUL", "Anidulafungin", + "ANSAMY", "Rifabutin", + "ANSMYC", "Ansamycin class", + "APALCI", "Apalcillin", + "APOXIC", "Apoxicillin", + "APRAMY", "Apramycin", + "ARABIN", "Arabinose", + "ARABIT", "Arabitol", + "ARBEKA", "Arbekacin", + "ARGINI", "Arginine", + "ASPOXI", "Aspoxicillin", + "ASTROM", "Astromycin", + "AVILAM", "Avilamycin", + "AZD256", "AZD2563", + "AZITHR", "Azithromycin", + "AZLOCI", "Azlocillin", + "AZT1", "Aztreonam 1 ug/ml", + "AZTREO", "Aztreonam", + "BACAMP", "Bacampicillin", + "BACITR", "Bacitracin", + "BAMMYC", "Bambermycin class", + "BAY12", "BAY12-8039", + "BERBER", "Berberine", + "BESIFL", "Besifloxacin", + "BETA", "Beta-lactamase", + "B", "HAEM Beta-haemolysis", + "BIAPEN", "Biapenem (L-627)", + "BLACT", "Beta-lactam class", + "BLINHB", "Beta-lactam Inhibitor class", + "B", "MGLU B-Methyl Glucoside", + "CAPREO", "Capreomycin", + "CAPRYL", "Caprylic Acid", + "CARBAD", "Carbadox", + "CARBAP", "Carbapenem class", + "CARBEN", "Carbenicillin", + "CARPEN", "Carboxypenicillin subclass", + "CASPOF", "Caspofungin", + "CATALA", "Catalase", + "CCARB", "Carbacephem subclass", + "CEFACL", "Cefaclor", + "CEFADR", "Cefadroxil", + "CEFAMA", "Cefamandole", + "CEFATR", "Cefatrizine", + "CEFAXE", "Cefuroxime (axetil)", + "CEFAZE", "Cefazedon", + "CEFAZO", "Cefazolin", + "CEFBUP", "Cefbuperazone", + "CEFCAP", "Cefcapene", + "CEFCLA", "Cefepime/ Clavulanic Acid", + "CEFCLI", "Cefclidin", + "CEFDIN", "Cefdinir", + "CEFDIT", "Cefditoren", + "CEFEP4", "Cefepime 4 ug/ml", + "CEFEPI", "Cefepime", + "CEFETA", "Cefetamet", + "CEFIXI", "Cefixime", + "CEFMEN", "Cefmenoxime", + "CEFMET", "Cefmetazole", + "CEFMIN", "Cefminox", + "CEFMTM", "Cefmetamet", + "CEFO32", "Cefotaxime 32 ug/ml", + "CEFONI", "Cefonicid", + "CEFOPE", "Cefoperazone", + "CEFORA", "Ceforanide", + "CEFOSE", "Cefoselis", + "CEFOTA", "Cefotaxime", + "CEFOTE", "Cefotetan", + "CEFOTI", "Cefotiam", + "CEFOVE", "Cefovecin", + "CEFOXI", "Cefoxitin", + "CEFOZO", "Cefozopran", + "CEFPAM", "Cefpiramide", + "CEFPIM", "Cefpimizole", + "CEFPOD", "Cefpodoxime", + "CEFPOM", "Cefpirome", + "CEFPRO", "Cefprozil", + "CEFQUI", "Cefquinome", + "CEFROX", "Cefroxidime", + "CEFSUL", "Cefsulodin", + "CEFTAR", "Ceftaroline", + "CEFTAZ", "Ceftazidime", + "CEFTER", "Cefteram", + "CEFTEZ", "Ceftezole", + "CEFTIB", "Ceftibuten", + "CEFTIF", "Ceftiofur", + "CEFTIX", "Ceftioxadine", + "CEFTIZ", "Ceftizoxime", + "CEFTOB", "Ceftobiprole", + "CEFTRI", "Ceftriaxone", + "CEFURO", "Cefuroxime (sodium)", + "CEFUZO", "Cefuzonam", + "CELLOB", "Cellobiose", + "CEPALE", "Cefalexin", + "CEPHAC", "Cephacetril", + "CEPHAL", "Cephalothin", + "CEPHAP", "Cephapirin", + "CEPHEM", "Cephem class", + "CEPHOR", "Cephem (oral) class", + "CEPHPA", "Cephem (parenteral) class", + "CEPHRA", "Cephradine", + "CEPLOR", "Cephaloridine", + "CHLORA", "Chloramphenicol", + "CHLTET", "Chlortetracycline", + "CI983", "CI-983", + "CINOXA", "Cinoxacin", + "CIPROF", "Ciprofloxacin", + "CIPROP", "CIPROP", + "CITRAT", "Citrate", + "CLARYT", "Clarithromycin", + "CLIN32", "Clindamycin 32 ug/ml", + "CLINAF", "Clinafloxacin", + "CLINDA", "Clindamycin", + "CLISPE", "Clindamycin/ Spectinomycin", + "CLOFAM", "Clofazimine", + "CLOXAC", "Cloxacillin", + "CMYC", "Cephamycin subclass", + "COAGUL", "Coagulase", + "COLFAZ", "Colfazamine", + "COLIST", "Colistin", + "COLMET", "Colistimethate", + "COMBO", "Combination class", + "CORAL", "Cephem (oral) class", + "COUMER", "Coumermycin", + "COXA", "Oxacephem subclass", + "CPAREN", "Cephem (parenteral) class", + "CPCA", "Cond. Pyridone Carboxylic Acid class", + "CSPOR", "Cephalosporin class", + "CSPOR1", "Cephalosporin I-Generation subclass", + "CSPOR2", "Cephalosporin II-Generation subclass", + "CSPOR3", "Cephalosporin III-Generation subclass", + "CSPOR4", "Cephalosporin IV-Generation subclass", + "CSPOR5", "Cephalosporin V-Generation subclass", + "CYCLAC", "Cyclacillin", + "CYCLOS", "Cycloserine", + "DALBAV", "Dalbavancin", + "DALFOP", "Dalfopristin", + "DANOFL", "Danofloxacin", + "DAPT25", "Daptomycin 25mg/L Ca", + "DAPT50", "Daptomycin 50mg/L Ca", + "DAPTOM", "Daptomycin", + "DEMECY", "Demeclocycline", + "DIBEKA", "Dibekacin", + "DICLOX", "Dicloxacillin", + "DIFLOX", "Difloxacin", + "DIRITH", "Dirithromycin", + "DORIPE", "Doripenem", + "DOXYCY", "Doxycycline", + "DTEST1", "DTest1", + "DTEST2", "DTest2", + "ENOXA", "Enoxacin", + "ENROFL", "Enrofloxacin", + "ERTAPE", "Ertapenem", + "ERY32", "Erythromycin 32 ug/ml", + "ERYSCH", "Erythromycin/ Sulphachloropyrid", + "ERYSDI", "Erythromycin/ Sulphadimethoxine", + "ERYSPE", "Erythromycin/ Spectinomycin", + "ERYSUL", "Erythromycin/ Sulfizoxazole", + "ERYTH", "Erythromycin", + "ESBL", "Extended spectrum beta-lactamase", + "ETHAMB", "Ethambutol", + "ETHION", "Ethionamide", + "FAROPE", "Faropenem", + "FLAVOM", "Flavomycin", + "FLEROX", "Fleroxacin", + "FLOMOX", "Flomoxef", + "FLORFE", "Florfenicol", + "FLQUIN", "Fluoroquinolone class", + "FLUCLO", "Flucloxacillin", + "FLUCON", "Fluconazole", + "FLUCYT", "5-Flucytosine", + "FLUMEQ", "Flumequine", + "FOPSUL", "Cefoperazone/ Sulbactam", + "FOSFOM", "Fosfomycin", + "FOSG6P", "Fosfomycin + Glucose6Phosphate", + "FOSMYC", "Fosfomycin class", + "FOSTRO", "Fosfomycin-trometamol", + "FOT1", "Cefotaxime 1 ug/ml", + "FOXSCR", "Cefoxitin Screen Test", + "FPINHB", "Folate Pathway Inhibitor class", + "FR1", "FR1", + "FR10", "FR10", + "FR12", "FR12", + "FR13", "FR13", + "FR14", "FR14", + "FR15", "FR15", + "FR16", "FR16", + "FR17", "FR17", + "FR18", "FR18", + "FR19", "FR19", + "FR20", "FR20", + "FR21", "FR21", + "FR22", "FR22", + "FR23", "FR23", + "FR24", "FR24", + "FR25", "FR25", + "FR26", "FR26", + "FR27", "FR27", + "FR28", "FR28", + "FR29", "FR29", + "FR3", "FR3", + "FR30", "FR30", + "FR31", "FR31", + "FR32", "FR32", + "FR5", "FR5", + "FR6", "FR6", + "FR7", "FR7", + "FR8", "FR8", + "FR9", "FR9", + "FRAMYC", "Framycetin", + "FRUCTO", "Fructose", + "FURALT", "Furaltadone", + "FURAZO", "Furazolidone", + "FUSACI", "Fusidic Acid", + "FUSIDA", "Fusidate", + "GARENO", "Garenoxacin", + "GARLIC", "Garlic", + "GATIFL", "Gatifloxacin", + "GE1000", "Gentamicin 1000 ug/ml", + "GE2000", "Gentamicin 2000 ug/ml", + "GEMIFL", "Gemifloxacin", + "GEN128", "Gentamicin 128 ug/ml", + "GEN500", "Gentamicin 500 ug/ml", + "GENTA1", "Gentamicin 1024 ug/ml", + "GENTAM", "Gentamicin", + "GLUCOS", "Glucose", + "GLYCER", "Glycerol", + "GLYCO", "Glycopeptide class", + "GREPAF", "Grepafloxacin", + "HETACI", "Hetacillin", + "HIPPUR", "Hippurate hydrolysis", + "HODGE", "Hodge Test", + "IB367", "IB-367", + "IBAFLO", "Ibafloxacin", + "ICLAPR", "Iclaprim", + "IMIDAZ", "Imidazole class", + "IMIP32", "Imipenem 32 ug/ml", + "IMIPEN", "Imipenem", + "INDOLE", "Indole", + "INOSIT", "Inositol", + "ISEPAM", "Isepamycin", + "ISONIA", "Isoniazid", + "ISOPEN", "Isoxazolyl Penicillin subclass", + "ITRACO", "Itraconazole", + "JOSAMY", "Josamycin", + "KANAMY", "Kanamycin", + "KETOCO", "Ketoconazole", + "KETOLI", "Ketolide class", + "LEVOFL", "Levofloxacin", + "LINCOM", "Lincomycin", + "LINCOS", "Lincosamide class", + "LINEZO", "Linezolid", + "LINFLO", "Linopristin-Flopristin", + "LINNEO", "Lincomycin/ Neomycin 2:1 ratio", + "LINSPE", "Lincomycin/ Spectinomycin", + "LIPGLY", "Lipoglycopeptide subclass", + "LIPOPE", "Lipopeptide class", + "LOMEFL", "Lomefloxacin", + "LORACA", "Loracarbef", + "LYSINE", "Lysine", + "MACCON", "Growth on MacConkey", + "MACRO", "Macrolide class", + "MALONA", "Malonate", + "MALTOS", "Maltose", + "MANNIT", "Mannitol", + "MARBOF", "Marbofloxacin", + "MECILL", "Mecillinam", + "MEROPE", "Meropenem", + "METHCY", "Methacycline", + "METHIC", "Methicillin", + "METRON", "Metronidazole", + "MEZLO", "Mezlocillin", + "MEZSUL", "Mezlocillin/ Sulbactam", + "MICAFU", "Micafungin", + "MICRON", "Micronomycin", + "MIDEKA", "Midekamycin", + "MINOCY", "Minocycline", + "MONOBA", "Monobactam class", + "MOTILI", "Motility", + "MOXALA", "Moxalactam", + "MOXIFL", "Moxifloxacin", + "MUPIRO", "Mupirocin", + "NAFCIL", "Nafcillin", + "NALAC", "Nalidixic Acid", + "NARASI", "Narasin", + "NEGCTL", "Negative Growth Control", + "NEOMYC", "Neomycin", + "NETILM", "Netilmicin", + "NFURAN", "Nitrofuran class", + "NIMIDA", "Nitroimidazole class", + "NIT16", "Nitrofurantoin 16ul", + "NITFUR", "Nitrofurazone", + "NITRAT", "Nitrate", + "NITRO", "Nitrofurantoin", + "NITSUL", "Nitrofurantoin/ Sulphadrazine", + "NORFLO", "Norfloxacin", + "NOVOBI", "Novobiocin", + "NYSTAN", "Nystantin", + "OFLOXA", "Ofloxacin", + "OLAQUI", "Olaquindox", + "OLEAND", "Oleandomycin", + "OPTOCH", "Optochin Sensitivity", + "ORBIFL", "Orbifloxacin", + "ORITAV", "Oritavancin", + "ORMSUL", "Ormetoprim/ Sulphadimethoxine", + "ORNIST", "Ornithine Spot Test", + "ORNITH", "Ornithine", + "OXACIL", "Oxacillin + 2% NaCl", + "OXAZOL", "Oxazolidinone class", + "OXIDAS", "Oxidase", + "OXOACI", "Oxolinic Acid", + "OXTSCH", "Oxytet/Tylosin Tar/Sulphachlor", + "OXTSDI", "Oxytet/Tylosin Tar/Sulphadimet", + "OXYCEP", "Oxyimino Cephalosporin subclass", + "OXYSCH", "Oxytetracycline/ Sulphachloropy", + "OXYTET", "Oxytetracycline", + "PASRAA", "Para-aminosalicylic acid", + "PEN003", "Penicillin 0.03ug", + "PENCIL", "Penicillin class", + "PENIC8", "Penicillin 8 ug/ml", + "PENICA", "Penicillin 1-2-8 ug/ml", + "PENICI", "Penicillin", + "PENMEN", "Penicillin(meningitis)", + "PENNME", "Penicillin(nonmeningitis)", + "PENNOV", "Penicillin/ Novobiocin", + "PENORA", "Penicillin (Oral)", + "PENSCH", "Penicillin/ Sulphachloropyridaz", + "PENSTR", "Penicillin/ Streptomycin", + "PERFLO", "Perfloxacin", + "PHENIC", "Phenicol class", + "PHEPEN", "Phenoxymethylpenicillin", + "PIGMEN", "Pigment", + "PIPACI", "Pipemidic Acid", + "PIPERA", "Piperacillin", + "PIPTAZ", "Piperacillin/ Tazobactam", + "PIRLIM", "Pirlimycin", + "PIVMEC", "Pivmecillinam", + "PLUERO", "Plueromutilin class", + "POD4", "Cefpodoxime 4 ug/ml", + "PODCLA", "Cefpodoxime/ Clavulanic Acid", + "POLION", "Polyether Ionophore class", + "POLPEP", "Polypeptide class", + "POLYB", "Polymyxin B", + "POSACO", "Posaconazole", + "POSCTL", "Positive Growth Control", + "PREMAF", "Premafloxacin", + "PRISTI", "Pristinamycin", + "PSPEN", "Penicillinase-stable Penicillin class", + "PYRUVA", "Pyruvate", + "QUIN", "Quinolone class", + "QUINOL", "Quinolones", + "QUINS1", "Quinolones subclass 1", + "QUINUP", "Quinupristin", + "R28965", "RU 28965", + "RAFFIN", "Raffinose", + "RAMOPL", "Ramoplanin", + "RAVUCO", "Ravuconazole", + "RAZUPE", "Razupenem", + "RHAMNO", "Rhamnose", + "RIFAMP", "Rifampin", + "RIFMYC", "Rifamycin class", + "ROKITA", "Rokitamycin", + "ROXITH", "Roxithromycin", + "S21420", "Schering 21420", + "S21561", "Schering 21561", + "S21562", "Schering 21562", + "S22591", "Schering 22591", + "S29482", "Schering 29482", + "S29486", "Schering 29486", + "S34343", "Schering 34343", + "S38609", "Schering 38609", + "SALCTL", "Positive Control +2% NaCl", + "SALINO", "Salinomycin", + "SANFET", "Sanfetrinem", + "SARAFL", "Sarafloxacin", + "SB2LB2", "SB265805/ LB20304", + "SBQLO", "SB265805", + "SDIMET", "Sulphadimethoxine", + "SIPRAM", "Sipramycin", + "SISOMY", "Sisomycin", + "SITAFL", "Sitafloxacin", + "SORBIT", "Sorbitol", + "SPARFL", "Sparfloxacin", + "SPECT", "Spectinomycin", + "SPIRAM", "Spiramycin", + "ST1000", "Streptomycin 1000 ug/ml", + "ST2000", "Streptomycin 2000 ug/ml", + "STREPT", "Streptomycin", + "STRGRA", "Streptogramin class", + "SUCROS", "Sucrose", + "SULAMI", "Sulfonamide subclass", + "SULBAC", "Sulbactam", + "SULBEN", "Sulbenicillin", + "SULCHL", "Sulphachloropyridazine", + "SULDIA", "Sulphadiazine", + "SULDIM", "Sulphadimidine", + "SULFAM", "Sulphamethoxazole", + "SULFIZ", "Sulfisoxazole", + "SULMET", "Sulphamethazine", + "SULOPE", "Sulopenem", + "SULTHI", "Sulphathiazole", + "SULTOS", "Sultamicillin Tosilate", + "SYNERC", "Quinupristin/dalfopristin", + "TANNAL", "Tannalbit", + "TAXCLA", "Cefotaxime/clavulanic acid", + "TAXMEN", "Cefotaxime (meningitis)", + "TAXNME", "Cefotaxime (nonmeningitis)", + "TAZCLA", "Ceftazidime/clavulanic acid", + "TAZOBA", "Tazobactam", + "TDA", "TDA", + "TEICOP", "Teicoplanin", + "TELAVA", "Telavancin", + "TELITH", "Telithromycin", + "TEMAFL", "Temafloxacin", + "TEMOCI", "Temocillin", + "TETCYC", "Tetracycline class", + "TETRA", "Tetracycline", + "THIAPH", "Thiaphenicol", + "TIAMUL", "Tiamulin", + "TICARC", "Ticarcillin", + "TICCLA", "Ticarcillin/ Clavulanic Acid", + "TIGECY", "Tigecycline", + "TILMIC", "Tilmicosin", + "TOBRAM", "Tobramycin", + "TOSUFL", "Tosufloxacin", + "TREHAL", "Trehalose", + "TRIBR", "Trimethoprim/ Sulphadiazine", + "TRICLA", "Ceftriaxone/clavulanic acid", + "TRIM", "Trimethoprim", + "TRIMEN", "Ceftriaxone (meningitis)", + "TRINME", "Ceftriaxone (nonmeningitis)", + "TRISUL", "Trimethoprim/ Sulphamethoxazole", + "TROSPE", "Trospectinomycin", + "TROVAF", "Trovafloxacin", + "TULATH", "Tulathromycin", + "TYLO", "Tylosin (Tartrate/ Base)", + "UNDECA", "Undecanoic Acid", + "UREA", "Urea", + "UREPEN", "Ureidopenicillin subclass", + "UVAURS", "Uva Ursa", + "VANCOM", "Vancomycin", + "VIRGIN", "Virginiamycin", + "VORICO", "Voriconazole", + "W49373", "Win 49373-3", + "W49548", "Win 49548-2A", + "W51692", "Win 51692", + "XYLOSE", "Xylose", + "YELPIG", "Yellow Pigment" +) + +codes$name <- gsub("Apoxi", "Aspoxi", codes$name) + +codes$name_gen <- generalise_antibiotic_name(codes$name) + +codes$ab_name <- ab_name(codes$name_gen) + + +codes$lev <- unlist(Map(f = function(a, b) { + as.double(utils::adist(a, b, + ignore.case = FALSE, + fixed = TRUE, + costs = c(insertions = 5, deletions = 1, substitutions = 10), + counts = FALSE + )) +}, codes$name_gen, generalise_antibiotic_name(codes$ab_name), USE.NAMES = FALSE)) + +codes$lev_pct <- codes$lev / nchar(codes$name) + +View(codes) + +import <- codes |> filter(lev <= 10 | name_gen == "PENICILLIN") |> as_tibble() |> mutate(ab = as.ab(ab_name, fast_mode = TRUE)) + +for (i in seq_len(NROW(import))) { + # put them in the abbreviations + abbr <- antimicrobials[which(antimicrobials$ab == import$ab[i]), "abbreviations"][[1]] + new_abbr <- c(abbr[[1]], import$code[i]) + new_abbr <- new_abbr[!is.na(new_abbr)] + antimicrobials[which(antimicrobials$ab == import$ab[i]), "abbreviations"][[1]] <- list(new_abbr) +} diff --git a/data/antimicrobials.rda b/data/antimicrobials.rda index 7c8a916c7778801de7635c3fb4aabfcb143a1074..8c460457a132b405bde470c218cec6af172bcb7d 100644 GIT binary patch delta 36122 zcmV(lK=i-l;sSu{0+1O5&aAaVu^n|Oe?jQWSfW3fZ%fGdTmE6TwH+R-yR{Y;B`}T! z6kRR5*s*MIb>DeyDBi8XcTA}xpGn&oYB7@Q?Pl7@Y6DdCd(>Rfi~%m-shBv|nW&m{ z=(1r+@qoiezK&K!=sictm0A<(wt0R@&;TnF>bzjQfF0*MtaumQNS7SYQ9WHXe+s*Y z+KsKo;@KT0?SLRNcNt(18D(BGF}xlZmJP;bOucze-t5+Z=m5uW3G+()a%HWRKf+XE>J9f)sS`L8F&{2 zeXQvYYZ~L#$A*bqCUYb!y~w2n<}7?hl9nyb6?8bUR|47}|Wuys_}a z)KMVyy)qj8^%fv2{Ltp&jFPm?DdRN9EC)vH$o~=f9ZU-2>qei`TXUA3e*#TTDv}BF z!48sPJfpkLF6ueX{WuUQmwsERH4?qhC9We~%sPD)ObdBT{@WyGof(yy;4+<9Cv3KN zl=j{;dMtqn(AN1$_U&p+%`$f2H!bB6lGf6Y2a+F}e}ci$EAW|+V!-+a6fADiW!D&M71Z|V5TaI|7w7`sAc8-7 zs*xDcvnF$^=|nJI7Fo`X$TU4v;e*~6rs(@S9J)<)M>E;sRW5)ycoW3}S^Er|lYY=H*9PAwD^FE~8ff0C?DP~YNN3^^0? zzxnW$$~(EdRZr?P^dO_i33qfI;Nj>oPa*2;FmMv#Da@WR2sX6l=Mo$4G<%keiv|Vd zPX4DzjS3Ln^jqm-oamLeHn106G9UPIPCf&+7i=^s`j%nvDA7?CtM;6~ zgqU7wm^&f<@0Yyrf0wI4s8&6bh^;5eGU2g4_ud8xv^fz2n|yGeLAsLDxs}NATL$P9 zhc~_<`dkRTju4{MQlVZZQ=#3m-%B+T$AT>wr3;VbzV(_kmm3bU^EO4mlr!a_5nAtL zVV*b_6uNmYqHt_7VuiW;iq!;`e4*; zeq%Aaw)8UVN9C4_k)moYdQ{TajupJt3QKOa)UO|jfmG3fNwoG#{=iUVlaEng^%ppL zad5!j$X|z++bahZrlD#Tr=~WXOt{hWU<^g-xp3*C;p~YOoMshbpX^N=oJ;6=pCV4T zD=H2SeWQ&3f3jFt?UVRt$ORhsYh_fpvn0RBQJ*y)T_SI^Q0}{9Nt^3^y&+a*edCPPRuDJpP z==Y|=Qve!IXbwG{lNnl1M+Gih`EfG&WBif#68Nn>!d$J4S(zJ;!+`Vxr-C!1jPSg(e7=- zQ4HfYXv>YAg{rwW>FWELF)Xf0^R%O7^6g(eu26u%;f!@Qjo3ot$rd3hH%kHyy!$v* zjUaN=UfwoeatmQ*98Pb0w;8=)=?I+LB>Iioe_|LhE^=#2o%J{7w0;6d@V8thc1oX* zR}lXUmPl$6_!yTGO&&Wq=5)XQgsiT93 z@z=tbZHON8@PdA6kbvCyJ}hHLO>^E@9BQ}@h+n*=^Tcs+htJmO{ zqNb$Z=EMaCn^H!~^aUJ}dV^<)N>vqBe}wT8xG)3CBU!AN_@go_V@ZH>NW?bQ*gK=?2gH+em!IP{R*dnUT^aZN=d!I3*7-f4AIU zZ0FQ?w5@i-rtNE|Gp)-}_TsDHR%P&ZyDT*Bwsuv2 z{!w(N{^UGqjL}~ox2Kz^uN?ZSk%vlHSLRzj&e#=RR1uGk`9AW0RY^GkXzriE4|vY~ zb!gTj2n7zXaU^@Etk9R-J&?4GfB3O4;VdZ$Ti2pe!3iCF@WGFutM6?#_o>JiPL^DI!I8aOwnl6wA2ta~hs`GMZp zx-)c1>dfU6mN=K8xLxd7e_vV=&^D`d*oIaf*yG)@w20ZpwM$V_cc3npRDY(T1`I<* z`BS2^cQ?}tXns|ZNax6g=2`-g_3DxjxGXhCA~b&- z+Xzt3rcASLKh?W@?FyW%YtHaiC~9($m|;z1mtCAo8AJwY5=TSsVkm~)!oGpqa~*t{ zHl9+ZEQO>?lFj&Kf81l;QHJKC0=vvJ`w+tt)XPvYvY{R#AY5vu*G&H5#b1rfnBq3O zJLFwLs9ye%|3l)0;8h#XpU(%dm~p_sZh>Si(`^ky__n?C;7tt`0OcJX!{qalORtZ*ds)8JGti zJ6;epq+4u>#vM4iq@2A5FIEGpJvm3@yp4p2wKf$t&ZAKb+$ciza3fMrUMcq>!@lq zhcN<9De8rwL3DkLe!;*KB|iER-K;BM?J*g^9n=3$f7RKU;vI=s#k-SJPKS`7f*>O~ z@lw+w_DNKRQ-jG_OMYQa{8MHQw8GAVa(=_`V7{zn+UiDqRhkE@=ddYmd8s!-cY-^%s?H4aCn}C-m;_ z)z(Bce*@`B!9VqadW+kdQ8;7UoBzulqrssIn<{98T}mL5mKn>O0|@_qLf-bmELaD( zx7DM7v~9#SYMPh_>xr9izqq?_x1IkwCoKGAM+>yzOi8qZ%aH0qYC6gK-3Um)h2kl5 z0vB!Ctl-o3>=tRXPwI+?`zwDm(m8W?{peyLfB4kZs2uPG1EFB3Mq%RjXMpFPx}5LS z?s92#N>Wc9UKkE_DKD^A6R3^$pAq2D%cpEiL*+JTNOJ0Yoqm&VK=(Dr%@B-bRC;rI zG7Cy&Uo`Cg$-RrWXz&I|#8D?NS|VKNj73E$`Q3C6+~vKo`M3BpdJr=jazDoDF36|C zf9OII`jNVPNkMSy_+&kmE19`W$0ikaTwR<+Tae#xj3O<#5=vl@>Q7GXd70*-GiNW* z0Nm;^XYs=U5UR#rzS`1Vjk5_XJ-CTrIN~7bda|pNtOodhf9H{HxYu}{5xB2@mC!?2 z)pe^8U9bNTg)a11sR5K8y3~hW##J+wV+!XdH=aw|mKm^LxXgSOK4CQo!q&ez8V6cM%`WEdg8arM;Dl$QfB9gB$ySq> z;{Hs*Z&Iik0;P3=L~e1mEO4?Vi-z{oA@U!lZ6vShcugiZJb2UDU@_xsfv)d9L|jo- z1|195FpBPB8A$rKpmQvk(8f#phcwSZ{+8$55?s3{d4xIFC~Mrf zSc1tb|3i#1i1D;zSzCi)thwLrpQm3u=$PioUBGutWrKB7+ z!g<8#dI44OM9U)00q6B1xwuPAKhTtc4`a;498|3W##`PEFtST1fM3B}fzpgO?i>Cki_pR<$0n zqD?!$aG0XE3cppi%0@Sf%ta^b09B|O?vK*DKz}SB-GTbS{xtt2$1G!GS69;M#^bMU zM}HAz%Um(^YL>wPYBn;q-u>~6e8yFUuZLC>Pv#@wfsFMjH8I|Kj5F%9G>* zkAbTUY!@z#5ZcF@YbMd*S}tP(7JYA)_2t8rBon12#ef$M+cW*Fl$%Y~@U&`2-Lh=M z^pIFrwJY&~f4A(m?o-5Em~E)*+h`Z_;Q3n=$*K}WF*MrVb;eaLzwYwRyID}Peu7~< z`Nc9nzT$><-!fM`L1LNI%eZMJ2tr;3+Fuo`RSg*;YYXak8>l2Bs1xbOCfeWD(zMZm z6M^h%(`n@47~;G?S^pO$9a^%v0;i$9Ijx5^kkEF4e^THH=x&%|F)Ht~F#!7(rvu;& zZOx&0)I$+qQ!iz`8S?G=);t2dSUZQFCm;E1<;heYO$rY-W_SH;4r42Om zKXUgBJ%UEwk69bf4D1E0f5p?jK)OV05}E&iNoWdDas<6WncIp)2l5*P9el&sXo?kd zy$5?se=mIQBkB;nxZ4B@p!Y5V=q09yS2vag%#ysv^9z|~%Uo8#Db!OQ6VB$A82ks6 zMG}RKtVj$Tw}e6-R7pT&L%%ftMv=dFlU%~sN{n?RgCXMDLP}|cM9*N5=M;3}3jnJ= z(nq3bF5Bh-mzC2It?%(rtA(JpVVL6}7=Wkge@21&%b5>1GDBT?hGa=(#}rZ&t%b3q zHW004OqepFOf+s@+|o?k>;9DDtsk2xGWIMqzJhk_l30a(^%4a12>AUyFAc!0Qh1dDFnWSkDrQM)-{SoOF!a*6x;MT?rMMb1i0oHceih7 ztoxm}!pvmu0ymXG;K;hzrrwBh%gn#ZvJcnu zLM;AoeS?qoBMbWBoUEt64AE`v7tBHzk~0P1W$Q1rfvcF^$}TY{ zVwV)iIxlIt?^Bw=YrPO7VB8y&^lv^tG#uhUj!4%c%A$gGQ11r2c`6W$E1okY^qm1YrgLXd5`F0Ua& z{4H^-(M&Zwi3LZ{iVc2a_fOOFN^gaeh?k7_03A62)FQQhT}iOlF3U$(<}L3^JgAU8 zp7Jq$ftx9YvKU zR=Hs>_A5Ka`tT~KQF=`dxpepl%8QI1#M}4K4Nz005&Zz#o#l>Po%{-NCJ((&2 zJ-v+8GiPmxjhh3xezTQXIM~M739KRw;ZkaKtTbSu@u{ci*WzPpu*-xpAgMnn&squj z;@M}Hp6z*H?^%6L9elIZpGcyYVY0S6I-`k|hNBBoJXmkL^IX2e)R<*bzZllaLnOUH zlJAURY(FZ};axwbe}l@CANf@EhRvWhC#@W$6sJ?n$C1O2z@(U@7IUrKOSb8Q3Hdi6 zGkV8FcU>9$lxjGp%ju!pUhAY_|52J(Q5C^A7y%j;ks+wvU{|uzQ7JYMonsZgv-Vqb z%z`N;r8Dk0BmMfIP<{KgU-g~%U+#)ifAd(Ujzupl4WE3wQr}M{ zc$JuJ-}|jP$pb>sdPg2sIWW49ijX@|4Gv@alT5fN&qmyu9_SNu%%AGc zA4NA0E^i{?*|#_5)&+=a71mmPek zYsF)Mup0l^f2Go@$I<*jq6zy<*!l>F64>v`s5XULI3L7G2%Y2H>j^kqn+mY+22+7* zM@jcPr6nm|`fS^7A@?@px(7PS0G#m#+VJae1U|k7Qyg3>1b@J{34M^4Q(|t+2y+HK z*AvE@)49x2@#`9&%OeOyJ`-Z*t_{vxKf@MKAav~Ce+l)4WBn|;eHu>z@?r-LNaNty zds^35^Nj1UzlLtv&P$ZzI+1z77S78GlxKf>ckVUOD{%EFwbbLk!`K7IA4BB*Z+8fe zML%#tZlp~Vl&&8@Sf4ulP}QR7Qm!4Cg=9x-i@?F=3dxS#q!fTN;NTV?xVtNFVi)k# z6^CQ2e?0Fj#z1|nLOsC`6DQ&rR=FSFg@!Nn7&>DkLVO?r*(wyyL@RngK`V+XB$FHL zFv@z3Eh+TEN)-=~71@`-N_aP&LO0@~o`2F>W*Dh#Q(SvbzN^@GqIQX0O^U5xfAtDLhkGiG|FCgb^j-OO)$-MgIzs0M zD73gQS|V*1ZbS^%l@#MlFW~u>Q=a}~)|mN)3QOQ&&F#@5C1T9YCh&A4pTu0x{1O$y zl7ORvKH@^riP<`xvY^487yi;lu>f+Ci;3+RJVM?uwwmANx%GDbe<>#`!k7ri6y7gqGdXUwS8t1pF2oyqmYfZCHPUF~psDp}}o} zz}gIk6-}_<$bQtxA=VtWxy$NJc)J;ofBvI~1RJsKn4swubd`wPL2gkv$CxfuX5P68 zd(v|DP^EE4&uvx%x|=MP=#rG1apRVXIXk-il(&6;YJk-khqRZk-TE5**A3Cqt&4sp z6W1R6FMNK;uwu%am??e&k~#x#0m5B^8!|S@VQc&4Dxg5_H7ewM`0dWaDI(p-Gne~BDBL^Vo?A^BJx&w82*BX^_WZcVZIAlaIK{nson zZan7C_*u2`E0wyPDjR`AD&*_QZ-@7J3*532^@q5T#zBhoyoRQ*n$`Xe6n9iA_sBH{ znXc5k^Gm}6^nAG!)Ec^~=Y2wZ-PjoKYNM#0iIK7$AL#UJ{G?uY`0$I z`C;TM--PO&e5B_{vp-bPfvBN}QZjhwRW;Yet2@U!Ye?0JIjY~o<{qH$r z2uIhDULY)Z%qstV@X@h%qW7fHmzeySD$KWab!4SXa+-I>u4!apW*LR0);0C?v#zsH z#tg2z%%AWN@Q+lXG8pSAXDkRqTF~y=hx~QUB=;t3xe!t+QR#Y9x zU>I+@p7xgpdg&RKw$xRPTGywN=KhwFCN5Q%)?Zvj32sOxd5Srr>eeP zfWcloI>bTCJ$lY!|JicI{S74naM?5a*ALVAbVQE%ylMfm-x6heh0N z^6q9mZ1OJvr5sNEj|r)v1XGHqH;!i{kynH>sDFgg2WN7F7fl{bvOF?=w;d^@x;t2U zt5b@A&S7|f>&iLLXCASw1dYPkT;`HPexQW&i?m=X@<(yH-Yt zHxcs+WtQhb`~bFFMwxd0ZtjnKDRI}Qd5CCrIxFZo2pP3RkuNLR>umIPLq!s_n{j1E z268devR+R1d`kRBPY&#@;&sgeFQ1&yh=gbd0YFT-e-0WywX-hSemXrJx5YpTgrQJa zrR>-sgWV~oy1w5&+N|!j>&qmfSbedlJaPlb8-0{~K%YDHfDz@h^LN$%MH)|7TR=s< zkaNmBu_yOK8r`;4IRC3n*31m1ZNiq}V`Y*y?5v4Dmx3{ebiZ;BRAbU5xZaPU5@NP} z=2<@bf0#~=u%#HXNs!;_0pTM?2Ikx0aG*0_tib5C;nu%sNAVqV6VJ4>tBqy*SuB4oNfriD}lec1oN2wP^ZvGu;? zHXG-~1?hwnVnWIEAHc$({B694-Th z;o!#g)DEU%tZ3;uQCL4SY$EihY0_7^Z{(q;l_FDBxxoR} ze{HMt`LEG0sTGo`p>>RYK7lVm+P3NQdm^{66=)BnkMULL3%Cfmrtc`)kdE<@%I&+a z5fC)$`Zqo7+dioSSgXkNQTT&U*2wb=TJGi!;@RpU=cKROXfugzBavA=z&q>ZLsP=k zpX7Z9FWIB4rFRv(q}l*{4WE9);2nty(B!Y(w{- zfkZ{>4zB{Tzhm7`Ns%s%g>lS^ffLp zQd-;i7P&_^xG^5tVd=rjYNTs+*C!9vv)k*pX7z5i62;V-xft4^=&9#(xi1)ICNvZo z^j)Y$zaWhLF{M2766^m$cDejy1S%pB3qt;4sK@&=wOri3nfSUEfIo-f2b6ajk|KA#l7rUi-6nLxfru>sDOsQ5FJ-!$P&az zNPhyKr7+(IPyaR0(&9bR<8Lx{bfK9?SAJlx&@(?Q-sX_BW9q9l>SnJo)t;Bq9Sm8^ zjCHx{Y6z+hYpP|c6!*%j_d^}kgOQ9iy%P}HNvrCqtjAFcxa|Ss!1oy!e`3qoE)po( zxCAJl+|hO1fv3cf=4)l}M|ZkbskZ27`YK1@^>wdkU7H%??6MDzgRwok67Aue1d*iU z1*N7(I#Nee9v=QZ@XR}_WL!>)>MwF*B4zI5kE6kO9kzKV&%CqKT2#Tw5h3FIb2~Al zZ`E8&Ailj_- zuv^H7gsvbpR@8s|WwdWYoLS`$NSGu5d5*f9XzvJdtzb2zdd5Q#e@Kg5e)-67<&pDp zur?$*{(LGTmsjxoRMrGnl}R_KhDb|cjq4OrX#+?hLHo9yA2oItX*tNl;s#KZcNV2L zNMjJ&*bz6<%)wGBNDErn+Izg1w#0hLyVdI48+_3^BY3;nrs2b%c|qD zXpkTt4BnV(4LamFo-jf%dp#y=akSjBrWKb$PgTV#E?=pNA%Jgtk-Zq6!SLhc;#2}8NS3T-XNN4ej+E_NRD#Vc@+$>=0fN^70iNu(=U_%e zY9t{_cW?u7OG>)`kGivua1Soc0$&fcST_`l#zrmYw=#=jy$0XvQ~R58v2JLA^+If zpFqnChA3~Qp-*B9`eAG;Ply9pRK2YrJ4)LS)Qr@ajE4|h`&2n{_%+v~*xX%6YVR2> zJluaef7>fWY)5pxE(4f#rDp4%R6&9;_FB@7jC~g$f&he?VUv|7s-`W%xPn-G*8upT|FPoc18&sG`~e~bnZTU7vc>3KmFHsG9fOQ_ylaX(CH zhda~0jLYighL}V5@+H^+VgKmOQ6=%jIY;cXe5#mM@4r5-eGr{5ljPFC3>n)zu`OJb z0}khI)9%J5-Jzdiw>VoBL+%uN3~T&NQ`&5+Hbfq8V;0%zRRtnd#x@8t&v)@=GeEIC ze`4NqZ(3eqxX{}!3>3hZRgR zBGq0sE)Chn&J4iB%xv}AT0zHpy@AF1G-$O0W(>A-;|=fWU)%_xZ_Ip_dnjwGb*zV zqqwkW+mTGlt_{??9bg)2aV8$89V?Ry0y;^%7wezdI}Pj&kFMI=O8S1R#M3rMKwKbE z4SeM5_!5~4WXsRzsTbT>-(leIo14Z(qyn@-$lIzPjM?761Wb}VUrB-S1=6q@EH*#SLT1rjF2r#nu8eJK6+ZEz~~xRauT(&dc}oYAxQ zcFJ@6Xl=wm?yXTYR-x4`Q=Ckxe{E8C#$Z?cqB7&(2FHRvwCVo|TShU9CDAu5lV3ca zp5;dNuBusq=dbaEm#O$(qdUQL0+Awfi-$>lHt%5!6=NA~PB=`RWA75Ru)viQ;AIRA zH!#K3u7_z&C2C>Bn_wmWC5C+a(UFzH0e~NCl_klxT=@%pH`h?oUBV!2G3BZg2+IYa_LN*$enE33%{uSm2h<&!O7Xy zQg3aQ#PTTB{&``4mE_i1IBPruou}zs|0DnTTG|`*%uK`IOx)n_8kgG%8Q|Jh6xJ&!Cp)h>#_BWnvi6=ao(VnLdaxO`w4~G4C zeu$`Mxn81IEwfFD5ic5IUemn5HOGl9)0T=}u)xk!rKO(6=)V&Ze_Z}tP;^?k>Kb|i2$70;Uid_d@OWVw~nlsww>2A8xPzCY^-OCWn+mh`bs2~ zu>_6qF$nQ1mc{z_5bzQLV2;fP+{e9|(}k$l&K{hP5Dl9lam2hpdIKT{T9NTa2Jgzt z3#Tj+C9d~*9;MHsf2yT(cGGckR~16WQnyl?qxP()=w-Mef~;&n2i3}9pwf$-k`C!$ zI33DR$i9qgU=@VAeWs^_baNeR`EO=ig36#zxJKP|8Gte|$PmQfw#FTiV)Ki31Shsp#Ly?AW`6%_MI-(_6 zwcjuFR~&WMe?bp^QBh#e)sdOKfEP+J(7`8~Cl4kxD<<8$>y|xY(EmY z2<8Wr6mFIVSN~x00cIH@_OvvRh^MRu=&m{LC0_mqF9FL?J%m1$e2Fm$f@N2GuB>}g zbdf_Ak!*jHz$*;*t5~nWL;Y2f{=~;0!g7-mF&%;3f0u8-y}V%3X1f&-ddXAl(vZ7D z)x=jK#a;42$+49|&jtj{Q}J1gD%)JU6f{Hke1>n;W_2f}avjaB%X;o^Yj$M|-S0tN z$pS2KFWA_VsM?!`lJ*6>l0a~)Fdybll{!aLk|TGE3qdMZ<+woQP;1w)pfwrKxW(lf zTpX^)e;;(w-Aa%eUo&yNOQ=Gw8141J zn~WebYmH5Xjg{~fY7{m*wR)nHxBY+QDlNTAEYND8I58Dn%TuGINbnWm1-Q7h044)h ze-vK`isIB=C}LE&tnG_`!%fH4H$i?Jk? z;b-MFC)qQ0VSq(SiRsThJ46w6eeQR;ry9HBifB=p3i;Y+_2X67*_vdGEi}|Qu7GHG zJV_UsAkb@}v*8`-0MPU$A|L~c^Wh}oe}?l-k<(Alns!~?(}7)kJOK6upPMrIL+aU* zm5jc(*76x6ni`LrgFWdWeS8O;%){y4R7(5la%mU^+pw7{hMbAjE`7D*j-38TFzDyy zLnnuzuXk-pjk1u^43he~383_*?FX=Bbh4#7m*=(xH0FXecuJlebwUxlEEfxU1Td_FeJu&uT)qbeGZMLlg=~|CnMT z22BSSbYEOh?+Ep~QU$k;H?Lc-iBkR^Vwse?7+1e<-THhVmPxK(pctQDX`e(7@7Oa=+f-e-{a+ z_)(Z^^AI^bZBF6hFz~Z-?Pfxeq`~4%BN4--Gu5Wjy)O^+Zy@$T6}MVe$Ovc4e&vy) zuI`EK8U=vpJ?5PLpRUBduqU6H31ZE(DDd03pHMJAD@y^ z24FqV)*gsxzbPe$vqrA70;0!VBz+Li>r!Xg4vvLts*m@eci%og2v8d3sCj8qcJ(*5 zi`Kb@Gybm5$G;=mRsG>lx^nwp_q}BqNl_ZxTe2pD(^ljP zDqdFegz$rogoee@DDs~;P7c=`77zAG^$1o6v1hD%U7W++5Jh^ddbCen)<#KGfU4R_ z=lx()1-=FT@xyX*a(QRdN%7M7TM*BGH86N5vGq4YOWV!_6kl}&vQ<(18>H#-Uyy6V|Ek}7 z(@;3BO5@&sr{2|m`L^-*-oo~jZ1yB%N50qj56jtu;f#zBI#y$9b;GA$>6MTMJ-quC z#So}YWtLxpRoze%X4$05O#ex8|0=v%^|W4Gp{-pg8xb{=e+TG|&5ft6%6$f zTp07JODF}t;$uzESLaZu{%&5t2fb`_hEi?vkskckdyiYlf_Wa$&1s?kadQc4u;**5 zt;PL4lHEQeqxP|b7OyI74Wt0aQ2ht*o40jwP*lZI;&)EIjEc7JlaTrCiJU z?~@(bh!9s*f1@8OKN|}=+WkN~@HCY;&&#JXYQ?AHBV@~(Z7_}RVh)4v6)zW%R*A4* zFr5wA3KI1~7M~MI5}#<6dXJ?$CMt7hEf)9xo_x9PiM>0CoTu!Y_S4_b1xCs!*>L?^ zYoS>Z_lHiWUqDRlLaRHYzYM5*eL1r~(Ekkyh(hc)+I2Ra+wv{4Q7jqD^v<&gC8n_Y?t0jp9on`s2?O=wk2RWpg7{i~dmNo@1ye=icgyn>>!Mut(hiwr0fxy!hMR>&%p zmtVP}Od@CyX-d-$RtVcFT~(D+H=&+&6kc}H5C0({>{?BN^MVx7$H<3mdCr)^)JUG? zz1-gOYQflwG?IEiZKw<;0m)YK8|{~YlMmv@?c);hdS8;>6j2+!;?015?~NDa8v~V5 zfArK^{5nenKnt@#AZeiqqh?Lz5JPzpnFhwQ5EC{=W}~k{)>t!u%UXj-7G zI)N64_4|q&G1d79(3cP5$#G2^v(4AxYA+Zs+3)gq(S$x`zSdZ~Xk!Qr{%tTjx5TSX z^l-&tNV`=IhG}N@4+e|BdAowEIt!Ste+!0@4a37Rs=pS}#U~A_tDPIbGLbPhDtkW#x>uz2@)|BS@T)76 zNoeR|2MRi(fC_-9x4$RSf6O`Hf4gW!%0SxrSfTpoYB93AtcNcte<5heDO@X=v4d@Q zHlsv67Oe=X!6a^`J8wio>Gg#7NS+HNXPzG&m85&8OS+VBe|YZ%6GBS5v?ZQ5)q7vl z_C&?WlGItCjr1E3OZKIx_iYrfci%L*Q|-N-A|r1HyQio5kKulY%2`+2V7To0f*M(;JS`Hewx^T5pnilP>S?+ z>T%?}&}{GAk>7P-@`L{0e;opf;_O-xVe;BIPdDNIAYuz`1>IzzCbaWeQ=5|%CT+So z6azf7(rw7bHlv+BXercf4HgR7(Mn*Yf;$ZPb!eV=F_;|m2F9Z`Sz@O%hG|`YAnO=Q zg+)M95RM%_zhU~##Ug7nu}$}qL1ksDiw5y=+m)u=VJ7BzGH?I^f2!5Y1@p!49GC-c z7YV{51VgW*_8ECwt8^_V@B60BD)0oQlqE%MMw3rijzo!%xd9h4=Hn%$x1r3&*nqe` zmir%TKh&K<@=VRBfY}=lhj8O4U32qT|8w8f+egk-1}xbL2#X3r^HJiuf<%&L!Fbje z43~p6Qqr-`(slHhe@0h5XIDISpz1nrnghs5Z(rZ;Tt$^nvDWMC_}i6maF6s7Qbnhg zyEOz?Pnd$Sfh82G&j$bic$)AB_XA%dFYl22E2*(O*(F!zFS0L{{awdHJX=l>>xlOI zkF|q+1Ucq}j!hNq3(|kxBNpG9zwIs**PNrb}pfMC;(wNvy$ke0gXK9`?iT5Jm9e0uKqdVfG&n2o6S^ zsjy|_p7y?oLDZ>*kX|fvF4J>!C3wwOtR{||lgUT9e3yOX_%gi!E^+lZkNW4{TYZzp z`M;v4r3veJf92b|$kzu?Z1O}feo%JK(L%gz^sTjiq8ov-ywJ~u?Y$yhR}|XK6~h@S zxc{a+8sz&qH_iCgK+u?dLF7@Wmwa|4WB2z zV5`|Eb4hEz4E!yTQ~+79oqO?sbhD`Czb7EYHfY~|gQ zn3NM1f9L9g6Kc+FRiMB`phNzC_@{&55UMLav!n0goiNBGjynqIcRa65Vqq5JJ$VQ& zAlF`BjeZyeC4Dh?HP|;trA6}fkn@haNiP(;u(oC7iamEe#`$=7Z*e{|zqK$~9lOJ4w_(_L3{|j zZJ#~uiOl$u8Y`gU#}@)9ShZ6jLytK7p&@D%;s_r>X|!sY=Te@$Am28OuNncG;ayp@ ze_;fwlJG2U$QG$X4kKQPaGhe=t{iIMC0|QJM_=NSA=bSZDI=Erp6q07cyMTqKAgBU zy{<1)EPU^VPcOHV5|%>JxWE*Z_3w?Hq&%x6n_&vGvyb8?4(_O~yHp#Ba>%C`k&5xk zU7XL>m}E5L&c8lErIL}on)MzhfFvcTe{eX*@(>iB`R}L0c#FzAq@?7>5NoJo)bP^l z_z0=^ksTXW>AO_`VYFywMjQe*!b`FCS+u;vy=$ua{XvLtPj&gpheyQD4BPBW{D2in z{6jP}$Cyf2;64Oh7VI01)Ik=e=(g=M*`e! z8NVjC4HYt$Mxv%w(wNg~1UDhu0DcYVXPyvOCICbYDRp7P0HBAwDoi_2-=3$Dx7uh^ z4#&$OjGeZ}*aO49ZZd&OB#p`>QNA0al&negs<+t+l<}z!S`|xz^MYuBUGRp(^ zT;nQ~4tk`Ya* zY!!LJXwEfLS7!HJN+qu{(0_j$^c;r|ZupJResJRwISAqtj740z<&_{2UX#+OW-V|d z1pyHuJ>Ow73^0E33xFJ(Hrp!_i$q)S!5;qLrb;1r7Jx_l2#R0@e?pJ_y?|H&rcM5` z^1or3dmKr7NjZu}5e*FIDVL*vyN0}nQ|lkhmR8)(df%jFz~{4tyDrWRXDFubKi~mF ziF}-$Lb?r*ziDFte@+BO2~rxt2>;J_XM91^2g1klsI`!iO*6uEvRigx@)tUQN;AH0 zuEq0>Z!V|m`LA=|f30Ywg4DdLUM&^y6QW~!dPL)%NuW>Z6_RB{=ZrYt&~BQ@NX1v2 zu@`>Z8(%aXg5sVhjz+gT0PUo(0hkJ6DC)c?cKs%G8f@|A=@TT%W-Q#YbzvldON|e6 zgPK`}UxF=8cx3K0rSzHg35x^PI9*XfHMR!azF@tBhwtMce*&jCVGjXI!V2|2Z%W>4 z3MxP^0A6w0X-Czpy7t8j^dX{}XIM-+Ai2Dd#@jTC0XbIb&L&A}{{OiOE)9AAt?Nqh zx%b}pOV>?mj}KjW{g%~j?7F-ArudT|_2Bq!T4(1X%ZgH6@g-aGmRTrFj^kDlx={+e zwktiE?bU=0TWQpV`rbCc?4Cma#!n zg-qKt;@}~8vSI&LSbLy}QhnwvlWkS4^0*Pl-gwF-e^H2*m9o5y; zN+FZgk;uR?F`iE!R9u(&Z5NaA`8-^r9_@|*wg?Kgz&KeIh!4W?^E-5Z)v-ppKzf@v zdZ`=9CtsEhm;{%VIDqwe@za_P*SO7%^jJv?qaJRNC-JnbZaZ(~1LG5=73Zt>Kzi^w zY10MQe=EB6B%Qk)g$5VM2G$}#53drTckc0!3U3Z!g}im@+fMm|-2*N=!y%H(ilrd- z*4YC}>#N$E0<;c&DHtf+e{hYN!63rUog~7`OKcny;O4fy_s85zi$!QlZ|lVK4s__= z;@f>rNuS;%SAG69o+U0`kZYE&6kGr?K+eD0k<8)B?SDT<2rCufuLW}BLVk|Up~r}y zYxAq4d{w1DyPT9xh`pr=PaCbCru|+3F}Lu^155puP5E7LmvWP3P_@%7 zmdwY>Kvn5&<2krJB2s0kxZI&bgltjQ4iP+OOUYr3Lja^DoieQ(Rt~f} zpV@g2!he3qZVq<20?>ycKYo>|FhGTp)n|{I5Lri4_mRwP|LS!)wYQs;Ic#_K)YiNl z9f>p6GEu(CVv(-{4fr@F^2O$$i1Um-xXvx8&$EGh)f>pm$t0^vO9cL6&rO{kc{P?Y zIN+dMUpFjs`C8xl{ZY1f&1KM%aS5J462dtgHGd{)Ja!q`H7CcP1cTn$Jwgpopf_?a z(=1E%8Lv000FNjEW08L0{x-IXw~%5~r-hb*z;U@DIfW@dh0@uYSPo%av;;KlV1T4ViN z+JCT5p?TBa(M5n5uT1h7ybx)-bvl9;peTVg}jz|JIiV0TS4Jl%`H&Re{WuUWrWjOMHr`kBOx|_*1egko(f*IBLAEI!S zE9caQ$kJ(@0Ux28t$GO&W|{SqAyr6YbARr@HTr*@e1?i2$;eEC20STZHHG_Df~_L% zg;Sws?~ht;@%&0Ek|!e2K3yyn>Zvc-p3r%V-38h_r!Eocfz&o)0@0n8B9DB)1rEG? zSIapy?m(N?O935^#h$<-D@j?j7D9N|&OrNjrysW{hK9!l9By;C6q+apFp@02pMM-H z%@RJCuA`~GpTsy7x|wvrw@wE(7%mt)|8A#BzK>X=Q_GjG%yAIq!8yKQ<8)=;=Sc%v zh|9TzfAsrVge7Lcrj0rBavA5%i?ld5qDVJGx`UwOuA&zhp~Ee>r9rP*zE~h04b0Pg zX=>j8p^2v`k8Au>UAN>$n7RSP&wuP^jG)Bhp#RLo4xizaPjn@z4z_hV)1a9%-gpbx z=j1l7$~KcrgF1Rd6~E!8yB6UX+-Y~XaGK2?Q#kOvb4e%$(9?aOugf}) zdlzJjfVkE>M`CR)?*gP~>8?Iy71)XAwc%e6aPf|CG`I{gSFN=l49VJ7N`I;cz{2>R zcSpV6QROY{lE1}9E_F=tO%ZUbkCt%B=lnK-q=JSV1VLtl*8kklOW3%AQ?(}>**$6| zB5oEoX7*(E^oykF?sLPnrZas4p{G|Wu*Obf@*E) zLY%T+zx!KkVP}4Dx5^`HxbO?X>Uo%$>w=eG)D>NNp?=kvJ3Qg zcUtQP)@(4F=8-6xjel2xpHilS*v<%?WUeg3_=}ogKDq9H=QxjZ9%b|NRbFsu25e7w z=M@2SY~&=Q$41j>8;4p|k{Rb>lR2MI@>I>^a@Vgp)<$4av6SZDfUQ#@oTer_d^iq) zz=-k|*6p6gLg#waeWTYGXf`Qdp+{Kd1E%(%|Ec1F+DEPZfPXc`$JC(0<8IaqSk6Cz zTD3>_?X!Tyb%2SGSZ-NM z?At_yr7uyk{`_()_zw1fNTzKG6YS!4YMm|zujHZZV3hH?jYAhZvRaEiB%mQr{5t)U zE0M_@=sy+An13KhdYVjPtuLl@CCj1-H8Bs|RZhwP)-b*lk?b^HhK7w+ z(DU(@)T79wMLw;8V+^LH>^DVsYb!Cjr%GHDD!Q}t(|=^9Sb~sgqbr_Zzr)m`2!T!l z4Bp=>cxm@zQK~T}YW|`}eVw?Jbh0b8Wm-~nSEmJK#^Z7!gq(41xI}% zSFJ;@>qf&c5bhNnGDJD^832ps70Qlk)&)`!h^#)Nn5segm@{_D79-q*mhL5{T|}Wp z`}5_igMT;-DVvNzm~!hKuAJYymhSnr-hr!#sTc-LY)?q$6cno*Sw9MS)6-3p5*O5i zWoG&rUW#tPaiMx(LqfByXz6i{L;)$rq5C!3cIHJ>Z(M|d6pm_0DJv%x`=W4LElz>0 z_ZSoPR(9H!RyR#V0a@_^f7h^qVOKO^#rb-ZPJiv)7A>6vJpsRYM2KiL!Z~>naC;hwCVDv)jVu7F5QgfC z7U!IYG(|(gz>dw3f1@=$g#@F3AsnS)8_!Jk#s|Lv4t!4`bW%wT=(DVIsc=dXTF1UX z`hWD;N-^=zzSQNPPtV-fvsytk!zHf@OHPJps}9iukD)E;JbXu0=M?y$b(mloNO9&@ zJ%5#U`OO>30c!?@X5Yiw)8rd^nC{~G>_gQ(dmCFxu>VH=Y(t}-z%q;-~MjuxKPG}Mz7y8dkGvtT0a33JvFuz?DrM1gN=GD&_{zShZvp=yfgvN#|fOF*HdKXn#0= zurFaN31ODn06`YZxW5O;&IISV-(D($VY^p&%huSKHMvhiWEJ^?MY=UXq}QUUnJ2k7 zp81pLuH^0t$$Lq3hV}zztBPg5l6AB8!=f4RAc&+6%zjetDen~~6lwmxU951Ks4~P# z9iNZty{x(EWSsnG7NJ2S319_1-+x`06KPvbO83%IbDVoG(5Zkm*dt}LP5^+F1DM=P zGAT!tPHqQ=*+rC<25-EWa0PWO<#|{_``G<1XRX@%qZ zb)^GwChdu4?vDz7@py0f5R&l1x7U|Jsx!$k+P0KRCkx>7vUVMQM?6KrQ;quOz6|L^`NKJAZw z_XrPx6<^8CtV|gwaGF4c%K_w+PPlp~TWGlf^Ms5X&71crdE5lHu8NrZV% z8gl61Gs^8>r0jLxzlWPKFUbO7vMFmuP4(LEgK2k3qqmXby_ea% zNX+zCQ62_M9y9)zDt|r|j1mM|0h3S?mxz8J#qOP8H&7W0r_u zP`9U_R@a-JYN&V5vdq$9{1b+3tie*0K@{yCWH3C?DWfLVr!&eWVU21%xZ+&7ivaxfjmS3?1ScxJb>$Q1|MNhkNQ?zcv+zl-A zEgZ@gi{!*9ByPG-ITM74`(aOqPRE5<^Eeqmus^_lp8)xQpFK5wzyu&>*e#qmNF|sP z9xs@>XV^t(_hf8idv9qUYzYfW(XtB*Uo9WnthK^10!&wr*=<& zwqwS(k(ety4kp}KUEYTUKZYt5p|#bwXYnzmXi(|JdR`$)LY=4bhJaqG(|ZRK@5CrC zRGz|WQYC|w5$R^Ss8lW5#udegrtX_6TZU2DSc&2UO@FwtOkxcAWGXshRV?&mX4xQV zp)dG2JTk8G#+{EOUP#QqL2F&;Geplr1PzEi)F4gcWDGOT-HW=L#(Fh$o&Q2!A8FPX zm-HGdZOdUCPqKJygcSc0b=_G*?^)PR3X-9yPC}J~&n*A*wECPn3=1vE078#q_Gs9D zBTg7k6@OT}S1AsAG^i;$URfo&^%3tssXj4$Wg`*X$yHJO_9B==x*DjvIR^OZEQHWd zFDrmmyMJEY2|YrE&NB7~l`oZ=O<0ZV-TPN5W5$Uq&l0-YFaE4Xo7f`(`nq&_5p1+% zG@zXExkZ>Jh%Votdk4BVsBGgWNPkcRn2w~NwSRi7I?E%Y+^UbkiGklK-;S-ek_JdO zZo;$=SpKx0Li=xHYpMgw3q3QMcZ6Y!hhxcN(yN|Qg!qD@x=r=(tN0d6bq2=k`pKoca-&FP8n)B1zbuJBbgWe?c zN8+49Eu?pb5tCYEN(k{E-_`qKVO2$N$+iLyD^Tm&)Va`PDMjFU8imSbsFqn+zt+4! zb*%9eUjiJ_X#^WA_vKCUCDsni?kM0zg@4)cAp%dXtYz)5a*>!%mo%XQ`)!a#ecai&PwI!sa0#REFI21cC)qm?8nS zf)bJ?OJ@a&*y64&^iOd~>}2I-d0$2k>FEIO^GG0ykU$#J0yoD9!6(O|5=Jv|jDOcl zEY(ZxD8cPKxXzpV2VD1DH{4hbgG=zdUqMzbGq`>(`<|hdp)+hF4i2CgfbR@Q!Soiv zI@iF*v?FG!tdb>XxQ^Bkl?xKJF6>BO5q^O1189j{)rV_j5zBqqGw=`2!D0l0eYx$a`)u9P8 z;zrS(9NI4})LRX`BvUiUP9aScB<|usG?j4C915KQF)-4%vH?Pm3fSBfqGk}SE6)8JvkE(NG@OTsPJJR8f(dro_g@O4M^yAEJ$*iO`!RK zV6OX$O((u0mzkF}zE}3|d{tq2)E0f%D&`+anA<{h{8MQ}1D1`LyT^+FsrD1JKvP*1 zz(!KR_l2K9ecb}?Hy@PrMt}IMxi<@Jh7sxloV1y^)%i6af{r1>D@h*|Z%2`*V$j>& zQ8%WXTZ4fXnGNfY>Efepfj+%Mj$_32zd6l2*O#J_g=R(hAQes!XF*02$|!4;PiKRg zdh&4K*0bfaHN?tL4>rx?Z|GU;sK~6IVSMB2q^SL8T=%45`P4H6;mi!3UYJk zT&8V(Akci$3h(#8C5+yxC(5;T-OF)pb6Uag{*zWfB9+W80$kA*05~z~b;0=hd=y*x z{XiiI8CQ*p0AALxD?6BR{;T;;gO%E}YA$BUZFTa0;t9|lz^TBRq?1}ah5YhQE1lzRDW|4ZytBXxc83}`30|T zn6t-#O8vwi*}E-iORu`%?OP7`ztqH z910G$aPqB3s+h^Xr=ea20&#j_K^Z67b35`$i>(D{Y6i}JGfqaS)N6(3ImS@pNZw6G z-;+oMMvb~eEq{>N2@Gs?6XorspBA&rWuV*>?Q^5T+o?gO6j$=>1y~76wQ+84CZACP zCp^qdFf^-oljEqYzMfkzr+aS{{AX!dq_MW5Dg7bm{nD^0dm<50{IJcwB2CTbXTJ~!7uZBE zTKm6nyipJD>0!-O_sQ{q;|sK4Ys}pPvatQU?tdX5)={Qi>2j1vXh=k^Yz8x&Vs0+z zyfjdJ2#RwM<5j*azusdJIXk5J=TwtsHZCCkf*lto45gEs;q<{2#NT4<1u5#q4S}HP z0(Itr{s=)U^y_>j6>A<`6e-Ei2%e? ziJ~%WQNzekOJPA%(jq*?6QsRQ8py8^i|A5Kz1fd;vcG4@W{>%8X~8tt9jE@c90sqgpKlp)lbKh`2{n)?5HanRc@Lcx@*ZC zXGin|UwW9)mV*-(vV~di^bfWVH*Q-gA*gdbAHpoWkoMnILpt?`5541&H~zWtr9Ge zYAjr8!?b1!whFw!0MiDBAB_bhdV3?vSt$KQGSwu~=J1C*6*#20g_~}kfq#K}Je>>% z=rzu>I+8_tYp)sqarkyeh(e)=Bm;2dI^vCGlG2BZMWHILvqh62vj1et(X;0eO|R2^ zC!v7q6{)o)Dlp#%D_%)gR9~XlsdnBA2Aei3s&ESUd4y`+r3Gk3Zk7Z0qG><^5O8G$8C`;M+Bo9X(sTYM4W(GcVvC zsnzrPXsL;{LDc)oNte>fOo=aWRATCZU*W=nLy@jl^T${AGFn>ZQt} zG9+qx6~3`IXI6Y4oB)w;MeH-|UFLn>E*Zg(bpuqsKR*4-SI6$kM%2WgSi9)-^ z73sv34#MzQAb9zt_hO(H!SS7|FMla0a-s(FfP#F_T^E`miIIE1X1c%`pL)HKEgAJt zgB@c(F$=C!_}$6|URn0evvB8?evZvg=jS~%Q}W8$6Mte_djn1)+KlE(pC@B6yWnXp z|Dx)8Esy(~w`PBNh*otXk|1Ip$ejrHBFsCfr~C6TZ52iKu(b;SHA?6Mq-uz_ z&>p*M*_ zWA0q9nAH7qE13;1m%qS4`d6;OPoAT|9R!Y}&gN4|18&pA7#Iz8?0y1Hqv+W*Ylhyi zGk=$I8;^&3&>}ycUNADf6Ta?Yy^l_rUG|9AM|BxY- zh<|AT1W+QW{e*ZukFX(0mx0xbvVE*NwgZAzngO*x7AX{%z#E75iXm@AHs^uG1y*?_ z{B@zy`$SYf)Y~bf9$@v$rWF#OP{p_!cPu>@c9j6iv0N(-PJrp44q3<=5wiZ3=f|PD z0v)SkHx~lmEHer4S!b z)4w0bD~|%0HGZIBzlG}vm2NTtFjaD_vgAZ0UVs#%@>NI3aTiExi93s)b1?%@MSmNI zliZtl=Xffiym9d;-^FVv9_}7`;e}lP%Vi#?9sQ`Le@@3`PZA9MrrOO9q|HMG>R3QH z_S1v?FX_zl|UH~Gsp|Mq+LwfC*);MTD?-zb7b0^68D zGSf&W-f78UD`U>AKDvtby__AL}x6MZaw?c-A>)+9DUl!Cy_ZLjEr%STC>9#p>|M;D*E`8vsQ^`wytC>&ItH5j{XVv(GB*5!2N>$_+_MqkrzpN+a(`T#CN<$?#oTWJEV1-3Mx!`&yT?IG^^t12^(} zTbIm+a_ZNOVJ}pVS;l}jtaWWNk=< z0j$IWdD zPo6*#OS`FK;xEE(L7~fH*>Njl)!Pqdk-t-_!#?hc=nD4b0GB!hr~g-bgHcYK*Jh@m z?Z*<#z67w z!$f2SwSmcMq?Zq^cg0SYd6&5<=fdG>b_VDsfChE=Xn~kJbXk!gc5zK<8qMMs>0>c` z8(}?@rroxyLWt!Js(sm{mRJd`NVV+9#@c>4-dwmaOs|^+`F|&s0h6WJanp>Yo0nis z-X;PEaW7gPv+aZiZyeGqSo%E42|NQ)9x{`KXZ&Ed9r#6!@QuMtv1`kXY~OoUDcjyjgCsecv0Sb@ug61^A>#0W#ucAi@2 zTJK5BV!l>9Hq~5(lO;$DO@oyi#6q;oKMIR(W6*GFYk7JA3^KC67z%}8E{(TPEhBUn zI{WbR5wA>T1@u0V2n$l81x`0BNtnYHsHh=gf7LJQDqin1w&-ftnF1XbZ5L(s{vNhm z=22ljaE1t&wN9>2Eo5JR--qQ@+%>i!BWIyj zcaFmnwB<;vs3dMGnb5T=`L=&}E^xlZd zlOUoyoo4L|A#1hA(O{)-!0VAlTLqqHQ6S{~gv{?Rr&T z$E0HiiBm=zm=&O+ojQjQpE(`+#V%wE{H8XO#H|efgx6 zwLg9CMR5U-`+;0LV7s-OP}#+60XQO0WSOkUn21AjFFvZcAWD`4haTK|k0Gumw8Kyo zKTL0VqeizuSTca|MJ)hw%|k(8hR+K;s(_N7nD`-I_rGF7XtdcIuVcO6TUfyx7F`J4;q*T_jBROy4+UX|`2Wcj;au`;VzPs@r*+Yl!ijcYkn;x*zyh z+b#UidPe!{tyrS>#*`>N9`^3$B+I8{ET($1?$LeCCVtSh^LgCfc%$X(uwxe~lhhYN zpXIK6`M3M|bA@^QdMLiKl5J9fb-4o%VmhzI1Kr3Kso4bQNJ1s&US(C|Yyxxw28tU7 zzjF)3(^T=4swqQdC7_SIk$)tj!m!9UzQVkDl}zZb#~Cu|9UYGQxX=mOdQ4|ZC~4G+ z;V!TKF*WOieaQUfvM^q)Je~_O3f}4)Nw?_NjHwEe3N2``QO2~Se_h360}|rJuM1dZ zzY)?HbZVVz->+?!0L#JxnCXTcHFG!3_vgD!!z3sp4NhG&cSbr~5VynxX=%KlZ zZ~y96HqsMbNsm`Ic$4FZ!Mu*E|N23)V`!k^t#mF?5g(uH3NSyX8V|@Rj^uWsdRp}T zJ|{~t?1hf0e1C$Nm!T*4n!0DZW9h@RgP7`X>BYcoO6FB`Sgu}Bbdby@K5Vz~@7EPs z5qyIV18B*YJO3$%<9{!-Uj?rY7)2RIq%|mp_3{f(O?bo=B0ACi+to8Rv$&mXwX}c* z(V7S2{^52{M&{9s-m2wh7%$AYBeq)86F1^qH0uJ2jSw2c(IZ6{H!-8Cq5%Rcc0H@( zf@n*=iF~iavQzU6?H{M!^liUQw0+`KTtyO2p}Vkmc?si7-+u_a&{5xY-+fX@4vZ5>eWu9|w|*C=fE&s-OG8^F}Z!5|LQDtaSll>Wlogv|7GsXcbl= z=#AI(vOoAKG^j7n@)nIeM3?cqhlc7K+r4=(>r4zA_YLZuW!p#?8B6;&9Iyj5r1ybc zaK>uUXZ0(0ezc&pX>6)^v*S##xIr^kGqwHL7NYliUVjbqV7^QDKCM7Ppc%X=4A7q@ zM#m~dyT`}#2aFZYs=Wv!sRucP$ZSpm?3vu-6s zwBcuvBhSP_iw=3p1N8`J1Yz{is1)A-5sEZSReB4rsb&KQ^5ZkODuRg<^iX3^F;;6s zM2Hc_HG`otf`0I(oDwL?6P1HO*aS;ZRSZGSKpxEjGXl+F1JP*%J3YX^}lupz&5 zfJC68ZGk#ii_&(!eD7q6HwC-xn7z1F^7w|E+*)2k(LC)@XMn28Z~wmtVEm0zFzxu+ zKbY7Xc_JvHp1rcF$a6brL}F#2C&ni`rKcncdyZn%QIdgumYgA1l%3zk=XBn7WGEe>l)40N(?C9>!XgAcznRBJ$tIqZt z`i>(4!#zS&4|v3sSus1h3S=PGux|41rhiOoDj#W(O9C5{p{v!h+`X;3hA~cN>{OJ! zWDF5?my9R7JA{wtOMvxf`~x66ZMS9C+wY%DE<-O$d5V2d#g@kB;Dp3L|1CdOqj4>W zxQsPAuManEx-^YK6~~~JH6SbBF_7QbBYrsl_a@{TIywbi1iKDLq4SE==Be;QjemvW zwsb?gQBN1VLp*d18$;J)xMt=J8GXnM5kI_K9IgOMsTRtgycj~m7IWmVeygN*aIq1r z%I#`mO2!5`qkccZv6-sDF`m%?+wLk2UzJIPZ7{wba;B7CIquEs2l}7fVZv9DdAi}R zl%VKmXdTX9W^4aX$^Y?lRaNZ>a)0VC_ciTBbpA*nR{7=w)2#1$M>gXX!WcA*7ByMo zY>_0Za2q ziNejnXQlT&ooYd0K#1t~n$1+9fR_ohi96z-YU2L%`QQ@<#j~XCe7t&HuBaV>-y%$> z*iOV5@S&Wo1*G4K%M2iG&7F@fE4Y+G0NP0EZd_O#Gk=C4x+bkFSc}u$0-VbG&)1A5E7ZZDWmz}`kNGXJkgqgu zcSp?&Mj>C$8-H1ysilx(fq?P&RY%W}Xz?tIiiar$pPPHuHm|Igk!FNk;u0ELz6T;U z>)uxoYeQnuVEeEP*IzQJw-d1OCh=i89FxF`NzMBwrI@?|i6nC@@_*XC?XheLXP{=2 zLMr1_oiyH~F7cErzDh|eU9OZn&lVOA_Od?2d1IS8%Bd<-W`>m6ISh z>g@KpnHqVJm?VR6&G8iX!+7#$sm|4SJ~pU&b`1TNxll+Dx$fEPUT&+_6aCQwd)JOY z=cAp(Nv{0!LTrOkzkkpDZr&qIk9C6Tf;5;zL)9y2Lpx`u-5(m8*20+-w=XoxK1vmA zH7?2V^WT*Y3jQ^CDEM{jCCvht{UQ@)2%;0*If96VF*oA072m?77u`km8)Sra4b>p2 zbB0P&R7;u*g_sg_JU!0phKUyQmij;9M$C|37-YzCSIJtMd4F>!YGkQ5<8p;=L>_-! zd`A(U?r+1DQnrQMMo%U1vsg>m=oGPMLu*?bg(| z5>J4*jT4SBgGzY8v<_#!`Il1IQ@5DGx6w`~o;N)>o_d)()p@ZOxY~r`W~X2z#*7y_<^fT5w>paq|Bi!^gKMPu4i9o{MK*EGU?gIVPOd`K zarAvGW9zC=!gbRDUuDAcg&dJmM5A1Uc(E7{W+!io9e<$D(g20Hg1ktF zqo&vVsK>gqf=p;@MS-O1?)%gdamdy7*JY+1u{rudSL1bYRW?xknCs8^M(%3g{a!Q< z@3_OiCx7?8EEW*Q9E*TjfikZ$;0H4~FA6haUYOEm$t>6cwqk8y^khk!{&rQA21bEv`f zTmcdmt=ixNc3fz1>Dc!~#pO|A`lE_NQnX0XZg@F7*C!huy20MuReI$^vG&i= z@c15=GHGg%>qt6Q=k0vV*|ja-{{2Bf8q{iA7X<14 z179z?7(&A{m_QtiJ@N6BtYb0x5=SqvAkbmEfH5R(d`{!rvt6Cl5{54Re&iD@q)d{g z)1tVc;~}sYjH)a1lYN&iatmut_ztukBCO)!0W*sHFWcJVrWIf-Jqp!j?%Si#M}I_B z2d%xjaZb41q(IK~q!$Ga6Y4^}n@?i@)Ug(2a8m>#Kvn(*-AGmI8(S<}q$iZ&=nL6|BE~Jpv|*; zPjF{Esg%tX?upb8Cio?4@+Ej!Z<*at7)zAhKo>XNI66Xi+Y-3#Kyii_Tzg=v`Bh}< z&b3Hc=LTTkHohSsAC~yDY^PMP)WC8`{aRGvY22gvc5)KdNqxjG*uB)-CV#k&H*a%a zDUx?sLs!GR8j@RdQtu?RFOE+%#O!rf-~KW%qDCFISRsmK79Od)uW>K43T-NP{OG)xKjsCNSd z%%M29JyiH$GY+^Tmk+L?;$O>e;q-$Z%1Yd8>q*Ura)Wl+&P&fnMhLWuY0po;EVoqebk(czgHUASEG;Roo^L zWDye{4DCl}d?0gfMEdV#b*$-ZcWkd*Abwo+OcG8|5|oJ^k$+#Fl+Um)AE9KcW~9mS z(%aU_4dzvv@AceXuX6T_E4^T@FgW?J1?{1jV62J31H@nPiu?$iALGW!?^puo!h@l@ zG_HU4*ZjEZynsN{(tIonavheQ+yZa2Ul#93ferq0tuVWq(sb@SXkfj0HAp!8Q1>JY~k!zEh1J)OAlkkTN3E`N4{$Nv`2pXsWQ{L>7vA&k5tsY-8MM(W;^m;R4vdJ>P0kDuX zG%%J=a`PSC#~xUF|AHI60=BDG{qU+WI2~FZD(Czx4G z_?H+m$$xER6pZ!Q^sOY9Eft7=a86c@tLq7otdrlYK@1I?-C-)XJs6Ybl7HBKl0hKO z5>rNAo)c#UyLQT{Fpc$zQ^M5N#Q&L^=nE{Y@%-8wgjx=eP_!?!l1zj1u(d+t0R_E` ztKn_h{E~`!Vh{*+r`IXr8|{0o*5w(29tR-)J%4#6)qjDblSKhsKW-8psSo6b#O&1P*Y!t%qRj3KI^EpVHhpOZ2n4eY^ zF;1b}l~*b(i2{o@5_RuyjfVIxNp&HLeUwBUC@=kobX)&>qL)qK zg;1f@;_HWSK6^D6cA+OUiHy15&knd~(0_$_SG$o!itv1sLAGWX7t5z1cri^em;Q<$ zMZ9|LE>uPCemWl#abOhpR>iT6{CV0?^C;+;>@kAu(N8x4SbwDL zLd@V%riui8+f@otk`pu5jv8j)$bY?~ASaaAbhJ2!hRWFKeFfFa2puGu79fz|GrD2tfzTH~Xwc!uzv4jc-$q-IDzdKEV70rtrTn$X z0WiPp>l`{S5h=gXfw#|?0s|yS=6{wX(L=L_igEql99#5h0(GY?JgT-zB&bbm5UCqHBa zcIqq#tW`$rhpL zDASv-6mwEG3A3Pfx(WWB?KNRbu$%T(&)NjCJi_liol2V9$5uqBZGTJX&D=|Vy|&lh zS;DJ6Qu*x%Rq3X$;RE_=ATk}gM)xdJ-O=u0!-g!?PqO2kr)nY4#pCPa{gm<)I3W;< zGcAy-OwJfRE|^r~Kzb6d_lu7@1*Utv+ldMLT2g1UT#d^>!cB0QU1&|S`IyHGxyyS8 z>-RZ#%!)Ck;Weahy?-$_Vwo>`KGA;`?Vpy+JmnNL50=^mngcb4=~O@? z`r+*-3T{c$K3G$`14Peg_5myf_m}4{gVTVGUyo^L1<#t|Z+~zu#347@ko-+WEy#`R zOMHNh#E}mi0BAS*&|`F6K6xS75}QTjusA9-IuS;qzjc33IqwB}Km=xVBrsl$VGN=7 z_8?Sk#tzN0S(>g4Vx=vAaKNzsJM9%rQbGVSj}W1l|0qbS(2sBSn8Ys{c2_f6a@3`- zjSt+$U|3KAaDQK{gMNb;kou3ymkQmcCFVT1Y?r=| z_?DuKTpe@zmyb{(`+eK(`*BOC=CmST37$iL2S)L zUT`|++!NW!hsh-ZY0wg%c=44=WCjI>XmX8999tM*Ecx! zxkiV#DSzq;!b|zFEe?%MljpEVDv)gLp*AQjK5;0qb1NBP)eQy}UHWUX8_*WM`zh+>a ziozE_968CE)E#24ViPKm|FOA=Y1N>4JP30%&VQbBbf5KKm`yGPg!pj?@<2B7EO+Dg zWkb|Fd)Xwal#6QulLDaLbWUgc&^CrM`XZlMK_2${P?=EVYINp}{`Em^sLZlPB; z!6VGK?@p~?PxVU0oJG?c|CrF4jmSsWL?;G&&!QYDZg{_NYyOm-diJXhArO0$u9!qg zPk*SgwS5B=86*$LrW=x4HqFp_y^XK&3W*DA}Qhd z$tR=j=;Ck}*8^cjA-S0jq9}@}z7Ae#AeLr6GDfLGG20!0P_QBkdC2Yw5j%=#OX^4~ zRb3OgW`Pk5*Ye3Q_h&5m+s}Dg5>>J!Uw>=hj%PdpRDNvHgP2w!G2OR^5J9tl47QIF znwzDSP-T>$g7WVSY6g?D;JCegrzhcbTOP?$21f#aFB^r6g z({#$VO!2$B^{XO`TJe%ilBDx&@3A+Fy+tPRk-2Q(BDLjqUgg$enVU-@UyVt0UyGXn z=I4V*>;D+w^VgkO^Fr{{9YEzVgn#AIC_m;e9rr7+DJcl22G2j(eCqFGxP#s{KPncu zAkqNbc0c=FO18y#qVJzG-2}BBtvJtHaPXh~Q6tGhXicZc-**0?Kiix<5X;&?3cb#6 zx=teP*-Kevd(0rY=#>QY$3yKw{PmcRT~+XM1!a?JcQvu00b?@WYz3Zd_RA#WN@kf;&MWCNtT=TZ~qYeO1WT`WFyN+By}vCLYLX4ow$Q>*Y0Mu|R|SXh?v z>9}Dp&DzS1QVW9zgPa`&u~qfmpv|x$Q@*9<2mQw@L4x<(7B~gj|WQqU(FB01}y8^)z`uT1)u4Vlmfp%-OIyN z2K_AD`Z`)i6e~POWP=N@QdkQa%pSWeF{F`c@^O)9CuG9|!EZx%R_iuws#vQ3^U%rQ)y{uFhhl0=n0^ZP=%m=Kaz_oC3KY+Ig$(&yzax} zhw%Q$=+4~SGJ$7MWA3r0CcJbR5ufPplE?g#@YvR2%zheb9@c-gkzh<~Gk#3^04#UQ z3;JQ^^!uBcUAbsa(0M*Tpp3?>ll}K0NJrE})QN&M&Xy(JCmS{|Bu7vM{e1nYC|@e) z^aWCPBO7><_D6L~mJz_kpx$Ep#+qXvft8!?*EO3BAZJ)In7tXC5+dnf}-a@E8YV z4MAn=>T7T7KJJ*80Io|XOC{5eGc#K|Cl3)+H1V_32{(UbvB5FbQOU+mnfxpGLcTP( z|1(GulqE&jsmBOa`WDWI_Jy!81_K1ms(%bPe)9#ZUbp{8yH6Cc%x_oBdP-3{K^X{I z`2=iR2Nlu3TG3q?cRLj8PH{Ti(X18vEi;~BYz0rjsKC&?irKe>zK{VuYJ)MXBiRry z0D25gems9gBi7akATNV#8i9K52V4fnv+DU0nqlGooDguA}#|;&05dwX*{0j2I8=8nfboc&z z96qW1tkiSoS83@M^7wZKC+rCxg3yM>EXxO>^>Kz!mlqkFO!M*`;?G(Az#9Q5rP2Fk z+Q@d`IjU-P0SaxOcbFX_9?@Y|!z)b+=h59>cL+0KkNSNWFo_HxXEb!x0@A=vD}`*6 z^AUd;euWJzlf_17+vO0(Qv?vzQ-z#gku?LCKJ;IMbu(>}pf&X>43Q5+N;)|H2mZ-0 z`uE^K5zzm>B`=CQ0C?%uI6*-(^wF6Un#DG?Yv#il!gv*1bXHtJ=B;~Ek5S^DKlm

5v%}^IWwuD{b>SzO#r07C8Myeea8=*`7ot04rG6d zoHx^(n$3_@-uQ8kLT7b5C*TgKn09bBzSO9B4pBYkO0H8Bi)zDiAZdDIZYa!sZd3Gl zybvjP-T%9fCnp8*X*DW?9U`)WWJSXzMU8o&j@5jj*MS3{ zNh_j<4u@$|&g21-?K^wr0yBp)Mkq%?uljdiG+J+5!$pgiGyDFjIz7BWXApm-8@hk& z&98Oe8Yp+x&u!caX)xwrG}*5*&)rQh))dA?K&?!Wd+YVlX0T?t8VJa5Td3N%Zk^x5 zDRFKerO2UM2_|5+1!w;)iYd1(h^zrY<8yVAFR9n6B5z$bl8RJ`|K$V1n!k|8JyQOj z>iI|bjJ}uhe{8sk0_l$#%r}4Y?A!jN*{jK#Hnd=Nv%$3npFCoW@ii3}7=#Igf7a@( z4gGG}b{ZVq&m5~dV2t)BA(Tnu+?^-9+~?UF1>5d=o3=R8{JXyo90TsRohz2JVauwf z7*We{b(za}ixnG@SdN0Rh=;nEwe`^Pc177{s)q z853CLNAODT*&4D#kT|L0SsSEIeJ)%Z?(5Y#haJ%s9ITsLX*_jdWMSpLfx<+jpWfI- z<5`>X5R>NyS2+-rYWminhw927+S{R>foTRJc8#c|D&W%`X98-J1-FJkR!NnPbwq*4`+jN~RU% zUQrotrY~mru`4EXs{p(`d_nkfOMF~9eINGgkEb_N=fg1?jKzN>m$k;Q&b^n|`7}-0 zS^qhM0~QWgf5H6LdaFzb9?-2cZFAY1oThL6tll6F-+v>_b@!~TG#A3vwB$yX|0&yS zkca3vZ-VmU29ZZ#A}cDY_gy`&cWma1Rg>ym{M7mYS-cK_77SCQgM|!5fevgeAKf=? z7PJ_17vOXo5RQNUo`mP&hdStmqO2sB)iRy=x@I6Lsthl;%nz1e@U}_j7W66aQXFm` z7St;IMGy<;iJbaA{eV^#8_Eu-gymo(eS;Ovx1Tn46_5A`*miaMC%2Ev7@03qXhHF^ zecpXHU6YoJf3tjj_itD-rR`8RjAJm_i4wf<7U>I58)$#D%H0f$bMiFF(3wbTwU5&C z=dBLzoE}$iVH=;p0p`$v^|8wqx za!HLpEN?54Ee%7qdl= zbaoYWP-hL0fvz~8c;$ZHYPE(4{lZY}Pg?}VCmMb@3Y>66y+S5S7>D{2^_B4?x|YRU z&EWbI`H5Imu$ZZ@#rhLGK1#=Z3h&()u@XxZOn8)3y|*;eWOk(Pb)06DXxA4XR0Cpn z3-^CT!?3ZbRAGEv=~8rpBJQHoFqHYHQdxH=9gWC|ddp!;zb!(L?4#>{C0L`Od3M8j zIZOP@R1o9C9_8CpLYHiaS|k)A+Jh67A^HzWI>Prgql zwT_l+NNIE!ElsetJgu)PndzD?tD#CDL^*#Y1r{b0P<`HP2>O1`=jD41<0*5fnoy)r zOglNfwoLjjQuWT{p3y^bSJbx~-s~Is@Q;c|6)D(18iCJA%8wewn2Gq-Bx}J{%bR&j zZWD7T%Pz~!p8Iz%n#c~T_mo(G{pBuc24vXybq`RbiyNrkqosdG z&<($eM((oQRrf+L{ai}mCNWU98&z7WIJ`%Ch?DkJ%qSiazx)>%J!m>=NBfzcO2Lvv zBJ9vz5CtCVq9_csf4r<@?E+;2#e5W_*^)yAd0iK{^7BIKK1HZnOikD$@i#Po)Z-5m zp=d#ca|*PZhEJE%Ljo6?q}ed1lZJm7?6kz)Hx@5y_6hu8OV0qSp(JEKWQm*m0IjHu zd^hPP#WvjYVCy_7`}W|A>Vv|z&2{F>F+b{V}XXw=h0X?-M&w)$YQN+}Q zkR-(NO8Xz3h;5{BxyP59b);214s}av9=i}JXCR-UvVt=GK4VC|zh!*b%$jGWcSe;g zga%N!SyOcPdUZi2YUe_&^+|uunJXAL;k4S6!%qdg%qHGBZC5=98gG4!*T7Jk=G!dS zd<$m+GA-}wO~kTa|HSOQz3#wfIY@fR7~)?^&uw2rmQR^vcR<3o#RV>rHo z5c_PZfO#<*lnCvN!-6+%nf(1e006tIa4!G>+v)YQ>jLEB0+1O5!y2(Du^n|Oe>cOiN9wNwTUT=@;agqnM6WVZ*eV0$eURiq z#EYj6DnHWCg)jMujYd^9{}OAk93>$rlG@OgU_9-WlHn>l+WcYIi#H{mcg;3XrwGvB zl{CD!OeE=Rl62)!An?o_L$jD%Zs~gl1=t381o&nWCKIIRUrtF!@T8e&3;4+%e*-D0 z=hMnu+)xywCERB{DYfiM6<{242EPN>v+$^Al%R#)Z4R0X5f{qrOL;5DOvF5!M7+Q` zrX^C_%Iu_#S?xu|T_Df1)c)9ajK@8e6gBxix{H?hJZ=(r=el%GF{HksrwY`nJ;I~e zy*cNxs02DFA}qn!9E*bnp%$E#f88)1{HM}`zcRgh#x2R^pZg zyVzxph-?$lEuMd(8uAU>wt($S=NuxlAbn24Ai8*^%x--g*A0`v%;s`7J-XlGK`LR1 za0NNQLbP_FG=&^z4es4iuQ~^ny+YrG3>ugL6Sp6kd(Y+M8EV{;e0;>Te?|XInV{Vv zxd%y)j|5OyHsL||q`;87*2~RwTzpM}dd2Sld)EQp6akLTt2WL7T=|+N9K5pH!7<9m zCuEbWXujyYtTx0o$8wWxI&&i>oF6Nv-;C1R0rv?oDQdD%_XD548jc!VhUZ_r*$K z$K^aha(d!4AgJJquWTEvapI&UnnnB-T_!p*-l#ImXQwt54LB1ruSCB@0xXxiURNW* z;O`<{%v!?mK&-BH8~0te$L@ItIzA~&Ug?d~R`o3{0e=&ueJ0Vv@;YC?)>#w?_ ziyf69@%Pf>=tw^K!H3qpXl6Y+>(e2dNJqJYv1xy%O6X{eEW>$UBc*nb(c zYuEJl5(@cO_>YH7SD{RvcvenU7=aso319Ke-V73O1v5=myw)|VH$F#}N8*z@J3 z-UWhTOy)h|F9t@3L|0JZv@}T9568odrL%+P*Y}uXe=+P2IQg*s6Ep7+h(l<@1KD!_ z%*~*^E_Q?L${yZ2;>R%J;P$mjz)3=YWMo})RwT{`rQ%<()?A;Qh-kF~Ev zjEN2Te;uTrGwl+wi-`mN1?`RNwUh@UFw$0$?UnyuSdnwmfJ-lF^A{8UYL!_mcL&Qc zH$!M0)}$>Juf^gn;Bdsn8g^zveO;Xm7(6_aLphrxk2($M~6QK%N2{nJ7Xh5@JrW!`a_lk{A*e>K)zF}Mi+tj00Hn*6%TbEOH`MjJvg$n z_m9A6>!f6uoVzps)%1WFo;6TIvGf}{#=q7+zO*juLAqNM0SogBiA6Mt^Ki{gU(@uD zH@^x#htXe+Nf9Jg!_vTe@bjR|U2Db$f8Z6r6?|%xW;O@o{k@M9)OON1Lfo?US0y*m zB#l5mU}8Ltq}YWYdctuA=PT%O8Pau`>IqwhGV(4z)z0O4Dxno!4)O;MS_SLmFv;h* z#Bmp#Yi{>!2VLwYA_+lWsDgA?SlL~?ZM{E>er4oFTAYVANrolm+{nQtve9A~fA8q= zKFDz4OC=YZnsd~E9Wfp_@6T}Ft(>J;9JI0$k;8bG12tIwt=Dg zG9<>~LG;297M&B8Lhs zc?8!DK*;E2WBoB{dO`0n1$mvzfB23r1#^sY%CoXyjI7@2hBi~dbZ;J^tsA?oT+fT) zS2&C3o>hp;IG+rSg!T(X+S^cVN*Ay11(}U)IA;q{yKxZXX4NqSB3aRYr7DrmwOF2Y zJ90a4@4fpUX9L6Sx3Y2fmR7KhLlx8m0}wq!mb&Btt! zuUb#mw?OWeayCGHc#8NwoEP3uF#td%;S6;Iu^y5Mmm)520eHI>O#eyM;TC1Jl}g#N ziDquNVCVt34uX7K>daR;f1sG67IuOZJ?#C)PibAKlptv_1QC_svuhG&sl|g{-cjId zLcWD$3;Lsx$L?9#pyYIgZ%H?hZx_6!`S6v!EW(G`i?XJ_4J6^Bd%#Vg1 zrdkoNb!M%`$>p7jeYpzQ^Bg$Iw!tRs>b;tn=G^&RaH~)Z_@uuUEp;DB!zoTS#4)z*EE05r zuJ3^wN@3e7TwgM4T5p6)8}pCn3^|6%69wEV<}+FL`^&)0>{&yqeZ@>JTyaA;EUL(X zk`pIg#&iex!Hfd+e~{qzJa(Lh-ZRF={OA0>6{D#UNQ4&C#+m*9lBSAC50x!1L|3e; z7xk>>YRN5Q4FqoOsJ9PYXFn?RICkR_m#WnR1_Ilng3f7pX+u`c2vf7sa!xmdGn=gbWVIF%uv z$uyFXn+wpNt0gGd(BEjXx2qC`!XPQP*H+uIh|g`$;*pK;#|am@ixNn7a}P?XDdpdl z#5?{OkCQ9nqT0YTXv;yO0{e!8n*E0LH-=otfXMJmEVjN5h47Tb8P-VT8##K8HpBq# z(^pcqwQ2l4eY-`u^gTsE zZydX`d_{awzF)8)LoikWpx^`7Mo7y&~StWN*&Y1PPUWzf{S z#_)!RY@oz82ar@)7`F)L{Gur*0cHDOiUOZ&`C)4g`AoUqj}cuEAf5HVA$a0vX-CNH zU;vy9f78GLgb{}_7&}U`iD+_{Snxa3$n%kpjxi_4>i&SSo!I=O4`~mUY=ZRamw$u% zSq$-Ssz&G}k(Q-}%+QhZodkZhh-}bM8=P@aoZklTJZ}l0Gon3(Mq<_GAg7#FUXNSS z_jj**Gzoh+p&YCHN{PObtV=a@0t2_WG?)m8e_#hr_vKEs`+lacGd6Inizqu`A-;?% zpviMB(H?YLrICVcATT2)@>s75C>!(T5?nw{RT>xN`+Q}hyn8dXoh;jQ-T+boFXLfx zQ)6IFoNl@8asO30j$zL4mBq=-YD!LuU0M?M4j(& zf4fVa$RE#PF90+y+xrey0LI(5Y-&`Dt}S;t(!ur03&v{-Qz^WMs25$^n6k(Bv|8=55KgUq4T^^{ zX|)14k(>|JJVv{T?7=EsF(TOt{oXa*e-H?(Q7G0IjY`JpPI0U%1qSxBw*C6g_=xuw zbA%yWibdzU8n%i*yOM8g06Vjj#u*)#;kpcPi5Xaxa}i3MK=qx73h@GeKlm*`q%<@_ zQ!xX5?pqHzNz0yTN55X<%Sg9pDEyNc`YQ&0_k5UKt_1-#bWM2DJ8fu(`GBr);0Y zkI5fd_8bzZm!m;d9*uJn6rygDt|-D-a_akxri*+h8OnOAC<`x|MBOTIf5}<{7||5?j^i#e$lvm__S0w708lX+r04iI6@V%6n>l>_>RA@nbM^Y!QCSpAPBMCTYzDMHpxPOaqt zuoq|8ms1dxXgsi@fA*e_8>9U6y7nyS?=osGkK^(NC1~p9aWo>#IqnacyRlk)KA_fk zVjEi$ce1@K7OE-&%3Sa;o;My6IMkBAawWQq&;62SvjM)^|GmsL$P}&D$V-Vv0XR;Z z9Rb#GheDeXwlu~xK_Qj!;d*zlbRJYC;Xu}DpeCz3nXFsFf0w>O(wr3LrjnRfs?54X ze=gUn+mHP`&*qZfOw*UsJ)G=mjW^a|x!3LD-|*Pm(M6yZ3r_!R4xa~`T^!^YG&g~9 zVX(5Q1%!8gZg1I8J?ul%f1y{nAw0RUk_O=ws&2=p=(vB; z$wWV^oJ!#kc@6;|L%tm0RSOh#g$ou%dK^zXtP^tTIT+1=CEnU#e6mmibwHo}kn|;@ zj=pt{9w;CRZz=&7w#$GJmnWS^{v~9A2@p^kG8sTCR{EP^FCt@oy9j;rAISY_ml_5x zP;s*_e*w{9++5o9#w_n~8O;G!@?IJ_VfVM~4H{_|*iGRnl8*?*&M5`ph9vP#U>|iz zH3*82=yqv_K}2P(rBhIlKYTkIYgTfVDj_Uf#&aBw@ZMKhe!6mvMN(MC`O&?EP#*eK zYJ5yP;dyvy=lRRB;|CJML8Nb1Wy~@kvz*H!e@LKJ9zHeP-lM%I>Jht*lLit@sp>$?&D>JfmHish|kDqXk*zky`$`)yAhyrCL^X-I7tuW zV9pyFjby72e4_(CQryfvW_Kp-4!D1Cf5yoH834Uhm)JHM+mtHv>m&~&h*~Cd zQ7SVYSXzbUyoy)G5o-aNmBvw5i2KtFXoG_J$h?A7=L-&y@5a#wcj|Nu@H#yGe;R8D z@PI(9f}K<@t6I8}w@kuiKENuM-W?w^l;Xq>><;E|){JJg5S!nGH?~TD?i}vCq5yu~ zla-A+fVkQNWb#W}+Q%(ZcEyA>5<~=QHl`ZMzkPt_Tq8rtxfCdReiGU*xY7jb-l>!nL<3f zSAniK#Li9mRH-_Gm5lBu3B%z318oS>L6e+!^W4XI+35U9f3E#D=R~AR zK#Xrfc*QOg{^5A=JmGI4azXCViD#hrbn<+>)oG+ofjjwx{zMRX22<19G{+pbqzL zPZ$iDB84-3Ud{UOQ2AG;p;mqi%V9vlYMM$EHWGjj`dy6;H|I`nI3RDXAO^+kI-}~j zEorUIqo$=HX3DctJUIMBL!<_OaI1$muOaZ+jf0J)^j9PneQBsFe|hy+oQSA~XqLro zKqC~Cl_V~*7IQf)d8xR7)Fhgp6vZ~j40wI%L5TL#{ zs;~cZs?A$Whr4x(eABUiJ2J_>3Gv1n9DSN$j{;*51|*~ZL>*h9uW)OPb{9pG2LANP(Q>M$}KKpSHsHH8%8`} zpB1xf-zzxWrS=g89w>KL6RA2)q(Ex`@KffJb~T1u*I1Q+URQu~+=y|%ZW}1WYkL^` zc;Y=wt7isLe;6Tvk03b*#Qw~KB7f=A(N0=|?Gg#ErGNeu5$vp5Z$+e}Ho=IN;&nd*RJrZ`(&VFb*Toy5orgvFF#bYXld-8^$?Aw9% zHTgA#1F_eQa34+d{+fD^1=nLgQ?zuFfKqS%PvD-&A5h-G9uKoq8FX47DzK0A9d3-| z^CnaFs3&HRf5JML>gd9Uq`^^kZOI$=0-?#(7k`ckm^9)JS-6`}{-((BhS%8Axe`!2 zCjrlmTD-oCgCT<)y?64qLz8k=mX3WRf#k(`ehSVJTi~C_S;-6JOsM%PG#CvLrF`1% z9-iS6ktXUQ1;o>U=HQ!oJGFW5ptPx?Uz>rL4!0LEf2=m~1}~Id^7@H9Ra)lQ#=^GL zi?^;HLfTj+#FNR&lTNx6-oCc=*gXWch-D`bMwoNbZzYA3dt<5LwJ)^S>TzV1=$sZE zF-gjNN#wTin6l#hqYfW&RrQ!5v^fD5l|cmi_M;<=ov;fF4jyyrVzBz@JYX?Wj^wv4 z^zas7e>IG(Pyp|Zb0xbIO!yfih9n##z8e>v7DnU#UL-8T=95Zs!XrOAvq@Ov!4`b_ z8HcbJCtLxTbohb^N*iaeRSs{a7r7lTaLF*yOIDA@c9AoDjTWwfHoeY2O&&Oj{R?$rH~(-n zC-iUZB^32R5;u$ty_kT~<4OQ{KYFPDZfZxb9q10@7C0;qO;3NTQb1)YkgIOzrnjc8 zg(?x@U?%G>xF+#J#v&2{c{-5B{?2TuK6N&g(xypOE~s`FS8|pUr(5BlJ-q?f6ZXw zSicNaN`|-qfX4l225TjeL7Onf@k5K{`nuV z`SoR={3K1JxzYl(6a}y1YdpU>f5DaeH9vpoer_(S;QB}FcnIllNK>%j_Ukwug4?Iv z-oyLfD`2;qfxIt+^7D2gUk33d*F6QsK$Y1Vru z1>8?mEHokfXjT@pzzi$bf7NiaVx)HHfB_|RIrGel04N2}i(hj4Hq`a{#CJ#~ul(Uf z3wk~I+^fMfmm2idshF=lQUs07{vbtDUw?Xjn(|J1@lCGfH#Z9AS%mrEA~Z`PTTjqv zwEqI`PwAI%x^6$~7Xnvs0OLk#qTNA=+X@yj`BWi7hbg==@CJB-e^0*f&{(|V9M&<8 zL>J#0xuohU0I}w~TV#<(moDd?|Jyo9`!WFlCN7UBBGu%{Y0 zY7OoX*Bs91kQ+q@haZ51+MakB(c~kK+5a|xqPv`fHEF6%y|huPywOFO2^);xMD`#E z2<~-4n5&&)TUy!de~#_#(-2i?zS-71fEGs=hRw4zmzgJCVkGf*c zT{KegLiV*$`FIkfO|gMa?MwwV9~wg;8e#K|wE&#bytashK%iLL7#Y`h>R7fhZj~f@8vE_d6G<&l0oZNa{sHvXqM@9id*GM?UL0#Na4bHsP zCf!HJ*xxqz-DpYBMBD8z^WMCPq~k4cv)I8%K5|GM+5N}_%wQM#ip|tZu@Z}}Qy^A{8YVu$fZs{2YAzOG#9%|=eeU`DYP6gA!#77>R#`}RApG8tiR%6*$5 zeSZF}i3btiHg81S|4-GrGbDii3r7Q5^h={QG;N;qFR9U)t>oxU`kHV}qXZ(XI13`v z=&}I+f8ita@go>|sW>uft*Ng%dkHc~ZyD(mnQgAcXUEaWgvgIuDy5w*W^m9DFRxc) zdF@!`Mqp~&?#k9temIw^MlCTrG#Y!SoWmjrafPW&<_Zr+Jgkk+K@9m|CY(X&5qej64d3728jU|Aor z5r7cRBgnob?kFNj1h2P>tZvOKUze`nz!k-gpKj5!QDSuwy?_>-`T3lvmdNLj|@qxj|% zdCy?K1A@QvzU4Tf<%(nnex^6An7L4!dmK0;39*l~CZC??(UiK(dbYc$oq^cxNGXL$ zzB^-R_Ulhs1*=6i(7eiC^nc_BG3$Ktbo|qEh`s}{iQuNh;0ePkv(Eh`elZ) zw|!oPWY;+{6`jyA(?V8j)?HltCJzL0m2Jt#fpl3M={Aa|@x6XbaHPnBV8hx7j6Q4R zZ`QH3dfoEcI$Ug1l~LLd+s;P!O0Bu>l=)hs8Q>B$$+(+gEK#{~EBQCA3n`j8cb0Jl zWWB5;R?GsW)1#UMXPP%be_YehW!Tqx-_QA^R|`ou?*S1ddqgNTwsT?f9>5t<&?630 z@Ati2z2on>=)GSbBv1fhtL{Nt+4;#6(I~1f5EkL*ivTA5HBJ@cs0nBhZfOl75~D`( zH~kRo3mD?_`l!+&c#5Bp*dBLcCnp6j2c6>LC0|x;Ov-7sq_s3ce{{#Ba+%da&W5|Q z6t^Ug1nJ^5h9U%PpPy_dvRb(qpE|xaNa9ul{f-&T1NviK&l@8&v|i%z+fpX8g{!yx zsRxfyGV3w+W(g+vf{ZdtIH zEAr{aR^r|V_f__dcF`je8eHqG>vo}E1;=UwHidVcpbi4jf99OY1AhgMQlsQcag@;` zl>{Vq{4?iJ&qN?O{;KRV1-TcO!&C1LI^0BY>ka2>h|z*7=B|mm%-@RaVOMCE5vH3G zw;!|7(CA(+R%4WSv}${Zvokny({T%Cm(Xcp3F)q)=`8J~B+PZLAU$CKABts6#TNQz zK}86Lcmp}jf9-JP#DtGs*JoSapi0PaQnD&6g*Z-8o&1ebGuy>Vh{=X$og4v2Wr%U9s1d#ot;KJlNqehqk%+r*GQ@ z6wm4Vf3AqMQruH)r$|5)f6tf1E(J6~?O^!$B%V;D9R>*tDPEQRD=yrOyYo~26bD4b zFOA3s>RG2gToBH#Qx3k{M<}@_VO)dUctJnjq6nP{;6j1O)#Idk#cCrXlu=!oMP6;~ zcVbVm4$vpV&E+$!c#*rtMYRp|v{;cL|9!FHf55c2#8>I?ZNv+Q4+h^mFc^VUa{i+kmtm47figX?-twL&@}#mD95{Lin}1flk#U}Egr)x;rr z$=t5ZFuG{zg;W{(Pux`SMjM&Tvd-1+xU0wP{92;JPw<3_lI$|qae^j3b_(xkh)Uh| zf7G+M_50lIR^{NiQ^*I8%H(U96B4R~ey3$~B4OS<@vXPDz6YS502?A5x_)D!J-KS^ikA+enKO)II=D#3gyzSMBP4q7^4cUZ|$XT;8zefBKr>zMEBdI3e$ADwd$ zZQLZojlj{8JWCRs#Y7AWZLH(VNJjh_c<2*MA&$?xWH=;*J>WA}<6VD)%WF=jYyQe|3&H;D6Ai zns#};^!Frp+dj(2vWuGceg6#KUs<>Vs;HUCHi_U^;@uFpO3Q`zjqAUz&&9szPmOs) zr0YoA<$pwXhb~-^!k!aOiqKQ~IGYn}$&ZebB(g=(6fBa;QVjf02p8(bhA=sPHzy zSTvU@cvobGFA!MR1DA;~%^D0J<{i1;(fp(hxBGnlL-x0By!FMkCz*!dr|%6JPX@0{ zOfHPuFF-2;9~%@-XdyY4DN{;D*#GhA;rX(jvn5d+N5w-G!N6r!Fsep=GEAvq%~Rk~ zj@L%dD^UO5y)Qv3e}2=w&LNFldR9F!S0su6_g{i{vl4@U9!)E;rAG6^Bf4?8K3#}A z@4L*;0*1AkgElNBHNSabxpn>Mrq-pwZ6hq2W>vt_O-z$@mY8 zEqFH8F`aB@ZSw>-<9n8wa@4(~9)U3^NPa4QT!EQC6!6#(R$DUP(`IMvSRcFrId#q( z8LYiK!=NL@BcJvzz{b6qV(oOxIjQ9J4{DN`@r2y4e=S82ZLyDFAKkqee>AX2u{uj5 zz|V>M$*&YahI;$K9XXRV)DRICPBL@bNEia3D>~|jH91}oz8_OS64X91ArE*pGoGH{ z*ZmF?QWw1W0?7lg+8pN9{JE+}|KF0TnX>5k>5V9O@!$`;f4n7tG{C1(TTONgjxEt_ zLP^h7e~iQGH}y&RvX3+(thkRc+Zq47^fez!_-^~fE&!l4o7^~JwqTyg3wtTGn^`vA zvMt&lGZ)(W>65)MK>5ao`M*!)t;ymTOC!v<3|x+K3vYn* z_J(0Hd8xo#bLA%2k*`1S^M{b3UcpMFM#;zue{52>n6C+gzrfqo!jnHhsGp>?mg;W@ zqr&oSVQEGzl%TJo8hHaQOwMnu{kJNds(*K17CgV+hV&^Efsy;nPJ3 z+mv9MQKLqV6|SEc`sT%@r=(zzPz!hbs$4k2@KTZo)ia(;F_GhKiVT-aO%7L}`Gnt# ze^<~c$Q|hj#3Zbt6=+_guS5F!z`*aWR39Tr3B;8m9ebt8Na8O73XS+31tHRl0*{hEu`2#q3Ui(}5m4r1r& zy@;K}b=RMhv{qa0Jdu{bzS;*iIMEBef6ie2!~Os=Rwu;C?`dvUMNbFh2^RL?C+BjC z4`1^oPiO*29j@*J&j;~XzuXIbLjleh6yxA5umt#Ln&J&lf2uyg zBB9E5mBh2wT8THIOvCz} zbnYt)`FygzlW=+}SH5uKR&!9isI_WMtf&@`WiRsWw{`zIvRW04>V{ivF|BE{3`h<~ zX)A6XZ!9!etV#2obpSEZi_sSWe*}%t7?>~hcqnNN+(-ExYnU@|84$(#AupQ1p6}u$mMmN= z=v0PGkb#)&ZWXhgexTOzu@&80B3ql{AH>7!KxCUt-4clKVTJL1jS^NHf5TA+)8PXm zw%i#vXz}v?2KhoEM7Qh_k4kgn@VUD=6e`Jwdhxy2@O})phM2j&6ruxq0{iv6 zE4nsS5dzhUxNIIb$~gA#HCTeOulHHJJW?R}f4~k~>;Au5*L*Wq zpHWDIF`4i+1S?QWFo$3tbsF5(c5|)vT7@nmjegKs=P-vQr<3^~s{lF1T`la>hW@pG z4}dNI&H*&S*Q$KNfWRl9_<#hcdg+I0!*ox7bP3tYTNL+&{mg-h_<%CFB{mXP3XoNC z22;&cN(-1i-__hTe?uSrjl*rPYcBJNa>MhF!+_)C{;7&c=Xuu-e`&2>z?IY%ARxDO zLE_?w4w!54SWDqCmxLRM#`oV+igvIidy!F4)~#bDruCSo-xNr4pa=qCZj+bBHO?=9 zq(W0ABD_GtLB4N*+gXa|x=*$Lk)ofSe@w=_(WZrwmX&GnvO}wl z7shBlB`0m7!<535bdw1?2K0zdq=Tm6nQc?kg8xiDN8S3aMZOK16;uBQ=2qm|Mv4*` z9zOR~JlaVt!t%Sr`bBvF>=f|WVAcwt!nv!f!~=yst$TboAW)2Yfx?f2+1Eh=FTT)k@a`E+5e8UxH6Yizn#iV4NBLBA*l^{ycO|#w3@xdV7?D zc0#eR6*P4mCA|?m1nPJ-rQ$1wA;5tl-eCKr<`9CfFjO|f(w{)grRi^zS+Q9$eUNSa zHSl|H|0J3<;CN;9ge&<*gAB_=EdT;P+yhMU3#RFPf4PQK?+_O!7h^Y7MvA{i|Mrgc z^76zuf+at7e&JNIKrja3;u2>0>!nRGub00xomJSU+8kb`#KHUpGc-0_kj_A<@^VCY+E7eSqZD9JFd6APUDs13(V*yPg-3(8cYKJUkSE|Vd)!*MK}Ya6_-`Diz|h~}Krya4PIR^jRb^VhJ%Hoc=U8m{E57~O zAscSBraay|LcgR-+elAVGW%rxB;CmoMRv2l+9?6Vfmlqa0P-x&o=*PqwrNR3nedMMIQj(;4O2As-+9HedvIPhV;VaR!p4m;N1gAhh;JP12t{k*Z6(+742ut1EX zVpikfB31XB$7zY9h7T5)V}R;QEK~DA8gV0B>b{$zy*4{KIGc`oQ=@_Cmm-u4j^i{& z+P{>o{=WGBRP-y9a^OAms{B1le=L^ik^x1LacH4qQi5v-7{)I{Qf`u{_OE6G_20{a z;>SGzJE++3+>ywqmul9Ur41e-&b=HG%iS08mWt72g3M?*H(jx+!Ag!H@Qdspw~#|J zd`20mHUg&xJd#={AoINUxZeUY`H_>e=VhkcTEYz%tW#mtR@T%yB`23|XQA4;+k$M1g?l=z|1>xK4aRh1RX~dNJzNdo@yO z|NR(?QOt|keKee}HXv^#f4YObuiH2l3t-qN3qs;x^lSEUCp%noE{+%D-}9^KV2ie? z$p!AMmUw!Rfh+VGSXPe`6opk8M~rrlUt0 za||33zk=SDgm$Ykbuoi5>itfV9#GB?R-e>di*j`#EO~VuQGqqhF9P&}i%(mp^|Y2# z@Y0N*-}%Eaf~bUtV@66>^%ilnzRQarm&kpT2&eqqwII7W$ z%*ba$2^YNc>5R}@f6Pr-HeC>US#J&ZXQxkP^IUc))+*N-YBZw z(qUJ$F4cVa9)qU5Y^AGfoQ2(8ZD5Im{9hAuA)REd>f0EuF%3HZT+jk{dNb6ZSF2s? zVAo=1L}xF&N7ZN>J$B&Dqzo-PML`Z^s>D8TO9R}ThW}Z9e_y8R5St&>xP{S_Q4}LY z)F7#Aok4+GGb55w#bBa3|gme_SVgBbh*k(7#|pO)`*UvXW^? zHTBnt3##&QAnA3C3YYR`Te5_PAelmeTu-$4_o5S-0F+lSK7Ib+t2--ZPEwlgI9?3={jE5NmU ze?g=3@o2Glt~HCj{Yow%MFUW9YNXdbZwiyPdh$G6AuwHTb4+{zi~lEvyuE3}*3rI< z!};RE!{c|8BDO%J%>l1vY1+_R3U~AD<+yR2|0Z`QgFE4}UmjDPWtv}= z-Rjxl37_L7j)M?w-`5Bs_v^!5G6QVie~kCMqR~pq=0W)RYCng}O&1K&PLPopJ!`Cm zI5ieDHH6L@O;(lK4(a@6rHE8l%29s5pm(W1Nw5d*Vo;@cm8;$@r`Atrb@l2P?@}zX zFWCTcV0)CYap43CH*@l&S)m$B`>3y*hNiQEY`!Bkuo=r(3)N2?*R3`E6IFU6f8n|P zaPHc*z+&!OPDf#Jy}U4D_C`Vh6DyUTv6#mdgy9Hdk!llZ|G}OVv^%~q>QgBEW@%^s zvz_Q+3RX4RKOt5}CnuhxhIeV3j3Fb`Lvm%NG`Mkr&IEMF>vk1ig_o8%%#}or_zGCk zU!V|g?cRmZUTkg~Fkp8vNB9Hif7Qw|Dq0!NDzHjb6lzr4h4_!u@KUGaBLuj}&^1Vy ze_F%quMVnFN=;y=zDq|fn|AOVx(VxV0xG8l(i^^HX!F>ZH~PB=KjZ$0=1Q zISSfzEYWJBT+(^0IN_~R@uY-U8^;=sv+3Fn!-mXH)1;_=nk9_e4vfZ6iT1b`D*HE= zb5|~+E6iAoG)STR1+d<8Cce2$%cCz&ZB&z$ZEb6m|FWr!#vD^ZKo9qUv&F#gaYNM(?zn!i^VYFnW-5ku!+kPS=is=v zNY?A^^4M2ok^n_U!rHMiOL1XAka72DgoCUp(0Bt2t3781hSe7`Eh z3t_JzhsB^cbVBwAT-iKR=MMtE=YrI}{l0*;gg`+f*Kb;|3Gi2>f2bWlgIvuw6f$H{ zgIi;ZdQQH@z5L?Z)iIy8IhjT)*Xtg!v(pld2MdAwCd)NNWcOgASp@VnO-9(%>=+LC zLWoU!uh;i);Slh0E`_~Lp@?T|rrf_3MC15CjMFObRNO&S>vHWiC$Bcv7e}YoUC_dH&pFYv*)v+WG zIhwFd5pf}z*Tc^N0NDqgaqBI4#4XWdtz6_amm$Fo??odExPI=~{aYFagYAz0Q(w>D zrP(AW0VAulJzXr-+FMErB=ylc?ty?-9A+G61=$#tIs{@qN5i6hnLyy&Y_9!(vi}x& zh4k=v9R`!ne_$@oQ>}lY__yB~VXR>V;C$w@2H_X1Ue$|=;kT+TVZhq;Y$;|%X&0jW za7U!6e}8B@lH^EFF)jxtL{Pq(iER((Kc%gIHYkN8K+fJi)Qa)9hxdTRy*?6sVfefd zUAjV9)|8?ig#PjKXtYbfd6P`%_5U5U{2W0v_uzWYe{-!gU`|1~(;jq1>32M>78O+i z1L`q6Ju)5GDwkY^T30Suz#zULGA$Qoshm0c3&3-e^1H2uz_MVIImQ1*58P;j3caIi z49=Sf+}%HLQK;NnrnxX+6G?C|^rp{!zGe%++k$S~s;m;?xSRk~Ml=G#iH@;V-f-+S zXsW}@f2z6rV8OE!L|MK6kVYvUKH-0K4SQ>HoQp7;_9wNfd+h)~8zR~69>DdAlOq5W z18&DV?sjwso`XU&Cnmgt>p_2I-_4fp)HC-ALz4fAW;XJjL>R@RS~7w9*`6l%w&*V5 z@&D{=-*9b)Vyk70?dkyX34$2XDVH1}ZJ5nw053q$zkljD>9Gsnu6->n1*r})b{z0r z>0ksANWi(R6ua53wGYlLHO2ivAs!_Z-e>@1$Rr!QB*i}0$-wn49w1m>ely=dbdfdm zMgr9@maXfCNC?&IwiU!np%m7Eo>;(W(fJ+Rl^rNwdb)2HFG8@;wXxu1$#!;llW(x*^1MY)iJ~ZYNe<=Q;q~ z4eD#iz;;n(-t?Z5$M=PKYJAD& zfk%h%rp5es@XA~TJ!w{F9}14wH3~;hk|H>%6}OaUi9vf)tc9NIBCsKr(7+9FypxkN z2B?X3c0tI+#9y<4j6_omv}(PdHXR?W7tCG(NxCg2Gu@-m?QIO)bq1QsgjvaWd+y6j!Kz9FX>!dKbb0>!#TB(s8pl%p z)OO!75mzoWefpB50qnmg=ghVG;(xvrSP+nnPW*-TR1Ov#EU}_b1Fr-=!wMn*gtGMv zF83%JN8}oDghn$=*i>pqrlE#w#Oa@n0=2}q?qyfPuep7EAIhARe|dJ{0L^6j&5+Je zm(?Z%W?@KPC6{KmB|f)WdpZLkiR)1*Th7l)( zoKoE1%s_Xy6)vOw@09*`M1@`z0~B9`h1u?H*znhXn7TtOaZ7C2^GbmV;Q71m#Nw0t zUW9E?VB*;U_o@zrES~-zgakK_vE@QL9*O>@6(A^JE+@IEe|sOU=Zo(!f3b!MnRLZX zverXDY?xncTH9pB{IArW#(&3_YscsB!P}e9q&|>4$h=Q+MR$rLKx(4nI(=`1*?^cB zT`*|qy9TJ3+yG4Kr~tZ%-^g})s`a;eUZG1nQ}4a`Rl?|6Sa%+uSs$DFdFOW!>eFG5ze8N+I&uCvZF>x_Mf zET|&_W- zp!hfs2&>aZ31YLOZJ-h4mkX+hkb<>S0kEMe>h~4TY8?g(7k>kQV?9OHIu)C8dtT|O zt#uj_G(;+k+4%liDDcVd3kPw&kW7!kWbLN~(EhI{J@)aW-Cle_H>@1+-uCSOuK3vx zZOIvVLOVc#pMX$+J1!6*9#}NWYaGY)K`cnLm*oEGwlN+DyslbDCKS39IBxWSLdV1m zizVe$+=$!&`hUl{ak6QP6*D&3t0dwfO=^&z^MBhkIM-(iuA9D-K$Ex~;;x>> z(c=bHEdc!QpG{6bSU_hk^f9Rbe;2hOg;82B+A*>x5zTL6A2w$VHU@BgQolNmsL0^- zl6CMDxvcI&XKzc{2<^z`7ZqBht^e28zhXZdDSL*(+>#?-2FQrxj@K&n2I!+Vg5@b7 z?=CzO<9``{IxmucHe~E7@NSGFD+Xtmk`~P(r7~zTp5~aGjyx>?LAZ{f?ZFT)vky=n zt%;>i?kQMZMIsBEs`jjFq=*)0>URYq`KZ z=$Qk#2#f4hQf*$Y=ztq%imfy45TXDceIUDKNPk;S6JtIzOyaq2O(+tg4dj3MRx~49 zEC}oDwL&KS)+r<`<-&Dz$(F)zim@#?#yt|x8V@>LhdXkYaqJ+rpi2FET1a3SObLMc=#F0A^PC|R@p=~3_ z28KSx!G9!_nUn!y&Z>MfUyYB&aXDOJde#<^oht|M1Nwb6^V95hSsBnS{+vAKOlTvD zmlMjZkqtU<=|%Z4fNVrvdAvN8z<;oe!2TQK*+L;IkVpxt_BI~_wa3r;Oe*z%A`Dvi ztT*6iLhaZh0mYnR%$4f$dzE2j(qOG>dv1_V(ZS5dW<3wpwZ|?yx85KqKfCetqK)ML zB@1t>S2XNC;3e_FEH?_Zck{WJn1DgH8hO%gVw(~jO1m@y1uiTxPsD1bNPnwpw*Zpp z`4(pL?{NP8LOd6-L8A*r7X^AQYU61Fqn|bos!#NcTqM$939M;_OH)bC1l6M1+nMkXIWq(-{nEyBJNzszn zgRt(br{hkuNgdRzvluCHt&Wf2k`?0Y;dIoN>^Ix!R8oo&3D$Ek7YId9Q}quBVfR{e z_z1&r*KM`ejW{mSU>vPa3$fDQUFIDY(NeT0ka;%n2V?0WkK9?I9!OtU5!eo8w~C5d zcaGKdyfG@=EwT6e<9}9kV_K_LY7mn#Rav;2{F8A&eLQ~8*_t-5goPqB4$LEhNK6s^=XW=K zUPo&Y-rE4VA9A6OdFC?k1f?gUWnv3J@27~deYVpDPdw*RCdZE~@HqsBAk8zbL zWIg}wP7ghOT#aHTtpR(z6-ZAr(l-xS$p=;TNc#dlMMs#Z%RZt{;-!WCq0MnSW2uWy zIy4$@fr(U{G$?{B1%msXx@hQJm711>A!S;~QqB+c$7&SUN z)Ke8+E@glarxnbmV-B)xA*a0-GUs$l(8ME9P>JM|mp3AP%`d0XAlgi(N9AL6C1QN< z=?d&_X#21yLL7Ud<)zw7g4CzykleqL1BGNt3KUeIWG#+ct~(0ej6s z^^+lg?smgQR!Woxled4?lWc7wEhh;;KyqJh|&Ir zBC0Wo%k8nt!p&B*E7K1!8L$K#Nx9dN4G_{HMsv5&%tCHpPs2`u2@~CDg1sq)hCF^f z%zs<$_{t{GTATcYSE+30|IreR@fWAW9P4a0QM(rx6i%`y#;c?O<%A3HoHBTjIkdZx zb!1m4dzVo#R>UPft9MqsGunJ;P0|pVfV2M0-YBksh^NdSTl>9qqX+b+?+Y4MvVYUv zhNTexV=AC*S=q)2U6!H^um400XyY%fx_=}XR~X4l)y@MgEI#)d;bRm`$8Wwd9)Z*D z`l&h}BK+<{%y*b$F!0!1TQb9yD1=p;z)o8`xg5VzqX$e!E71MsGOYBTpWo`^Fu?cn zx1hNOCURb?p0+5-h20SBRh6!fR435@OS=~X%a25yQ3pBX^Aa_HgmQXxcMSkIC4bN& zs5MUXD<0Ov(@v%9P9eAE>s&X5{p6MwW&OBV=jV~%{qrB`dfBidc8yF^CyvP)H+wso ztZC%bk0gu|G-peB7Wq4}(^WA3ED}yNeMYXU8knkgHQhg+xd&aHA{@ZTi05*vX#pGb zylatPO@f1uNq3+DGmje-4dx+ZcYi3$$+f2k%CPV7jCDu9p{cs5rw~C<4{2u_*JB9L zTIWVLAKEGbe{T5Qj^-$s$-!VLN&(J=s;15UxWoP54@BAZB+Gje=izLWU;Kg%XXFtI zL(~fkp^IZo8f`8q1!w67>%%NDV;zxu88vWJSk~$5#;OT!-<@o(bhu(IReu-!$Lik$ z*tLhE8)w`;+I9Z}dr~@9s6bvI!kKvsgzoA9IJLqJ<__>q;KIJYULHug+P2WD<4ma) zFCmzH!yK7lgXw1_d->ks2<91RuEI7nYq>h8pNT`L;kr9rS$nZlB<6<=ziNi#{5FlZ ze+HPp*o9GBp(#*BEMB|l;mRBD*^8)z#4KH?nW34+%EGbCP$Fz;f$@?J2;LYB@4DLD5M ze_ds~SMndj{>2f0R_)vg>(E!C1`6}8bQ+O@xc5TZZ=QdGt*e(uQGetndNsAZf`sC% zHwtI;*0`J4o?Fctz2hvyoX;9gRsiWfO8J@I7MXwv_&jz=|^QdnG0)xFIazLLf5{I>@AnFSu#V-<*-** z9nPPWM=zC!`(rT$@#HzlA+6Xf3^fez6~i+hJTJMla&8pX9Eg>LyAt` z%X!Zyv1ZkQ=c}R~>SFd#_8_|I)83cNUN1943fP>fB~Tg1%FjA|`TttBVN3%}s=B6H z;)zx*101W4JmlkWr(FRsHd=YTXe>;rL}hh8XV1MiB>$aymwgsX6^!}_3T_VjCR#Km zXy8wYyNN0n8h@>D(M|k;h?5KOD3MZdVC<-OL8#W&fPF-L%Z#0!!0~y?4~SyUL2Ayj z1*eHl4`U{_Q4ty+@B}CmPRcI47o>>n6(u?aRq@eFQoS~tBFQj|E}N>LXExpB-@bQI zA#5VPXr5^@kp+~xy@ER2I>T9i{fGb~23{GdjM7gaM}LG*JCxzd;09usa`)l-|H|Qf z@7X*{N|Dt(a0MvNg0tE*G7jWD&e)dP-QNX36D)&vuiQ@>6!_3~1NYm~2Uuas+JX`BGHNH(> zc|YV$;9WVTY7f6;grY~_pP^i|?_OabnRltjtbfUw!$Jp38+MxCdqqOdT{&io$kz`3 z#6icdF;YQVgB?E5Q}N{QA4=~|_?`|VKjuBZXG4`5et(S6%H@K3jb&+tKEyHJn(A2x zo=p^YAA7r5?i~1ky;&DInfK^Ye@%PF7gqqfrs2h2L2ZY`f&i)Dbd+lT+3P(Pwi@t~ z!++A!-+?8YA~PX2PdSP;G>ESvsCx5SS>Jmk62uH~uMckSC1yTY@QGZ7CmG+f?Ga@v)o>oKUkD>PR(W-@;Tro?~ z{I6>YRDJe4?KamiMK2ZqW9Bs$art39SX_M~vH!TodfdOs>u->xWjDf>)_ZQ@PinZ9 z&NR(NBJubW#BhvK_q%P&{9m72pL3tw96Pe{^1A?`g7k|o@ zKfBHzAHsjaY9LwpapF^XZlQ)AVEsV82y7m0oI_j?5IcGFU;cszabAZ)xcZvaP*xfz zAg7~JxUCZsN$7gn7FN)Sg_qeIXr%rIyd_<`3L_o8X9U&4F?Nad%Tb3dZd>}Zy(1pY zIbvN!ukbgk1ls3#mdiNp>|09eP=9&nE@N1LqXtaOIb>IZnV=b(Vdjy%`gmJDNoT6u z8W1ZDXiT36@ZAil1SZ_(Sv!DN5m4pd6(OA9+pU1^s6@Qj8GTSYTi&AQD`jnehaaw8 zND~1&6k@mZRtl8^|3fdf?uJUW)ptUed_!?oQjwO^MSkKt$NEXfl)UQ*PNqG~f}asIQ4+GVWhtFH(DDe5*qU?~%| zb=h~4nt4gqMguCPtBl)Scz>4XH`-7Vjc?Lq0(u{I!96Se!qJNL^_2kl+mAM%NMQ!JL|gXr$7xbysX7JrlDgW;R5?VZR- zJ=gQUvHYf;(36ssDfJh7wc?^my*-4I5VFnF>z3V-3cm)|rRk<3>u~4@qmK4VBAED4 zx}2$Cz-3|~t$6##4dlB4w~K+i;jxG(P9H=wBOCk@yDPNIU;T7yDmP_6P-Us;k69|A(d-Es^nMkp@`nP&mW2&%Ouc z%p4^To9Pk9r&2`c25_ppjl+@PQb9Y$?3{ZFb(YA3TEu~pk4O=a{=M-+s>wZe{VXD? zS}FfH4Qw88qOw7~^3YNwl(v0Jq8I@9XVrA%oQ$OgBH^~D9Dk^*I|fTUh!oG3l0=-7 zq>*nze!0a26*X6+`^n-6OCTO_>KtA=sJTY}?%ODYBIkS`0)0c?x>~#^001BO>-_#X z&&aF;nw(=gtQ-)IKOXl$iruDNpBqlG2S-$Lv*&!bRSRFzj7g+?Ope(pB%I%OOkIFi z=InX|jw2oYXn&r*&?Ib#Fosmdfpb=R)6$i642(ep7=RSz*qyR9CL?#z+3f~A@lM}J zxLok7s%Hf4L-Sz18zmCMpf#9Qx}6s6JuvP#A4u;?Uu9-gV+2x*sfV0rSP=KG=;o#w7R%N2fA>&FLU1Hju796K|SJh9Ox^bfS5{) z#bv&4rUe}#IsTn=ZXKRk4;7-GXzR?N+BnANVL>`XaDP)N3XM)3Nt}4>1fNntWwKyPuB)-d zgp_U^W8Du+t^>}W*o*V9azhSbX|*el+__?ffXup$ps#Vb#HtpxL!LYyQqoi`-kF*w zyR?v*JTw4eky)ZbZ#b~ka5UE&?^HN%>Um2%ALu`ZZabIcY}!`4j>ubB8Enn9O!Bj+ zeSaUlm*F%PFrqfJsYG&Dv0hceWI5Sq#=v|Lq8EDD7=%LBj(S3}jaXDU(M6GH{p=_E z%h=Lz>>5DIMf)(cPit*>Zbmd<6Rp?okP(VhEh}=@iP4Iw+kTf`qDvRE?6%NOcuXG| zO5bI7MVA#`5^Zz_WLI7q_KHu`EgvtI>3<+@yS}gx+xtgB)c_@>gkMqyZ_{JM?$4#M zHTx2A20%IOZpLpUyQoUYm%o4p&woNKV?U2R^!7D--8nt-q#XrgrQdmQf@f#R{M+`+ z%CO;eb==$3GUr_P4%+1NxykGp2hZ3JkV#PE!9nid@Dkw@G;{;f*}NvUJ#|HCHGf8F zkk_FsL0?&~hPiDH$THeU%9G~46V;=(?FLvnK4yI^KDBF$WJe=&wH&B=s3A0Lf(k)} zi<<{uk$ok`!An3g4M91D6g&F!FL&zNCTG;9)QPkB9uz(g)%?T-`3DV1ZkdkKY44^1 zYy2u{%eLdC9!1bLZF!Xu!PHtgsejV|{zKE85v3W|B*DR&n3YTT+f*f5(0?rW8^xu9 z8bSi6QI!{RTG5OA!p}pQdVe&PZo_4fN2io|{)sqRbQ&TJQMB>cAcAu}6YM5$`ZS5|R@iE*6nK!pu!EWB9=S z-uY9`=__Y<5G#RhSBi(i2vbewYb*4;k~4dOP3O~7ba z057p)j$F~G{IgKq?gSQ8zc#I~v1YaV(lh8E3m;G&2_~9EmMh2S1m(YvDiz`H|Ay{2 z)YGl7&j%I9uxmLf95=rwU3CZkqO6Hnm?@yMsKunFENy;2h#6l=(Y@+GySD8d*vGXT zM?K;>sqxa#4d3HtHGj((RgUNr7MmIx{A6joL@&6v)TV?Glu~S=-+?E)t$RZ9wn8CT7Ge2sGcNd3wcQOQ0DdY@QXqdoecQl~?~X zA#u{VIt!JBh?PKzRl1&8Jm5t9y9%2xk4)1oQYNG`Zdph%T>hK52b6HP(acE7Vu(3xi~>tMfiy{hW%2>@eQn~o*~#iUCL)=#{^qM{{ys6pY7VH(#= z7|TC^VC2bkD}SeJ_m6SabgM(X{;3g`kjutIfqfl0F0~tLe$Ij8&U5?3^=1?tnLmHt zw!#5=Iil}fZ>q|Z%6sSQeSdyh%p{PewBp<#x%~s@*3?>4*lL*ZwyvP#FNTBT^}Q4N z{_;QIMC?N%E!OWkKJTmY-iMd~))w=fs!l`4)gH19XMbTNyl1IkNd&VDBcBJr3;B?I zbu}Mg#LP%X@m zsp&9aZ4722zrE579Fb==9bR_@HIiteiT2h!H(N(l{pdUOdiYYmhjJrG-~(81|f9`yg)SkPzrc(v>V8c8k;#Uc&2R%i?NPq zbm)iC_jR7M)yJ^>wbFQI!CEy~!t=wfU_`MMtU-zl{Qc1t_>Q3LIj%Icp$sE$F{(oPmkw&rCkJS&G;R>^{Q8EUfY+PJ! zIQGy>T%v{NvogO{B0Al2&g8u9Q*an3g>-E0IwR4xfM@45Gi+DUJv4@}q#1PRJ=|W# z-rxYKg(X2(w6;_kV@!;%F4|=1lOmfQ|B{NnV!*Fs2n^XWC)ERLy&tO-;It(e)azD3 zOMj75sFkaT=OTT8Fj|~l6R5I_WQShsRw!IN&Ij0 zz^Q2ClVLt2J>qjGA1@h!Huu+;<@f_a_;r3Qe7lq!@9aBoY2=~sN{G6iHim>+AF(3P z4!#6XHiW@5C@z`3D)uv zb5~fHHayPjFFFFE@(_M3O-&PTw13iSrY&xU!C}`d8JFcn4vcDiK|r_ulbydsaQYAzA(NC?r^ZuH)6z#l7`%u~-klnZwg= z+d>@~OXxnx``t9{Lj4nlc~c+3LRY!2gjui?{a03aqj?7}H_U91%7w+e4S%AbJg3)U zD%u43O%c@+W}w{QMh1;^$|_R8Bd9CRcT;n%i$XK#Aqa4lCz3-(2bDRB2McJ+W%)uD za#UgG(S_`MW(;4Q{f}U%+zOV&e^$k40I3&&&SeGHIfUg7nIY6oIH|;wXZT|c<{s<= zi|(Hirfe8g`XQlZ8rX^p?0@*c40<#p_y?`~Qh_Jps*+IeZ46spOkR0p6CV*LgmbK-=CB<$n%7sM4icS}dP|YkG(wVT?e5d2>s)c0gtja2xLYot!rgl>6 zyV^OXB|G08@=3~rGM1KTYVG)=$48^SmgSW%k z&4T5T4VJ#L|5=DWOEbgJNWO~s!%Ys}?iRZ@=yXP5c4c1WSbMK=-^TYZXtjbmCfPvd zc2}?i1})os3K5T-RwPooPmX@2EveAqYK`-n)e@4uE;KW)r3Wt78(?yJrR36CH&SG6 zvdf;YTXE24cz--#AdDqH5A5#IPL_lZQy?uABS^AL@!dT?HL|&wP1rJ6u_w@a7kt~l zo#7tu+wb&rCkV|ae1@)rr<9w3#lHF?Bbrj;GmAExp zuitnt6MwR-7%=C65+B>%;$S$7>V?`H(fr(^TuYNwe1k~?II>`}V}>1H3!}N_B_f7- zM_o3=XsdwX;{%Zm{c%ao*+kvHS zT7MY9I-&a!9u&)FjEO`+tYm`y@!#%P&mCscJ(@;$pRhrsBm!etZrWGPN}YADscG;11FGcQfF zl(}GpI_}Ibpeq&&V90W+^-5SM@LnZ-9)D5y#VWdWkn43|Skn^>zqkZ(xc?rN9wb zm}7cKSc%qqMrW=dHdWi5O|RGaR!8RA7648OvSa=&%A)Z2fLi+BJE8o58nejcp?@EH zYjE$(G*YS93HJS1ZceShb2j!*cKnFsFY!17fmqSwUS^sB*s@DG_UEf*k{u`PF@J!8 zpuw?lv%?(7h%*8ejm@~*^bGw+6Moypet+Au@?#{`dvd(J60X+EM#vz`A4UD-(LZZ5MDYdDr3F(yTyL2Tv88Fzs9|0L^ z9nDW(0PgEB2t+Go4}S^e%p0vj&G-#F{$H~=#iNl(-7;}6M*Rul67xB@53#2?vZgol zk6vx{MnE>9>mwPSV7Ql!M}*ZThZxXBH|Ev`VR^V*ymC0BXW`uvELb*L$10a{Jm&oS z9DYfCw+s8>Tx-9VbzFwCgIGE5ag|~|Lr0Wl1@o1HzM}3;oqr%bZCJ?Du!ZqutM$zy z@8oW=m8mD*6NfRy$OO_X)ko>Inb_qN$QU+$KG`fc35C!{YNN44F^nsIUq#1zu<3|$ zS(v;;RU~rr2cMFyY|`^GovimK9NO!`^pt})&iQ^;`bEYf`gaP3NfHRMueYC5s_;zx zH&qweR`wy7Cx3mnkpgyr^?zTLcOEQQl4qX^MOw0r9(0;AE z-X7RM`$@8Rx4>3gMi;*|h`psGgs?^0$)J(%L2nl>ihmh^juOy1Z@^cIYg))nPXm&4 zsKqXI{T}-x)tn0+d|=eK-9nH3(cuA}QZt(7{IYkGVvwebFU_fKrpgg^$%$YrAT>G9 z>ZJd@T^BqdD?#4aw9|HZbvfJ(tX;+0MfP%im@sJm4Lrlv>DGE5_n!#RWubHhHSZG7wSaNSh}Lophp6z5Q~#LSPt0tdgZ@?d9EM*EDOj# zLRI|4oz&o*($>Gf&e?wGuo*;)?#@v=4rmwrCV#on+v{H;>!$Q&T47N9#_UngF;C^7 z^t>aveH^i;$1`e*A3bG3Xd3@%kyMM~1d-^Pd(oVy_G-%&S*=$)KsPQ6ej48kr%z(i zTZl2+4DssIFL#!JSSG*Tpf|yRdNK0zIEs=KgM2`d%Vrn-nUg^K8O;<>{AafKf+)mY zy??-w0VbdMatEC-Nu5KN>AE;TYlLvzCGEgCemZC^b5B}aq%BzQWW~)*$%zBTZtoms zo2|ZcG*L7vH*KNsPDKzujW$rp1UXl8Q?9n}NU0JzLB4jhpD%^`T^W*fKdA)P(;cr% z&p#9F@Wz4y{OUB$pii!N^dw|{HLqHNnmn#5eCMP2gW`boD&Ii>V@ zq9*YBiz5^mls6(3pTA{dR*t!k98C6cX6;^n%qd?Ejxe2B`tG7Oro#F_0Won?v3_R9 zHfhA)zuD1tX!^biuP(Sky>0A}d4EV}oU2`lG&fah&dMsVV)}v-Zy|XNhNGjaLVMYc z%UuS-AXsnF;(C>_1lPxX)dtbxZ!Pnxxj*h^?dw?6U(MBzxFq z^%fVG!A_re2ILvu-P`RTjrlHZpHW=4%7#YRZsOg9DGN(`#jh}lVcCLzjh8BrXBSA zr|>(ML< zB^KqSZWTisDtLlyJ4KO5i+`X4>tQ>&)+b5aECOwkOCeRxic>5)Ogh)ABUv8mTli8e ztd9yYYcoYIHAOzGVfaf}_%^CKbyiUTeAw@*a{w_hI+E8(OY1#DHSy2kBamC7_lH47 zlWPIoH@V9JwiGZAoC~FNMj?|>j8;2;qcd|<?rqk7@dX~JxRy`u;jk5fXiY3ykJaL5I!c7v@=X5U@hB1!` z)$AW1Y!jFH^H0&0o_|`NYbq*(g~Fx6j)Oedj5L}ko$7>FHr^e3y+ie%UuZNen4KRh zaQW%fQdVLyR%4pH3K*;@JHfVW0&2o>#63dRW>N_n!}P`eyhD6}IzxhqT-F}Lj$h~| z7(Vy=|4<>Q9^Bmk4kUH+u{(Si=LqB+i7NRd5i1V+m{Y` zrOsqagI_4$GAk@VO`4l0Bf=*r$v*X~mqOmZeJWvA+jd8@n2()W1NK))q09B)3GaS$ zQbe{|XkHo-$A7ZKq`BLm`#51fJm|5=aYE4jR=_;7biWyjBDosBHUp=tA*2ncY)L@v zjF>sIi-2N3zKt~~TDej4&bhgx%eJn=tzmE2vlyK&JahlxEb`DKqXJ<`->WbTUf=fh zbB%Ku3wlv{u?RiXx5PrQY-W+7nH(7{#NY4FnZ8)3Jb$rp9l2sANr!RFBN&vC?h1Yu8hnWPGo~^Eq*q2t}-@J{!C_AhY|XGo`KdYIrQ4X!h%l z6NTU_RevIn6We}xvmAypL76`=&4^TIfCeq41T7xeGgc`px#)G`ZgO>0?jr#TwNR2S z8cHx8A=)$u`OVC*a1{+k<*RMagW7^?5sLJ>FHBKUHQaO_`)#ha)r4g1QV1Hzptrgv zU06l%l{e)paB`F7ksOsnr*J%jOV^ENMt*#ae}CTxr3!m;Mgd=ucXz*kzKn{6e5;F` zGbf2t-~!uG`yNUdZSh063Zjw*Bs5!<*jW>@o;^x7<-{JL;N#vU(%#@ij4KJbko z`E!oBD5Z4ZvWLTxfA#PxdQ_4_P#xIC_AwVv6y6}?XY;cc9rc0Q5ItF!W=} ze}Bj~7X?AYTW|%yFdkV6Wj~Eml#fX22ZeYL1H$Qdm#&sE%wq&F6$3)KfL8^i7PBI@ zA<+pbsO5aqhqLaV>-VDyAnM<`%hIA2%QP9h3y;nono|Wi?YBG`UVVq1bW&C94{unO zjdpEC+Fp1N>@%tm5y;1&peI){VSEh{+<&QwT9qV7V(J}nVeTVu@arSQY=M{rQW3@w zA8!QfEbKh{TmwnnAH_49a8oTQ)jU%3+w7@>)SKWa^t-OYvC%gQ5Bh=av+|-b#^J@< z@_8KL-LQ{b(+|_R5e-gY$Uow;uspcF1`pVQF#!zBz>P7Vbod|778c9R9)Qpjmwymd zuQP>;=NlWNth>)DO_}Xx)ThOuz6>GfPqyS$VN7Z>xBfD&qaVAmXW2hIm zC*|)d@B2};n8h81Wy}Y>U%XkV>mJ$tlZcNftfz-~A{L@dnrWmqY1p^#pq&JYh@I-Am7Z z;qt4)TimAtu2Mz9m`X3&CP6hLg*f?w!4G2Y$+sHw+6=>ZsVI7B9e*4xj6II%@$U}# z!Dpf1!gx+kCLPJDoURLvOUF?pM;;@JIs^;AY6;_oHVWCB&Ddu$=$v62@l2)9a5FW@ z1GQrYaEF-S2;CW|Uva#zgrKR`pjX5r)0tZufVjNr@M;yP2g^W2zuvIEIU8X)Kk!1& z&<)p39pM&+0b|&+4}Y2=+vLB0nu5ggA;}o zB|nz5@w|E(Y8OK{u5$V}CvlvwF;~qTi$s=hq@VL_={ooD5J@*MZU}A-@5h)!ynn#k$V9g9Y zEbGeat}UQ#-s^>67-hrs5Ffvt4dCR+qZ8Sw<&z>!9$Bufv+G#1js|yPuUVkVQh$pT zNBPte>^)3OH6`QY`Kb!H@d~Kyi2Nl>5Jr1$6`l6!{(puONz-K)6*kJum1i5P)~KxP z~jO(>Z&P!QWae7kHm@B*gstU@E7j29P@5I30u#b^JA;kB*U`IeZ!$AJAR;reg%#KW7=X#n7B6H;lNAha&IlH-pDY0x{H)fb9s)BrcvRosy6`PyK zxaoK;O^Fq_r*~^_peHc|7WPgWQR8V-!4&uuP{LHn@9`Fon=GBK=tx}SJ$j&+La(1Y zqZU{{{=JMeJa4wlYL-wjY*7_Z4Q522NPkvjF#IM*Y1Wa4M7iWZt9iv_0pE}}KnpIU ze^bGbDtm=Rs?GUNKeywSPM#nk))a1|(_M$y-V6`t=h2%HL>3NQ=`dTgY$7{56ntKNhLlB2o zN><{K5!1&Nn!)K7N`-7K?y~{;5NQ$o-v^Owin3o?U4XD|@ULYsT;lO3$rYC#ns%J& zAX6x|(|S{~u)~dSD8}@J^RAy>FMqtNk=a4Ke>CCXBwYjy*f4l0*C5#_u=NfUtV)(g zf_mSqJG^%wN$tv;71P@?&KfcXA9ofN`Yvc6x9j@!ml*0)Oy+W#;(JqUY2xi*>W<{A zq;MxR&TD8~6*^8XbzWbXD%*>HXME>n<^Pp*x?XrB4j)#ri-gLA;%)dXkAH1wB2G2H zth>Qnj}>L(>6!i_8B2KDhZU=i`g<;B{UlhBVP0?|ewfNJje~rK&XBlTw3h6qZ9d0f zEk(;=o5~c$(JU;+oB*eZ#r@6*t?M@%=f8v#wv)!HE~bRc$FSJ)bIr!bzRqswOEeHx zdPB@YM1M7a^d?6?#Lm zOe(Gf+wZ=J5*3->Tp6J`?LrMpYD0i@L_ReTe($D)M>p zMvem>D#}w!lsJkR{qR?p*xnf^r#Q3nb@yOV(zdys`jV9pRp*xObP?sC=#Cc0eP-R1 zK}ASU&Q1YQHyVi-E1O#@&NM9j2Q-4n?6?Rd#E zPJQ%gjbH<2*ilevLk05^na5k@6U4D@x+?~NGk+X0o>!>Q>9DW58zh^Is+MphH>Rvy zA*WP}L+4qpC!$!pfmAV1CwZ|T5WE_13H0ksH9_b;{oSf<0#eJIn1902JC z=6FLvE#7vWa8h~_Jvl@ZF#DV3a`yFXHb(qfsF6mP^@n zfOUd*s&AIJf+KIrsThC64r|9{%67kVXA&(4IJ{wT7QqO#?5rJ{jIk}LuRyt{Ix^w{ zC*WK$O^V$Rnd1{+qKVK^S7+=?Xn_gH=yBMzgCxp{K$Yevxp9%yM`Z8y4ZnK_IxrF8 z%VW0RXqsuEd6W-Y>|=ZLi}Qukk3;-bB8#3l#Q*xsiE8EFmpFgI?t;}d-UlioH-|8P zK0;8}v>43ou8A~O5DL%5f-~IRPl-6DRV-FbbU_u9_Z|GU?)$!Ij0fYC3IhR8CyMpz zpc3WN&NYQa0RRWB0nH1R6qr2r^iI%eSgOEoa0o?_!4INf>iWm?C2^R{8S zWQytf?;CtE7LNH@^Tf)0GTrg;k7qqwjER%(WdZ@m>}h||K$!G<&sc+0%O z2@Psya+-DWjqoFRT-aHl`CIJ)d(L?i>ZHh8S!g8?6AUiYC~|*Fj%N#-zptk@)+lVa zo#|EF6!L#vz|lnDYmfR6H3R}Ij}~5Ps1N6odi-+z3$Xdk&HCbl{Ubw7Nt${y-YRQ> z5Al2;erH~*s6@EVhTnN4<(5^6#{zz2dP(3cTNZwBWrnVBC^vV4HIa}^a^^BVMB@)+ zOjQ~4vMq*T8ICn<8{H2xatC^b$C9az=9%676+nN6a4){lqPfZlZ?HXS6!c9@>_0>P zU2UPFNnU+^BflMw5iVB%Jft=}%i|=XixO?VB6IcOF-pGs5NB&I+0c$q??9e&8jC_o z5_rxj>qP51@^iU;G@29);DyGDZBpARY#65MVg3gFJKmxB&^c+*G^& znRtJWy&3vOj$*jr#avrXODcc%5`qM`;mWI;OgL}Zj|@kSq%%L_FhN{lLT4|HKO{Z8#lNzx$%Xe^;u0Ri@`qKt_E=NT2* z2JPvpe$i2vClDL<_H@P_>MAI`wg3P>l3;&s>7V){Ctx;xQ-Tsou4FFVkFFgi%Nzo}K4-1(x90wkUn zaWvC~b?%&c9*FO@(t&%yrRQs28QVoW9_eI6%5#A5$?kMIWZijy@ zDp%~!>+!MD195yAv-F4n790vj{j)^OhEyi)1rShGSQN8 z1_#`=d^s_*(-SfmXKkl1NokiEb#0Rc7xfgII>tcn9WnH5FJLLrhceA7)tI^9Ds} zwlxGIeKf?a%VeAImi4`hSoj-wrC;DeI0QbEp~#8cF)8OJ?HaO%WI_SXA8IbRfmiAu z-v%ce_-`evjptF7uStK;=Tm}7dK>T-6Kk^W;QGn98oTjuRPtep_dr7h!}A^L*V|m! zXJkhQFPPr3^|Alv132LgzsN#g2PNLL+iG*p*|PdBw`yZ7OfXW!`&ZpHJ2AhhKXe!L z${wXsqz(3#@-94DTgOyx;Tjxi@1>>FDFt9w1nd7hJ-!m<-wJk*RqrJukeW?7PYQx%a^PD!hzfb-240B>}m^)mAJHiWoxH1~g zDGbVNm}qT+pY4DC=^ge(%*XrZNn!+LN`-_))2?^=JcO%n7bNu^Nmi>E#7Ij-CEo=g z>z9i81{Auzlzv-mjwKJ44iRi?y*vI{JOHQ^GkH6^pi;0Y#s_PE?A}Qd0s$3SGb*=@ z#MwdF+Q%BqdvKEO1I+h2y>kl=M$}>{unvSK&nH_`FEL|s^7VD$+{}m$Lk1A%1m diff --git a/index.Rmd b/index.Rmd index 7fa00a711..d3c5e7089 100644 --- a/index.Rmd +++ b/index.Rmd @@ -36,7 +36,7 @@ AMR:::reset_all_thrown_messages() ---- -### Introduction +## Introduction The `AMR` package is a peer-reviewed, [free and open-source](#copyright) R package with [zero dependencies](https://en.wikipedia.org/wiki/Dependency_hell) to simplify the analysis and prediction of Antimicrobial Resistance (AMR) and to work with microbial and antimicrobial data and properties, by using evidence-based methods. **Our aim is to provide a standard** for clean and reproducible AMR data analysis, that can therefore empower epidemiological analyses to continuously enable surveillance and treatment evaluation in any setting. We are a team of [many different researchers](./authors.html) from around the globe to make this a successful and durable project! @@ -44,7 +44,7 @@ This work was published in the Journal of Statistical Software (Volume 104(3); [ After installing this package, R knows [**`r AMR:::format_included_data_number(AMR::microorganisms)` distinct microbial species**](./reference/microorganisms.html) (updated June 2024) and all [**`r AMR:::format_included_data_number(NROW(AMR::antimicrobials) + NROW(AMR::antivirals))` antimicrobial and antiviral drugs**](./reference/antimicrobials.html) by name and code (including ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all about valid SIR and MIC values. The integral clinical breakpoint guidelines from CLSI `r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, grepl("CLSI", guideline))$guideline)))`-`r max(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, grepl("CLSI", guideline))$guideline)))` and EUCAST `r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, grepl("EUCAST", guideline))$guideline)))`-`r max(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, grepl("EUCAST", guideline))$guideline)))` are included, even with epidemiological cut-off (ECOFF) values. It supports and can read any data format, including WHONET data. This package works on Windows, macOS and Linux with all versions of R since R-3.0 (April 2013). **It was designed to work in any setting, including those with very limited resources**. It was created for both routine data analysis and academic research at the Faculty of Medical Sciences of the [University of Groningen](https://www.rug.nl) and the [University Medical Center Groningen](https://www.umcg.nl). -##### Used in over 175 countries, available in `r length(AMR:::LANGUAGES_SUPPORTED)` languages +### Used in over 175 countries, available in `r length(AMR:::LANGUAGES_SUPPORTED)` languages @@ -58,9 +58,9 @@ lang_txt <- AMR:::vector_and(paste(img, langs), sort = FALSE, quotes = FALSE) With the help of contributors from all corners of the world, the `AMR` package is available in `r lang_txt`. Antimicrobial drug (group) names and colloquial microorganism names are provided in these languages. -### Practical examples +## Practical examples -#### Filtering and selecting data +### Filtering and selecting data One of the most powerful functions of this package, aside from calculating and plotting AMR, is selecting and filtering based on antimicrobial columns. This can be done using the so-called [antimicrobial selectors](https://amr-for-r.org/reference/antimicrobial_selectors.html), which work in base R, `dplyr` and `data.table`. @@ -82,7 +82,7 @@ example_isolates %>% With only having defined a row filter on Gram-negative bacteria with intrinsic resistance to cefotaxime (`mo_is_gram_negative()` and `mo_is_intrinsic_resistant()`) and a column selection on two antibiotic groups (`aminoglycosides()` and `carbapenems()`), the reference data about [all microorganisms](./reference/microorganisms.html) and [all antimicrobials](./reference/antimicrobials.html) in the `AMR` package make sure you get what you meant. -#### Generating antibiograms +### Generating antibiograms The `AMR` package supports generating traditional, combined, syndromic, and even weighted-incidence syndromic combination antibiograms (WISCA). @@ -111,7 +111,7 @@ antibiogram(example_isolates, language = "uk") # Ukrainian ``` -#### Interpreting and plotting MIC and SIR values +### Interpreting and plotting MIC and SIR values The `AMR` package allows interpretation of MIC and disk diffusion values based on CLSI and EUCAST. Moreover, the `ggplot2` package is extended with new scale functions, to allow plotting of log2-distributed MIC values and SIR values. @@ -148,7 +148,7 @@ ggplot(data.frame(mic = some_mic_values, -#### Calculating resistance per group +### Calculating resistance per group For a manual approach, you can use the `resistance` or `susceptibility()` function: @@ -188,7 +188,7 @@ out %>% set_ab_names() out %>% set_ab_names(property = "atc") ``` -### What else can you do with this package? +## What else can you do with this package? This package was intended as a comprehensive toolbox for integrated AMR data analysis. This package can be used for: @@ -199,7 +199,7 @@ This package was intended as a comprehensive toolbox for integrated AMR data ana * Calculating antimicrobial resistance ([tutorial](./articles/AMR.html)) * Determining multi-drug resistance (MDR) / multi-drug resistant organisms (MDRO) ([tutorial](./articles/MDR.html)) * Calculating (empirical) susceptibility of both mono therapy and combination therapies ([tutorial](./articles/AMR.html)) - * Apply AMR function in predictive modelling ([tutorial](./articles/AMR_with_tidymodels.html)) + * Apply AMR functions in predictive modelling ([tutorial](./articles/AMR_with_tidymodels.html)) * Getting properties for any microorganism (like Gram stain, species, genus or family) ([manual](./reference/mo_property.html)) * Getting properties for any antimicrobial (like name, code of EARS-Net/ATC/LOINC/PubChem, defined daily dose or trade name) ([manual](./reference/ab_property.html)) * Plotting antimicrobial resistance ([tutorial](./articles/AMR.html)) @@ -209,9 +209,9 @@ This package was intended as a comprehensive toolbox for integrated AMR data ana * Machine reading the EUCAST and CLSI guidelines from 2011-2021 to translate MIC values and disk diffusion diameters to SIR ([link](./articles/datasets.html)) * Principal component analysis for AMR ([tutorial](./articles/PCA.html)) -### Get this package +## Get this package -#### Latest official version +### Latest official version [![CRAN](https://www.r-pkg.org/badges/version-ago/AMR)](https://cran.r-project.org/package=AMR) [![CRANlogs](https://cranlogs.r-pkg.org/badges/grand-total/AMR)](https://cran.r-project.org/package=AMR) @@ -226,7 +226,7 @@ It will be downloaded and installed automatically. For RStudio, click on the men **Note:** Not all functions on this website may be available in this latest release. To use all functions and data sets mentioned on this website, install the latest beta version. -#### Latest beta version +### Latest beta version [![check-old](https://github.com/msberends/AMR/actions/workflows/check-old-tinytest.yaml/badge.svg?branch=main)](https://github.com/msberends/AMR/actions/workflows/check-old-tinytest.yaml) [![check-recent](https://github.com/msberends/AMR/actions/workflows/check-current-testthat.yaml/badge.svg?branch=main)](https://github.com/msberends/AMR/actions/workflows/check-current-testthat.yaml) @@ -244,11 +244,11 @@ install.packages("AMR", repos = "beta.amr-for-r.org") remotes::install_github("msberends/AMR") ``` -### Get started +## Get started To find out how to conduct AMR data analysis, please [continue reading here to get started](./articles/AMR.html) or click a link in the ['How to' menu](./articles/). -### Partners +## Partners The initial development of this package was part of, related to, or made possible by the following non-profit organisations and initiatives: @@ -260,7 +260,7 @@ The initial development of this package was part of, related to, or made possibl -### Copyright +## Copyright This R package is free, open-source software and licensed under the [GNU General Public License v2.0 (GPL-2)](./LICENSE-text.html). In a nutshell, this means that this package: diff --git a/man/as.sir.Rd b/man/as.sir.Rd index 43442a3b3..6f952f4c5 100644 --- a/man/as.sir.Rd +++ b/man/as.sir.Rd @@ -44,8 +44,8 @@ is_sir_eligible(x, threshold = 0.05) FALSE), include_screening = getOption("AMR_include_screening", FALSE), include_PKPD = getOption("AMR_include_PKPD", TRUE), breakpoint_type = getOption("AMR_breakpoint_type", "human"), host = NULL, - verbose = FALSE, info = interactive(), conserve_capped_values = NULL, - ...) + language = get_AMR_locale(), verbose = FALSE, info = interactive(), + conserve_capped_values = NULL, ...) \method{as.sir}{disk}(x, mo = NULL, ab = deparse(substitute(x)), guideline = getOption("AMR_guideline", "EUCAST"), uti = NULL, @@ -55,7 +55,8 @@ is_sir_eligible(x, threshold = 0.05) FALSE), include_screening = getOption("AMR_include_screening", FALSE), include_PKPD = getOption("AMR_include_PKPD", TRUE), breakpoint_type = getOption("AMR_breakpoint_type", "human"), host = NULL, - verbose = FALSE, info = interactive(), ...) + language = get_AMR_locale(), verbose = FALSE, info = interactive(), + ...) \method{as.sir}{data.frame}(x, ..., col_mo = NULL, guideline = getOption("AMR_guideline", "EUCAST"), uti = NULL, @@ -66,8 +67,8 @@ is_sir_eligible(x, threshold = 0.05) FALSE), include_screening = getOption("AMR_include_screening", FALSE), include_PKPD = getOption("AMR_include_PKPD", TRUE), breakpoint_type = getOption("AMR_breakpoint_type", "human"), host = NULL, - verbose = FALSE, info = interactive(), parallel = FALSE, - max_cores = -1, conserve_capped_values = NULL) + language = get_AMR_locale(), verbose = FALSE, info = interactive(), + parallel = FALSE, max_cores = -1, conserve_capped_values = NULL) sir_interpretation_history(clean = FALSE) } @@ -132,6 +133,8 @@ The default \code{"standard"} setting ensures cautious handling of uncertain val \item{host}{A vector (or column name) with \link{character}s to indicate the host. Only useful for veterinary breakpoints, as it requires \code{breakpoint_type = "animal"}. The values can be any text resembling the animal species, even in any of the 28 supported languages of this package. For foreign languages, be sure to set the language with \code{\link[=set_AMR_locale]{set_AMR_locale()}} (though it will be automatically guessed based on the system language).} +\item{language}{Language to convert values set in \code{host} when using animal breakpoints. Use one of these supported language names or \href{https://en.wikipedia.org/wiki/ISO_639-1}{ISO 639-1 codes}: English (en), Arabic (ar), Bengali (bn), Chinese (zh), Czech (cs), Danish (da), Dutch (nl), Finnish (fi), French (fr), German (de), Greek (el), Hindi (hi), Indonesian (id), Italian (it), Japanese (ja), Korean (ko), Norwegian (no), Polish (pl), Portuguese (pt), Romanian (ro), Russian (ru), Spanish (es), Swahili (sw), Swedish (sv), Turkish (tr), Ukrainian (uk), Urdu (ur), or Vietnamese (vi).} + \item{verbose}{A \link{logical} to indicate that all notes should be printed during interpretation of MIC values or disk diffusion values.} \item{conserve_capped_values}{Deprecated, use \code{capped_mic_handling} instead.} diff --git a/vignettes/welcome_to_AMR.Rmd b/vignettes/welcome_to_AMR.Rmd index 527ccfcec..5a89ed561 100644 --- a/vignettes/welcome_to_AMR.Rmd +++ b/vignettes/welcome_to_AMR.Rmd @@ -43,7 +43,7 @@ This package was intended as a comprehensive toolbox for integrated AMR data ana * Calculating antimicrobial resistance ([tutorial](https://amr-for-r.org/articles/AMR.html)) * Determining multi-drug resistance (MDR) / multi-drug resistant organisms (MDRO) ([tutorial](https://amr-for-r.org/articles/MDR.html)) * Calculating (empirical) susceptibility of both mono therapy and combination therapies ([tutorial](https://amr-for-r.org/articles/AMR.html)) - * Apply AMR function in predictive modelling ([tutorial](https://amr-for-r.org/articles/AMR_with_tidymodels.html)) + * Apply AMR functions in predictive modelling ([tutorial](https://amr-for-r.org/articles/AMR_with_tidymodels.html)) * Getting properties for any microorganism (like Gram stain, species, genus or family) ([manual](https://amr-for-r.org/reference/mo_property.html)) * Getting properties for any antimicrobial (like name, code of EARS-Net/ATC/LOINC/PubChem, defined daily dose or trade name) ([manual](https://amr-for-r.org/reference/ab_property.html)) * Plotting antimicrobial resistance ([tutorial](https://amr-for-r.org/articles/AMR.html))